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Diagnosis and differential diagnosis
EP1274
Multiple sclerosis, depression and voice: a new tool for  
diagnosis?
L. Bruckert1, O. Heinzlef2, S. Jeannin3, G. Leboucher4,  
M.C. Gay3
1Psychology, University of Lorraine, Nancy, 2Neurology, Poissy-
St Germain en Laye Hospital, Poissy, 3Psychology, 4Ethology, 
University of Paris Ouest, Nanterre, France
Prevalence of depression in Multiple Sclerosis (MS) is high (from 
27 to 54%) and depression is under-diagnosed. Because of symp-
toms overlap between depression and MS, diagnostic question-
naires might fail to diagnose depression in MS. Voice study 
(comprising the uses of voice) is expanding in several fields since 
the last 10 years: for example, Tsanas et al., (2012) showed that 
Parkinson disease could be detected precociously from voice 
thanks to acoustic analyses. To explore if voice analysis could 
help clinicians to diagnose depression in MS patients, we recorded 
2 groups of female speakers: healthy women (28 non-depressed 
and 25 depressed); and MS patients without dysarthria (32 non-
depressed and 30 depressed). Depression was diagnosed accord-
ing to the Zigmond & Snaith HAD Scale. Our study consists of 
combining both acoustic measures and judgments made by non-
expert listeners, from recorded voices. For each voice recorded, 
the listeners had to rate pleasantness and depression. We found 
significant differences in 4 voice parameters between the 2 non-
MS groups and the 2 MS groups. For the non-MS groups, the 
values for the pitch (p≤0.01), the amplitude (p≤0.001), the speech 
rate (p≤0.05) and the variation of the pitch (p≤0.01) were higher 
than in the MS groups. In other words, the voices from the MS 
groups are lower (in intensity), deeper, slower and less expressive. 
We found differences between the depressed and the non-
depressed women inside each group for 2 parameters: the voices 
from the depressed women were less expressive (p≤0.05) and 
lower (p≤0.001). The results from the listeners’ judgments are 
similar to those from the voice analyses since non-MS/MS groups 
and non-depressed/depressed groups could be distinguished 
(Depression and MS make the voices sound less pleasant). In con-
clusion, our results highlight that it is possible 1) to detect depres-
sion in MS patients using voice analysis; and 2) to distinguish 
healthy people and MS patients, even if the MS patients with a 
dysarthria have been excluded.
Disclosure
Laetitia Bruckert: this research has been supported by GENZYME 
Company.
Olivier Heinzlef: nothing to disclose
Sarah Jeannin: nothing to disclose
Gérard Leboucher: nothing to disclose
Marie-Claire Gay: nothing to disclose
EP1275
Comparison of central vein detection in MS at 1.5T,  
3T and 7T
A. Fechner1, J. Savatovsky1, J.-C. Sadik1, D.S. Reich2, P. Roux1, 
P. Sati2
1Radiology, Fondation A. de Rothschild, Paris, France, 2NIH/
NINDS, Bethesda, MD, United States
Introduction: The central vein sign (CVS) is a new finding in MS 
studies, which could help improve MS diagnosis. This sign has 
yet to be studied on 3D isotropic sequences at different magnetic 
fields, especially on 1.5T for everyday clinical practice. Our pur-
pose was to evaluate the central vein across 1.5T, 3T, and 7T MRI 
scanners.
Methods: Three MS patients from the NINDS (National Institute 
of Neurological Disorders and Stroke) cohort underwent brain 
imaging on 3 different MRI scanners (1.5T, 3T, and 7T). Three MS 
plaques detected on the different scans were selected for each 
patient. Central vein assessment used a whole-brain high-resolution 
isotropic T2*-weighted sequence acquired in under 6 minutes at the 
three different field strengths. At 1.5T and 3T, this sequence was 
acquired during, or shortly after, the injection of gadolinium-based 
contrast agent (GBCA). Assessment of MS plaques and veins were 
made using the definitions from the 2016 North American Imaging 
in MS Cooperative consensus statement.
Results: Eight out of 9 lesions were central vein-positive on the 3 
scanners. Four were located in the deep white matter and 5 were 
periventricular. Only one lesion had a vein that was visible at 3T 
and 7T but not at 1.5T.
Conclusion: This pilot study indicates that it is possible to detect 
central veins in MS plaques on 1.5T images with a good reproduc-
ibility compared to 3T and 7T images. More MS patients will 
undergo the same imaging protocol to confirm these initial findings 
and investigate whether GBCA injection is required at 1.5T and 3T 
when assessing CVS.
Disclosure
Alix Fechner: nothing to disclose
Julien Savatovsky: nothing to disclose
Jean-Claude Sadik: nothing to disclose
Daniel S. Reich: nothing to disclose
Pascal Roux: nothing to disclose
Pascal Sati: nothing to disclose
EP1276
Comparison between proton density and T2 weighted 
sequences for detection of cervical cord lesions in multiple 
sclerosis
A. Abolhasani Foroughi1, F. Rafiei1, M. Nazeri2
1Medical Imaging Research Center, Department of Radiology, 
Shiraz University of Medical Sciences, 2Clinical Neurology 
Research Center, Department of Neurology, Shiraz University of 
Medical Sciences, Shiraz, Islamic Republic of Iran
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Introduction: Magnetic resonance imaging (MRI) is the gold 
standard imaging technique for identification of demyelinating 
lesions such as Multiple Sclerosis (MS). The Consortium of MS 
Centers Consensus (CMSC) Guidelines has recommended 2D 
proton density/T2 weighted sequences in standard MS spinal cord 
imaging protocol. The present study is conducted to compare two 
major CMSC standard spinal cord sequences, proton density (PD) 
and T2 weighted images, in the detection of cervical spinal cord 
lesions of patients with MS.
Material and methods: 130 patients with clinically definite 
MS were imaged during a period from February 2014 to June 
2015. 100 of these patients, who had cervical spinal cord lesions 
were included in this study. An institutional protocol for MS 
lesion detection consistent with the CMSC clinical guidelines 
which include sagittal T2-fast spin echo, sagittal T1-fast spin 
echo, sagittal PD-fast spin echo and axial T2WI through cervi-
cal cord from C1/2 to T1 vertebrae, were performed for all 
included patients. The data were analyzed in order to assess 
lesion-to-cord contrast ratio (LCR) and lesion-contrast-to-noise 
ratio (LNR).
Results: LCR was significantly higher in T2 weighted images 
(35.3), in comparison to PD images (24.2). No statistically signifi-
cant difference was detected between LNR of T2 and PD weighted 
images (P= 0.2). PDWI could not detect the black hole plaques of 
MS due to more water content of such lesions.
Conclusin: Sagittal T2 weighted imaging appears to be supe-
rior in comparison to PD sequence for detection of cervical cord 
MS lesions. Our study questions CMSC guideline in using the 
PD as a core spinal cord imaging sequence.
Keywords: Multiple sclerosis (MS), magnetic resonance imaging 
(MRI), T2, Proton density (PD), Consortium of MS Centers 
Consensus (CMSC), Cord lesions
Disclosure
The authors have no conflict of interest to be declared regarding 
the manuscript.
EP1277
Prognostic factors for multiple sclerosis in patients with iso-
lated spinal syndromes
G. Dalla Costa1, G. Di Maggio1, F. Sangalli1, L. Moiola1, B. 
Colombo1, R. Furlan2, G. Comi1, L. Leocani3, V. Martinelli1
1Neurological Department, 2Neuroimmunology Research Unit, 
3Neurolophysiological Department, San Raffaele Hospital, 
Milan, Italy
Background: The early identification of patients with isolated 
spinal syndromes at high risk of multiple sclerosis (MS) repre-
sents the main purpose of the evolving diagnostic criteria and of 
clinicians in everyday clinical practice. The aim of this study was 
to investigate the prognostic role of different biomarkers in 
patients with an isolated spinal syndrome.
Methods: We evaluated baseline clinical, MRI, CSF and neuro-
physiological data of 218 patients (mean age 32.9 years) with a first 
spinal inflammatory episode. We used discrimination and calibra-
tion characteristics and reclassification of risk categories to assess 
incremental utility of different biomarkers for MS prediction.
Results: During follow-up (median 7.3 years), 112 of the 218 
participants developed clinically definte MS (CDMS). In Cox 
proportional-hazards models adjusted for age at onset and gen-
der, the number of brain T2 lesions (>9 lesions vs < 2 lesions, 
HR 6.5 95% CIs 1.4 -15.7), the presence of CSF OCBs (HR 2.3 
95% CIs 1.0-4.0) and the multimodal evoked potential score (4th 
quartile vs 1 quartile, HR 2.5 CIs 1.2-4.2) significantly predicted 
the subsequent development of CDMS. The same biomarkers 
were significantly associated also with the development of MS 
according to 2010 diagnostic criteria in the follow-up. The use 
of multiple biomarkers led to a 27% net-reclassification improve-
ment (p < 0.001) over the use of current MRI criteria for MS in 
the prediction of patients with spinal isolated syndromes who 
develop multiple sclerosis at 2 years.
Conclusions: The simultaneous addition of several biomarkers 
improves the risk stratification for MS in patients with isolated 
spinal syndromes beyond that of a model based only on MRI 
criteria.
Disclosure
G.D.C., G.D.M., F.S., B.C. report no disclosures V.M. has 
received honoraria for activities with Biogen, Merck Serono, 
Bayer Schering, TEVA, and Sanofi Aventis as a speaker. L. M. 
has received honoraria for speaking in scientific meetings and for 
advisory board from Biogen TEVA, Sanofi- Genzyme, and 
Merck. R.F. has received honoraria for speaker activities from 
Biogen, Merck, Novartis, Roche, and Teva. L.L.has received hon-
oraria for consulting services and/or speaking activity from 
Biogen Idec,, Novartis, Excemed. G.C. has received personal 
compensation for consulting services and/or speaking activities 
from Novartis, Teva, Sanofi, Genzyme, Merck, Biogen, Excemed, 
Serono Symposia International Foundation, Roche, Almirall, 
Receptos, Celgene, Forward Pharma.
EP1278
Clinical, investigational and outcome profile of acute myelitis 
in the city of Kolkata, India
T.K. Banerjee1, E. Ghosh1, M. Saha2, A. Das1, D. Chowdhury1, 
S. Ojha1, S. Nandi3, A. Haldar4, A. Ghosh5, A. Datta6, S. 
Purakayastha6
1Neurology, National Neurosciences Centre Calcutta, 
2Neuroradiology, Advanced Medicare & Research Institute, 
3Neurology, Calcutta Medical Research Institute, 4Neurology, 
Medica Superspeciality Hospital, 5Neurology, Apollo Gleneagles 
Hospital, 6Neurology, Institute of Neurosciences Kolkata, 
Kolkata, India
Background: Acute Myelitis (AM) could be infectious/ para-
infectious or secondary to conditions like multiple sclerosis (MS), 
neuromyelitis optica (NMO), systemic lupus erythematous, etc. 
Besides, AM may be idiopathic where the underlying etiology is 
undetermined.
Objective: In this multi-centric study from India, we aim to 
determine
(1) the distribution of AM on the basis of etiology and
(2) rate of conversion of AM to MS.
Method: In the period 2009-2016, consecutive AM cases were 
recruited from several centers in the city of Kolkata, India. 
Compressive, toxic, metabolic, vascular, hereditary and paraneo-
plastic myelopthies were excluded. Following careful history and 
examination, all had baseline routine blood, anti-nuclear antibody, 
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angiotensin-converting enzyme and serum NMO-IgG (cell-based 
method). Routine CSF analysis and identification of oligoclonal 
band by iso-electric focusing method were performed. 
Cerebrospinal MRI with contrast were carried out in all cases. 
Idiopathic AM cohorts were followed up with cerebrospinal MRI 
performed annually or earlier if required.
Results: Out of the total 64 (men 37, women 27) AM cohorts (age 
range, 18-54 years; mean ± SD, 37.27 ± 9.98 years), there were 12 
(18.7%) post-infectious/ infectious and 4 (6.2%) NMO spectrum 
disorders. In a ≥ 2 year follow up of 24 idiopathic AM cohorts, 8 
(33.3%) converted to MS. Six individuals had recurrent AM but 
they had no evidence of MS or NMO. All who converted to MS 
had 1 or more cerebral lesions at baseline, whereas none of those 
who failed to convert had any cerebral lesion.
Conclusion: The conversion rate from idiopathic ON to MS in 
our study is similar to that in the Western countries. On the other 
hand, NMO spectrum disorder is more prevalent in our country.
Disclosure
1. TK Banerjee: The study is funded by Biogen
2. Ghosh E: nothing to disclose
3. Saha M: nothing to disclose
4. Das A: nothing to disclose
5. Chowdhury D: nothing to disclose
6. Ojha S: nothing to disclose
7. Nandi SS:nothing to disclose
8. Halder A: nothing to disclose
9. Ghosh A: nothing to disclose
10. Dutta A: nothing to disclose
11. Purakayastha S: nothing to disclose
EP1279
Evaluation of the predictive value of three serum and CSF 
biomarkers for the development of clinically definite multiple 
sclerosis (CDMS) following an initial clinically isolated demy-
elinating event (CIS)
N.E. Yaghmour, P. Petrou, I. Kassis, M. Halimi, D. Karussis
Multiple Sclerosis Center and Unit of Neuroimmunology and 
Cell Therapies, Department of Neurology, Hadassah University 
Hospital, Jerusalem, Israel
Objective: To evaluate the possible correlation of the presence in 
the serum and/or CSF of Tau protein, CXCL13 and Neurofilaments, 
with the risk of developing Clinically Definite MS, following an 
initial clinically isolated syndrome CIS.
Design and methods: 29 patients with CIS from our MS Centre at 
Hadassah were included in a prospective study in addition to 23 
controls and followed up for 1-5 years. The primary end point of 
the study was the conversion from CIS to CDMS. We compared 
the percentage of patients who were positive for 1 or more of the 
suggested biomarkers in their sera/CSF who developed CDMS 
after 1-5 years of follow up, with the percentage of those who were 
negative for the same biomarkers. A secondary end point was to 
establish a quantitative correlation between the levels of the bio-
markers in the serum and/or CSF and the probability of conversion 
to CDMS. ELISA was used for measurement of the serum and CSF 
levels of the fore mentioned biomarkers.
Results: During the follow up period, 20 patients were finally 
diagnosed with CDMS and 9 patients remained as CIS with 
similar gender distribution between the two groups. A significant 
difference between the values of 2 of the tested biomarkers 
(CXCL13 and neurofilaments) in the sera of patients who con-
verted to CDMS as compared to patients who remained CIS 
throughout the study period. 75% of patients and 70% of patients 
who were diagnosed as CDMS tested positive for CXCL13 or 
NFL in their serum vs only 1 out of 9 (for either CXCL13 or NFL) 
who remained as CIS (P value 0.0009 with a median value of 9 pg/
ml for CIS patients and a median value of 48.5 pg/ml for CDMS 
patients, risk ratio 6.75, odds ratio 24 from CXCL13; median 
level of NFL 622 pg/ml for CIS vs 1119 pg/ml for CDMS patients).
Double positivity was found to have a strong negative predictive 
value as zero percent of the CIS patients were double positive, and 
10 out of 20 CDMS patients (50%) were found to be positive for 
both CXCL13 and NFL (95% confidence interval, risk ratio of 2 
and odds ration approaching infinity value). The values in the CSF 
were insignificant which could be attributed to the long period of 
preservation of the CSF or could signify the need of more sensi-
tive methods for their measurement. Tau levels were not signifi-
cant neither in the CSF nor in the sera of the tested population.
Conclusions: CXCL13 and neurofilaments in the serum of 
patients with CIS, may represent significant predictive biomark-
ers for conversion to CDMS
Disclosure
Nour Eddine Yaghmour: Nothing to disclose
Panayiota Petrou: Nothing to disclose
Ibrahim Kassis: Nothing to disclose
Michel Halimi: Nothing to disclose
Dimitrios Karussis: Nothing to disclose
EP1280
Anti-MOG-IgG associated syndromes: report of 22 cases
S. Mariotto1, S. Ferrari2, R. Capra3, C. Mancinelli3, R. 
Bombardi4, L. Zuliani5, M. Zoccarato6, R. Tanel7, A. Bonora8, 
A. Polo9, A. Pavone10, L. Grazian11, D. Alberti2, A. Farinazzo2, 
K. Schanda12, E. Sechi13, D. Urso13, R. Delogu13, J. Francesco14, 
M.D. Benedetti2, S. Monaco2, M. Reindl12, A. Gajofatto2
1Department of Neuroscience, Biomedicine and Movement, 
University of Verona, Section of Neurology, University of 
Verona, 2Department of Neuroscience, Biomedicine and 
Movement, University of Verona, Verona, 3Multiple Sclerosis 
Centre, Spedali Civili di Brescia, Montichiari, Brescia, 
4Neurology Unit, St Bassano Hospital, Bassano del Grappa, 
Vicenza, 5Neurology Unit, ULSS 2 Marca Trevigiana, Ca’ 
Fondello Hospital, Treviso, 6Neurology Unit, O.S.A, Padova, 
7Neurology Unit, S. Chiara Hospital, Trento, 8Ophthalmology 
Unit, AOUI Verona, 9Neurology Unit, Mater Salutis Hospital, 
Legnago, Verona, 10Neurology Unit, Garibaldi Hospital, 
Catania, 11Pediatric Unit, ULSS 2 Marca Trevigiana, Ca’ 
Fondello Hospital, Treviso, Italy, 12Clinical Department of 
Neurology, Medical University of Innsbruck, Innsbruck, Austria, 
13Neurology Unit, Department of Clinical and Experimental 
Medicine, University of Sassari, Sassari, 14Neurology Unit, 
Department of Neuroscience ASUIUD, Udine, Italy
Background: Serum anti-myelin oligodendrocyte glycoprotein 
antibodies (MOG-IgG) have been described in different CNS 
inflammatory disorders. We report longitudinal clinical, MRI and 
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CSF data of a series of patients seronegative for anti-aquaporin-4 
antibody (AQP4-IgG) and positive for MOG-IgG.
Methods: A commercial cell-based assay was used to analyze 
AQP4-IgG, while a live-cells (HEK293A) immunofluorescence 
assay was used for the detection of MOG-IgG with a positive titer 
cut-off set at 1:160. Consecutive serum samples referred to Verona 
University Neuropathology Laboratory for AQP4-IgG/MOG-IgG 
testing were analyzed between March 2014 and April 2017.
Results: Among 444 tested patients, 22 MOG-IgG positive cases 
(13 females) were identified. In the 4 weeks before the onset, 10 
patients had fever, upper respiratory tract and/or gastrointestinal 
infection and one received anti-influenza vaccination. Three cases 
had serological evidence of a recent infection with HSV1, Borrelia 
Burgdorferi, and Cytomegalovirus. Clinical presentation included 
optic neuritis in 10 cases, myelitis in 10, both in one and confusion 
and lethargy in one subject. In addition, cerebellar and/or brainstem 
signs were present in two patients. Eleven patients experienced 
relapses. Spinal cord MRI showed short lesions in 11 patients, and 
longitudinally extensive lesions in 3 subjects. Seven patients had 
CSF pleocytosis and/or increased protein level, while 4 had CSF 
oligoclonal bands. Recovery was partial in 17 cases, complete in 3, 
and absent in 2. Of 6 patients retested for MOG-IgG after 3-168 
months from the index event in absence of relapses, 4 resulted neg-
ative while 2 were positive, at a lower titer compared to initial test.
Conclusion: Serum MOG-IgG are associated with neurological 
syndromes usually characterized by involvement of the spinal 
cord and optic nerve. In rare cases a syndrome resembling viral or 
autoimmune encephalitis can also be the presenting feature. 
MOG-IgG are preceded or accompanied by an acute infection and 
followed by relapses in half of cases. Most patients have neuro-
logical sequelae. It is essential to test MOG-IgG in the acute phase 
since antibody titer tends to decrease in non-relapsing patients.
Disclosure
Dr.ssa Mariotto is supported by the EAN Research Fellowship.
Dr. Capra received consulting fees from Novartis, Biogen-Idec 
and lecture fees and/or travel grants from Novartis, Biogen-Idec, 
Genzyme and Sanofi-Aventis. The Neurological Research 
Laboratory (Medical University of Innsbruck and Tirol Kliniken) 
receives payments for antibody assays (AQP4- and anti-neuronal 
antibodies) and AQP4 antibody validation experiments organized 
by Euroimmun (Germany).
Research studies of Prof. Markus Reindl are supported by the fol-
lowing research grants: Bridge I project EDNA (FFG and 
Euroimmun) and “BIG-WIG MS” from the Austrian Federal 
Ministry of Science, Research and Economy.
Dr. Gajofatto received travel support to attend scientific meeting 
by Almirall, Biogen, Merck, and Novartis.
Sergio Ferrari, Chiara Mancinelli, Roberto Bombardi, Luigi 
Zuliani, Marco Zoccarato, Raffaella Tanel, Adriana Bonora, 
Alberto Polo, Antonino Pavone, Luisa Grazian, Daniela Alberti, 
Alessia Farinazzo, Kathrin Schanda, Elia Sechi, Daniele Urso, 
Rachele Delogu, Janes Francesco, Maria Donata Benedetti, 
Salvatore Monaco have nothing to disclose.
EP1281
Cerebrospinal fluid CD4+/CD8+ ratio in diagnosing neuro-
sarcoidosis
S. Nordström1, B. Andersson2, C. Malmeström1,2
1Dept of Physiology and Neuroscience, University of 
Gothenburg, 2Laboratory for Clinical Immunology, Sahlgrenska 
University Hospital, Gothenburg, Sweden
Background: Neurosarcoidosis affects between 5-10 % of all sar-
coidosis patients and is a major differential diagnosis to multiple 
sclerosis. Diagnosing neurosarcoidosis becomes particularly dif-
ficult when it appears primarily in the nervous system and is a 
challenge to the neurologist. It has previously been suggested that 
an elevated cerebrospinal (CSF) CD4+/CD8+ ratio >5 can be an 
aid in diagnosing neurosarcoidosis.
Method: In this study we studied the cases of 66 patients who 
were subject to the analysis of CSF CD4+/CD8+ ratio by flow 
cytometry where neurosarcoidosis was a differential diagnosis. 
The final diagnoses from patient charts were sub-grouped into sar-
coidosis, other neuroinflammation and non-inflammation.
Results: We found 11 cases of neurosarcoidosis who, as a group, 
had a higher mean CSF CD4+/CD8+ ratio than the other two 
groups, with a significant difference only against the non-inflam-
matory group.
The mean CSF CD4+/CD8+ ratio was 4.39, hence not reach-
ing the suggested level of >5 for diagnosing neurosarcoidosis. 
We added the elevated CSF CD4+/CD8+ value >5 together 
with an elevated CSF lymphocyte count (2xULN) and found a 
positive predictive value of 60 % and a high negative predic-
tive value of 92 %.
Interpretation: CSF CD4+/CD8+ ratio >5 measured by flow-
cytometry in combination with elevated lymphocyte-count is a 
method the can be utilzed in diagnostic workup in neurosarcoidosis.
Disclosure
CM has recived lecture honoraria and served on AdBoards for 
Biogen, Merck, Novartis and Sanofi-Aventis.
SN and BA has no conflict of interest and nothing to disclose.
EP1282
Changes in the profile of patients with multiple sclerosis over 
the last 30 years due to evolution of diagnostic criteria
A. Czlonkowska1,2, J. Przybek2, I. Malecka1, D. Mirowska-
Guzel1,2
12nd Department of Neurology, Institute of Psychiatry and 
Neurology, 2Department of Clinical and Experimental 
Pharmacology, Medical Univeristy of Warsaw, Warsaw, Poland
Aim: The main purpose of this study was to investigate demo-
graphic and clinical characteristics of patients with multiple scle-
rosis (MS) diagnosed according to different criteria between 1986 
and 2015.
Material and methods: We analysed medical records of patients 
with MS diagnosed between 1986 and 2015. The patients were 
divided into 4 separate subgroups according to following criteria: 
A) Poser, n=145, B) McDonald 2000, n=66, C) McDonald 2005, 
n=62, and D) McDonald 2010, n=60. We aimed to investigate: 1) 
demographic characteristics, including sex and age, 2) the time 
between first symptoms suggestive of MS and confirmed diagno-
sis of MS, 3) severity of impairment at diagnosis assessed with the 
EDSS and symptoms that prompted workup for MS.
Results: We included 333 patients with definite MS. The female-
to-male ratio for the whole group was 2.3:1, whereas in subgroups 
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it differed significantly (A - 1.9; B - 1.6; C - 4.6; D - 3.6, A vs D, 
p=0.001).
The mean age at diagnosis decreased gradually in subsequent 
groups (A - 39.6±13.3; B - 37.7±12.8; C - 35.4±13.0; D - 29.9±9.3 
years, p< 0.001). Moreover, the time from the first symptom sug-
gestive of MS to confirmed diagnosis shortened significantly (A 
- 88.9 ±80.2; B - 39.1±68.4; C - 36.2 ±58.4; D - 33.5±68.2 months, 
p< 0.0001). The disability level measured at diagnosis on the 
EDSS decreased in consecutive subgroups (A - 4.4±2.2; B - 3.1 
±1.7; C - 2.7 ±1.3; D - 2.8±1.4). Pyramidal symptoms remained 
the most common manifestation of the disease at diagnosis regard-
less of the diagnostic criteria (A - 50.34%, B - 54.55%, C - 32.26%, 
D - 31.67). However, an increasing trend for visual dysfunction 
was observed (A - 15.9%, B - 14%, C - 19%, D - 23.3%; A vs. D, 
p< 0.0001).
Conclusions: Our study indicates a significant change in demo-
graphic and clinical characteristics of patients with MS diagnosed 
according to the relevant criteria. Over the analysed period, the 
diagnosis was made at a younger age and more often in women, 
the time gap between first symptoms suggestive of MS and con-
firmed diagnosis shortened, and disability at diagnosis decreased.
Disclosure
Nothing to disclose
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The MRZ reaction in rheumatological disorders with CNS 
involvement and primary CNS lymphoma
T. Hottenrott1, R. Dersch1, D. Endres2, N. Venhoff3, S. Rauer1, 
O. Stich1
1Department of Neurology and Neuroscience, 2Department of 
Psychiatry and Psychotherapy, 3Department of Rheumatology 
and Clinical Immunology, Medical Center - University of 
Freiburg, Freiburg, Germany
Introduction: The MRZ reaction (MRZR), composed of the three 
respective antibody indices (AI) against measles, rubella and vari-
cella zoster virus, has been found positive almost exclusively in 
patients with multiple sclerosis (MS)1-2. Rheumatological disor-
ders with involvement of the central nervous system (RDwCNS) 
and primary CNS lymphoma (PCNSL) can display similar symp-
toms, MRI findings and cerebrospinal fluid (CSF) routine results 
compared to MS and thus may be difficult to distinguish from MS 
but require a different therapy.
Methods: MRZR-2 (defined as positive by at least two AI ≥ 1.5) 
was assessed in patients with RDwCNS (n = 23), PCNSL (n = 37), 
MS (n = 203) and patients with a schizophreniform or bipolar dis-
order (n = 76). MRZR-2 results were compared using the Fisher’s 
exact test (two-tailed) with p < 0.05 for statistical significance.
Results: Demographic data of all study cohorts are shown in 
Table 1. MRZR-2 results are presented in Figure 1. A positive 
MRZR-2 was statistically significantly more frequent in MS 
patients (48.8%) compared to RDwCNS (8.7%), PCNSL (8.1%) 
and psychiatric patients (2.6%; p < 0.001 for all comparisons with 
the MS group).
Discussion: These MRZR-2 results confirm the comparable high 
specificity for MS also in the context of RDwCNS and PCNSL 
and thus indicate its potential as a diagnostic tool to differentiate 
these diagnoses from MS. Nevertheless, a brain biopsy remains 
the diagnostic gold standard for PCNSL. In respect of rheumato-
logical disorders detection of extractable nuclear antigens (ENA) 
is helpful in case of present antinuclear antibodies (ANA), because 
MS patients show slightly elevated unspecific ANA titers in 
around 30% as well3.
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Role of visual evoked potentials in spatial dissemination for 
multiple sclerosis diagnosis
G. Fenu, L. Lorefice, G. Coghe, J. Frau, M. Arru, C. Maggiore, 
M.G. Marrosu, E. Cocco
Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy
Background: Multiple Sclerosis (MS) diagnosis is based on clin-
ical and para-clinical tools to demonstrate dissemination in space 
(DIS) and time. Although Visual Evoked Potentials (VEPs) are 
commonly used in MS diagnosing, 2010 diagnostic criteria (DC, 
Polman Ch et al.2011)) did not include the optic nerve (ON) 
within typical sites considered to meet DIS. In 2016 MAGNIMS 
(Filippi et al, 2016) group proposed, inclusion of optic nerve (ON) 
lesions and alteration of VEP parameters to demonstrate DIS.
A further proposal from the MAGNIMS group is to use a more 
restrictive criterion to locate the periventricular involvement (at 
least 3 lesions).
The aim of our study is to evaluate whether the inclusion of VEPs 
among the typical sites of demyelinating disease allows to antici-
pate the diagnosis of MS.
Material and methods: We retrospectively evaluated patients 
hospitalized between 2010 and 2015. All patients included were 
subsequently diagnosed with MS. For all patients included were 
detected major clinical and demographic variables, MRI of the 
brain and spinal cord, VEPs were performed at the time of hospi-
talization for MS diagnosis.
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We evaluated 4 DIS definitions:
- 4 areas DIS (according to 2010 DC: involvement of at least 2 of 
the following 4 CNS areas: iuxtacortical, periventricular, infraten-
torial and spinal cord demonstrated on MRI);
- 4 areas DIS plus VEPs (involvement of at least 2 areas of the 
following 5 CNS areas: iuxtacortical, periventricular, infratento-
rial and spinal cord demonstrated on MRI or ON demonstrated by 
VEPs);
- 3 Areas DIS (involvement of at least 2 of the following 3 MRI 
areas: suvratentorial, infratentorial and spinal cord);
- 3 Areas DIS plus VEPs (involvement of at least 2 of the follow-
ing 4 CNS areas: suvratentorial, infratentorial and spinal cord 
demonstrated on MRI or ON demonstrated by VEPs).
Results: We included 200 MS patients. At the time of hospitaliza-
tion, space dissemination was demonstrated in 154 /200 patients 
(77%) using 4 areas DIS and in 174 / 200 patients (87%) using 4 
areas DIS plus VEPS, in 121 / 200 patients (60.5%) using 3 areas 
DIS and in 153/200 (76.5%) using 3 areas DIS plus VEPs.
Discussion and conclusion: Integrating VEPs into DIS allows to 
anticipate diagnosis in 10% of patients by supplementing DC 2010 
and 16.5% using a more restrictive MRI criterion. Our data support 
the importance of assessing ON involvement through VEPs to 
achieve DIS according with the MAGNIMS group proposes.
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Integrin and IL-16/IL-23 biomarker clusters differentiate 
AQP4-IgG+ NMO spectrum disorders, relapsing-remitting 
MS and healthy controls
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T. Petersen4, T. Csepany5, G. Lovas6, M. Simo7, T. Molnar8, J. 
Baumbach3, B. Hemmer9, Z. Illes1
1Department of Neurology, Odense University Hospital, 
Odense, Denmark, 2Department of Neurology, Klinikum rechts 
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Intensive Therapy, University of Pecs, Pecs, Hungary, 9Munich 
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Background: Neuromyelitis optica spectrum disorder (NMOSD) 
and multiple sclerosis (MS) are relapsing inflammatory diseases 
of the CNS. NMOSD is caused by antibodies against aquaporin 4 
(AQP4) in the majority of cases.
Objectives: To examine if soluble biomarkers of endothelial 
stress, cytokines, and chemokines can differentiate AQP4+NMOSD 
from relapsing-remitting multiple sclerosis (RRMS) and correlate 
with the levels of anti-AQP4.
Methods: We examined serum from 46 patients with anti-
AQP4+NMOSD, 30 patients with RRMS and 22 healthy subjects 
(HS). IgG and IgM anti-AQP4 antibodies were determined by 
cell-based flow cytometry assays with human glioblastoma cell 
line stably transduced using a lentiviral vector to overexpress 
human AQP4-M23. Twenty-six biomarkers were measured by the 
Mesoscale Discovery technique.
Results: Hierarchical clustering was able to differentiate 
AQP4+NMOSD and RRMS. Correlation among biomarkers 
defined major clusters of endothelial stress (VCAM, ICAM, 
SAA), IL-12p40/IL-23 and IL-16, and an inflammatory cluster 
including IL-8, IL-1b, TNF-a, IL-6, IL-12p70. Seventeen bio-
markers were differently expressed in AQP4+NMOSD compared 
to RRMS; among them, IL-6, IL-8., IL-16, and IL-12p40/IL-23 
were significantly increased in AQP4+NMOSD and MS compared 
to HS. Concentration of biomarkers did not correlate levels of 
AQP4 IgG in the sera. Decision tree defined the endothelial clus-
ter important in AQP4+NMOSD and RRMS differentiation, and 
the IL-12p40/IL-23/IL-16 cluster further differentiating RRMS 
from HS.
Conclusion: Elevated levels of biomarkers and biomarker cluster 
reflecting endothelial stress (VCAM, ICAM, IL-6, IL-8) may dif-
ferentiate AQP4+NMOSD from RRMS, while Th17 expansion 
may be important in both diseases reflected by elevated levels of 
IL-23 compared to HS.
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Frequency of anti-AQP4 and anti-MOG antibody positivity 
in patients with demyelinating diseases in Rio de Janeiro / 
Brazil
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The oligodendrocyte myelin glycoprotein (MOG) is a potential 
target of cellular and humoral response in the inflammatory pro-
cess of demyelinating diseases of the Central Nervous System 
(DDs). Anti-Aquaporin 4 receptor antibodies (AQP4) are sensi-
tive serologic markers of autoimmunity in Neuromyelitis Optica 
(NMO) and NMO spectrum disorders. Both can be used for diag-
nosis and differential diagnosis of these syndromes and can be 
performed by two laboratory methods, indirect immunofluores-
cence (AQP4) and live cell based assays for AQP4 and MOG.The 
frequency of antibody positivity against AQP4 and MOG- using 
the live cell based assays for AQP4-Abs and antibodies against 
MOG was investigated in patients with DDs treated in 2016 at a 
reference center in Rio de Janeiro/Brazil.A total of 67 patients 
were evaluated: Multiple Sclerosis (MS): 7 patients; Acute dis-
seminated encephalomyelitis (ADEM): 3 patients; Optic-spinal 
Multiple sclerosis (OS-MS): 9 patients; NMO: 26 patients, 
Recurrent bilateral optic neuritis (RON): 16 patients and 
Transverse Myelitis (TM): 6 patients. 21 patients were seroposi-
tive for AQP4 and 3 for MOG. According to the diagnosis distri-
bution, positive for AQP4: NMO: 50% (13/26); RON: 25% (4/16); 
TM: 33% (2/6); other cases were seronegative. Positive for MOG 
was observed in 2 patients with RON and 1 patient with TM after 
infection by Zika virus.Regarding NMO patients, the frequency of 
anti-AQP4 positivity was 50%, comparable to the results obtained 
by indirect immunofluorescence method already described in the 
literature, as well as in cases of RON (25% positivity) and TM (33 
%). Regarding anti-MOG screening, it was not observed in most 
patients, except in 2 NOR patients (12.5%) and one case of post-
infectious myelitis by the Zika virus, the first described in the lit-
erature so far. There was no simultaneous positivity between 
AQP4 and anti-MOG in this series.
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Serum aquaporin-4-IgG and MOG-IgG in patients with an 
initial demyelinating event: protocol and preliminary results 
of an Italian prospective multicentre study
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Introduction: Serum anti-Myelin Oligodendrocyte Glycoprotein 
antibodies (MOG-IgG) have been detected in patients with vari-
ous demyelinating disorders. However, the lack of prospective 
studies leaves uncertainty on the clinical significance of MOG-
IgG detection. This study is aimed at clarifying the diagnostic and 
prognostic value of MOG-IgG testing in patients with demyelinat-
ing events and presentation features atypical for MS.
Methods: 16 Italian centres will participate in the study. Eligible 
patients are aged 18-80 years, with a first demyelinating event 
occurred within 12 months from screening and not fulfilling 2010 
McDonald criteria for MS. Each patient will be followed prospec-
tively for 2 years, with baseline evaluation including clinical 
assessment, brain and spine MRI, lumbar puncture, and evoked 
potentials. Serum aquaporin4 (AQP4)-IgG and MOG-IgG testing 
will be performed at Verona Neuropathology Laboratory using a 
commercial fixed cell-based assay for AQP4-IgG and an in-house 
live cell-based immunofluorescence assay for MOG-Ig (positive 
cut-off titre ≥1:160). Clinical assessment will be repeated every 6 
months, while MRI and evoked potentials annually. AQP4-IgG 
and MOG-IgG will be retested in case of relapse and every 6 
months in seropositive patients.
Results: By May 2017, 15 patients (11 females) have been 
enrolled in 3 centres. Median onset age was 43 (25-59) years and 
follow-up duration was 6 (0-12) months. Clinical presentation 
was optic neuritis in 7, acute myelitis in 6, and other in 2 cases. 
Three patients were MOG-IgG positive at baseline, while one was 
AQP4-IgG positive. Compared to MOG-IgG negative, MOG-IgG 
positive cases had more frequently severe presentation (median 
EDSS score at nadir 2.0 vs. 3.5), longitudinally extensive spinal 
lesions on MRI (20% vs. 100%), CSF pleocytosis >50/µl (0 vs. 
67%), and absence of CSF-restricted oligoclonal bands (30% vs. 
67%). MOG-IgG assay was repeated at 6 months in 2 initially 
positive patients and it resulted negative in both cases.
Conclusions: In this prospective multicentre study we recruited 
adult patients with non-MS demyelinating events and we per-
formed a comprehensive evaluation including serum AQP4-IgG 
and MOG-IgG assessment. Our results suggest that MOG-IgG 
positivity seems to be around 20% in this population and is associ-
ated with distinct MRI and CSF features. MOG-IgG needs to be 
tested as early as possible after clinical onset as seropositive cases 
may become negative in few months.
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detection of anti mog antibodies in demyelinating disorders 
of the central nervous system (CNS)
A. Sala1, M. Spadaro1, M. Capobianco2, A. Bertolotto2
1Neurobiology Laboratory, Neurologia 2 - CRESM, 2Neurologia 
2 - CRESM, AUO S. Luigi, Orbassano, Italy
MOG is a CNS-specific antigen expressed on the surface of mye-
lin sheaths. Anti MOG antibodies (Abs) have been recently 
described as diagnostic marker of acquired demyelinating CNS 
diseases different from Multiple Sclerosis (MS), as seronegative 
Aquaporin-4 Neuromyelitis Optica spectrum disorders, pediatric 
ADEM or very early onset pediatric MS. To date there is not a 
standardized protocol to detect anti-MOG Abs although the most 
specific methods are cell based assays (CBA). Here we present 
our work to set up the FACS procedure for routine detection.
Glial LN18 cell line untransfected or stably transfected with full-
length MOG were provided by Hemmer lab (Monaco). They were 
incubated with patients’ sera, marked with anti-human IgG sec-
ondary antibody and analyzed by FACS. In each assay we tested 4 
internal controls: 1 healthy commercial serum (NC), 1 purified 
anti-MOG Ab, 1 human IgG anti-MOG+ patient serum and 1 
human IgG1 anti-MOG+ patient serum. We expressed the Ab 
titers as the difference in median fluorescence intensity (ΔMFI) 
between the MOG-transfected and untransfected LN18. The 
ΔMFI threshold was 23, i.e. the average ΔMFI plus 6 SD of 
healthy control (HC). Values higher than 23 were tested again to 
evaluate the IgG subclasses.
Medium values of positive controls were 1982 for purified anti-
MOG Ab and 357 for IgG anti-MOG+ human sample. The low 
and high CBA detection limits were assessed using serial dilution 
of both positive controls (R2= 0.99). All 61 HC and 13 MS tested 
sera were negative for anti-MOG (mean ΔMFI 2.5, SD 3 and 
mean 1.5, SD 2, respectively). No differences were found between 
HC and MS, while the difference between HC and both positive 
controls was significant (p< 0.0001). From June 2015 to April 
2017 we performed 570 anti-MOG Ab detections on 488 patients 
from different Italian neurology department. Cross reactivity to 
AQP4 and MOG was never detected at the same time. We identi-
fied 21 IgG anti-MOG+ patients (4.3%), mostly IgG1, except for 
one IgG3. We identified also 4 BORDERLINE PATIENTS with 
Ab titre around the threshold. In this case we suggested a retest 
after 3 months. In fact, 1 of these patients became IgG1 anti-
MOG+ 3 months later.
Our CBA test is reliable and reproducible and do not provide false 
positive results. We are the only one Italian laboratory offering a 
CBA test for diagnostic routine. The anti MOG detection repre-
sents a new diagnostic tool to discriminate from different inflam-
matory CNS diseases.
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Which treatment strategies for highly refractory forms of 
Neuro-Behçet disease?
F. London1,2, V. van Pesch1
1Neurology, Cliniques Universitaires Saint-Luc, Université 
catholique de Louvain, Brussels, 2Neurology, CHU UCL Namur, 
Université catholique de Louvain, Yvoir, Belgium
Introduction: Over the past years, the use of anti-tumor necrosis 
factor- α (TNF- α) agents and IL-6 blockade by tocilizumab for 
the management of Neuro-Behçet disease (NBD) has increased 
progressively, but still remains off-label. However, some patients 
remain refractory and warrant a different approach to treatment.
Objective: To describe a case of NBD refractory to traditional 
immunosuppressive agents with secondary failure of anti-TNF-α 
and anti-IL-6 therapies.
Methods and results: We present the case of a 32-year-old male 
patient with a history of recurrent oral ulcerations, bilateral anterior 
uveitis, papulo-pustular skin lesions, erythema nodosum on both 
legs. He was diagnosed with NDB after presenting T2/FLAIR 
hyperintense white matter lesions in the midbrain and hypothala-
mus showing Gadolinium-enhancement, responsible for cerebellar 
syndrome, diplopia and hypersomnia. The International Criteria for 
BD were fulfilled and azathioprine (AZT) 150mg/day combined 
with oral steroids started. Following 2 relapses at 12 and 18 months 
respectively after starting AZT, monthly pulses of intravenous 
cyclophosphamide (1000 mg) were started but the patient relapsed 
again 8 months later. Given the aggressive disease course, anti-
TNFα therapy with infliximab (INFX) was started (5 mg/kg every 
8 weeks), in combination with 100 mg of AZT and oral steroids. 
The patient remained relapse-free both clinically and radiologically 
until he presented a severe spinal cord relapse with paraplegia and 
paresis of upper limbs 26 months after starting INFX. Tocilizumab 
infusions were started (8 mg/kg/month) but did not lead to remis-
sion as 2 subsequent relapses were observed within 3 months. The 
patient was started on another anti-TNF-α agent (golimumab). He 
remains free of disease activity 4 months later.
Conclusion: NBD is a devastating CNS inflammatory disease for 
which there is an unmet need for effective therapies in patients 
failing several lines of immunosuppressive treatment to avoid 
unfavourable outcome. Randomized controlled trials or pragmatic 
trials are needed to determine the best treatment algorithm.
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Neuromyelitis optica spectrum disorders with myelin oligo-
dendrocyte glycoprotein or aquaporin-4 antibodies: clinical 
and paraclinical characteristics in Algerian patients
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Wildmann2, M. Reindl3, S. Jarius2
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Neuromyelitis optica(NMO) is a severe autoimmune inflamma-
tory disorder of the central nervous system. NMO and its abortive 
forms are referred to as NMO spectrum disorders (NMOSD). 
NMOSD are mostly associated with antibodies to aquaporin-4 
(AQP4-IgG). However, recent studies have demonstrated anti-
bodies to myelin oligodendrocyte glycoprotein (MOG-IgG) in a 
subset of patients. The data on NMOSD in NorthAfrica are sparse.
Objective: To describe the frequency of MOG-IgG.
and AQP4-IgG among patients with optic neuritis (ON) and/or 
myelitis in Algeria as well as the clinical and paraclinical features 
associated with these antibodies.
Methods: Retrospective testing of 42 patients treated at the teach-
ing hospital of TiziOuzou for MOG-IgG and AQP4-IgG, and ret-
rospective evaluation of the patients´ medical records.
Results: Six of 42 (14.3%) patients were positive for AQP4-IgG 
and 3/42 (7.1%) were positive for MOG-IgG. No patient was posi-
tive for both AQP4-IgG and MOGIgG. All antibody-positive 
patients were women. MOG-IgG was associated with severe epi-
sodes of ON in all MOG-IgG-positive patients. Steroid treatment 
was followed by complete remission in two patients. AQP4-IgG 
was associated with ON and/or longitudinally extensive transverse 
myelitis (LETM),often with severe onset. While all six of the 
AQP4-IgGpositive patients met the 2015 IPND criteria for 
NMOSD, only one of the three MOG-IgG-positive patients did so. 
Interestingly, clinically silent extensive spinal cord or brain lesions 
were present in two of the three MOG-IgG-positive patients, and 
altered visual evoked potentials without clinical evidence of ON 
were found in three of the six AQP4-IgG-positive patients.
Conclusion: MOG-IgG and AQP4-IgG are found in a substantial 
subset of Algerian patients with ON and/or myelitis, are present 
predominantly in women, and may be associated with differences 
in clinical presentation and, possibly, outcome. Only a subset of 
MOG-IgG positive patients meets the current diagnostic criteria 
for NMOSD.
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Not all optic neuritis are multiple sclerosis: drusen and para-
neoplastic autoimmune disease as cause of optic neuropathy 
in young people
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Background and objective: The most frequent cause of visual 
loss in young adults is optic neuritis, whose pathogenesis is usu-
ally inflammatory and demyelinating. Up to 75% of the cases will 
meet multiple sclerosis (MS) criteria in 15 years. But there are 
other pathologies that can mimic optic neuritis and should be 
included in the diferencial diagnosis. We report two cases of optic 
neuritis, uncommon in the literature, and to be taken into account 
in the differential diagnosis of MS.
Method: Case report of a 14-year-old man with a optic neuritis 2ª 
to drusen and a case report of a 41-year-old man with a optic neu-
ropathy caused by antibody anti recoverina.
Results: We report a case of a 14-year-old man who goes to the 
emergency room for a blurred vision of the left eye, eminently in 
the lower field, without added pain. He was seen by the ophthal-
mology service, that warn pseudo edema papila, advising assess-
ment by the neurology service and review by them the next day. 
That day, they noticed splinter hemorrhages around the papilla 
motive for which they entered the neurology service. Brain CT, 
OCT and ultrasound were obtained, which evidenced papilla 
drusen. Diagnosis of non-arteritic ischemic optic neuritis second-
ary to drusen was issued. A 47-year-old man who visited the neu-
rology service due to episodes of vision of spots in the right eye 
and double vision, lasting minutes, that were repeated 2 to 3 times 
a month. As personal background he referred Hodgkin´s disease, 
treated with bone marrow transplantation 10 years earlier. No 
abnormalities in the review by the ophthalmology service. Brain 
MRI with peri-ventricular demyelinating lesions, negative oligo-
clonal bands, pathological evoked potentials, and anti-recoverine 
positive body. He was diagnosed of paraneoplastic syndrome.
Conclusions: Although multiple sclerosis is a relatively frequent 
disease in young people with optic neuritis, other diseases have to 
be considered in the differential diagnosis of these diseases. It is 
necessary to recognize those atypical forms of optic neuritis in 
which the aetiological study must be extended. Important 
advances have been made in the knowledge of some of them 
thanks to the determination of specific markers.
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Brainstem syndrome and longitudinally extensive transverse 
myelitis (LETM) as first manifestation of Adult T-Cell Leu-
kemia/Lymphoma (ATLL)
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A.B. Ayroza Galvão Ribeiro Gomes1, H. Soares Neto1, M. 
Delboni Lemos2, D. Callegaro1, S.L. Apostolos Pereira1
1Neurology, 2Radiology, Universidade de Sao Paulo, Sao Paulo, 
Brazil
Introduction: Multiple sclerosis and neuromyelitis optica are the 
most common inflammatory disorders of the central nervous sys-
tem (CNS) and commonly initially present as brainstem syn-
dromes or myelites. They can be mimicked by other inflammatory 
systemic diseases. We report a fatal case of Chronic Adult T-Cell 
Leukemia/Lymphoma (ATLL) which initially manifested as a 
brainstem syndrome associated to a longitudinally extensive 
transverse myelitis (LETM).
Case presentation: A 38 year old previously healthy female was 
admitted to our service with a one and a half month history of 
corticosteroid unresponsive tetraparesis with a sensory level and 
brainstem symptoms. She had a family history of HTLV-I-
associated myelopathy/tropical spastic paraparesis.
Blood workup revealed significant leukocytosis, positive human 
T-lymphotropic virus (HTLV) serum screening test and normal 
cerebrospinal fluid analysis. Magnetic resonance imaging dis-
played multiple tumefactive lesions with contrast enhancement 
primarily in the pons with extension to the remaining of the brain-
stem, cervical and thoracic spine. High dose intravenous methyl-
prednisolone was initiated with no clinical response. In spite of 
treatment the patient developed a locked in syndrome with acute 
ventilatory failure within days of admission. Plasmapheresis was 
initiated. Subsequently, a peripheral blood smear found the pres-
ence of “flower cells” with a positive CD25 marker - a diagnose 
of Chronic Adult T-Cell Leukemia/Lymphoma (ATLL) was per-
formed and specific treatment (interpheron alpha-2b and zidovu-
dine) was offered. Despite our efforts the patient passed away due 
to severe dysautonomia. Post mortem analysis revealed nonspe-
cific perivascular and parenchymal lymphocytic infiltrates with 
no positivity to antiaquaporine-4 or lymphoma markers.
Discussion: Worldwide approximately 10-20 million people are 
infected with HLTV. The risk of development of ATLL amongst 
infected patients is 2- 5%, few of which will ever present neuro-
logic symptoms. There are few reports of ATLL with CNS 
involvement as an initial manifestation- it is even rarer in the 
chronic subtype. To the best of our knowledge this is the first case 
of chronic ATLL opening with a rapidly progressive corticosteroid 
unresponsive brainstem syndrome.
Conclusion: Inflammatory disorders of the CNS comprise a range 
of differential diagnosis. A high level of suspicion is needed in order 
to perform timely differential diagnosis and offer treatment.
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Marcelo Delboni Lemos: nothing to disclose.
Dagoberto Callegaro: received grants related to congress meet-
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In-vivo axon diameter dynamics in clinically isolated syn-
drome: a powerful biomarker in early diagnosis of MS
A. Horowitz1,2, Y. Assaf1,2, A. Achiron3,4
1Sagol School of Neuroscience, 2Neurobiology Department, Tel 
Aviv University, Tel Aviv, 3Sheba Medical Center, Ramat Gan, 
4Sacker School of Medicine, Tel Aviv University, Tel Aviv, Israel
Introduction: Patients with Clinically Isolated Syndrome (CIS) 
are at extremely high risk to develop multiple sclerosis (MS). 
However, a prediction tool of CIS patients that will early convert 
to MS, is missing. AxCaliber is an innovative MRI based technol-
ogy that enables in-vivo measurements of axon diameter dynam-
ics in healthy population and MS patients.
Objective: Evaluate whether measurements of axon diameter dis-
tribution (ADD) dynamics will predict CIS patients that will con-
vert to MS within 1 year from diagnosis.
Methods: 12 CIS patients ,9 females, age 34.0±9.6; disease dura-
tion 0.22±0.1 years; EDSS 1.3±0.7; without any lesions in the 
mid-sagittal plane of the corpus callosum (CC) performed brain 
MRI examination 3T (GE) using AxCaliber-1D protocol. Images 
were used to calculate ADD following the representation of each 
CC voxel by gamma-distribution expected value. CIS data was 
then inserted to our MS classifier to early detect MS from CIS 
cohort. CIS patients were followed up for 12 months.
Results: CIS patients showed significant lower ADD values than 
healthy controls (2.5mm±0.27 and 3.5mm, respectively, P< 0.001) 
and similar diameter sizes compared to MS patients (2.5mm±0.18, 
P>0.05). ADD was the only significant parameter among other 
MRI data (mean diffusivity (MD), fraction anisotropy (FA) and 
CC volume, all P>0.05) that differentiated between CIS and MS. 
Our classifier, which uses ADD, MD values and age, classified 11 
CIS as MS and one as non-MS. After 12 months, all 11 CIS who 
were classified as MS were definitively diagnosed as MS (all had 
dissemination in space).
Conclusions: The ability to early detect reduction in axon diam-
eter in the CIS stage, will allow early treatment of MS and provide 
better disease outcomes.
Disclosure
Assaf Horowitz - Nothing to disclose
Yaniv Assaf - Nothing to disclose
Anat Achiron - Nothing to disclose
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Misdiagnosis of multiple sclerosis and common alternate 
diagnoses
M. Kaisey1, B. Giesser2
1Neurology, Cedars-Sinai Medical Center, 2Neurology, University 
of California, Los Angeles, Los Angeles, CA, United States
Background: Diagnosing multiple sclerosis involves evaluation 
of the patient history, examination, imaging, and ancillary testing. 
No one test can rule in nor rule out MS, and many diseases can 
mimic the often vague symptoms of MS or cause white matter 
lesions in the central nervous system. While specific diagnostic 
criteria exist with revisions under review, there is still room for 
error in this process. A survey of MS specialists found that 94% 
had evaluated at least one patient in the last year who had an 
incorrect diagnosis of MS. Studies of groups of misdiagnosed 
patients found migraine and psychiatric disease to be the most 
common correct diagnoses. We evaluated the referrals to our sub-
specialty multiple sclerosis clinic in an effort to understand the 
types of and reasons for these errors.
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Objectives: To identify the incidence of misdiagnosis of MS and 
any patterns or common mistakes that lead to these errors.
Methods: All new consults seen in an MS clinic from July 2016 
- May 2017 were evaluated and categorized by initial diagnosis on 
referral, category of disease, and correct diagnosis after appropri-
ate workup was completed. The 2010 McDonald criteria were 
used and, when necessary, lumbar puncture, serum, and evoked 
potentials testing. 142 new patient consults were completed in this 
time and included in this study. This study was reviewed and 
approved by the institutional review board of the University of 
California, Los Angeles.
Results: 32% of new patients did not meet diagnostic criteria for 
MS or were felt to have a much more likely alternate diagnosis. 
9% of these non-MS patients were on disease modifying therapy 
to treat MS. The most common alternate diagnoses were headache 
(20%), spine spondylosis (11%), and white matter ischemic dis-
ease (11%). The diagnostic tests most likely to help differentiate 
MS from alternate diagnoses are recent imaging of the entire cen-
tral nervous system and lumbar puncture.
Conclusions: This review highlights the importance of careful 
evaluation of a patient’s presentation prior to diagnosing multiple 
sclerosis and also on receiving a referral for treatment options. 
Neurologists, and MS specialists especially, should re-evaluate an 
existing MS diagnosis given the high rate of misdiagnosis. 
Diseases misdiagnosed as MS vary but, concordant with some 
previous studies include headache, spine disease, and white mat-
ter ischemic disease.
Disclosure
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Detailed characterization of pain and depression in NMOSD: 
prevalence, clinical features, management and impact on 
quality life
I. Ayzenberg1, E. Henke1, I. Kleiter2
1Neurological Department, St.Josef Hospital, Ruhr-University 
Bochum, Bochum, 2Marianne-Strauss Clinic, Berg, Germany
Objective: To evaluate prevalence of pain syndromes and depres-
sion as well as their effects on the activities of daily life (ADL) 
and quality of life (QoL) among patients with neuromyelitis 
optica spectrum disorder (NMOSD).
Methods: All NMOSD patients of one academic centre were con-
tacted. Detailed characterisation of pain syndromes was done 
based on McGill, PainDetect and Brief Pain Inventory. Effects of 
symptomatic and immune therapies on pain severity were evalu-
ated retrospectively. Using the Beck Depression Inventory (BDI), 
depression was classified into severe, moderate or minimal. QoL 
was evaluated with the SF-36 questionnaire.
Results: We achieved a high response rate of 93% (42 of 45 
patients). 83% were female, the mean age was 44.1±12.4 years, 
79% were antibody (ab)-seropositive: 26 AQP4-ab, 7 MOG-ab. 
The majority (79%) of patients reported NMOSD-associated pain 
syndromes, 70% had neuropathic pain and 64% painful tonic 
spasms. The mean pain intensity was moderate (3.8±1.5, scale 
0-10). Almost half of the pain sufferers (49%) had chronic pain. 
There were no differences between seronegative and seropositive 
patients, as well as between those with AQP4- and MOG-abs. 
70% took pain relieving medications, however, they had still a 
pain intensity of 4.3±1.3 (scale 0-10). Among those with painful 
spasms, 33.3% only had antispastic medication. Tocilizumab was 
the only immune therapy with probable pain relieving effect: 3 of 
4 patients reported improvement after a switch to tocilizumab. 
Pain syndromes were associated with a substantial reduction of 
ADL (4.1±2.0, scale 0-10) and the health related QoL (34.2 vs. 
46.0 in pain free patients, p=0.015). Pain intensity significantly 
correlated with the following SF-36 items: physical and social 
role functioning, general health perception and bodily pain. 45% 
of patients had BDI scores indicative of depressive disorder 
(BDI>13), 32% of them moderate or severe (BDI>19). The BDI 
score was significantly higher in patients with chronic pain com-
pared to episodic pain (15.1 vs. 8.1, p=0.02). Depressive disorder 
was clearly undertreated, only two patients, both with mild 
depression, took antidepressants.
Conclusion: Pain syndromes and depression are highly preva-
lent, undertreated and associated with reduced QoL and ADL in 
NMOSD. It is crucial for an adequate targeted therapy to dif-
ferentiate between the following 3 pain patterns: neuropathic 
pain, painful tonic spasms and chronic pain associated with 
depression.
Disclosure
I.Ayzenberg has nothing to disclose
E.Henke has nothing to disclose
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Antinuclear antibodies as potential markers of disability and 
recurrence in patients with Neuromyelitis optica
A. De León Murillo
Demyelinating Diseases Clinic, Instituto Nacional de Neurología 
y Neurocirugía, Ciudad de Mexico, Mexico
Background: Neuromyelitis Optica (NMO) is associated with 
systemic autoimmune diseases and serological markers of non 
organ- specific autoimmunity. Clinical significance of autoanti-
bodies in patients with NMO is still unclear, specially in patients 
with significant elevations of these autoantibodies and with no 
evidence of a rheumatic syndrome.
Objective: To determine the association among the presence of 
antinuclear antibodies and the number of episodes of transverse 
myelitis and optic neuritis in patients who have been diagnosed 
with NMO.
Materials and methods: The study was transversal, analytical, 
retrospective and homodemic, 187 records of patients with NMO 
were analyzed between 2009 and 2016, of those only 46 met 
inclusion criteria.
U de Mann Whitney and Spearman´s Rho was used to determine 
the relationship between antibody titers and the number of epi-
sodes of optic neuritis, number of relapses of myelitis and the 
Expanded Disability Status Scale (EDSS).
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Results: We found a statistically significant difference in the 
number of relapses between patients with positive and negative 
ANAs, being higher in the patients with ANAs positive (U = 85, p 
= 0.000 and U = 84, p = 0.000) respectively, both with a signifi-
cance level of 5% (0.05).
A positive and statistically significant correlation was identi-
fied between ANAs titration with the EDSS score (r = 0.5632 
p = 0.001).
Conclusion: The positive association between the severity of 
the disease and the presence of autoantibodies, which until now 
are not involved in the pathogenesis of the NMO, could suggest 
that these antibodies reflect the degree of inflammatory disease 
activity if this can be confirmed in subsequent studies, the 
autoantibodies particularly the ANAs could be a useful clinical 
prognostic tool.
Disclosure
De León Murillo Azucena, nothing to disclose.
Flores Rivera José de Jesús, has been speaker of Genzyme, 
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Maintenance therapeutic plasma exchange in patients with 
neuromyelitis optica spectrum disorders
I. Dujmovic Basuroski1,2, V. Martinovic2, J. Ivanovic2, T. 
Zegarac2, M. Andabaka2, S. Mesaros1,2, J. Drulovic1,2
1Clinic of Neurology, Clinical Centre of Serbia, 2University of 
Belgrade School of Medicine, Belgrade, Serbia
Background: Therapeutic plasma exchange (TPE) is performed 
for the treatment of severe neuromyelitis optica spectrum disor-
ders (NMOSD) relapses, but the efficacy of maintenance TPE 
(mTPE) in NMOSD has been underreported so far.
Material and methods: Eighteen NMOSD patients (15 female, 3 
male; median age, 46.3 years), were treated with mTPE, once 
monthly. In the group A (n=9), mTPE was initiated after the treat-
ment of severe relapse and performed until the maximal neuro-
logical recovery was achieved. In the group B (n= 9), mTPE was 
used as an add-on therapy to steroids and/or classical immunosup-
pressants, in cases of disease activity in spite of the optimal treat-
ment (4 patients), or in addition to steroids in patients with a poor 
compliance, intolerance or contraindications for immunosuppres-
sive therapy (5 patients). The Expanded Disability Status Scale 
(EDSS), including total EDSS score and functional systems 
scores, were used to assess the level of neurological disability 
before and after mTPE treatment. Annual relapse rate was used as 
a clinical disease activity marker.
Results: Median duration of mTPE treatment in the overall group 
of patients was 1.15 years (range 2.4 months-3.8 years). The 
EDSS score after the last mTPE procedure was significantly lower 
than before the first mTPE in the total group of patients (p< 
0.001), and also in the group A (p< 0.05), while the EDSS score in 
the group B was unchanged during mTPE. The statistically sig-
nificant improvements after mTPE were observed in pyramidal, 
sensory and bowel/bladder scores. The average annual relapse 
rate was significantly lower during mTPE than before mTPE ini-
tiation in the total patient group (p< 0.001), as well as in both 
subgroups A (p< 0.01) and B (p< 0.05).
Conclusion: Our results show that the use of mTPE as an add-on 
therapy is associated with the reduction of disease activity and/or 
with neurological improvement in patients with NMOSD.
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Clinical course and prognosis of neuromyelitis optica spec-
trum disorder in a Moroccan cohort
A. Bennis, H. El Otmani, F. Dany, B. El Moutawakil, M.A. 
Rafai, I. Slassi
Departement of Neurology, Ibn Rochd University Hospital, 
Hassan II Universiy, Casablanca, Morocco
Background: Neuromyelitis optica spectrum disorder (NMOSD) 
was suggested to have a more severe course in low and middle 
income countries, particularly among populations from North 
Africa.
Objectives: To describe the clinical course and prognosis of 
NMOSD in a Moroccan NMOSD population.
Patients and methods: A retrospective monocenter study was 
conducted. Patients from January 1999 to December 2015 fulfill-
ing the 2015 International Consensus Criteria for NMOSD were 
included.
Results: Sixty four patients were included. Mean age at onset was 
35,7 ± 10,7 years, and the sex ratio was 1/3,56. Non transverse 
myelitis (NTM) was the initial clinical event in 29,4%, 17,2% pre-
sented with a Devic’s syndrome and 15,6% with intractable hic-
cups nausea and vomiting syndrome. Half of patients had more 
NTM attacks than transverse myelitis. Brain lesions were found in 
71,2%. Twenty four percents had associated autoimmune dis-
eases. Approximately half of patients reached an EDSS score of 6 
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after a median disease duration of 5,7 years, and 18,8% had an 
EDSS less than 1,5 on follow up. Median progression index was 
0,78 and median multiple sclerosis severity score was 8,64. 
Disease age of onset (HR 1,51 for each decade; 95% CI 1,08-
2,11), myelitis (HR 2,72; 95% CI 1,05-7,05) or multifocal first 
clinical event (HR 3,34; 95% CI 1,20 - 9,35), ratio of NTM (HR 
0,04; 95% CI 0,01-0,30) and being under disease-modifying ther-
apy (HR 0,31;
95% CI 0,15-0,64) were the only factors associated with progres-
sion to an EDSS score of 6.
Conclusion: We could not found any study using the new criteria 
for NMOSD to study their prognosis. Hence, comparisons are dif-
ficult to make and conclusions difficult to draw. However, our 
patients seem to have a worse outcome, even with broad criteria 
that include subtypes of patients with a better prognosis.
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Is there any relation between tumefactive demyelinating 
lesions and antibodies against MOG and AQP4?
A. Altintas1, T. Takahashi2, A. Siva1, S. Saip1, U. Uygunoglu1, 
C. Yalcinkaya1, K. Fujihara2
1Istanbul University, Istanbul, Turkey, 2Tohoku Medical and 
Pharmaceutical University, Sendai, Japan
Background: Tumefactive demyelinating lesion (TDL) is a rare 
form of demyelinating disorder, which recently has received more 
attention. TDL is defined as a demyelinating lesion larger than 2 
cm. In most cases, although TDL represents a form of multiple 
sclerosis(MS), according to current knowledge TDL refers a het-
erogeneous group of inflammatory central nervous system demy-
elination. The pathogenesis of TDL is unknown. But, recent case 
reports demonstrated the presence of aquaporin 4(AQP4) IgG in 
cases with TDLs.
Objective: To reveal if there is any relation between the occur-
rence of TDL and antibodies against myelin-oligodendrocyte 
glycoprotein(MOG) and AQP4.
Methods: All patients were seen in Istanbul University Cerrahpasa 
School of Medicine Neuroimmunology Unit. Twenty-four patients 
with TDL which larger than 2 cm were included. All serum sam-
ples were analyzed at Tohoku University. The cell-based assays 
(CBA) were used to test AQP4 and MOG antibodies.
Results: Most of the patients were female (17 female). The 
mean age of the patients was 34.26 (range:16-56). The mean 
age at the time of first symptom was 27.66 (range: 11-40). No 
patients were receiving any treatment such as natalizumab or 
fingolimod during or before the development of TDL. The 
mean follow-up duration was 46.89 months. During follow-up, 
patients with TDL either converted to MS or didn’t have any 
further attack. None of them diagnosed as neuromyelitis optica 
or Balo’s concentric sclerosis. All patients with TDL were 
found to be negative regarding to anti-aquaporin-4 IgG and anti 
MOG IgG.
Conclusions: Our study did not reveal any relation between TDL 
and the presence of antibodies against MOG and AQP4.
Disclosure
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Genetic polymorphism of aquaporin-4 gene in neuromyelitis 
optica spectrum disorder
A. Cakar1, H.I. Akcay1, C. Ulusoy2, C.I. Kucukali2, E. Tuzun2, T. 
Gunduz1, M. Kürtüncü1, M. Eraksoy1
1Department of Neurology, Istanbul University, Istanbul Faculty 
of Medicine, 2Department of Neuroscience, Aziz Sancar Institute 
of Experimental Medical Research, Istanbul University, Istanbul, 
Turkey
Background and aim: Neuromyelitis optica spectrum disorder 
(NMOSD) covers a variety of demyelinating autoimmune disor-
ders of the central nervous system (CNS) caused by aquaporin 4 
(AQP4) immunoreactivity at least in a subset of patients. 
Understanding the genetic polymorphisms of patients with 
NMOSD and other demyelinating disorders with resembling clin-
ical phenotypes may disclose its pathogenesis. In this study, we 
genotyped AQP4 gene in patients with NMOSD, relapsing inflam-
matory optic neuropathy (RION), and optico-spinal multiple scle-
rosis (OSMS) and compared clinical and genetic features of these 
disorders.
Methods: We included patients with NMOSD, RION, OSMS, 
and healthy controls in our study. We collected demographic and 
clinical data of the patients and sequenced five exones of AQP4 
gene using Sanger sequencing method.
Results: We recruited 35 NMOSD, 15 RION, 10 OSMS patients, 
and 30 healthy controls in our study. Of the patients, 48 (80%) 
were female and 12 (20%) were male. Age, gender, follow-up 
period, annualized relapse rate, and progression index were simi-
lar between the groups. Cerebrospinal fluid protein levels were 
higher in patients with NMOSD (NMOSD: 50.0+/-33.2 mg/dl, 
RION: 24.2+/-4.9 mg/dl, OSMS: 20.0+/-4.0 mg/dl; p=0.02). 
Oligoclonal band positivity in OSMS patients were more frequent 
compared to other groups (NMOSD: 12.0%, RION: 7.0%, OSMS: 
80.0% p=0.01). Compared to healthy controls, there was no sig-
nificant difference in the frequency of any AQP4 allele in patients 
with NMOSD and OSMS. On the other hand, we detected three 
new single nucleotide polymorphisms in patients with RION.
Discussion: Clinical and laboratory features of NMOSD suggest 
that it is a distinct disorder rather than a spectrum of diseases that 
covers RION and OSMS. Our study did not reveal any allelic dif-
ference in AQP4 gene in patients with NMOSD and OSMS, sug-
gesting that polymorphisms of AQP4 gene are unlikely to confer 
NMOSD susceptibility.
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Neuromyelitis optica phenotype associated with anti-TNF 
therapy in psoriatic arthritis
M. Boaventura1, S. Apóstolos Pereira1, C. Rimkus2, D. Sato1, D. 
Callegaro1
1University of São Paulo, 2University of Sao Paulo, São Paulo, 
Brazil
Introduction: To describe a case of intractable hiccup and vomit-
ing, followed by new retrobulbar optic neuritis that presented 
within 8 years of adalimumab treatment initiation in a patient with 
psoriatic arthritis and prior optic neuritis 4 years ago.
Methods: This case was evaluated with visual field testing, brain 
magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) 
analysis, and laboratory evaluation, and treated with intravenous 
methylprednisolone followed by plasmapheresis.
Results: A brain and orbital MRI showed T2-weigthed hyperin-
tensity of the postrema area and left optic nerve, this with gado-
linium enhancement. CSF findings were 8 cells/µl, with normal 
protein and absence of oligoclonal IgG bands. Serum aquaporin-4 
antibody was negative (analysed by cell-based assays with live 
transfected cells). Our patient made only a partial visual recovery 
and was subjected to treatment with Rituximab.
Conclusion: Optic neuritis is a potentially sight-threatening com-
plication of anti-TNF therapy. This unusual case can suggest an 
additional association: lesion of postrema area and recurrence of 
severe optic neuritis, both considered spectrum of neuromyelitis 
optica’s phenotype.
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Atypical multiple sclerosis and idiopathic inflammatory 
demyelinating diseases in a series of 74 consecutive cases
P. Labauge1, P. Codjia1, X. Ayrignac1, M. Cohen2, C. Carra 
Dalliere1, M. Charif1, A. Lippi1, N. Collongues3, L. Corti1, F. 
Durand Dubief4, J. de Seze3, C. Lebrun Frenay2
1Neurology, CHU Montpellier, Montpellier, 2Neurology, Nice, 
Nice, 3Neurology, Strasbourg, Strasbourg, 4Neurology, Lyon, 
Lyon, France
Objectives: To classify patients with atypical MS findings and 
Idiopathic Inflammatory Demyelinating Diseases (IIDD).
Background: More and more cases have been recognized with 
atypical clinical or MR findings, suggesting atypical MS diagno-
sis or (IIDD).
Material and methods: Since 2007, we conducted a nationwide 
study to collect all the patients with atypical MS / IIDD. Patients 
have been categorized into 6 groups as previously described: cavi-
tary MS (defined by large area of hypointensities within high 
intensities on Flair sequences), solitary sclerosis ( isolated lesion 
involving the upper cervical spinal cord / medulla junction), 
ADEM like lesions (defined by a first clinical episode with MRI 
showing extensive enhanced lesions by gadolinium injection), 
tumoral demyelinating lesion (TDL) (isolated lesion > 20 mm 
diameter of the white matter). Two other IIDD types are identi-
fied: “MS with normal brain MRI” type (defined by a persistent 
normal brain MRI despite clinical temporal and spatial dissemina-
tion) and “pseudo-leukodystrophy MS” (defined by symmetrical 
demyelinating lesions on the initial brain MRI).
Results: 74 patients met the inclusion criteria. Cavitary MS con-
sist of 11 cases (F: 7 / M: 4, mean age of onset: 41.0, range: 
30-52), characterized by a progressive course in 10/11 with a 
mean EDSS score of 6.4 (range 2-8). Solitary sclerosis included 4 
cases (1F / 3M), mean age 32.3 (28-39), TDL group consisted of 
25 cases (19F / 6M), mean age: 34.3 (18-65). During a mean fol-
low of 70.1 (6-181) months, 36 % fulfilled McDonald 2010 MS 
criteria. 76% did not present any clinical relapse. Normal brain 
MR group consisted of 12 cases (F 9/M 3; mean age: 29.3yo, 
range: 12-46). All of them presented spatial and temporal dissemi-
nation, but none fulfilled Wingerchuk 2015 criteria for seronega-
tive NMOSD. Initial symptoms included optic neuritis in 5, 
myelitis in 5 and brainstem related symptoms in 2. 
Pseudoleukodystrophy MS consisted of 10 cases (4F/6M, mean 
age: 35.0 yo, range: 16-47), with a progressive evolution in 7/10 
of these cases and a mean EDSS score of 4.7 (range 0-9). ADEM 
group consists of 12 cases with multiple enhanced lesions. Careful 
analysis of the MRI led to objective a few lesions without gado-
linium enhancement in 11/12 . 9/12 presented occurrence of fur-
ther relapses.
Conclusions: Spectrum of atypical MS and IIDD is enlarged in 
this series. These results lead to extend the previous classification 
of IIDD / atypical MS.
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Atypical myelitis of multiple sclerosis: description of a 
French cohort
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P. Labauge4, X. Ayrignac4, C. Carra-Dalliere4, J. De Seze1, N. 
Collongues1
1Hôpital de Strasbourg, Strasbourg, 2Hopital Pasteur - Service 
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The “atypical” myelitis of multiple sclerosis (MS), are character-
ised by longitudinally extensive myelitis (≥3 vertebral segments), 
transverse myelitis (> 50% of spinal cord in the axial plane), or 
pseudovascular (anterior or central) cord lesions.
This study is observational, retrospective, multicentric, and 
includes incident cases between 2012 and 2017. Sixteen patients 
were included in the University Hospital of Strasbourg, Nice, 
Poitiers and Montpellier in France. We collected demographic 
information, clinical and radiological characteristics of myelitis, 
laboratory results including CSF, brain and spinal cord MRI, treat-
ment, and clinical follow-up.
The aim of this study was to collect atypical cases of myelitis 
related to MS to better characterise this population.
All patients fulfilled 2010 Macdonald criteria without any other 
alternative diagnosis. The mean age of onset was 39,1 +/- 12,4 
years, the sex ratio was 1,6 women for 1 man. The myelitis was 
the first relapse for 12 patients, the second for 2 patients and the 
third for 1 patient. The intrathecal synthesis of immunoglobulin 
was found in all cases. On spinal cord MRI, we observed 3 longi-
tudinally extensive myelitis, 9 transverse myelitis, 3 transverse 
and longitudinally extensive myelitis and 3 patients have an asso-
ciation with a central cord lesion. The median EDSS was 4,75 
[1-8] during the relapse, 4,5 [0-6,5] after 6 months and 3,5 [0-7] 
after 3,9 +/- 3,1 years of follow-up.
Myelitis occurred as a second relapse for 2 patients and 5 patients 
experienced a progressive course of the disease. The small size of 
our cohort is a consequence of the rarity of this clinical manifesta-
tion in MS. These atypical myelitis are the first relapse for 12 of 
16 patients, it seems to be the starter of the pathology in this form.
A better recovery than in the NMO spectrum disorders or systemic 
diseases seems to emerge at the beginning of the pathology but 
also a quicker evolution towards progressive form.
The atypical myelitis are not frequent in MS and seem to be an 
entity which have a medullary tropism, during the first relapse and 
the recurrences.
Disclosure
Nothing to disclose
Paediatric MS
EP1304
Visual pathway changes in children with multiple sclerosis 
and acquired demyelinating disorders
G. Longoni1, A. Oyefiade1, S. Shams1, R.A. Brown2, A. 
Noguera1, S.A. Grover1, C. Wilbur1, M. Wan1, F. Costello3, B. 
Banwell4, R.A. Marrie5, A. Bar Or4, D. Arnold2, D. Mabbott1, 
A. Reginald1, E.A. Yeh1, on behalf of the Canadian Pediatric 
Demyelinating Disorders Network
1The Hospital for Sick Children, University of Toronto, 
Toronto, 2Montreal Neurological Institute and Hospital, McGill 
University, Montreal, 3University of Calgary, Calgary, ON, 
Canada, 4University of Pennsylvania, Philadelphia, PA, United 
States, 5University of Manitoba, Winnipeg, MB, Canada
Background: Cross-sectional studies show structural and func-
tional visual pathway changes in youth with acquired demyelinat-
ing syndromes (ADS).
Objective: To assess longitudinal structural and functional visual 
pathway changes in pediatric MS and monophasic ADS (mono-
ADS), and to determine the relationship of sex to such changes.
Methods: Standard visual assessments including optical coher-
ence tomography (OCT) (Cirrus HD-OCT) and visual function 
metrics (best corrected high-contrast and low-contrast letter acu-
ity, color vision, visual field, visual evoked potentials) were col-
lected prospectively (2010-2017) in children with MS and 
monoADS at variable intervals after incident demyelination and 
after clinical episodes of optic neuritis (ON), if any. Data acquired 
within 90 days from ON were excluded. Changes in structural and 
functional metrics were assessed using joint mixed multivariate 
longitudinal modeling. Results are reported for p< 0.05. No cor-
rection for multiple comparisons was performed given the explor-
atory nature of the study.
Results: We included 42 youth with MS (30f, mean follow-up 
(f-u) (SD) 1.4y (1.3)), and 41 with monoADS (23f, f-u 1.0y (1.3)). 
38% MS and 43% monoADS had no episodes of ON. The first 
year post incident demyelination showed thinning of ganglion 
cell-inner plexiform layer (GCIPL) in males with MS (-25.4 
µm/y) and retinal nerve fiber layer (RNFL) in females with MS 
(MSf) (-11.2 µm/y) and with monoADS (-9.8 µm/y). Thereafter, 
MSf showed milder, progressive RNFL and GCIPL thinning (-1.8 
µm/y and -2.1 µm/y). Greater RNFL and GCIPL thinning was 
seen with increasing ON episodes (avg. -5.5 and -5.3 µm/epi-
sode). MSf with no history of ON had progressive RNFL and 
GCIPL thinning in the first year post incident demyelination 
(RNFL -12.0 µm/y; GCIPL -9.7 µm/y) and afterwards (RNFL -1.7 
µm/y). Analysis of functional metrics showed progressive wors-
ening of color vision in MSf (-0.02%/y), which correlated with 
RNFL (R=0.6) and GCIPL (R=0.4) decreases over time. No sig-
nificant longitudinal changes were detected in other functional 
metrics.
Conclusions: Longitudinal assessment suggests progressive thin-
ning of RNFL and GCIPL in youth with MS, which correlate with 
changes in color vision, and are more pronounced in females and 
in the first year post incident demyelination. Our results, which 
are limited due to the small number of male participants, may 
point to sexual dimorphism in the mechanisms of visual pathway 
damage or repair in pediatric MS.
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EP1305
Gut microbiota function and relapse risk in pediatric mul-
tiple sclerosis (MS): using predictive metagenomics
H. Tremlett1, D.W. Fadrosh2, A.A. Faruqi2, J. Hart2, S. Roalstad3, 
J. Graves2, S. Lynch2, E. Waubant2, on behalf of the US Nework 
of Pediatric MS Centers
1Medicine (Neurology), Faculty of Medicine, University of 
British Columbia, Vancouver, BC, Canada, 2University of 
California, San Francisco, San Francisco, CA, 3University of 
Utah, Salt Lake City, UT, United States
Background: Previous work suggests a role for the gut microbi-
ota in relation to relapse risk in paediatric MS. However, little is 
known about which microbial metabolic pathways might be 
involved.
Objective: To explore the association between the predicted rela-
tive abundances of gut microbial genes encoding metabolic and 
related pathways and relapse risk.
Methods: Children ≤18 years old attending a University of 
California, San Francisco pediatric MS clinic were invited to par-
ticipate. All met McDonald criteria and were within 2 years of 
onset. Stools were shipped on ice and stored at -80C. The 16S 
ribosomal RNA gene was amplified from extracted DNA and 
sequenced via the Illumina MiSeq platform. Predicted function 
was assessed via the validated Phylogenetic Reconstruction of 
Unobserved States algorithm mapped to the Kyoto Encyclopedia 
of Genes and Genomes pathways. Longitudinal follow-up post-
stool sample (‘baseline’) was obtained by mixed methods; both 
prospectively and through retrospective chart review. Assessors 
were unaware of the gut microbiota profiles. Associations between 
11 a priori selected pathways (based on the wider literature and 
categorized as ‘high vs. low’ [≤ vs. > median] relative abundance 
of inferred microbial genes), were assessed in relation to subse-
quent relapse risk using survival analyses. Cox models were 
adjusted for age and disease-modifying drug (DMD) use.
Results: 17 relapsing-remitting MS cases (10 girls) aged 12.5 
years (mean) with a mean disease duration of 10.3 months (range 
2-23) provided stool samples. Eight (47%) were DMD naïve. 
Over a subsequent follow-up of up to 41.6 months (mean=19.8 
months), 7 relapsed. A shorter time to relapse was associated 
with a lower relative abundance of microbial genes related to 
tryptophan metabolism (p=0.011, log-rank test) and higher 
abundances for both biotin metabolism and flavonoid biosynthe-
sis (both p=0.018). After covariate adjustment for age and DMD 
exposure status, only flavonoid biosynthesis remained signifi-
cant, although the 95% confidence intervals were wide (hazard 
ratio=20.3;95%CI:1.3-315.9, p=0.032).
Conclusions: Findings suggest that gut microbiota function may 
be associated with subsequent relapse risk. A high abundance of 
inferred microbial genes encoding flavonoid biosynthesis were 
associated with a shorter time to relapse relative to a child with 
low abundance. Further investigations are warranted.
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Society, and the Race to Erase MS.
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EP1306
Physical activity and its association with white matter integ-
rity and cognitive efficiency in pediatric-onset multiple scle-
rosis
E. De Somma1, N. Akbar2, R. Datta3, E.A. Yeh4, B. Banwell3,4, 
C. Till1,5
1Department of Psychology, York University, Toronto, 2School 
of Rehabilitation Therapy, Queen’s University, Kingston, ON, 
Canada, 3Children’s Hospital of Philadelphia, University of 
Pennsylvania, Philadelphia, PA, United States, 4Department of 
Neurology, 5Neurosciences and Mental Health, Hospital for Sick 
Children, Toronto, ON, Canada
Background: The association of physical activity (PA) on white 
matter (WM) integrity and cognition has yet to be fully described 
in pediatric-onset MS patients.
Objective: To determine whether level of self-reported strenuous 
PA is associated with WM integrity and cognitive efficiency (CE) 
in pediatric-onset MS patients.
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Methods: Participants included 24 pediatric-onset MS patients 
(mean age=18.45±2.76yrs; mean disease duration=53.39± 
32.30mths) recruited from the Hospital for Sick Children (Toronto, 
Canada). Healthy age-/sex-matched controls (HCs) were recruited 
from the community (N=34). Participants completed a neuropsy-
chological test battery from which a CE composite score was 
derived by averaging the z-scores of two processing speed tasks 
(i.e. Symbol Digit Modalities Test [SDMT] and WJ-III Decision 
Speed). Self-reported strenuous PA was calculated based on the 
frequency of strenuous PA engaged in for more than 15 minutes 
per week. WM integrity was evaluated via diffusion tensor imag-
ing (DTI), using tract-based spatial statistics (TBSS). DTI metrics 
(FA, AD, and RD) were extracted for the entire WM matter skel-
eton, and 26 specific tracts. Groups were compared via independ-
ent samples t-tests on CE, PA, and WM integrity. Pearson partial 
correlations (two-tailed, adjusted for age; a=0.01) were conducted 
to examine the association between white matter integrity, CE, 
and self-reported strenuous PA.
Results: Patients had significantly reduced WM integrity relative 
to healthy controls in 21 of 26 interrogated tracts (p< .01). This 
was further exhibited by lower avg-FA, and higher avg-AD and 
avg-RD in the entire WM skeleton (p< .001). CE z-scores did not 
differ between MS and HC, and fell in the age-expected range. 
Mean self-reported strenuous PA did not differ between groups 
(MS:2.66x/week; HC:2.96x/week). CE did not associate with 
indices of WM integrity or self-reported strenuous PA in either 
group. Self-reported strenuous PA also did not associate with WM 
integrity.
Conclusion: DTI metrics are sensitive to disease pathology in 
pediatric-onset MS. This study did not confirm that WM integrity 
is associated with CE; however, this cohort of MS patients was 
relatively cognitively preserved. While no association between 
self-reported strenuous PA and WM was observed, future con-
trolled studies evaluating exercise interventions are required to 
determine whether the integrity of WM can be favorably improved 
in MS patients and positively impact cognition.
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Serum tryptophan is associated with paediatric multiple scle-
rosis onset and disease activity
B. Nourbakhsh1, H. Tremlett2, J. Graves3, J. Hart3, E. Waubant3
1Neurology, Johns Hopkins University, Baltimore, MD, United 
States, 2University of British Columbia, Vancouver, BC, Canada, 
3UCSF, San Francisco, CA, United States
Background: Tryptophan (Trp) metabolites have been shown to 
modulate the immune response in EAE. We sought to determine if 
serum Trp levels are associated with the risk of MS or relapse rate 
in children with MS.
Methods: Paediatric-onset MS and clinically isolated syndrome 
(CIS) patients within 4 years of disease onset and controls < 22 
years old were recruited at UCSF, a tertiary care center. Prospective 
relapse data after enrollment were used. Serum Trp was measured 
using liquid chromatography-mass spectrometry.
We extracted and amplified DNA from available stool samples 
(n=17) and performed 16S rRNA sequencing. We applied a vali-
dated algorithm to enable metagenomic predictions from this 
sequencing data, and drew inferences as to the potential functional 
capacity of the gut microbiota (PICRUSt; Phylogenetic Investigation 
of Communities by Reconstruction of Unobserved States).
Association between serum Trp level and disease risk was 
assessed by a logistic regression model, adjusted for age, sex and 
race/ethnicity. Negative binomial regression models adjusted for 
age, race/ethnicity, sex and disease-modifying therapies were 
used to assess the association between serum Trp levels and 
relapse rate. Association between relative abundance of microbial 
genes involved in Trp metabolism and time to relapse was assessed 
using Kaplan-Meier curves.
Results: Serum Trp was measured in 82 MS/CIS cases and 17 
controls. The mean (standard deviation) of serum Trp level was 
11.0 (2.3) mcg/ml in cases and 12.8 (2.7) mcg/ml in controls. 
Each 1 mg increase in serum Trp level decreased the odds of hav-
ing MS by 24% (95% CI: 4% - 40%, p=0.024). There was no 
association between serum Trp levels and relapse rate in male 
patients, while each 1 mcg/ml increase in serum Trp in female 
patients was associated with a 26% decreased in the relapse inci-
dence rate ratio (IRR: 0.74, 95% CI: 57% - 97%, p=0.026). 
Patients with a lower relative abundance of microbial genes 
involved in Trp catabolism had a shorter time to relapse during 
follow-up than those with higher abundance (log-rank test 
p=0.011, ≤ vs. > median relative abundance).
Conclusion: Higher serum Trp levels are associated with lower 
risk of developing MS in children and lower relapse rate in female 
patients with paediatric MS. Trp metabolism by gut microbiota 
may be involved in this process. Additional case and control sam-
ples are being tested.
Disclosure
Authors report no potential conflict of interest related to this work.
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Epidemiological aspects of childhood MS in Iran
S. Izadi, M. Sharifian Dorche, M. Nidavody
Clinical Neurology Research Center, Department of Neurology, 
Shiraz University of Medical Sciences, Shiraz, Islamic Republic 
of Iran
Introduction: Childhood multiple sclerosis (early-onset multiple 
sclerosis) approximately incorporates 3-5% of the MS population. 
In this study we tried to investigate prevalence, incidence and epi-
demiological aspects of childhood MS in last decade in Fars, 
southern Iran.
Patients and methods: During a retrospective study between 
2005 to 2016 all patients with childhood MS (onset before age 16) 
were in enrolled in the study. Prevalence, Incidence, demographic 
data, primary clinical presentation and month of birth of all 
patients were collected via a data gathering form. Statistical anal-
ysis was performed under supervision of statistical specialist.
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Results: In this duration overall 209 patients with childhood MS 
were diagnosed. Prevalence of Childhood MS was 4/24(Per 
100.000) and mean incidence in this duration was 0.85 (Per 
100.000 in each year). The incidence rate increased significantly 
from 2005 to 2016 (P value < 0.01).
13.4% (28 Patients) were boys. Mean age of the patients at the 
time of diagnosis was 14.02 years
(± 2.8) (Range: 1 to 16 years). Mean age of diagnosis in boys was 
12.64 ± 4.24 and in girls was
14.24 ± 2.45 years. The difference between the age of diagnosis in 
girls and boys was statistically significant. (P value: 0.005) Only 
6% of patients had < 10 years in the time of diagnosis. Optic 
Neuritis was the most common initial presentation in our patients. 
(37%).
Discussion: Here we showed that Childhood MS in Iran is not a 
rare condition especially in the girls and the incidence rate 
increased recently. Nowadays, Prevalence is similar to the west-
ern countries. Clinical suspicious is very important for correct and 
early diagnosis.
Keywords: Childhood MS, Iran, Epidemiology
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CSF kappa free light chains in early-onset multiple sclerosis
A. Emersic1, N. Bizjak2, U. Rot1
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2Department of Child, Adolescent& Developmental Neurology, 
University Medical Center Ljubljana - University Children’s 
Hospital, Ljubljana, Slovenia
Background: Inflammatory patterns in cerebrospinal fluid (CSF) 
are fully evolved already at the first clinical manifestation of mul-
tiple sclerosis (MS), therefore CSF analysis may help considera-
bly in establishing correct diagnosis in childhood or adolescence. 
CSF specific oligoclonal bands (OB) demonstrate comparable 
diagnostic sensitivity in early and adult-onset MS, however result 
is only qualitative and rater-dependent. Measurement of kappa 
free light chains (KFLC) could provide a faster and easier to 
standardize tool but was not yet performed in paediatric MS.
Objective: In our study we aimed to evaluate the diagnostic sig-
nificance of CSF KFLC in paediatric MS.
Methods: CSF and serum samples of paediatric patients with MS 
(n = 18, 15 girls) and other non-inflammatory neurological disor-
ders (n = 9, 5 girls) were analysed. Median age at the time of spi-
nal tap was 16 years (range 13-17) in the MS group and 13 years 
(range 7-17) in controls who presented mainly with headache syn-
dromes. KFLC concentrations were measured by nephelometry, 
using monoclonal antibody immunoassay. The presence of OB 
was determined with agarose isoelectric focusing followed by 
alkaline phosphatase immunoblotting.
Results: Eighty-nine percent of our MS patients had CSF specific 
oligoclonal bands. CSF KFLC concentrations were higher in MS 
patients with a median 2.7 mg/l (range 0.1 - 19.4 mg/l) compared 
to the controls median 0.1 mg/l (range 0 - 1.1 mg/l); p < .0001. 
Diagnostic sensitivity of CSF KFLC concentration was 83% if the 
cut-off 0.3 mg/l derived from our previous adult-onset MS data 
was used. Diagnostic specificity of OB was 100% and 89% for the 
CSF KFLC concentration. CSF KFLC to total protein ratio, which 
roughly accounts for brain CSF barrier integrity, demonstrated the 
same diagnostic accuracy as KFCL concentration with a median 
1.0% (range 0.02% - 5.5%) in young MS compared to 0.03% 
(range 0.02% - 0.26%) in the control group (p < .0001).
Conclusion: Our results show the relevance of KFLC as a diag-
nostic biomarker in the early MS. Study in a larger paediatric 
cohort is needed to investigate the age-related differences in CSF 
concentrations and to elucidate characteristics in other demyeli-
nating disorders. Quantitative differences in CSF KFLC levels 
among the young and adult onset MS patients may require adjust-
ment of the optimal cut-off value.
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Natalizumab treatment in pediatric multiple sclerosis 
patients does not affect pubertal and developmental genes
M. Gurevich, B. Robinson, S. Menascu, D. Magalashvili, A. 
Achiron
Sheba Medical Center, Ramat Gan, Israel
Background: Natalizumab treatment in pediatric multiple sclero-
sis (MS) population has a good efficacy reducing relapse rate and 
disability progression. However, the effect of Natalizumab on 
children puberty and development is not fully covered.
Objective: To determine whether Natalizumab treatment affects 
the expression of age, gender and Tanner developmental stage 
related genes.
Methods: Peripheral blood mononuclear cells (PBMC) were 
obtained from pediatric MS patients at baseline and at one year of 
Natalizumab treatment. Gene expression microarray analysis 
using Affymetrix Inc. technology (HU-133A-2 microarrays) was 
performed. Transcriptional changes associated with Natalizumab 
treatment and patients´ age, gender and Tanner developmental 
stages were analyzed by weighted gene co-expression network 
analysis (WGCNA) software. This method creates clusters of 
highly correlated genes which can be related to treatment and chil-
dren developmental external traits. Biological functional analysis 
was performed by Ingenuity software.
Results: Gene expression data of 10 pediatric MS patients, 6 
females, age 13.9±0.6 years, disease duration 1.5±0.3 years and 
Tanner scale measurements ranging from pre-adolescent to fully 
mature morphology, demonstrated a network of 722 coordinately 
changing genes organized in 3 WGCNA modules induced by 
Natalizumab treatment (p< 0.05). This signature was associated 
with differentiation of pre-B-Cells (p=3.05E-09) and B-Cells 
(5.34E-07), proliferation (p=4.23E-06) and expansion 
(p=1.04E-04) of B-Cells, similarly to Natalizumab molecular 
effects in adult MS patients. Age, gender and Tanner stage were 
associated with two modules each, all distinct from Natalizumab-
induced modules. No significant correlations were found between 
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Natalizumab induced gene-modules and age, gender and Tanner 
stage related traits.
Conclusion: Natalizumab treatment in pediatric MS population 
does not affect pubertal and developmental genes.
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EP1311
Five-year follow-up of pediatric onset Neuromyelitis Optica 
Spectrum Disorders (NMOSD)
R.B. Paolilo1, J.A. Paz1, S.L. Apostolos-Pereira1, C.D.M. 
Rimkus1, A.L.P.C. Araujo1, L.M.G.D.B. Ventura1, M.S. 
Pitombeira1, A.B. Gomes1, A.D.M.B. Matos1, P.H.B. Torretta1, 
U.C. Reed1, D. Callegaro1, D.K. Sato2
1University of Sao Paulo, São Paulo, 2Pontifical Catholic 
University of Rio Grande do Sul, Porto Alegre, Brazil
Introduction: NMOSD is an inflammatory central nervous sys-
tem condition mediated by serum aquaporin-4 immunoglobulin G 
antibody (AQP4-IgG). After knowledge of importance AQP4 IgG 
new diagnostic criteria to adult NMOSD has been described. 
Pediatric onset NMOSD is rarely described and long-term follow 
up are missing. The present report aim to describe a long-term 
follow-up pediatric onset NMOSD using the International Painel 
of NMO Diagnosis (IPND) updated in 2015.
Method: We assessed all patients enrolled in our neuroimmunol-
ogy service from January 2005 to April 2017 whose NMOSD 
symptoms began before 18 years-old and met the updated 2015-
IPND diagnostic criteria.
Results: from 375 patients with NMOSD, 16 were pediatric cases 
(4,2%). There were 2/16 males, 4/16 caucasian and 12/16 of 
mixed ethnic background. Three patients had previous infectious 
disease. Two patients had other autoimmune conditions. Median 
age at onset was 11(6-18) years. Presenting symptoms were optic 
neuritis (9), myelitis (4) and acute brainstem syndrome (3). 
Median time to the second relapse was 6(1-36) months. Median 
annualized relapse rate was 1relapse/year. The main relapse syn-
dromes were: optic neuritis (45), myelitis (36), brainstem (5), area 
postrema (2) and diencephalic (1). Eleven (68,8%) patients were 
AQP4-IgG positive. Thirteen patients had abnormalities in the 
cerebrospinal fluid but none had positive oligoclonal bands. MRI 
findings were compatible with NMOSD in all patients. No patient 
full field Mcdonald-2010 Multiple Sclerosis criteria. All patients 
were acutely treated with methylprednisolone, followed by plas-
mapheresis (8), cyclophosphamide (6) and immunoglobulin (3). 
The median relapse number prior to maintenance treatment intro-
duction was 2(1-6). Patients were first treated with azathioprine 
(14) or mycophenolate (2). Five patients switched azathioprine to 
mycophenolate (4) or rituximab (1), due to relapses. Median 
EDSS of 3.5(1-8) after 5(1-17) years of follow-up. Eleven patients 
had visual acuity less than 20/200 in the worst eye.
Conclusion: Our results confirm literature emphasizing optic neu-
ritis as mainly inaugural presentation in pediatric NMOSD. This is 
the first long term follow up of pediatric NMOSD using 2015-
IPND criteria showing a higher disability than previous report.
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EP1313
Body Mass Index multiple sclerosis trajectories in paediatric
J.N. Brenton, E. Woolbright, M.D. Goldman
University of Virginia, Charlottesville, VA, United States
Background: Obesity is a recognised risk factor for the develop-
ment of paediatric multiple sclerosis (MS). Obesity is associated 
with an increase in pro-inflammatory adipokines and also contrib-
utes to vitamin D deficiency. The aim of this study was to assess 
the trajectories of body mass index (BMI) in paediatric MS 
patients both prior to and post MS-onset.
Design and methods: A retrospective chart assessment was com-
pleted on 27 paediatric MS subjects and 100 healthy controls. 
Height and weight trajectories were collected on paediatric MS 
subjects prior to, at, and post-MS diagnosis. Paediatric MS sub-
jects were excluded if disease duration was less than 2 years at the 
time of data collection. In addition, clinical demographics (age of 
first symptom, race/ethnicity, age of puberty, and Expanded 
Disability Status Scores (EDSS)) were collected. BMI categories 
were classified by the Center for Disease Control (CDC) growth 
charts with dependence upon subject age and sex.
Results: Of the 27 paediatric MS subjects, 33% were of normal 
BMI, 41% were overweight, and 26% were obese at the time of 
the first symptom of MS. At 2 years post-diagnosis, 30% of sub-
jects were of normal weight, 30% were overweight, and 40% were 
obese. Of subjects who transitioned BMI categories over 2 years: 
all obese subjects remained obese, 36% (n=4) of overweight sub-
jects became obese, and 11% (n=1) of normal weight subjects 
became overweight. No subject transitioned to a lower BMI status 
within 2 years of disease onset.
Conclusions: Paediatric MS subjects have high rates of being 
overweight or obese at disease onset. Despite low EDSS scores 
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(all scores < 2.0), subjects of normal BMI at diagnosis tend to stay 
within a normal BMI range, whereas a third of our overweight 
subjects transitioned to obesity within 2 years of disease onset. 
Data analysis is ongoing for paediatric MS data prior to MS diag-
nosis in addition to the healthy control cohort.
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EP1314
Pediatric neuromyelitis optica is more severe than pediatric 
multiple sclerosis in Brazilian patients
M.O. Fragomeni, M.F.C.R. Campos, D.B. Bichuetti, E.M.L. 
Oliveira
Neurology, Universidade Federal de São Paulo, São Paulo, 
Brazil
Introduction: Recurrent demyelinating diseases during child-
hood are still a challenge. Pediatric multiple sclerosis (pMS) and 
neuromyelitis optica (pNMO) show some degree of overlapping 
but pNMO seems to be a more disabling disease. Randomized 
controlled clinical trials in children haven’t been published to 
date. However, disease modified drugs (DMD) for MS and immu-
nosuppressive agents for NMO remain the mainstay of the current 
treatment, based on the practice in adult patients.
Objectives: To evaluate the clinical and epidemiological features 
in patients with pediatric MS and NMO and compare both groups, 
in a Brazilian cohort.
Methods: Retrospective review of patients’ files followed at the 
Neuroimmunology Clinic - Universidade Federal de São Paulo, 
Brazil, from 2005 to 2016, fulfilling the 2010 McDonald criteria 
for MS and the 2006 criteria for NMO with onset before 18 years. 
Statistical analysis was performed using chi-square, Fisher’s exact 
test or Wilcoxon sign test when appropriate. The Kaplan-Meier 
method was used for estimating the time to reach EDSS 6. Data 
are presented as median and mean ± standard deviation and sig-
nificance was set at P ≤ 0.05.
Results: Sixty-eight patients fulfilled the inclusion criteria for MS 
and 11 for NMO. The female:male ratio was 2,8:1 and 2,6:1 for 
MS and NMO, respectively. The mean ARR was 0.82 (±0.8) for 
MS and 1,5 (±1.8) for NMO; the mean PI was 0.31 (±0.4) for MS 
and 2.2 (±4.2) for NMO. Analyzing the number of relapses after 
and before the treatment with DMD for MS and azathioprine for 
NMO, both groups presented significant reduction in relapse rate. 
When comparing the groups, patients with NMO had higher 
EDDS on last appointment and they reached EDSS 6 earlier than 
those with MS.
Discussion: Pediatric demyelinating diseases in Brazil are similar 
to the diseases described in other countries with higher preva-
lence. Data suggests that NMO is more severe than MS in adults 
and this study shows that the same happens with pediatric patients. 
DMD treatment was effective in reduce relapse rate in MS and 
standard immunosuppression with azathioprine was effective in 
NMO. Treatment was well tolerated in both groups.
Conclusion: NMO is a more severe disease than MS in children. 
The treatment with DMD or azathioprine was safe and effective in 
the population analyzed.
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EP1315
Educational outcomes in pediatric multiple sclerosis
W. Vargas1, H. Street1, G. Tosto1, J. Sumowski2, V. Leavitt1
1Columbia University Medical Center, 2Mount Sinai School of 
Medicine, New York, NY, United States
Background: Cognitive impairment occurs in 30 to 50% of chil-
dren and adolescents with multiple sclerosis (MS). The conse-
quences of cognitive disability in adults with MS are well 
documented, however, little is known regarding the functional 
impact of cognitive impairment in children with MS. To our 
knowledge, no study has examined the concordance of perfor-
mance on standard neuropsychological measures and academic 
achievement in children with MS.
Objective: To evaluate whether the Symbol Digit Modalities Test 
(SDMT), which is the most commonly used standard screening 
measure of cognition in MS, is related to academic achievement 
in a pilot sample of children and adolescents with MS.
Methods: Three metrics were used to assess academic perfor-
mance in a small cohort of subjects with childhood-onset MS 
(n=11). General academic performance was quantified using 
grade point average (GPA), performance on a New York State 
standardized exam (Regents) and the Woodcock Johnson-III Test 
of Achievement (WJ-III; verbal and math subtests). The SDMT 
was also administered. All GPAs are reported on a scale out of 
100. Normative scores were calculated for each test. Impairment 
was considered z ≤ -1.5 (SDMT), z ≤ -1.5 (WJ-III) and below a 65 
on any Regents exam. A score of 65 is determined by New York 
State as the lowest score meeting competency in the associated 
subject area. Regents results were unavailable for two subjects.
Results: 10 of the 11 MS subjects were female, with a group mean 
age of 16.6 years (±3.0) and a mean grade level of 11.2 (±2.8). 
Mean overall GPA was 82.6 (±12.4). SDMT performance did not 
correspond well with academic performance. 8 participants had 
normal SDMT, of which 4 (50%) were impaired on at least one of 
two WJ-III categories (verbal and math). Of these 8 participants 
with normal SDMT, 3 (38%) scored below 65 on at least one 
Regents exam.
Conclusions: The SDMT, though a widely used screening meas-
ure for detection of cognitive impairment in pediatric MS, is not 
always concordant with academic achievement in this pilot sam-
ple. Future work in larger samples is needed to determine whether 
standard neuropsychological tests adequately capture/predict dec-
rements in academic achievement in children with multiple 
sclerosis.
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EP1316
Ocular flutter as presenting manifestation of pediatric mul-
tiple sclerosis with positive anti-MOG antibodies - a case 
report
M. Breza1, C. Kotsalis2, N. Smyrni2, G. Koutsis1, E. 
Anagnostou1, J. Tzartos1,3, C. Kokkinis4, C. Kilindireas1, A. 
Papavasiliou2
11st Department of Neurology, Eginition Hospital, National 
and Kapodistrian University of Athens, Medical School, Athens, 
2Department of Neurology, Penteli Children’s Hospital, Attica, 
3Tzartos Neurodiagnostics, Athens, 4Department of Radiology, 
General Hospital KAT, Attica, Greece
Introduction: Ocular flutter is an opsoclonic disorder with rapid, 
low-amplitude horizontal saccadic oscillations without inter-sac-
cadic intervals. It has been described in the context of infectious 
diseases, drug toxicity, or paraneoplastic syndromes. The neuro-
anatomical region associated with ocular flutter has not been 
clearly defined. However, in a few cases, cerebellar or PPRF 
lesions have been reported. Ocular flutter has been described once 
in adult-onset Multiple Sclerosis (MS) during disease course. 
However, ocular flutter has never been reported as a presenting 
symptom of MS, particularly pediatric MS with positive anti-
MOG antibodies.
Case report: We describe a 13 year-old girl who presented with a 
5-day history of abnormal ocular movements with concomitant 
blurred vision and involuntary head movements. On neurological 
examination rapid, horizontal saccadic oscillations of low ampli-
tude in association with mild cerebellar signs were found. Brain 
MRI revealed three periventricular and one subcortical non-
enhancing lesion. Furthermore, oligoclonal bands and IgG index 
were negative. The atypical presentation and MRI findings not-
fulfilling Barkhof criteria led to an original diagnosis of “opso-
clonus-myoclonus”. The patient followed the protocol for 
malignancy and was treated with corticosteroids with good 
response. The search for neuroblastoma or other malignancy was 
negative. She remained free of symptoms for the next three years 
until she presented again with the same ocular oscillations without 
any other clinical manifestations. Brain MRI was repeated and 
lesions were now typical for MS. A second LP revealed oligoclonal 
bands in CSF. A diagnosis of MS was made. Further investigations 
included positive serum anti-MOG antibodies and negative anti-
bodies to antigen of neural receptors and glial cells.
Conclusions: Ocular flutter is an extremely rare clinical mani-
festation of MS that can be the presenting feature of the disease. 
The presence of positive anti-MOG antibodies, which is found 
in a minority of pediatric MS cases, is a further interesting 
observation.
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EP1317
Case studies of Rituximab in pediatric patients with multiple 
sclerosis
A. Ulatowska1, K. Sadowski1, K. Kotulska-Jóźwiak1, I. Puzio-
Bochen2, S. Jóźwiak3, K. Tomaszek2
1Neurology and Epileptology, 2Child Neurology and 
Epileptology, Children’s Memorial Health Institute, 3Child 
Neurology, Medical University of Warsaw, Warszawa, Poland
Introduction: Around 3-5 % of multiple sclerosis (MS) cases 
have their first attack during childhood. Some of these patients 
continue to suffer acute relapses and progression of disability 
despite initiating an appropriate treatment, hence, there is justified 
need to introduce new biological therapies in pediatric population. 
Rituximab [Mabthera (R), Roche, Basel, Switzerland] is a mono-
clonal antibody directed against the B cell marker CD20, and was 
found quite successful in treatment of MS in adults.
Patients and methods: We report four cases of pediatric patients 
with MS, who were treated with Rituximab. Clinical outcome as 
well as safety profile of treatment were assessed.
Findings: Median age at disease onset was 13.7 years. In all 
patients high number of the lesions was found in MRI. The treat-
ment with Rituximab was initiated 3, 4, 8 or 36 months after dis-
ease onset (median age 14.8). In two cases Rituximab was the first 
line of the treatment due to rapid progression of disease in the 
clinical status and MRI images. In other case, despite application 
of intravenous immunoglobulin, another relapse occurred within 
one month and Rituximab was introduced. In the fourth case, both 
interferon beta-1b and glatiramer acetate were tested sequentially, 
however, none of them stopped progression of disease and con-
secutive attacks. Finally, Rituximab was administrated 3 years 
after MS onset. In three patients no progression of MS was found 
in MRI images one or two years after administration of Rituximab 
(500 mg in a single dose). In one case progression of MS was 
observed in MRI after three months. Because of deep depletion of 
B-lymphocytes in all patients, further doses of Rituximab were 
not administrated.
In three patients a stabilization of clinical status was achieved 
despite the initial rapid progression.
Conclusions: This case series indicates that Rituximab may be a 
promising and effective complement to currently established 
treatment of MS in pediatric patients not responding to conserva-
tive therapy. Further research is required.
Disclosure
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Depression and physical performance in pediatric onset MS 
patients
C. Bauer1, H. Li2, M. Rensel3
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Objective: To describe depression in Pediatric onset MS (POMS) 
patient and determine whether it associate with physical 
performance.
Background: POMS has been shown to lead to significant disa-
bility. Patient reported outcome (PRO) measures in POMS have 
been shown to be associated with disease duration in small series 
but require validation in longitudinal studies. We aim to determine 
association between depression and physical performance and 
potentially reduce disease progression.
Design/methods: POMS patient charts were reviewed for demo-
graphics, clinical characteristics, PRO and functional outcome 
(FO). Patients’ demographics, FO and PRO were compared 
between nonslow and SG (if 7 or more seconds). Both 9 hole peg 
test (9HPT) and timed 25 foot walk (T25FW) were examined for 
its associations with clinical depression parameters.
Results: A total of 44 POMS patients’ charts were reviewed, over-
all median (IQR) PHQ9 score was 4.0 (1 to 7), 38.6% was 
depressed Patient health questionnaire (PHQ9>4), 18.2% had 
T25FW 7 or higher and 37.5 % of the SG group required assis-
tance with gait and 25% needed assistance with transfers. Both 
PHQ9 (Spearman r=0.46, p=0.002) and Euro Qol five dimension 
questionnaire (ED5Q) [r=-0.40, p=0.07] were moderately associ-
ated with T25FW, and EQ5D was moderately associated with 
both non-dominant (r=-0.43) and dominant 9HPT (r=-0.32). Age 
of onset, gender, and race and disease course was not associated 
with SG. In addition to older age (Median 33 vs. 21 years), longer 
disease duration (17.5 vs. 5.9 years) were found in SG group, 
PHQ9 (6.5 vs 3.0) was also higher in SG, 62.5% in SG and 33.3 in 
non-SG were depressed (PHQ9>4).
Conclusions: POMS patients commonly had both depression and 
gait disorder. In addition to age and disease duration which are not 
modifiable, modifiable psychological status may contribute to 
quality of life in POMS. POMS rehab may need to consider psy-
chology treatment.
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Longitudinal evaluation of cognitive, academic, and adaptive 
functioning in pediatric MS
K.D. Evankovich1,2, K. Kingery1, N. Shukla2, T.E. Lotze2
1Pediatrics - Psychology, 2Pediatrics - Neurology, Baylor 
College of Medicine/Texas Children’s Hospital, Houston, TX, 
United States
Objective: To assess changes in cognitive, academic, and adap-
tive functioning in pediatric onset multiple sclerosis (POMS). 
Studies demonstrate early weaknesses in attention and fine motor 
ability but investigations of functional outcomes including aca-
demic and adaptive functioning are limited.
Methods: 18 children/adolescents with POMS underwent initial 
and follow-up neuropsychological evaluations. Impairment was 
defined as > 1 standard deviation below published normative data. 
72 percent were female. Ethnicity was 39% Hispanic, 28% 
African American, 33% Caucasian. Mean age of onset was 12.6 
years. Mean time from symptom onset to initial neuropsychologi-
cal evaluation was 1.36 years ± 1.2 and 3.2 ± 1.2 years at follow-
up. Minimal physical disability accrued from initial evaluation 
(mean EDSS = .44) to follow-up (mean EDSS = .35). All received 
disease modifying therapy.
Results: Consistent with the literature, cognitive impairment rate 
was 33% initially and at follow-up. Mild impairments were noted 
in visual-motor integration (initial SS = 80 ± 16, follow-up SS= 
75 ± 12) and attention (initial T = 61 ± 30, follow-up T = 62 ± 
17.6).
Parents reported inattention (initial T = 62 ± 8; follow-up T= 64 ± 
6.2) and lower adaptive functioning (initial SS = 82 ± 10, follow-
up SS = 81.9 ± 12.5).
Multiple regression analysis revealed that 86 percent of the vari-
ance in adaptive functioning was accounted by a model including 
self-report anxiety/depression, attention, and fine motor ability 
(F= 6.4, p = .04).
Conclusion: Consistent with the literature, early weaknesses in 
attention and visual-motor ability were noted and remained stable. 
Academic functioning remained in the Average range, despite mild 
cognitive weaknesses and increased school absences. Adaptive 
functioning was below age-expected levels early and remained low 
at follow-up. Adaptive functioning was predicted by self-report of 
anxiety/depression, attention, and fine motor ability.
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Characteristics of pediatric multiple sclerosis in the west of 
Algeria
Z. Barka Bedrane, S. Allal, A. Reguig, K. Saadi, C. Louhibi, O. 
Dendene, M. Boujelal, A. Merad, D. Bouchenak Khelladi
Universite Abou Bekr Belkaid, Tlemcen, Algeria
Introduction: Multiple sclerosis (MS) is a disease of young 
adults, but its onset in
Childhood is frequently observed. In recent years a number of 
Number of networks participated in advancing the management of 
this disease in the child.
Objectives: Describe the clinical, paraclinic characteristics of 
pediatric MS.
Appreciate the response to different treatments.
Describe the evolution and compare it to adult onset.
Patients and methods: Prospective and retrospective study of 
MS patients with baseline age less than 18 Years. The positive 
diagnosis was made according to McDonald´s criteria. Cerebral 
and spinal cord was performed with cerebrospinal fluid study.
Was appreciated by the EDSS. The substantive treatment was pre-
scribed according to the clinical form.
Results: We collected 25 patients. The sex ratio (F / H) 3.3. 
Average starting range was
15 ± 4.38 years. The mono symptomaticonset was the most fre-
quent (76.6%).cerebral MRI showed hypersignals peri ventricular 
(91%), cerebellum and corpus callosum (38% and 36%). Interferons 
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were prescribed in 76%, Natalizumab in 9.5%. The reccurent-
remitting form was observed in 87.5%. The current EDSS of 
patients is between 4-6 in 28.5% and greater than 6 In 19%. The 
median time to reach EDSS 6 in our patients was 8.27 -10.68 years 
where as in the adult form it was 12.17 - 13.24 years.
Conclusion: During childhood MS, functional and cognitive 
dysfunction
Interferes with academic achievement. Start treatment as early as 
possible
Could improve the quality of life of young patients.
Disclosure
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Risk of transition to secondary progressive multiple sclerosis 
and accumulation of disability in progressive multiple sclero-
sis are not influenced by current therapies
C. Alcalá1, F. Gascón2, F.-C. Pérez-Miralles1, M. Escutia1, F. 
Coret2, B. Casanova1
1Hospital La Fe, 2Hospital Clínico, Valencia, Spain
Objective: Current approved disease modifying therapies (DMTs) 
are effective to prevent relapses but are not effective to arrest the 
accumulation of disability once the progressive phase of MS 
(SPMS) have started. Phase III trials in relapsing-remitting multi-
ple sclerosis (RRMS) are not long enough to answer whether 
DMTs have an influence in reaching SPMS or in the long-term 
course of the disease. The objective of this study was to evaluate 
if current DMT are preventing the transition to SPMS or changing 
the evolution of the progressive phase of these patients.
Methods: RRMS patients later diagnosed of SPMS, followed in 
the MS Unit of two tertiary hospitals,
(La Fe and Clinic, in Valencia, Spain), since the first relapse of the 
disease to the present, were selected. All patients received DMTs 
after a definitive diagnosis of RRMS. A second cohort of primary 
progressive multiple sclerosis (PPMS) patients were selected. Age 
at disease onset, type of DMTs administrated, basal EDSS, time to 
SPMS diagnosis and time to reach an EDSS of 3.0, 6.0, 8.0 and 
10.0 was recorded. A comparison of the age and the time to reach 
a fixed disability for all groups was done by the Kaplan-Meier 
survival analysis. A Cox regression multivariate analysis in order 
to explore predictive variable of progression was realized.
Results: A total of 204 RRMS patients were selected and 77 
(37.7%) of them were diagnosed of SPMS. A second cohort of 
139 PPMS was selected, so a total of 217 progressive MS (PMS) 
were followed-up for a mean time of 16 years (sd 7.3). SPMS 
patients were all treated with first-line DMTs and 47 of them 
(61.0%) with second line therapy because of treatment failure. 
The mean time under treatment was of 12.9 years (sd 5.0). 
Progressive MS was initiated at a mean age of 42.7 year, without 
significant differences between PPMS and SPMS. Reaching an 
EDSS score of 3.0 in less time predicted a worse evolution in 
SPMS. Mean time to reach an EDSS score of 6.0, 8.0 and 10.0 
was 8.8, 13.1 and 15.4 years respectively, without differences 
between SPMS and PPMS.
Conclusion: The course of progressive MS (SPMS and PPMS) is 
very homogeneous, independently of has received current treat-
ments from first relapse in SPMS form. Treatment could prevent 
disability related to relapses but has a limited influence to prevent 
the transition to SP or to modify the posterior evolution.
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The Bayesian Risk Estimate at Onset (BREMSO) correlates 
with cognitive and physical disability in patients with early 
multiple sclerosis
M. Said1, N. El Ayoubi1, S. Hannoun1,2, B.I. Yamout1, R. 
Haddad1, L. Saba1, Y. Jalkh1, S.J. Khoury1,2
1Nehme and Therese Tohme MS Center, 2Abu-Haidar 
Neuroscience Institute, American University of Beirut, Beirut, 
Lebanon
Background and purpose: Prevention of long-term disability is 
the goal of therapeutic intervention in relapsing remitting multiple 
sclerosis (RRMS). The Bayesian Risk Estimate for MS at Onset 
(BREMSO) was designed to give an individual risk score predict-
ing disease evolution into Secondary Progressive MS (SPMS). 
The aim of this study is to investigate whether BREMSO corre-
lates with physical disability, cognitive dysfunction, and regional 
brain atrophy during the early disease course.
Method: We investigated 100 patients with RRMS or clinically 
isolated syndrome (CIS) enrolled in the AUBMC Multiple 
Sclerosis Interdisciplinary Research (AMIR) study, with at least 
two years of follow-up and disease duration of less than six years. 
BREMSO score was calculated for all participants at disease 
onset. At each visit, cognitive function was assessed using the 
Symbol Digit Modalities Test (SDMT) and physical disability 
using the Multiple Sclerosis Severity Score (MSSS), Timed 
25-Foot Walk Test (T25-FW) and 9-Hole Peg Test (9-HPT). Out 
of the 100 patients, 30 had a baseline MRI performed at the radiol-
ogy department of the AUBMC. 3DT1 with gadolinium injection 
and 3DFLAIR images were acquired. The intra cranial volume 
(ICV) as well as the subcortical gray matter structures and the 
corpus callosum (CC) were automatically segmented and their 
volumes measured.
Results: The mean (SD) age was 28.1 (11.19) years, MSSS 3.17 
(2.36) and disease duration was 2.4 (1.78) years. In multivariate 
linear regression analyses, controlling for age and education, the 
BREMSO score correlated negatively with SDMT at visit 1 (β=-
0.33 p=0.019), visit 2 (β=-0.34 p=0.017), and visit 3 (β=-0.34 
p=0.014). BREMSO correlated positively with MSSS at visit 1 
(r=0.38, p=0.006), visit 2 (r=0.47, p< 0.0001), and visit 3 (r=0.42, 
p=0.002), but did not correlate with T25-FW and 9-HPT. MRI 
results showed a negative correlation between the BREMSO 
score and the CC volume at baseline (p< 0.03). No correlation was 
found between the BREMSO score and the intracranial volume 
and the subcortical gray matter structures volume. This can be due 
to the small sample size or short interval follow up.
Conclusions: The BREMSO score is directly correlated not just 
with the physical progression of the disease (MSSS) but also with 
the cognitive disability (SDMT and CC volume measurements) 
in early MS. Future studies might incorporate MRI measures into 
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the BREMSO score increasing the sensitivity and specificity of 
this score.
Disclosure
All authors have no conflict of interest to disclose.
EP1323
Prognostic value of cerebrospinal fluid kappa and lambda 
free light chains in clinically isolated syndrome in Argentina
J.I. Rojas1, C. Azcona1, J. Miguez1, L. Patrucco1, E. Cristiano1, 
M.V. Lorenzon2, P. Sorroche2, M.S. Sáez2
1Centro de Esclerosis Multiple de Buenos Aires, Hospital 
Italiano, 2Laboratorio Central, Hospital Italiano de Buenos 
Aires, Buenos Aires, Argentina
Cerebrospinal fluid (CSF) immunoglobulin free light chains (FLCs) 
have been suggested to provide prognostic information in clinically 
isolated syndrome (CIS). The objective of this study was to assess the 
prognostic value of FLCs in patients with CIS suggestive of multiple 
sclerosis (MS) in a group of patients from Buenos Aires, Argentina.
Methods: Paired CSF and serum samples from 36 patients present-
ing with CIS were collected between 2014 and 2017. CSF and serum 
kappa (K) and lambda (L) FLC concentrations were measured using 
the FLC immunoassay Freelite™(The Binding Site, Birmingham, 
UK) on a SPAPLUS analyzer. Demographic and clinical data was 
recorded, and mainly included time between CIS diagnosis and con-
version, and the degree of disability (determined by the EDSS scale). 
MRI at baseline and follow-up (every 12 months) was evaluated to 
determine the percent brain volume change (PBVC) as a measure of 
brain atrophy. FLC concentrations were compared in CIS-MS con-
verters vs. CIS non-converters and expressed as median±SD and the 
correlation between FLC and PBVC was assessed by binary logistic 
and Cox regression analyses.
Results: A total of 36 patients were included, median age 37±4 
years, median follow-up time 28 ±9 months, during which 22 
(61.1 %) patients converted to MS. The median concentration of 
FLCs at CIS diagnosis was slightly higher in CIS-converters com-
pared to non-converters, but this did not reach statistical signifi-
cance (KFLC: 7±5.3 mg/L vs. 5±2.3 mg/L, p= 0.11; LFLC: 
0.7±0.33 mg/L vs. 0.5±0.23 mg/L p=0.16). A strong inverse cor-
relation was observed between the concentration of K and LFLCs 
at diagnosis and the change in PBVC during follow-up (r= - 0.72 
and r= - 0.65, respectively).
Conclusion: FLC concentrations at CIS diagnosis were not sig-
nificantly higher in CIS-converters compared to CIS non-convert-
ers, but patients with higher CSF FLC concentrations tended to 
have increased brain atrophy during follow-up.
Disclosure
No funding
EP1324
Prognostic factors related to the severity of multiple sclerosis 
in the Japanese population
H. Houzen1, H. Sato2, K. Kondo3, M. Niino4
1Department of Neurology, 2Department of Pharmacy, Obihiro 
Kosei General Hospital, 3Hokuto Hospital, Obihiro, 4Hokkaido 
Medical Center, Sapporo, Japan
Background: We previously reported that the prevalence and inci-
dence of multiple sclerosis (MS) in Tokachi province, northern 
Japan, have increased in the last15 years; accordingly, there have 
been changes in the clinical characteristics of patients with MS.
Objectives: To clarify the prognostic factors of MS in the 
Japanese population in Tokachi province using data obtained from 
4 epidemiologic studies in the last 15 years.
Methods: Beginning in 2001, we have conducted prevalence 
studies every five years in the Tokachi province of Japan contain-
ing relevant clinical data for all included patients. Poser’s criteria 
were used for diagnosis of MS in the four studies. The Expanded 
Disability Status Scale (EDSS) and Multiple Sclerosis Severity 
Score (MSSS) were used to evaluate disease severity and disabil-
ity progression, respectively. In our 2016 survey, MS patients 
were divided into two groups: the mild progression group (MSSS 
< 3) and the non-mild progression group (MSSS >3).
Results: The MS prevalence and female/male ratio in Tokachi 
province increased from 8.1/100,000 (95% confidence intervals 
[CI] 5.4-11.7) and 2.6 in 2001 to 18.6/100,000 (95% CI 14.3-23.8) 
and 3.6 in 2016, respectively. Conversely, mean/median EDSS 
decreased from 3.0/2.3 in 2001 to 2.3/1.0 in 2016, respectively. 
Our 2016 surveillance data revealed that the mild progression 
group received fewer treatments with disease-modifying drugs 
(DMDs) than the non-mild group (50% vs 85%, p< 0.05), although 
there was no significant difference in disease duration between 
groups. Based on the multivariate analysis of factors influencing 
the non-mild progression group, male gender (OR 19.0; 95% CI 
2.8-128), older age (OR 1.18; 95% CI 1.06-1.31), and positivity 
for oligoclonal bands (OCBs) (OR 19.1; 95% CI 1.6-233) were 
associated with a higher risk of progression. Age at onset was not 
correlated with disease progression.
Conclusions and relevance: Lower rates of treatment with 
DMDs in the mild progression group suggest that some patients 
do not necessarily need DMDs for good MS prognosis. Our data 
obtained from all MS patients in this cohort demonstrate that gen-
der, birth year, and OCBs may be candidate prognostic factors for 
MS in the population in northern Japan. The increasing preva-
lence of MS in younger female patients may result in an increased 
proportion of patients with mild MS regardless of the use of 
DMDs treatments in northern Japan.
Disclosure
H. Houzen has received funding for travel and/or speaker hono-
raria from Biogen, Mitsubishi Tanabe Pharma Corporation, and 
Takeda Pharmaceutical Company.
H.Sato and K. Kondo reports no disclosures.
M. Niino has received funding for travel and/or speaker honoraria 
from Biogen, Mitsubishi Tanabe Pharma Corporation, and Takeda 
Pharmaceutical Company; is part of a scientific advisory board for 
Biogen and Chugai Pharmaceutical Company; and has received 
research support from Grants-in-Aid for Scientific Research from 
the Ministry of Health, Labor and Welfare of Japan.
EP1325
Utilizing the topographical model of MS to Identify leading 
indicators of progression
S.C. Krieger1, K. Cook2, B.M. Laitman3, M. Fletcher2
1Corinne Goldsmith Dickinson Center for MS, Icahn School of 
Medicine at Mount Sinai, 2MS Working Group, Harrison and 
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Star, 3Neurology, Icahn School of Medicine at Mount Sinai, New 
York, NY, United States
Objective: To demonstrate how the topographical model of MS 
can depict early manifestations of progressive disease utilizing a 
longitudinal clinical cohort.
Background: The topographical model depicts the admixture of 
relapsing and progressive aspects of MS. Central to this model is 
the observation that progression recapitulates a patient’s prior 
relapse symptoms and clinically reveals previously silent lesions, 
incrementally manifesting a patient’s underlying “disease topog-
raphy”. Using this cohort, we have previously demonstrated pro-
tracted diagnostic uncertainty during the transition to SPMS. 
Earlier identification of progressive disease may have implica-
tions for patient care and trial design.
Methods: We examined a subgroup of 10 patients from our pub-
lished longitudinal cohort who transitioned from RRMS to SPMS. 
Neurologic exams were analyzed from all MS relapses during the 
RRMS phase, at time of formal SPMS diagnosis, and at most 
recent clinical visit. Functional Systems (FS) affected, location/
laterality, and extent of recovery were recorded. Given its prognos-
tic significance, the pyramidal/motor system served as the target 
FS for assessment of laterality and severity of symptoms at relapse 
and SPMS timepoints. Each patient’s clinical course was mapped 
using the topographical model disease simulation software.
Results: Our cohort was 80% female, aged 31.6±8.6 years at diag-
nosis, followed for an average of 23.8±8.8 years with a mean of 3.1 
relapses prior to SPMS classification. Symptoms were categorized 
by topographical regions of the model (spinal cord/optic nerve, 
brainstem/cerebellum, cerebral hemispheres). 83.3±0.2% of acute 
relapse symptoms were present at the transition to SPMS, increas-
ing to 91.0±0.2% at most recent visit. These data demonstrate a 
correlation between the topographical distribution of relapse 
symptoms and accumulated deficits from subsequent progression. 
Mapped in the topographical model, above-threshold progressive 
disease became apparent an average of 7.3 years (range 5-11) ear-
lier than the diagnosis of SPMS was applied in practice.
Conclusions: We have demonstrated the model’s utility in depict-
ing patients’ disease topography as the loci of clinical progression. 
We utilize the recapitulation hypothesis to identify leading indica-
tors of progression in individual patients to allow for precise, 
early recognition of progressive disease. Future empirical refine-
ment using large clinical cohorts is planned.
Disclosure
SC. Krieger has received compensation for consulting and advi-
sory board work with Acorda Therapeutics Inc.; Bayer; Biogen; 
EMD Serono (Merck & Co., Inc.); Genentech; Genzyme; 
Mallinckrodt; Novartis; and Teva Pharmaceutical Industries Ltd. 
and has given non-promotional lectures with Biogen.
K. Cook, and M. Fletcher are employees of Harrison and Star, 
LLC, a healthcare communications company, which provided ser-
vices for this project on a pro bono basis.
BM. Laitman has nothing to disclose.
EP1326
Time to, and rate of secondary progression in patients with 
multiple sclerosis: results of a systematic search
V. Khurana1, J. Medin2
1Patient Access Services, Novartis Healthcare Private Limited, 
Hyderabad, India, 2Global Patient Access, Novartis Pharma AG, 
Basel, Switzerland
Objectives: A number of studies have previously described rates 
of conversion from relapsing remitting multiple sclerosis (RRMS) 
to secondary progressive multiple sclerosis (SPMS), and times to 
the onset of secondary progressive disease. However, a compre-
hensive review of all the available evidence base has not been 
undertaken. The objective of this review was to synthesize the 
evidence on disease progression in MS patients.
Methods: A systematic search was conducted on MEDLINE, 
EMBASE, and Cochrane Database of Systematic Reviews using 
the OVID platform to identify the articles reporting clinical course 
of multiple sclerosis. Studies were included that described risk of, 
or time to, conversion from RRMS to SPMS, or from relapsing 
SPMS to non-relapsing SPMS.
Results: In total, 5482 articles were identified and of these, 92 
articles reported findings relevant to progression to SPMS. 
Following an initial relapsing-remitting course, there is a gradual 
increase in the number of patients converting to SPMS, with 
around 25% progressing by 10 years, 50% by 20 years, and more 
than 75% by 30 years. Estimates for the time to SPMS onset had 
significant variation ranging from 5 to 41.8 years, with most stud-
ies reporting a mean age of approximately 40 years at conversion 
to SPMS. Earlier onset of MS is associated with longer time to 
secondary progression, but also with conversion at a younger age. 
Frequent relapses in the relapsing-remitting phase, particularly 
within the first 2 years, correlate with early progression to SPMS. 
No studies described conversion from RRMS to relapsing SPMS, 
or from relapsing SPMS to non-relapsing disease.
Conclusions: Although there are a large number of studies report-
ing data on progression from RRMS to SPMS but there is signifi-
cant variation in the reported data. Further studies may be required 
to understand the transition between RRMS to relapsing SPMS, 
and from relapsing SPMS to non-relapsing disease.
Disclosure
Jennie Medin is an employee of Novartis Pharma AG, Basel, 
Switzerland;
Vivek Khurana is an employee of Novartis Healthcare Private 
Limited, Hyderabad, India.
Funding: This study was funded by Novartis Pharma AG, Basel, 
Switzerland
EP1327
Paroxysmal and unusual symptoms as first clinical manifes-
tation of multiple sclerosis do not indicate benign prognosis 
- the PaSiMS II study
G. Bsteh1, R. Ehling1,2, L.-M. Walchhofer3, H. Hegen1, M. 
Auer1, S. Wurth1, F. Di Pauli1, M. Wagner3, M. Reindl1, F. 
Deisenhammer1, T. Berger1
1Department of Neurology, Medical University Innsbruck, 
Innsbruck, 2Department of Neurology, Clinic for Rehabilitation 
Muenster, Muenster, 3Department of Neuroradiology, Medical 
University Innsbruck, Innsbruck, Austria
Background: Paroxysmal (PS) and unusual symptoms (US) 
account for approximately 1.6% of initial manifestations of 
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multiple sclerosis (MS) and have comparable conversion rates to 
clinically definite MS (CDMS) as classical bout onset symptoms 
(CS). However, long-term prognosis and clinical outcome of 
patients experiencing PS or US as first clinical manifestation are 
unclear.
Methods: Clinical, MRI and cerebrospinal fluid data were 
obtained retrospectively and patients presenting with PS or US 
were compared to patients with CS presentation.
Results: In a cohort of 532 relapsing onset MS patients followed 
for a mean period of 11.4 years (SD 3.6), 10 (1.9%) patients ini-
tially presented with PS/US. PS/US patients received disease 
modifying treatment (DMT) in a significantly smaller proportion 
immediately after the first clinical symptom (30% vs. 61.7%; 
p=0.021) and during the observation period (60% vs. 83.5%; 
p=0.033). In multivariate models correcting for sex, age at initial 
symptoms, complete remission of initial symptoms, total number 
of T2 and contrast-enhancing lesions, presence of oligoclonal 
bands and DMT exposure, PS/US were not associated with lower 
annualized relapse rate or lower EDSS over time.
Conclusion: In addition to a similar conversion rate to CDMS, 
patients presenting with PS/US at disease onset display very simi-
lar relapse and disability rates as patients with CS onset. 
Consequently, initial presentation with PS/US does not indicate 
benign or atypical MS, but requires DMT initiation based on the 
same criteria as in CS patients.
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GB has has participated in meetings sponsored by Biogen, Merck 
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RE has participated in meetings sponsored by and received hono-
raria (lectures and consultations) from Biogen, Merck Serono and 
Teva Ratiopharm, has received grants for educational purposes 
from Biogen, Böhringer Ingelheim, Merck Serono, Novartis 
Pharma GmbH, Ottobock and Teva Ratiopharm, and has received 
honoraria for acting as consultant for Teva Pharmaceuticals Europe.
LMW has participated in meetings sopnsored by Bayer and 
Stryker.
HH has participated in meetings sponsored by, received speaker 
honoraria or travel funding from Bayer Schering, Biogen, Merck 
Serono and Novartis, and received honoraria for acting as consult-
ant for Teva Pharmaceuticals Europe.
MA received speaker honoraria from Novartis.
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or travel funding from Biogen, Merck Serono, Novartis, Sanofi 
Genzyme, Teva Ratiopharm, Allergan, Ipsen Pharma and Roche.
FDP has received speaking honoraria from Biogen-Idec and 
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MW reports no conflict of interest.
MR reports no conflict of interest.
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Biogen, Genzyme-Sanofi, Merck, Novartis Pharma, Roche and 
TEVA.
TB has participated in meetings sponsored by and received hono-
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cal companies marketing treatments for MS: Bayer, Biogen, 
Genzyme, Merck, Novartis, Octapharma, Ratiopharm, Roche, 
Sanofi Aventis, TEVA. His institution has received financial sup-
port in the past 12 months by unrestricted research grants (Biogen, 
Bayer, Merck, Novartis, Ratiopharm, Sanofi Aventis) and for par-
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Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, 
Sanofi Aventis, TEVA.
EP1328
Clinical presentation of clinically isolated syndrome (CIS); a 
long term follow up study in Iranian patients
S. Izadi, M. Ahmadi, M. Sharifian Dorche, A. Nikseresht
Clinical Neurology Research Center, Department of Neurology, 
Shiraz University of Medical Sciences, Shiraz, Islamic Republic 
of Iran
Introduction: In this study we tried to describe the clinical pres-
entation of the patients with CIS in southern Iran and their follow 
up in 10 years.
Patients and method: 143 patients with CIS (124 females and 19 
males) were enrolled in the study. Demographic data, clinical 
presentation and MRI findings of the patients were collected and 
patients were followed for 10 years.
Results: The most common initial clinical presentation was optic 
neuritis (40.6%). After a mean follow-up of 3.4 ±1.1 years, 38/143 
patients (26.6%) had converted to CDMS.
The mean age at diagnosis was lower in CIS patients who con-
verted to MS (27.6 versus 29.4 years), but it was not statistically 
significant (p=0.23).
The conversion rate to CDMS was 49.2% (30/61) for patients who 
had≥3 Brain MRI lesions, but it was 9.8% (8/72) in patients who 
had 3< lesions (OR =8.95, 95% CI=3.69-21.7, p< 0.001).
Conclusion: The conversion rate in this Iranian population was 
similar to Western countries. Also, this study confirms this con-
cept that the number of MRI lesions at baseline can be used as 
strong predictors of CIS conversion to CDMS.
Keywords: Clinical Presentation, Iranian Population, Multiple 
Sclerosis , Clinically isolated syndrome
Disclosure
There is no Conflict of interest.
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The effect of exclusive breastfeeding on postpartum multiple 
sclerosis relapses
N. Sahebi Vaighan1, A. Abadi2, R. Ghozat1, H. Delavar 
Kasmaei3, K. Gharagozli4
1Shahid Beheshti University of Medical Sciences, 2Department 
of Community Medicine, Shahid Beheshti University of Medical 
Sciences, 3Department of Neurology, Shohadaye Tajrish 
Hospital, Shahid Beheshti University of Medical Sciences, 
4Loghman Hospital, Shahid Beheshti University of Medical 
Sciences, Tehran, Islamic Republic of Iran
Importance: The rate of multiple sclerosis relapses increases 
after giving birth. Making decision between starting breastfeeding 
or disease modifying drugs are difficult for most patients.
Objective: To assess if exclusive breastfeeding could reduce the 
risk of postpartum relapse.
Design: 66 women with relapsing remitting multiple sclerosis 
became pregnant during the years 2010-2013 were enrolled in our 
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prospective study .27 patients were excluded because of spontane-
ous abortion. 39 pregnant patients with the mean age of 30.6+_5.1 
were closely followed up in each trimester and 3,6,12,24 and 36 
months after delivery. Disease-modifying drugs were terminated 
in all patients. The effect of exclusive breastfeeding ( no supple-
mental feeding for at least 3 months) was compared on the first 
postpartum MS relapse with non exclusive breastfeeding(partial 
or no breast feeding at all), using Cox proportional hazards regres-
sion model.
Results: Out of 39 patients with full term delivery 27 (69.2%) 
were intended to exclusively breastfeed for at least 3 months and 
12 (30.9%) did not breastfeed at all (25.8%)or included supple-
mental feeding(5.1%). Relapse did not occur during pregnancy.
For those who did not exclusively breastfeed, the chance of expe-
riencing at least one relapse during the first 6 months postpartum 
was 21.66 times(hazard ratio: 21.66, CL: 2.65-177.01, p=0.004).
During the 36 months follow up, those who did not exclusively 
breastfeed were as almost as 2.45 times as likely to have at least 
one relapse in comparison to those patients who had exclusively 
breastfeed. (hazard ratio: 2.541 CL: 1.19-5.40 p=0.015)
Conclusion: In our sample, the women with multiple sclerosis 
could benefit from exclusive breastfeeding in order to signifi-
cantly reduce the rate of postpartum relapses. Encouraging these 
women to exclusively breastfeed could be regarded as one of the 
modalities of treatment and a better approach to the disease.
Disclosure
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The incidence of cognitive impairment among Hungarian 
relapsing-remitting multiple sclerosis patients
D. Sandi1, T. Biernacki1, Z. Fricska-Nagy1, D. Szekeres1, Z.T. 
Kincses1, J. Füvesi1, C. Rózsa2, K. Kása2, J. Matolcsi2, D. 
Zboznovits2, Z. Burány2, É. Langane1, L. Vécsei1,3, K. Bencsik1
1Department of Neurology, University of Szeged, Szeged, 
2Department of Neurology, Jahn Ferenc Dél-Pest Hospital, 
Budapest, 3Neuroscience Research Group, MTA-SZTE, Szeged, 
Hungary
Introduction: Multiple Sclerosis (MS) frequently causes cogni-
tive impairment aside from somatic symptoms, its prevalence 
ranging from 43-70%. Despite its frequency, there is very little 
data on its incidence, and none, utilizing the BICAMS screening 
battery.
The aim of our study was to determine the incidence of cognitive 
impairment among patients with relapsing-remitting (R-R) MS 
and clinically isolated syndrome (CIS) and assess possible pre-
dicting factors.
Patients and methods: We followed-up 242 R-R MS and CIS 
patients after 1 year, treated at the Department of Neurology of the 
University of Szeged and at the Jahn Ferenc Dél-Pest Hospital of 
Budapest from the originally recruited 553 patients. We used the 
BICAMS battery to assess their cognitive state. For statistical 
analysis, we used logistic regression analysis, Chi-square and 
Fisher exact tests. We calculated the incidence rate.
Results: The mean age of our patients was 45.5±11.3 years, the 
mean age at disease onset was 31.3±9.8 years, the mean disease 
duration was 15.2±7.6 years and the median EDSS score was 2 
points (range:0-6.0). Of the 243 patients, 62 were men and 180 
women (man-women ratio was 1:2.9).
At baseline, 110 of the 242 patients were cognitively preserved. 
At the time of the follow-up, 25 patients developed some level of 
cognitive impairment (22.7%), the incidence rate was 103/1000 
person-years. We found no significant predictor of developing CI 
with regression analysis. There was no significant difference 
between the genders, yet the proportion of male patients was 
higher (31% against 21%; p>0.05).
Discussion: At a 1 year follow-up, we found the incidence of cog-
nitive impairment to be 103/1000 person-years among our patient 
group, which is in accordance to a previous report from Italy after 
a longer follow-up. We found no significant difference between 
the genders (unlike in our prevalence investigation), yet the pro-
portions were slightly higher among males, so the lack of signifi-
cance may be due to the relatively low number of male patients. 
We found no significant predictor of developing CI in this short 
follow-up period.
Disclosure
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The prevalence of multiple sclerosis in the Province of Padua, 
North-East Italy, is significantly higher in urban areas and 
associates with air quality
F. Tadeo1, F. Grassivaro2, M. Puthenparampil2, P. Gallo2
1Institute of Geosciences and Earth Resources - National 
Research Council of Italy, 2Department of Neuroscience DNS, 
Università degli Studi di Padova, Padua, Italy
Background: The incidence and prevalence of Multiple Sclerosis 
have progressively and quite linearly increased in the Province of 
Padova, North-East Italy, over the last 5 decades. The cause(s) of 
this epidemiological trend are unknown. The role of environmen-
tal factors has to be considered.
Aims: To analyse the distribution of MS cases in the territory of 
Padua’s Province and its association with residential locality types 
and local environmental features.
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Methods: 1419 MS patients born and living in the province of 
Padua were included in the study. The following environmental 
parameters were considered: the residential locality type, the 
chemical composition of soil and the air quality (i.e., particulate 
matter < 2.5).
Based on the 2011 National Italian Territory classification, the 
province surface was classified in four different locality types: 
urban areas (789,233 inhabitants), isolated villages (50,570 inhab-
itants), productivity places (1,875 inhabitants) and countryside 
(79,683 inhabitants). Each patient’s address was labelled accord-
ing to such territorial classification. Furthermore, the urban 
domain of Padua was considered as an additional locality type.
Results: In the urban areas, MS prevalence was much higher 
(162/100,000) compared to isolated villages (109/100,000) or rural 
domains (98/100,000, p< 0.0001). Moreover, when the city of 
Padua was separately considered, the prevalence significantly 
increased to 195/100,000 (p< 0.00001). No association could be 
demonstrated with the content of selected metals (Cr, Co and Ni) in 
the soil. Three classes of air quality were used for grading the 
urban zones and their inhabitants (19.4-21.8, 21.8-23.0, 23.0-24.7 
micrograms/cubic meter, annual average 1998-2015). Interestingly, 
the MS prevalence closely follows the three classes of air particu-
late (137, 165 and 193/ 100,000, respectively; p< 0.001).
Discussion: Our findings suggest that the prevalence of MS asso-
ciates with the residential type locality. Moreover, in the urban 
areas (the most impacted by the disease) a further increment of the 
risk associates with air quality. These observation indicates that 
environmental factors play a major role in the increased MS prev-
alence in the Province of Padua, North-East Italy, that rose from 
16/100,000 in the early ‘70ies to 182/100.000 in 2017.
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EP1332
Autoimmune diseases in multiplex MS families in the Neth-
erlands
J.Y. Mescheriakova, R.Q. Hintzen
Neurology, MS Centre ErasMS, Erasmus MC, University 
Medical Center, Rotterdam, The Netherlands
Background and objective: Clustering of autoimmune diseases 
(AIDs) has been described in individuals with multiple sclerosis 
(MS) and their first-degree family members. However to what 
extent MS and other AIDs co-occur in MS multiplex families with 
two or more affected individuals is still controversial. We aimed 
to evaluate co-existing AIDs in MS patients and their first-degree 
family members from the Dutch MS multiplex families and com-
pare them to spousal controls.
Methods: A total of 155 multiplex families (155 MS probands, 789 
first-degree relatives and 212 spouses) were characterized for a his-
tory of 11 AIDs by means of a self-administered questionnaire.
Results: An AID was reported in 17 (11%) MS probands. In 67 
(43.2%) MS multiplex families at least one AID was present in the 
first-degree relatives. Overall frequency of AIDs was similar in 
MS probands (11%), their first-degree family members (11%) and 
in spousal controls (5.2%). After correction for age at inclusion 
and gender, the odd ratios (OR) for AIDs were not significant for 
MS probands compared to spouses (OR=1.8, 0.77-4.34, p=0.17), 
and for first-degree family members compared to spouses 
(OR=2.0, 0.98-4.10, p = 0.06). Frequency of AIDs in mothers of 
MS index cases was more than twice of that in fathers (19% vs 
8%, p= 0.0052). Maternal second-degree relatives reported more 
often a presence of AIDs than paternal second-degree relatives 
(23% vs 10%, p=0.0020).
Conclusion: Although nearly half of the Dutch MS multiplex 
families reported an AID, no excess of AIDs was present in MS 
patients from multiplex families or their first degree family mem-
bers compared to their spouses. Increased autoimmunity in moth-
ers and maternal relatives of MS index cases suggest that there 
might be a maternal parent-of-origin effect for AID in MS patients 
from multiplex families.
Disclosure
JY Mescheriakova reports no disclosures.
RQ Hintzen reports no disclosures.
EP1333
Rising prevalence of multiple sclerosis in Mexico: a new esti-
mation based on a multicenter registry and sanitary admin-
istrative data
E. Chiquete1, F.G. Flores-Ramirez2, E. Duriez-Sotelo3, V. 
García-Talavera4, M.L. Cabral-Alvarez5, R. Salinas-Estebané4, 
J.A. Félix-Félix6, G. Ivens-Mares7, R. Cavazos-Sandoval8, M.A. 
Candia-Oyervides9, M. de la Maza10, E.A. Zuñiga-Gonzalez7, 
J.E. Garcia-Gonzalez11, M. Alanis-Quiroga12, J.A. Venegas-
Torres13, J.O. Ulloa-Alday14, A. Hernandez-Martinez6, R. 
Estrada-Renteria15
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1Neurology, Instituto Nacional de Ciencias Medicas y Nutricion 
Salvador Zubiran, Mexico, 2Neurology, ISSSTE Regional, 
Monterrey NL, 3Neurology, UMAE 25, IMSS, Monterrey, NL, 
4Neurology, Hospital General de Zona 33 IMSS, Monterrey, 
5Neurology, UMAE 71 IMSS, Torreon, Coah, Torreon, 
6Neurology, Hospital General de Zona 2, IMSS, Saltillo, 
7Neurology, Hospital General de Zona 6, IMSS, Tampico, 
8Neurology, Centro de Neurología Integral, Reynosa, Tam, 
Reynosa, 9Neurology, Hospital ISSSTE, Saltillo, Coah, Saltillo, 
10Neurology, Hospital San Jose, 11Neurology, Clínica NOVA, 
Monterrey, 12Neurology, ISSTE Regional, Torreon, Coah, 
13Neurology, UMAE 71 IMSS, Torreón, Coah, Torreon, 
14Neurology, Clínica la Concepcion, Saltillo, 15Neurology, 
Hospital PEMEX, Tampico, Mexico
Background: Prevalence of multiple sclerosis (MS) in Mexico 
has been previously estimated between 10 and 15 per 100,000 
inhabitants. With increasing mortality and hospitalizations associ-
ated to MS diagnosis in recent years, there have been insights 
about the possible rise in MS prevalence explaining this epide-
miologic behavior.
Objective: To estimate MS prevalence in Mexico.
Methods: We first used information of a regional multicenter reg-
istry of Northeastern Mexico conducted during 2014. For the 
prevalence estimation we analyzed data of individuals pertaining 
to a captive State workers population covered by three regional 
hospitals (ISSSTE; Instituto de Seguridad y Servicios Sociales de 
los Trabajadores del Estado). Weighted mean prevalence (WMP) 
was calculated using information of individual institutions and 
95% uncertainty intervals (95% UIs) are provided. WMP was 
validated with official National death certificates and hospital dis-
charges databases for 2014 assuming a rate of 10.5 hospitaliza-
tions per 100 person-years and mortality of 2.5 per 100,00 MS 
patients. WMP estimate was considered reliable if UIs included 
the point estimations based on administrative databases provided 
by the National Health Information System.
Results: Of 641 patients included in the registry, we analyzed data 
of 140 individuals pertaining to a total population of 563,214 State 
workers covered by three regional ISSSTE hospitals. WMP was 
23.67 per 100,000 inhabitants (95% UI: 15.86-35.31 per 100,00 
inhabitants). In the remaining 501 individuals pertaining to hospi-
tals covering non-captive population (i.e., floating population 
without constant insurance coverage) prevalence ranged from 
3.59-9.88 per 100,000 inhabitants. Estimates based on hospitaliza-
tions and mortality of the whole Nation fell within the UIs WMP 
range (29.70 and 18.89 per 100,000 inhabitants, respectively).
Conclusion: The prevalence of MS in Mexico is 24 per 100,000 
inhabitants. This new estimate may reflect a transition to a better 
diagnosis and a higher awareness within the community. However, 
we cannot completely rule-out a true increasing prevalence of MS 
in Mexico.
Disclosure
Dr. Erwin Chiquete has received research grants from Sanofi and 
Ferrer Grupo; has served as research advisor for Sanofi, Novartis 
and Genzyme; and has received speaker honoraria from Novartis 
Mexico, Genzyme and Ferrer Grupo.
None of the other authors have relevant conflicts of interest to 
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Temporal trend in the disease activity of multiple sclerosis in 
Korea
H.-J. Shin1, W. Kim2, S.-H. Baek3, B.-J. Kim3, J.-W. Hyun1, S.-
H. Kim1, H.J. Kim1, S.-M. Kim4
1Department of Neurology, Research Institute and Hospital of 
National Cancer Center, Goyang, 2Department of Neurology, 
The Catholic University of Korea, Yeouido St. Mary’s Hospital, 
3Department of Neurology, Korea University Medical Center, 
Korea University College of Medicine, 4Department of 
Neurology, Seoul National University, College of Medicine, 
Seoul, Republic of Korea
Background and goals: Epidemiologic studies have suggested 
an increasing temporal trend in the prevalence of multiple sclero-
sis (MS) across Asian countries. Nevertheless, the temporal trend 
in the disease activity of MS in these countries has not been fully 
evaluated yet.
Methods: One hundred seventy seven MS patients according to 
the international panel criteria
(112 females, mean age at onset of 30.7 ± 8.2 years) were retro-
spectively included from four MS-referral hospitals in Korea. The 
T2 lesion burden in brain MRI at disease onset was analyzed and 
clinical outcome after disease modifying treatment (DMT) was 
examined. The positive rate of oligoclonal band (OCB) by isoe-
lectric focusing (IEF) method and the frequency of IgG index 
more than 0.67 were investigated for each birth year group.
Results: From the 1950s to the 1990s, the number of patients born 
in each decade was 4, 25, 65, 67, and 16, respectively. Patients 
born in more recent decade had a significantly higher number of 
T2 lesions (β=0.614 lesion per each year; 95% CI: 0.153-1.075; 
p=0.010) at disease onset. The birth year was a significant risk 
factor for relapses within 1 year and within 2 years after initiation 
of DMT (p = 0.020 and p = 0.001, respectively). The risk of clini-
cal relapse within 2 years after DMT was 1.513 times higher when 
the birth year was delayed by 10 years (95% CI: 1.179-1.941; 
p=0.001). Onset age did not show a significant difference in terms 
of relapse risk. The positive rate of OCB and the proportion of 
raised IgG index > 0.67 tended to be higher in whom belong to a 
patient group of later born (p< 0.001 and p=0.003, respectively).
Conclusions: Our data imply that the disease activity of adult-
onset MS patients in Korea is increasing over last five decades in 
terms of radiological and prognostic aspects. In addition, the pat-
terns of CSF biomarkers have also been changing over time. This 
is a preliminary result from four MS-referral hospitals and further 
nationwide study is in progress.
Disclosure
H.-J. Shin, W. Kim, S.-H. Baek, B.-J. Kim, J.-W. Hyun, S.-H. 
Kim, and S.-M. Kim have nothing to disclose.
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Sclerosis Journal - Experimental, Translational, and Clinical, and 
an associated editor for the Journal of Clinical Neurology.
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EP1335
Disease-modifying therapies use in relapsing-onset multiple 
sclerosis patients in real-life settings in France: data from the 
OFSEP database over the period 1996 - 2017
E. Leray1,2, F. Rollot3, R. Casey3, J. de Sèze4, D.A. Laplaud5, S. 
Vukusic3,6,7, for the OFSEP Investigators
1Département METIS, EHESP School of Public Health, 2EA 
7449 REPERES, EHESP / Rennes 1 University, Rennes, 
3Observatoire Français de la Sclérose en Plaques, OFSEP, 
Université Claude Bernard Lyon I, Hospices Civils de 
Lyon, Lyon, 4Département de Neurologie, CHU Strasbourg, 
Strasbourg, 5Département de Neurologie, CHU Nantes, Nantes, 
6Service de Neurologie, Sclérose en Plaques, Pathologies de la 
Myéline et Neuro-Inflammation, and Fondation Eugène Devic 
EDMUS contre la Sclérose en Plaques, Hospices Civils de Lyon, 
7INSERM 1028 et CNRS UMR 5292, Centre des Neurosciences 
de Lyon, Lyon, France
Background: Beta interferon, first disease-modifying therapy 
(DMT) for multiple sclerosis (MS), was approved in France in 
1996. Twenty years later, 12 medications are available, improving 
the therapeutic arsenal regarding acceptance and tolerability 
(injectable, oral and infused medications) but first of all efficacy, 
despite potential adverse effects. Approval of natalizumab in 2007 
and oral first-line treatments in 2014 were major steps in the ther-
apeutic strategy. Increased availability of DMTs associated with 
better knowledge of their efficacy and their risks had conse-
quences on therapeutic decisions made by neurologists in daily 
practice.
Objectives: To describe use of DMTs in relapsing-onset MS 
patients in France over the last 20 years, the therapeutic sequences 
and switches; to assess impact of the arrival of new drugs on the 
practices; to search for a period effect in DMTs use.
Methods: This national observational cohort study was based on 
data collected through the ‘Observatoire Français de la Sclérose 
en Plaques’ (OFSEP), the French MS registry that included more 
than 54,000 MS patients in December 2016. All patients with a 
relapsing-onset MS and alive in 1996 (to get a chance to be 
treated) were included. All treatments (including off-label drugs) 
were considered, whatever their duration. Treated patients were 
described, as well as the DMTs prescribed (type, dates and rea-
sons of stopping) and all the potential switches (considering place 
in the strategy as well as way of administration). Analysis was 
done globally (and will be done by periods: before 1996, 1996-
2007, 2007-2014, since 2014).
Results: As a whole, 41,952 patients were included; 30,341 
(72.3%) received at least one DMT, accounting for a total of 
73,012 DMT initiations over a mean (±SD) follow-up duration of 
13.6±10.7 years from MS onset. First DMT was initiated after 
mean disease duration of 6.1±7.2 years and the cumulative treat-
ment duration was 6.3±5.3 years, i.e. 49% of the follow-up dura-
tion. Injectable, oral, infused medications and off-label drugs 
concerned respectively 54.3%, 13.3%, 12.8% and 19.6% of 
DMTs. The most frequent switches were within first-line DMTs 
(n=10,874; 8,438 switches within injectable drugs and 1,837 
switches from injectable to oral drugs), first to second-line DMTs 
(n=5,688), and within off-label drugs (n=1,918).
Conclusion: The OFSEP cohort offers the opportunity to describe 
therapeutic practices in France and their changes over time.
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This work has been performed with the help of the French 
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by a grant provided by the French State and handled by the 
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Merck, Novartis, Sanofi-Genzyme and Roche, and grants from 
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Familial multiple Sclerosis: a Portuguese hospital-based 
cohort study
D.S. Ferro1, M. Seabra1,2, T. Mendonça1, J. Reis1, J. 
Guimarães1,2, P. Abreu1,2, E. Mesquita3, M.J. Sá1,4
1Centro Hospitalar de São João, 2Faculty of Medicine, 
University of Porto, 3Public Health Institute, University of Porto, 
4Fernando Pessoa University, Porto, Portugal
Introduction: Little is known about familiar Multiple Sclerosis 
(MS). It seems that MS appears earlier in familiar forms with an 
anticipation of age from older generations to younger ones within 
a family. In this study we characterize the familiar MS cohort 
from our hospital and compare clinical and imaging findings with 
non-familiar patients.
Methods: From 656 MS patients, 31 (4.7%) presented one or 
more relatives with the disease
(11 families). We compared this group (1) with 66 age and sex-
matched patients with non-familiar MS (group 2), regarding: sub-
type, age of onset, time from onset to diagnosis, initial syndrome 
and Expanded Disability Status Scale (EDSS) score, Multiple 
Sclerosis Severity Score (MSSS) and first Magnetic Resonance 
Imaging (MRI) data. In group 1 we also analysed MS age of onset 
between different generations. In the statistic analyses, significant 
differences were considered for p< .05 and marginally significant 
for p< .10.
Results: The female/male ratio was 2:1 in both groups, the mean 
age of onset was 31.2 and 34.5 years in groups 1 and 2, respec-
tively, the most common subtype of MS was relapsing-remitting 
(group 1, 83.9%; group 2, 77.3%); these differences were not sig-
nificant. The time between onset and diagnosis was similar in both 
groups (2-3 years) and sensory symptoms were the most frequent 
onset complains. For familiar cases, the most common form of 
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kinship was between first degree relatives: siblings (38.7%) and 
parent-child (22.6%). A marginally significant difference was 
found when testing for anticipation of disease in younger vs. older 
generation (p=0.066). Initial EDSS was significantly lower for 
familiar cases (p=.024) while no differences were found in MSSS. 
At initial MRI, the group 1 had significantly less infratentorial 
involvement (p=.013) and less contrast enhancing lesions (p=.019).
Discussion: As reported in the literature, our study´s familiar 
cases had younger age at onset than sporadic MS, although this 
difference didn’t reach statistical significance. As reported by oth-
ers, there seems to be a propensity of anticipation of MS and a 
milder initial disability in familiar cases. However no differences 
were observed in MSSS or progression to Secondary Progressive 
form between groups. We also found a milder lesion burden at 
initial MRI. If this is part of a genetic contribute or if family cases 
are more aware of MS symptoms leading to an earlier diagnosis, 
is still an intriguing question.
Disclosure
Daniela Ferro: Nothing to disclose
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Computer-based registry for central nervous system demy-
elinating disease in Brazil - REDONE databank
D.G. Brum1, C.C.F. Vasconcelos2, E.R. Comini-Frota2, M.F. 
Mendes2, S.C.N. Machado2, A.W.D. NobregaJr.2, H.L.S. 
Cabeça2, D.D. Sisterolli2, N.A.D.C. Souza2, A.K. Grzesiuk2, 
R.M. Dias2, F.C.G.d. Rocha2, M.V.M. Gonçalves2, J.B.B. 
Brooks2, D.R.K. Maciel2, R.M. Papaiz-Alvarenga2, P.S. Rippel2, 
Y.D. Fragoso2, D.K. Sato2, M. Parolin2, M.L. Brito2, D.B. 
Bichuetti2, E.D. Tosta2, REDONE / Neuroimmunology Disorders 
Study Group from the Brazilian Academy of Neurology
1Faculdade de Medicina de Botucatu, Universidade Estadual 
Paulista, UNESP, Neurology, Psychology and Psychiatry, 
Botucatu, 2Departamento Cientifico de Neuroimunologia, 
Academia Brasileira de Neurologia, São Paulo, Brazil
Background: The inflammatory Central Nervous System disor-
ders include multiple sclerosis (MS), optic neuromyelitis (NMO), 
acute disseminated encephalomyelitis (ADEM), and other demy-
elinating syndromes. Genetic and ambiental factors may be differ-
ent across the Brazilian regions, given the different rates of 
European, African and Amerindian ancestry and enviromental 
factors in a continental country. However, no study has evaluated 
the possibility of an eletronic registry in Brazil to generate rele-
vant epidemiological information on autoimmune neurological 
diseases.
Methods: This pilot study included 67 neurologists distributed 
across all regions from Brazil whom have been granted access 
during the first quarter of 2016 to the Neuroimmunology module 
from the Brazilian Registry for Neurological Disorders (BRA-
REDONE) sponsored by the Brazilian Academy of Neurology.
Results: During a 3 months period (1Q2016), half of the neurolo-
gists logged-in to the system. The distribution of registered mem-
bers in the different Brazilian regions was: North 5.9%, Midwest 
11.8%; Southeast 47%, Federal District 8.8%, and South 26.5%. 
From these, 25% (8/34) have successfully included more than 830 
patients into the database.
Conclusions: In a very short period of time, we registered a large 
number of patients from all regions using a computer-based tool, 
indicating the feasibility and utility of such databases for large 
countries such as Brazil. These early results may provide data to 
establish incidence and prevalence across the Brazil regions with 
potential use in the promotion of public health policies.
Disclosure
Doralina G. Brum: Nothing to disclose
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Neuromyelitis optica spectrum disorder in Tehran, Iran
S. Eskandarieh1,2, M.A.S. Sahraian2, S. Nedjat3, A.R. Azimi2, 
A.N. Moghadasi2
1Tehran University of Medical Sciences, Brain and Spinal 
Cord Injury Research Center, Neuroscience Institute, 2Tehran 
University of Medical Sciences, MS Research Center, 
Neuroscience Institute, 3Department of Epidemiology and 
Biostatistics, School of Public Health, Knowledge Utilization 
Research Center, Tehran University of Medical Sciences, 
Tehran, Islamic Republic of Iran
Background: Neuromyelitys optica is an infrequent demyeli-
nating disease and epidemiological information on NMO is rare. 
The aim of this study was to estimate the prevalence, clinical 
features and serology of NMO in Caucasian population in 
Tehran, Iran.
Method: A cross sectional study was performed during 2015 to 
2016 in Tehran among patients registered with NMO diagnosis 
based on international 2015 consensus criteria in Sina hospital a 
tertiary care referral center in Tehran. A structured questionnaire 
was design in MS Research Center of Tehran university of medi-
cal sciences to measure the baseline characteristic, severity of 
symptoms and significant epidemiological variables which were 
associated for NMO.
The goals of study were described for 103 registered patients and 
data were collected from hospital database registry system and 
patient’s information through face to face interview.
The logistic regression was applying in analysis by software pack-
age SPSS.
Result: The prevalence of NMO in Tehran was 0.86 per 100,000 
in 2016 with point prevalence for females and males rate of 1.35 
and 0.26 per 100,000 respectively.
Female to male ratio was 5:1. The mean age at the disease onset 
was 31.54 years old. NMO-IgG was positive in 44 (46.8%) and 
first presenting symptoms among patients were TM 29 (28.2%), 
ON in (23.3%), (17.47%) had unilateral declined visual acuity, 
TM + ON in (46.6%) and 2 (1.9%) of them presented NMO with 
other appearances. Based on our study, ON had significant asso-
ciation with female gender.
The adjusted odds ratio for sex was estimated for depression (OR 
= 6.83; 95% CI: 1.47, 31.71), migraine (OR = 1.27; 95% CI: 1.13, 
1.42) and hypothyroidism (OR = 1.25; 95% CI: 1.12, 1.39).
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Conclusions: We indicated that the risk of NMO is significantly 
higher among females and younger age group and patients who 
had background of depression, migraine and hypothyroidism.
Disclosure
Funding Source: This study was funded by Tehran University of 
medical sciences.
Conflict of Interest: Authors declare no conflict of interest.
Although this study (the largest population based study) provides 
important current epidemiological data and we believe that our 
results provide crude minimum estimate rates of prevalence then 
are expected to rise dramatically in future studies.The outcomes 
of this study examined some significant epidemiological factors 
and clinical features for NMO. We indicated that the risk of NMO 
is significantly higher among females, younger age and patients 
who had history of depression, migraine and hypo toroid.
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Characteristics and therapeutic management of patients with 
relapsing-remitting multiple sclerosis - data from a French 
multiple sclerosis population-based registry (the Multiple 
Sclerosis Registry in Lorraine Region)
J. Epstein1, G. Mathey1, F. Guillemin1, M. Debouverie1, B. 
Tehard2, L. Bitoun2, P.-H. Depoortere2
1CHRU - Nancy, Nancy, 2Roche France, Boulogne-Billancourt, 
France
Background: New disease-modifying treatments (DMTs) 
approved since 2006 have probably changed the management of 
multiple sclerosis (MS) patients in current medical practice. 
However, few recent data are available on real-life therapeutic 
strategies implemented in MS patients.
Objective: To describe the characteristics and therapeutic man-
agement of MS patients since January 2007, using a French 
regional MS population-based registry (Registre Lorrain des 
Scléroses en Plaques, ReLSEP).
Methods: Data from patients with confirmed MS, first MS symp-
toms between 2000 and 2014, at least one medical consultation 
with a neurologist between 2007 and 2015, and without combined 
DMTs during at least 3 months were extracted from the ReLSEP 
database. Following descriptive results focused on patients with 
relapsing-remitting MS (RRMS).
Results: From the 6090 MS patients registered in the ReLSEP 
database, 1926 MS patients met all the predefined selection crite-
ria, including 1663 RRMS patients at initial diagnosis (86%). 
Among these 1663 RRMS patients, 1483 patients (89%) received 
at least one DMT from diagnosis and 180 patients (11%) never 
received any DMTs. The characteristics of non-treated and treated 
patients were respectively as follows: women (73% and 76%), 
mean age at first MS symptoms (36±10 and 31±10 years), mean 
irreversible score on the Disability Status Scale (DSS, 1.4±0.8 and 
1.2±0.5), and median patients’ follow-up duration [9 years (Q1-
Q3: 5-13) and 9 years (Q1-Q3: 5-12)]. Among the 1483 RRMS 
patients with at least one DMT from diagnosis, 507 patients (34%) 
from the 943 registered before 2007 started first DMT before this 
date (interferons and assimilated products 96%; non-selective IV 
(2%) and oral (2%) immunosuppressants). The other patients 
(n=976, 66%) received first DMT after January 2007: interferons 
and assimilated products (83%), oral Nrf2 pathway activators 
(6%) oral selective immunomodulatory (4%), humanized mono-
clonal antibody anti-alpha-4 integrin (3%), non-selective IV (1%) 
and oral (1%) immunosuppressants, and oral selective immuno-
suppressants (1%).
Conclusions: Despite recent approval of new DMTs for MS, 
interferons and assimilated products remain the standard treat-
ment for RRMS patients of the ReLSEP population. The propor-
tion of RRMS patients treated with oral DMTs increased over 
time. However, a substantial proportion of RRMS patients (11%) 
never received any DMTs over the 9-year follow-up period from 
MS diagnosis.
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Prevalence of multiple sclerosis in Quito, Ecuador
E.P. Correa Díaz1, M.A. Ortiz Yépez1, M.E. Buestán Zumba1, 
G.E. Torres Herrán1, E.C. Jácome Sánchez1, J.J. Zambrano 
Godoy1, V. Vásconez Dávalos1, H. Arroyo Ortega2, V.E. Paredes 
González1, B. Narváez3
1Neurology, Hospital Carlos Andrade Marín, 2Hospital Eugenio 
Espejo, 3Neurology, Hospital Militar de Quito, Quito, Ecuador
Background: Ecuador has a low prevalence of multiple sclerosis 
(MS). An epidemiological study conducted 10 years ago showed 
that the prevalence of MS in Ecuador was 1.2 / 100,000 and in the 
city of Quito (latitude 0) 5 / 100,000 inhabitants. Since 2007 no 
new epidemiological studies have been carried out and we do not 
know if the prevalence has increased like it has in other regions of 
the world.
Objectives: To determine the prevalence of multiple sclerosis in 
the population of Quito and to describe its epidemiological 
characteristics.
Methods: We performed a retrospective descriptive study from 
January 1, 2014 to December 31, 2016. Patients included in the 
study were those who met the McDonald 2010 criteria for MS and 
lived in the city Quito for at least one year. Patients come from 
three third-level hospitals; Carlos Andrade Marín, Eugenio Espejo 
and Militar, which are institutions of national reference for diag-
nosis and treatment of MS. Patients who did not live in Quito were 
excluded from the study.
Results: We identified a total of 101 patients with MS, with a 
prevalence of 4.51 / 100,000 (CI 95%, 3.63-5.39). The average 
age was 41.85 years old (SD +/- 12.38). 66% of the cases were 
women; The female to male ratio was 2: 1. Eighty-two percent of 
the cases were relapsing-remitting MS, 9% clinically isolated syn-
drome, and 9% progressive MS. The mean EDSS was 3.18 (SD 
+/- 2.05).
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Conclusions: The prevalence of MS in the city of Quito is low and 
is similar to that reported 10 years ago. The disease was more fre-
quent in women. The present study has limitations due the fact that 
it is not a community study and it is imperative to create a surveil-
lance system that allows us to obtain a better patient registry.
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α-Linolenic acid (ALA) serum levels are associated with 
reduced MRI activity in a prospective cohort of MS patients
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Background: The omega-3 fatty acid α-Linolenic acid (ALA) has 
anti-inflammatory properties, and consumption of food rich in 
ALA has been associated with a decreased risk of developing mul-
tiple sclerosis (MS) (1). It is, however, not known if serum levels 
of ALA affect disease activity in MS- patients.
Objective: To study whether disease activity is associated with 
ALA serum levels in patients with relapsing-remitting MS.
Methods: We conducted a prospective cohort study of 87 patients 
with relapsing-remitting MS, originally included in a randomized 
placebo-controlled trial (RCT) of omega-3 fatty acids in MS (the 
OFAMS Study), and followed them for two years with repeated 
MRI- and serum measures. The patients received no immunomod-
ulatory treatment during the first six months, and all patients were 
initiated on subcutaneous interferon β-1a (IFNB) after month 6 
and throughout the follow-up period.
MRI and serum ALA measurements were performed at baseline 
and at months 6, 12 and 24. We used random-intercept logistic 
regression to estimate the effect of ALA on disease activity adjust-
ing for age and EDSS at baseline, treatment allocation in the RCT 
and IFNB-status. In a second multivariable model, we addition-
ally adjusted for vitamin D, cotinine, HLA-DRB1*15, vitamin A 
and BMI.
Results: Higher serum levels were inversely correlated with 
MRI disease activity. Each weight percent increase in ALA of 
total serum phospholipid fatty acid levels were associated with a 
subsequent reduced risk of new MRI-activity: OR 0.52 (95% CI: 
0.29-0.95) for new T2-lesions, OR 0.68 (95% CI: 0.40-1.17) for 
new T1Gd+ lesions and OR 0.53 (95% CI: 0.28-0.97) for com-
bined unique activity (the sum of T1Gd+ and new or enlarging 
T2 lesions). Similar Associations were found after further 
adjusting for HLA-DRB1*15 status, vitamin D, cotinine, vita-
min A and BMI.
Conclusions: We detected an inverse association between serum 
levels of ALA and MRI-disease activity. The association remained 
similar after adjusting for all several known cofounders. This indi-
cates that ALA could have unique anti-inflammatory properties 
relevant for the pathogenesis of MS.
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Late onset multiple esclerosis
G. Valero López, A.E. Baidez Guerrero, E. Garcia Molina, 
E. Carreón Guarnizo, R. Hernandez Clares, J. Díaz Pérez, L. 
Fuentes Rumi, J.M. Cabrera Maqueda, J.E. Meca Lallana
Hospital Virgen de la Arrixaca (IMIB-ARRIXACA), Unidad de 
Esclerosis Múltiple, Cátedra de Neuroinmunología Clínica y 
Esclerosis Múltiple, UCAM Universidad Católica San Antonio 
de Murcia, Murcia, Spain
Introduction and objetives: Multiple sclerosis (MS) typically 
debut between the age of 20 and 40; however, the first symptoms 
can occur after age 50 and is classified as late-onset MS (LOMS). 
The purpose of the present study was to review the prevalence, 
presentation, and clinical characteristics of late-onset MS.
Methods: In this retrospective study what we include 450 patients 
with the diagnosis of MS established according to Poser or Mc 
Donald criteria, select those older than 50 years and review demo-
graphic characteristics, first onset symptom, diagnostic delay, dis-
ability at the time of diagnosis (EDSS), Progression Index (PI) 
disease course and findings in CSF, and MRI studies.
Results: We included 21 patients with LOMS (4,7%), of the total 
450 MS patients, diagnosed between 1982 and 2016. 15 (71%) 
females and 6 (29%) males. Mean age at onset was 53(SD±3,4). 
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The most frequent first symptoms were motor deficits (52%), fol-
lowed by brainstem disorder (24%), and sensory deficits (10%). 
The clinical course was in 42% relapsing-remitting(RR), in 38% 
primary progressive(PP) and in 19% secondary progressive(SP). 
The initial EDSS score was 3,7 (SD ±1,8). The mean PI was 0, 48. 
The mean of diagnostic delay was 52 month. The brain MRI has ≥ 
nine lesions in 86%, and spine MRI has ≥ three lesions in 52%. 
IgG oligoclonal bands were positive in 71% of patients in the CSF 
study. In addition 5 out of 21 (31%) patients had suffered a major 
depressive episode and 44% had cognitive impairment. In six 
cases there was a previous wrong diagnosis, being the most fre-
quent the spondyloartrhitic cervical myelopathy.
Conclusions: The onset of multiple sclerosis (LOMS) after age 
50 is infrequent, in our series the most common type is RR but PP 
is more frequent than in another younger groups and motors 
symptoms are the most frequent initial neurological presentation.
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Comorbidity prevalence in a multiple sclerosis center
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Objectives: Comorbidity is an area of increasing interest in mul-
tiple sclerosis (MS) and may have adverse impacts on MS course 
causing greater disability progression and influencing treatment 
choices and treatment outcomes. Our aims were to characterize 
the comorbidites of the MS center of Bergamo.
Materials and methods: We retrospectively evaluated the clini-
cal history of 601 consecutive patients afferent to our MS center 
in 2016. We reported all comorbidities which could be relevant to 
health care utilization and could influence treatment choices in 
MS patients.
Results: Overall we evaluated the data of 487 patients with 
relapsing remitting MS, 103 patient with secondary progressive 
MS and 11 patients with primary progressive MS. 67% of our 
cohort were females and 33% were males. Mean age was 43.9 
years old (SD 11.7). Median EDSS was 2.0 (range 1.0-9.0). 42.2% 
of patients had at least one comorbidity (28.2% only one comor-
bity, 14.0% two or more comorbidities). Overall, at least one 
comorbidity was already present at diagnosis in 8.8% of our sam-
ple; 33.4% of subjects developed at least one comorbidity during 
MS disease course. 9.8% of our patients were affected by hyper-
tension, 5.8 % by dyslipidemia, 2.3% by diabetes, 2.8% by car-
diac diseases, 4.7% by malignant tumors (21.4% breast cancer, 
25.0% genito-urinary tumors, 7.1% gastrointestinal tumors, 3.6% 
lung cancer, 32.1% skin cancers, 10.8% other tumors), 20% by 
psychiatric disorders ( 86.6 % anxiety-depressive disorder, 13.4% 
psychosis or bipolar disorder) and 9.7% by autoimmune diseases 
(64,7% autoimmune thyroiditis, 9.8% psoriasis, 7,8% celiac dis-
ease, 17,7% other mixed autoimmune diseases). Diabetes and 
autoimmune disorders were equally detected before and after MS 
diagnosis, while the remaining comorbidities onset was more fre-
quent during MS disease course.
Discussion and conclusions: We reviewed the prevalence of 
comorbidities in a single MS center. The high prevalence of 
comorbidities in our cohort underlines the complexity of MS 
patients, which is not confined to MS direct complications. A high 
rate of subjects developed comorbidities after diagnosis. An ade-
quate prevention and a prompt management of comorbidities dur-
ing MS disease course is essential and might be the key to 
ameliorate the health care utilization, prevent serious adverse 
events during MS treatment and obtain better clinical outcomes.
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Prevalence of multiple sclerosis in San Vicente del Raspeig, 
Spain: a population-based study
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Background and objectives: Available epidemiological data 
suggest that the prevalence of multiple sclerosis (MS) in Spain is 
progressively increasing during the last four decades. The aim of 
this study was to estimate the actual prevalence rate of MS in the 
southeast of Spain.
Methods: This epidemiologic study was conducted in the city of 
San Vicente del Raspeig, located in the southeast of Spain, lati-
tude 38° 23′, with a population of 56.715. April 10, 2017 was 
selected as the prevalence day. Case ascertainment included com-
puterised primary care medical records system, the MS database 
of Alicante General Hospital, the district hospital that offers spe-
cialized care to MS patients and data from the MS patients´ asso-
ciation. 2010 McDonald´s criteria were used for the diagnosis of 
multiple sclerosis. Lublin criteria (2013 revisions) were used for 
MS phenotypes.
Results: A total of 58 patients (45 women, 13 men) had a con-
firmed diagnosis (Poser and 2010 McDonald´s criteria). The over-
all crude prevalence rate was 102.3/100.000 (95% CI 79,1-132,2), 
157.1/100.000 (95% CI 117.5-210.2) in women and 46.3/100.000 
(95% CI 27.1-79.2) in men. Women/men ratio was 3.5. Mean age 
was 44.7±11.1 years, 45.4±11.2 in women and 42.3±10.9 in men. 
A total of 45 of the 58 patients (77.6%) were treated with disease 
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specific therapies: glatiramer (13.8%), beta-interferon (17.2%), 
dimethyl-fumarate (17.2%), rituximab/ocrelizumab (12%), fin-
golimod (8.6%), natalizumab (6.9%), azathioprine (1.7%). MS 
phenotypes (2013 revisions) were: relapsing remitting MS 
(RRMS) with activity, 10.3%; RRMS without activity, 69%; sec-
ondary progressive MS (SPMS) with progression but without 
activity, 3.4%; SPMS without progression or activity, 6.9%; pri-
mary progressive MS (PPMS) without activity or progression, 
3.4%; PPMS with activity and progression, 3.4%; PPMS with 
progression but without activity, 3.4%.
Conclusions: Our study suggests that the prevalence rate of MS 
and the women to men ratio is increasing in the southeast of Spain. 
The revised Lublin criteria for the clinical course gives a more 
dynamic description of MS phenotypes and should be included in 
epidemiological studies of MS.
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Background: Novel disease-modifying therapies (DMTs) for 
multiple sclerosis (MS) have greatly improved treatment of the 
disease. However, real world data on long-term safety, tolerabil-
ity, and comparative effectiveness, are still scarce. COMBAT-MS 
(COMparison Between All immunoTherapies for Multiple 
Sclerosis, EudraCT 2016-003587-39) is a Swedish, nationwide, 
long-term, prospective cohort study, including all patients with 
relapsing-remitting MS (RRMS), starting a first DMT or switch-
ing DMT for the first time, between 1st Jan 2011 and 30th June 
2018, at any of Sweden´s University Clinics. This corresponds to 
approximately 50% of the nationwide, eligible population. The 
primary objective of this study is to compare rituximab (RTX) 
with other MS-approved DMTs, regarding long-term safety and 
comparative effectiveness.
Methods: Current patients fulfilling the inclusion criteria were 
identified through the nationwide Swedish MS registry (SMSreg). 
For these patients, already registered data in the SMSreg, 
regarding disease history, disease status, treatments, relapses, and 
imaging, were validated by medical-chart review. These initial 
patients, together with future patients also fulfilling the inclusion 
criteria, are followed with annual, structured follow-up visits, for 
a minimum of three years after enrolment.
Results: A total of 3626 patients fulfilling inclusion criteria were 
identified through the SMSreg and included in the medical-chart 
review. Primary analyses of baseline characteristics for these 
patients suggest that geographic location (centre) is the main fac-
tor driving channelling to either RTX or another DMT. However, 
patients starting RTX at inclusion were in general a few years 
older (median 38 vs 35 years [p< 0.001]), had had the disease a 
few months longer (median 17 vs 13 months [p=0.023]), and had 
a slightly higher EDSS at the start of therapy (median 2 vs. 1.5 
[p=0.001]), compared to all other therapies. Prospective follow-
up began in June 2017.
Conclusions: Primary analysis suggest that the main driver for 
treatment choice is geographic location, rather than patient char-
acteristics. However, some differences in characteristics were still 
observed and will have to be taken into consideration in future 
observational comparisons between RTX and other DMTs.
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Background: Multiple Sclerosis (MS) affects women more often 
than men. It is reported that MS is more aggressive in non-Cauca-
sian men. The Puerto Rico MS (PRMS) Registry reported the high-
est incidence and prevalence among other Hispanic population.
Objective: Describe the Hispanic male MS patient in Puerto Rico 
(HMMS-PR).
Methods: Data was collected from the PRMS registry of newly 
diagnosed patients for the period 2013-2016. Data was analyzed 
using descriptive statistics.
Results: Out of 633 evaluated patients 159(25.12%) were male. 
Average age at onset was 33.4 and at diagnosis were 38.9. The time 
lag between symptom onset and diagnosis showed that 73.74% of 
patients were diagnosed within 0-5 years of their first symptom, 
21.21% were diagnosed within 6-15 years, 3.03% were diagnosed 
within 16-25 years, and 2.02% within 26-31 years. The most com-
mon initial symptom was a sensory symptom (53.92%), followed 
by visual (40.20%), and then motor (32.35%). One fourth of the 
HMMS were disabled. 68.33% had EDSS scores from 0-3.0, 
28.33% had a score of 3.5-6.0, and 3.33% had an EDSS score from 
6.5-9. Vitamin D was also evaluated and it was shown that 65.22% 
of these patients had deficient/insufficient levels. 62.37% of 
patients had no smoking history and only 14.0% had a blood rela-
tive with MS. Hypertension, hyperlipidemia, and diabetes was 
seem in 17.82%, 6.93%, and 5.94% of patients respectively.
Conclusion: Our results show that HMMS-PR patients in this 
sample do not present a more aggressive MS presentation as was 
previously believed. The majority of the newly diagnosed male 
cases have an EDSS score bellow 3.0, which suggests that these 
individuals have low level of disability at diagnosis. The most 
common first symptom among newly diagnosed HMMS patients 
is a sensory symptom, followed by a visual and motor symptom. 
The time lag to diagnosis is in concordance with previously calcu-
lated number (4.1 years) and is similar to female patients. Vitamin 
D levels were found to be insufficient/deficient on most HMMS 
patients further validating the belief that it is a risk factor for MS. 
This study helps elucidate MS disease course in HMMS. Also, it 
shows that there is need to characterize more ethnic specific prog-
nostic factors for MS patients since these non-Caucasian male 
patients do not depict a more severe MS presentation. Comparing 
these results to other MS male ethnic groups could help define 
racial differences among male MS patients.
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Background: Multiple Sclerosis (MS) is an autoimmune disease 
of nervous System which affects young adults, especially young 
females. This study aimed to assess the geographical distribution 
of MS in Fars province in southern Iran using the spatial methods. 
Fars Province is one of the largest provinces in Iran which has a 
population of 4.6 million people.
Patients and methods: A total number of 5,868 patients diag-
nosed with MS according to the McDonald’s criteria during 1990-
2016 in Fars Province. Demographic and case-related information 
was obtained from the Iran MS Society (IMSS), Shiraz office 
database. Overall Fars Province has 29 counties. We used 
Bayesian spatial and Bayesian spatio-temporal models to study 
relative risk and trend of MS incidence in the Province and each 
county separately.
Results: Out of 5,868 registered MS patients, 82% were female. 
County-level crude incidence ratio ranged from 0.31 to 9 cases 
per 100,000 populations. The highest smoothed SIR (1.80) was in 
the Shiraz County in the center of Fars province, while the lowest 
smoothed SIR (0.11) was in the Zarindasht County in southern 
Fars. Moreover, there is an increase trend in MS incidence but 
very smooth.
Conclusion: Here we analyzed the geographical distribution of 
MS in part of Iran, to obtain a reliable map of disease incidence. 
This map may help us to identify the possible cluster and localize 
the risk areas. This epidemiologic approach may help us to find 
any possible underlying environmental causes of MS in Iran.
Keywords: Bayesian Spatio-tempral, BYM model, Multiple scle-
rosis, Incidence
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Incidence and prevalence of multiple sclerosis in Saint 
Petersburg
M. Shumilina1,2, A.A. Skoromets2, E. Evdoshenko1
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Introduction: Multiple sclerosis is characterized by a non-homo-
geneous distribution around the world. There are no system epide-
miological data for multiple sclerosis (MS) in Saint-Petersburg.
Objective: To calculate the incidence and the prevalence of mul-
tiple sclerosis (MS) in Saint-Petersburg (located in North-West 
region of Russia).
Methods: This is an observational, cross-sectional, descriptive 
study. The City Center of MS was founded in October 2011. This 
is the first center in Russia conducting electronic health records, 
which allowed us to estimate the incidence and the prevalence of 
MS in St. Petersburg with the city population of just over 5 mil-
lion. Patients (n=3150) with definite MS according to McDonald 
criteria 2010 were included in the study on March 1, 2017.
Results: The incidence rate in 2016y for St. Petersburg was 
6,4/10^5 and prevalence rate was 60/10^5 . It´s noted a gradual 
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increase in the incidence of the MS with 1-2/10^5 (2000-2007y) 
to 4,9/10^5 (2011y) and 6.4/105 (2016y).70 % of patients with 
relapsing- onset MS and 50 % patients with progressive onset MS 
are women (sex ratio for RRMS m:f = 1:2,3). Types of MS distri-
bution in our Center is 80% for RRMS, SPMS - 14% and PPMS 
- 6 %. The diagnosis was done at mean age of 34 with relapsing-
onset MS and 45 with progressive-onset MS (p < 0,0001). Men 
are diagnosed on average two years earlier than women (p < 
0,0001). Depending on the type of MS at the Center of observed 
patients with RRMS in younger age group (peak is 20-40 years, p 
< 0,0001), older patients more often have progressive type (SPMS 
and PPMS, p > 0,08) with peak of 40-60 years. 70 % of MS 
patients (n=2205) receive DMD, among them 36% - glatiramer 
acetate, 50 % - interferones, 5% - natalizumab and others - fin-
golimod, mitoxantrone, cyclophosphamide, rituximab, azathio-
prine and in clinical trials.
The incidence of pediatric MS (< 18 years) is 1,01/10^5 and the 
prevalence is 3,0/10^5 . About 10% patients had a first relapse in 
pediatric age, 2/3 of them was diagnosed of MS after18 years. Only 
2 patients with PPMS (less then 1 %) had onset before 18 years.
Conclusion: According to our study results St. Petersburg has 
high prevalence rate of MS. Increased incidence warrants further 
observation to clarify the truth of the growth and elimination of 
factors influencing a better detectability of MS and accessibility 
of health care.
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Genzyme, Pharmstandart, R-Pharm, Pharmsyntez, Genfa Medica, 
Takeda and Generium.
A.A. Scoromets: financial support from Roche, Genzyme/Sanofi, 
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EP1349
Clinical and paraclinical characterization of Neuromyelitis 
Optica Spectrum Disorder in Venezuela: a multicenter study
G.A. Chique-Alfonzo1, A. Soto1,2, S. Paccione2, I. Monasterios1,2, 
I. Soto3, O. Molina3, E. Armas1,4
1Department of Neurology, Centro Medico Docente La Trinidad, 
2Neurology Unit, Hospital ‘Dr. Domingo Luciani’ IVSS, 
Caracas, 3Department of Neurology, Hospital Universitario de 
Maracaibo, Maracaibo, 4Department of Neurology, Hospital 
Universitario de Caracas, Universidad Central de Venezuela, 
Caracas, Bolivarian Republic of Venezuela
Introduction: Neuromyelitis Optica Spectrum Disorders 
(NMOSD) is an autoimmune demyelinating disease of Central 
Nervous System(CNS). Venezuela, according to recent publica-
tions shows the highest frequency cases of South America, how-
ever no previous characterization has been reported.
Objectives: To first characterize clinical and paraclinical NMOSD 
in Venezuela and create a data base.
Methods: In a descriptive, retrospective, multicenter study in a 
population with NMOSD from three centers: Centro Médico 
Docente La Trinidad, Hospital Universitario de Caracas, and 
Hospital IVSS Dr. Domingo Luciani. 104 clinical files were 
reviewed from April 2011 to April 2016. From the total of cases, 
n=86 were selected based on complete data and inclusion criteria. 
Gender, age, age of onset, number of relapses, oligoclonal bands 
(OCB), AQP4-IgG status, Brain and Spine MRI, Visual Evoked 
Potentials(VEP) and Optic Coherent Tomography(OCT) were 
determined. Disability (EDSS), mobility (T25WT) were evalu-
ated and cognitive profiles in a randomized subpopulation(n=15) 
were studied.
Results: Mean age was 42.46±13.74 and age of onset for NMOSD 
was 33.13± 14.69. Mean number of relapses 5.22± 4.74. Time 
from first to second relapse 29.84±56.96 months. (OCB) 15.41%. 
AQP4-IgG status positive 26%, negative 38%, unknown 36%. 
Coexisting autoimmune diseases 11.86%. EDSS 4.39±2.26. 
T25WT 9.23±4.65. First onset symptoms were LEMT 52%. 
Bilateral ON 26%, Unilateral ON 12%, Brainstem 10%. >3 med-
ullar segments in 52%. MRI brain lesions 35.71%. Bladder dys-
function 79.76%. Fatigue 75%, Painful Paroxistic Tonic Spams 
(PTS) 50.57%. Cognitive dysfunction was observed in 80% of a 
subpopulation showing severe cognitive impairment in working 
memory and processing speed domains.
Conclusions: Venezuelan population with NMOSD showed 
unique characteristics. A further analysis is required.
Keywords: Neuromyelitis Optica, characterization, multicenter, 
Venezuela.
Disclosure
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EP1350
Demographic and clinical feature among patients with neu-
romyelitis optica in Iran
S. Eskandarieh1,2, M.A. Sahraian2, A.R. Azimi2, A.N. 
Moghadasi2, S. Koolaji2,3, N. Sistany Allahabadi2
1Tehran University of Medical Sciences, Brain and Spinal 
Cord Injury Research Center, Neuroscience Institute, 2Tehran 
University of Medical Sciences, MS Research Center, 
Neuroscience Institute, 3Tehran University of Medical Sciences, 
Tehran, Islamic Republic of Iran
Background: Neuromyelitys optica is a rare disease and epide-
miological data on NMO is limited. The goal of this study was 
evaluation of demographic and clinical features of NMO in 
Caucasian population in Tehran, Iran.
Method: A cross sectional study among patients registered with 
NMO diagnosis was performed in Tehran during 2015 to 2016. 
We design a questionnaire to cover the epidemiological and clini-
cal data of NMO in Tehran. Structured face to face interviews 
were conducted with 147 patients. The logistic regression was 
applied in analysis via software package SPSS.
Result: Among 147 patients, mean age was 36.09 years and 127 
(86.4%) were female. Mean of disease onset age was 31.53 years. 
NMO-Ig G was positive in 71 (54.2%) patients and did not differ 
significantly between male and female (female positivity=56.3%, 
male positivity=42.1%; p-value=0.32). 42.2% of patients had pri-
mary presentation by transverse myelitis (TM) and optic neuritis 
(ON). In the next rank were patients presented only with TM 
(25.9%) or ON (18.4%). Totally 61 (46.6%) patients had a history 
of head trauma with 59 % NMO-Ig G positivity but it was not 
significantly higher than patients with no history of head trauma 
(p-value=0.38; OR= 1.44 (0.72-2.87).
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Conclusions: NMO is higher among female and younger age. Most 
of NMO patients present with TM and ON. Sex and history of head 
trauma did not significantly influence NMO-Ig G positivity.
Disclosure
Funding Source: This study was funded by Tehran University of 
medical sciences.
Conflict of Interest: Authors declare no conflict of interest The 
outcomes of this study examined some significant epidemiologi-
cal factors and clinical features for NMO.
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Care consumption of multiple sclerosis patients in France: an 
analysis of health insurance administrative databases using 
multichannel sequence analysis from 2007 to 2013
J. Roux1,2,3, O. Grimaud1,2, E. Leray1,2,3
1EA 7449 REPERES, EHESP / Rennes 1 University, 2METIS 
Department, EHESP French School of Public Health, 3INSERM 
CIC-P 1414, University Hospital of Rennes, Rennes, France
Background: In France there is a lack of accurate and up-to-date 
data on care consumption of people with multiple sclerosis 
(PwMS). Identification of patterns among care pathways is help-
ful for understanding variation of practices and optimizing com-
prehensive care for PwMS.
Objectives: We aimed to describe care consumption of PwMS in 
France and identify specific patterns using multichannel sequence 
analysis (MCSA), an innovative method derived from social 
sciences.
Methods: A random sample from French health insurance data-
bases was analysed for the period 2007-2013. As no clinical data 
was available, PwMS were identified in January 2007 thanks to a 
three-criterion algorithm using diagnoses of hospital admissions, 
disease-modifying therapies (DMTs) and multiple sclerosis (MS) 
long disease duration status. Care consumptions of interest were: 
consultations with general practitioners (GPs), private neurolo-
gists, private rehabilitation physicians, nurses, physiotherapists 
and hospitalizations for MS. These six dimensions were analysed 
simultaneously and led to classifying patients into homogeneous 
clusters.
Results: On the whole, 543 PwMS were identified with a median 
follow-up duration of 7 years. The sex-ratio was 2.8 with a 
median age of 48 years in 2007. MCSA revealed a 5-cluster 
typology of care consumption. A main group (n=271, 49.9%) 
corresponded to young patients with a probable recent MS onset, 
a remitting form and low disease activity. The 124 patients 
(22.8%) in the second group were more often treated in hospitals 
(received natalizumab) with a high number of visits to physio-
therapists, probably reflecting an active disease. The third group 
(n=61, 11.2%) was routinely followed by private neurologists 
and almost all treated with a DMT (85.2%) possibly in relation 
with a controlled disease. The fourth group (n=47, 8.7%) 
included patients with high motor disability having a very high 
contact with physiotherapists, nurses and GPs, probably linked 
to a progressive phenotype. A defining feature of the last group 
of patients (n=40, 7.4%) was that they all deceased during fol-
low-up. They were older, presented multiple comorbidities and 
had frequent contacts with nursing services.
Conclusion: This pioneer study, using an innovative method in 
health field, gives a first overview of patterns of care consumption 
of PwMS in France. Our results suggest that it is possible to iden-
tify from administrative databases groups of MS patients which 
are clinically relevant.
Disclosure
This work was supported by the French National Agency for 
Medicines and Health Products Safety (ANSM).
Jonathan Roux was funded as PhD fellowship by the French 
National Agency for Medicines and Health Products Safety 
(ANSM) for this work.
Olivier Grimaud has nothing to disclose.
Emmanuelle Leray reports personal fees as speaker or consult-
ant from Novartis and Sanofi Genzyme, outside the submitted 
work, and travel grants from Novartis and Roche SAS. Sources 
of funding in the last year came from the French ARSEP 
Foundation, the French National Security Agency for Medicines 
and Health Products, the EDMUS Foundation, and donation 
from Roche SAS.
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Prevalence and prognosis of multiple sclerosis in a cohort of 
Algerian patients
Z. Barka Bedrane, S. Allal, A. Reguig, K. Saadi, C. Louhibi, M. 
Boujelal, O. Dendene, A. Merad, D. Bouchenak Khellad
Universite Abou Bekr Belkaid, Tlemcen, Algeria
Introduction: Multiple sclerosis (MS) is known to accumulate 
within families. It’s a complexe neurological disorder resulting 
from an interaction between environnemental and genetic risk 
factor 0A lot of loci have been identified that playing arole in MS 
disease suceptibility Although most MS cases occur sporadically,. 
While this accumulation of cases clearly suggests that first-degree 
relatives of MS patients are at increased risk of MS, previous 
attempts to assess the magnitude of the familial MS risk have 
arrived at variable estimates.
Aims: To report the frequency of familial MS .To compare the 
demographic and clinical characteristics between those with and 
without a positive family history of MS .Evaluate the prognosis
Patients and methods: All patients with MS are included in the 
study, the diagnosis is made according to the McDonald 2010 cri-
teria. The family history of MS is obtained by the interview, 
demographic data including information on immediate family 
member and degree of relationship. clinical information was 
sourced By neurological examination. The disability was appreci-
ated by the EDSS .
Results: 450 MS patients were monitored at the Tlemcen 
University Hospital Neurology Department in 2017, 57 of them 
had a family history of MS. The prevalence of MS was 12.6%. 
They reported at least one first-degree relative . There was no sig-
nificant demographic and clinical difference between FMS com-
pared to the non-familial form. In 36% EDSS Iis greater than 6. 
12% died 25-50 years. The familial form of MS is more severe, 
EDSS 6 is reached more rapidly than NSE.
Conclusion: The evolution is more severe in the familial form 
probably of the genetic context with the Maghrebian profile con-
sidered as severe
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EP1353
Gender effect on cortical thickness measurements in  
primary progressive and relapsing remitting multiple sclero-
sis patients: a paired cross sectional study
K. Pardo1,2, L. Or Bach1,2, S. Menascu2, M. Dolev2, D. 
Magalashvili2, A. Achiron1,2
1Sackler School of Medicine, Tel Aviv University, Tel Aviv, 
2Multiple Sclerosis Center, Sheba Medical Center, Tel 
Hashomer, Israel
Background: Cortical demyelination and gray matter atrophy are 
more prominent to occur in primary progressive multiple sclerosis 
(PPMS) than in relapsing-remitting multiple sclerosis (RRMS) 
patients. PPMS course is more common in males while RRMS 
course is more common in females.
Objectives: To identify the differences regarding changes in cor-
tical grey matter thickness (CGMT) between males and females 
PPMS patients as compared with RRMS patients.
Methods: Cross sectional, paired study comparing brain meas-
urements of PPMS and RRMS patients using high resolution 3D 
brain MRI. Patients were matched by age, gender, and disease 
duration. Freesurfer 5.3 software was applied to obtain whole 
brain volumetric segmentation of subcortical regions and cortical 
thickness measurements. Paired t-test was performed to assess 
differences between groups.
Results: Ninety two patients were included, divided into 46 pairs 
of PPMS and RRMS patients; 25 female pairs mean±SD age 
50±12yr, range 22-65yr, disease duration 10.7±8.5yr, and 21 male 
pairs age 50±10yr, range 31-67yr, disease duration 10.6±9.9yr. 
Cortical analysis of the female pairs demonstrated an overall 
decreased CGMT of the left hemisphere in PPMS as compared to 
RRMS patients (-11.67%, p=0.032), and no significant differ-
ences in the right hemisphere. Surface based analysis revealed 
focal clusters of decreased CGMT in the PPMS female group in 
the inferior-parietal and entorhinal in the left hemisphere and pre-
cuneus, superior-frontal and pre-central gyri in the right hemi-
spheres as compared to RRMS female patients (-11% to -15%, p< 
0.03). Cortical analysis of male patients demonstrated no signifi-
cant difference between the groups.
Conclusion: Gender specific patterns of CGMT differ between 
female PPMS and RRMS patients.
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Brain MRI activity in multiple sclerosis(MS) before and after 
pregnancy
A. Nikseresht, F. Rezaiean Jahromi, M. Sharifian Dorche
Clinical Neurology Research Center, Department of Neurology, 
Shiraz University of Medical Sciences, Shiraz, Islamic Republic 
of Iran
Introduction: Postpartum disease and MRI activation is common 
among MS patients. In this study we tried to investigate the rela-
tion between Gd-enhancing lesions before and after pregnancy in 
Iranian MS patients.
Patients and methods: During a retrospective study between 
2011 to 2016, we evaluated the medical records of all women 
patients with MS in our MS outpatient clinic in Shiraz Southern 
Iran. We detected that 75 patients had history of pregnancy in this 
period. These patients were selected. Demographic data, clinical 
findings, history of relapse , brain MRI findings and Gd-enhancing 
lesions during one year prior to pregnancy, type of medication, 
time of withdrawal of medications before pregnancy in one hand 
and history of relapse , MRI Gd-enhancing lesions , history of 
lactation during 9 months after pregnancy in the other hand were 
collected via a questionnaire . Statistical analysis was performed 
under supervision of statistical specialist.
Results: Seventy five MS patients were enrolled in the study. The 
mean age of the patients at the onset of pregnancy was 33.2±4.5 
years. 76%, 86.7% and 70.7% of the patients were relapse-free in 
one year duration before, during and 9 months follow up after preg-
nancy. After pregnancy the rate of relapse increased significantly 
and 29.3% of patients had at least one relapse. (P value < .001)
Presence of Gd-enhancing lesions in brain MRI during one year 
before pregnancy was significantly correlated with new 
Gd-enhancing lesions in brain MRI in 9 months follow up after 
pregnancy. (P value< 0.001)
Other factors such as type of medications and history of lactation 
did not have any significant correlation with MRI Gd-enhancing 
lesions or relapse after pregnancy.
Conclusion: Post-partum activation of the disease is common 
phenomenon among mothers with MS. In this study we showed 
that presence of Gd-enhancing lesions in MRI before pregnancy is 
correlated with MRI activity after delivery.
Keywords: Pregnancy, Multiple sclerosis, MRI, Gd-enhancing lesions
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There is no Conflict of interest.
EP1355
Long term effect of delaying disease modifying therapy in 
patients with multiple sclerosis due to pregnancy planning
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1University of Calgary, Calgary, AB, Canada, 2King Saud Bin 
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Background: The effect of pregnancy on long-term disability in 
women with relapsing-remitting multiple sclerosis (MS) is poorly 
understood.
Aim: To determine the association between delaying Disease 
Modifying Therapy (DMT) for pregnancy planning and long-term 
disability, as measured by the expanded disability status scale 
(EDSS), in women with relapsing-remitting MS.
Methods: Using data from the Calgary MS Clinic database, we 
identified 426 women with EDSS < 5, who delayed starting DMT 
for more than one year after it was recommended during the 
period 1999 to 2006. Thirty-seven consenting women declined 
DMT due to planned pregnancy. EDSS at diagnosis was com-
pared with EDSS at 5, 7, 10 and 15 years. The association between 
the cumulative time on DMT during the first 5 years of MS and 
EDSS change at 5, 7, 10, and 15 years was determined. EDSS 
change was compared with EDSS change in a control group of 
101 women with relapsing-remitting MS (diagnosed between 
18-40 years) who declined DMT for other reasons.
Results: Mean follow-up after diagnosis was 14.05 years. Prior to 
the diagnosis of MS 86.5% were nulliparous compared with 19% at 
the end of follow-up. Mean time to pregnancy was 2.38 years from 
MS diagnosis and 0.84 years from declining DMT for pregnancy. 
Eventually, 67.6% of the patients started DMT. Mean time to initiat-
ing DMT was 4.02 years after declining DMT for pregnancy. 
Confirmed relapses occurred in 70.3% of women between declining 
DMT due to pregnancy and starting DMT; the mean time to a relapse 
was 1.92 years. There was an increase in the mean EDSS score 15 
years after diagnosis of 1.13 points (paired t-test, p= 0.002) among 
women declined DMT for pregnancy planning. There was a moder-
ate to high moderate negative correlation between the cumulative 
time on DMT during the first 5 years after the diagnosis of MS and 
EDSS change at 7 (R= -0.49, p=0.008), 10 (R= -0.44, p=0.017), and 
15 (R= -0.67, p=0.006) years. When compared to the control group 
who delayed DMT for other reasons, change in EDSS at 5, 7, 10, and 
15 years was not significant even after adjustment for age.
Conclusion: Delaying DMT initiation for a planned pregnancy 
did not have a major impact of disability over 15 years in our 
patients despite the frequent occurrence of relapses and statisti-
cally significant change in EDSS. Greater time on DMT during 
the first 5 years after their MS diagnosis was associated with a 
statistically significant reduction in EDSS change.
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Differential gene expression in men and women with multiple 
sclerosis compared with healthy individuals
H.-M. Laigaard, A. Oturai, C. Ammitzbøl, L. Börnsen, P. 
Soelberg Sørensen, F. Sellebjerg, H. Bach Søndergaard
Danish Multiple Sclerosis Center, Department of Neurology, 
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Background: Multiple sclerosis (MS) is an autoimmune disease 
that affects women more than twice as often as men, a difference 
that is still increasing. Still, sex-related underlying differences in 
gene expression in MS patients and healthy controls (HCs) have 
only been scarcely investigated.
Objective: To analyze differentially expressed genes in women 
and men with untreated MS by comparing them with HCs of the 
same sex.
Methods: We included 30 women with relapsing-remitting (RR) 
MS and 28 HC women and 17 men with RRMS and 30 HC men. 
RNA was extracted from whole blood and gene expression levels 
measured by Affymetrix Gene 2.0 ST array. Data normalization 
and analyses were performed in Partek Genomics Suite and the 
enrichment of annotated genes was investigated using the data-
base DAVID. We applied false discovery rate (FDR) (q< 0.01, 
±2-fold) on p-values to adjust for multiple comparisons.
Results: We found no differences between MS and healthy men 
and only PDK4 was higher expressed in MS women than in HC 
women (2.2-fold, q=1.75x10-9). Next we analyzed gene expres-
sion at ±1.3-fold difference by ANCOVA adjusted for age and 
scan-date (p< 0.05) and observed 21 differentially expressed 
genes in women with MS and HCs, including a higher expression 
of HLA-DRB1, -DQA1, -DQB1, -DRA and -DRB5 in MS 
women. At the same conditions 158 genes were differentially 
expressed between men with MS and HCs, however only HLA-
DRB1 and -DRB5 were significantly up-regulated in MS men 
compared to healthy individuals.
Functional annotation clustering, using the highest stringency, of 
all 21 genes identified 7 clusters of which 4 had significantly 
enriched (FDR< 0.01) pathways and enrichment scores from 6.63 
to 3.47. These 4 clusters consisted primarily of the above men-
tioned HLA-genes. In men functional annotation clustering of the 
158 genes resulted in 8 clusters with the highest enrichment score 
of 2.13 encompassing genes from the type 1 interferon signaling 
pathway and a cluster with granzyme proteins, however these 
clusters were not significant after FDR correction.
Conclusion: Interestingly, of the HLA-genes only HLA-DRB1 
and -DRB5 were higher expressed in both MS men and women. 
Most likely this reflects an effect of the MS-associated HLA-
DRB1*15:01 genotype. Of interest, the most differentially 
expressed gene in MS women (PDK4) is a mitochondrial protein 
involved in regulating the conversion of pyruvate to acetyl-CoA, 
and is inducible by several steroid hormones.
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Fertility, maternal and pediatric development outcomes: 
interim report from the PREG-MS registry
T.D. Mahlanza, M. Houtchens, on behalf of the PREG-MS Study 
Group
Ann Romney Center for Neurologic Diseases, Partners Multiple 
Sclerosis Center, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA, United States
Background: Multiple Sclerosis (MS) is commonly diagnosed in 
women of childbearing age and pregnancy management and out-
comes are highly relevant to this patient population. PREG-MS, 
the first prospective regional MS pregnancy registry in the United 
States, follows women with MS and their children from pre-con-
ception and any stage of conception to three years postpartum.
Methods: Detailed information on fertility, Assisted Reproductive 
Technologies (ART) disease modifying therapy (DMT) exposure, 
disease course, pregnancy course, and pediatric developmental 
outcomes is being collected through structured telephone inter-
views every 3 months, and medical records review.
Results: To date, study enrolled 50 women. 34% are in pregnancy 
planning stages, and 66% have either completed pregnancy or are 
currently pregnant with average time to conception of 3.4 (0.5-24) 
months. 30% of all subjects used ART. 10% of this group have 
failed one or more IVF cycles and all had moderate relapse within 
6-months post treatment. Spontaneous 1st trimester pregnancy 
loss was 9%. 31% of pregnancies were exposed to DMTs includ-
ing 2 patients who received glatiramer acetate (GA) throughout 
pregnancy. A third of patients reported pregnancy complications, 
regardless of DMT exposure, including preeclampsia, preterm 
labor, hypertension, low amniotic fluid, preterm amniotic sac rup-
ture and excessive hemorrhage during labor. Preeclampsia and 
placental abruption were seen in mothers, and low birth weight 
and increased muscle tone at birth was seen in infant,with full-
term GA exposure. Persistent motor developmental delay and 
ventricular septal defect were seen in infant of mother exposed to 
fingolimod. Infants born to non-DMT exposed mothers had low 
birth weights (22%) and reversible developmental delays (24%).
Conclusion: Data from this pregnancy registry contributes to our 
understanding of disease activity and DMT exposure effects on fertil-
ity, maternal and pediatric developmental outcomes. Prospective real 
world pregnancy registries can provide foundation for comprehensive 
disease management programs during pregnancy and postpartum.
Disclosure
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Inflammatory active peri- and postmenopausal patients in 
multiple sclerosis - a crosssectional study
B. Elias-Hamp1, C. Hebell-Siewers1, K. Hellwig2, L. Feddersen3, 
W.-G. Elias1
1Neurologic Practice, Hamburg, 2Department of Neurology, St. 
Josef Hospital, Ruhr University Bochum, Bochum, 3Department 
of Psychiatry, Friedrich-Ebert-Krankenhaus Neumünster, 
Neumünster, Germany
Objective: The objective was to determine MS disease activity 
peri- and postmenopausal in comparison to not menopausal 
patients in our private practice in Hamburg, Germany. Disease 
activity was documented via MRI and relapse rate.
Background: MS is widely known as a common neurological dis-
ease in especially young female patients. But these patients get 
older, and data on disease activity in peri- and postmenopausal MS 
patients are scarce. According to lacking experience neurologists 
may expect, that after or around menopause MS disease activity 
may disappear and therefore stop disease modifying therapy.
Design and methods: In our private practice 410 women with 
MS were retrospectively enrolled into the study. Detailed infor-
mation on the course of MS (relapses before 10, 5 and 2 years) as 
well as MRI-data in the most recent MRI (active T1-lesions, pro-
gress of T2-lesions) was obtained with a questionnaire developed 
for gynecologic and neurologic purposes.
Results: 304 questionnaires were included into analysis. 190 
patients (62,5%) were not menopausal, 83 patients (27%) peri- and 
24 patients (8%) postmenopausal, 7 patients (2%) remain unknown.
As to expect relapse activity was higher in not menopausal 
patients (57%), but still 38% of the perimenopausal patients had 
relapses in the last 2 years.
Whereas 11,4% of the not menopausal patients had active 
T1-lesions, 7,1% of the perimenopausal patients showed activity 
in the MRI.
Progress in T2-lesions was higher in not menopausal patients 
(30,3%) compared to peri- and postmenopausal patients (14,1%).
Conclusions: Disease activity in MS seems to decline with older 
age and during hormonal changes (menopause) in female patients, 
but in some of the patients disease activity is persisting clinically 
and in neuroimaging even in a higher age.
Clinical and radiological disease activity should therefore contin-
uously be monitored and disease modifying therapy adjusted 
accordingly.
Disclosure
Study supported by Genzyme.
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Kerstin Hellwig: Has received speaker honoraria, payments for 
consultancy, research grants and travel expense compensation 
from Biogen, Merck Serono, Bayer Healthcare, Almirall, 
Novartis, Teva, Genzyme and Roche.
Lena Feddersen: Has nothing to disclose.
Wolfgang-G. Elias: Has received speaker honoraria, payments for 
consultancy and travel expense compensation from Biogen, 
Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva and 
Genzyme.
EP1359
Pregnancy outcome and change in lymphocyte subset in 
peripheral blood in Japanese patients with multiple sclerosis 
after assisted reproductive treatment
Y. Shimizu, R. Ikeguchi, K. Kitagawa
Neurology, Tokyo Women’s Medical University, Shinjuku-ku, 
Japan
Background: Multiple sclerosis (MS) predominantly affects 
females, with clinical onset during the childbearing years. In MS 
patients, assisted reproduction treatment (ART) may significantly 
increase the risk for a relapse. However, whether ART is related to 
relapse in Japanese patients with MS is unclear.
Objective: To determine the pregnancy outcome and whether 
Japanese patients with MS have an increased risk of relapse after 
ART.
Subjects and methods: We studied five Japanese patients in our 
hospital with relapsing-remitting MS (RRMS) who were treated 
with ART and five RRMS patients who became pregnant naturally. 
All patients received disease-modifying drugs. The relationship 
between ART and relapse occurrence was analyzed. Peripheral 
blood lymphocyte subsets were analyzed by flow cytometry. 
Pregnant patients treated with ART were compared to patients who 
became pregnant naturally. We studied the CD4+CXCR3/
CD4+CCR4 ratio, CD8+CXCR3/CD8+CCR4 ratio, natural killer 
(NK) cells, and regulatory
T cells before and during pregnancy, after delivery, and after 
failed ART.
Results: Four patients treated with ART became pregnant and deliv-
ered a baby, and one patients experienced a missed abortion. No 
patients used GnRH for ART. No relapses occurred in the year prior 
to ART, during pregnancy, or after delivery in patients with success-
ful pregnancies. However, the RRMS patient who miscarried after 
IVF relapsed prior to ART and 2 months after the miscarriage. 
Peripheral blood lymphocyte subsets were not significantly different 
between patients treated with ART or not. The patient who failed 
IVF had increased NK cells at the time of abortion and a relapse 
compared with patients who became pregnant with/without ART.
Conclusion: No increase in relapses occurred in association with 
ART in patients with RRMS with stable disease activity. ART-
related relapses may be associated with relapses in the year prior 
to ART and after failed IVF. Increased NK cells may be a cause of 
ART failure and relapse.
Disclosure
YS has received honoraria for talks from Bayer Yakuhin, and has 
received personal compensation for consulting services from 
Biogen Idec Japan, Teijin Pharma, Takeda Pharmaceutical 
Company and Novartis Pharma.
RI and KK have no conflicts of interest to declare. This work was 
supported by a Health and Labour Sciences Research Grant on 
Intractable Diseases (Evidence-based Early Diagnosis and 
Treatment Strategies for Neuroimmunological Diseases) from the 
Ministry of Health, Labour and Welfare of Japan.
EP1360
Levels of serum anti-Muellerian hormone in women with 
relapsing-remitting multiple sclerosis
I. Srotova1, M. Svobodova1, I. Crha2, E. Kralickova 
Nekvapilova1, P. Valkovska1, M. Podborska3, E. Vlckova1, P. 
Stourac1, J. Bednarik1
1Neurology, 2Obstetrics and Gynecology, 3Clinical Biochemistry 
and Hematology, The University Hospital Brno, Brno, Czech 
Republic
Background: Multiple sclerosis (MS) is a neurological disease 
mostly affecting women of childbearing age.
Recent studies suggest that MS may have a negative impact on 
fertility. In general, decreased ovarian reserve is supposed to be 
one of the most important factors for fertility impairment.
It is not known if ovarian decline contributes to accumulation of 
disability in women with MS when evaluated using the Expanded 
Disability Status Scale (EDSS). Anti-Mullerian hormone (AMH) 
is a peptide hormone that represents a simple and widely available 
measure of ovarian reserve unrelated to the menstrual cycle.
The purpose of this study was to determine AMH levels in females 
with relapsing-remitting MS (RRMS) in comparison with healthy 
volunteers.
Methods: A total of 104 reproductive-age females (mean age 33.3 
± 5,7) with RRMS and 107 age-matched healthy controls (HC, 
mean age 33.3 ± 5.6) were included in this case control study.
In females with MS, the median EDSS score was 2.5 points and 
the median disease duration was 5.1 years.
An enzymatically amplified two-site immunoassay was used to 
measure serum AMH level.
Results: On a group level, only an unsignificant trend to reduced 
AMH values was found in RRMS patients (2.91±2.4 ng/ml) in 
comparison to healthy controls (3.50±2.6 ng/ml) (p = 0.09).
However, when being analyzed in 6 separated age-related sub-
groups, significant reduction of AMH values was found in MS 
patients at the age of 35-40 (2.2 ± 1.4 ng/ml) compared to age-
related healthy controls (3.8 ± 2.1 ng/ml) (p=0.01).
AMH values were not associated with EDSS in MS patients, but 
showed significant decrease with age both in healthy controls and 
MS group.
Conclusions: In general, no clear reduction in follicular reserve 
was found in MS women comparing to healthy controls. However, 
when being analyzed in particular age-related subgroups, the 
AMH values were lower MS patients than in HCs at the age of 
35-40. These results suggest possible negative impact of MS dis-
ease on fertility particular at the age above 35, which should be 
considered in parenthood planning.
This study was supported by the Masaryk University Specific 
Research Grant, MUNI/A/1028/2016.
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Srotova: nothing to disclose.
Svobodova: nothing to disclose.
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MS symptoms
EP1361
Study on the adherence to the Spanish Neurological Society 
consensus guidelines on the treatment of multiple sclerosis 
generalized spasticity in Spanish multiple sclerosis units
J.M.O. Prieto
Neurology, Hospital Clínico Universitario, Complejo 
Hospitalario Universitario de Santiago (CHUS), Santiago de 
Compostela, Spain
Background: The Spanish Neurological Society (SEN) 2013 
consensus guidelines on the treatment of generalized multiple 
sclerosis (MS) spasticity recommend early control of spasticity 
triggers and other external factors and initiation of physiotherapy. 
At the stage where spasticity becomes troublesome and pharma-
cological treatment is required, the guidance reflects that the type 
of spasticity (generalized or focal/regional) determines two sepa-
rate treatment pathways: while botulinum toxin is the option for 
focalized cases, baclofen or tizanidine are first-line treatments of 
choice for generalized spasticity. Diazepam is acknowledged also 
as an effective treatment for generalized spasticity but associated 
sedation advices to limit its use. In patients who respond inade-
quately to baclofen or tizanidine as monotherapy, second-line 
options are the use of THC+CBD oromucosal spray (Sativex) as 
add-on therapy or to use baclofen + tizanidine in combination; 
non-responders to each option can be switched over to the alter-
nate option.
Aim: Dimension the adherence in Spanish multiple sclerosis units 
to the SEN 2013 consensus guidelines on the treatment of MS 
spasticity.
Methods: Retrospective, multicenter data collection of MS mod-
erate to severe spasticity patients’ features and treatments. Patients 
should have reached at least a second drug treatment at recruit-
ment moment, and the data collected on MS and MS spasticity 
will go back in time as much as possible.
Results: 36 MS units were involved, data from 215 patients ana-
lyzed. Baseline data: mean age 52y, 62% women, mean 15y since 
MS diagnosis, mean EDSS score of 5.6, mean spasticity Ashworth 
scale score of 7.7(n=76), mean spasticity 0-10 NRS score of 
2.7(n=52). Regarding their MS spasticity management, 48% had 
resourced to rehabilitation/physiotherapy and 2% to botulinum 
toxin. The first line generalized spasticity drug treatments reported 
were: 81% baclofen, 23% tizanidine, , 16% benzodiacepines, 24% 
others. Second line treatments were: 7% baclofen + tizanidine, 
94%, baclofen or tizanidine + THC:CBD spray.
Conclusions: The 2013 SEN MS spasticity management guide-
lines are heterogeneously followed across cases and centers. 
Reported use of rehabilitation/physiotherapy seems low, botuli-
num toxin use reflects a limited identification of partial spasticity, 
baclofen is widely used as first line therapy, while use of 
THC:CBD as add-on is common in second line. Further educa-
tional activities on these guidelines seem required.
Disclosure
Study sponsored by Almirall S.A.. No other conflicts of interest 
apply.
EP1362
Balance and gait impairment at the early stages of multiple 
sclerosis
H. Ayan1, O. Ertekin2, T. Kahraman3, P. Yigit4, S. Ozakbas5, 
Multiple Sclerosis Research Group
1Department of Physiotherapy, Vocational School of Health 
Services, Izmir University of Economics, 2School of Physical 
Therapy and Rehabilitation, Dokuz Eylül University, 
3Department of Physiotherapy and Rehabilitation, Izmir Katip 
Celebi University, Faculty of Health Sciences, 4Dokuz Eylül 
University Hospital, 5Department of Neurology, Dokuz Eylül 
University, Faculty of Medicine, Izmir, Turkey
Background: Impaired balance is one of the most important risk 
factors for falls in persons with multiple sclerosis (PwMS). 
Majority of the studies have been limited to PwMS with signifi-
cant clinical disability. However, recent studies have suggested 
that even “PwMS with absence of clinical disability’’ (PwMS-AD) 
may also have balance and gait impairment.The aim was to evalu-
ate balance and gait performance in PwMS-AD and compare them 
to “PwMS with minimal disability’’ (PwMS-MD) and healthy 
controls (HC).
Methods: 19 PwMS-AD with the Expanded Disability Status 
Scale (EDSS) score ≤ 1.5 ,16 PwMS-MD with EDSS ≤ 3.0 and 39 
HC were assessed using a posturography, a laboratory-based 
movement analysis system and a clinical test, the Brief-Balance 
Evaluation Systems Test (Brief-BESTest). Limits of stability 
(LOS), postural stability (PS) and fall risk (FR) tests were per-
formed. The Activities-Specific Balance Confidence Scale (ABC) 
was used to evaluate subjective confidence in balance. Walking 
ability assessed with Timed 25 Foot Walk Test (T25FW) and 
12-Item Multiple Sclerosis Walking Scale (MSWS-12).
Results: Both MS groups had significantly worse LOS, PS and 
FR scores according to HC. Significant differences were found 
between PwMS-AD and healthy controls in all domains of LOS, 
PS and FR tests (p< 0.05), with an exception of the difference in 
anteroposterior PS (p>0.05). There was a significant difference in 
Brief-BESTest and T25FW scores (p< 0.05) but no significant dif-
ference was found in the ABC scale score (p>0.05) between 
PwMS-AD and HC. In addition, significant differences were 
observed between PwMS-AD and PwMS-MD in terms of PS, 
Brief-BESTest, T25FW, MSWS-12, ABC (p< 0.05).
Conclusion: This study has suggested that the PwMS-AD have 
impaired balance and gait performance compared to HC; how-
ever, subjective confidence in balance is not significantly different 
from HC. Although walking speed and balance parameters were 
affected before disability occurs in MS subjects, when minimal 
disability occurs, anteroposterior PS and subjective confidence in 
balance become significantly different according to the HC. 
Although the PwMS-AD do not complain about the balance and 
gait impairment, they should be assessed regularly regarding to 
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balance with clinical and laboratory-based analysis tools. This can 
lead to early detection of impaired balance and fall risk to design 
appropriate rehabilitation programs.
Disclosure
All authors declare nothing to disclose
EP1363
Presence of occipital neuralgia predicts high cervical spinal 
cord lesion in multiple sclerosis
N.R. Kissoon, J.C. Watson, O.H. Kantarci
Neurology, Mayo Clinic, Rochester, MN, United States
Background and purpose: Neuropathic pain can be the present-
ing feature or occur during relapses of Multiple Sclerosis (MS). 
The association of trigeminal neuralgia with MS has been well 
documented and is typically related to a pontine lesion. Limited 
data exists regarding occipital neuralgia in patients with MS. We 
tested the hypothesis that occipital neuralgia in MS is associated 
with high cervical spinal cord lesions (C2-3).
Methods: We reviewed the records of 29 patients diagnosed with 
both occipital neuralgia and MS, clinically isolated syndrome or 
radiologically isolated syndrome (RIS) by a neurologist at our 
institution from January 2001 to December 2014. We collected 
data on demographics, disease course of MS, description of pain, 
sensory findings, comorbid headache disorders, history of trauma, 
presence of C2-3 demyelinating lesions, and treatment response.
Results: The patients with both occipital neuralgia and MS were 
typically female (76%) and had a later onset (age > 40) of occipi-
tal neuralgia (72%). Of those (28 patients) with available imaging 
for review, 18 patients (64%) had the presence of a C2-3 lesion. 
The majority of patients with a C2-3 lesion had unilateral symp-
toms (83%) and episodic pain (78%). All patients with docu-
mented sensory loss (3/3) had a C2-3 lesion. Six out of the 8 
patients with progressive MS (PMS) (75%) had a C2-3 lesion with 
the remaining 2 patients having a potential alternative cause to 
their occipital distribution headache with moderate to severe cer-
vical spondylotic changes on imaging. Of the 8 patients with a 
C2-3 lesion and imaging at onset of occipital neuralgia, 5 (62.5%) 
had evidence of active demyelination with enhancement on MRI. 
All of the 8 patients with long term follow-up that had either 
relapsing remitting MS (5/5), RIS (2/2) or transverse myelitis 
(1/1) had a good response (as defined by pain freedom for greater 
than 1 month) after treatment with occipital nerve blocks (ONB) 
and/or high dose intravenous (IV) steroids. None of the patients 
with PMS (3/3) responded to treatment with ONB or high dose IV 
steroids.
Conclusions: Predictors of an association between occipital neu-
ralgia and presence of a C2-3 lesion were unilateral episodic 
symptoms, sensory loss, onset occurring later in life (age > 40), 
and PMS phenotype. Patients with PMS did not respond to ONB 
or high dose IV steroids, whereas other phenotypes responded to 
those treatments.
Disclosure
Narayan R. Kissoon: nothing to disclose
James C. Watson: nothing to disclose
Orhun H. Kantarci: nothing to disclose
EP1364
Cognition is not cognition: different aspects of cognitive defi-
cits in MS patients
E. Kannamueller1, S. Gierer2, S. Gierer2
1Neurologische Gemeinschaftspraxis Dillingen, Neurology, 
2Neurologische Gemeinschaftspraxis Dillingen, Dillingen, Germany
During the past years, increasing attention is being paid to opera-
tionalize cognitive deficits in MS-patients. Thereby it is generally 
assumed that affected persons suffer from cognitive decline in the 
course of the disease. Cognition itself is not a singular ability of 
the brain but indeed consists of various skills.
Objective: The aim of the study was to evaluate, whether the dis-
ease affects cognition in general or whether various aspects of 
cognitive dysfunction are impaired in particular.
Methods: 123 MS patients have been examined by the The Vienna 
Test Expert System Traffic, a test system which has been estab-
lished for testing driving ability skills. It consists of 5 different 
parts, each one tests an aspect of cognition: reaction time (RT), 
reactive stress tolerance(DT), visual orientation performance(LVT), 
attention, concentration (COG), observational ability and skills in 
gaining an overview(ATAVT). We examined by t-Test if there were 
any significant differences between the test outcomes. Furthermore, 
we analyzed if there were any connections between disease dura-
tion and cognitive deficits.
Results: The mean age of the 123 patients was 41,2 years (SD 
=10,7)), 21% were male and 79% female. Mean EDSS was 1,5 (SD 
= 1,6) and mean disease duration 123,4 months (SD = 102,7). The 
t-Test revealed that the patients had better test results in the test 
measuring attention and concentration compared with the other 
tests. There was a significant difference between attention/concen-
tration and reaction time (t(22) = 7.172, p < .001), visual orientation 
performance (t(244) = 5.705, p < .001), observational ability 
(t(237.2) = 3.768, p < .001) and reactive stress tolerance (t(241) = 
5.302, p < .001). There was also a significant correlation between 
disease duration and all kinds of cognitive deficits: disease duration 
and RT (r = -.22, p < .05), ATAVT (r = -.21, p < .05), LVT (r = -.26, 
p < .01), DT (r = -.29, p < .01) and COG (r = -.41, p < .01)
Conclusion: In comparison to a normal population, cognitive 
deficits of the examined MS patients include reaction time, visual 
orientation performance, observational ability, reactive stress tol-
erance and skills gaining an overview. In contrast, attention and 
concentration are not affected. Cognition is not impaired as a 
whole but in single aspects. Furthermore, disease duration was 
linked to cognitive decline.
Disclosure
The work was supported by a scientific grant of Novartis Pharma 
GmbH Deutschland
EP1365
Prognostic assessment of cognitive impairment, fatigue devel-
opment and depression according to brain lesions in patients 
with multiple sclerosis
O. Mialovytska, Y. Khyzhniak
Bogomolets National Medical University, Kiev, Ukraine
Background: Multiple sclerosis (MS) is a chronic, progressive, 
inflammatory, autoimmune, neurodegenerative disease of central 
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nervous system. Prevalence of cognitive impairment in patients 
with multiple sclerosis (MS) ranges from 40 to 70%. Presence of 
cognitive dysfunction at the early stages of the disease is an unfa-
vourable prognostic factor for the disease progression.
Objectives: Prognostic assessment of cognitive impairment, 
fatigue development and depression according to demyelinating 
lesions in patients with multiple sclerosis.
Methods: Cognitive impairment assessment was conducted using 
Montreal cognitive assessment scale (MoCA). For detecting 
fatigue was used Krupp´s Fatigue Severity Scale (FSS). Depression 
was detected using Beck´s Depression Inventory (BDI). For prog-
nostic assessment of cognitive disorders, fatigue or depression 
development in case of presence of lesions in the white matter of 
the brain (with various localization or characteristics), we deter-
mined the relative risk of their detection depending on presence or 
absence of demyelinating process in a particular area of the brain 
(risk assessment in terms of odds ratios - OR and 95% CI).
Results: A total of 170 patients have been examined: 57 - with 
cognitive decline, 62 - with symptoms of fatigue, 51 - with depres-
sion. In case of atrophy of the corpus callosum, statistically sig-
nificant increased risk of cognitive impairment in MS patients 
was determined (OR = 26 (3,40-198,9), p = 0.0001). Prognostic 
assessment of fatigue symptoms reliably depended on the pres-
ence of the atrophy of corpus callosum (OR = 2,82 (0,98-8,11), p 
= 0.047), lesions in the parietal lobes (OR = 2,46 (1,02- 5.9),
p = 0.041) and confluent lesions (OR = 2,58 (0,96-6,97), p = 
0.05). Statistically significant prognostic assessment of depres-
sion development in MS patients was obtained by the following 
indices: the corpus callosum atrophy (OR = 2,81 (1,15-6,86), p = 
0.021), lesions in the temporal lobes (OR = 5,22 (2,29-11,89), p = 
0.001) and confluent lesions (OR = 3,45 (1,42-8,41), p = 0.005).
Conclusions: particular localization of demyelinating lesions in 
the white matter of the brain may be a prognostic factor for the 
development of cognitive and emotional disorders in patients with 
multiple sclerosis.
Disclosure
Nothing to disclose
EP1366
Cognitive dysfunction in a Spanish cohort with multiple 
sclerosis: evaluation of cognitive reserve and other predictive 
factors
N. Cerdá Fuertes, M. Díaz Sánchez, L. Lebrato Hernández, M. 
Prieto León, J.L. Casado Chocán, A.J. Uclés Sánchez
Neurology, Hospital Virgen del Rocio, Sevilla, Spain
Cognitive dysfunction(CD) in multiple sclerosis(MS) is one of the 
most disabling symptoms of the disease, affecting 30-65% of 
patients. Most commonly affected cognitive domains are memory, 
attention and processing speed. The protective effect of cognitive 
reserve(CR) has been demonstrated. We aim to analyze the preva-
lence of CD and the type of domain impairment in a Spanish MS 
cohort. In addition, we examine the effect of CR, mood disorders, 
fatigue, psychiatric drugs, demographic and clinical variables on 
cognitive performance(CP).
We enrolled MS patients over 24 years old diagnosed according to 
the McDonald Criteria 2011. We excluded patients with other 
neurologic diseases or conditions that may affect CP(relapses, 
corticoid treatment or changes in disease modifying therapies in 
the last 4 weeks, psychiatric disorder...).We used Rao abbreviated 
Neuropsychological battery to analyse the prevalence of CD; edu-
cational level, years of education, professional complexity, vocab-
ulary knowledge and leisure activities to evaluate CR; and 
validated questionnaires for demographic variables, clinical forms 
of MS, EDSS, fatigue, anxiety and depression.
We included 62 MS patients(74.2% women) with a mean age of 
39.98 years. The prevalence of cognitive dysfunction was 38.7%. 
Verbal memory (64.5%) and processing speed(32.2%) were the 
most affected domains. Educational level(p=0.014), years of 
education(p=0.004), professional complexity(p=0.005), vocabulary 
knowledge(p=0.006), and leisure activities(p=0.014) were associ-
ated with a better CP in univariate analyses. Disability(p=0.045) 
and the usage of psychiatric drugs(p=0.002) were associated with 
worse CP in univariate analyses. Multivariate logistical regression 
model showed that low scores in leisure activities(p=0.031) and 
vocabulary knowledge (p=0.047) were independent variables for 
prediction of CD in MS.
Our results confirm a similar prevalence of CD and the type of 
domain impairment in a Spanish MS cohort as previously 
described in the literature. We also confirm a protective value of 
CR(measured by leisure activities and vocabulary knowledge) in 
the appearance of CD in MS.
Disclosure
Cerdá Fuertes N: nothing to disclose
Díaz Sánchez M: nothing to disclose
Lebrato Hernández L: nothing to disclose
Prieto León M: nothing to disclose
Casado Chocán JL: nothing to disclose
Uclés Sánchez AJ: nothing to disclose
EP1367
Validation and cross-cultural adaptation of the Composite 
Autonomic Symptom Score-31 (COMPASS-31) in Croatian 
and Serbian multiple sclerosis patients
J. Drulovic1, A. Gavrilovic2, L. Crnosija3, D. Kisic-Tepavcevic4, 
M. Krbot Skoric5, J. Ivanovic1, I. Adamec5, I. Dujmovic1, 
A. Junakovic5, G. Maric4, V. Martinovic1, S. Mesaros1, T. 
Pekmezovic4, M. Habek5
1Clinic of Neurology, CCS, Faculty of Medicine, University 
of Belgrade, 2Department of Neurology, Clinical Center 
Zvezdara, Belgrade, Serbia, 3School of Medicine, University of 
Zagreb, Zagreb, Croatia, 4Institute of Epidemiology, Faculty of 
Medicine, University of Belgrade, Belgrade, Serbia, 5University 
Hospital Center Zagreb, Department of Neurology, Referral 
Center for Autonomic Nervous System Disorders, Zagreb, 
Croatia
Aim: To validate and cross-culturally adapt both Croatian and 
Serbian versions of the Composite Autonomic Symptom Scale-31 
(COMPASS-31) questionnaire for the detection of dysautonomia 
in multiple sclerosis (MS).
Methods: A total of 179 patients, 67 with clinically isolated syn-
drome (CIS) and 112 with MS at two MS centers (Zagreb and 
Belgrade) between April 1 and October 31, 2016 completed the 
COMPASS-31 questionnaire. Demographic and clinical data, 
including age, gender, MS phenotypes and the Expanded Disability 
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Status Scale (EDSS) were collected. Internal consistency of the 
Serbian and Croatian versions of the COMPASS-31 was evaluated 
using Cronbach’s alpha coefficient. Test-retest reliability of scores 
was evaluated by calculation of the intra-class correlation coeffi-
cient (ICC). Receiver operating characteristic (ROC) curve analy-
sis was used to determine a cut-off value of COMPASS-31 total 
score.
Results: The Cronbach’s alpha coefficient of total COMPASS-31 
for the Croatian MS sample was 0.844 and for the Serbian MS 
sample 0.779. Joint analysis demonstrated range of Cronbach’s 
alpha coefficients from 0.394 to 0.796, with values of four domains 
higher than 0.700. In both Croatian and Serbian samples, and in the 
total group, the Cronbach’s alpha coefficient of COMPASS-31 was 
0.785. Reproducibility measured by ICC was acceptable (0.795). 
With regard to the clinical validity, significant correlation (p< 
0.001) was found between EDSS and the total COMPASS-31 
score. Furthermore, significant differences between MS pheno-
types were detected for Bladder and Gastrointestinal domains, and 
for the total COMPASS-31 score (p< 0.001, p=0.005, and p=0.027, 
respectively). Finally, significant differences between MS pheno-
types in the proportion of participants with score >0, implicating 
the existence of at least one of the symptoms investigated in each 
domain, were detected for Secretomotor and Bladder domains 
(p=0.015 and p< 0.001, respectively). According to the ROC anal-
ysis, the highest sensitivity and specificity was detected for 
Orthostatic intolerance domain. The COMPASS-31 questionnaire 
sensitivity was 94.4% for MS patients who were experiencing 
orthostatic intolerance symptoms prior to testing; the specificity 
was 82.4%.
Conclusions: COMPASS-31 represents a valid and well accepted, 
self-assessment instrument for detection of dysautonomia in MS.
Disclosure
Jelena Drulovic serves on scientific advisory boards for Bayer 
Schering Pharma, Merck Serono, Teva, Genzyme, a Sanofi 
Company, and received honoraria for speaking from Merck 
Serono, Teva, Bayer Schering, Genzyme, a Sanofi Company, 
Medis, Roche; and has also received research grant support from 
the Ministry of Education and Science, Republic of Serbia (pro-
ject no. 175031).
Andjela Gavrilovic: nothing to disclose.
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Serono, and has received research grant support from the Ministry 
of Education and Science, Republic of Serbia (project no. 175031).
Tatjana Pekmezovic has received compensation for consulting ser-
vices, travel expenses for scientific meetings, and speaking hono-
raria from Bayer Schering Pharma, Merck Serono, Actavis/Teva, 
Roche, Gedeon Richter, Novartis; supported by a grant of the 
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Republic of Serbia (No. 175087 and 175090).
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EP1368
Are inhibitory and excitatory neurotransmitter levels in the 
posterior cingulate cortex associated with MS fatigue?
J. Arm1, K.A. Ribbons2, R. Lea3, S. Ramadan1, J. Lechner-
Scott2,3,4
1School of Health Sciences, University of Newcastle, 2Neurology, 
John Hunter Hospital, 3Hunter Medical Research Institute, 
4School of Medicine and Public Health, University of Newcastle, 
Newcastle, NSW, Australia
Background and aims: Fatigue is one of the most debilitating 
symptoms for MS patients. However, the role of neurotransmitters 
such as Gamma aminobutyric acid (GABA) and Glutamate in the 
pathology of fatigue is poorly understood. In this study, we utilized 
two-dimensional localised correlation spectroscopy (2D L-COSY) 
to determine if there was any association between GABA and 
Glutamate+Glutamine (Glx), in the posterior cingulate cortex, 
with clinical fatigue in relapsing remitting MS (RRMS).
Methods: 58 adult RRMS patients and 44 age and sex matched 
healthy subjects (HC) were recruited to the study. All patients 
were undergoing treatment with Fingolimod or Interferon or 
Glatiramer Acetate therapy. Self-reported fatigue status was 
measured on all participants using the Modified Fatigue Impact 
Scale (MFIS). All participants were scanned on a Siemens Prisma 
3T MR system with 64 channel head coil and 2D L-COSY was 
acquired from a 3x3x3 cm3 voxel in the normal appearing poste-
rior cingulate cortex (PCC) with TEinitial=30ms and 96 increments. 
Spectral analysis was undertaken using Felix software with all 
peaks normalised to total creatine (tCr) as an internal reference. 
To evaluate the differences in fatigue status between MS and con-
trol groups, independent student t-tests were used. Correlation 
(Spearman’s rho) assessed the association between fatigue scores 
with GABA and Glx levels.
Results: Total MFIS, physical fatigue and cognitive fatigue were 
significantly increased by 54.35%, 59.6% and 49.12%, respec-
tively, in RRMS compared to HCs (p≤ 0.05). The levels of PCC 
GABA/tCr and Glx/tCr in RRMS were significantly reduced by 
3.22% and 4.52% (p≤0.05), respectively, compared to those in 
HCs. In RRMS, we saw a positive association between GABA 
and Glx (r=0.28, p≤0.05). However, there was no significant cor-
relation between either Glx/tCr or GABA/tCr PCC levels with 
fatigue levels in RRMS.
Conclusions: The reduced levels of GABA and Glx in this study 
may reflect pathological alterations in RRMS patients with 
fatigue. The close link between GABA and Glx, primarily gluta-
mate, production in the GABAergic pathway could explain the 
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positive association. Although we could not find a correlation 
with fatigue levels, this study is the first to investigate changes in 
these neurotransmitters using 2D L-COSY in MS fatigued 
subjects.
Disclosure
Jameen Arm: Nothing to disclose.
Karen Ribbons: Funding for this study was supported by an 
Investigator-Initiated Grant provided by Novartis.
Rod Lea: Nothing to disclose.
Saadallah Ramadan: Nothing to disclose.
Jeannette Lechner-Scott: Accepted travel compensation from 
Novartis, Biogen and Merck. Her institution receives the hono-
raria for talks and advisory board commitment from Bayer Health 
Care, Biogen, Genzyme Sanofi, Merck, Novartis, Teva and 
Roche, has been involved in clinical trials with Biogen, Novartis 
and Teva.
EP1369
Correlation of fatigue with cognitive and physical disability 
using clinical outcomes and MRI measurements
M. Said1, S. Hannoun1,2, N. El Ayoubi1, D. Bacha1, B.I. 
Yamout1, S.J. Khoury1,2
1Nehme and Therese Tohme MS Center, 2Abu-Haidar 
Neuroscience Institute, American University of Beirut, Beirut, 
Lebanon
Introduction: Fatigue is an underestimated symptom affecting up 
to 95% of patients with multiple sclerosis (MS). It doesn’t only 
exacerbate impairment, but also affects a patient’s sense of control 
over the illness. In order to help patients cope with this disabling 
but treatable aspect of MS, it is necessary to understand the cor-
relation between fatigue domains, cognitive functioning, and 
physical ability.
Methods: Adult MS patients diagnosed as relapsing remitting 
(RRMS) or progressive were clinically evaluated. The Modified 
Fatigue Impact Scale (MFIS) was administered to both MS and 
healthy age-and-sex-matched control subjects. Processing speed 
was assessed using the Symbol Digit Modality Test (SDMT) and 
global brain atrophy was evaluated using MRI examinations. 
3DT1 and 3DFLAIR images were acquired and processed. 
Intracranial volume (ICV) and subcortical gray matter structures, 
lateral ventricles and corpus callosum were segmented and their 
volumes measured using the volBrain pipeline (http://volbrain.
upv.es) and the SIENAX tool in FSL. Univariate analysis was per-
formed to explore differences between subjects with and without 
fatigue. Multivariate analysis controlling for age, gender, educa-
tion level, EDSS, disease duration, clinical depression, and MS 
type and treatment was performed to see the correlations between 
fatigue and the different variables.
Results: 113 MS patients with mean disease duration of 8.6 years 
and 57 healthy subjects were recruited. Significant fatigue was 
seen in 32.3% of MS patients and 6.2% in controls. Among 
fatigued MS participants, 66% and 75% had respective physical 
and cognitive fatigue. Multivariate analysis showed that SDMT 
correlated negatively with fatigue (p=0.001, OR=0.88), more spe-
cifically with its cognitive domain (p= 0.003, OR=0.9). In addi-
tion, Physical fatigue positively correlated with EDSS (p=0.04, 
OR=1.4), particularly with the pyramidal FS score (p=0.031, 
OR=2.5). In multivariable linear regression and adjusting for age, 
disease duration, EDSS, and depression, there was a negative cor-
relation between MFIS scores and ICV (β = -0.54, p< 0.0001) and 
a positive correlation with the volume of lateral ventricles (β= 
0.37, p=0.006) and all-ventricular volume (β = 0.35, p=0.007).
Conclusion: . There is an association between cognitive fatigue 
and SDMT, as well as physical fatigue with EDSS pyramidal FS 
score. There is also an association between cognitive and physical 
fatigue and brain atrophy.
Disclosure
All authors have no conflict of interest to disclose.
EP1370
Sleep disorders in patients with multiple sclerosis and their 
link with fatigue
I. Gómez-Estévez, Y. El Berdei Montero, M. Fiz Santelesforo, 
J.C. Gómez-Sánchez
Complejo Asistencial Universitario de Salamanca, Salamanca, 
Spain
Introduction: Recent studies propose that patients with Multiple 
Sclerosis (MS) are at increased risk for sleep disturbances and they 
are undiagnosed. Fatigue is perceived as one of the most disabling 
symptoms in MS. The relation between fatigue and sleep distur-
bances is a subject of study due to it is not yet fully understood.
The primary endpoint of this study is to analyze the prevalence of 
sleep disorders in a cohort of adult patients with MS evaluating 
the link between these disorders and their clinical features (type of 
MS, disease duration, clinical severity, presence of spinal demy-
elinating lesions and presence or absence of Interferon).
The other main objective is to evaluate the relations between sleep 
disturbances and fatigue of the MS patients enrolled in the study.
Methods: Fifty-nine patients with MS took part in this cross-sec-
tional study. Participants completed standardized validated ques-
tionnaires related fatigue (Modified Fatigue Impact Scale-MFIS) 
and sleep disturbances (Insomnia Severity Index-ISI, STOP-
BANG questionnaire, Pittsburgh Sleep Quality Index -PSQI and 
patients who meet International Restless Legs Syndrome Study 
Group criteria for the diagnosis of Restless Legs Syndrome com-
pleted Restless Legs Syndrome Rating Scale-RLS).
Results: As concerns sleep evaluation, 35.6% patients suggesting 
RLS, 54.2% have insomnia (ISI score>5), 10.2% have a high or 
medium risk of Sleep Apnea Syndrome (SAS) according to the 
STOP-BANG questionnaire and 35.6% patients were considered 
fatigued (MFIS>45).
Statistical analysis showed that clinical findings are not associated 
whit sleep quality and sleep disturbances; except high risk of 
OSAS which was associated with disease duration (U-test=77.500; 
p=0.041).
Patients with fatigue show higher prevalence of poor sleep quality 
(p=0.012) and sleepiness (p=0.001) whit higher PSQI scores 
(U-test=225.000; p=0.006) and sleepiness score (U-test=201.000; 
p=0.001). They have higher prevalence of RLS (p=0.022), insom-
nia (p=0.000), and OSAS (p=0.018), with higher severity of 
symptom: U-test=235.500, p=0.002; U-test=170.500, p=0.000 
and U-test=245.500, p=0.009 respectively.
Conclusions: The present study demonstrates the association 
between MS and a higher prevalence of sleep disorders. Besides, 
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it shows the close link between insomnia, sleepiness, sleep qual-
ity, OSAS presence, RLS and fatigue. On the contrary, sleep qual-
ity and sleep disorder are not related with the analyzed clinical 
findings.
Disclosure
Irene Gómez-Estévez: nothing to disclose
Yasmina El Berdei Montero: nothing to disclose
Marta Fiz Santelesforo: nothing to disclose
José C. Gómez-Sánchez: nothing to disclose
EP1371
Patient-reported outcomes are worse for progressive-onset 
MS than relapse-onset MS, particularly early in the disease 
process
Y. Zhang, B. Taylor, I. van der Mei
Menzies Institute for Medical Research, Hobart, TAS, Australia
Background: Dramatic progress has been made for people with 
relapse-onset multiple sclerosis(MS). However, for the 15% pro-
gressive-onset MS cases, the knowledge is limited, and only ocre-
lizumab was recently confirmed as an effective therapy. To 
increase our knowledge and improve disease management for 
progressive-onset MS, understanding the differences between the 
two MS onset types is vital.
Objective: To examine differences between progressive-onset 
MS and relapse-onset MS in relation to disability, disability pro-
gression, MS symptoms and quality of life on the basis of patient-
reported outcomes.
Method: The Australian Multiple Sclerosis Longitudinal Study 
(AMSLS) database of 1985 cases was used in this cross-sectional 
study. Associations between onset-type and outcomes were assessed 
with negative binomial regression and adjusted for confounders 
such as age, disease duration, gender, and age of diagnosis.
Results: Seventeen of the nineteen outcomes of progressive-onset 
MS patients were significantly more severe than relapse-onset MS 
patients after adjustment for confounders, including disability, pro-
gression over the last year, fatigue, sensory symptoms, walking 
difficulties, pain, balance, sexual dysfunction, bladder problems, 
bowel problems, spasticity, anxiety, depression and EQ-5D (the 
adjusted mean ratios ranged from 1.11 to 1.52). Importantly, the 
difference between the two onset types was most pronounced early 
in the disease process and reduced with increasing MS duration, 
with the interaction between onset types and MS duration being 
significant for disability, progression over the last year, walking 
difficulties, bladder problems, bowel problems and spasticity.
Conclusions: People with progressive-onset MS were signifi-
cantly worse off on nearly all patient-reported outcomes com-
pared to relapse-onset MS counterparts. The differences were 
most pronounced early in the disease course. The findings support 
the work of the International Progressive MS Alliance and high-
light the urgency of identifying early interventions for progres-
sive-onset MS.
Disclosure
Yan Zhang: nothing to disclose
Ingrid van der Mei: nothing to disclose
Bruce Taylor: nothing to disclose
EP1372
Perceived cognitive impairment and cognitive test perfor-
mance assessment in multiple sclerosis patients
R. Totaro1, C. Raparelli1, S. Sciamanna1, C. Di Carmine1, P. 
Cerrone1, C. Marini2, A. Carolei3
1Multiple Sclerosis Center, San Salvatore Hospital, 2MESVA, 
3DISCAB, University of L’Aquila, L’Aquila, Italy
Background: Discrepancy might exist between perception of 
cognitive functioning and cognitive performance in multiple scle-
rosis (MS) patients, as a consequence of under- or overestimation 
of cognitive dysfunction.
Objective: The aim of this study was to explore the correlation 
between perceived cognitive dysfunction on a self-reported ques-
tionnaire and performance on specific cognitive domains and 
Brief Repeatable Battery (BRB) in a cohort of patients with MS.
Methods: Between November 2015 and December 2016, 94 
relapsing-remitting MS patients afferent to our MS center were 
asked to complete the Perceived Cognitive Deficit (PCD) ques-
tionnaire, an 11 item self-reported assessment tool exploring the 
patient perceived degree of cognitive impairment in 6 major cog-
nitive domains (verbal memory, visuo-spatial memory, learning, 
sustained attention and concentration, speed of information pro-
cessing, and verbal fluency. Answers reported on a 5-degree scale 
were further converted into dummy variables (yes/no) according 
to low (grade 1-3) or high (grade 4-5) self-perception of cognitive 
impairment. Domain-specific perceived cognitive performance 
was then correlated with corresponding scores in selective BRB 
subtests exploring verbal memory (SRT-LTS, SRT-CLRT), visuo-
spatial memory (SPART), learning (SRT-D SPART-D), sustained 
attention and concentration (SDMT), speed of information pro-
cessing (PASAT-3, PASAT-2) and verbal fluency (WLG).
Results: Out of 94 included patients, 29 were men and 65 women. 
Mean age was 44.3±8.5 years. Mean duration of the disease was 
10.7±5.2 years. Mean schooling values were 14.1±3.5 years. 35 
patients perceived a deficit of verbal memory while a deficit was 
found in 44. 25 patients perceived a deficit of visuo-spatial learn-
ing while a deficit was found in 38. 26 patients perceived a deficit 
of learning while deficit was found in 52. 33 patients perceived a 
deficit of sustained attention and concentration while a deficit was 
found in 49. 26 patients perceived a deficit of speed of informa-
tion processing while a deficit was found in 59. 28 patients per-
ceived a deficit of verbal fluency while a deficit was found in 19.
Conclusions: Results of our study showed a discrepancy 
between perceived and estimated cognitive impairment. For 
most of the cognitive domains patients underrated cognitive dys-
functions while the perception of deficit of verbal fluency was 
overestimated.
Disclosure
None
EP1373
Continuous facial myokymia and hemifacial spasm at initial 
presentation of multiple sclerosis
O. Cousins1, Y. Collins-Sawaragi1, S. Harikrishnan1,2
1Neurology, Kent and Canterbury Hospital, Canterbury, 
2Neurology, King’s College Hospital NHS Foundation Trust, 
London, United Kingdom
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Introduction: Involuntary facial movements including continu-
ous facial myokymia (CFM) and hemifacial spasm (HFS) are rare 
clinical manifestations of multiple Sclerosis (MS). CFM is char-
acterised by rhythmic, vermiform movement of unilateral facial 
musculature with MS being the most common aetiology. 
Meanwhile, HFS presents with irregular, synchronous unilateral 
tonic or clonic facial muscle contractions which is very rarely 
associated with MS. We present three patients with abnormal 
facial movements at initial neurology review who were subse-
quently diagnosed with MS.
Case 1: 37-year-old man presenting after two months of diverse 
focal neurological symptoms. Left sided CFM noted on examina-
tion. MRI showed florid T2 lesions in brain, brainstem (left mid-
brain/pons) and spinal cord with multiple contrast enhancing 
lesions.
Case 2: 46-year-old woman presenting with right sided CFM. She 
had a previous episode of transient right leg numbness. MRI 
showed multiple T2 lesions in the brain and spinal cord but none 
involving the brainstem (previously presented at the Association 
of British Neurologists conference 2017).
Case 3: 47-year-old man presented with HFS recorded by patient 
on video which spontaneously resolved. MRI showed one subcor-
tical and two periventricular T2 lesions but no brainstem lesion. 
He declined investigation at this point. Six years later he devel-
oped an ataxic gait and MRI showed progression.
All patients fulfilled the 2010 Revised McDonald Criteria for a 
diagnosis of MS.
Discussion: There are only 2 case reports of CFM and 1 case 
report of HFS as the presenting symptom of MS in the literature. 
CFM is usually associated with an ipsilateral lateral pontine lesion 
on MRI. Only one of the two patients demonstrated this lesion. 
HFS is commonly attributed to a vascular compression of the 
facial nerve. However, in MS, an ipsilateral facial nucleus lesion 
has occasionally been described although not in our case.
Although MS presenting with HFS or CFM is rare, knowledge of 
the association is essential to enable timely diagnosis. These cases 
also demonstrate that typical MRI lesions may be absent.
Disclosure
Oliver Cousins: Nothing to disclose
S Harikrishnan: Nothing to disclose
Yoshua Collins-Sawaragi: Nothing to disclose
EP1374
Symptoms of bowel dysfunction in people with muliple scle-
rosis
K. Goodman1, D. McClurg1, S. Hagen1, S. Doran1, S. 
Manouokian1, F. Harris2, P. Donnan3, A. Emmanuel4, J. Norrie5, 
S. Treweek5, M. Coggrave6, H. Mason1
1Nursing, Midwifery and Allied Health Professions Research 
Unit, Glasgow Caledonian University, Glasgow, 2University of 
Stirling, Stirling, 3University of Dundee, Dundee, 4University 
College London, London, 5University of Aberdeen, Aberdeen, 
6Kings College London, London, United Kingdom
Background: Overall prevalence of bowel dysfunction symp-
toms is unknown in people with multiple sclerosis (PwMS). This 
is due to variations in definition and reticence of patients and cli-
nicians to discuss them. Faecal incontinence is recognised as life 
changing whilst constipation is often dismissed as minor, but our 
findings report otherwise.
Methods: 237 PwMS were assessed for eligibility of a ran-
domised controlled trial at 12 centres throughout the United 
Kingdom . Symptoms were recorded at the initial assessment visit 
whilst ano-rectal dysfunction tests were undertaken at one 
centre.
Results: 29 (12.2%) did not meet the inclusion criteria i.e. trou-
blesome constipation, with a further 17 (7.1%) meeting the crite-
ria, but were not randomised. 35 males and 154 females were 
recruited with a mean age of 52.3 years (SD 10.83), duration of 
MS 14.3 years (SD 9.18). 106(56.1%) reported having relapsing 
remitting MS, 59(31.2%) secondary progressive and 22 (11.6%) 
primary progressive, with 88 (46.6%) using unilateral or bilateral 
assistance to walk 20-100m. 71(37.6%) reported they had had 
constipation for more than 10 years, 82(44.4%) from 2-10 years 
and 34(28%) less than 2 years. 150(79.4%) reported severity of 
symptoms as moderate or severe. The primary symptom was 
bloating 162(85.7%), straining more than 50% of the time 
123(59.3%), incomplete emptying more than 50% of the time 
151(79.8%) and spending from 5 to 20 minutes per attempt at 
evacuation was found in 111 (59.1%) participants. Analysis of the 
ano-rectal sub-study indicated that 15(65.2%) had slow transit. 
112 (59.3%) participants were passing stool 2-4 times per week.
Discussion: Constipation is not just infrequent passing of stool. 
Considerable time, effort and discomfort is associated and such 
questions need to be asked when assessing bowel dysfunction. 
Our qualitative data supported our quantitative findings in that 
often PwMS required significant time for toileting and were 
reluctant to leave home without going to the toilet or indeed use 
public toilets. Furthermore, bloating is embarrassing with some 
females being mistaken for being pregnant; incomplete evacua-
tion is very uncomfortable, whilst overflow incontinence may 
not be recognised as a diagnostic symptom that may require 
hospitalisation.
Conclusion: Symptoms of constipation are multifactorial and 
awareness of the impact on quality of life needs to be raised so 
that effective and timely management can be implemented.
Disclosure
None
EP1375
The role of fatigue and cognitive impairment in early retire-
ment due to multiple sclerosis
T. Heinonen1, K. Mäkinen1, E. Castren1, P. Hämäläinen2, H. 
Kuusisto1
1Neurology, Kanta-Häme Central Hospital, Hämeenlinna, 
2Masku Neurological Rehabilitation Centre, Masku, Finland
Multiple sclerosis (MS) is the most common cause of non-trau-
matic neurological disability affecting mainly young adults during 
their best working years. For the past couple of decades fatigue as 
well as neuropsychological deficits have been recognized to be 
crucial symptoms in majority of the patients. It seems that major-
ity of the patients are unable to retain employment long term and 
retire soon after the diagnosis is made. We have previously 
reported the median time for the disability pension to be 6 years. 
Therefore, we aimed to evaluate the role of cognitive impairment 
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and fatigue in the risk of early retirement due to MS in a commu-
nity dwelling MS cohort.
Patients diagnosed with MS between 2000 and 2016 where col-
lected from the electronic patient records. The retention rate of 
retirement was evaluated by Kapplan Maier method. The presence 
of fatigue was collected from the patient files and the presence of 
cognitive impairment from the neuropsychological assessments. 
Both results were analysed by the Cox proportional hazard regres-
sion analysis.
Altogether 260 patients were identified (63 males and 197 
females). 56/260(21.5%) patients were retired by the time of the 
analysis and 66/260(25.3%) patients had gone through a neu-
ropsychological assessment. 115/260(44.2%) patients suffered 
from fatigue and 59/260(22.7%) patients from other neuropsycho-
logical symptoms. Fatigue was a risk factor for the retirement (age 
adjusted HR 2.78 (95% CI 1.59-4.34)) but the presence of cogni-
tive dysfunction or deficit in any of the domains in neuropsycho-
logical testing showed no statistical significance (age adjusted HR 
1.22 (95% CI 0.73-2.1).
Fatigue in patients with MS is a major risk factors for early retire-
ment. There is a clear unmet need to find effective therapies for 
fatigue to prevent early retirement. We did not find the presence of 
neuropsychological deficits to be an independent risk factor for 
early retirement due to MS. This might be due to the previously 
found correlation to the EDSS and disease duration.
Disclosure
Tommi Heinonen: nothing to disclose
Kati Mäkinen: nothing to disclose
Elina Castren: nothing to disclose
Päivi Hämäläinen: consultation fees and travel grants (Teva, 
Merck, Biogen, Genzyme, Novartis, Roche)
Hanna Kuusisto: consultation fees and travel grants (Teva, Merck, 
Biogen, Genzyme, Novartis, Roche)
EP1376
Symptoms related to multiple sclerosis: experience based on 
the systematic data collection from an electronic device
R. Robles Cedeño, H. Perkal Rug, E. Quintana Camps, M. 
Merchán Ruiz, L. Ramió-Torrentà
Neuroimmunology and Multiple Sclerosis Unit, Neurology 
Department, Dr. Josep Trueta University Hospital, Girona. 
Biomedical Research Institute (IDIBGI), Girona, Spain
Objective: The appropriate measurement and management of 
symptoms related to multiple sclerosis (SymR-MS) could improve 
the quality of life of patients. Clinician-rated measures of these 
symptoms purport to be objective but do not measure the patient’s 
experience and may not be sensitive to changes that are meaning-
ful to the patient. In addition, obtaining this crucial information is 
often time-consuming and therefore not routinely collected. We 
present our experience in the systematic data collection of a total 
of 10 validated scales for different SymR-MS from an electronic 
device. The patients complete the scales in the waiting room and 
the data are automatically uploaded to the electronic medical 
records being evaluated in real time by the neurologist.
Material and methods: The analysis included MS clinical form, 
Disease Modifying Therapies (DMT), administration route and a 
total of 10 patient-based measures including Numeric Rating 
Scale (NRS) for Spasticity, Penn Spasms Frequency Scale, 
Bladder Control Scale, Sleep Quality Scale, Gait Quality Scale, 
NRS for pain, Barthel index, Fatigue Severity Scale, The European 
Quality of Life-5 dimensions and Sexual Satisfaction Scale.
Results: 20 patients with MS (80% RRMS, 20% SPMS) and 13 
controls were analyzed. Most of patients (75%) were treated with 
first line DMT (44% oral, 33% subcutaneous). Patients with MS had 
a higher Kurtzke scale (EDSS) (p>0.001), increased spasticity 
(p=0.006) and greater gait difficulty (p=0.007) than controls. 
Patients with SPMS complained of greater spasticity (p=0.001), fre-
quency of spasms (p=0.002), gait difficulty (p=< 0.001), degree of 
dependence (p=0.027), worse bladder control (p=0.028) and worse 
sexual satisfaction (p=0.034) than controls. When comparing SPMS 
and RRMS patients, these differences were significant only for gait 
difficulty (p=0.027). Patients with EDSS >3.0 complained of worse 
spasticity (p=0.007), bladder control (p=0.009) and gait difficulty 
(p=0.002) compared to patients with EDSS < 3.0. No significant dif-
ferences were observed with respect to DMT or route of administra-
tion. In the correlation analysis, the parameters related to a worse 
quality of life were the sleep disorders and the pain.
Conclusions: The application of an electronic method in the col-
lection of SymR-MS provides crucial information in real time 
during the visit of the patient. In our experience allows us to sys-
tematically quantify these symptoms and make appropriate thera-
peutic decisions.
Disclosure
Robles-Cedeño, René reports no disclosures.
Perkal Rug, Héctor reports no disclosures.
Quintana Camps, Ester reports no disclosures.
Merchán Ruiz, Miguel reports no disclosures.
Lluís Ramió-Torrentà: has received compensation for consulting 
services and speaking honoraria from Biogen Idec, Novartis, 
Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries 
Ltd and Almirall.
EP1377
Analysis of pre-randomization run-in data demonstrates 
muscle cramps and spasms are common, and associated with 
pain in MS
G. Short, B. Hegarty, J. Szegda, W. McVicar, C. Westphal, T. 
Wessel
Flex Pharma, Boston, MA, United States
Background: FLX-787 is a TRPA1/TRPV1 ion channel activator 
that is efficacious in decreasing muscle cramp intensity in an elec-
trically-induced cramp (EIC) model in healthy volunteers, and 
cramp frequency in otherwise healthy subjects with nocturnal leg 
cramps (NLC). Muscle cramps result from spontaneous activity 
arising from hyperexcitability of α-motor neurons in the spinal 
cord. FLX-787 is believed to dampen α-motor neuron hyperexcit-
ability by chemical -rather than electrical- neurostimulation. In 
this process, TRPA1/TRPV1 activation in the oropharynx and 
esophagus leads to excitatory sensory input to stimulate brainstem 
nuclei and subsequently descending spinal tracts to inhibit motor 
neuron hyperexcitability. The Flex-201 study was initiated in 
patients to evaluate the safety and efficacy of FLX-787 in a dis-
ease state where cramps, spasms and spasticity are prevalent, such 
as Multiple Sclerosis (MS).
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Objectives: To monitor the prevalence of cramps/spasms and 
pain severity in MS subjects during a 14-day placebo run-in 
period. Cramp/spasm frequency and subject-reported spasticity 
and pain were analyzed. The analysis was performed to confirm 
that the baseline signal was adequate, and initial power assump-
tions were appropriate.
Methods: Flex-201 is a multicenter, randomized, blinded, cross-
over study to investigate the effects of FLX-787 in subjects with 
MS and symptoms of spasticity, spasms and cramps (n up to 60). 
Interactive voice response system (IVRS) data from the run-in 
period were analyzed to quantify cramps/spasm frequency, spas-
ticity and pain. Pearson correlation analysis was performed to 
identify statistical associations between these datasets.
Results: This analysis of partial (n=25) run-in data demonstrated 
that 80% of subjects experienced ≥ 9 cramps/spasms, and 40% of 
subjects experienced ≥ 25 cramps/spasms over the 14-day run-in 
period. Pain was a common complaint reported by 84% of sub-
jects. Muscle cramp/spasm frequency was highly correlated with 
self-reported pain (p=0.0002), and stiffness to a lesser degree (p< 
0.05).
Conclusion: Correlations from this analysis suggest that subjects 
who experience higher cramp/spasm frequency suffer more pain. 
Given the potential of FLX-787 to reduce both muscle cramp fre-
quency and pain, seen in healthy subjects with nocturnal leg 
cramps, if FLX-787 can reduce cramp/spasm frequency and alle-
viate pain, then the selected study population should allow these 
effects to be measured in subjects with MS.
Disclosure
1.  Glenn Short is an employee of Flex Pharma and Flex Pharma 
Stock Holder.
2.  Brooke Hegarty is an employee of Flex Pharma and Flex 
Pharma Stock Holder.
3.  Jennifer Szegda is an employee of Flex Pharma and Flex 
Pharma Stock Holder.
4.  William McVicar is an employee of Flex Pharma and Flex 
Pharma Stock Holder.
5.  Christoph Westphal is an employee of Flex Pharma and Flex 
Pharma Stock Holder.
6.  Thomas Wessel is an employee of Flex Pharma and Flex 
Pharma Stock Holder.
EP1378
Cognitive dysfunction and pseudobulbar affect comorbidity 
in MS
G. Pardo1, F. Husain2, A.S. Loughran-Fjeldstad3, C. Fjeldstad1
1Oklahoma Medical Research Foundation, 2VA Hospital 
Oklahoma City, Oklahoma City, OK, 3Kinesiology and Health 
Sciences, Virginia Commonwealth University, Richmond, VA, 
United States
Background: Pseudobulbar affect (PBA) is a neuropsychiatric 
syndrome where an individual’s affect does not reflect their mood. 
It is characterized by periods of involuntary laughing or crying 
that may occur without any distinct stimulus. PBA episodes are 
typically exaggerated and do not match how the person feels. It 
commonly occurs in people with neurological conditions or inju-
ries like stroke, amyotrophic lateral sclerosis,traumatic brain 
injury, Alzheimer’s disease,Parkinson’s disease and multiple 
sclerosis (MS). PBA has been reported in approximately 10% of 
MS individuals. Cognitive dysfunction (CD) is estimated to affect 
about 60% of MS patients and may occur at early or late stages of 
the disease. Common CD changes in MS include decreased mem-
ory, information processing, attention, executive function, visuos-
patial function and verbal fluency. Impairments in cognitive 
function have been postulated to be more common in MS patients 
with PBA than those without PBA.
Purpose: To examine the frequency at which MS individuals with 
clinically proven CD also have PBA. The secondary objective 
was to examine the relationship of specific cognitive components 
in people with PBA.
Method: MS subjects with self-reported CD underwent comput-
erized cognitive testing (NeuroTrax Mindstreams (NTM)) and 
completed questionnaires regarding PBA (Center for Neurologic 
Study-Lability Scale), and Beck Depression Scale, Fatigue 
Severity Scale and QOL (SF-36).
Results: Of a total of 32 participants, 24 (75%) had CD as meas-
ured by NTM of which 11 (46%) had PBA. Of those with self-
reported CD that did not have demonstrable deficits by NTM, only 
1 (12.5%) had PBA. Although of no statistical significance, patients 
with PBA scored lower than average on memory and motor skills. 
Scores on executive function, attention and information speed were 
better than memory and motor skills. No significance was found for 
relationship between CD and depression or fatigue (P > .05). The 
only QOL component that significantly correlated with CD was 
physical function (P < .05).
Conclusion: We documented a high incidence of PBA in MS 
individuals with demonstrable CD, at a rate that far exceeds the 
reports of PBA in the overall MS population. CD in individuals 
with PBA was not driven by any specific domain and followed a 
similar pattern of those without PBA. Studies to evaluate these 
relationships at a greater scale are warranted and might reveal 
common pathophysiologic mechanisms.
Disclosure
Gabriel Pardo, MD has nothing to disclose.
Farhat Husain, MD has nothing to disclose.
Anette S. Loughran-Fjeldstad, PhD has nothing to disclose.
Cecilie Fjeldstad, PhD has nothing to disclose.
EP1379
Early life residence in Gulf is associated with rapid multiple 
sclerosis progression in young Egyptians
S. Hamdy, M. Abdelnaseer, H. Shehata, A. Elmazny, A. Hassan, 
N. Shalaby
Neurology, Cairo University School of Medicine, Cairo, Egypt
Background: There is increasing evidence that environmental 
factors play a role in the development and may be progression of 
multiple sclerosis (MS).
Objectives: To assess MS severity and progression in MS 
Egyptian patients who have been residing in Gulf area in their 
early life.
Patients and methods: The study design was retrospective 
case-control approved by the Review Board of Neurology 
Department, Cairo University. The medical records of 21 
patients with relapsing remitting MS (RRMS) in a tertiary refer-
ral center in Cairo were reviewed. Those patients were residing 
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in Gulf in their early life (15 patients were born in Gulf and 
stayed till adolescence and 6 started living there since their early 
childhood and settled for at least 10 years) (group 1). The clini-
cal and radiological parameters of these patients were compared 
with age and gender matched 21 RRMS patients who lived their 
entire life in Egypt (group 2).
Results: There were no significant differences between the two 
groups regarding age of disease onset, time from onset to diag-
nosis, or from diagnosis to treatment. The most frequent pre-
senting symptom was motor dysfunction in group 1 (38.09%); 
and optic neuritis (ON) in group 2 (33.33%). The median 
Expanded Disability Status Scale (EDSS) was significantly 
higher in group 1 than in group 2 (5 vs. 3.5; P 0.03). Median 
durations from disease onset to EDSS of 4 and 6 were signifi-
cantly shorter in group 1 compared with group 2 (3 and 6.5 
years vs. 5.5 and 8 years; P 0.02 and 0.001 respectively). 
Number of infra-tentorial lesions was higher in group 1 (P 
0.04); otherwise no differences in the number of black holes, 
supratentorial lesion load or contrast enhancement on initial 
MRI brain between both groups.
Conclusions: More rapid progression of MS course is observed 
among Egyptian RRMS patients who had their early life in Gulf, 
which points to a possible role of environmental factors character-
istic of Gulf region in disease severity and progression.
Disclosure
Sherif Hamdy. Nothing to disclose
Maged Abdel-Naseer. Nothing to disclose
Hatem Shehata. Nothing to disclose
Alaa Elmazny. Nothing to disclose
Amr Hassan. Nothing to disclose
Nevin Shalaby. Nothing to disclose
EP1380
Clinic model for intrathecal baclofen therapy in patients with 
multiple sclerosis: a retrospective review
A.S. Thiessen, J. Smith, T. Reyna
MS Center, Oklahoma Medical Research Foundation, Oklahoma 
City, OK, United States
Background and Purpose: Limited research has been conducted 
evaluating the benefits of Intrathecal Baclofen Therapy (ITBT) in 
Multiple Sclerosis (MS) patients, specifically ambulatory patients. 
This study demonstrates a possible ITBT patient care model for 
patients with MS in the clinical setting.
Methods: Post Hoc chart reviews completed at MS Center at 
Oklahoma Medical Research Foundation (OMRF), Oklahoma 
City, Oklahoma, USA, a multidisciplinary MS clinic offering 
ITBT for previous 6 years. Review included standard MS care, 
ITBT screening, referral and monitoring process, continued ITBT 
management and functional outcome measures. Demographics, 
disease status and clinical outcomes were compared with overall 
MS population.
Results: Clinic model of ITBT treatment sequence: Identification 
by provider; Physical Therapy (PT) evaluation; ITBT trial with 
PT monitoring; decision of patient with providers for surgical 
referral and surgical pump implantation; ongoing management of 
ITBT dose, rehabilitation, and MS care.
Demographics Data (n=54):
Patient gender ratios; percentages of Relapsing Remitting MS, 
Primary Progressive MS, Secondary Progressive MS, and 
Neuromyelitis Optica mirrored general MS population.
Clinical Care Data:
Average time since diagnosis: 17 years ±15; Average time ITBT 
42.3 months ±38; gait speeds stable over 24 months of ITBT; no 
preference indication of Disease Modifying Therapies; 54% 
required additional oral antispasmodics or onabotulinumtoxin A 
injections; average daily dose of baclofen was 470.29micg/day.
Discussion: An integrated referral model can be used to identify and 
effectively treat MS patients with spasticity. OMRF patients mir-
rored demographics of general MS population. Ambulatory patients’ 
function remained stable over 24 months. Average daily dose and 
use of additional antispasmodics are also consistent with literature. 
ITBT in MS clinics using this model can be used to treat spasticity as 
comprehensive symptom management. Further research regarding 
decision algorithms and functional outcomes need to be addressed.
Conclusion: Management of ITBT in MS patients includes simi-
lar demographics to the MS population. This ITBT model may be 
used as guide for clinics to implement ITBT. Additional antispas-
modic may be required for optimal spasticity management in MS 
patients.
Disclosure
Amy Thiessen, PT, MEd, has the following Disclosure speaker 
for Accorda Therapeutics.
Jennifer Smith, PA-C, has the following disclosures: speaker for 
Teva and Genzyme, consultant for Genentech and EMD Serano.
Tania Reyna, MD: nothing to disclose.
EP1381
Cognition, depression and clinical disease activity in the 
course of MS: a 4 year follow up
S. Gierer1, E. Kannamueller2, S. Gierer1
1Neurology, 2Neurologische Gemeinschaftspraxis Dillingen, 
Dillingen, Germany
Cognitive deficits in MS-patients have moved into the focus of 
interest in the past few years. Many studies have demonstrated 
that the disease leads to cognitive decline. Cognition itself is not a 
singular ability of the brain but indeed consists of various skills.
In a follow-up study we examined different cognitive abilities in 
MS-patients using the Vienna Test Expert System Traffic which 
has been established for testing driving ability skills.
Objective: The aim of the study was to look for the change of dif-
ferent aspects of cognition after a 3-4 year follow-up and their asso-
ciation with depression, disease activity and physical impairment.
Methods: 40 patients with relapsing remitting MS at baseline and 
a 3-4 year follow-up have been examined by using cognitive tests 
(MUSIC), a fatigue scale (FSMC), two depression scales (HAMD, 
BDI II) and the Expert System Traffic of the Vienna Test System 
consisting of 5 subtests including reaction time, reactive stress tol-
erance, visual orientation performance, attention, concentration, 
observational ability and skills in gaining an overview. The mean 
value-differences between the examinations were compared by 
Mann-Whitney-U-Test.
Results: Between baseline and follow-up 41% of patients suf-
fered from one or more relapses. During this time 43% changed 
their prophylactic medication. The medium EDSS score increased 
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from 1.54 to 1,57. There were no significant differences between 
the results in the Vienna Test System. Depression (MBaseline = 
11,55, MFollowUp = 11,15) fatigue (MBaseline = 60,50, MFollowUp = 
59,26) and cognitive impairment (MBaseline = 22,28, MFollowUp = 
23,5) didn’t show any significant differences either. The asymp-
totic significance of all variables ranged between p = .337 and p = 
.996. More than 40% of the MS-patients showed disease activity 
in terms of relapses, which led to a change of prophylactic medi-
cation. The results of all kinds of cognitive testings remained sta-
ble in all aspects within 4 years.
Conclusion: Despite the fact that the disease was clinically active 
in almost half of all patients, there was no significant change in 
cognitive performance or in depression. Disease activity does not 
necessarily lead to cognitive decline.
Disclosure
The work was supported by a scientific grant of Novartis Pharma 
GmbH Nürnberg
EP1382
The spectrum of acute cardiopulmonary events associated 
with multiple sclerosis exacerbations
C. Valencia-Sanchez, D.M. Wingerchuk
Neurology, Mayo Clinic Arizona, Scottsdale, AZ, United States
Introduction: Acute neurological injuries may cause acute cardio-
pulmonary (CP) events including neurogenic pulmonary oedema 
(NPO) and Takotsubo cardiomyopathy (TTC). Sympathetic over-
stimulation is an important mechanism underlying central nervous 
system (CNS) deleterious effects on pulmonary and cardiac func-
tion. Focal CNS lesions, including demyelinating lesions in multi-
ple sclerosis (MS), may cause CP disturbances.
Objective: Describe acute CP events associated with acute MS 
relapses.
Methods: We present the case of a 32 year-old woman with TTC 
after a brainstem MS exacerbation. We review the literature on 
acute CP events, specifically NPO and TTC, associated with MS 
relapses.
Results: A 32 year-old woman with a 3-year history of relapsing 
MS treated with subcutaneous interferon beta-1a presented with a 
brainstem exacerbation and active MS lesions in the cerebellum, 
cerebral peduncles, pons, right frontal and left occipital lobes on 
brain magnetic resonance imaging (MRI). After a 3-day course of 
intravenous (IV) methylprednisolone her deficits improved par-
tially. Three weeks later, she presented with lethargy and chest 
tightness. Her electrocardiogram showed inverted T waves and 
she had elevated serum troponin levels. Echocardiography showed 
basal left ventricular (LV) akinesia consistent with TTC. Brain 
MRI revealed a new enhancing lesion in the left medulla. She 
completed a 3-day course of IV methylprednisolone with improve-
ment of her symptoms and resolution of LV dysfunction.
Our literature review identified 30 relapsing MS patients with 
acute CP events in the setting of MS exacerbations. They pre-
sented with NPO (n=8), TTC (n=12), or concurrent unclassified 
myocardial dysfunction and pulmonary oedema (n=10). 26 
patients had acute demyelinating lesions in the brainstem. In 21 
cases, these lesions involved the medulla. 24 patients received 
treatment with high dose IV steroids. Three patients died but most 
survivors had a favourable outcome after treatment.
Discussion: NPO and TTC are increasingly recognized complica-
tions associated with acute brainstem MS relapses. Active demy-
elinating lesions involving the medulla may damage vasomotor 
centers at the dorsomedial medulla leading to autonomic dysfunc-
tion with profound sympathetic overstimulation. Clinicians 
should be aware that new cardiac or pulmonary symptoms may 
accompany MS relapses that involve the brainstem; the risk of CP 
complications of such attacks requires further systematic study.
Disclosure
Cristina Valencia-Sanchez: nothing to disclose
Dean M. Wingerchuk: nothing to disclose
EP1383
Multiple sclerosis and cognition: the impact of psychotropic 
medications
D. Golan1,2, K. Wissemann3, M. Zarif3, B. Bumstead3, L. 
Fafard3, C. Sullivan4,5, J. Wilken4,5, K. Blitz3, M. Buhse3,6, G.M. 
Doniger7,8, M. Gudesblatt3
1Department of Neurology, Carmel Medical Center, 2Ruth 
and Bruce Rappaport Faculty of Medicine, Technion - Israel 
Institute of Technology, Haifa, Israel, 3South Shore Neurologic 
Associates, Patchogue, NY, 4Neuropsychological Associates, 
Fairfax, VA, 5Department of Neurology, Georgetown University 
Hospital, Washington, WA, 6Stony Brook University, Stony 
Brook, NY, United States, 7NeuroTrax Corporation, Modiin, 
8Joseph Sagol Neuroscience Center & Center of Advanced 
Technologies in Rehabilitation, Sheba Medical Center, Ramat 
Gan, Israel
Background: Psychotropic medications can potentially impact 
cognitive performance. MS consequences can impact mood, but 
MS can also directly impact both cognition and/or mood. Regardless 
of whether mood is a consequence of disease or disability, psycho-
tropic medications are frequently prescribed. Limited data objecti-
fies the degree/pattern that psychotropic medications impact 
cognitive performance in people with Multiple Sclerosis (PwMS).
Aim: To explore the association between the chronic use of psy-
chotropic medications and cognitive function in PwMS.
Methods: PwMS completed a standardized validated computer-
ized cognitive assessment battery (NeuroTrax) with analysis of 
age-and education-adjusted individual cognitive domain scores 
and a global cognitive (average) summary score (GCS). Use of 
chronic psychotropic medications were uniformly recorded and 
PwMS were requested not to take these within 6 hours prior to 
testing. Depression was evaluated (Beck Depression Inventory). 
Analysis of covariance determined the effect of each psychotropic 
medication on cognitive scores, while controlling for the impact 
of other medications, depression, cardiovascular risk factors, thy-
roid disorder and EDSS.
Results: 699 PwMS were evaluated [Female: 526 (75%), EDSS 
2.7±2, Education years: 14.5±2.7]. Antidepressants, benzodiaz-
epines, stimulants (modafinil, methylphenidate, amphetamine-
salts, amantadine), anticonvulsants, spasmolytics, opioids, 
fampridine, anticholinergics and 5HT-antagonists were used by 
296 (42%), 141 (20%), 94 (13%), 94 (13%), 91 (13%), 70 (10%), 
22 (3%), 20 (3%), and 16 (2%) patients, respectively. Use of anti-
convulsants, anticholinergics and 5HT antagonists was indepen-
dently associated with decreased global cognitive scores, but 
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effect sizes were miniscule [P=0.005, 0.02 and < 0.001, partial 
Eta2= 0.01, 0.01 and 0.02, respectively). The number of impaired 
cognitive domains (>1SD below age-education average) was 
slightly, but significantly higher with these medications. Other 
medications (including antidepressants, stimulants) had no sig-
nificant impact on objective cognitive scores.
Conclusion: As long as chronic psychotropic medications are not 
taken in the 6 hours prior to testing, they do not substantially inter-
fere with NeuroTrax cognitive assessments of PwMS.
Disclosure
Glen M. Doniger is an employee of NeuroTrax corporation.
All other authors have nothing to disclose.
EP1384
The comparison of core stability and trunk position sense in 
patients with multiple sclerosis and healthy controls
T. Ozkan1, A. Guclu-Gunduz2, K. Cekim2, C. Irkec3, C. Ozkul2, 
Y. Aydin2
1Physical Therapy and Rehabilitation, Ankara Yıldırım Beyazıt 
University/Faculty of Health Sciences, 2Physical Therapy and 
Rehabilitation, Gazi University/Faculty of Health Sciences, 
3Neurology, Gazi University Medical Faculty, Ankara, Turkey
Introduction: Motor and sensorial problems are seen at various 
grades due to influence of central nervous system in patients with 
Multiple Sclerosis (MS). Motor and sensory parameters such as 
core stability and body position sense must be at sufficient level 
for a good balance and postural control.
Purpose: To compare core stability and trunk position sense in 
mild to moderately disabled MS patients according to healthy 
individuals.
Method: 45 MS patients (EDSS, median=2 (1-3)) and 29 healthy 
individuals of similar age and sex were included in the study. 
Core stability was examined with assessing core endurance and 
core power. Core endurance was assessed with trunk flexion test, 
modified Biering-Sorensen test, prone bridge test, right and left 
lateral bridge tests; core power was assessed with sit-ups and 
modified push-ups tests. Trunk position sense was assessed using 
J-Tech Dualer IQ digital inclinometer with trunk reposition tests. 
Measurements were made at 2 levels; Lumbosacral (LS) and 
Thoracosacral (TS) regions. Tests were performed on eyes open-
firm surface, eyes closed-firm surface and eyes open-foam 
surface.
Comparison of core stability and trunk position sense were 
assessed with Mann Whitney U and Wilcoxon tests.
Results: As a result of the study, it was seen that all parameters of 
core endurance, core power and trunk position senses of MS 
patients were decreased statistically significantly according to the 
control group (p< 0.05).
Conclusion: These results indicate that core stability and trunk 
position sense decreased in patients with MS according to healthy 
individuals. Although the level of disability is low, from the early 
stage of disease, we think that investigating the core stability and 
the trunk position sense and planning the necessary intervention is 
important to improve postural control and balance.
Disclosure
There is no conflict of interest and source of funding.
EP1386
Emotional status in relapsing remitting MS patients
A. Guerra1, D. Passafiume1, N. Caputi1, M. Fratino2, A. Francia2, 
D. Di Giacomo1
1Life, Health and Environmental Science, University of L’Aquila, 
L’Aquila, 2Neurology and Psychiatry, University of Roma La 
Sapienza, Roma, Italy
Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating 
and degenerative disease of Central Nervous System. The aim of 
the present study was to evaluate depression, anxiety and alex-
ithymia, which are often associated with MS. 98 subjects were 
recruited: 51 patients affected by Relapsing Remitting (RR) MS 
(18 males and 33 females) and 47 healthy controls (CG) (18 males 
and 29 females) matched by gender, age and education. We 
recruited participants aged between 23 and 60 (SM group Age: x̄ 
45 ± 9.89; Education x̄ 13 ± 3.58; Expanded Disability Status 
Scale (EDSS) x̄ 2.8 ± 2,05; CG group Age: x̄ 46 ± 10.72; Education 
x̄ 14 ± 2.63). Diagnosis and type of MS and EDSS score were 
established by a neurologist not involved in the study. All patients 
underwent a clinical evaluation, including Beck Depression 
Inventory (BDI-II), The State-Trait Anxiety Inventory (STAI-Y) 
for state (STAI y1) and trait (STAI y2) anxiety, the Toronto 
Alexithymia Scale (TAS) and the Frontal Assessment Battery 
(FAB). None of the subjects obtained a pathological score in the 
clinical evaluation. We performed a one way ANOVA and a 
Bonferroni correction was used to analyze the differences between 
MS patients and CG. The differences were considered significant 
at α=0,0125. MS group obtained higher and statistically signifi-
cant scores at BDI-II (p=0,005), TAS (p=0,002), and at STAI-Y, 
both as regards the trait anxiety, STAI-y1, (p=0,0001) and as 
regards status anxiety, STAI-y2, (p=0,00009). A correlation study 
also showed a positive correlation (0,30) between the EDSS 
scores and alexithymia predisposition. The MS scores at TAS 
were not pathological, but an higher score at the EDSS correlated 
with an higher score at TAS. In addition, a negative correlation 
occurred between FAB and BDI-II (-0,38). An higher score at the 
BDI-II corresponded to a lower score at FAB and viceversa. 
Within the MS group, all the clinical scales correlated to each oth-
ers. In our study MS patients do not have a full-blown depression 
or anxiety or alexithymia. Our results seem to suggest that our MS 
patients, although not achieving pathological scores, still have a 
lower mood and an heightened anxiety compared to CG. These 
results seems to indicate the importance of an accurate evaluation 
of the psychological status of the MS patients.
Disclosure
Guerra A: Nothing to disclosure;
Passafiume D: Nothing to disclosure
Caputi N. : Nothing to disclosure
Fratini MA: Nothing to disclosure
Francia A. Nothing to disclosure
Di Giacomo D. Nothing to disclosure
EP1387
Effects of anxiety on motor imagery abilities in persons with 
multiple sclerosis
T. Kahraman1, S. Savci2, A.T. Ozdogar2, Z. Gedik3, E. Idiman4
1Department of Physiotherapy and Rehabilitation, Faculty of 
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Health Sciences, Izmir Katip Celebi University, 2School of Physical 
Therapy and Rehabilitation, Dokuz Eylül University, 3Department 
of Psychology, Faculty of Humanities and Social Sciences, Izmir 
Katip Celebi University, 4Department of Neurology, Faculty of 
Medicine, Dokuz Eylül University, Izmir, Turkey
Background: Motor imagery is defined as the ability to mentally 
perform movement without movement execution. Although motor 
imagery has been used in many populations for a long time, its 
importance as a possible therapeutic tool for persons with multi-
ple sclerosis (pwMS) has been recently understood. In order to 
add motor imagery into the rehabilitation programs, it is necessary 
to examine possible situations that may affect it. Since motor 
imagery processes play a crucial role in the experience of anxiety, 
it is also important to know the effects of anxiety on motor 
imagery abilities. Although there is relatively little evidence about 
how motor imagery is affected by anxiety in healthy people, to the 
best of our knowledge, this situation has been never examined in 
pwMS. The aim was to compare motor imagery abilities in pwMS 
with and without anxiety.
Methods: This cross-sectional study enrolled 27 pwMS. The par-
ticipants were divided into two groups according to the cut off ≥ 8 
on the Hospital Anxiety and Depression Rating Scale-A. Motor 
imagery ability was assessed using the Kinesthetic and Visual 
Imagery Questionnaire (KVIQ) and mental chronometry test for 
the Timed Up and Go (TUG) test. Temporal congruence between 
actual and imagined TUG was expressed as delta time calculated 
according to the formula: (actual TUG - imagined TUG)/[(actual 
TUG + imagined TUG)/2] x 100.
Results: There were 12 participants with anxiety and 15 without 
anxiety. Although the clarity of the image (KVIQ-Visual) and inten-
sity of the sensations (KVIQ-Kinesthetic) were not significantly dif-
ferent between the groups (p>0.05), the participants with anxiety had 
less clarity of the image and intensity of the sensations with medium 
and small effect sizes (Cohen´s d=-0.62 and -0.39, respectively). No 
significant difference was observed in the delta time of TUG tests 
(p>0.05); however, the effect size was medium (Cohen´s d=-0.51).
Conclusions: Although the significance levels were not enough, 
the effect sizes have suggested that the pwMS with anxiety have 
less clarity of the image and intensity of the sensations, and tem-
poral congruence between actual and imagined movements. These 
findings suggest that motor imagery ability can be affected by 
anxiety in pwMS and further studies with larger sample size were 
highly warranted.
Disclosure
Turhan Kahraman: nothing to disclose
Sema Savci: nothing to disclose
Asiye Tuba Ozdogar: nothing to disclose
Zumrut Gedik: nothing to disclose
Egemen Idiman: nothing to disclose
EP1388
Evaluation of sleep quality and risk assessment of obstructive 
sleep apnea among MS patients
N. Manouchehri, O. Mirmossayeb, N. Hashemi, M. Kiani, M. 
Barzegar, S. Allahdadian, V. Shaygannejad
Isfahan Neuroscience Research Center, Isfahan University of 
Medical Sciences, Isfahan, Islamic Republic of Iran
Background: Multiple sclerosis is a demyelinating disease, 
marked by deficient neural conduction and axonal loss. Fatigue as 
a common complaint of MS patients has several possible explana-
tions. Sleep disorder contributes to chronic fatigue and decreased 
sleep quality is reported among MS patients. We aimed to assess 
the sleep quality and risk of obstructive sleep apnea (OSA) among 
MS patients and see whether severity of MS is correlated to sleep 
quality.
Method: 514 MS patients including 70 men and 435 women were 
enrolled in the study. Age range was 13 to 67. Basic demographic 
and disease characteristic data was collected from all patients. 
Disease severity was assessed by extended disability score scale 
(EDSS). Sleep quality and sleepiness was assessed by Pittsburgh 
sleep quality index (PSQI) and Epworth sleepiness score (ESS). 
Likelihood of OSA was assessed using the Berlin and STOP-
BANG questionnaires.
Results: Regarding the quality of sleep, the mean ± SD of PSQI 
score was 6.6 ± 3.2 with 60.9% of the patients having poor sleep 
quality. ESS results however showed that 8.6% of the patients 
reported mild to severe sleepiness during the day. In regards to 
likelihood of OSA, evaluation of patients with STOP-BANG 
questionnaire revealed that 13 percent of the patients had high risk 
for OSA; Berlin questionnaire also indicated that 21.2 percent of 
the patients had high likelihood of sleep disordered breathing. 
PSQI scores were weakly correlated to the patients’ EDSS score 
(P value: 0.02, r = 0.4). Berlin questionnaire results were also cor-
related to the patients’ EDSS score (P value: 0.04, r = 0.35).
Conclusion: Our results indicates that MS patients have poor 
sleep quality and that OSA could be partially relevant. We also 
found that MS severity directly affects sleep quality.
Disclosure
Navid Manouchehri: nothing to disclose
Omid Mirmosayyeb: nothing to disclose
Niloofar Hashemi :nothing to disclose
Marjan Kiani :nothing to disclose
Sepideh Allahdadian : nothing to disclose
Mahdi Barzegar : nothing to disclose
Vahid Shaygannejad: nothing to disclose
EP1389
Preliminary fatigue subtype discovery from the MS mosaic 
study
L. Hartsell1, K. Heller2
1Neurology, 2Statistical Science, Duke University, Durham, NC, 
United States
Background and Goals: Greater than 80% of MS patients expe-
rience significant fatigue during their clinical course. Several 
assessment tools attempt to characterise fatigue, but they have 
significant limitations and are too infrequently administered to 
represent this highly dynamic symptom. As a result, intervention 
studies poorly assess response, and MS patients undergo com-
monly ineffective empiric treatment trials. Progress in our under-
standing and management of MS fatigue requires more frequent 
symptom reporting, nearly continuous data collection on effect 
modifiers, and effective analytic tools capable of interpreting mul-
tiple data types. To improve our understanding of fatigue among 
people with MS, we developed a novel mobile application that 
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captures data on many of these variables and utilises novel 
machine learning methods to identify patterns within this data to 
improve our understanding of fatigue.
Methods: MS Mosaic is a longitudinal study (NCT02845635) 
that combines data from a mobile platform with existing bio-
markers and then utilises machine learning methods to help 
reveal a more comprehensive picture of MS. Initial focus on data 
analysis has been on improving fatigue characterisation. 
Continuously collected data from participants’ daily symptom 
surveys, medication diaries, weekly study tasks (timed walk, 
PASAT, finger tapping, 9-Hole Peg Test), and mobile sensors 
(sleep, steps) is analysed through a Bayesian generative hierar-
chical model that uses a Dirichlet process at a higher level and 
then represents the observed data at a lower level, providing a 
particular patient’s “fatigue group” memberships.
Results and Conclusions: Fatigue subtypes can be discovered 
using MS Mosaic app data, and machine learning clustering meth-
odology. Clustering analysis from the MS Mosaic Study provides 
readily identifiable subtypes (with the use of monitoring plat-
forms like MS Mosaic) and will prove useful in the design of 
upcoming fatigue intervention studies.
Disclosure
Lee Hartsell: nothing to disclose.
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EP1390
Epilepsy in multiple sclerosis (MS): clinical, electroencepha-
lographic (EEG) and magnetic resonance imaging (MRI) 
characteristics
L. Averianova, S. Shakirzianova, T. Khaibullin, F. Khabirov, E. 
Granatov, N. Babicheva
Neurology Department, Kazan State Medical Academy, Kazan, 
Russian Federation
Introduction: In according to classical viewpoint epilepsy in MS 
is thought to be neither frequent, nor typical clinical manifesta-
tion. Precise mechanisms of epileptic seizures in MS patients and 
their relation to disease are still poor understood.
Aims: to investigate clinical phenotype of epileptic seizures in 
MS and to evaluate their relations to MS characteristics, EEG and 
MRI abnormalities.
Patients and methods: Among 1850 patients from local MS reg-
istry of Tatarstan Republic epileptic seizures were noted in 48. All 
patients with epileptic seizures besides clinical neurological eval-
uation undergo routine EEG (NeuroSoft) and MRI (Siemens, 3T; 
besides routine, double inversion recovery (DIR) sequences was 
performed for better cortical lesions visualization).
Main results: The prevalence of epilepsy among patients with 
MS in Tatarstan Republic was 2,59% (48/1850). The most fre-
quent seizure types were partial (33%) and secondary generalized 
(71%). In most (90%) cases epileptic focus was clinically located 
in frontal or temporal lobes. Among rare variants 1 case of 
Kojevnikovs epilepsy, and 2 cases of epileptic cortical myoclonus 
were noted. In all cases epilepsy was associated with relapsing 
remitting (52%) or secondary progressive (48%) MS. Notably, 
epilepsy was also associated with more rapid MS progression: 
median MS severity scale (MSSS) score was 5,88 vs. 5,24 in total 
MS population. In 19% of cases seizures occurred before 
diagnosis MS, in 29% they were associated with MS relapses, in 
52% such association was not observed. Regional and generalized 
epileptiform discharges on EEG were noted in 48 and 10% respec-
tively. Correlation of seizure pattern, epileptiform discharges and 
lesions on MRI was noted in 27% cases, but with DIR sequence 
such correlation became higher - up to 50%. Antiepileptic therapy 
was completely successful in only 73% of cases.
Conclusions: Typically epilepsy in MS is presented with partial 
and secondary generalized seizures from frontal and temporal 
lobes, and associated with poor prognosis and unsatisfied treat-
ment response.
Disclosure
Timur Khaibullin: nothing to disclosure
Farit Khabirov: nothing to disclosure
Liudmila Averianova: nothing to disclosure
Evgenii Granatov: nothing to disclosure
Natalya Babicheva: nothing to disclosure
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EP1391
Patient-based outcome measures of the impact of disease in 
patients with multiple sclerosis and vitamin D deficiency
C. Tiu, E.O. Terecoasă, V.E. Tiu, A. Grigore, C. Găvan, O.A. 
Băjenaru
Department of Neurology, University Emergency Hospital 
Bucharest, Bucharest, Romania
Introduction: Vitamin D deficiency is currently regarded as a 
potential environmental risk factor for multiple sclerosis (MS) but 
the clear relationship between low vitamin D levels and disease 
manifestations and severity is not certainly established.
Aim: We performed a cross-sectional study aimed to investigate 
the relationship between vitamin D status, depression and self-
reported impact of disease in patients with MS.
Methods: 106 patients treated with immunomodulatory drugs in 
the MS center of our hospital were included. Depression was 
assessed with the Beck Depression Inventory for Primary Care 
and patient-reported impact of MS was assessed with the Multiple 
Sclerosis Impact Scale (MSIS-29v2). Serum 25-hydroxyvitamin 
D levels were measured by chemiluminescence immunoassay 
method and 30 nanograms/milliliter was considered the cut-off 
point for deficiency.
Results: Mean age of the patients was 38.7+/- 10.1 years, with a 
female/male ratio of 2.1/1. Median EDSS score was 2 points (25-
75 IQR 1.5-2.5). Mean serum 25-hydroxyvitamin D level was 
23.2 +/- 11.8 nanograms/milliliter and 86 patients (81.1%) had 
low vitamin D levels. Median MSIS-29v2 - PHYS scores were 21 
points (25-75 IQR 20.5-27) in patients with normal vitamin D lev-
els and 32 points (25-75 IQR 24-48) in patients with vitamin D 
deficiency (p=0.0002). Median MSIS-29v2 - PSYCH scores were 
13.5 points (25-75 IQR 10-17.5) in patients with normal vitamin 
D levels and 18 points (25-75 IQR 13-24) in patients with vitamin 
D deficiency (p=0.009). Depression was diagnosed in 10% of the 
patients with normal vitamin D levels and 19.7% of the ones with 
vitamin D deficiency (p=0.5).
Conclusions: We found no significant association between low 
vitamin D levels and depression but the physical and psychologi-
cal patient-based outcome measures of the impact of multiple 
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sclerosis were significantly worse in patients with vitamin D 
deficiency.
Disclosure
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Carmen Găvan: Nothing to disclose
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Foundation of The Romanian Society of Neurology
Clinical assessment tools
EP1393
Critical flicker frequency is reduced in multiple sclerosis 
patients independently of retinal axonal damage
N. Ayadi1, H. Zimmermann1, J. Mikolajczak1, J.-M. Dörr1, A.U. 
Brandt1, F. Paul1,2,3
1NeuroCure Clinical Research Center Charité - 
Universitätsmedizin Berlin, 2Department of Neurology, Charité - 
Universitätsmedizin Berlin, 3Experimental and Clinical Research 
Center, Max-Delbrück Center for Molecular Medicine, Berlin, 
Germany
Background: Critical flicker frequency (CFF) has been sug-
gested as a marker for neuro-axonal damage resulting from demy-
elinating optic neuritis (ON). Neuro-axonal damage of the retina 
is frequently observed in patients with multiple sclerosis.
Objective: To examine CFF in eyes with and without ON (NON) 
of MS patients and eyes of healthy controls (HC) and to further 
investigate possible associations with visual function as well as 
with the Expanded Disability Status Scale (EDSS).
Methods: A total of 140 eyes from 39 MS patients (28 ON-eyes; 
50 NON-eyes) and 31 HC were evaluated. All patients and HC 
underwent monocular and binocular CFF measurements with the 
HEPAtonorm™-Analyzer, monocular high contrast visual acuity 
(HCVA) testing with ETDRS charts (logMAR units), binocular 
low contrast letter acuity (LCLA) testing with 2.5% contrast Sloan 
charts, visual evoked potentials (VEP) and spectral domain optical 
coherence tomography (OCT) with analysis of the peripapillary 
retinal nerve fibre layer (pRNFL) thickness. Trained neurologists 
assessed the EDSS for all patients. Monocular measurements were 
analyzed with generalized estimating equations (GEE), binocular 
measurements with t-test and Spearman correlation analysis.
Results: Mean monocular CFF for eyes of MS patients amounted 
to 40.9 ± 4.4 Hz and was significantly lower than in HC (44.8 ± 
4.4 Hz, p < 0.001). Worse EDSS was a moderate predictor for 
reduced CFF
(r2 = 0.261, B = -2.060, p < 0.001). In contrast, there was no sig-
nificant difference in CFF between ON-eyes (39.7 ± 5.2 Hz) and 
NON-eyes (41.5 ± 4.3 Hz, p = 0.127). Likewise, there was no 
association between CFF and pRNFL thickness (B = 0.009, p = 
0.750). CFF was mildly associated with VEP P100 latency (r2 = 
0.069, B = -0.056, p = 0.043), HCVA (r2 = 0.074, B = -6.021, p = 
0.002) and LCLA
(r2 = 0.120, ρ = 0.41, p = 0.010).
Conclusion: CFF reduction in MS occurs independently of ON, 
and is not dependent on retinal axonal damage. Its moderate cor-
relation with EDSS suggests that CFF potentially reflects global 
disease processes or higher cortical processing and neurodegen-
eration rather than focal optic nerve damage.
Disclosure
This study was supported by a research grant from Novartis
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Paul: received research support from the Deutsche 
Forschungsgemeinschaft (DFG) (grant Exc. 257) and from the Guthy 
Jackson Charitable Foundation and National Multiple Sclerosis 
Society, research grants and speaker honoraria from Bayer, Teva, 
Genzyme, Merck, Novartis, MedImmune and is member of the steer-
ing committee of the OCTIMS study (Novartis), unrelated to this work.
EP1394
Long-term predictors of disability worsening in patients with 
multiple sclerosis in the phase 3 TRANSFORMS study
P. Repovic1, A. Boster2, S. Ritter3, D. Tomic4, X. Meng3, D. 
Piani Meier4, T. Sprenger5, F. Barkhof6
1Swedish Neuroscience Institute, Seattle, WA, 2OhioHealth, 
Columbus, OH, 3Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, United States, 4Novartis Pharma AG, 5University 
Hospital Basel, Basel, Switzerland, 6VU University Medical 
Center, Amsterdam, The Netherlands
Background: In patients with multiple sclerosis, disease and 
treatment history, early magnetic resonance imaging (MRI) lesion 
activity, and/or relapses may predict long-term clinical outcomes.
Objectives: To assess the ability of variables at baseline and dur-
ing the 1-year TRANSFORMS trial to predict long-term disability 
worsening during the study extension.
Methods: This was a post hoc analysis of data from the 36-month 
follow-up to the randomized, double-blind TRANSFORMS study 
comparing fingolimod and intramuscular (IM) interferon (IFN) 
beta-1a. During follow-up, patients randomized to IFN beta-1a 
IM were switched to fingolimod. Multiple logistic regression was 
used to assess which patient or disease characteristics from base-
line to month (M) 12 predicted two disability outcome measures 
(6-month confirmed disability progression [6MCDP]; Expanded 
Disability Status Scale [EDSS] score >6) during M12–48. 
Baseline variables included sex, age, duration of MS since diag-
nosis, previous treatment for MS, number of relapses in the previ-
ous 2 years, EDSS score, number of gadolinium-enhancing [Gd+] 
lesions, T1 hypointense volume and total volume of T2 lesions. 
Baseline to M12 variables included the number of confirmed 
relapses, EDSS score change, presence of new T2 lesions and 
presence of MRI lesion activity.
06_MSJ731285.indd   736 13/10/2017   11:10:55 AM
ePosters 23(S3) 737
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Results: In total, 1292 patients were randomized in TRANSFORMS 
(analysis sets for the multiple regression analysis: 6MCDP, n=758; 
EDSS score >6, n=934). Predictors of both outcomes were base-
line EDSS score (odds ratio [95% confidence interval]: 6MCDP: 
1.353 [1.138-1.609], p=0.0006; EDSS score >6: 3.335 [2.530-
4.396], p< 0.0001) and the presence of MRI lesion activity during 
M0-12 (≥1 Gd+ or ≥2 new T2 lesions, 6MCDP: 1.854 [1.038-
3.310], p=0.0369; EDSS score >6: 3.434 [1.292-9.128], p=0.0134). 
Change in EDSS score during M0-12 (2.794 [1.990-3.921], p< 
0.0001) and T1 hypointense lesion volume at baseline (1.297 
[1.082-1.555], p=0.0049) were predictors of EDSS score >6 only.
Conclusions: In TRANSFORMS, baseline EDSS score and MRI 
lesion activity during
M0-12 were predictors of both disability outcomes in the long 
term. Change in EDSS score during M0-12 and T1 hypointense 
lesion volume at baseline were predictors of patients reaching an 
EDSS score >6. These findings support early review of treatment 
regimens to help to prevent worsening disability.
Disclosure
Pavle Repovic: Acorda Therapeutics, Biogen Idec, EMD Serono, 
Genzyme, Novartis Pharmaceuticals Corporation, Pfizer and 
Teva Pharmaceuticals (multiple sources).
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EP1395
Modified brief international cognitive assessment for multi-
ple sclerosis (mBICAMS): towards validating the first Arabic 
version
H. Darwish1, N. Farran2, P. Zeinoun3, B. Yamout4, S.J. Khoury4
1Hariri School of Nursing, American Unviersity of Beirut, 
2Hariri School of Nursing, 3Psychology, 4Neurology, American 
University of Beirut, Beirut, Lebanon
Background: Cognitive performance is a sensitive indicator of 
disease progression in Multiple Sclerosis (MS). The BICAMS 
psychometric characteristics have not been established in Arabic-
speaking populations.
Objective: To validate and provide normative and psychometric 
data for the BICAMS in Arabic.
Methods: In this cross sectional study, mBICAMS will be admin-
istered to 184 healthy subjects with no history of neurological dis-
orders, traumatic brain injury, psychiatric disorders, and cognitive 
impairment, aged 16-90 years [n=62; age 16-35, n=72; 36-65, 
n=50; 66-90 years], and 50 MS patients. Additional screening 
using the Hopkins Symptom Checklist-25 (depression score ³ 3.3, 
excluded) and Montreal Cognitive Assessment (score< 26, 
excluded) is performed. mBICAMS consists of 3 tests; the Symbol 
Digit Modalities Test (SDMT), the Brief Visuospatial Memory 
Test-Revised (BVMTR), and a newly developed Verbal Memory 
Arabic Test (VMAT) - a learning test of 15 culturally sensitive 
words, consisting of five learning trials, immediate and delayed 
trials, with and without cues, and a recognition trial). Cognitive 
reserve and non-verbal intelligence quotient are also assessed. 
The BICAMS validation method is based on Benedict et al. 2012’ 
recommendations.
Results: To date, 93 participants were screened (10 excluded; for 
drug dependence, psychiatric disorders, antidepressant use, or 
high depression score, and 5 participants dropped out). Of these 
participants, 77 healthy subjects (43 females and 34 males) and 1 
MS patient completed the study, and retest has been performed on 
45 of these subjects after 21 days on average (M age 29.5±10.8 
years). Most participants (80%) obtained medium cognitive 
reserve scores (M 105.86±12.78), and showed average nonverbal 
intelligence quotient (105.78±16.03). SDMT yielded 61.38±8.96 
correct answers (test-retest r=0.64). On the VMAT, mean number 
of words recalled on the first 5 learning trials was 10.99±1.49, 
short delay recall 11.23±2.29, cued recall 11.53±2.15, long delay 
recall 11.88±2.29, cued recall 11.99±2.24, recognition trial 
43.45±1.98 out of 45 words). VMAT showed acceptable test-
retest reliability; r=0.43. On the BVMT-R, participants scored 
5.42±2.42 on trial 1, 8.75±2.42 trial 2, and 10.42±1.88 trial 3 (test-
retest Cohen’s d=1.15).
Conclusions: Recruitment and data collection are ongoing. 
Validating the mBICAMS will allow more accurate clinical use 
and research utilizations of these measures in the Arab world MS 
patients.
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travel awards from Novartis, Merck and Genzyme, and research 
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Body worn sensors accurately and reproducibly quantify dis-
ability and walking impairment in a clinical setting in people 
with MS
W. Hodgkinson1, C. Smith1, J. Moorman Dodd1, H. Young2, A. 
Radford2, S. Kelly2, J. Kemp2, B. Sharrack3, J. Ray4, C. Mazza5, 
F. Storm5, D. Paling3
1Medical School, University of Sheffield, 2Clinical Research 
Facility, 3Department of Neurology, 4Department of ENT, Royal 
Hallamshire Hospital, 5INSIGNEO, University of Sheffield, 
Sheffield, United Kingdom
Introduction: Accurate quantification of disability in people with 
MS is becoming increasing relevant. In clinical care the discovery 
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of disease modifying therapies with impact on progressive MS 
requires accurate serial assessment of disability to assess eligibility 
and clinical effect1. In research there is an unmet need for reliable 
clinical measures that would be expected to change over the 2-3 
year life span of a progressive MS trial2. Expanded Disability Status 
Scale (EDSS) has proven to be both insensitive and unreliable to 
these tasks3. Body-worn sensors offer the potential of a sensitive, 
objective and reproducible measure of a walking disability.
Aims: We investigated whether data from body worn sensors 
would be able to distinguish between controls, people with MS 
with moderate disability (EDSS 2.5-5.0) and people with MS with 
more advanced disability (5.5-6.5), whether the data was repro-
ducible and whether parameters correlated with current validated 
measures.
Method: 69 patients with MS and 24 age and gender matched 
healthy controls participated in the study. Participants completed a 
10m Walk, Instrumented Timed-Up-And-Go (iTUG), Instrumented 
Sway (iSway) and six-minute walk (6MW) on two separate visits.
Results: Sensor measures captured during the 10m Walk, iTUG 
and 6MW showed significant difference between the three groups 
(p=< 0.001). Sensor data showed high reliability with excellent 
reproducibility across most of the walking parameters (ICC>0.75). 
Many parameters showed significant correlations (varying from 
strong to moderate) with validated measures. Particularly strong 
correlations were found between the walking parameters and 
EDSS.
Conclusion: Body-worn sensors offer a highly reproducible and 
sensitive way of disability in people with MS. They show poten-
tial for implementation into clinical practice as well as clinical 
trials as a measure of disability progression.
1 Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical 
course of multiple sclerosis: the 2013 revisions. Neurology 2014; 
83: 278-86.
2 Chataway J. Inadequate outcome measures are the biggest 
impediment to successful clinical trials in progressive MS--YES. 
Multiple Sclerosis Journal 2016; : 1352458516671821.
3 Cohen JA, Reingold SC, Polman CH, Wolinsky JS, International 
Advisory Committee on Clinical Trials in Multiple Sclerosis. 
Disability outcome measures in multiple sclerosis clinical trials: cur-
rent status and future prospects. Lancet Neurol 2012; 11: 467-76.
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Can MS patients accurately self-time the 25-foot walk?
J.L. Freiburger1, L. Mourany1, M. Weber2, D. Kemeny1, A. 
Long1, C. Reece1, F. Bethoux2, D. Miller2, R. Bermel2, D. 
Schindler3, J. Alberts3, R. Rudick4, G. Phillips4, J. Rhodes4, 
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1Lou Ruvo Center for Brain Health, 2Mellen Center for MS 
Treatment and Research, Cleveland Clinic Neurological 
Institute, 3Biomedical Engineering, Cleveland Clinic Lerner 
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United States
Background: The MS Performance Test (MSPT), a self-
administered iPad®-based neurological performance assess-
ment tool, is designed to be integrated into routine clinical 
care. One of the MSPT test modules, the Walking Speed Test 
(WST), allows MS patients to self-time their walk along a 25 
foot track. Typically, the 25-Foot Walk is timed by a technician 
using a stopwatch. For the MSPT WST, patients click a hand-
held Bluetooth button at the start and stop of their walk; time is 
recorded on the iPad.
Goals: To determine if self-timed walking speed is as accurate, 
sensitive and reliable as technician timed walking speed.
Methods: The participants consisted of 30 MS patients (course: 
25 relapsing remitting, 3 secondary progressive, 2 primary pro-
gressive; disease duration: mean=8.3 yrs, SD=7.7) and 29 healthy 
controls (HC). The two groups were equivalent in age (MS: 
mean=45.6 yrs, SD=11.6; HC: mean=46.3 yrs, SD=10.4), educa-
tion (MS: mean=15.2 yrs, SD=2.7; HC: mean=15.7 yrs, SD=2.3), 
and sex (MS: 20 females; HC: 19 females). Both groups of sub-
jects completed the WST twice on the same day. A technician 
simultaneously timed their walk with a stopwatch.
Results: As expected, MS patients had significantly slower walk-
ing times than the HC group both for the self-timed (p=0.02; 
Cohen’s d effect size=.660) and technician-timed (p=0.01; 
Cohen’s d=.708) latency measures. Absolute differences between 
the self-timed and technician-timed measures were small and 
comparable (MS, mean=0.48 sec.; HC, mean=0.37 sec.; p=0.285). 
Correlations between self-timed and technician-timed walking 
speeds were high and comparable (MS, r=0.943; HC, r=0.928). 
Test-retest reliability was high and comparable for the self-timed 
(MS, r=0.931; HC, r=0.854) and technician-timed (MS, r=0.977; 
HC, r=0.927) measures.
Conclusions: These results validate the use of self-timed walking 
speed measures for both MS patients and healthy individuals. 
Compared to technician-timed latency measures, self-timed meas-
ures were equally sensitive in detecting differences in walking 
speed between MS and HC groups. Absolute latency differences 
and test-retest reliability were comparable for the self-timed and 
technician-timed measures for both MS patients and healthy con-
trols. Because it is self-administered, the WST, as part of the 
MSPT battery, has the advantage of being integrated into clinical 
practice without involving clinic personnel.
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The use of a mobile-phone-based E-diary for evaluation of 
patient-reported outcomes and adherence to treatment of 
patients with multiple sclerosis
D. Golan1,2, S. Sagiv2, S. Ratzabi1, L. Glass-Marmor1,2, I. 
Lejbkowicz1,2, A. Miller1,2
1Division of Neuroimmunology & Multiple Sclerosis Center, 
Lady Davis Carmel Medical Center, 2Ruth and Bruce Rappaport 
Faculty of Medicine, Technion - Israel Institute of Technology, 
Haifa, Israel
Background: Little is known regarding the applicability of smart-
phone technology to promote clinical care of patients with 
Multiple Sclerosis (PwMS).
Aim: To assess the usefulness of a smartphone-based e-diary to 
the estimation of adherence to disease modifying drugs (DMDs), 
as well as to the collection of patient-reported outcomes (PROs).
Methods: Patients downloaded a MS tailored e-diary into their 
personal smartphones. The application prompted patients to take 
their DMDs and recorded their adherence. Report of PROs was 
conveyed once monthly through the application, using previ-
ously validated tools (Multiple Sclerosis Quality of Life inven-
tory, Neuro-QoL short forms and CNS lability scale). Adherence 
data from the e-diary was compared to medication pack collec-
tion. PROs gathered by the e-diary were compared to corre-
sponding functional system scores, determined by neurologic 
examination, as well as to patients´ subjective reports during 
routine follow up visits, as documented in their electronic medi-
cal record (EMR).
Results: Data from 83 PwMS was used in this analysis [Female: 
54 (65%), EDSS 3.4±2.1]. Patients were using the e-diary for a 
median duration of 17 weeks [range:4-29 weeks]. Only 7 patients 
(8%) dropped out and another 3 (3%) did not agree to participate 
in PRO survey but continued to report their medication intake. 
Adherence to DMDs as reported in the e-diary was 87.1±17.8% 
compared to 84 ±19.2% according to pack collection. E-diary 
derived PROs were significantly correlated with the correspond-
ing functional system scores (0.46< r < 0.8, P< 0.0001). The 
E-diary captured more MS related symptoms than documented in 
the EMR (e-diary compared to EMR: poor sleep 49% vs. 5%, 
pseudobulbar affect 17% vs 3%, upper limb dysfunction 10% vs 
3% of participants). In patients with a relapse we noted increased 
PRO scores, which decreased following remission.
Conclusion: Smartphone-based e-diary seems suitable for PwMS 
and can provide useful information regarding PROs and adher-
ence to DMDs.
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QuantemTool - automated measurement of lesion load and 
cerebral volume from magnetic resonance images in multiple 
sclerosis
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Gonçalves1, P. Figueiredo4, R. Nunes4, J. Graça2
1Faculdade de Ciências e Tecnologia - Universidade Nova 
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Técnica de Lisboa, Lisbon, Portugal
Background: In multiple sclerosis (MS), brain magnetic reso-
nance imaging (MRI) is the standard method for evaluating and 
monitoring brain lesions. Conventional MRI lesion measures only 
modestly predict disability. There is an increasing amount of 
research correlating brain tissue loss, in particular grey matter 
(GM) atrophy, to clinical disability, suggesting the need of quanti-
tative analyses of MRIs in clinical practice.
QuantEmTool (QET) is an automated tool based on a standard 
analysis pipeline that segments the brain and quantifies its main 
structures, also quantifying lesion load volumes.
The main goal of this work is to evaluate whether QET results, as 
correlated with clinical data, are in line with related published 
studies, hence contributing to support its use in clinical practice.
Methods: We selected all consecutive patients with a MS or 
Clinical isolated syndrome (CIS) who perfomed an MRI since 
January 2016. Correlations between MRI parameters (grey matter 
(GM), parenchymal volume (PV), white matter (WM) and T2 
lesion volume (T2LV)) and clinical variables (age, disease dura-
tion, Expanded Disability Status Scale (EDSS) and Multiple 
Sclerosis Severity Score (MSSS)) were estimated using Pearson’s 
correlation coefficient (R), and multiple regressions.
Results: 27 females and 24 males, from 19 to 60 years (mean 42) 
and mean age of disease onset at 32 years were analysed; 1 patient 
with clinically isolated syndrome, 43 patients with relapsing-
remitting MS, 1 patient with secondary progressive MS and 4 
patients with primary progressive MS, were included.
There was a negative correlation between brain atrophy parame-
ters and disability: between GM and EDSS and MSSS respec-
tively R=0.54 (p< .001) and R=0.37 (p=0.01); between PV and 
EDSS and MSSS respectively R=0.49 (p< .001) and R=0.30 
(p=0,03). MRI parameters of atrophy are also correlated with age 
and disease duration, as well as with T2LV (R=0.50 (p< .001) for 
SC). An even stronger correlation with EDSS was disclosed com-
bining patient’s age with PV and namely with SC (R=0.64; 
R2=0.41; p< .001).
Discussion: These results suggest that MRI parameters of brain 
atrophy are correlated with the disability degree of MS patients. 
Additionally, grey matter atrophy seems to have a stronger corre-
lation with disability than whole brain atrophy. This is also in line 
a variety of recent studies suggesting that GM atrophy could be a 
more sensitive marker of disease progression in MS.
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Validation of a clinical risk score for long-term progression 
of MS
J.C.K. Aurenção1, C.C.F. Vasconcelos1, L.C.S. Thuler2, R.M.P. 
Alvarenga3
1Neurologia, Universidade Federal do Estado do Rio de Janeiro, 
2Estatistica, Instituto Nacional do Cancer, 3Neurologia, Hospital 
Federal da Lagoa, Rio de Janeiro, Brazil
Introduction: Reducing risk of multiple sclerosis (MS) progres-
sion is a challenge in the MS treatment. The application of the 
clinical risk score to predict long term progression is useful and 
has been little explored.
Objective: To validate a clinical risk score (CRS) for long-term 
severity based on demographic and clinical factors present in the 
disease onset.
Methods: CRS-MS was derivate based on five factors identified 
as more significant after a Cox regression model analysis in 150 
patients with ten or more years of the disease. African ancestry, age 
onset above 30 years, two or more relapses at first year of the dis-
ease, pyramidal and cerebellar impairment as first manifestation, 
and to have EDDSS 3 before the first treatment were identified as 
independent variables that influence the time to reach progression. 
The numerical value of 1.0 was given to all factors because hazard 
ratios (HR) and beta coefficients had close values. The sum of the 
single scores gives the overall risk score. In the second phase, we 
validated the score: The CRS-MS was applied in another 270 
patients with at least two years of the disease duration.
Results: Progression was observed in 21% (57/270), with mean 
disease duration of 19,07 years (4-47; SD+- 10,6 years). Among 
these patients, 66% percent had three or more clinical risk factors 
and the risk for progression was 14.3 (95% CI 7.2-28.4, p < 
0.001). All patients with none factor were progression free.
Conclusion: The CRS-MS was able to predict the risk of long-
term progression to patients with two or more years of disease, 
and it can assist in the choice of an early treatment and individual-
ized to avoid long-term disability.
Disclosure
nothing to disclose
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Novel integrative approach combining patient, physician and 
empirical assessments for diagnosing secondary-progressive 
multiple sclerosis
D. Piani Meier1, B. Bennett2, C. Tolley2, S. Kilgariff2, D. 
Tomic1, T. Ziemssen3
1Novartis Pharma AG, Basel, Switzerland, 2Adelphi Values, 
Macclesfield, United Kingdom, 3Zentrum für klinische 
Neurowissenschaften, Universitätsklinikum Carl Gustav Carus, 
Dresden, Germany
Background: Diagnosis of secondary-progressive multiple scle-
rosis (SPMS) is challenging due to active and non-active progres-
sive phases, following an initial relapsing course. To support 
timely diagnosis, a screening tool was previously developed based 
on qualitative interviews with patients and physicians, and data 
from a real-world observational study.
Objective: To create a scoring algorithm for the newly developed 
screening tool to support
physicians in the diagnosis of SPMS.
Methods: Multiple logistic regression analyses were performed 
on observational study data (n=2791) to identify predictive varia-
bles for SPMS. Qualitative interviews (n=8) were conducted to 
determine physician-perceived importance of variables for pro-
gression to SPMS. Additional variables were identified in qualita-
tive interviews apart from those included in the observational 
study. Ranking
(1─26; 1=most important) and weighting (%) outputs were ana-
lysed by descriptive statistics; interview transcripts were qualita-
tively analysed. Variables of high, moderate or low importance 
were integrated in the algorithm. Concordance levels among phy-
sicians were assessed by Kendall’s coefficient.
Results: Regression analyses identified mobility (odds ratio, 
4.457, p< 0.0001) and self-care
(2.388; p< 0.0001) as the strongest patient-reported predictors. 
Expanded Disability Status Scale score (1.789; p< 0.0001), age 
(1.037; p< 0.0001) and MS disease activity (1.681; p< 0.05) were 
identified as the most significant physician-reported predictors. In 
physician interviews, the most important variables were stability/
worsening of symptoms (average weighting [range]; average 
rank: 11% [1─33%]; 5), intermittent/persistent symptoms 
(7% [0─17%]; 7) and presence of ambulatory symptoms (7% 
[0─15%]; 8). Moderately important variables included signs of 
new magnetic resonance imaging activity (6% [0─20%]; 14), 
recovery from last relapse (5% [0─12%]; 13) and impact on daily 
activities (5% [1─10%]; 13). Presence of fatigue, visual symp-
toms and impact on hobbies/leisure time were considered less 
important (2% [0─10%]; 16─19). Overall, concordance levels 
among physicians were significantly low to moderate (0.278; 
p=0.0004); greater agreement was observed within countries (US: 
0.522, Germany: 0.385; p< 0.01).
Conclusions: Findings confirm the need for a prognostic tool to 
support early identification of SPMS. This is the first algorithm 
that integrates patient, physician and empirical assessments to be 
developed for clinical validation.
Disclosure
Funding source: This study was funded by Novartis Pharma AG, 
Basel, Switzerland.
Tjalf Ziemssen has received personal compensation for participat-
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Biological rhythms in MS patients with mood disorders: 
what impact on quality of life?
L. Lorefice1, G. Fenu1, J. Frau1, G. Coghe1, R. Pitzalis1, M.G. 
Carta2, M.G. Marrosu1, E. Cocco1
1Multiple Sclerosis Center, Department of Medical Sciences 
and Public Health, University of Cagliari, 2Psychiatric Unit, 
Department of Medical Sciences and Public Health, University 
of Cagliari, Cagliari, Italy
Background: Multiple Sclerosis (MS) is a chronic neurological 
disease that mainly affects young adults, adversely impacting on 
many aspects of their life. Notoriously, mood disorders may be 
associated with abnormalities in biological rhythms (BR), with 
changes in sleeping and eating patterns as well as in social and 
daily activities. Psychiatric comorbidities are very common 
among MS patients (Carta et al., 2014), while the presence of dys-
regulation of BR has not been adequately explored.
This study aimed to investigate the relationships between circa-
dian BR disturbance with MS clinical features and psychiatric 
comorbidity. In addition, we evaluated the weight of BR impair-
ment on patients’ quality of life (QoL).
Methods: MS patients, diagnosed according to McDonald crite-
ria, were enrolled and clinical features were collected.
DMS IV psychiatric diagnoses were determined by ANTAS-SCID 
interview (Carta et al., 2010).
The Italian Version of the BRIAN questionnaire was used to 
assess abnormalities in BR (sleep, eating, activities and social 
rhythms) (Moro et al., 2010). QoL was evaluated with the Short 
Form Health Survey (SF-12) (Ware et al., 1996). Descriptive sta-
tistics, hierarchical regression analyses, t-test, and the Pearson’s 
correlation were conducted.
Results: The sample included 178 MS patients (61 male); of these 
38/178 had progressive course. Mean value for the disease duration 
was 10.5 years, while mean EDSS was 2.5. The diagnosis of unipolar 
depression was established in 43/178 (24.1%) patients, and bipolar 
spectrum disorders in 32/178 (17.9%). BRIAN scores were respec-
tively 43.6 and 34.4 in patients with and without moods disorders
(p < 0.001). Psychiatric comorbidity, in particular bipolar disor-
der, was the strongest determinant of BR dysregulation (p < 0.01), 
independent from MS clinical features (EDSS and disease dura-
tion). However, an association between BR impairment and EDSS 
score was observed (p < 0.01). In addition, BRIAN score was 
negatively associated with SF-12 score (r= -0.529; p < 0. 001).
Conclusions: Psychiatric comorbidities seem to strongly influ-
ence BR dysregulation in people living with MS. BRIAN ques-
tionnaire could be a useful tool in clinical practice to identify BR 
abnormalities also in MS, bearing in mind the impact of these 
abnormalities on QoL as well as their association with psychiatric 
comorbidities.
Keywords: biological rhythms abnormalities; BRIAN question-
naire; psychiatric comorbidities; quality of life.
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How do people with multiple sclerosis feel about MRI?
K. Engels1, I. Schiffmann2, A. Rahn1, I. Backhus1, H. 
Pinnschmidt2, G. Pust2, C. Heesen2
1University of Hamburg, 2UKE Hamburg, Hamburg, Germany
Background: Magnetic resonance imaging (MRI) is frequently 
applied in diagnosis, prognosis and therapy monitoring of mul-
tiple sclerosis (MS). MS-patients regularly undergo MRI scan-
ning and are therefore constantly confronted with MRI results 
and images. But little is known about MS-patients’ knowledge 
of and attitude towards MRI. We hypothesized that MS patients 
would rate their MRI results as very important and that relevant 
anxiety is associated with the scanning and delivery of results. 
Fear of MRI-results might diminish with longer disease dura-
tion, higher number of MRI scans as well as higher knowledge 
about MRI.
Objective and methods: An online survey was conducted 
among n=498 MS-patients in November/December 2016 via 
the website of the German MS-society. N=388 MS-patients 
answered a 23-item MRI-risk knowledge questionnaire (MRI-
RIKNO) based on earlier work (Brand et al. 2014). N= 490 
patients answered an MRI-emotions and attitude questionnaire 
(MRI-EMA), in which participants rated 17 statements about 
MRI (e.g. „My last MRI result was very important to me.“) on 
Likert scales. Chi-Q-test was used to examine differences 
between patient subgroups.
Results: The majority of participants were female (70%) and had 
a relapsing-remitting MS (RRMS) course (80%). Mean age was 
43, MS was diagnosed between 1975 and 2016 and mean disease 
duration was 8 years. The average score in the MRI-RIKNO was 
15/23 correctly answered questions (65%). MRI-results were very 
important to the majority of patients (55%), but importance 
seemed to fade when transition to secondary MS had been reached 
(35% versus 60% in both RRMS or primary-progressive MS (PP-
MS)). Almost all patients wished to discuss their results with a 
radiologist/neurologist (80%), however 25% did not at all feel 
competent to do so. The MRI scan itself was not stressful to the 
majority of patients (50%), but a third of patients declared that 
they were anxious before having received their most recent MRI-
results. This fear seemed to diminish with longer duration of the 
disease (MS-diagnosis < 5 years: 40%, MS-diagnosis 20 to 30 
years: 20%) and higher number of MRI-scans (< 5 MRI-scans: 
40%, >10 MRI-scans: 20%).
Conclusion: MRI is very important to the majority of MS patients, 
but MRI knowledge is only modest. The MRI results, but not the 
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procedure itself, are associated with anxiety. This anxiety inversely 
correlates with disease duration as well as number of MRIs.
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Clinical validity of EDSS and SDMT in the detection of MS 
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Introduction: Relapse rate and changes in MRI and the Expanded 
Disability Status Scale (EDSS) are universally used as indicators 
of therapeutic efficacy in disease modifying treatments in multi-
ple sclerosis (MS). Though, the EDSS has limitations, namely, in 
the assessment of cognitive dysfunction.
Objective: To investigate the accuracy of clinical measures in the 
detection of disease activity.
Methods: Patients with MS were evaluated using clinical and 
MRI measures in two different moments. Disease activity was 
defined as ≥1 relapses and/or changes in MRI (≥2 Gd-enhancing 
or new T2 lesions). It was considered a change (“clinically mean-
ingful worsening”) if EDSS≥1, Timed 25-foot walk (T25FW) 
≥20%, 9-hole peg test (9HPT) ≥20%, and symbol digit modality 
test (SDMT) ≥10%. Classification accuracy statistics and Fisher’s 
exact were applied.
Results: Of the 132 patients included (67% females, age=42±11, 
education=14±6, disease duration=12±7 years; first evaluation 
EDSS=2.6±3.4, 85% were under disease modifying treatment 
and time between evaluations=12±5 months), 43 (33%) met the 
criteria for disease activity. Changes in EDSS and SDMT cor-
rectly classified (sensitivity) respectively 23/43 (54%) and 26/43 
(61%) patients with disease activity. However, there was a mod-
est association between changes in EDSS and SDMT (p=0.029; 
34/132 patients had changes in one measure but not on the 
other). When combined, the sensitivity and specificity of EDSS 
and SDMT reached respectively 93% and 97%. The sensitivity 
of changes in T25FW (16%) and 9HPT (5%) was low.
Conclusion: Changes in EDSS and SDMT have high accuracy in 
the detection of disease activity. Though, these clinical measures 
may be sensitive to different aspects of disease activity.
Disclosure
Nothing to disclose
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Optimizing standards of approach in multiple sclerosis result 
in better outcomes. A Brazilian open label study on quality 
of care
F.F.A. Figueira, G.M.A. Figueira, P.V.S. Bilouro, R.C. Silveira, 
M.F. Xavier, D.B.M. Angst
Neurology, Hospital São Francisco, Rio de Janeiro, Brazil
Objective: A critical analysis on whether optimization of 
approach and follow up in relapsing remitting MS (RRMS) 
patients impact long term outcomes in real world scenario.
Background: Multiple sclerosis (MS) treatment evolved on last 
two decades, mostly after introduction of so called disease modi-
fying drugs (DMDs). Parallel to advent of new drugs our expertise 
applying diagnostic protocols and custom therapy improved. 
Nevertheless, paradigms for optimal care in MS still depend upon 
prompt and correct diagnosis together with an early as possible 
onset of treatment.
Design and methods: Consecutive naive RRMS patients 
(McDonald 2001), all using a first line DMD, were stratified 
according to year of inclusion on treatment program, from 2002 to 
2004 (n=101), 2005 to 2007 (n=93) and 2008 to 2010 (n=128). 
There were 17
treatment discontinuations: 9 in first, 6 in second and 2 in third 
cohort. Intentionto-treat data were plotted after 4 years in each 
group.
Results: Cohorts matched for age, gender, age at first relapse, 
prior annualized relapse rate (ARR) and time from first to second 
relapse. On baseline, time delay to beginning of DMD (p< .0001) 
and number of T2W hyperintense MRI lesions (p< .01), were sig-
nificant especially when comparing cohorts 1 and 3. Annual num-
ber of visits (p< .001) and frequency of imaging studies (p< .001) 
were also noteworthy. On follow up, ARR (p< .0001), EDSS 
worsening more than 1 point confirmed at 6 month (p< .0001), 
NEDA 3(no relapses, no Gd+ and/or new T2W lesions, no EDSS 
progression) (p< .0002) and annualized corpus callosum index 
(CCI) loss (p< .001) was also relevant. All differences had more 
impact when comparing first and third cohorts.
Conclusions: Prompt and early institution of treatment had a pos-
itive impact on inflammation (ARR and NEDA3) as well as a pos-
sible benefit on degenerative domain (EDSS and CCI). Our 
findings suggest that optimization of standards of care can posi-
tively impact on long term disease course.
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Histologic validation of rapid myelin detection using quanti-
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M. Warntjes1,2, A. Persson1, J. Berge3, W. Zech4
1CMIV, Linköping University Hospital, 2SyntheticMR AB, 
3Institute of Forensic Medicine, Linköping, Sweden, 4Institute of 
Forensic Medicine, Bern, Switzerland
06_MSJ731285.indd   742 13/10/2017   11:10:55 AM
ePosters 23(S3) 743
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Background: Myelin detection is of great value in monitoring 
Multiple Sclerosis, both for global assessment of brain atrophy as 
for local probing of brain tissue integrity in e.g. DAWM or peri-
lesional tissue. Most MRI methods to measure myelin, however, 
are impractical to perform in clinical routine due to excessive scan 
or post-processing times. Recently, a novel method was published, 
where the presence of myelin is inferred using its effect on the 
intra- and extracellular water relaxation rates and proton density, 
observable by rapid quantitative MRI. The method provides high-
resolutions myelin maps in about 5 minutes scan time and 10 sec-
onds post-processing time. The purpose of this work was to 
validate this method further using comparison with gold-standard 
histology.
Materials and methods: The brains of 12 fresh, intact cadavers 
were scanned with the quantitative MRI sequence. R1 and R2 
relaxation rates and proton density PD, as well as myelin maps 
were automatically calculated using SyMRI (SyntheticMR, 
Sweden). Subsequently, the brains were excised at autopsy and 
brain slices were stained with Luxol Fast Blue to verify the pres-
ence of myelin. The stained brain specimens were photographed 
and converted to optical density maps. The LFB optical density 
maps were registered and correlated with the qMRI myelin maps.
Results: A correlation was found between the two methods with a 
mean Spearman’s correlation coefficient for all subjects of 
0.74±0.11. Linear regression showed a mean intercept of 
1.50±2.84% and a mean slope of 4.37±1.73 %/%.
Conclusion: The observed correlation with LFB histology sup-
ports the validity of myelin measurement using rapid quantitative 
MRI. Rapid, automatic myelin measurements may improve quan-
titative monitoring of MS patients.
Disclosure
MW is part-time employed at SyntheticMr AB
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Health-related coping and social interaction in people with 
multiple sclerosis supported by a social network: a pilot 
study with a new methodological approach
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V. Brescia Morra3, A. Gallo2, G. Tedeschi2,5,6, S. Bonavita2,5,6
1Ist Clinic of Neurology University of Campania ‘Luigi 
Vanvitelli’, 2Ist Clinic of Neurology, University of Campania 
‘Luigi Vanvitelli’, 3Department of Neurosciences, Reproductive 
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Naples, 4Department of Business and Management, LUISS 
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Background: Social media are a vital link for people with 
Multiple Sclerosis (pwMS) who find in web-communities a com-
forting source for information exchange, debates and knowledge 
enrichment. PwMS are well informed about the disease but are 
vulnerable to hopes of being cured or saved by therapies whose 
efficacy is not always scientifically proven. To overcome this 
issue, we created an MS experts social network (SMsocialnetwork.
com), guaranteeing a constant online presence of the medical 
team to oversee and participate on the public wall and intervening 
promptly in case of posts with false or inappropriate medical 
information.
Objective: To assess the impact of SMsocialnetwork.com on 
pwMS health-related coping and social interaction analyzing the 
areas of interest through a web-based survey.
Methods: Referring to previous marketing studies analyzing the 
online platforms role in targeted healthcare, we conducted a 39 
item web-based survey. To investigate health related coping and 
social interaction in pwMS we performed a construct validation 
procedure, with a factorial analysis, gathering together akin items 
of the survey, related of the following areas of interests:“utility”, 
“proximity”, “sharing”, “interaction”, “solving uncertainty”, 
“suggestion attitude” and “explore”.
Results: We collected 130 web-based survey. Our analysis dem-
onstrated that the users-pwMS (UP) positively evaluated 
SMsocialnetwork.com to
a) obtain information, approach and solve problems and to 
make decision (“utility”: median 4,2)
b) improve feeling of closeness (“proximity”: median 5)
c) catalyze relationship (“sharing”: median 5.6)
d) get in touch with other users to receive innovative, effec-
tive and practical solutions
 (“interaction”, “solving uncertainty” and “suggestion atti-
tude” medians were, respectively: 4.1, 3 and 3)
e) share information about innovative therapeutic 
approaches and treatment options
 (“sharing”: median: 5.3).
Conclusion: SMsocialnetwork was perceived by UP as a useful 
tool to support health-related coping and social interaction, and 
may suggest a new kind of therapeutic alliance between physi-
cians and pwMS.
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Reliable cross-sectional correlations between a visual rating 
brain atrophy scale and quantitative MRI volumetric mea-
sures in multiple sclerosis
C. Guevara1, J.A. de Grazia2, P. Orellana2, C. Garrido2, M. 
Martinez1, C. Silva1, G. Farias1, V. Diaz1, FONIS SA1610026
1Neurology, 2Radiology, Universidad de Chile, Santiago, Chile
Background: Measuring whole brain atrophy has become a topic 
of interest in the clinical assessment of multiple sclerosis (MS). 
Conventional magnetic resonance imaging (MRI) in the real clini-
cal setting may suggest the degree of cross-sectional whole brain 
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atrophy. The generalized Pasquier scale (four-step) is simple, and 
is one of the main visual brain atrophy scales used for neurorradi-
ologists in order to give a semi-quantitative insight on the axonal 
degeneration in MS patients.
Goal: In this study we aim to assess the correlations between the 
generalized Pasquier scale and quantitative automated MRI volu-
metric measures.
Method: Thirty-seven patients with MS were recruited from the 
MS Clinic at the Hospital Clínico de la Universidad de Chie 
(recurring-remitting MS 78%, clinically isolated syndrome 22%). 
They were assessed by conventional MRI imaging; semi-quanti-
tative whole brain atrophy assessment was performed by two 
neurorradiologists using the generalized Pasquier scale. Cross-
sectional Structural Imaging Evaluation with Normalization of 
Atrophy (SIENAX) analysis was performed in order to assess the 
global brain volume, and its partitions of grey matter - matter, 
peripheral gray mater and ventricular volume.
Results: The mean age was 32.4 years (range 18-52), 70% female, 
disease duration 1.7 years (0.7 -7), baseline Kurtzke EDSS 1.4 
(0-4). There was 10.8% of patients without cortical atrophy 
according to generalized Pasquier scale, mild atrophy 51.4%, 
moderate 35.1% and severe 2.7%. These categories correlated 
positively well with the ventricular volume (r: 0.74; p< 0.001), 
and negatively well with the whole brain volume (r: -0.51, 
p=0.001), peripheral grey matter volume (r: -0.45, p=0.005), 
white matter volume (r: -0.47, p=0.003), and the total grey matter 
volume (r: -0.42, p=0.009).
Conclusion: These results suggest that a semi-quantitative asses-
ment using a visual rating of brain atrophy scale correlates well 
with the automated volumes that SIENAX provides. This may be 
useful when assesing the baseline profiles in MS patients in the 
real clinical practice in order to select the first disease-modifying 
agent.
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Association between perceived fatigue and balance measured 
by posturography in patients with multiple sclerosis
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Background: Fatigue is one of the most common symptoms seen 
in about 80% of patients with Multiple Sclerosis (MS). It is known 
that imbalance that affects physical performance are closely 
related to symptoms such as fatigue, but the relationship between 
fatigue and balance is not yet clear in patients with MS.
Objective: The purpose of this study was to investigate the effect 
of fatigue severity on balance in patients with MS.
Methods: Participants: Forty-one ambulatory patients with MS 
(Age:36.46±8.61 years, EDSS: 1.62±1.06) participated in the 
study.
Main measures: Fatigue was assessed using the self-report Fatigue 
Severity Scale (FSS). Balance was assessed using the Biodex 
Balance System which included the postural stability test, the limit 
of stability test, and the sensory organization test. In the postural 
stability test, the patients were asked to stand for 30 seconds on 
both feet and 10 seconds each on one foot. In the sensory organiza-
tion test, the patients were asked to stand on both feet under four 
altered sensory conditions (1. Eyes open-firm surface, 2. eyes 
closed-firm surface; 3. Eyes open-foam surface, 4. Eyes closed-
foam surface). In the limit of stability test, the patients were asked 
to reach to 8 predetermined target positions in the forward, back-
ward, rightward, leftward, forward-rightward, forward-leftward, 
backward-rightward, and backward-leftward directions
Statistical analysis: Spearman correlation analysis was used to 
determine relationships between balance and fatigue.
Results: In patients with MS, the fatigue severity was associated 
with the postural stability scores on both feet (r: 0.391, p:0.011); 
on right foot (r:0.398, p:0.01); on left foot (r:0.351, p:0.024), and 
was associated with the sensory organization test scores under all 
condition (r:0.379-0.537, p< 0.05). The fatigue severity was asso-
ciated with the limit of stability score in only the backward direc-
tion (r:- 0.358, p:0.021), but not associated with the limit of 
stability in others directions (p>0.05).
Conclusion: This study showed that postural sway and fatigue 
affect each other negatively. More effective results can be obtained 
by adding fatigue management strategies and balance exercises to 
the rehabilitation program in patients with MS.
Disclosure
There is no conflict of interest and funding in this study.
EP1410
Effect of physical activity level on functional exercise capac-
ity in patients with multiple sclerosis
A. Guclu Gunduz1, C. Ozkul2, Y. Aydin1, K. Cekim1, C. Irkec3
1Gazi University / Faculty of Health Sciences, 2Faculty of 
Health Sciences, Department of Physiotherapy and Reha, Gazi 
University, 3Gazi University Medical Faculty, Ankara, Turkey
Background: Both functional exercise capacity, and physical 
activity level decrease in patients with Multiple Sclerosis (MS). 
Which physical activity domains are associated with functional 
exercise capacity is not yet clear in patients with MS.
Objective: The purpose of this study was to examine the effect of 
physical activity domains on the functional exercise capacity in 
patients with MS.
Methods: 
Participants: Forty-one ambulatory patients with MS 
(Age:36.46±8.61 years, EDSS:1.62±1.07) participated in the study.
Main Measures: The International Physical Activity Questionnaire 
(IPAQ) was used to measure total physical activity domains includ-
ing leisure time, domestic and gardening (yard) activities, work-
related, and transport-related activity over the last 7 days. In addition, 
the total scores for the each activity type including walking, moder-
ate-intensity activities, and vigorous-intensity activities were calcu-
lated by using the answers given to these domains. Functional 
exercise capacity was assessed with the six-minute walking test 
(6MWT) and walking distance was recorded as the meter.
Statistical analysis: Spearman correlation analysis was used to 
determine relationships between physical activity and functional 
exercise capacity.
Results: In patients with MS, the functional exercise capacity was 
associated with domestic and gardening activity level (r: - 0.379, 
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p:0.015), work-related activity level (r: 0.409, p:0.008), walking 
activity level (r: 0.334, p:0.033), and vigorous-intensity activity 
level (r: 0.452, p:0.003).
Conclusion: This study demonstrated that while the work-related, 
the walking, and the vigorous-intensity activities are positively 
associated with the functional exercise capacity, the domestic and 
gardening activities are negatively associated with functional 
exercise capacity. Therefore, functional capacity can be improved 
by increasing physical activity level in patients with MS.
Disclosure
There is no conflict of interest and funding in this study.
EP1411
A longitudinal study correlating brain volumes, RNFL, and 
cognitive functions in MS patients and healthy controls
J. Frau1, G. Fenu1, A. Signori2, G. Coghe1, L. Lorefice1, M.A. 
Barracciu3, V. Sechi3, F. Cabras3, M.G. Marrosu1, E. Cocco1
1Centro SM - Osp. Binaghi, University of Cagliari, Cagliari, 
2Department of Health Sciences, Section of Biostatistics, 
University of Genova, Genova, 3Ospedale Binaghi ATS 
Sardegna, Cagliari, Italy
Background: Brain volume (BV) is a biomarker of neurodegen-
eration in MS. Retinal nerve fiber layer (RNFL) measured by 
OCT is another arising biomarker. Both are able to differentiate 
MS patients from healthy controls (HC) and showed a correlation 
with physical disability and cognitive impairment. The relation-
ship between RNFL and BV has been generally evaluated in 
cross-sectional studies, while there are not longitudinal data com-
bining RNFL, BV and cognitive functions (CF) at the same time.
Aim: We aimed to assess longitudinally the relationship between 
RNFL, BV, and CF in MS patients and HC.
Method: At baseline (T1) relapsing remitting MS patients and 
matched HC underwent to 1.5 T brain MRI. SIENAX software 
estimates the normalized volume of the brain (NBV), grey (NGV), 
white (NWV) and peripheral grey (pNGV) matter. CF evaluated 
by BICAMS (including SDMT, CVLT, BVMT), RNFL by 
Spectral Domain OCT (Heidelberg Engineering), demographic, 
and clinical data were collected. The eyes with previous clinical or 
subclinical optic neuritis were excluded. Cognitive reserve (CR) 
was estimated using a validated tool. The evaluations were 
repeated after 12 +/- 3 months (T2). Group analyses were per-
formed with T test for unpaired samples. In MS patients, Pearson 
test analyses the correlation between continuous variables within 
the 2 groups.
Results: We included 54 MS patients (F: 38; mean age: 44 years; 
disease duration: 11.7 years; mean EDSS: 2.5) and 16 HC (F: 8; 
mean age: 46 years). At T1 MS patients and HC differ for NBV 
(p=0.003), NWV (p=0.001), RNFL (p=0.04), SDMT (p=0.01). 
Pearson test showed a correlation between RNFL and CVLT (R: 
0.366, p=0.02), BV (R: 0.483, p=0.005), NGV (R: 0.478, 
p=0.006), pNGV (R: 0.494, p=0.005), between pNGV and each 
BICAMS test (R: 0.3, p=0.01) and between CR and SDMT (R: 
0.38, p=0.003). Longitudinally a significant correlation was found 
between Delta (T2-T1) RNFL and Delta BICAMS tests (R: 0.473, 
p=0.006) Delta RNFL and number of BICAMS altered tests at T2 
(R: 0.343, p=0.04), Delta BV and Delta BICAMS tests (R: 0.494, 
p=0.001). No correlation was found in HC between BV, RNFL, 
and BICAMS tests.
Conclusions: Our data support that MRI, OCT and CF could dis-
tinguish MS from HC. RNFL, such as BV, is a valid biomarker of 
neurodegeneration, and contribute to explain the complex inter-
play determining CF. Our study showed that RNFL, measured 
with an easy and repeatable instrument as OCT, is useful to longi-
tudinally assess the MS patients.
Disclosure
The authors have nothing to disclose about this work
EP1412
Brief international cognitive assessment for multiple sclerosis 
and corpus callosum atrophy index: the correlation between 
quick and easy-to-use tools in MS patients
M.A. de Caneda1, M.G. Longo2, M.C.A. de Vecino1
1Neurology, 2Radiology, Hospital Moinhos de Vento, Porto 
Alegre, Brazil
Background: Cognitive Impairment (CI) raises concerns since ear-
lier in the course of Multiple Sclerosis (MS) and causes great impact 
on patients´ quality of life. CI correlates with damage of cortical and 
subcortical cerebral structures. For instance, the atrophy of Corpus 
Callosum (CC) seems to contribute to cognitive dysfunction in MS. 
Generaly, both CI identification and volumetry of brain structures 
requires sophisticated techniques that are often inaccessible in clini-
cal practice. The Corpus Callosum Index (CCI) has been suggested 
as a marker of atrophy and does not require the use of any advanced 
software. The BICAMS (Brief International Cognitive Assessment 
for Multiple Sclerosis) is a battery of Neuropsychological Tests 
(NTs), which includes the SDMT, CVLT-II and BVMT-R, that has 
been recently proposed as a quick and easy-to-use screening instru-
ment. We have studied the association between these tools, consid-
ered ideal for daily clinical practice.
Objective: To investigate the correlation between the CC atrophy, 
evaluated by CCI, and the BICAMS in patients with MS.
Methods: Thirty patients with relapsing-remitting MS were included. 
The BICAMS was applied to these and the CCI were measured in a 
follow-up routine MRI. The CCI and BICAMS were also estimated 
in sixty healthy controls. The Correlation Coefficients (r) between 
NTs and CCIs, and their respective effect sizes (d), were calculated. 
All participants signed an Informed Consent Form.
Results: There was a significant correlation between SDMT and 
CCI (r = 0.41, p < 0.025, d = 0.57). BICAMS detected CI in 60% 
of MS patients with low CCI. When CCI shows no atrophy, 82% 
of patients present normal NTs.
Conclusions: The consistent association between SDMT and CCI 
points this index as a predictor of information processing speed 
impairment, oftentimes pattern of CI in MS. The cognitive dys-
functions detected by BICAMS find corresponding damage in 
brain structures, remarkably the CC atrophy.
Disclosure
Marco Aurélio Gralha de Caneda: nothing to disclose
Maria Gabriela Longo: nothing to disclose
Maria Cecília Aragon de Vecino: nothing to disclose
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EP1414
Treatment optImization using a multidimensional decision 
model (TIME study): a proof-of concept study to assess a 
multidimensional standardized documentation model to 
optimize management of patients with multiple sclerosis in 
Germany
M. Stangel1, B. Kallmann2, R. Schruefer3, I.-K. Penner4,5
1Medizinische Hochschule Hannover, Clinical 
Neuroimmunology and Neurochemistry, Department of 
Neurology, Hannover, 2MS Zentrum Bamberg, MSZB, Bamberg, 
3Biogen, Ismaning, 4Heinrich Heine University Düsseldorf, 
Medical Faculty, Department of Neurology, 5COGITO - Centre 
for Applied Neurocognition and Neuropsychological Research, 
Düsseldorf, Germany
Objective: The TIME study aimed at evaluating whether physi-
cians, MS nurses and MS patients will benefit from a novel com-
puter-based management and documentation tool (Multiple 
Sclerosis Decision Model, MSDM) in terms of optimization of 
treatment efficiency and uncovering treatment failures.
Background: Effective treatment regimens and absence of clini-
cally relevant disease activity are essential goals in today’s MS 
therapy. However, there is no standardized documentation tool to 
evaluate the complexity of symptoms in MS patients longitudi-
nally. The MSDM has been proposed as an algorithm to detect 
multimodal clinical changes based on factors such as relapse, dis-
ability progression, MRI, cognition, and patient reported out-
comes. The feasibility of this tool in everyday practice was 
investigated including physician, nurse, and patient satisfaction.
Study design: This 15-months non-interventional, open-label, 
multi-center, proof-of-concept study focused on patients with 
relapsing forms of MS in Germany. The study consisted of a 
3-months core and a 12-months extension phase.
Methods: MSDM was evaluated on a tablet PC. Acceptance was 
assessed by physicians, MS nurses and, patients by using specific 
questionnaires.
Results: 110 patients have been recruited in 9 MS outpatient 
treatment centres. 3-months after the start of the observation, 
most neurologists (n=6) agreed that the inclusion of neuropsy-
chological factors and the involvement of patients for decision 
making is highly warranted. However, acceptance rates from 
neurologists were only moderate, primarily due to demands in 
time and effort. Acceptance of the tool by MS nurses (n=8) was 
good. The tool showed high acceptance rates in patients (n=69). 
Presented numbers so far are preliminary and final data will be 
presented.
Conclusion: A standardized, multidimensional approach to docu-
ment clinical symptoms longitudinally is warranted to optimize 
treatment in MS patients. MSDM represents a novel and useful 
approach covering various relevant disease aspects and support-
ing disease management.
Disclosure
MS has received honoraria for scientific lectures or consultancy 
from Bayer Healthcare, Biogen, Baxalta/Shire, CSL Behring, 
Euroimmune, Grifols, Merck-Serono, Novartis, Roche, Sanofi-
Genzyme, and Teva. His institution received research support 
from Bayer Healthcare, Biogen Idec, Genzyme, Merck-Serono, 
Novartis, and Teva.
BK has received honoraria for serving on advisory boards and as 
speaker from Merck Serono, Biogen-Idec, Sanofi/Genzyme, Teva 
and Novartis.
RS is a Biogen Employee. IKP has received honoraria for speak-
ing at scientific meetings, serving at scientific advisory boards 
and consulting activities from Adamas Pharma, Almirall, Bayer 
Pharma, Biogen, Genzyme, Merck Serono, Novartis and Teva. 
She has received research support from Merck Serono, Novartis, 
the German MS Society and Teva.
EP1415
Epicardial fat tissue in patients with multiple sclerosis
M. Seferoğlu1, B. Şensoy2, D. Yıldız1, N. Büyükkoyuncu Pekel1
1Neurology, 2Cardyology, Bursa Yüksek Ihtisas Training and 
Research Hospital, Bursa, Turkey
Background and purpose: The epidemiological studies confirm 
an increased risk of cardiovascular disease in multiple sclerosis 
and epicardial adipose tissue (EAT), a type of visceral adipose tis-
sue surrounding the heart and coronary vessels has been impli-
cated in the development of coronary artery disease. We sought to 
investigate the correlation between EAT and the disease - disease 
severity in multiple sclerosis (MS) patients.
Methods: Twenty eight multiple sclerosis (MS) patients (MS 
duration 8 (4-16) years, aged 41 ± 16 years; female/male: 16/10) 
and 28 healthy controls both with no known cardiovascular risk 
factors were enrolled into the study. Disease severity was evalu-
ated by Extended Disability Status Scale (EDSS). The EAT was 
measured via two-dimensional (2D) M-mode echocardiography.
Results: EFT was significantly higher in patients compared to 
controls (3.6 ±1.2 mm vs. 3.1 ± 0.7 mm, P < 0.05). We did not 
observe correlations between the EFT levels and MS duration, 
relapses, EDSS, optic neuritis, oligoclonal bands (p>0.05).
Conclusions: The reason for the increase in EAT in patients with 
MS is unknown, but it is probably multifactorial, with genetic, 
immune-mediated inflammatory factors having a role. Thus, 
along with the increased prevalence of cardiometabolic risk fac-
tors and systemic inflammation, EAT can probably be another 
important contributor to the higher cardiovascular risk observed 
in MS. These findings deserve to be studied closer in a broader 
spectrum of comorbidities in MS.
Disclosure
No conflict of interest
EP1416
An improved assay for therapeutic dose monitoring of natali-
zumab
B. Messmer1, J. D’Angelo2, S. Nocchi2, L. Ruff2, J. Fecteau2
1Abreos Biosciences | Research, 2R&D, Abreos Biosciences, San 
Diego, CA, United States
Natalizumab is a highly efficacious treatment option for patients 
with relapsing-remitting multiple sclerosis (MS), but carries a risk 
of JC polyomavirus driven progressive multifocal leukoencepha-
lopathy (PML). Recent data has suggested that patients on 
extended interval dosing schedules have a reduced rate of PML 
consequent to lower natalizumab exposure. However, there is 
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significant variation in steady state drug levels in natalizumab 
patients, suggesting a need for a therapeutic dose monitoring 
assay tha t can identify the patientswith the highest free trough 
levels of natalizumab that are candidates for dose extension. We 
have previously described a specific mimetope peptide for the 
capture and quantification of free and active natalizumab in 
serum. The peptide binds to the antigen binding site of natali-
zumab and competes for binding with the target α4 chain of inte-
grin as shown by flow cytometry. We compared a mimetope 
peptide based ELISA assay with an anti-idiotype based assay 
using a commercially available anti-natalizumab antibody. Both 
assays were benchmarked against a cell based assay in which 
samples were applied to VLA -4 positive cell lines. The peptide 
based ELISA was consistently closer in value to the cell based 
assay while the anti-idiotype assay almost always reported a 
higher value. While both the peptide and anti-idiotype cross com-
pete in ELISA and block natalizumab binding in the cell based 
assay, we hypothesized that the anti-idiotype antibody could bind 
to natalizumab that was incapable of binding target. We gently 
heat denatured natalizumab and observed a loss of binding in the 
cell based assay that was also observed in the peptide ELISA, 
whereas the anti-idiotype reported the full natalizumab concentra-
tion regardless of the time of heat treatment. Thus we postulate 
that there is significant but variable amounts of natalizumab that 
is no longer able to bind target at the time of trough sampling in 
treated patients and that the surrogate ligand peptide mimetope 
ELISA is a more accuratemeasure of active drug. A second gen-
eration peptide was developed by amino acid replacement scan-
ning of the original mimetope. When used in the ELISA assay, this 
affinity matured peptide had roughly 10 times greater sensitivity, 
resulting in an assay with an estimated limit of detection of less 
than 500ng/ml. Full assay validation is ongoing.
Disclosure
Bradley Messmer: nothing to disclose
EP1417
Evaluation of the Human Activity Profile on patients with 
multiple sclerosis
L. Savsek1,2, V. Strojnik3, Z. Spiclin4, S. Sega Jazbec2
1Department of Neurology, General Hospital Celje, Celje, 
2Neurology Clinic, University Medical Centre Ljubljana, 
3Faculty of Sport, 4Faculty of Electrical Engineering, University 
of Ljubljana, Ljubljana, Slovenia
Objective: To investigate the reliability, validity and responsive-
ness to change of the Human Activity Profile (HAP), a self-report 
questionnaire measuring physical activity, in patients with multi-
ple sclerosis (MS).
Methods: Group of 25 patients with MS completed the following 
self-report questionnaires: HAP, Modified Fatigue Impact Scale 
(MFIS), Multiple Sclerosis Quality of Life-54 (MSQOL54). 
EDSS disability level was determined and walking speed assessed 
by 10-Meter Walking test (10MWT).
Responses on the HAP resulted in 2 scores: maximum activity 
score (MAS) and adjusted activity score (AAS). These scores 
were statistically correlated with the other tests and examined for 
test-retest reliability. A subset of patients (12) participated in a 
12-week supervised aerobic exercise programme, while others 
served as control. Same measures were repeated at end of 12 
weeks.
Results: Intraclass correlation coefficient (ICC), calculated on 
control group, was 0,97 for both MAS and AAS. Significant cor-
relations were found between HAP scores and subscale scores 
from MFIS and MSQOL54, that assess physical functioning, 
EDSS and 10MWT. After 12 weeks of exercise, a decrease of 
physical fatigue, as measured by Body subscale of MFIS (MFIS-B), 
was found, although not statistically significant (p=0,054). A sta-
tistically significant increase in Energy subscale of MSQOL54 
(MSQOL54-E; p=0,022) was reported by control group. No sig-
nificant correlation between MFIS-B and MSQOL54-E was found. 
In both groups, no statistically significant change was observed in 
HAP, EDSS and 10MWT. In response to 12 weeks of exercise, the 
effect sizes for MAS and AAS were 0,2 and 0,04, respectively, 
similar to that of the MFIS and MSQOL54.
Conclusion: The correlations between HAP and physical func-
tion subscale scores from MFIS and MSQOL54, EDSS and 
10MWT demonstrate that HAP is a valid and, as demonstrated by 
ICCs, also a reliable measure of physical function in patients with 
MS. After 12 weeks of exercise, no major change in physical 
functioning was detected by any of the measures. HAP displays a 
similar sensitivity to change as the other questionnaires. Along 
with simplicity of use, HAP could be a valuable assessment tool 
for patients with MS.
Disclosure
Lina Savsek: nothing to disclose. Vojko Strojnik: nothing to dis-
close. Ziga Spiclin: nothing to disclose. Sasa Sega Jazbec: nothing 
to disclose.
EP1418
Do color vision testing and OCT parameters reflect the sub-
clinical optic nerve involvement in multiple sclerosis?
B. Yuksel1, B. Dogan2, B. Koctekin3, N. Atis1, A. Erdal1, F. 
Kurtulus1, Y. Bicer Gömceli1
1Neurology Department, 2Ophthalmology Department, 
3Physiology Department, Antalya Training and Research 
Hospital, Antalya, Turkey
Introduction: Multiple sclerosis (MS) is an inflammatory demy-
elinating disease of central nervous system (CNS). Acute idio-
pathic demyelinating optic neuritis is frequently the initial 
manifestation. In this study, we aimed to discuss the value of color 
vision testing to detect possible optic nerve involvement in 
patients with MS who had no history of optic neuritis.
Methods: 28 RRMS patients with 56 eyes and age-sex matched 
25 healthy controls with 50 eyes were included to this study. We 
evaluated color vision with Farnsworth-Munsell 100 hue test and 
retinal nerve fiber layer thickness (RNFL) was determined by 
optical coherence tomography (OCT). Pattern visual evoked 
potentials (PVEP) were also performed. EDSS scores, duration of 
disease, history of treatment were all recorded.
Results: 28 RRMS patients (mean age 39,68±9,68) and 25 healthy 
controls (mean age 38±5,94) were included. In patient group, 20 
were female (71,4%), 8 were male (28,6%). Control group con-
tained 17 female (68%), 8 male (32%). P100 latencies were sig-
nificantly delayed in patient group than controls. (p=< 0.05). In 
patient group mean RNFL thickness was 85.79±13.8µm while the 
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thickness of RNFL was 89.24±8.55 µm in controls. Mean tempo-
ral RNFL thickness was 57.64±14.13 µm in patients and 
67.64±11.68 µm in controls. Statistically significant thinning was 
found in temporal quadrant in patient groups than controls 
(p=0.002). There was a negative correlation between the total 
error scores and RNFL thickness in patient group (p=0,016; 
r:-0,320). There were also negative correlations between the red 
green-blue yellow scores and temporal quadrant thickness in 
patient group, respectively (p=0,006;r:-363,p=0,004; r: -0,383).
Conclusion: This ongoing study showed that PVEP, OCT param-
eters, Farnsworth-Munsell 100 hue test were all correlated to 
detect subclinical optic pathway involvement in multiple sclerosis 
patients.
Disclosure
None of the authors identify a conflict of interest. This research 
did not receive any grant from funding agencies.
Economic burden
EP1420
Disability and unemployment utilization in patients with 
multiple sclerosis
B. Wong1, J. Cahill2, A. Bouley1, A. Daigle1, T. Zhang3, S. 
Rizvi2
1Brown University, 2Clinical Neurosciences, The Neurology 
Foundation, Brown University, 3Brown University School of 
Public Health, Providence, RI, United States
Background: Multiple sclerosis (MS) is a disease that affects 
young adults and can lead to significant disability and unemploy-
ment. The aim of this study is to explore the effects of multiple 
sclerosis on employment across age groups.
Methods: This is a cross-sectional retrospective data analysis 
using a clinical database containing patient data from a single ter-
tiary care MS center after IRB approval. Patients were divided by 
years since diagnosis: < 10, 10-19, 20-29, ≥30. For each group the 
percentage of patients on government certified disability and/or 
unemployed was calculated. The percentage of patients who were 
on disability, unemploymed, and/or retired was also calculated.
Results: A total of 854 patients age 18 to 65 with a diagnosis of 
MS were included in the study
(F=620, M=234). Patients < 18 or >65 years of age or with no 
employment data available were excluded. Of these patients 612 
(71.6%) carried a diagnosis of relapsing remitting MS (RRMS), 
179 (21.0%) carried a diagnosis of secondary progressive MS 
(SPMS), and 63 (7.4%) carried a diagnosis of primary progressive 
MS (PPMS). Among all patients 186 (21.8%) patients were on 
disability and/or unemployed. Furthermore, 267 (31.3%) patients 
were on disability, unemployed, and/or retired. The percentage of 
patients who were either unemployed or on disability was higher 
among patients who were at least
10 years from diagnosis (33.8% vs. 23.1%). Age at diagnosis was 
not associated with disability and/or unemployment status 
(p=0.822). The percentage of patients on disability, unemployed, 
and/or retired increased with number of years since diagnosis and 
included 28.4% of patients with < 10 years since diagnosis and 
77.8% of patients with ≥30 years since diagnosis. Patients w/ 
PPMS were more likely to be disabled, unemployed, and/or 
retired (p< 0.001). Male and female patients were equally likely to 
be unemployed and/or on disability.
Conclusion: The percentage of patients who are on disability or 
are unemployed is higher in patients who have carried a diagnosis 
of MS for at least 10 years. PPMS patients were the more likely to 
be unemployed when compared to patients with either RRMS or 
SPMS. Furthermore, neither age at diagnosis nor patient sex was 
associated with employment status.
Disclosure
Brian Wong: nothing to disclose
Jonathan Cahill: nothing to disclose
Andrew Bouley: nothing to disclose
Alison Daigle: nothing to disclose
Tinting Zhang: nothing to disclose
Syed Rizvi: nothing to disclose
EP1421
Satisfaction analysis of nursing care delivered to patients 
with multiple sclerosis using virtual technology in British 
Columbia, Canada
G. Vorobeychik, A. Kazimirchik, J. Nelson
Fraser Health Multiple Sclerosis Clinic, Burnaby, BC, Canada
Background: The Fraser Health Authority (FHA) is the largest 
and fastest growing health region in British Columbia (BC), serv-
ing a population base of 1.46 million in an area of approximately 
10,000 square kilometres. Travel time from east to west borders is 
2 hours. The Fraser Health Multiple Sclerosis (FHMS) Clinic was 
established August 2004 in Burnaby BC to serve more than 3000 
persons living with multiple sclerosis (MS). The large geographi-
cal area, coupled with the limited specialized resources creates 
physical, financial and/or geographical accessibility barriers. To 
address this issue, in April 2015, the FHMS Clinic opened a 
Satellite Clinic in Abbotsford Regional Hospital, located more 
centrally in the area. To maintain a high level of specialty care, a 
nurse clinician and MS neurologist travelled to the clinic weekly.
However, travel time and cost to the satellite clinic and the inability 
to attend to the nursing duties in the Burnaby clinic were signifi-
cant factors that lead to the development of a unique tele health 
model of nursing care. The Virtual Nursing Program (VNP) com-
menced in June 2016, and continues to function with a rotation of 
MS neurologists, who see the patients in Abbotsford, and an assis-
tant, to connect the patient through Skype for Business (S4B) with 
the nurses who are situated in the clinic in Burnaby.Nurses repli-
cate educating, counselling, monitoring and managing MS symp-
toms through technology. The physician can communicate with the 
nurses via S4B to discuss each patient and the care plan, as they do 
in the Burnaby site. Additionally, education materials are handed 
to the patients, by the assistant, as directed by the nurses.GOAL: 
To determine if MS patients, MS neurologists and MS nurses par-
ticipating in the VNP are satisfied with this mode of care.
Method: A satisfaction survey using a 5-point Likert scale was 
given to 59 MS patients, 3 neurologists and 2 nurses.
Results: Results of the survey were analyzed for level of partici-
pant satisfaction, recommendations, and verbal feedback of expe-
rience. A majority of the patients scored very satisfied, with 
overall scores improving as the clinic gained experience in this 
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mode of care delivery. Few patients noted preference for face to 
face interaction. Neurologists and nurses scored similarly.
Conclusion: Satisfaction with the virtual nursing program con-
firmed the viability of providing specialized care to patients in 
poorly accessible areas of the health region.
Disclosure
Dr. Galina Vorobeychik reports personal compensation for con-
sulting and research support for Biogen Idec, Genzyme, Novartis, 
Roche, Serono Merck, Teva Neuroscience.
Anna Kazimirchik, RN, MSCN: I have received honorariums for 
participation in nursing advisory boards from the following 
Pharmaceutical companies: Novartis Pharmaceuticals Canada 
Inc., EMD Serono, Genzyme Canada, Teva Canada Innovation, 
Biogen Canada Inc.
Jill Nelson, RN, BScN, MSCN: I have received honorariums for 
participation in nursing advisory boards from the following 
Pharmaceutical companies: Novartis Pharmaceuticals Canada 
Inc., EMD Serono, Genzyme Canada, Teva Canada Innovation, 
Biogen Canada Inc., Roche Canada
EP1422
Multiple sclerosis treatment decisions: EDSS independent 
disease impact/reserve and the use of additional economically 
impactful milestones that matter
M. Gudesblatt1, K. Wissemann1, M. Zarif1, B. Bumstead1, L. 
Fafard1, M. Buhse1,2, D. Golan3,4, C. Sullivan5,6, J. Wilken5,6, G. 
Doniger7
1South Shore Neurologic Associates, Patchogue, 2Nursing, State 
University of Stony Brook, Stony Brook, NY, United States, 
3Department of Neurology, Carmel Medical Center, 4Faculty of 
Medicine, Technion Israel Institute of Technology, Haifa, Israel, 
5Neuropsychology Associates, Fairfax, VA, 6Dept of Neurology 
and Washington Neuropsychology Research Group, Georgetown 
University Hospital, Washington, DC, United States, 7NeuroTrax 
Corporation, Modiin, Israel
Objective: Explore objective computerized cognitive outcome 
measures to identify MS disability trajectory as it relates to impact 
not always apparent by relapse, EDSS or MRI.
Background/rationale: MS, characterized by relapses/progres-
sion, is traditionally measured by EDSS/MRI change and relapse 
rate reduction. EDSS change is primarily driven by walking 
impairment but this does not account for cognitive impact/reserve 
nor accumulation of cognitive impairment. Cognitive impairment 
impacts abilities not addressed by traditional metrics (e.g. employ-
ment, ability to drive, and fall risk for simple or complex daily 
activities. There are multiple available disease modifying thera-
pies (DMT) of varied routes/potencies making individual treat-
ment choice/change problematic. A patient centric objective 
analysis of likely trajectory of economically important milestones 
relating to predictive loss of such abilities an alternative approach 
to guiding treatment choice/change. This objective/quantitative, 
EDSS independent, approach of likely disability trajectory might 
improve decision making regarding DMT choice/change and 
offer a path to compare outcome measures across clinical trials.
Methods: Retrospective cross-sectional review of a prospective 
digital MS registry obtained in the course of routine care utilizing 
standardized computerized cognitive testing to evaluate the 
relationship of cognitive impairment (number of cognitive 
domains impaired (CDI) >1 standard deviation from age/educa-
tion normal) on patient reported outcome disability (unemploy-
ment, loss of driving, increased fall risk) in people with EDSS< 7.
Results: Increasing accumulated number of CDI is associated with 
progressive loss of: employment (N=543, CDI-0=63%, CDI-
1=53%, CDI-2=45%, CDI-3=23%) driving (N=126, CDI-0=86, 
CDI-1=69%, CDI-2=61%, CDI-3=20%) and reduced safety with 
increased fear of falling for simple daily activities [(FOF-SDA), 
N=174, CDI-0=74%, CDI-1=69%, CDI-2=35%, CDI-3=29%) and 
increased fall of falling for complex daily activities [(FOF-CDA), 
N=174, CDI-0=71%, CDI-1=65%, CDI-2=33%, CDI-3=32%).
Conclusions: Tracking disease impact by economically important 
milestones trajectory beyond EDSS/MRI or relapse can be 
obtained by use of cognitive testing to provide patient centric 
information predicting loss likelihood of important milestones not 
completely dependent upon EDSS which might provide a path-
way of actionable change to monitor therapy choice or disease 
progression.
Disclosure
This study was not supported by outside funding
Gudesblatt M: Research support from Biogen, Teva, Sanofi-
Genzyme, Novartis and EMD Serono; and speaker fees/consult-
ant for: Biogen, Novartis, Teva, Sanofi-Genzyme, Amgen, Saol 
Therapeutics, Medtronic, Accorda, TG Therapeutics, EMD 
Serono
Wilken J: grants and personal fees from Biogen, Sanofi Genzyme 
and George Washington University.
Wissemann K: nothing to disclose
Golan D: nothing to disclose
Sullivan C: nothing to disclose
Fafard L: nothing to disclose
Bumstead B: Speaker fees from Biogen, Genentech, Sanofi-
Genzyme, and Teva. Buhse M: Speaker fees from Sanofi-
Genzyme, and Teva.
Zarif M: Speaker fees from Acorda, Biogen, Sanofi-Genzyme, 
and Teva
Doniger G: employee of NeuroTrax
EP1423
Dutch trial-based economic evaluation of an intensive social-
cognitive treatment (Can Do Treatment) in patients with 
relapsing remitting multiple sclerosis and low disability
G.A.P.G.V. Mastrigt1,2, P.J. Jongen3,4, S.M.M.A. Evers1,2, &. 
The Can Do Treatment Study Group4
1Health Services Research, 2Public Health Research Institute 
(CAPHRI), Maastricht University, Maastricht, 3Community & 
Occupational Medicine, University Medical Center Groningen, 
Groningen, 4MS4 Research Institute, Nijmegen, The Netherlands
Objective: To evaluate the cost-effectiveness of the Can Do 
Treatment (CDT) which aims to improve self-efficacy and estab-
lish autonomy in patients with relapsing remitting multiple scle-
rose (RRMS) and low disability.
Treatment: The CDT, an intensive social cognitive program con-
tains various sessions provided in one weekend to patients and 
partners by a multidisciplinary team aiming to identify and reduce 
“stressors’’ which they experience due to RRMS in their daily life.
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Methods: The economic evaluation from a societal perspective 
with a follow up of 6 months was performed alongside a rand-
omized controlled trial evaluating two groups; CDT patients 
(CDT) and care as usual patients who had the option to receive 
CDT after the controlled study phase (control). Included costs 
were medical costs (inpatient and outpatient), cost of productivity 
losses, informal care and travel costs. The incremental cost effec-
tiveness ratio (ICER) is expressed in cost on the Multiple Sclerosis 
Self-Efficacy Scale-Control (MSESS control) and the incremental 
cost utility ratio (ICUR) in the cost per Quality Adjusted Life 
Years (QALY). Bootstrap analyses and sensitivity analyses were 
performed to determine the robustness of the findings. The costs 
of (un)prescribed drugs, aids and tools were not taken into account 
in the current analyses. The final results, including these previ-
ously mentioned cost categories will be available for the presenta-
tion at the congress.
Results: The two groups of 79 patients showed comparable base-
line characteristics. Results from the preliminary analyses suggest 
that the average total cost difference was not significantly differ-
ent between the two groups; that the ICER shows higher costs and 
more effects in the CDT group; and that the ICUR shows higher 
costs and lower effects for the CDT group. The bootstrap and sen-
sitivity analyses confirm the preliminary base case findings.
Conclusions: These preliminary results of the economic evalua-
tion suggest no cost effectiveness of the CDT. A reduction of 
intervention costs could improve change of the CDT being cost 
effective.
Disclosure
This study is funded by the National MS foundation, The 
Netherlands, Rotterdam and The Netherlands.
EP1424
Health needs, utilization and cost coverage in MS: a NAR-
COMS, NMSS, iConquerMS survey
D. Miller1, S. Planchon2, S. Givens3, M.B. Mercer2, C. Musil3, H. 
Schmidt4, S.S. Cofield5
1Cleveland Clinic Foundation, 2Cleveland Clinic, 3Case 
Western Reserve University, Cleveland, OH, 4Accelerated Cure 
Project, Waltham, MA, 5Biostatistics, University of Alabama at 
Birmingham, Birmingham, AL, United States
Background: Health care services needed for management and 
treatment of MS are not always covered by health insurance (HI). 
Even with HI coverage, out of pocket costs are often incurred, 
resulting in emotional, physical, or financial stress.
Objective: Assess need for services, utilization when needed, and 
insurance coverage and costs in persons with MS in the prior 12 
months.
Methods: Persons diagnosed with MS, US residents, ages 18-65, 
were surveyed in Fall 2016 through the National MS Society, the 
North American Research Committee on MS (NARCOMS), iCon-
querMS, and regarding healthcare services needed, used, and cov-
ered by HI in the prior 12 months. Services included medical 
professionals (MP: primary care, neurologists, nurse practitioners), 
behavioral health (BH), rehabilitation (Rehab), integrative/comple-
mentary medicine (ICM), medical equipment (MEQ), Laboratory 
(Lab) or imaging (IMG) services, prescriptions (Pres), inpatient 
care (INP), short-term/home-care nursing or rehabilitation (STC), 
emergency room (ER), and preventative medicine/wellness 
(PrevM). Results are presented as percent (%), Mean(SD), or 
Median(IQR).
Results: Of the 2507 respondents that met the general eligibility 
criteria, 2323 (92.7%) completed information regarding age, gen-
der, duration of MS, had HI and needed at least one healthcare 
service: 53.6(8.4) years old, 3.4% Hispanic/Latino, 91.8% 
Caucasian, 3.2% African American, 82.8% female, with a mean 
disease duration 16.5(8.4) years, 67.0% Relapsing MS, 20.5% 
SPMS, 5.6% PPMS. The median(IQR) services needed was 6(4, 
7), used 5(4, 6), and covered by HI 4(4, 6). Over 90% of respond-
ents indicated they needed MP (97.5%), 95.0 Pres, 92.1 each Lab 
or IMG; with less than 40% needing all other services 38.9 Rehab, 
36.6 PrevM, 32.4 ICM, 28.6 MEQ, 22.6 BH, 21.5 ER, 13.5 INP, 
4.6 STC. More than 80% of services needed were used, excepting 
73.1 IMG. Of services used, more than 85% were covered by HI, 
excepting 61.3 MEQ, 42.1 PrevM, 41.5 ICM.
Conclusions: As expected standard healthcare services such as 
practitioner visits, lab and imaging were the most needed services, 
though imaging was the least used of needed services. And while 
most used services were covered by HI, nontraditional services 
such as medical equipment, integrative or complementary medi-
cine, and preventative medicine and wellness were least likely to 
be covered by insurance.
Disclosure
This work supported by grant HC-1411-02012 from National MS 
Society. NARCOMS is supported in part by the Consortium of 
Multiple Sclerosis Centers(CMSC) and The Foundation of the 
CMSC.
Stacey S. Cofield: grant support from Pfizer, consulting fees from 
Department of Defense, American Shoulder and Elbow Society, 
Oxford University Press, MedImmune, Inc.
Sarah Planchon: nothing to disclose
Sarah Givens: nothing to disclose
Mary Beth Mercer: nothing to disclose
Carol Musil: nothing to disclose
Hollie Schmidt: nothing to disclose
Deborah Miller: Scientific Advisory Board for Evidera Inc., con-
sultant for and recieved support for scientific writing from 
Hoffman-Roche, Ltd.
EP1425
Relapse resolution and HCRU in patients with multiple scle-
rosis: a retrospective study of relapse therapy alternatives to 
corticosteroids
T. Nazareth1, R. Sheer2, M. Datar2, P. Schwab2, T.-C. Yu1
1Health Economics and Outcomes Research, Mallinckrodt 
Pharmaceuticals, Inc, Hampton, NJ, 2Comprehensive Health 
Insights, Humana Inc, Louisville, KY, United States
Background: Corticosteroids (CS) are the mainstay treatment of 
relapses in patients with multiple sclerosis (MS); other agents 
include repository corticotropin injection (RCI; H.P. Acthar® 
Gel), intravenous immunoglobulin (IVIG), or plasmapheresis 
(PMP). Our study evaluated patients with MS relapse, healthcare 
resource use (HCRU), and effectiveness of CS alternatives in 
relapse resolution using the Humana Research Database. Humana 
policy considers CS to be first-line relapse therapy.
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Methods: Humana’s Commercial and Medicare Advantage 
claims data from 1/1/08-7/31/15 were utilized. An MS relapse was 
defined as an inpatient stay (IP) with a principal diagnosis of MS 
(ICD-9-CM 340.xx) or an outpatient visit [OP, including emer-
gency department (ED)] with a MS diagnosis, and a medical or 
pharmacy claim for second-line treatment (RCI, IVIG, PMP) 
within 30 days. The first relapse event and treatment were consid-
ered the index event and treatment. Relapse events were consid-
ered unresolved if >1 relapse occurred within 30 days. In RCI and 
PMP/ IVIG groups, relapse events and HCRU (IP, OP, ED, total 
visits) were evaluated during 1-year follow-up (1 year); relapse 
events were also evaluated during 2-year follow-up (2 years). 
Comparative analyses were conducted, using chi-square tests for 
categorical variables and t-tests for continuous variables.
Results: PMP and IVIG were combined into 1 group, due to sam-
ple size. At 1 year, 232 RCI and 141 PMP/IVIG patients were 
identified with mean (SD) unresolved relapse events of 0.6 (2.0) 
and 5.3 (7.1), respectively. 81.5% of patients receiving RCI had 
no unresolved relapses vs. 36.2% receiving PMP/IVIG. Patients 
receiving RCI had lower all-cause HCRU, except ED (mean dif-
ferences): total visits (12.9), IP (0.2), ED (0.0), and OP (12.7). At 
2 years, 155 RCI and 104 PMP/IVIG patients were identified with 
mean (SD) unresolved relapses of 1.2 (3.5) and 8.0 (11.6), respec-
tively. 73.5% of patients receiving RCI had no unresolved relapses 
vs. 33.7% receiving PMP/IVIG. All results, except for ED visits, 
were significant at p< 0.02.
Conclusions: At 1 year, patients receiving RCI had significantly 
lower unresolved relapses and lower mean total, IP, and OP visits; 
superior resolution with RCI continued at 2 years. Results suggest 
RCI should be considered for relapse treatment prior to PMP/
IVIG in appropriate patients. Limitations of claims data apply; 
index events were first observed and not incident.
Disclosure
This study was funded by Mallinckrodt Pharmaceuticals, Inc.
Manasi Datar: A shareholder of Humana Inc. and an employee of 
Comprehensive Health Insights, Inc., a wholly-owned subsidiary 
of Humana Inc.
Richard Sheer: A shareholder of Humana Inc. and an employee of 
Comprehensive Health Insights, Inc., a wholly-owned subsidiary 
of Humana Inc.
Phil Schwab: A shareholder of Humana Inc. and an employee of 
Comprehensive Health Insights, Inc., a wholly-owned subsidiary 
of Humana Inc.
Tara Nazareth: An employee and stock holder of Mallinckrodt 
Pharmaceuticals, Inc.
Tzy-Chyi Yu: An employee and stock holder of Mallinckrodt 
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EP1426
Access Barriers to disease-modifying therapies in Latin 
America: the impact of who makes treatment decisions and 
when and why this is done
A.J. Carra1,2, Y.D. Fragoso3, M.A. Macias-Islas4,5,6, J. Steinberg2, 
C. Carcamo Rodriguez7, J.C. Duran Quiroz8, A. Finkelsztejn9, J. 
Garcia Bonitto10, R. Leon Aponte11, G. Orozco12,13,14, C. Oehninger 
Gatti15, A. Tarulla16, D. Vizcarra Escobar17,18, C. Vrech19
1Neurociencias, Fundacion Favaloro-INECO, 2Hospital 
Britanico Buenos Aires, Caba, Argentina, 3Universidade 
Metropolitana de Santos, Santos, Brazil, 4Neurociencias. CUCS. 
Universidad de Guadalajara, 5Doctorado en Farmacología. 
CUCS, Universidad de Guadalajara, 6Sistema Nacional de 
Investigadores. Consejo Nacional de Ciencia y Tecnología, 
Guadalajara, Mexico, 7Pontificia Universidad Catolica de Chile, 
Santiago, Chile, 8Facultad de Medicina, Universidad Mayor de 
San Andres, La Paz, Plurinational State of Bolivia, 9Hospital 
de Clinicas de Porto Alegre, Porto Alegre, Brazil, 10Clinica 
Marly, Bogota, Colombia, 11Hospital Universitario de Valencia, 
Valencia, 12Hospital Alemán Patrocinio Peñuela Ruiz, 13Instituto 
Venezoloano de los Seguros Sociales, 14Centro Especialidades 
San Sebastian, San Cristobal, Bolivarian Republic of Venezuela, 
15Instituto de Neurología, Hospital de Clínicas de Montevideo, 
Montevideo, Uruguay, 16Neuroimmunology-MS Section Hospital 
Agudos Parmenio Piñero, Caba, Argentina, 17Universidad 
Peruana Cayetano Heredia, 18Clinica San Felipe, Lima, Peru, 
19MS Section Sanatorio Allende, Cordoba, Argentina
Introduction: Multiple Sclerosis (MS) patients who are pre-
scribed disease-modifying therapies
(DMTs) may lack access to their medication for reasons such as inter-
changeability from providers, copayment costs, pharmacy require-
ments, provider requirements, insurance coverage changes and 
restrictions. The consequences are associated with poorer adherence 
and increased risk. There is a need in Latin America to understand 
MS patients’ perspectives on access barriers to DMT medication.
Objectives: To describe and to analyze problems for accessing 
DMTs in Latin America.
Methods: Responses were obtained from nine countries 
(Argentina, Bolivia Brazil, Chile, Colombia, Mexico, Peru, 
Uruguay and Venezuela) regarding four main questions: 1) How 
do patients resolve their DMT access issues? 2) What are the clini-
cal and ethical consequences of DMT access barriers? 3) Who is 
involved in helping patients access their DMTs? 4) What percent-
age of patients access their DMTs?
Results: 6/9 countries: neurologist non-expert confirms diag-
nosis and decides treatment. Time diagnosis-treatment: 7/9 
countries 4-6 months; 2/9 time was longer (8-12 months). 
Between 90 and 100% of patients access their DMTs in 7/9 
countries; however, in 3/9 countries the Social Security decides 
what treatment patients need, according to the cost. This means 
that many choices are made between innovative and -generic 
drugs differing from what the neurologist prescribed, which 
impacts on clinical and ethical issues. Some of the countries 
have more than three generic version available for some inno-
vative drugs. We discuss the ethical issues at the time of deci-
sion-making regarding treatment.
Conclusion: Every country represented in this Latin American 
forum needs to understand who is responsible for managing the 
risks of a given treatment. One of the most important aspects of 
this new era of generics, biosimilars and follow-on drugs is not 
only the cost but also what place the expert has in making deci-
sions on treatments.
Disclosure
A. Carra; Y. Fragoso; MA. Macias-Islas; J. Steinberg; C. Carcamo 
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Activities of daily living, work productivity, and reliance on 
caregiver in patients with primary progressive multiple scle-
rosis
N. Wu1, N. Thomas1, E. Ma1, W.-S. Yeh1, E. Jones2
1Genentech Inc, South San Francisco, CA, United States, 
2Adelphi Real World, Manchester, United Kingdom
Background: Primary progressive multiple sclerosis (PPMS) is 
characterized by steadily increasing neurologic disability from dis-
ease onset, with or without temporary plateaus in disease progres-
sion. PPMS is a chronic disease that primarily affects patients of 
working age; however, there is a lack of data on the impact PPMS 
has on patients’ work productivity and ability to live independently.
Goals: To compare the ability to perform daily self-care activities, 
work productivity, and reliance on caregiver between patients 
who have PPMS and patients who have relapsing remitting MS 
(RRMS).
Methods: This study used data from the patient record form 
(PRF) of the Adelphi Multiple Sclerosis Disease Specific 
Programme, a cross-sectional study collecting data from 487 neu-
rologists and 5402 patients in the France, Germany, Italy, Spain, 
United Kingdom, and United States between November 2015 and 
March 2016. A total of 916 PPMS and 3,472 RRMS patients were 
included. Self-care activities were assessed by activities of daily 
living (ADL) and instrumental activities of daily living (IADL). 
Productivity and independency were examined by whether a 
patient was able to work full time and whether he/she had a car-
egiver, respectively. Adjusted analyses were performed to control 
for potential confounders.
Results: PPMS patients were older (51.2 vs. 38.1, p< 0.001), 
more likely to be males (54.8% vs. 31.8%, p< 0.001), had a longer 
disease duration (7.0 vs. 4.6 years, p< 0.001), had a higher 
Expanded Disability Status Scale (EDSS) score (4.9 vs. 2.1, p< 
0.001), and were less likely to be on a current treatment with a 
DMT (36.7% vs. 83.4%, p< 0.001) than RRMS patients. 
Compared to RRMS, a higher proportion of PPMS patients 
needed assist on at least one ADL (45.0% vs. 6.4%, p< 0.001) and 
IADL (62.2% vs. 15.2%, p< 0.001). In addition, PPMS patients 
were less likely to work full time than RRMS patients (18.8% vs. 
52.3%, p< 0.001). Finally, a higher reliance on professional car-
egiver (18.2% vs. 1.4%,
p< 0.001) and family caregiver (53.7% vs. 16.7%, p< 0.001) was 
observed in PPMS than in RRMS.
In adjusted analyses, all of the above findings were consistent 
after controlling for confounders.
Conclusions: Compared with RRMS patients, PPMS patients had 
a significantly higher burden on their ability to perform self-care 
activities, work full time, and live independently. These findings 
highlight the high unmet need in PPMS for an effective DMT.
Disclosure
Funded by Genentech, Inc.
N. Wu is an employee of Genentech, Inc.
N. Thomas is an employee and shareholder of Genentech, Inc.
E. Ma is an employee and shareholder of Genentech, Inc.
W-S Yeh is an employee and shareholder of Genentech, Inc.
E. Jones has no conflict of interest and is a paid employee of 
Adelphi Real World
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Cost analysis of a relapse-free patient in relapsing-remitting 
multiple sclerosis
L. Romero-Pinel1, E. Matas1, L. Bau1, R. Juvany2, V. Casado3, 
M. Huerta4, A. Martínez-Yélamos1, S. Martínez-Yélamos1
1Department of Neurology, Multiple Sclerosis Unit (EMxarxa), 
2Pharmacy Department, Hospital Universitari de Bellvitge-
IDIBELL, L’Hospitalet de Llobregat, 3Department of Neurology, 
Hospital de Mataró, 4Department of Neurology, Hospital de 
Viladecans, Barcelona, Spain
Background: Nowadays efficacy and safety of disease-modify-
ing therapies (DMTs) in multiple sclerosis (MS) are well known 
but it lacks data to evaluate its cost-effectiveness. This knowledge 
would be useful to improve clinical management and to establish 
risk-sharing schemes of payment in health systems.
Objective: To analyze the cost per year of a relapse-free patient in 
a cohort of relapsing remitting multiple sclerosis (RRMS) treated 
with first or second-line DMTs.
Patients and methods: Patients diagnosed with MS, followed in 
our MS unit and belonging to our health district in 2016 were 
evaluated. Our health district comprised 201192 inhabitants by 
2016 and our center has the only MS unit. From them, patients 
diagnosed with RRMS were retrospectively selected for this 
study. Clinical and radiological data was collected prospectively 
using the European Database for Multiple Sclerosis (EDMUS) on 
a 6-monthly basis and at the time of relapse. Patients were classi-
fied in two groups, treated and not treated with DMTs during 2016 
and in another two groups according to the presence or absence of 
at least one relapse during the same year. The mean cost of DMTs 
during 2016 of all RRMS patients was analyzed as well as the cost 
of a relapse-free patient.
Results: 181 patients from our health district were diagnosed with 
MS and followed in our MS unit, resulting in an MS prevalence of 
90 per 100000 inhabitants. This rate was representative of the 
expected prevalence of MS in epidemiological population-based 
studies performed in our area. 158 patients diagnosed with RRMS 
were selected for our study. They were 71% women, their mean 
age at onset was 30.6 years, their mean disease duration was 16.3 
years, and their median irreversible EDSS was 2.0. From them, 
101 patients (63.9% of the cohort, 95% CI: 56,2-71.0%) were 
treated with DMTs during 2016. 120 patients (75,9% of the cohort, 
95% CI 68.7-81.9%) remained free of relapses during 2016. The 
mean cost of DMTs per patient in 2016 was 7414.3 euros (95% 
CI: 6325.2-8503.4) when we considered all RRMS patients. The 
cost per year of DMTs of a relapse-free patient was 9762.2 euros.
Conclusion: The cost per year of a relapse-free patient may be a 
good health indicator to evaluate cost-effectiveness in RRMS 
patients treated with DMTs and to compare one population to 
another.
Disclosure
L.Romero-Pinel received research support, funding for travel and 
congress expenses and honoraria from speaking engagements and 
scientific advisory board from Biogen Idec, Teva Pharmaceutical 
Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare 
Pharmaceuticals and Merck Serono.
E.Matas received research support, funding for travel and con-
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Neuro-ophthalmology
EP1429
Is retinal oximetry useful in diagnosis of neuromyelitis optica 
Devic?
T. Svrčinová1, J. Mareš1, V. Sladková1, Z. Matejčíková1, J. 
Vysloužilová1, M. Šín2, M. Rybáriková2, P. Kaňovský1
1Department of Neurology, 2Department of Ophthalmology, 
Palacky University Hospital, Olomouc, Czech Republic
Purpose: An assessment of retinal oxygen saturation in the optic 
nerve in patients with demyelinating disease and comparation the 
difference between clinically isolated syndrome (CIS), relapse 
remitting multiple sclerosis (RRMS) and neuromyelitis optica 
Devic (NMO).
Methods: There were investigated 46 patients with MS (29 with 
CIS, 17 with RRMS) and 5 with diagnose of NMO. All patients 
were examined by using optical coherence tomography (OCT 
Spectralis, Heidelberg Engineering, Germany), automatic optical 
oximetry (Oxymap, ehf. Reykjavik, Iceland), and by using visual 
evoked potentials (Metronic Keypoint®, Minneapolis, USA).
Results: Arterial and venous saturation and arterio-venous differ-
ence (AVD) were reported. The results were compared among the 
three groups. There were found out changes in the saturation, 
especially in patients with acute relapse of ON. The most signifi-
cantt changes of AVD were observed in group of NMO.
Conclusion: Assessment of retinal oxygen saturation could be 
used as another diagnostic method in suspicion from NMO. 
There is an assume that oximetry could reflects changes in 
acute phase of ON. The higher metabolic demand cause bigger 
oxygen consumption and higher AVD, while degenerative pro-
cess cause lower AVD. There will be needed more patients to 
confirm the fact.
This work was supported by the Institutional support of the 
Research Organisation - Ministry of Health, Czech Republic, 
RVO - FNOL 2017 and present study was partially supported by 
grant project IGA_LF_2017_020.
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Vogt-Koyanagi-Harada disease is an important  
differential diagnosis for autoimmune acute visual  
impairment
Y.D. Fragoso1, T. Adoni2, E.Y. Chiovatto3, S. Gomes4, M.V. 
Goncalves5, M. Kim3, E.P. Maciel6, A. Muniz7, R.I. Pasquarelli-
Neto8, M.C. Pereira1, L.M. Simao9, M.A. Sousa10, N.A. Sousa11
1Universidade Metropolitana de Santos, Santos, 2Hospital 
Sirio Libanes SP, Sao Paulo, 3ABC Medical School, Santo 
Andre, Brazil, 4Hospital Beneficencia Portuguesa and Hospital 
Paulistano, Sao Paulo, British Indian Ocean Territory, 
5Universidade da Regiao de Joinville, Joinville, 6Hospital 
de Base do Distrito Federal, Brasilia, 7Hospital da Bahia, 
Salvador, 8Instituto Santista de Olhos, Santos, 9Minas Gerais 
Medical School, Belo Horizonte, 10Universidade Federal do 
Triangulo Mineiro, Uberaba, 11University Hospital Getulio 
Vargas, Manaus, Brazil
Introduction: Vogt-Koyanagi-Harada (VKH) disease is a sys-
temic illness of autoimmune origin in which T cells target mel-
anocytes in individuals susceptible to the disease. Clinical 
manifestations typically include signs and symptoms relating to 
the eye, ear, skin and central nervous system (CNS). Acute vis-
ual manifestations of VKH include acute uveitis with bullous 
serous retinal detachment and optic disk hyperemia. Previous 
ocular penetrating trauma, eye surgery and any other ocular dis-
ease that could be confounded with VKH must be ruled out for 
correct diagnosis and treatment of the condition. Among these 
differential diagnoses are other autoimmune diseases poten-
tially leading to visual loss, such as multiple sclerosis (MS) and 
neuromyelitis optica (NMO). The objective of the present study 
was to report on a series of 22 well-documented VKH cases 
from Brazil.
Methods: Detailed reports on patients diagnosed with VKH were 
reviewed by neurologists and ophthalmologists caring for these 
individuals. Data are presented descriptively.
Results: There was clear predominance of females (91%), and 
the median age at the initial manifestation of VKH was 34 
years. All patients had severe visual manifestations of the dis-
ease and 68% of them had concomitant neurological signs and 
symptoms (headache, ataxia, vertigo, dysphagia, motor deficits 
and neuropsychiatric manifestations). Despite prompt diagnosis 
and treatment in all cases, three patients presented new episodes 
of uveitis, five patients evolved with cataracts and one with 
glaucoma, and two patients were left with severe permanent 
loss of vision. Seven patients had been referred to the neurolo-
gist with the diagnosis of “optical neuritis” by the first physi-
cian attending the case. Other diagnoses for referral to 
neurologists were viral meningitis, vertigo, Behcet’s disease, 
MS and NMO.
Conclusion: Like MS and NMO, VKH is a cause of acute visual 
impairment mainly affecting young women. Awareness of VKH 
disease is of essence in neuroimmunology.
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North American Susac syndrome collaboration classification 
criteria: labels for a broader spectrum of Susac syndrome
G.R. Paton1, R. Carruthers2, C. Sheldon3, T. Vertinsky4, A. 
Traboulsee2, M. Carruthers5, R. Rennebohm6
1Pediatric Neurology, 2Neurology, 3Ophthalmology, 4Radiology, 
5Rheumatology, University of British Columbia, Vancouver, 
BC, Canada, 6Rheumatology, Cleveland Clinic, Cleveland, OH, 
United States
Background: Recently proposed diagnostic criteria Susac syn-
drome (SuS) may not serve patients who have early or atypical 
SuS. A classification criteria will enable identification and facili-
tate research for those patients.
Objective: To propose classification criteria and rules for classifi-
cation for SuS that recognize heterogeneity in limited forms of 
disease.
Methodology: Using reported manifestations of SuS, criteria for 
demonstrating Eye, Ear and Brain involvement were developed. 
Corpus callosum (CC) lesions were used as an independent bio-
marker. Classification Rules include all combinations of the pres-
ence/absence of CC lesions and the classic triad.
Results: Eye involvement can be demonstrated by:
1) Branch/Central Retinal Artery Occlusion (BRAO),
2) arterial wall hyperfluoresence on fluroscein angiogram,
3) history of purported past BRAO, without current FA evidence 
of diminished dye flow through any vessels but with residual sco-
toma (documented by visual field testing) and OCT evidence of 
past BRAO, or
4) chronic changes in the retinal periphery that are consistent with 
residual damage from past Susac retinal vasculopathy (such as 
capillary dropout, peripheral non-perfusion, neovascularization) 
and are best explained by SuS.
Brain Involvement can be demonstrated by diffuse encephalopa-
thy and/or a neuropsychiatric syndrome such as psychosis, para-
noia, personality change, or amnesia. Ear involvement can be 
demonstrated with subacute/acute onset of unilateral or bilateral 
low frequency sensorineural hearing loss, documented by audio-
gram. Classical CC lesions include typical “snowball” lesions (of 
various sizes and shapes), “spoke” lesions, “icicle” lesions, and 
corpus callosal “holes” that are located in the central portion of 
the CC. The number of lesions may vary from many to a single 
(but definite) lesion. Classification rules recognize all possible 
combinations of the above findings and with a total of 11 catego-
ries, including definite/probable/possible/isolated feature and 
classical/atypical depending on presence of CC lesions.
Conclusion: The proposed NASSC Classification Criteria use 
established manifestations of SuS including the presence/absence 
of the complete triad and CC lesions to provide labels for early 
SuS who do not meet published diagnostic criteria.
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Long-term outcomes in MOG-IgG+ Optic Neuritis
B.K. da Costa1,2, G.R. dos Passos1,2, R.C. Sommer3, J. 
Becker1,2,3, D.K. Sato1,2,3
1Neurology Department, Pontifical Catholic University of Rio 
Grande do Sul, 2Brain Institute of Rio Grande do Sul, 3School of 
Medicine, Pontifical Catholic University of Rio Grande do Sul, 
Porto Alegre, Brazil
Introduction: The association between Optic Neuritis (ON) and 
autoantibodies against myelin oligodendrocyte glycoprotein (MOG-
IgG) have been reported by several groups but there are still not defi-
nite recommendations about long-term treatments to prevent 
recurrences. In this study, we evaluated the clinical characteristics 
and the long-term recurrence of our MOG-IgG positive ON cases.
Methods and results: We included all patients who presented 
with isolated ON between December 2014 and December 2015 in 
a tertiary center in South Brazil. We excluded patients diagnosed 
with Neuromyelitis Optica Spectrum Disorders (NMOSD) and 
Multiple Sclerosis (MS). We included 6 ON cases who were 
MOG-IgG+ and negative to aquaporin-4-IgG using in-house live 
cell-based assays. They were mainly male (4 males and 2 
females), with a mean age of 47 years and all patients, except one, 
presented bilateral and/or recurrent ON. The brain MRI of all 
MOG-IgG+ patients was normal or had unspecific white matter 
T2 lesions. Five patients were followed for a median of 53 (range 
43-120) months, but one patient did not return for follow-up vis-
its. Three patients did not present any other attack. Two patients 
had recurrent ON attacks during follow-up. Three patients 
received azathioprine. One patient with recurrent ON had persis-
tent MOG-IgG+ at the last visit.
Discussion: Previous studies found higher frequencies of recur-
rent ON in MOG-IgG+ patients, but we observed recurrence in 
only two MOG-IgG+ patients in a cohort with a first ON attack. 
Although based on a small sample, our results suggest a signifi-
cant portion of patients with a single attack, indicating a benign 
course when comparing to NMOSD and MS.
Conclusion: The MOG-IgG+ ON apparently have a benign 
course with low number of relapses, but the use of long-term 
immunosuppression may be considered in relapsing and severe 
cases with persistent MOG-IgG+.
Disclosure
Dr. da Costa receives PhD scholarship from CNPq of Brazil.
Mr. Sommer has nothing to disclose.
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Dr. Becker received speaking honoraria and research or travel grants 
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The use of visual evoked potentials to differentiate optic neu-
ropathies
M. Seabra, L. Braz, J. Guimarães
Neurology, Centro Hospitalar de São João, Porto, Portugal
Introduction: Visual evoked potentials (VEPs) have long been 
used to investigate patients with optic neuropathies. They comple-
ment the structural information given by magnetic resonance 
imaging and clinical assessment of visual acuity by detecting 
functional loss in the visual pathway. The analysis of VEPs ampli-
tudes and latencies may aid in the differential diagnosis.
Methods: 115 patients admitted in our hospital with suspected 
optic neuropathy were selected. According to current diagnosis cri-
teria, 4 etiological groups were defined: Multiple sclerosis (MS) 
(N=36), Neuromyelitis optica (NMO) (N=8), Idiopathic (N= 57), 
Ischemic (N=9). We analysed VEPs performed in the acute phase 
and compared these results according to the final diagnosis.
Results: 110 patients and 220 eyes were selected. Fourteen 
patients had bilateral symptoms (N=2 MS, N=9 Idiopathic, N=3 
NMO). The VEP analysis showed visual pathway abnormalities in 
sixty-nine eyes, and none of these were asymptomatic. Mean 
P100 latency differed among groups (p=0,0023), with those diag-
nosed with MS and NMO showing prolonged latencies, respec-
tively 139 (IQR=30,5) and 126. Analysis of P100 amplitudes did 
not show significant differences (p=0.0852). NMO and ischemic 
optic neuropathies were associated with a greater proportion of 
absence visual evoked responses: 50% and 37.5%, respectively, 
compared with 16.0% in MS (p=0.013).
Conclusion: Recently a new role for VEPs in MS has been sug-
gested. They are advocated as possible diagnosis and prognostic bio-
markers. Nevertheless, their value extends beyond MS and they may 
help differentiating this entity and NMO or ischemic neuropathies. 
Our study further confirms previous reports of utility of PEVs in dif-
ferentiating the etiology of optic neuropathies with different profiles.
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Mood disorders and multiple sclerosis: a study based upon 
the French national health insurance databases
A. Guilleux1,2, J. Roux1,2,3, E. Leray1,2,3
1EA 7449 REPERES, EHESP / Rennes 1 University, 2METIS 
Department, EHESP French School of Public Health, 3INSERM 
CIC-P 1414, University Hospital of Rennes, Rennes, France
Background: Mental comorbidities are considered as common 
among patients with multiple sclerosis (MS). They may have 
impact on care consumption, delay to diagnosis, disability pro-
gression, adherence to disease-modifying therapy but also on 
quality of life. International literature shows that the frequency of 
mental comorbidity in MS patients is higher than in general popu-
lation. However, few data are available in France. In this context, 
the present study was performed to assess the frequency of 
patients affected by MS having mental comorbidity and more pre-
cisely mood disorders.
Method: MS Patients were identified between 2011 and 2015 in a 
random sample issued of French national health insurance system 
if they meet at least one out of the three following criteria: being 
under MS long disease duration status, being prescribed at least 
one disease-modifying therapy (DMT) specific for MS (dimethyl 
fumarate, beta interferon, fingolimod, glatiramer acetate, natali-
zumab or teriflunomide), having at least one hospital admission 
with a MS diagnosis. Mood disorders were considered as present 
if at least one reimbursement of a specific list of treatments was 
identified in 2015.
Results: A total of 1,153 patients with MS were alive in 2015. 
Most of them were declared as LDD status (N=1,009) from a 
median duration of 10 years, female to male sex-ratio was 2.5 and 
their median age was 50 years. At least one reimbursement for 
mood disorders treatment was observed for 349/1153 (30.3%) of 
patients. Of them, 187 received only a treatment specific to 
depression and 25 only a treatment specific to bipolar disorders. 
Patients with mood disorders were older than patients without 
mood disorders (median age: 54 vs 49, respectively) and their 
number of general practitioner visits was higher (median at 7 vis-
its per year vs 5).
Conclusion: This study performed on sample of national health-
care databases available in France shows that about one third of 
patients affected by MS had a prescription for treatment of mood 
disorders over 1 year period. The next objectives are to extent this 
analysis on a healthy control group from the French general popu-
lation in order to compare the frequencies of mental comorbidities 
but also with control group from the population of people diag-
nosed with rheumatoid arthritis to estimate the burden of MS on 
mental health compared to another chronic disease.
Disclosure
This work was supported by the ARSEP foundation
Alice Guilleux has no disclosure to report.
Jonathan Roux has no disclosure to report.
Emmanuelle Leray reports personal fees as speaker or consultant 
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Frequency of sleep abnormalities in a Brazilian cohort of 
patients with neuromyelitis optica spectrum disorder
M.M.M. Perin, D.B. Bichuetti, N.A. Souza, E.M.L. Oliveira
Neurology, Universidade Federal de São Paulo, São Paulo, 
Brazil
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Background: Among patients with neuromyelitis optica spec-
trum disorder (NMOSD), sleep abnormalities, fatigue and mood 
disorders are common comorbidities that can impair quality of life 
if they are not correctly identified.
Goals: To evaluate the frequency of sleep disorders, fatigue and 
depression in a Brazilian cohort of patients with NMOSD.
Methods: Between September 2014 and December 2016, 66 
patients with NMOSD were interviewed, in a cross-sectional 
study. Sleep disorders, fatigue and depression were evaluated 
through specific questionnaires: Pittsburgh index for sleep quality, 
restless legs syndrome severity scale, fatigue severity scale, 
Beck’s depression inventory, Epworth scale, and Berlin question-
naire. Unpaired t test or Mann-Whitney test were used for com-
paring NMOIgG positive and negative patients. A logistic 
regression model was built to investigate factors associated to the 
quality of sleep.
Results: Mean age of disease onset was 33,85 (±13,5), with 
median disease duration of 9,03 (±5,5) years; 50% were Afro-
descendants with a 4:1 female:male rate. A complete NMO syn-
drome (with 2 of the core symptoms: optic neuritis, longitudinal 
extensive transverse myelitis and/or area postrema syndrome) 
were observed in 77% of the patients. Only 18 (27%) patients 
presented a good sleep quality; 35% had excessive daytime sleepi-
ness; 30% were at high risk for presenting obstructive sleep apnea 
syndrome; 15% had moderate to severe restless legs syndrome; 
62% had depression, and 33% had moderate to severe fatigue. 
When NMOIgG positive patients (n= 32) and negative (n = 30) 
were compared, no difference was observed between the two 
groups. The regression model showed only age was significantly 
associated with poor quality of sleep (coef 0.84, p=0.03).
Conclusion: Sleep disorders and depression are frequent among 
patients with NMOSD, regardless their NMOIgG status. Older 
patients seem to have a poor quality of sleep.
Disclosure
Perin MMM has been awarded an educational grant by Bayer 
Health Care to study for an online Masters in Neuorimmunologiy 
at Universitat Autònoma de Barcelona (UAB), has received 
speaking honoraria from Novartis and financial assistance to 
attend neurology congress paid by Bayer Health Care, Merck 
Serono and TEVA.
Bichuetti DB has received speaking/consulting honoraria from 
Bayer Health Care, Biogen Idec, Merck Serono, Genzyme-Sanofi 
and TEVA and had travel expenses to scientific meetings spon-
sored by Bayer Health Care, Merck Serono, TEVA and Roche.
Souza NA had travel expenses to scientific meetings paid by 
Bayer Health Care, Merck Serono and TEVA.
Oliveira EML has received speaking/consulting honoraria from 
Novartis, Biogen Idec, Merck Serono, Genzyme Sanofi and 
TEVA and had travel expenses to scientific meetings sponsored 
by Novartis, Genzyme Sanofi, Merck Serono and TEVA.
EP1436
Assessing the risk of cervical dysplasia in women with MS 
compared to women without disease using a data linkage 
approach
E. Foster1, M. Malloy2,3, V. Jokubaitis4, C.D. Wrede5,6, H. 
Butzkueven1,4, A.-L. Nguyen1,4, J. Brotherton2, A. van der 
Walt1,4
1Neurology, The Royal Melbourne Hospital, Parkville, 
2Victorian Cervical Cytology Registry, 3Melbourne School of 
Population of Global Health, 4Melbourne Brain Centre at RMH, 
Department of Medicine, University of Melbourne, 5Department 
of Oncology and Dysplasia, The Royal Women’s Hospital, 
6Department of Obstetrics and Gynaecology, University of 
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Background and aims: The risk of persistent Human 
Papillomavirus (HPV) infection, cervical dysplasia and HPV-
related cancers is unknown in women with multiple sclerosis 
(MS). Given the long-term and serial exposure of patients to 
immunomodulatory and immunosuppressive treatments, it is 
important to determine the prevalence of cervical dysplasia in the 
MS population compared to other women. Understanding this risk 
may help guide vaccination guidelines for the highly effective 
HPV vaccine in this population.
Methods: We identified all women aged 18 to 70 with a primary 
diagnosis coded at hospital separation as MS through the Victorian 
Admitted Episode Database. The cervical screening history of this 
cohort was identified using probabilistic data linkage to women 
who had at least one cervical screening episode between 2009 - 
2013 recorded on the Victorian Cervical Cytology Registry. 
Cervical dysplasia outcomes identified were: cytological low- and 
high-grade abnormalities (LGA, HGA) and histologically con-
firmed abnormalities (HisA). Results were stratified by age and 
intergroup comparisons were performed.
Results: A cohort of 2382 patients with MS was identified, and 
compared with 929,670 women in the general population. Overall, 
the results show a similar proportion of cytological and histological 
abnormalities between the MS cohort and the general population. In 
the MS cohort, 7.18% had LGA, 2.35% had HGA, and 1.68% had 
HisA; these rates were 6.84%, 2.46% and 2.31%, respectively, in 
the general population. In the younger age groups (25-34 years), the 
MS cohort had higher rates of all abnormalities, but these rates 
dropped below that of the general population in the later age groups
(60-69 years).
Conclusion: The data demonstrates similar rates of cervical dys-
plasia for women with MS and the general Victorian population. 
While the results are reassuring, the lack of data on DMT-exposure 
makes it difficult to assess risk on an individual basis. Physicians 
should remain vigilant and recommend screening and vaccination 
to all patients with multiple sclerosis.
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A prospective study of fracture risk, fall risk and serum 
vitamin D levels in ambulatory patients with moderately 
advanced multiple sclerosis
S.M. Yap, N. McNicholas, S. Jordan, L. Buckley, P. Iyer, E. 
Shaikh, N. Tubridy, M. Hutchinson, C. McGuigan
Department of Neurology, St. Vincent’s University Hospital, 
Dublin, Ireland
Background: People with MS (pwMS) are at risk of osteoporosis 
due to immobility and repetitive steroid use. PwMS are also at risk 
of falls due to physical, visual and/or cognitive disability. Vitamin 
D deficiency is associated with both disease progression in MS 
and increased risk of osteoporotic fractures.
Objectives: To assess fracture risk, fall risk and serum vitamin D 
in ambulatory patients with moderately advanced MS; to compare 
the utility of 3 fracture risk scoring methods and a fall risk tool.
Methods: Consecutive pwMS aged 18-75 years with Expanded 
Disability Severity Scale (EDSS) score of 3.0-6.5 attending the 
MS clinic were invited to participate in the study involving meas-
urement of serum vitamin D level and administration of an amal-
gamated questionnaire containing all question items included in 
the Fracture Risk Assessment Tool (FRAX), QFracture, an 
MS-Specific Fracture Score (MSSFS) and the Johns Hopkins 
Fall Risk Assessment Tool (JHFRAT). Data was analysed using 
SPSS v24.
Results: Of a total of 26 pwMS (n=13, RRMS; n=11, SPMS; n=2 
PPMS), 58% were female, median age 51 years, median MS dis-
ease duration 12.5 years, median EDSS 5.0. Only 15% (4/26) had 
ever received specific advice on bone protection in MS. 46% had 
a serum vitamin D level (overall median 96nmol/l, range 16-315) 
below the threshold (70nmol/l) required for optimal bone health. 
No significant associations existed between serum vitamin D and 
fall risk score, prior falls, fracture risk scores or prior fracture.
Although there were moderate to strong correlations between 
each fracture risk score with one other score (MSSFS and 
QFracture, rs=0.484, p=0.01; MSSFS and FRAX, rs=0.83, p< 
0.0001; FRAX and QFracture, rs=0.835, p< 0.0001), there was a 
wide variation in proportion of patients exceeding threshold for 
intervention (bone mineral density measurement +/- anti-osteo-
porotic therapy) across the 3 fracture scores (54% MSSFS; 38% 
FRAX; 19% QFracture; p< 0.0001).
46% (12/26) reported prior falls. Using JHFRAT, 54% (14/26) 
were categorised as having moderate fall risk. JHFRAT did not 
distinguish between patients with and without prior falls 
(p=0.671). JHFRAT showed a moderate correlation with MSSFS 
(rs=0.505, p< 0.0001) but not with FRAX or QFracture.
Conclusion: These results highlight the underestimated impor-
tance of assessing bone health in pwMS. Serial serum vitamin D 
measurements may be of value. Choice of fracture and fall risk 
assessment tools for pwMS should be further studied.
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Multiple sclerosis and the risk of venous thrombosis: a sys-
tematic review
O. Ahmed1, R. Geraldes2, A. Ahmed3, G. DeLuca2, J. Palace2
1Oxford University Hospitals NHS Foundation Trust, 2Nuffield 
Department of Clinical Neurosciences, Oxford University 
Hospitals, Oxford, 3Barts & The London School of Medicine & 
Dentistry, London, United Kingdom
Objective: Our aim is to estimate the incidence of Venous 
Thromboembolic (VTE) disease in Multiple Sclerosis (MS) 
patients compared to those without MS, through a critical and sys-
tematic review of the literature. Additionally, if data is available 
we aim to assess if MS clinical features, such as MS type, disease 
duration and severity, are associated with a higher risk of VTE.
Methods: We searched PubMed and EMBASE. The records 
were initially screened using their titles then abstracts. Full text 
articles were read by two independent reviewers to assess if they 
met the following inclusion criteria: study population consists of 
patients with a confirmed diagnosis of MS according to the 
accepted diagnostic criteria at the time of the study; comparison 
group consists of patients with no diagnosis of MS; clinical out-
comes include incidence rates of VTE events with Deep Vein 
Thrombosis (DVT) and Pulmonary Embolism (PE) diagnostic 
strategies clearly stated, as well as risk ratios of MS vs non-MS. 
Data was extracted by one reviewer using a standardized form 
and verified by a second. A metanalysis was carried out using 
OpenMeta[Analyst] software. Each study was critically appraised 
using the Newcastle-Ottowa Quality Assessment scale.
Results: We included 7 articles and carried out a metanalysis on 
6. The analysis showed MS to be associated with a 1.907 (95% 
confidence interval 1.676-2.171) increased risk of VTE. Studies 
varied greatly in design and quality. MS severity, secondary pro-
gressive MS, disability, steroid use, spasticity and antidepressant 
use were found to be associated with an increased risk of VTE.
Conclusion: This review highlights just how little research there 
is on this topic. The limited literature suggests that MS may confer 
an increased risk of VTE. It also suggests MS related factors such 
as spasticity, steroid use and disability may be associated with a 
higher risk of VTE in MS patients, but there is still uncertainty. 
More studies are needed to recognize these particular risk factors 
to allow risk stratification and identification of particular MS 
patients that may potentially benefit from VTE prophylaxis.
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Low bone mineral density in neuromyelitis optica spectrum 
disorder: correlation with disease severity and body mass 
index
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Introduction: Neuromyelitis optica (NMO) is a female-predomi-
nant autoimmune disorder of CNS with a disease-specific anti-
body against CNS water channel, aquaporin 4 (AQP4). Patients 
with NMO experience reduced mobility and are susceptible to 
falls; moreover, many patients are being treated with glucocorti-
coids which are known risk factors for osteoporosis. However, 
there is no study for osteoporosis in NMO. This study aims to 
investigate the frequency of the osteoporosis and the association 
between bone mineral density (BMD) and disease disability, glu-
cocorticoid use, or disease duration in NMO.
Methods: Bone mineral density (BMD) was measured by dual 
x-ray absorptiometry in patients, who were diagnosed as NMO 
spectrum disorder (NMOSD) with anti-AQP4 antibody (anti-
AQP4). We analyzed clinical features including the Expanded 
Disability Status Scale (EDSS) score, cumulating steroid dose, 
annual relapse rate (ARR), and body mass index(BMI).
Results: A total of 37 patients (mean age, 48.89±13.98 years; F:M 
=36:1) were included in this study. The disease duration at the time 
of BMD test was 8.86±6.57 years. BMD was correlated with the 
EDSS score (r2 = 0.172, p=0.10) and the BMI at the time of BMD 
test. (r2 = 0.078, p=0.016) However, BMD was not correlated with 
age, disease duration, and the total dosage of steroid. The incidence 
of osteopenia and/or osteoporosis was significantly higher, com-
pared to normal population, according to the ages (10-19 years, 
67% vs %; 20-29 years, 63% vs ; 30-39 year, 86% vs ; 40-49 years, 
86% vs %; 50-59 years, 86% vs %; 60-69 years; 67% vs %).
Conclusion: Our study showed that NMO patients had higher fre-
quency of low bone mass compared with normal population, even 
at an early age and BMD was correlated with disease severity and 
BMI. Since low BMD was present in NMO patients at their early 
age, NMO patients should be screened for early detection and 
treatment, particularly with high disease severity and low BMI.
Disclosure
nothing to disclose
EP1440
Reverse takotsubo in a severe case of neuromyelitis optica
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Background: Takotsubo is very rare in neurological diseases, 
where a release of catecholamine due to bulbar vegetative areas 
lesions could lead to sympathetic overactivation. Demyelinating 
diseases were not classically associated with takotsubo cardio-
myopathy. Recently, Androdias et al. reported five cases of multi-
ple sclerosis (MS) with takotsubo associated with a new 
demyelinating lesion in the medulla oblongata on brain MRI were 
reported.
Objective: To report the case of a reverse takotsubo during an 
acute tetraplegia and brainstem syndrome revealing neuromyelitis 
optica (NMO).
Results: A 49 year-old woman without significant medical his-
tory, developed tetraparesia with dysarthria, dysphagia, oculomo-
tor impairment, urine retention, tachycardia and hypotension 
leading to mechanical ventilation over one week. CSF analysis 
revealed a lymphocytic cellular reaction (210/mm3), an elevated 
protein level (2 g/L) and presence of oligoclonal bands with ele-
vated IgG index. Electrocardiogram showed a sinus tachycardia 
without ST-segment modification associated with elevated tro-
ponine levels (1327 ng/L). Echocardiography revealed a severe 
left ventricular dysfunction (ejection fraction of 20%) with basal 
akinesia and residual apical mobility, typical of reverse takotsubo. 
Cardiac MRI showed no argument in favor of myocardial ischemia 
or myocarditis. MRI revealed the presence of longitudinal exten-
sive transverse myelitis (LETM), lesions of the medulla oblon-
gata, corpus callosum and left temporal lobe with gadolinium 
enhancement. Anti-aquaporin 4 antibodies (anti-AQP4) were 
positive, confirming the diagnosis of NMO. Cardiac dysfunction 
fully recovered in three days while neurologic outcome at 2 
months was very poor despite plasma exchange, high dose ster-
oids and Rituximab.
Discussion: To our knowledge, this is the first reported case of 
takotsubo occurring in NMO. Only two cases of LETM with 
brainstem involvement and takotsubo were previously described 
in a 10 year-old boy and in a 27 year-old woman, without confir-
mation of NMO diagnosis. The five cases of MS with takotsubo 
recently reported were also younger (16-27 year-old) with good 
neurological recovery. As in our case, reverse takotsubo was 
observed in 3 of them.
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Conclusion: This observation suggests that MS and NMO share 
some common features in relationship with takotsubo, possibly 
due to the localization of inflammatory lesions in the medulla 
oblongata in both demyelinating diseases.
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Bone health in neuromyelitis optica spectrum disorder: 
association with disability, steroid treatment, or leisure time 
exercise?
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Park4, S.-M. Kim1
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Introduction: Patients with multiple sclerosis (MS) are at high 
risk for bone loss and/or fracture, which are one of the major 
cause of morbidity and mortality. However, the prevalence and 
risk factors for bone loss in neuromyelitis optica spectrum 
disorder(NMOSD) has not been evaluated, yet.
Methods: We performed a cross-sectional survey in two major 
referral center for NMOSD in Seoul, Korea from April 2006 to 
May 2017. Fifty-nine NMOSD patients with aquaporin-4 IgG and 
twenty MS patients were included. Self-report questionnaire (lei-
sure time exercise, history of fracture, comorbidity, menopause, 
and lifestyle) and laboratory test (bone mineral density (BMD) 
using central dual energy X-ray absorptiometry, serum level of 
vitamin D, hormones, and bone turn over markers) were per-
formed. Diagnosis of low bone mass was made using International 
Society for Clinical Densitometry and World Health Organization 
criteria. The 10-year probability of hip or osteoporotic fracture 
was calculated using the Fracture Risk Assessment Tool (FRAX) 
score.
Results: The NMOSD group had poorer bone health than MS 
group in terms of the prevalence of low bone mass (67.8 % vs 10%, 
p< 0.0001) and the FRAX score {12.85 ± 10.67 (mean± standard 
deviation) vs 4.54 ± 2.86, p< 0.0001}. In NMOSD group, multi-
variate linear regression analysis indicated that only the duration of 
oral steroid therapy (p=0.030) was significantly associated with 
the BMD of patients. However, their BMD were not associated 
with the expanded disability status scale, degree of leisure time 
exercise, daily or cumulative dose of the oral steroid treatment.
Conclusions: The proportion of NMOSD patients with reduced 
bone mass can be higher than in MS. The BMD in NMOSD is 
disproportionate to their disability from disease, reduced physical 
activity nor dosage of daily oral steroid, rather consistent with the 
duration of oral steroid therapy. Prolonged steroid treatment 
reduces BMD and could result in increased fracture risk. 
Identifying these risk factors may allow earlier detection and 
treatment of osteoporosis, minimize future fracture risk, and 
maintain the functional status of the patients.
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A pilot study evaluating changes in clinical outcomes with 
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Background: Overweight and obesity have been correlated with 
worse clinical outcomes in people with multiple sclerosis (pwMS), 
but little research has evaluated changes in outcomes with weight 
loss. Calorie restriction and time-restricted feeding (i.e. daily 
16-hour fasts) are two dietary interventions that are associated 
with weight loss and improved fatigue and metabolic outcomes in 
the general population. However, whether these diets lead to 
improvements in symptoms among pwMS is unknown.
Objective: To evaluate the effect of weight change due to calorie 
restriction and time-restricted feeding on patient-reported outcomes 
(PROs) including fatigue, sleep quality, depression and self-esteem.
Methods: We conducted a 6-month pragmatic pilot study of 
either calorie restriction or time-restricted feeding in 43 pwMS 
who were being treated with natalizumab at the Johns Hopkins 
MS Center. At months 0, 3 and 6 weight and waist and hip circum-
ference were collected. Participants provided information on 
fatigue (MS-specific PROMIS short-form), sleep (Pittsburgh 
Quality Sleep Index), and depression (emotional well-being com-
ponents of the functional assessment of MS [FAMS]) at each time 
point. We assessed whether changes in anthropometric measures 
were associated with changes in PROs using linear regression 
models adjusting for age and gender.
Results: Of the 43 participants (86% female), 21 (48.8%) of the 38 
who have completed to date lost weight over 6 months (4 of the 5 
who will soon complete had lost weight at 3 months), with median 
weight change of -1.40kg (interquartile range [IQR]: -3.2 to 1.25kg) 
and median change of waist circumference of -0.25cm (IQR: -2.47 
to 1.25). Change in waist circumference was associated with 
changes in fatigue scores, where a 5 cm decrease (or increase) in 
waist circumference was associated with an average decrease (or 
increase) of 1.85 points in fatigue severity (95% CI: -3.41 to -0.26; 
P=0.02). Similarly, each 5 kg decrease in weight was marginally 
associated with a 2.24-point decrease in fatigue score (95% CI: 
-4.52 to 0.06; P=0.09). Changes in weight or waist circumference 
were not associated with changes in sleep or depression.
Conclusions: In this pilot study of various fasting-mimicking 
diets, a reduction in waist circumference was associated with 
improvements in fatigue. Further studies investigating the impact 
of weight reduction, and mechanisms by which it is achieved, on 
classical MS endpoints and symptoms are needed.
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Background and aims: Recently it has been suggested that the 
dysregulation in the neurovisceral integration of cardiovascular 
modulation can lead to many multiple sclerosis (MS)-related clin-
ical symptoms like depression, fatigue and sleep disorders, 
migraine, osteoporosis and cerebral hemodynamic impairments. 
Furthermore, both adrenergic and cholinergic dysfunctions may 
play roles in the pathology of MS depression. The aim of the pre-
sent study was to investigate possible association between auto-
nomic dysfunction and depression in MS.
Design/methods: In this study, 44 patients with MS were included 
(30 females, mean age 37.18±10.93), 37 of them (group 1) had 
clinically isolated syndrome (CIS) or relapsing remitting MS 
(RRMS) and 7 (group 2) had primary progressive (PPMS) or sec-
ondary progressive (SPMS) MS. All patients filled the Beck 
depression scale (BDI) and Epworth Sleepiness Scale (ESS). The 
following autonomic tests were performed: heart rate and blood 
pressure responses to the Valsalva maneuver, heart rate response to 
deep breathing (RSA), and blood pressure response to passive tilt. 
All tests were interpreted in the form of the composite autonomic 
scoring scale (CASS) through adrenergic and cardiovagal indices.
Results: Patients from group 2 had significantly higher BDI com-
pared to patients from group 1 (median 16 vs. 7, p=0.002). There 
was no statistically significant difference in two groups between 
frequencies of pathological values of CASS indices (score >0). 
Both adrenergic and cardiovagal indices correlated with EDSS (rs 
0.394, p< 0.05 and rs 0.495, p=0.001).
Patients with pathological adrenergic index had higher BDI score 
in comparison with patients with normal index (8 vs. 4.5, p< 
0.05), while there was no difference between patients with patho-
logical and normal cardiovagal index.
For group 2, there was statistically significant correlation between 
BDI scale and adrenergic and cardiovagal indices (rs=0.797, p< 
0.05; and rs=0.775, p< 0.05), while there was no correlation for 
patients from group 1.
Conclusion: These result suggest possible association between 
autonomic dysfunction and depression in MS patients. Further stud-
ies are encouraged in order to further elucidate this association.
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Tobacco, alcohol, drug use and comorbidity issues in multiple 
sclerosis (MS): a pilot study
E. Sukockiene1, B. Dirziuviene1, D. Mickeviciene1, R. Balnyte1, 
S. Jesmanas2, G. Adomaviciute2
1Department of Neurology, 2Lithuanian University of Health 
Sciences, Academy of Medicine, Kaunas, Lithuania
Background: MS is a complex illness with the wide range of 
symptoms. The MS subtype can be categorized, however, indi-
vidual disease characteristics are variable. Comorbidity and other 
individual features such as smoking, alcohol or drug use status in 
MS patients may contribute to the factors associated with the out-
comes, disability levels and the burden of the disease.
Objectives: We evaluated the frequencies of tobacco, alcohol, 
drug use together with existance of other diseases than MS in our 
study group. Moreover, we explored the relationship between 
demographic and clinical MS characteristics and smoking, alco-
hol or drug use status, levels of fatigue, subjective quality of life 
(QOL) and various comorbidities.
06_MSJ731285.indd   760 13/10/2017   11:10:56 AM
ePosters 23(S3) 761
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Materials and methods: Totally, 125 patients filled in the ques-
tionnaire about tobacco, alcohol, drug use together with data 
about other diseases than MS and the SF-36 scale. Two measures 
of physical (PCS) and mental (MCS) health were calculated, and 
the fatigue was evaluated in the 10-point scale. Demographic and 
clinical data with the Expanded Disability Status Scale (EDSS) 
scores were collected.
Results: Women comprised 70.4% of the group, and men-29.6%. 
The mean of the age was 41.1±11.8 years. The mean EDSS score 
was 2.92±1.32. The majority of the patients had a relapsing-
remitting MS (97.6%). Firstly, 20% of patients had arterial hyper-
tension (AH), 8.8% had dyslipidemia, 1.6% had diabetes mellitus 
(DM), and 5.6% - pulmonary diseases. Secondly, 16% reported 
depression, and 12% - anxiety disorder. In total, 15% of patients 
were smoking, and 2.4% reported drug use. The mean alcohol use 
was 1.14±2.12 alcohol units per month. The mean scores of PCS 
were 53.06±19.83, and of MCS 53.14±18.26, accordingly. The 
mean score of fatigue was 6.02±2.25. There was no association 
between comorbidity, disease course and EDSS (p>0.05). Fatigue 
measures were higher in patients with AH, depression and drug 
use, also measures of PCS were lower in patients with depression 
and dyslipidemia, and the measures of MCS were lower in patients 
with depression and anxiety (p< 0.05). We found the higher 
relapses rate in patients with dyslipidemia (p=0.039). There was 
no association with mean alcohol consumption and clinical MS 
parameters, QOL and fatigue.
Conclusions: Our study showed that comorbidity in MS affects 
levels of fatigue and subjective QOL. We found the association 
with relapse rate and dyslipidemia. We plan to continue this study 
and expand the cohort.
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Background: Weight loss diets are primary recommended treat-
ments for metabolic disease and are often associated with 
improved sleep. Both sleep and metabolic disorders are overrep-
resented in people with multiple sclerosis (MS); however, whether 
weight loss diets are associated with improvements in sleep qual-
ity in this vulnerable population is unknown.
Methods: We conducted a controlled feeding study of different 
calorie restriction diets in 36 people with MS for a period of 8 
weeks. Energy expenditure was determined using indirect calo-
rimetry, and patients were randomized to receive 1 of 3 diets: a 
continuous calorie restriction diet (22% daily reduction in energy 
needs), an intermittent calorie restriction diet (75% reduction in 
calorie needs 2 days/week; 100% of daily needs 5 days/week), 
and a weight-stable diet (100% of daily calorie needs). At baseline 
and at week 8, participants provided information on sleep by com-
pleting the Pittsburgh Quality Sleep Index (PSQI), from which a 
global sleep quality score was calculated.
Results: Of the 36 patients enrolled, 31(86%) completed the trial. 
Participants randomized to calorie restriction diets lost an average 
of 7.3(SD: 4.6) lbs over 8 weeks; changes in weight did not differ 
by type of calorie restriction diet (P=0.12). At baseline, partici-
pants had median PSQI scores of 7 (interquartile range [IQR]: 3.5 
to 8.5) and 19 (53%) participants reported scores indicative of 
poor sleep quality. Weight loss was marginally correlated with 
improvements in sleep quality score (r= -0.32; P=0.06). 
Individuals in the top quartile of weight loss - corresponding to a 
³8.2lb weight loss - experienced an average 3.99 point improve-
ment in global sleep quality score when compared to individuals 
in the lowest quartile of weight loss- corresponding to a < 3lb 
weight loss (quartile 4 vs. quartile 1 mean reduction in PSQI 
score=3.99; 95% CI: 0.58-7.39; P=0.03). Changes in sleep quality 
did not differ between weight loss diets.
Conclusions: This preliminary study suggests that among people 
with MS, weight loss is associated with improved sleep quality. 
Subsequent results will assess effects of weight loss diets on 
changes in fatigue levels.
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Headache characteristics in multiple sclerosis
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Objectives: The objectives of this study were to study the preva-
lence and characteristics of headache in patients with multiple 
sclerosis (MS) and to clarify the relationship between headache 
and MS treatment.
Method: 782 MS patients were consecutively admitted. All 
patients filled out a detailed headache questionnaire and 754 
patients were included.
Results: Of 754 patients, 515 (68.3%) reported having headache. 
According to the International Headache Society (IHS) criteria, 
we detected 202 (39%) suffering from migraine, 103 (20%) suf-
fering from tension-type headache (TTH) and 198 (38%) with 
medication overuse headache (MOH). Twelve patients (2%) had 
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unclassified headache. Three hundred and seventy seven patients 
(73%) were treated with immunomodulators (interferon beta/ 
glatiramer acetate), 81 (16%) with fingolimod, 35 (7%) with 
teriflunamide and 22 (4%) with natalizumab, respectively. One 
hundred and one (20%) reported that onset of headache occured 
prior to onset of MS spesific treatment, while 414 (80%) had 
headaches occured after therapy. A higher incidence of headache 
was found in patients treated with immunomodulators. Three hun-
dred and twenty two (62%) patients have never sought help from 
a physician despite the severity and frequency of headache.
Conclusion: In our study, the prevalence of headache MS patients 
was 68%. The results of this study indicate a possible relationship 
may exist between headache and MS. Interestingly, MOH was far 
more prevalent in MS patients than in previously reported com-
munity populations.
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Occurrence of cardiovascular (CV) risk factors and meta-
bolic syndrome (MetS) in multiple sclerosis (MS)
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Background: Last years there is an emerging interest on meta-
bolic and CV comorbidities in MS patients, especially on the asso-
ciation of these parameters with outcome and prognosis of MS. 
It’s known that inflammation play a fundamental role in both con-
ditions and maybe by treating MetS or modifying CV risk factors 
one can reduce the odds for disability and progression of MS.
Goals: This study aim to determine the frequency between CV 
risk factors, metabolic syndrome (according to the criteria of 
International Diabetes Federation) and MS.
Methods: 59 patients (42 males and 17 females, 25 to 60 year-
old) with relapsing remitting MS (mean EDSS=3 and mean dura-
tion of disease 9 years) under disease modifying treatment were 
recorded for hypertension, smoking, dyslipidemia, obesity, type 2 
diabetes and positive family history for CV disease. Body mass 
index (BMI), waist circumference and levels of fasting glucose, 
HDL, LDL cholesterol and triglycerides were also obtained.
Results: MetS was evaluated on 22.3% but half of our patients 
had at least two CV risk factors. Furthermore, abnormal BMI was 
frequently recorded (overweighed 32.20%, with obesity 16.9%), 
and 49% of our cohort admitted that they didn’t do any gym or 
physical exercise. Smoking is a frequent habit among MS patients 
(47.2%) and regarding the family history it is positive for CV risk 
factors almost at half of them.
Conclusions: Metabolic and CV comorbidities in MS are not yet 
elucidated and future research should be elaborated in order to 
improve our understanding for the possible interaction in etiology, 
disability and prognosis of MS.
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Background and goals: Epidemiological findings suggest a rela-
tionship between MS clinical outcomes and several cardiovascular 
comorbidities, including obesity, insulin resistance, dyslipidemia, 
and hypertension; the latter being the most frequent cardiovascular 
comorbidity reported in MS. In chronic conditions, cardiovascular 
comorbidities are associated with decreased quality of life and 
increased mortality. In MS in particular, comorbidities are associated 
with delayed diagnosis and increased risk of disease progression. 
Despite the strong epidemiological evidence, there is a paucity of 
studies exploring pathophysiological mechanisms to explain the 
association between MS and cardiovascular comorbidities. In partic-
ular, the mechanisms linking MS severity and elevated blood pres-
sure are poorly understood. Here, we aim to establish whether high 
blood pressure contributes to white-matter injury and brain atrophy in 
patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: Estimates of cerebral fractional anisotropy, grey-matter 
volume and lesion load were obtained from 3-Tesla MRI in 95 
patients with RRMS between December 2013 and July 2015. We 
used fractional anisotropy voxel-based statistics to establish the effect 
of blood pressure on white matter tracts. Additionally, we used voxel-
based morphometry to study the effect on grey matter integrity. 
Finally we utilized linear models with log-transformed white matter 
lesion volume as the dependent variable and systolic blood pressure 
as the predictor to establish the effect of hypertension on lesion load.
Results: 57 female and 38 male patients (mean age 38.9 years, SD 
10.5) underwent brain MRI. Only 29.5% had normal blood pres-
sure levels, with 52.6% suffering from prehypertension and 17.9% 
with hypertension. Increasing systolic blood pressure was associ-
ated with damage to posterior white-matter tracts as well as 
greater levels of grey matter atrophy, in particular in the frontal 
cortex. Age-adjusted linear regression indicated that neither lesion 
volume (β=0.002, 95% CI -0.02 to 0.02; p=0.85) or lesion number 
(β=-0.004, 95% CI -0.03 to 0.02; p=0.74) were associated with 
systolic blood pressure.
Conclusions: Prehypertension and hypertension are frequent in 
MS patients. Increased blood pressure is related to white- and 
grey-matter integrity, both related to MS disability outcomes. 
These findings suggest attention to the control of blood pressure 
in MS patients.
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EP1449
Insulin resistance and multiple sclerosis: a pilot study in drug 
naive patients
S. Kostic1, E. Dincic1, M. Zivkovic2, R. Raicevic1
1Neurology Department, Military Medical Academy, Belgrade, 
Serbia, 2Laboratory for Radiobiology and Molecular Genetics, 
Institute of Nuclear Sciences ‘Vinča’, Belgrade, Senegal
Objective: The main objective of our study was to demonstrate 
whether a dysbalance of glucose and insulin metabolism exist in 
patients with MS with the natural course of the disease. Our 
hypothesis is that the metabolic disorder that characterizes state of 
the insulin resistance (IR) and reduced insulin sensitivity (IS) in 
untreated patients with MS could play a role in disease progres-
sion and degree of functional disability.
Methods: The study included 31 patients with relapsing-remitting 
(RR) MS and 14 healthy controls from the same geographic area 
matched by age, ethnicity and number of smokers. The glucose 
tolerance IS, and IR were examined from an oral glucose toler-
ance test (OGTT) and from basal plasma glucose and insulin lev-
els. The functional disability and disease progression were 
evaluated by the Expanded Disability Status Scale (EDSS) and 
Multiple Sclerosis Severity Score (MSSS).
Results: MS patients tolerated glucose equally well as the healthy 
controls. Basal concentrations of insulin were significantly higher 
in MS group (p< 0.05) as well as insulin in 30 min after oral glu-
cose load (p< 0.01).
Patients with MS had significantly higher values of homeostasis 
model assessment indexes of IR (HOMA-IR) (p=0.027; p=0.028). 
The percentage of IS (HOMA2 %S) and whole body IS index (ISI 
Matsuda) showed significantly lower values in MS patients than 
in controls (p=0.005; p=0.001).
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Interaction between comorbidities and use of disease modify-
ing treatment in impact on quality of life in a Regional Mul-
tiple Sclerosis Registry
T. Stuchiner1, L. Lucas1, E. Baraban1, C. Chen1, S. Cohan2
1Providence Brain and Spine Institute, Providence Health & 
Services, 2Providence Multiple Sclerosis Center, Providence 
Brain and Spine Institute, Portland, OR, United States
Background: Studies have shown that comorbidities impact 
health outcomes and quality of life (QoL) in the multiple sclerosis 
(MS) population. However, less is known about how use of dis-
ease modifying treatment (DMT) mitigates the impact of comor-
bidity on QoL.
Objective: To determine which specific comorbidities impact 
QoL and if DMT use reduces the impact of comorbidities on QoL 
among participants in the Pacific Northwest Multiple Sclerosis 
Registry (PNWMSR).
Methods: PNWMSR participant survey data from 2011 to 2016 
was used. Participants who had relapsing disease were included. 
Those who had progressive MS, reported use of more than one 
DMT, were on their reported DMT for less than six months, or had 
not reported duration of DMT were excluded. Comorbidities 
included were cardiovascular disease, respiratory disease, smok-
ing, cancer, thyroid disease, gastrointestinal (GI) disease, depres-
sion and obesity. Chi-square tests were used to determine 
differences in the prevalence of comorbidities among those who 
used and did not use DMT. Physical and psychological QoL was 
measured using the Multiple Sclerosis Impact Scale (MSIS), with 
higher scores indicating more severe impact. Multiple linear 
regression, adjusting for participant characteristics, was used to 
determine the impact of comorbidities and DMT use on physical 
and psychological QoL scores. Interactions between DMT use and 
comorbidities that significantly impacted MSIS were tested using 
Type III F-tests to determine whether DMT use moderated the 
effect of comorbidities on QoL.
Results: Survey data from 1,163 participants were included in the 
final analysis. Cancer, thyroid and GI disease were significantly 
more prevalent among participants not on DMT. Depression was 
significantly more prevalent among those on a DMT. Physical 
MSIS scores worsened with depression (β=3.26; p< .001), respir-
atory diseases (β=2.59; p=.001), and thyroid diseases (β=2.55; 
p=0.04). Psychological MSIS scores worsened with depression 
(β=4.37; p< .001), thyroid disease (β=2.17; p=.002), and smoking 
(β=1.12; p=0.04). All interactions between DMT use and comor-
bidities were not significant.
Conclusions: The prevalence of comorbidities differed based on 
DMT use. Depression was highly prevalent among DMT users 
and had the largest impact on psychological and physical QoL in 
this regional cohort. The use of DMT had no significant moderat-
ing effect on the impact of comorbidities on physical or psycho-
logical QoL.
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Risk of developing cancer and its impact on patients with 
multiple sclerosis under treatment with immunomodulators
M.C. Curbelo, J. Steinberg, A. Carra
Hospital Britanico Buenos Aires, Buenos Aires, Argentina
Introduction: The incidence of multiple sclerosis (MS)-associated 
neoplasms was not a frequent report before the advent of immu-
nomodulators (IMDs). In fact, it was assumed that MS granted a 
certain protective effect against the risk of developing cancer (Ca).
With the advent of IMDs, the potential association of MS with 
cancer events was first noted.
To date, the relationship between the impact of Ca and of cancer 
treatments with the progression of MS remains to be established.
PURPOSES: To analyze the characteristics of a group of patients 
with Demyelinating Diseases (DD) who developed cancer, the 
therapeutic behaviors and their progression.
Methods: We conducted a retrospective observational study of 
1,192 patients with DD, and assessed 27 patients who developed 
cancer during the progression of their baseline disease. We evalu-
ated the type of DD, the type of cancer, age at onset, treatments 
used, and progression of the DD within 2 years of cancer onset: 
presence of relapses, changes in the EDSS and MRI.
Results: n=27 patients with DD and Ca. Age at diagnosis: 
28.9years and age at Ca onset: 47years. Clinical form: n: RRMS 
21; SPMS 3; NMO 2; RIS 1.
IMDs: 21 patients. IMDs discontinued: 12 patients.
- n=cancer types: 6=breast; 5=thyroid; 7=gynecological; 3=colo-
rectal; 2=skin; 4=others. 4=multiple.
- n=cancer therapy: 20=surgery; 7=chemotherapy; 3=radiother-
apy; 8=combined; 1=none.
MS behavior in cancer patients:
- Relapses: 4=Yes; 14=No; 6=No data.
- Changes in EDSS: 2=Better; 14=No changes; 11=Worse (3=dead)
- Changes in MRI: 14=No changes; 3=New lesions; 10=No data
Conclusion: Only 4 patients had relapses after the development 
of cancer. Sixteen patients had the same or better scores at EDSS 
and over half of them evidenced MS progression in MRI. The 
coexistence of two potentially severe diseases (Ca and MS) would 
not necessarily involve a more unfavorable progression of MS.
Disclosure
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Cognitive profiles in Hong Kong Chinese with relapsing and 
progressive multiple sclerosis
A.Y. Lau1,2, A. Ng1, C. Au1, K.Y. Yuen2, V. Mok1,2, J.C. Wu1,2, 
A. Wong1,2
1Department of Medicine and Therapeutics, 2Hong Kong 
Institute of Integrative Medicine, Chinese University of Hong 
Kong, Hong Kong, Hong Kong
Background: We evaluated the cognitive profiles in Hong Kong 
Chinese with multiple sclerosis (MS).
Methods: We recruited subjects from the Hong Kong Multiple 
Sclerosis Registry. We administered a 45-minute neuropsycho-
logical battery, covering verbal learning and memory, processing 
speed, selective attention, executive function, visual perception, 
simple auditory attention span, and auditory working memory. 
Hong Kong version of Montreal Cognitive Assessment 
(HK-MoCA) was performed as a cognitive screening tool. Fatigue 
and physical disability were assessed by Modified Fatigue Impact 
Scale (MFIS) and Expanded Disability Status Scale (EDSS), 
respectively. Neuropsychological test scores were converted into 
z-scores using normative data for local Chinese, with impairment 
defined as z-score < -1.0.
Results: Fifty-five subjects (87% females; 78% relapsing MS, 13% 
PPMS, and 9% SPMS) were recruited. The mean age, education, 
and EDSS were 38.5±11.0 years, 13.6±3.32 years, and 3.6±2.6, 
respectively. Relapsing MS subjects were younger (36 vs. 47 years), 
better educated (14 vs. 11 years), and less disabled (EDSS 2.5 vs. 
6.75) than progressive MS (p< 0.05). Overall, 52/55 (95%) subjects 
had cognitive impairment(s): verbal learning and memory-62%, 
executive function-50%, processing speed-50%, auditory working 
memory-49%, visual perception-43%, selective attention-37%, 
simple auditory attention span-16%. Multiple (>=3) impaired 
domains are found in 54% subjects; progressive MS subjects had 
worse cognitive performance (p< 0.05). Cognitive impairment was 
strongly correlated with high EDSS, low HK-MOCA and education 
years (p< 0.01). In multivariate regression model, HK-MOCA pre-
dicted multiple cognitive domain impairments (OR 0.70, 95% CI 
0.50-0,98, p=0.035). At a cut-off score of 24, HK-MOCA has sen-
sitivity of 81% and specificity of 71% (AUC 0.80). MFIS was not 
predictive of impaired cognitive performance.
Discussions: Cognitive impairment is highly prevalent among 
Chinese MS patients, affecting one or more cognitive domains in 
95% patients. HK-MOCA is useful to screen for subjects with 
multiple impaired cognitive domains. Cognitive fatigue may be 
compensatory to preserve cognitive function.
Disclosure
The study is funded by the Health and Medical Research Fund of 
Food and Health Bureau, Hong Kong SAR (HMRF #14152291).
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Interaction between comorbidities and use of disease modi-
fying treatment in impact on disability status in a regional 
multiple sclerosis registry
L. Lucas, T. Stuchiner, E. Baraban, C. Chen, S. Cohan
Providence Brain and Spine Institute, Portland, OR, United 
States
Background: Comorbidities can have a negative impact on disa-
bility in the multiple sclerosis (MS) population. However, disease 
modifying treatments (DMT), which prevent disease progression, 
could potentially moderate the effect of comorbidities. Little is 
known about the relationship between DMT use and comorbidi-
ties and its impact on disability.
Objective: To determine the impact of comorbidities and DMT 
use on disability in participants in the Pacific Northwest Multiple 
Sclerosis Registry.
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Methods: Participant survey data collected between 2011 and 
2016 were used. Participants who had progressive disease, reported 
use of more than one concurrent DMT, were on DMT less than six 
months if used DMT, or did not report time on DMT were excluded. 
Comorbidities included were cardiovascular disease, respiratory 
disease, smoking, cancer, thyroid disease, gastrointestinal (GI) dis-
ease, depression and obesity. Disability status was measured using 
the Patient Determined Disease Step (PDDS) score and disability 
was categorised as follows: none (0), mild (1 or 2) and moderate to 
severe (3 to 7). Polytomous logistic regression, adjusting for par-
ticipant characteristics, was used to determine the impact of 
comorbidities and DMT use on reported disability status. 
Interactions between significant comorbidities and DMT use were 
tested in the regression model to investigate moderating effects.
Results: Survey data from 1,163 participants were analysed. 
Depression (33.6%, n=391), cardiovascular disease (29.0%, 
n=337), and respiratory disease (11.6%, n=135) were the most 
prevalent comorbidities. Participants were more likely to be mod-
erately/severely disabled when they reported GI disease (Adjusted 
Odds Ratio (AOR) =4.09; p=.001), depression (AOR=3.20; p< 
.001), cardiovascular disease (AOR=2.21; p< .001), smoking 
(AOR=1.85; p=.004), and respiratory disease (AOR=1.43; 
p=0.05). For participants who smoked, DMT users had a decreased 
likelihood of being moderate or severely disabled (AOR=0.32; 
p=0.01). However, DMT use increased the likelihood of moderate 
to severe disability for those with depression (AOR=3.10; p< 
.001) and respiratory disease (AOR=3.67; p< .001). DMT had no 
moderating effect on those with GI or cardiovascular disease.
Conclusions: Results suggest the effects of smoking and depres-
sion on disability are moderated by DMT use, resulting in differ-
ing effects on disability. Further research is needed to understand 
the underlying mechanisms for these differences.
Disclosure
L. Lucas, T. Stuchiner, E. Baraban and C. Chen have no conflict 
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Characterization of TSPO expression by conventional and 
mutliplex immunohistochemistry in marmoset EAE
I.N. Falk1,2,3, D. Maric1, J. Lefeuvre1, N. Luciano1, P. Sati1, E. 
Leibovitch1, J. Billioux1, D. Reich1, D. Owen3, P. Matthews3, S. 
Jacobson1
1National Institute of Neurological Disorders and Stroke, 
Bethesda, MD, United States, 2Clinical Neurosciences, 
University of Cambridge, Cambridge, 3Division of Brain 
Sciences, Imperial College Londen, London, United Kingdom
The 18 kDa translocator protein is a mitochondrial transmembrane 
protein that is lowly expressed in the healthy CNS but strongly 
upregulated in CNS injury and thus of interest as a biomarker of 
neuroinflammation. TSPO is abundantly expressed in activated 
microglia and macrophages, and numerous studies have shown the 
transporter to be highly upregulated in inflammatory CNS lesions 
in multiple sclerosis (MS) and animal models of experimental 
autoimmune encephalomyelitis (EAE). Marmosets are small New 
World monkeys of particular interest for their neurological similar-
ity to humans, which renders them a powerful model of neuroin-
flammatory disease. Most crucially, marmosets exhibit white 
matter-grey matter ratios similar to those of humans, and EAE 
marmosets manifest lesions that are pathologically and radiologi-
cally similar to lesions seen in MS patients. However, TSPO 
expression in marmoset EAE remains largely uncharacterized.
To better understand the utility of TSPO as a biomarker of inflam-
mation in EAE, this study seeks to characterize the cellular local-
ization of TSPO in marmoset EAE by immunohistochemical 
analysis of pathological brain and spinal cord tissues. Specifically, 
this study characterizes the cellular localization of TSPO and the 
immunophenotype of TSPO+ microglia/macrophages at different 
stages of lesion development. Our study confirms the common 
marmoset model of EAE to recapitulate the expression of TSPO 
in microglia and macrophages that is observed in rodent models. 
In early lesions that are less than 4 weeks old (as determined by 
serial magnetic resonance imaging scans), TSPO is expressed in 
over 90% of Iba1+ microglia/macrophages, particularly in the 
hypercellular nodules observed at the core of many lesions. In 
these Iba1+TSPO+ cells, TSPO is frequently co-expressed with 
MRP14, a marker of early activation, and CD74, the invariant 
chain of HLA-DR. In older lesions (over 7 months old), TSPO 
expression is observed in less than 15% of Iba1+ cells, and the 
percentage of Iba1+TSPO+ cells co-expressing MRP14 or 
HLA-DR is also observed to decrease. These findings gives 
insight into the timecourse of TSPO expression in neuroinflam-
mation, which has significant implications for its clinical utility 
as an imaging target in the monitoring of neuroinflammatory 
disease.
Disclosure
Irene Falk: Nothing to disclose.
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Markers of intestinal permeability defects are related to 
clinical activity in early multiple sclerosis
N. Tellez1, B. Gutierrez2, P. Mulero1, M. Hernandez2, M.J. Neri1, 
I. Gallardo2, N. Redondo1, M. Nieto2
1Hospital Clínico Universitario Valladolid, 2IBGM-UVA/CSIC, 
Valladolid, Spain
Background: Recent evidence suggests that the intestine might 
be an early site of MS disease in response to environmental toxins. 
Disruption of the intestinal barrier integrity is one potential mech-
anism for which the noxious luminal products (including bacterial 
lipopolysaccharide, LPS) induces mucosal immune dysfunction 
and systemic immune activation, which might trigger the develop-
ment of MS. The interaction of LPS with factors such as LPS 
binding protein (LBP) and soluble CD14 (sCD14) are key events 
on LPS-induces activation of the innate immune system. Thus, 
LBP and sCD14 are considered as indirect markers of bacterial 
translocation.
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Aims: To explore the utility of intestinal permeability markers 
(intestinal fatty acid binding protein, I-FABP) and microbial 
translocation (LBP and sCD14) in early MS.
Methods: Tirthy six patients were included (19 early MS, 3 RIS, 
and 14 patients afected by other CNS diseases different from 
MS). Blood samples were collected with a mean delay from the 
MS onset to the blood test: 5,6 month, and all were free of 
immunomodulatory treatment. Clinical and MRI data were col-
lected and correlated with the biological molecules. Serum lev-
els of LBP, sCD14 and I-FABP were measured by commercial 
ELISA kit.
Results: Serum levels of LBP, sCD14 and I-FABP did not differ 
between the 3 clinical phenotypes. Considering the MS group, 
levels of LBP positively correlated with the relapse rate through-
out the follow up (r 0.54, p=0.02). Findings are in accordance with 
both the LBP role in activating innate immune responses, and the 
involvement of the innate inmune system in the acute inflamma-
tory events in MS.
Conclusions: LBP could have utility in the clinical activity to 
improve the prediction of relapse risk in early MS patients. Further 
research should be performed in a larger cohort of patients in 
order to confirm these results.
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Anti-AQP4 autoantibody, C5a, neutrophils and glutamate - 
four necessary, related components essential for neuromyeli-
tis optica inflammation
P. Piatek1, M. Domowicz1, N. Lewkowicz2, P. Przygodzka3, M. 
Matysiak1, K. Dzitko4, K.W. Selmaj1, P. Lewkowicz1
1Department of Neurology, 2Department of General Dentistry, 
Medical University of Lodz, 3Institute of Medical Biology, Polish 
Academy of Sciences, 4Department of Immunoparasitology, 
University of Lodz, Institute of Microbiology, Biotechnology and 
Immunology, Lodz, Poland
Neuromyelitis optica (NMO) is a neuroinflammatory disease 
characterized by severe optic neuritis and longitudinally extensive 
transverse myelitis. For many years NMO was believed to be a 
rare variant of multiple sclerosis (MS). In contrast to MS, autoan-
tibodies against aquaporin-4 (AQP4), a water channel densely 
expressed on astrocytic end-feet, has been detected exclusively in 
sera from patients with NMO. Many studies have suggested that 
AQP4 autoantibodies are pathogenic, but the precise mechanism 
triggering inflammation and astrocyte impairment following anti-
AQP4 Abs binding remains unknown. Some in vivo studies advo-
cated for the role of complement system and neutrophils activation, 
while other highlighted glutamate pathological distribution as the 
main mechanism.
In this study we showed direct evidence of pathogenicity of the 
AQP4 Abs-positive serum derived from NMO patient, which by 
consecutive action of anti-AQP4 Abs, complement system and 
neutrophils triggered the reaction towards astrocytes. Based on 
our results we postulated the new theory about NMO pathogene-
sis which assumes that, there are two parallel-complementary 
mechanisms which can be initiated by anti-AQP4 autoantibody. 
First one was dependent on the complement cytotoxicity via C5b-
C9 complex formation, and the second one was dependent on the 
reverse of astrocyte glutamate pomp into extracellular space on 
the C5a-preactivated neutrophils. As a consequence, part of the 
astrocytes was destroyed, however a certain population of astro-
cytes polarized into proinflammatory cells which characterized 
pathological glutamate removal from extracellular space.
Disclosure
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Influence of CBD in mesenchymal stem cells therapy in 
adoptively transferred experimental autoimmune encephalo-
myelitis: an in vivo and in vitro study
C. González-García1, R. García-Hernández1, I. Moreno Torres1, 
L. Campos-Ruíz1, M.J. Coronado2, A. García Grande3, J.A. 
García-Merino1, A.J. Sánchez López1
1Neuroimmunology Unit, 2Confocal Microscopy Unit, 3Flow 
Cytometry Unit, Puerta de Hierro Hospital Research Institute. 
Universidad Autónoma de Madrid (UAM), Majadahonda, Spain
Background: Mesenchymal stem cells (MSCs) are promising 
candidates for MS therapies due to their anti-inflammatory prop-
erties. Although little is known about endocannabinoid system in 
MSCs, it has been described that Cannabidiol (CBD), a non-psy-
chotropic cannabinoid, might enhance the therapeutic effect of 
these cells.
Objectives: To explore the influence of CBD in MSCs cultures as 
well as to test the ability of CBD to improve MSCs therapeutic 
effect in adoptively transferred EAE (at-EAE).
Methods: At-EAE was induced in C57BL6 mice by inoculation 
of encephalitogenic cells. Treatment consisted in 0.5x106 bone 
marrow MSCs infused twice a week. Cell infiltration, axonal loss 
and demyelination were analyzed ex vivo by confocal microscopy 
in lumbar spinal cords.
In vitro, cannabinoid receptors were determined in MSCs and 
encephalitogenic cells by confocal microscopy and flow cytome-
try. Toxicity and cytokines production mediated by CBD in co-
cultures of MSCs and encephalitogenic cells were revealed by 
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MTT and ELISA respectively. Influence of CBD in capacity of 
differentiation and migration of MSCs was also evaluated. 
Additionally, clinical parameters in at-EAE animals treated with 
MSCs in combination with CBD (50mg/kg/d) were studied.
Results: MSCs treatment ameliorated clinical signs of at-EAE accom-
panied by a reduction of cell infiltration and axonal damage. In vitro, 
CB1, CB2 and GPR55 receptors analysis revealed a scarce surface 
expression in MSCs compared to encephalitogenic cells. Furthermore, 
MSCs and encephalitogenic cell co-cultures, showed a reduced viabil-
ity of encephalitogenic cells, a reduction in IFN-gamma and GM-CSF 
and an increase in CXCL-10 and IL-6 cytokines.
Addition of CBD in co-cultures resulted in a decrease in IL-6 pro-
duction and adipogenic differentiation whereas migratory capac-
ity was not modified in MSCs.
CBD concomitant treatment with MSCs cells caused a higher 
trend to reduce clinical signs in at-EAE compared to MSCs-
treated group.
Conclusions: MSCs reduced clinical signs in vivo, diminishing 
neuro-inflammation and infiltration in at-EAE, concurrently with 
a modulation in viability and cytokines production in encephalito-
genic cells in vitro. The CBD influence in IL-6 cytokine produc-
tion might be related to the therapeutic effect showed in the 
concomitant in vivo treatment. The beneficial effect of the combi-
nation of CBD and cellular therapy opens new possibilities for the 
treatment of neurodegenerative disorders.
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Increased post-translational lysine acetylation of myelin basic 
protein is associated with peak neurological disability in a 
mouse experimental autoimmune encephalomyelitis model of 
multiple sclerosis
T. Khorshid Ahmad1, M. Namaka2, T. Zhou2, T.M. Lakowski2, 
R. Lillico2, N. Stesco2, K. Gozda2, J. Truong2, J. Kong2, 
Pharmacy
1Univeristy of Manitoba, 2University of Manitoba, Winnipeg, 
MB, Canada
Background: Post-translational modifications (PTM) that 
decrease the positive charge of myelin basic protein (MBP) are 
implicated in myelin damage and multiple sclerosis (MS). The 
citrullination of the arginine residues on MBP has been identified 
as a potential cause.
Objective: To identify changes in lysine and arginine PTMs to 
MBP in spinal cord tissue and correlated these changes to neuro-
logical disability scoring as a marker for the degree of myelin 
damage.
Methods: Increases in lysine acetylation and methylation of MBP 
isolated obtained from an experimental autoimmune encephalo-
myelitis (EAE) animal model of MS were assessed by using a 
mass spectrometry assay.
Results and conclusion: We show lysine acetylation increases by 
two-fold on MBP during the peak inflammatory phase post-EAE 
induction. We also find that MBP mono- and dimethyl-lysine, as 
well as asymmetric dimethyl-arginine are significantly elevated at 
peak EAE disability. These findings suggest that lysine PTM of 
MBP may play a pivotal role in the neurological disability that is 
associated with MS. Histone deacetylase inhibitors have been pre-
viously shown to improve neurological disability. Here we show 
that treatment with trichostatin A significantly improves the neu-
rological disability of EAE mice through some other mechanisms 
other than increasing acetylation.
Disclosure
The Authors declare no conflict of interest.
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Oleanolic acid protects against intestinal permeability defects 
and its causes in experimental autoimmune encephalomyeli-
tis
M. Nieto1, B. Gutierrez1, I. Gallardo1, M. Hernandez1, M.I. 
Cabero1, N. Tellez2
1I3U, IBGM-UVA/CSIC, 2Servicio de Neurología, Hospital 
Clinico Universitario de Valladolid, Valladolid, Spain
Background: Multiple sclerosis (MS) is a pro-inflammatory 
demyelinating disease of the central nervous system, in which 
oxidative stress also plays an important role. Accumulating evi-
dence from studies in patients and animal models (experimental 
autoimmune encephalomyelitis, EAE) suggest that disruption of 
intestinal homeostasis may affect disease progression, thus repre-
senting a potential therapeutic target in MS. The triterpene, 
oleanolic acid (OA), has proven effective protecting blood-brain 
barrier integrity in EAE via anti-oxidant and immunomodulatory 
mechanisms, therefore, its impact on intestinal barrier homeosta-
sis deserves investigation.
Aims: To determine the efficacy of OA in the prevention of gut 
barrier alterations in EAE, with a focus on intestinal inflamma-
tory- and oxidative-stress.
Methods: C57/BL6 mice were MOG35-55-inmunized and treated 
with OA (25 mg/kg/day, i.p) or saline. On day 21, parameters 
related to i) oxidative stress (O2- ions, lipid peroxidation), ii) 
inflammation (IL-1β, TNFα) and iii) gut dysfunction (sCD14, 
intestinal fatty acid binding protein, I-FABP) were determined in 
serum and intestine. Studies related to intestinal permeability/
structure were also performed.
Results: Histopathological analysis of colon and ileum showed 
high levels of O2- ions (DHE stain), mucin loss (Alcian Blue/PAS 
stain) and an altered morphology (H&E stain), in untreated-EAE 
mice, whereas these effects were not detectable in tissues from 
healthy or OA-treated EAE mice. Intestinal permeability analysis 
showed an increase over 5-6 fold in EAE mice compared to 
healthy controls (p< 0.01) that positively correlates with clinical 
symptoms, while in OA-treated EAE mice permeability only 
increased 2.5 fold (p< 0.01). Accordingly, the expected high 
serum levels of sCD14 and I-FABP in EAE mice were prevented 
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by OA-treatment, only increased 1.2 and 1.3 times compared to 
controls (p>0.05). Similarly, OA intervention abolished lipid per-
oxidation, and the increased IL-1β and TNFα levels found in 
colon of EAE mice (2.7±0.4pg/mg tissue and 1.2±0.7pg/mg tis-
sue, respectively) were attenuated (1.1±0.5pg/mg tissue and 
0.5±0.1pg/mg tissue, respectively) in tissues of OA treated-EAE 
mice (p< 0.001)
Conclusion: Our data contribute to the idea that intestinal dys-
function influences multiple sclerosis pathogenesis, and provides 
new findings regarding the beneficial activity of OA in EAE.
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Is DPP4/GLP-1 pathway a possible target for remyelination? 
- A first cerebellum-focused approach using the cuprizone 
mouse model
F. Palavra1,2, S. Henriques2, S. Nunes2, I. Pita2, J. Dinis2, 
J. Simões2, J. Martins3, M. Madeira3, R. Santiago3, A.F. 
Ambrósio3, F. Pereira2, L. Almeida2, F. Reis2
1Centre for Child Development, Neuropediatrics Unit, Pediatric 
Hospital, Coimbra Hospital and University Centre, 2Laboratory 
of Pharmacology & Experimental Therapeutics, Institute 
for Biomedical Imaging and Life Sciences (IBILI), 3Centre 
for Neuroscience and Cell Biology - Institute for Biomedical 
Imaging and Life Sciences (CNC.IBILI) Research Consortium, 
Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Introduction: Cuprizone (CPZ) is a copper chelator that pro-
duces a reversible oligodendrocytopathy in animals, similar to 
human multiple sclerosis (MS). This model is attractive to study 
remyelination, but some of its fundamental properties are not yet 
fully characterized.
Aims: To deepen the knowledge about the biochemical profile 
associated with CPZ-induced demyelination and subsequent 
remyelination in the cerebellum, focusing on gliosis, inflamma-
tion markers and on the dipeptidyl-peptidase 4 (DPP4)/glucagon-
like peptide-1 (GLP-1) pathway.
Material and methods: Two groups of male C57BL/6 mice 
(n=10 each) were fed an oral solution of CPZ (0.2%) for 5 weeks 
(W5); half of the animals were subsequently kept under treatment 
with the vehicle (water) for another 2 weeks (W7). A vehicle-
treated group was used as a control. After 5 and 7 weeks, the ani-
mals were subjected to gene expression and/or protein analysis 
studies of GFAP, myelin proteolipid protein (PLP), TNF-α, IL-1β, 
DPP4, GLP-1 and GLP-1R in the cerebellum, using techniques of 
RT-PCR, western blot and immunohistochemistry.
Results: Myelin PLP expression decreased in the cerebellum of 
CPZ-treated animals (W5), and these changes reverted at 7 weeks. 
GFAP levels varied in the opposite direction. The model also cor-
roborated the existence of an underlying inflammatory process, 
revealed by the elevated expression of TNF-α and IL-1β in W5, 
normalizing in W7. Finally, the lack of changes in DPP4 and 
GLP-1 levels was accompanied by a reduction in GLP-1R levels 
in the cerebellum of W5 animals, as revealed by western blot.
Conclusion: The observed changes validate the use of W5 and 
W7 temporal moments for the study of demyelination and early 
remyelination in the cerebellum of these animals. The expression 
profile of DPP4, GLP-1 and GLP-1R maintains intact the possi-
bility of using this pathway as a possible therapeutic target in MS.
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NMO IgG and AQP4 peptide can induce aggravation of 
EAMG and immune mediated muscle weakness
L. Brill1, T. Mizrachi1, M. Rabie2, Y. Nevo2, Y. Fellig1, M. 
Zur1, D. Karussis1, O. Abramsky1, T. Brenner1, A. Vaknin-
Dembinsky1
1Hadassah University Hospital, Jerusalem, 2Schneider 
Children’s Medical Center of Israel, Petach Tikva, Israel
Background: Neuromyelitis optica (NMO) also known as 
Devic´s disease is a central nervous system (CNS) autoimmune 
disease that preferentially affects the spinal cord and optic nerve. 
The disease is mediated by autoantibodies against Aquaporin 4 
(AQP4). Myasthenia gravis (MG) is also an antibody-mediated 
disease that affects the neuromuscular junction, caused by autoan-
tibodies against the nicotinic acetylcholine receptor (AChR) in 
85% of patients. Recently increased prevalence of NMO was 
found in patients with MG and vice versa.
Currently the experimental autoimmune MG (EAMG) murine 
model is a good model for MG, but there is no good model for 
NMO.
Aims: To verify whether passive and active immunization with 
NMO-Ig and AQP4 peptides respectively, affect the severity and/
or induce CNS pathology in EAMG.
Methods: We used EAMG induced in C57bl mice by immuniza-
tion with Torpedo AChR and subjected the animals to passive 
transfer of NMO-IgG or to immunization with AQP4-derived 
peptide.
Results: Injection of either AQP4 peptide or NMO-Ig to EAMG 
or to naïve mice caused increased fatigability and aggravation of 
EAMG symptoms as expressed by augmented muscle weakness 
(but not paralysis), decremental response to repetitive nerve stim-
ulation, increased neuromuscular jitter, and aberration of immune 
responses.
Conclusions: Increased disease severity in EAMG mice follow-
ing immunization with the NMO autoantigen AQP4 or by NMO-Ig 
mediated by augmented inflammatory response can explain the 
clinical observation of increased susceptibility of patients with 
one autoimmune disease to develop a second autoimmune syn-
drome. Those models can serve as a tool to advance our under-
standing of how autoimmunity progresses and could help tailor 
therapy for those patients.
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Innate immune activation is at the root of NMO-like lesion 
development
S.O. Rohr1, P. Ponsaerts2, M. Kipp1
1Department of Neuroanatomy, Ludwig-Maximilians-University, 
Munich, Germany, 2Laboratory of Experimental Hematology, 
Vaccine and Infectious Disease Institute (Vaxinfectio), Faculty of 
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Neuromyelitis optica (NMO) is a heterogeneous condition with the 
histopathological hallmarks inflammation, demyelination and focal 
loss of aquaporin 4 (AQP4). While antibodies targeting AQP4 are 
believed to be central to NMO pathogenicity, anti-AQP4 immuno-
globulin is absent in approximately one-fourth of NMO patients. 
Two distinct pathological entities might mediate tissue damage in 
NMO: innate and adaptive inflammation. We assume that innate and 
adaptive immunity cascades differentially regulate AQP4, and spe-
cifically contribute to the development of destructive NMO lesions.
Innate inflammation was triggered by feeding young mice with 
0.25% Cuprizone (Cup) mixed into ground rodent chow for 5 
weeks. The liaison of innate and adaptive immunity was realized 
by combining the cuprizone model with active Experimental 
Autoimmune Encephalomyelitis (i.e. Cup/EAE). AQP4 distribu-
tion was further characterized in post mortem samples of progres-
sive MS patients. ELISA was performed to screen for anti-AQP4 
antibodies in our model. Discrimination of microglia and recruited 
monocytes was done using CX3CR1+/eGFP CCR2+/RFP mice.
Activation of innate immunity by cuprizone resulted in a pronounced 
diffuse AQP4 deposition within the demyelinated white matter. The 
same staining pattern was found in lesions of progressive MS 
patients. In the grey matter cortex, polarized AQP4 expression on 
astrocytic foot processes was lost, paralleled by a modest increase of 
diffuse staining intensity. Such lesions were characterized by reac-
tive gliosis and pronounced microglia activation, but absence of 
T-cells and granulocytes. In Cup/EAE mice, several perivascular 
inflammatory infiltrates were found, and these were intensively pop-
ulated by CCR2+ monocytes, CD4+ T-cells and granulocytes. 
Interestingly, anti-AQP4 staining intensity dramatically reduced at 
the close vicinity of perivascular infiltrates. Furthermore, some of 
these lesions showed retraction of perivascular astrocyte processes. 
These pathological changes occurred despite the absence of anti-
AQP4 antibodies or focal complement deposition.
This study highlights the simultaneous effects of innate and adap-
tive immunity on AQP4 pathology. We propose that tissue damage 
in seronegative NMO patients begins with innate immune activa-
tion followed by secondary peripheral immune cell recruitment. 
The relation to types 4-6 lesions (Misu, Lassmann, Acta. 
Neuropathol. 2013) remains to be clarified.
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Gender features of hyperprolactinemia as a protective factor 
in animal models of multiple sclerosis
A. Predtetchinski1, E. Predtechenskaya2, I. Sorokina3, A. Guzev2
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2Novosibirsk State University, 3Novosibirsk Institute of Organic 
Chemistry, Novosibirsk, Russian Federation
Multiple sclerosis (MS) is a demyelinating disease which pos-
sesses significant gender differences: mostly progressive type in 
males and relapsing in females. Pregnancy alters the course of 
MS, which is presumably connected to the surge in prolactin 
secretion during 3 trimester. This makes prolactin a potential ther-
apeutic agent and calls for further research. Cuprizone demyelina-
tion is one of the most relevant models of MS, as it mimics the 
progressive type of MS in mice. Prolonged cuprizone intoxication 
causes chronic demyelination with axonal degeneration, the main 
reason for permanent neurological damage.
This study was performed to estimate the protective role of drug-
induced hyperprolactinemia in functional disability and morpho-
logical features of cuprizone demyelination in both male and 
female mice. The experiment featured mice strain C57BL/6 with 
0,03 % cuprizone solution replacing drinking water for 12 weeks. 
Hyperprolactinemia was induced by subcutaneous injections of 
125 µg metoclopramide, a widely-known dopamine-receptor 
antagonist, every two days. Control mice received saline injec-
tions on the same schedule. Central nervous system disabilities 
were evaluated with functional tests. The tests featured modified 
open field test (Tru Scan, Coulbourn Instruments) to evaluate gen-
eral locomotor activity and anxiety, rotarod test for motor coordi-
nation, hot plate test for pain sensitivity and Noldus CatWalk for 
gait evaluation. Morphological analysis was performed with 
semi-thin sections for optical microscopy and ultra-thin sections 
for transmission electron microscopy with demyelinated and 
degenerated axons as morphometrical criteria.
It was shown that cuprizone intoxication causes more severe mor-
phological CNS features than functional features. Furthermore the 
females are more susceptible to the demyelination, but the remy-
elination is more effective among females than males. Drug-
induced hyperprolactinemia resulted in less severe CNS damage 
in both males and females on 6 and 12 weeks, but females fea-
tured much more efficient remyelination which is almost identical 
to the intact control group. Hyperprolactinemia has also shown 
almost identical and significant axonal degeneration reduction in 
both males and females. Therefore, prolactin shows a significant 
protective effect in both males and females by reducing demyeli-
nation and axonal degeneration lesions and requires further 
research as a potential therapeutic agent in multiple sclerosis.
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Antinociceptive effects of a chronic fingolimod treatment in 
an optimized recurrent-remittent experimental autoimmune 
encephalomyelitis mouse model of multiple sclerosis-neuro-
pathic pain
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Dol, Clermont-Ferrand, France
Background and aims: Multiple sclerosis (MS) is an inflamma-
tory demyelinating disease of the central nervous system that 
causes different debilitating symptoms including neuropathic pain 
in many patients (47%)1. Among current treatments, fingolimod, a 
non-selective sphingosine-1-phosphate (S1P) receptor modulator 
showed promising effect on MS outcome. In the same time, the 
S1P pathway emerged as a novel therapeutic target for neuro-
pathic pain2. While the antinociceptive effects of fingolimod have 
already been demonstrated in neuropathic pain3 models no study 
have investigated this effect in an MS model. So our aim was to 
characterize the fingolimod effect in a relapsing-remitting (RR) 
experimental autoimmune encephalomyelitis (EAE) mouse model 
with neuropathic pain symptoms4.
Methods: We evaluated the effects of an early curative fingoli-
mod treatment (0.5mg/kg/day) on clinical scores, motor perfor-
mances as well as paw sensitivity to mechanical and thermal (cold 
and heat) stimuli.
Results: We showed in treated EAE mice that fingolimod: signifi-
cantly ameliorates the clinical symptoms, totally reverses the 
mechanical allodynia and partially improves cold allodynia and 
thermal heat hypersensitivity.
Conclusion: We then showed for the first time that fingolimod 
can not only improves the EAE clinical scores but also amelio-
rates nociceptive symptoms. Given that neuropathic pain is lack-
ing of efficient treatment, fingolimod could represent a first-line 
therapy in this subtype of MS patients.
Perspectives: We have to decipher if the fingolimod effects on 
nociceptive symptoms is dependent or independent to its effect on 
EAE score. In such a way we will evaluate the effect of sub 
chronic, late curative or local (i.e. intrathecal) treatment on both 
symptoms, as well as, characterize the cellular changes associated 
with these clinical improvements.
1 Foley et al., Pain 2014
2 Welch et al., Biochem. Pharmacol. 2012
3 Janes et al., Journal of Biological Chemistry 2014,
4 Khan et al., Pharmacology, Biochemistry and Behavior 2014
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Autoimmune and toxic demyelination is affected by HSP70 
overexpression in oligodendrocytes and astrocytes
A. Jurewicz1, G. Galazka1, M. Zawadzka2, M. Domowicz1, G. 
Kollias3, K. Selmaj1
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2Nencki Institute, Warsaw, Poland, 3Institute for Immunology at 
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Heat shock protein (HSP) are conservative proteins involved in 
proper protein folding, stress-induced cell responses, facilitating 
autoimmune response and neuroprotection. The role of HSP, 
which are overexpressed in demyelinating lesion in MS brain, is 
unknown .
To examine HSP function in autoimmune (experimental autoim-
mune encephalomyelitis- EAE model) and toxic (lysolecithine- 
LL injury) demyelination we produce transgenic mice with HSP70 
overexpression specifically in astrocytes (GFAP/hsp70Tg) or oli-
godendrocytes (MBP/hsp70Tg). The MBP/hsp70Tg and GFAP/
hsp70Tg mice were sensitized for EAE with myelin oligodendro-
cyte glycoprotein (MOG) peptide 35-55 and EAE was clinically 
scored to 1-5 grade scale. The remyelination processes were 
assessed after toxic demyelination induced by injection of LL into 
thoracic spinal cord. The remyelination in LL model of demyeli-
nation was assessed with toluidin blue staining.
The MBP/hsp70Tg mice showed enhance EAE symptoms in 
compare to control mice (2,5 v. 1,5, respectively). In LL model of 
demyelination enhanced damage of tissue and almost complete 
lack of remyelination was observed in MBP/hsp70Tg mice in 
compare to control mice (remyelination rank: 2,5 v. 7,8, respec-
tively). These data suggest that hsp70 overexpression did not pre-
vent oligodendrocyte demise but enhance inflammatory responses. 
Confirming this hypothesis was the observation that oligodendro-
cytes isolated from MBP/hsp70Tg mice were not resistant to 
TNF-induced death and lymphocytes isolated from EAE MBP/
hsp70Tg mice showed enhance response to myelin antigen in 
compare to control mice (SI: 5,6 v. 2,2). In GFAP/hsp70Tg mice 
EAE symptoms were milder in compare to control mice (0,8 v. 
1,5, respectively). The lymphocyte proliferation in response to 
myelin antigens were similar in GFAP/hsp70Tg and control mice. 
However the remyelination in GFAP/hsp70Tg mice after LL 
injection was slightly inhibited in compare to control mice as 
assessed by remyelination rank (6,1 v. 7,8, respectively).The 
hsp70 overexpression in oligodendrocytes did not change oligo-
dendrocytes resistance to inflammatory-induced death but 
enhanced EAE symptoms and inflammatory responses. The hsp70 
overexpression in astrocyte have protective effect on EAE course 
however do not enhance remyelination.
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Inhibition of bone morphogenetic protein signaling with 
small molecules as a therapeutic approach in experimental 
autoimmune encephalomyelitis
H. Eixarch, L. Calvo-Barreiro, C. Costa, G. Reverter-Ribes, M. 
Castillo, X. Montalban, C. Espejo
Vall Hebron University Hospital | Multiple Sclerosis Centre of 
Catalonia, Cemcat-Vall Hebron University Hospital, Barcelona, 
Spain
Background: Bone morphogenetic proteins (BMPs) are secreted 
proteins that belong to the TGF-beta superfamily. In the adult brain, 
BMPs modulate neurogenesis, favour astrogliogenesis and inhibit 
oligodendrogenesis, and they are also involved in demyelination 
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processes. Moreover, BMPs have been proposed as regulators of 
the immune response.
Objective: We aimed to test the therapeutic potential of two small 
molecules that inhibit BMP signaling (dorsomorphin and its ana-
logue DMH1) in MOG-induced experimental autoimmune 
encephalomyelitis (EAE). Disclosure of conflict of interest: HE, 
LC-B, CC, GR-V, CE declare no competing financial interests.
XM has received speaking honoraria and travel expenses for sci-
entific meetings, has been a steering committee member of clini-
cal trials or participated in advisory boards of clinical trials in the 
past with Bayer Schering Pharma, Biogen Idec, EMD Merck 
Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva 
Pharmaceuticals and Almirall.
Methods: EAE was induced in 8-week old C57BL6/J female 
mice with the 35-55 MOG peptide. Mice were randomized once 
EAE clinical signs were established, and animals were treated 
daily with 3mg/kg dorsomorphin (n=13), 5mg/kg DMH1 (n=13), 
or vehicle (DMSO; n=12). At the end of the experiment (day 
29-33 postimmunization), we quantified inflammation and demy-
elination in the CNS. We evaluated the proliferative capacity of 
splenocytes upon antigen-specific (MOG35-55) or polyclonal (phy-
tohematoagglutinin or PHA) stimulus, and the frequency of 
peripheral immune populations (T cells, B cells and myeloid 
cells) by flow cytometry.
Results: Therapeutic treatment with dorsomorphin ameliorated 
EAE outcome measured as the area under the curve (AUC) of the 
mean daily clinical score for each group (vehicle group: 
68.33±10.65 and dorsomorphin group: 54.52±19.27; p=0.039). 
Treatment with DMH1 also resulted in a better EAE outcome 
(AUC: 52.65±18.34) compared with vehicle-treated mice 
(p=0.017). Conversely, we did not find differences in the prolif-
erative response of splenocytes upon stimulation with MOG35-55 
or PHA in vehicle-treated mice compared with dorsomorphin- and 
DMH1-treated groups. Because DMH1 is a more specific BMP-
signaling inhibitor, we performed the histopathological study and 
the evaluation of the frequency of peripheral immune cells in 
DMH1-treated mice and vehicle-treated mice. DMH1-treated 
mice presented less inflammation in the CNS (inflammation score 
for vehicle group: 3.36±0.67, and for DMH1 group: 2.69±0.85; 
p= 0.047), and also presented a lower frequency of myeloid cells 
in the spleen (vehicle group: 70.86±6.72% and DMH1 group: 
61.70±4.77%); p=0.015). Moreover, macrophages were also 
decreased in the DMH1 group although no statistical significance 
was reached (vehicle group: 16.13±6.57% and DMH1 group: 
10.11±3.34%; p=0.056).
Conclusion: These data points to the specific inhibition of BMP 
signaling as a novel potential therapeutic target for MS.
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Functional regulation of abcg2 by apolipoprotein E in con-
text of immunotherapies for multiple sclerosis
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Background: The multi-drug resistance transporter ABCG2, 
a member of the ATP-binding cassette (ABC) family, mediates 
the efflux of different immunotherapeutics, e.g. teriflunomide 
(teri) and mitoxantrone (MX), across cell membranes and 
organelles. Functional relevance of ABCG2 on MX-treatment 
was demonstrated in MS and its animal model, experimental 
autoimmune encephalomyelitis (EAE), but data are lacking 
for teri.
Apolipoprotein E (apoE) is known to have modulatory effects on 
ABC-transporter activity as demonstrated in experimental stroke. 
We therefore hypothesize that apoE affects teri-efficacy via 
abcg2-modulation.
Objective: To investigate effects of apoE-deficiency on abcg2-
transporter expression and its functional impact on teri-induced 
cellular effects in vitro.
Methods: abcg2-mRNA expression (spleen/splenic T cells and B 
cells) from wildtype (wt) and apoE-/--mice were analyzed by qRT-
PCR. Stimulated T cells from wt, apoE-/- and abcg2-/--mice (anti-
CD3, 10µg/ml + anti-CD28, 10ng/ml; 48h) were treated with teri 
(12.5-100µM). T cell apoptosis (annexinV/PI) and proliferation 
(CSFE) were analyzed by flow cytometry.
Results: We observed a 1.8-fold (p=0.003) higher abcg2-mRNA 
expression in splenic T cells from apoE-/--mice compared to wt, 
which was not present in B cells (p=ns). Consistently, inhibition 
of T cell proliferation was 1.2-1.6-fold lower in apoE-/--mice than 
in wt (p< 0.05, 50-100µM teri, 48h). In line with the hypothesized 
effect of abcg2 on teri-efficacy, T cells from abcg2-/--mice 
revealed increased inhibitory effects of teri (1.3-1.9-fold increase 
compared to wt, p< 0.05, 12.5-100µM teri, 48h). Teri-induced T 
cell apoptosis as independent functional readout demonstrated 
analogous results (apoE-/-: 1.2-fold decrease, p< 0.01, 50µM teri 
and abcg2-/-: 1.2-fold increase, p< 0.05, 12.5µM teri; each com-
pared to wt).
Conclusions: Our data indicates that regulation of abcg2-expres-
sion by apoE has functional effects on cellular effects of teri. This 
ongoing work aims at contributing to an understanding of inter-
individual differences in efficacy and adverse events of prominent 
ABCG2-transporter substrates such as teri.
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A new evaluation strategy to measure remyelination in the 
cuprizone model
U. Chrzanowski, M. Kipp
Department of Neuroanatomy, Ludwig-Maximilians-University, 
Munich, Germany
Background: In multiple sclerosis (MS) patients, remyelination is 
pivotal for the maintenance of axonal integrity. While endogenous 
remyelination is robust in some patients, this regenerative process 
fails in others, especially during the progressive disease stage. One 
of the most popular animal models to test the pro-myelinating 
capacity of drugs is the cuprizone model. Effective drug testing 
requires, however, a detailed knowledge about regions where 
demyelination occurs in a reproducible and predictive manner.
Objectives: In this study, we aimed to define which part of the 
corpus callosum is consistently demyelinated and, thus, can serve 
as region of interest (ROI) to study remyelination.
Method: Acute demyelination was induced by a five week cupri-
zone (0.25%) intoxication protocol. Brain-slides were stained 
immunhistochemically for the mature myelin proteins PLP (prote-
olipid protein), MAG (myelin-associated glycoprotein) and 
CNPase (2´,3´-cyclic nucleotide 3´-phosphodiesterase ). Relative 
myelin densities were densitometrically analyzed within distinct 
sectors of the corpus callosum at the level of the anterior commis-
sure and rostral hippocampus. Regions are given according to the 
Allen Brain reference Atlas (i.e. plate number).
Results: In all three stains, robust loss of immunoreactivity was 
observed within the corpus callosum. At the level of the anterior 
commissure (plate 54), demyelination of the midline of the corpus 
callosum was highly variable, irrespective which part was ana-
lyzed. At the level of the rostral hippocampus (plate 70), the extent 
of demyelination was relatively consistent within the most medial 
parts of the corpus callosum. At that level, the medial portion of 
the cingulum bundle served as a reliable landmark where demyeli-
nation becomes inconsistent.
Conclusions: This study clearly shows that reproducible demyeli-
nation can be obtained in the cuprizone model, allowing straight 
forward analyses of the pro-myelinating capacity of drugs. 
However, a pilot trial should be performed to define which region 
of the corpus callosum is demyelinated in a reproducible manner 
under the given experimental conditions.
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EP1469
In vivo evolution by brain magnetic resonance imaging of 
interleukin 1 induced cortical demyelinating lesions in adult 
rats
B.A. Silva1,2, J.C. Avalos3, M.I. Farías1, M.C. Leal1, C.H. 
Besada4, F.J. Pitossi1, C.C. Ferrari1,2
1Leloir Institute Foundation, 2IUHI, Institute of Basic 
Science and Experimental Medicine, 3Neurology Department, 
4Neuroimaging Department, Italian Hospital, Buenos Aires, 
Argentina
The relevance of the interleukin 1beta (IL-1b) has been demon-
strated in both Multiple Sclerosis (MS) pathology and MS animal 
models. The aim of this work is to analyze rat brain magnetic reso-
nance imaging (MRI) and their correlation with the histological 
features of cortical demyelinating lesions induced by the long-term 
expression of IL-1b in adult rats. Adult rats were injected in pre-
frontal cortex with an adenovirus expressing IL-1b (AdIL-1). 
Then, 21 days after they were peripherally injected with either 
AdIL-1 or control adenovirus (CI/PI and CI/PC, respectively) and 
analyzed by 3 T MRI and histological techniques 7 days after the 
peripheral stimulation. Anatomopathological studies and brain 
blood barrier (BBB) integrity were assessed. The peripherally 
stimulated cortical lesions of CI/PI showed hyperintensity on 
T2-weighted sequence and homogeneous enhancement on T1- 
weighted sequence, after injection of a gadolinium-based contrast 
agent, with maximum enhancement six minutes after gadolinium 
injection, indicating lack of blood-brain barrier. We do not observed 
hyperintensity and gadolinium enhancement in cortical lesions of 
CI/PC animals. In spite of that, cortical lesions exhibited neuroin-
flammation, neurodegeneration, demyelination, meningeal inflam-
mation and BBB disruption in both groups CI/PI and CI/PC. We 
analyzed the differences in the composition of both cortical lesions, 
and we found that the presence of neutrophils is significantly 
higher in CI/PI cortex, which could be responsible for MRI visuali-
zation on T2-weighted sequence. Given that no MRI lesion images 
can be visualized in CI/PC animals, even though tissue damage 
and BBB leakage is present, the phenomenon describes as normal 
appearing gray matter could explain these results. In addition, this 
study constitutes another evidence confirming that the low sensi-
tivity of gadolinium in reflecting BBB disruption. Therefore, the 
use of conventional MRI protocols and the sensitivity of gadolin-
ium to demonstrate BBB integrity should be discussed.
Disclosure
There are no conflicts of interest of the authors for this work
Genetics/Epigenetics
EP1470
Dimethyl fumarate changes the methylation pattern in CD4+ 
cells of MS patients
J. Lechner-Scott1,2,3, V.E. Maltby4, K.A. Ribbons1, M. Min1, R. 
Lea2
1Neurology, John Hunter Hospital, 2Hunter Medical Research 
Institute, 3Medicine and Public Health, 4Health and Medicine, 
University of Newcastle, Newcastle, NSW, Australia
Background and aims: The mode of action of the MS disease 
modifying therapy Dimethyl fumarate (DMF) is thought to be via 
the nuclear factor-like 2 pathway, leading to transcription of anti-
inflammatory and cytoprotective genes. We have recently 
described significant differences in the methylation profile of 
CD4+ T-cells of MS patients compared to age and gender- matched 
controls. In this study we explored if DMF can change the CD4+ 
T-cell methylation profile.
Methods: Peripheral Blood Mononuclear Cells (PBMCs) were 
isolated by density gradient centrifugation on lymphoprep, and 
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CD4+ T-cells enriched using EasySep magnetic negative selection 
from 7 relapsing remitting MS patients before and 6 months after 
treatment with DMF. Change in methylation was calculated using 
paired Tests. Point-wise FDRs and magnitude of change was used 
to rank CpGs.DNA was bisulfite converted and hybridized to 
Illumina EPIC methylation arrays and analysed as previously 
described (Graves et al 2013). Data was background corrected and 
control-normalized aligned to the human genome using BOWTIE. 
Methylation levels were produced from each probe and ranged 
from 0 (completely unmethylated) to 1 (completely methylated). 
Change in methylation was calculated by subtracting the median 
values of group 1 to group 2 to produce scores ranging from -1 
(hypomethylation) to 1 (hypermethylation).
Results: We included 3 males and 4 females with a mean age of 
35 years, 3 of which were treatment naïve. Mean disease dura-
tion was 2.8 years, mean EDSS 2.1 and an annual relapse rate of 
1.1 prior to treatment. In total 1347 CpGs showed a change in 
methylation over time (FDR< 0.05) with 97% showing an 
increase in methylation, while only 3% showed a decrease. 216 
CpGs had a larger than 10% difference in methylation. Most 
methylated regions were in known genes. GSEA-KEGG of the 
1347 CpGs showed pathways involved in Wnt-signalling, axon 
guidance, focal adhesion and MAPK enriched. In particular 
tumour necrosis factor (TNF) on chromosome 6 showed 
increased methylation associated with DMF treatment. This is in 
contrast to our previous study where we demonstrated that this 
gene was significantly hypomethylated in MS patients compared 
to controls.
Conclusion: This study suggests that DMF potentially alters the 
methylation profile of CD4+ T-cells in MS patients. We have pre-
viously shown that TNF is differentially methylated in MS patients 
compared to healthy individuals. This effect might to be corrected 
by DMF treatment.
Disclosure
Jeannette Lechner-Scott: accepted travel compensation from 
Novartis, Biogen and Merck. Her institution receives the hono-
raria for talks and advisory board commitment from Bayer Health 
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and Teva.
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Occurrence of allele T of glypican 5 polymorphism is associ-
ated with sex and age at onset in multilple sclerosis patients
M. Chorąży1, N. Wawrusiewicz-Kurylonek2, R. Posmyk3, 
J. Gościk2, A. Zajkowska1, A. Kułakowska1, K. Kapica-
Topczewska1, M. Szczepański1, A.J. Krętowski2, J. 
Kochanowicz1
1Department of Neurology, 2Department of Endocrinology, 
Diabetology and Internal Medicine, 3Department of 
Perinatology, Medical University of Bialystok, Białystok, Poland
Introduction: GPC5 gene has been implicated in multiple sclero-
sis (MS) susceptibility polymorphism studies as well as in the 
pharmacogenomic GWAS (genome wide association study). It 
codes a glypican, a type of heparan sulfate proteoglycan that ful-
fills signaling functions in the extracellular matrix. Although, its 
exact mechanisms of action are still unknown, glypicans have 
been shown to contribute to neuronal development and function. 
A follow-up study successfully confirmed the connection between 
GPC5 single nucleotide polymorphisms (SNPs) and IFN-b 
responsiveness. The aim of our study was to determine the asso-
ciation of selected polymorphisms of GPC5 gene with the treat-
ment approach of our MS patients.
Material: The study group consisted of 174 patients (50 males 
and 124 females, age from 19 to 61,), who were sequentially 
recruited from the neurology outpatient clinic of Clinical Hospital 
in Bialystok. All of them were relapsing-remitting MS patients 
undergoing immunomodulatory treatment, with EDSS ranging 
from 0 to 4,5.
Description of methods: The study was based on DNA analysis, 
that was extracted from the peripheral blood leukocytes using a 
classical salting out method. The SNP rs10492503 in the GPC5 
gene were genotyped by TaqMan SNP genotyping assay using the 
real-time PCR method.
Results and conclusion: A strict correlation between the occur-
rence of allele T of rs10492503 polymorphism of GPC5 gene and 
sex and age of onset in MS patients was observed in our study. 
The male patients in the studied group with allele T were diag-
nosed earlier than female patients with the same allele (28 ± 0.94 
vs. 34.4 ± 0.84, p < 0.01) and both, female and male patients with 
ancestral allele A (p < 0.01, p < 0.05). No significant association 
was found between clinical characteristics like scheme of treat-
ment and EDSS scale changes. This result suggests, that the allele 
T of rs10492503 GPC5 gene can be a strong predictor of early-
onset MS in male patients.
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EP1473
Single nucleotide polymorphism in vitamin D hydroxylase 
gene is associated with susceptibility to multiple sclerosis in 
Slovaks
D. Cierny1, J. Michalik2, E. Kantorová2, J. Javor3, E. Kurca2, D. 
Dobrota1, J. Lehotsky4
1Department of Clinical Biochemistry, 2Department of 
Neurology, Comenius University in Bratislava and University 
Hospital Martin, Jessenius Faculty of Medicine in Martin, 
Martin, 3Institute of Immunology, Comenius University in 
Bratislava, Faculty of Medicine, Bratislava, 4Department of 
Medical Biochemistry and BioMed, Comenius University in 
Bratislava and University Hospital Martin, Jessenius Faculty of 
Medicine in Martin, Martin, Slovakia
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Background: Vitamin D has a large scale of immunomodula-
tory and antiinflammatory effects and it has been found to be 
involved in modulation of the risk and clinical course of 
multiple sclerosis (MS). The production of active form of 
vitamin D (calcitriol) is catalysed by 25-hydroxyvitamin D-1α-
hydroxylase, also known as CYP27B1. It is still not completely 
clear, whether the single nucleotide polymorphisms in CYP27B1 
gene could be related to the biological effects of vitamin D and 
thus to MS pathogenesis.
Objectives: The aim of our present study was to assess the asso-
ciation of the allele and genotype variants of rs703842 (C/T) in 
CYP27B1 gene with the risk of MS development in Slovaks.
Methods: In our study, genotypes of rs703842 in CYP27B1 gene 
were analysed in the group of 261 MS patients (87,4 % relapsing-
remitting, 12,6 % secondary progressive) and 291 healthy age and 
sex-matched control subjects from central and northern Slovakia. 
Genotyping was performed by the polymerase chain reaction and 
restriction analysis.
Results: The allele T was found to be present in higher frequency 
in MS patients when compared to healthy controls (0.715 vs. 
0.637, p< 0.01). We also detected a significantly higher frequency 
of genotype TT in MS patients when compared to controls (0.513 
vs 0.436, p< 0.01).
Conclusions: We identified an increased frequency of minor 
allele T and genotype TT of rs703842 in CYP27B1 gene in a 
cohort MS patients of Central European Slovak origin. The 
results of our study confirmed the role of rs703842 in MS patho-
genesis, suggesting the allele T and genotype TT to be the 
genetic risk factors of MS development in Slovaks. Our findings 
support the hypothesis of genetic regulation of vitamin D effects 
in MS disease.
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EP1475
Cell-specific transcriptional modulation induced by fingo-
limod treatment in relapsing remitting multiple sclerosis 
patients
L. Ferrè1,2, F. Clarelli2, P. Provero3,4, E. Mascia2, G. Sferruzza2, 
M. Sorosina2, L. Moiola1, V. Martinelli1, G. Comi1, F. Martinelli 
Boneschi1,2, F. Esposito1,2
1Department of Neurology, 2Laboratory of Human Genetics of 
Neurological Disorders, CNS Inflammatory Unit & INSPE, San 
Raffaele Scientific Institute, Milan, 3University of Turin, Turin, 
4Center for Translational Genomics and Bioinformatics, San 
Raffaele Scientific Institute, Milan, Italy
Background: Fingolimod (FTY) is a second-line drug approved 
for Relapsing Remitting Multiple Sclerosis (RRMS). It is known 
to prevent lymphocyte egress outside lymph nodes, thus reducing 
peripheral lymphocytes counts.
Aims: To investigate transcriptional changes induced by FTY in 
immune cell subtypes using RNA-seq technology, in order to bet-
ter elucidate FTY mechanism of action at the molecular and path-
way level.
Methods: 24 RRMS patients were sampled at baseline and after 6 
months of FTY treatment. CD3+
T cells, CD20+ B cells and CD 14+ monocytes were sorted 
through the MACS MicroBeads system. RNA sequencing was 
performed on the three cell types using the Illumina TruSeq-
Stranded mRNA preparation kit, on the NextSeq500 platform. 
Differentially expressed genes (DEGs) were identified for each 
cell type using DESeq2 R package. Genes strongly modulated by 
FTY (fold change [FC]>2 or
FC< 0.5 and false discovery rate [FDR]< 5%) were considered for 
a pathway enrichment analysis performed using WebGestalt tool, 
based on KEGG and Reactome databases.
Results: A marked up-regulation was observed in both T and 
B lymphocytes (695 up- and 492 down-regulated genes in T 
cells; 857 up- and 261 down-regulated genes in B cells), with 
evidence of significant overlap between the 2 cell-types; a less 
pronounced transcriptional induction was observed in mono-
cytes, mainly regarding down-regulated genes (n=189). Most 
of FTY-responsive genes had immune-related function; among 
the top 10 DEGs, CCL4 was up-regulated in T cells (adjusted 
p-value [adjp]=5.4x10-55, FC=4.5), FCGR3A in B cells 
(adjp=1.4x10-31, FC=5), whereas CCR7 was down-regulated 
in monocytes (adjp=3.1x10-30, FC=0.2). Up-regulated DEGs 
from T and B cells were enriched of genes involved in shared 
immune-related pathways (e.g. cytokine-cytokine receptor 
interaction, chemokine signaling pathways); similarly, also 
down-regulated genes in monocytes seemed to be involved in 
immune modulation (e.g. Th1 and Th2 cell differentiation 
pathways).
Conclusions: FTY induces major transcriptional changes at the 
immune level, that appear to be shared between T and B lympho-
cytes, whereas the induced gene expression modulation in mono-
cytes is quite different. Our data suggest that at least part of the 
immunomodulatory action of FTY seems to be regulated at the 
transcriptional level.
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Familial involvement in multiple sclerosis
M. Terzi1, S. Şen2, Ö. Evin1, M. Onar1
1Ondokuz Mayis University Medical Faculty, 2Vezirköprü State 
Hospital, Samsun, Turkey
Introduction: Multiple sclerosis (MS) is defined as a chronic, 
inflammatory, and demyelinating disease of the central nervous 
system. MS is more frequently diagnosed in women and in indi-
viduals aged between 20 and 40 years. MS is an autoimmune dis-
ease caused by genetic and environmental factors that may be 
accompanied by other autoimmune diseases. Among our patients, 
177 (11.2%) had a history of MS in other members of the family. 
The incidence of MS in the families of MS patients is 5%-26%.
Results and conclusion: Based on the data obtained from hospi-
tals, 1,787 patients were determined to be living in the Middle 
Black Sea Region and were diagnosed with MS. The clinical and 
radiological diagnoses of MS of 1,584 patients were confirmed, 
whereas the diagnoses of MS in 203 were withdrawn. The preva-
lence of MS in Samsun province was 46.5/100,000. It was 
43.2/100,000 in the Middle Black Sea Region, which was calcu-
lated based on the total population and total number of patients in 
the provinces and districts (Table 1).
The mean ± standard deviation age of the patients was 38.2±10.9 
years; 1,121 (70.8%) patients were females, while 463 (29.2%) 
were males. The mean age at disease onset was 29.3±7.6 years, 
with a mean age at disease onset of 29.33±7.5 years in females 
and 29.53±7.9 years in males.
A history of MS in other family members of patients was present 
in 177 (11.2%) patients. MS occurred in the sisters of 25 (14.1%) 
patients, mothers of 22 (12.4%) patients, brothers of 19 (10.7%) 
patients, daughters of 10 (5.7%) patients, fathers of 8 (4.5%) 
patients, and other relatives of 93 (52.5%) patients.
In the present study, familial MS was observed most often in sec-
ond- and third-degree relatives. Among first-degree relatives, the 
frequency of familial MS was the highest in sisters, followed by 
mothers, brothers, daughters, and fathers. Although a higher fre-
quency of familial MS in sisters and mothers is explained by the 
higher frequency of MS in women, some studies have reported a 
high rate of maternal inheritance of MS. A higher inheritance rate 
of familial MS in sisters than in mothers might be related to envi-
ronmental factors. This can be explained by the fact that sisters 
and brothers are exposed to the same environmental factors during 
their childhood. The high frequency of familial MS in brothers in 
the present study might also support this opinion
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Role of CYP2R1 rs10766197 in MS risk and disease progres-
sion
G. Salemi1, C. Scazzone2, S. Realmuto1, L. Agnello2, B. Lo 
Sasso2, C. Bellia2, G. Bivona2, R. Schillaci2, P. Ragonese1, M. 
Ciaccio2,3
1Department of Experimental Biomedicine and Clinical 
Neuroscience, 2Section of Clinical Biochemistry and Clinical 
Molecular Medicine, Department of Medical Biotechnologies 
and Biopathology, 3UOC of Laboratory Medicine, AOUP ‘P. 
Giaccone’, University of Palermo, Palermo, Italy
Background: Multiple sclerosis (MS) is a neurodegenerative 
autoimmune disease resulting from a complex interaction of 
genetic and environmental factors. Among these, vitamin D and 
genetic variants associated with vitamin D-metabolism gain great 
attention from scientific community.
Objectives: The aim of our study was to assess the role of 
NADSYN1 and CYP2R1 genes in relation to serum 25-OH-vitamin 
D3 levels in MS.
Materials and methods: We investigated on five single nucleo-
tide polymorphisms in NADSYN1 and CYP2R1 genes in relation 
to serum 25-OH-vitamin D3 levels in 105 MS patients and 130 
controls. Genotyping of CYP2R1- and NADSYN1-SNPs was 
performed by TaqMan allelic discrimination
(Life Technologies).
Results: We found lower 25-OH-vitamin D3 concentrations in 
MS patients than in controls. The most relevant finding obtained 
allows us to propose that rs10766197 CYP2R1 SNP is associated 
with MS risk. After stratifying MS patients according to gender, 
we found that the minor allele A of rs10766197 had a higher fre-
quency in men in comparison to women affected by MS and an 
association with disease progression, assessed by EDSS and 
MSSS scores, only in MS men.
Conclusions: This finding opens new perspectives for a role of 
CYP2R1 in both risk and progression of MS.
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Association between DRB1*15:01 allele and five distinct Sin-
gle Nucleotide Polymorphisms in the Brazilian familial form 
of multiple sclerosis
C.C. Ferreira Vasconcelos1, P.T. Figueiredo Alves1, E. Paradela1, 
M. Bernardes2, R.M. Alvarenga1, M.P. Alvarenga1
1Hospital Universitario Gaffree e Guinle, 2Hospital Federal da 
Lagoa, Rio de Janeiro, Brazil
Background: Considerable epidemiological and laboratory data 
have shown that Multiple sclerosis (MS) results from a complex 
interaction between genetic and environmental factors. To better 
understand the mechanisms among the genetic variations and sus-
ceptibility to the disease, the familial form of MS (ffMS) are being 
studied.
Objective: To investigate, regarding susceptibility to MS, the 
association between HLA type II allele and five differents Single 
Nucleotide Polymorphisms (SNPs) in genes Interleukin 7 receptor 
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alpha (IL7Ra), Estrogen receptor (ESR), Vitamin D receptor 
(VDR) and CIITA.
Methods: A case-control study was conduct with a miscigenated 
sample of 29 Brazilian familial MS patients (22 females and 7 
males, 26 of whom were white, and 3 were black) from referral 
centers in Rio de Janeiro-Brazil, and 296 free disease controls 
(200 females and 96 males). DRB1*15:01 allele and SNPs in 
genes IL7Ra (rs6897932), VDR (rs731236), ESR (rs1033182) 
and CIITA (rs3087456; rs4774) were assessed by techniques of 
PCR, electrophoresis and DNA sequencing. In the association 
analysis, it was used Qui-square test.
Results: DRB1*15:01 allele was significantly more frequent in 
Familial MS patients (62% vs. 7.4%, p< 0.001). In addition, all 
studied SNPs were more frequent in the free disease group 
(rs6897932 IL7Ra: 27.5% vs. 32%, p=0.61; rs731236 VDR: 
27.5% vs. 55%, p=0.004; rs1033182 ESR: 31.8% vs. 50.6 %, 
p=0.006; rs3087456 CIITA: 17.2% vs. 44.2%, p=0.004; rs4774 
CIITA: 7.4% vs. 43.2%, p=0.0001), which shows a tendency of 
non-association with ffMS, in the miscigenated Brazilian sample 
of patients.
Moreover, in these patients with Familial MS, no association was 
found between the presence or not of HLA DRB1 15*01 allele 
and frequency of SNPs rs6897932 IL7Ra (33% vs. 18.1%, 
p=0.37), rs731236 VDR (33% vs. 18.1%, p=0.375), rs1033182 
ESR (22.2% vs. 27.2%, p=0.757), rs4774 CIITA (11% vs. 9%, 
p=0.86), and rs3087456 CIITA (11% vs. 27.2%, p=0.263).
Conclusion: A strong association between ffMS and the presence 
of the DRB1 15*01 allele was evidenced, suggesting that, in a 
miscigenated population such as Brazil, this is the most related 
factor with disease susceptibility, more than the studied SNPs.
No association between those SNPs and disease was found in the 
small sample of ffMS patients. Therefore, more studies with a 
larger sample should be implemented.
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EP1479
Modulation of the Treg: Th17 axis in relapsing remitting 
multiple sclerosis after dimethyl fumarate therapy
B. Moran1, N. McNicholas2, K. O’Connell2, C. McGuigan2, J.M. 
Fletcher1
1Department of Biochemistry and Immunology, Trinity College 
Dublin, 2Department of Neurology, St. Vincent’s University 
Hospital, Dublin, Ireland
Dimethyl fumarate (DMF) is a disease modifying therapy licensed 
as a first line therapy for relapsing remitting multiple sclerosis 
(RRMS). The exact mechanism of action of DMF is not clear, 
although it has been proposed to exert both anti-inflammatory and 
antioxidant effects on immune cells, and to cause apoptosis in T 
cells. Pro-inflammatory T cells such as Th1 and Th17 cells are 
proposed to have a pathogenic role in MS, whereas regulatory T 
(Treg) cells suppress pathogenic T cells and prevent autoimmun-
ity. We examined the immunomodulatory effects of DMF treat-
ment in RRMS patients, comparing baseline, 1, 3 and 6 months 
post treatment. We used multi-parameter flow cytometry to deter-
mine the frequency and phenotype of peripheral CD4 T cells. 
Preliminary data indicated a significant reduction in the frequency 
and absolute numbers of memory CD4 T cells, with a correspond-
ing increase in the naïve compartment after 6 months of treatment. 
Pro-inflammatory cytokines IL-17, IFN-γ, TNF, GM-CSF pro-
duction by CD4 T cells was not altered by DMF treatment, how-
ever there was a significant reduction in the expression of the 
CD161 Th17 lineage marker after 6 months. In addition we 
observed a significant increase in the frequency of IL-2 producing 
T cells after 3 and 6 months relative to baseline. There was a non-
significant trend towards an increase in Treg cells in response to 
DMF treatment, however the proportion of memory Treg cells 
was significantly reduced after 6 months.
In summary, DMF therapy appears to specifically target memory 
CD4 T cells within both the effector and Treg compartments, 
resulting in a reciprocal increase in the proportion of naïve CD4 
T cells. The increase in IL-2 production may reflect a decrease in 
effector memory T cells which have a reduced capacity for IL-2 
production. The reduction in CD161 expression in response to 
DMF therapy suggests that DMF may specifically target Th17 
lineage cells, however no corresponding reduction in IL-17 
cytokine was observed and increased patient numbers need to be 
analysed. Finally DMF therapy for 3 or 6 months significantly 
decreased the CD161+ Th17:Treg cell ratio suggesting that DMF 
therapy may in part exert its effects via reciprocal effects on Th17 
and Treg cells.
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IL-24 is produced both locally and peripherally by activated 
immune cells of MS patients
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Background: IL-24 is a cytokine of the IL-10 family and IL-20 
subfamily. It shares receptor chains with IL-22 and IL-26, two 
cytokines which have shown to be associated with the IL-17 pro-
ducing T helper (TH) subset TH17. It is well established that 
TH17 lymphocytes, as well as the cytokines they produce, are cru-
cial in the pathogenesis of multiple sclerosis (MS). IL-24 has been 
shown to be elevated in patients with chronic inflammatory/auto-
immune disorders such as rheumatoid arthritis, inflammatory 
bowel disease and psoriasis, however studies in MS are lacking. 
Here, we evaluate the unexplored role of IL-24 in MS.
Methods and results: Using quantitative PCR (qPCR), we show 
that IL-24 mRNA is expressed by activated T cells, B cells and 
monocytes of healthy donors (HD). In naive T cells, IL-24 mRNA 
is specifically induced by the combination of IL-6 and TGF-beta. 
Memory T cells, after differentiation into either TH1 or TH17 
cells, express both IL-24 mRNA and protein, as assessed by qPCR 
and ELISA respectively, in HD and MS patients. Interestingly, the 
concentration of IL-24 is significantly higher in plasma samples 
of MS patients, compared to HD, as measured by ELISA. In our 
study cohort, immunomodulatory treatment significantly reduced 
the concentration of IL-24 in plasma samples. Using immuno-
histofluorescence on active MS lesions, we identified IL-24 
expressing myelin-phagocytosing myeloid cells, as well as reac-
tive astrocytes, which were both validated using in vitro cultures 
of primary human macrophages and astrocytes.
Conclusions: In summary, IL-24 is increased in the blood of MS 
patients, and it is expressed by activated lymphocytes, myelin-
phagocytosing myeloid cells and reactive astrocytes in the context 
of neuroinflammation, warranting further investigation into its 
biological role in the context of MS.
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Melanocortin receptor mediated anti-inflammatory effect 
of repository corticotropin injection on human monocyte-
derived macrophages
L.M. Healy1, J.H. Jang1, Y.H. Lin1, V. Rao1, J.P. Antel1, D. 
Wright2
1Neurology and Neurosurgery, McGill University, Montreal, 
QC, Canada, 2Mallinckrodt Pharmaceuticals, Inc, Hampton, NJ, 
United States
Introduction: Repository corticotropin injection ((RCI), H.P. 
Acthar Gel®) contains a purified porcine pituitary ACTH-analogue 
and is FDA-approved to treat acute multiple sclerosis (MS) exac-
erbations. ACTH may have activity at all five melanocortin recep-
tor (MCR) subtypes that are differentially expressed on multiple 
immune and non-immune cell populations. MRC agonists are 
reported to inhibit pro-inflammatory responses in blood-derived 
macrophages. Monocyte-derived-macrophages (MDMs) are the 
dominant cell type in an MS lesion and play a pivotal role in regu-
lating the immune response and development of plaques in MS.
Objective: To explore the direct effects of RCI on human mac-
rophages in vitro, focusing on induction of pro-inflammatory 
mediators following lipopolysaccharide (LPS) stimulation.
Methods: Human blood derived monocytes were selected for 
CD14 expression using magnetic bead selection (MACs) and 
plated in presence of macrophage colony-stimulating factor 
(M-CSF). Cells were stimulated with LPS and incubated for a 
minimum for 24h with and without RCI preparations (3h pre-
treatment). Assays: qPCR assays were performed using Taqman 
platform. ELISA reagents for various cytokines were sourced 
from BD Biosciences. Receptor expression data was mined from 
microarray and RNAseq datasets.
Results: MDMs express MC1R exclusively as shown by tran-
scriptomic and PCR analysis. Expression of MC1R was reduced 
by LPS stimulation and this was not affected by RCI application. 
Treatment of MDMs with RCI suppressed LPS-induced produc-
tion of TNF and IL6 (range, 75-80%). Furthermore, RCI treatment 
of MDMs induced expression of heme oxygenase-1 (HMOX1), a 
gene that is upregulated during periods of metabolic stress.
Conclusion: Our in vitro study showing that RCI directly inhib-
its the pro-inflammatory response of human MDMs indicates 
that this agent can induce an anti-inflammatory effect independ-
ent of the corticosteroid pathway. Whether this anti-inflamma-
tory effect on MDMs can impact other functional roles such as 
phagocytosis, tissue repair or promoting remyelination remains 
to be established.
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Differential gene expression of SMAD family members and 
S1PR1 in circulating CD4+ T cells in multiple sclerosis
L. López Fernández1, A. Lozano Ros2, I. Marín Jiménez3, M.I. 
García García1, M.L. Martínez Ginés2, H. Goicochea Briceño2, 
B. López Cauce3, F. Romero Delgado2, J.M. Garcia Dominguez2
1Pharmacy, 2MS Unit, 3Gastroenterology, Hospital General 
Universitario Gregorio Marañón, Madrid, Spain
Background: CD4+Th17 cells play a predominant role on T cell-
mediated immunity on Multiple Sclerosis (MS). Previously, we 
showed that SMAD7 and S1PR1 were differentially regulated in 
relapsing-remitting MS (RRMS) patients versus healthy donors 
(HD). SMAD family mediates signalling of the TGF-ß pathway, 
related to Th1/Th17 shift in autoimmune CNS inflammation. 
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Sphingosine 1-phosphate regulates lymphocyte egress from lym-
phoid organs. To date, conflicting data about SMAD member’s 
expression and S1PR1 have been described in RRMS. In Crohn’s 
disease (CD), another autoimmune condition, SMAD7 is clearly 
upregulated in the gastrointestinal mucosa.
Objectives: To compare gene expression changes of SMAD 
members and S1PR1 in RRMS, compared to CD patients and HD.
Methods: PBMCs were purified by gradient density from 20 ml 
of fresh blood. CD4+ T lymphocytes were isolated by negative 
selection and magnetic separation. RNA was isolated from CD4+ 
T cells and cDNA transcribed. SMAD2, SMAD3, SMAD4, SMAD7 
and S1PR1 genes were quantified by qRT-PCR in 20 HD, 20 
RRMS patients without disease activity, 40 RRMS patients during 
a relapse, and 20 CD patients on active relapse. False discovery 
rate corrected by Benjamini-Hochberg was calculated for com-
parisons between groups.
Results: Compared to HD, we found SMAD7 and SMAD3 were 
underexpressed in stable RRMS patients (-3.2x-fold and -1.4x-fold, 
respectively). SMAD7 (-2.4x-fold), SMAD4 (-1.2x-fold) and 
S1PR1 (-1.4x-fold) were downregulated in RRMS patients during 
a relapse. Finally, all analyzed genes were downregulated in active 
CD patients (SMAD7, -4.8x-fold; SMAD4, -1.7x-fold; SMAD3 
-1.9x-fold; SMAD2, -1.3x-fold and S1PR1, -1.7x-fold).
Conclusions: Transcription of SMAD family members and S1PR1 
gene is lower in RRMS patients during both relapsing and remit-
ting phases, and in active Crohn disease patients.
Disclosure
Work with funding by Genzyme, as Young Investigator´s Award 
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Evaluation of neutrophil lymphocyte ratio in multiple scle-
rosis
A.E. Gürsoy, Z.C. Renk, T. Asil
Department of Neurology, Bezmialem Vakif University, Medical 
Faculty, İstanbul, Turkey
Background: Neutrophil-to-lymphocyte ratio (NLR) is usually 
considered as a simple and cost effective parameter to evaluate 
inflammatory status. Studies have shown high NLR values in 
cases of acute or chronic inflammation, such as acute pancreatitis, 
chronic tonsillitis, acute mesenteric ischaemia, coronary artery 
disease, heart failure, diabetes mellitus, psoriasis and other malig-
nancies. There are very few studies examining the relationship 
between multiple sclerosis (MS) and NLR.
Aims: The aim of this study was to investigate NLR in patients 
with MS in relapse and during remission.
Methods: In this study we analyzed data of patients with a diag-
nosis of MS according to revised Mc Donald criteria who admit-
ted to our hospital between September 2016 and April 2017. 
Patients who have infection, chronic diseases such as diabetes 
mellitus, hypertension, malignancy, liver disorders, kidney disor-
ders, other autoimmune diseases and patients recieving 
Fingolimod, Dimethyl fumarate and Natalizumab treatment were 
excluded from the study. Blood samples were collected before 
treatment with intravenous corticosteroids in patients with relapse. 
Complete blood counts as well as demographic and clinical data 
from MS patients were evaluated.
Results: Nintynine MS patients (36 patients in relapse; 63 patients 
in remission) were included in the study . The neutrophil count 
was significantly higher in patients who were in relapse than in 
patients in remission (5.90±2.88 x 109/L vs. 4.24±1.54 x 109/L; p 
= 0.001). Altough lymphoctye count was found higher in patients 
during relapse than in patients in remission (2.36±1.11 x 109/L vs. 
2.06±0.7 x 109/L) this difference was not statistically significant 
(p=0.122). NLR was significantly higher in patients with relapse 
than patients in remission (3.79±0.6 vs. 1.26±0.17).
Conclusions: NLR may be a simple and inexpensive laboratory 
method to evaluate inflammmation in MS patients but further pro-
spective studies with the high number of patients and long follow-
up time are needed.
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Multiple arboviral infections and the risk of development of 
neurological complications
R. Dias Molina1, R. Zalewsky1, A. de Moura Brasil Matos2, F. 
Martins Maia3, R. Costa Pires3, D. Malta Lima3, S. Dornelas 
Mesquita4, F. Falcão Albuquerque4, M.L. Brito Ferreira4, D. 
Cantarelli Machado1, D. Kazutoshi Sato1
1Brain Institute of Rio Grande do Sul, Pontifical Catholic 
University of Rio Grande do Sul, Porto Alegre, 2General 
Hospital of Fortaleza, 3University of Fortaleza (UniFor), 
Fortaleza, 4Restoration Hospital, Recife, Brazil
Introduction: There was a sharp increase of patients with periph-
eral nervous system (PNS) disorders such as Guillain-Barré 
Syndrome (GBS) and central nervous system (CNS) disorders 
after the outbreak of the arbovirus infections in Brazil. However, 
it is unclear which patient is at an increased risk to develop neuro-
logical complications after Zika (ZIKV), Chikungunya (CHIKV), 
and Dengue (DENV) infections.
Objective: To evaluate the seropositivity for ZIKV, CHIKV and 
DENV in patients with neurological complications after arbovi-
ruses infections, and assess antibodies against aquaporin-4 
(AQP4) and myelin-oligodendrocyte glycoprotein (MOG).
Methods: We evaluated 35 patients from 2 centers in the Northeast 
of Brazil (Fortaleza and Recife) who presented with neuroimmu-
nological disorders after arboviruses infection. We detected serum 
IgM and IgG antibodies against ZIKV, CHIK, DENV using 
ELISA kits. Anti-AQP4 and anti-MOG were tested using the cell-
based assay.
Results: Among the total of 35 patients, the majority (n=21) had 
PNS manifestations - nineteen (90.4%) had GBS and two patients 
(9.5%) developed chronic inflammatory demyelinating polyra-
diculoneuropathy (CIDP). Thirteen of 21 (61.9%) patients were 
positive for two viruses - 12/13 DENV+ZIKV and 1/13 
DENV+CHIKV. Two of 21 (9%) patients were positive for all 
three viruses DENV+CHIKV+ZIKV. Six of 21 (28.6%) patients 
were positive only for DENV. The remaining 14/35 (40%) patients 
developed CNS complications (myelitis, encephalitis and optic 
neuritis). Eight of 14 (57%) patients had positivity for two or three 
viruses - 2/14 ZIKV+DENV, 3/14 CHIKV+DENV, 3/14 
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DENV+CHIKV+ZIKV. The remaining six patients were positive 
for one virus (5/14 DENV; 1/14 CHIKV). None of the patients 
had AQP4 antibodies and one patient was anti-MOG IgG positive 
(positive for ZIKV+DENV IgG).
Conclusion: Multiple viral infections may increase the risk of 
development of neurological complications. The development of 
autoantibodies such as anti-AQP4 and anti-MOG in those patients 
is rare.
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Effect of serum of patients with optic neuromyelitis on the 
differentiation of neural stem cells. Preliminar study
Y. García Ávila1, L. Gallego Villarejo1, V. Pytel1,2, M.S. Benito 
Martín1, L. Moreno Jiménez1, L. Torre Fuentes1, Á. Gómez 
Graña1, J. A. Matías-Guiu1,2, I. González-Suárez2, C. Oreja-
Guevara1,2, U. Gómez Pinedo1, J. Matías-Guiu1,2
1Neuroscience, San Carlos Institute for Health Research 
(IdISSC), 2Neurology, Hospital Clínico San Carlos, Madrid, 
Spain
Background: Optic neuromyelitis (NMO) is an autoimmune, 
demyelinating, and neurodegenerative disease that primarily affects 
the optic nerve and spinal cord. AQP4-IgG (IgG-NMO), a specific 
autoantibody against aquaporin 4 channel is expressed in certain 
areas of the brain and some particular cells, such as astrocytes, has 
been linked to the etiopathogenesis of the disease. Our aim was to 
evaluate in vitro the effect of this immunoglobulin on the prolifera-
tion and differentiation capacity of neural progenitor cells in culture 
to elucidate the possible role of the antibody in the disease.
Methods: Serum samples from six patients diagnosed with NMO 
and seropositive for IgG-NMO and four healthy controls were 
used Neurospheres were extracted from young BALB/c mice and 
cultured in complete medium (DMEM supplemented with hor-
mone mix, trophic factors and 5% FBS), at passage 5 the neuro-
spheres were divided into three groups and the culture media were 
supplemented with: 2% HC serum; 2% of patients serums with 
NMO and sham which only contained the culture medium; after 
10 days of differentiation the neurospheres were fixed for later 
analysis by immunohistochemistry for the identification of Tuj1, 
GFAP and OLIG2.
Results: In the neurosphere cultures, alterations in the differentia-
tion were observed, showing a lower rate of OLIG2 cells (Sham: 
20,22 ± 3,2; HC: 21,6 ± 2.4; NMO: 8,93 ± 3,7; P < 0.05). Higher 
number of GFAP positive cells in patients with NMO compared to 
sham and HC (Sham: 64,04 ± 3,2; HC: 60,9 ± 4,5; NMO: 80,82 ± 
2, 5; P < 0.05) were observed. In the differentiation to the neuronal 
strain only Tuj1 decrease was found (Sham: 15,74 ± 2,6; HC: 17,5 
± 1.5; NMO: 10,82 ± 3,3; P < 0.05).
Conclusions: The serum affects the proliferation and differentia-
tion of the neurospheres in the different cell lineages, mainly com-
promising the number of neuronal cells and oligodendroglia.
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Cell mechanical phenotyping of peripheral blood leukocytes 
in multiple sclerosis patients
K. Akgün, P. Shalchi Amirkhiz, T. Ziemssen
Center of Clinical Neuroscience, University Hospital Carl 
Gustav Carus, Dresden, Germany
Background: There is a growing interest on modulation of bio-
physical properties of immune cells. Cell deformation and 
mechanical phenotyping is of special interest as cytoskletal altera-
tions are supposed to be intimately connected with important cell 
function. The real-time deformability cytometry (RT-DC) is a 
novel method to characterize mechanical properties of cells. 
Previous reports presented how RT-DC can distinguish cell-cycle 
phases, stem cell differentiation and cell populations in whole 
blood by their mechanical fingerprints. It is discussed, that physi-
ological and pathological changes could be reflected by mechani-
cal phenotyping. Only few data are available regard mechanical 
phenotyping in immune cells and no studies are available in MS.
Methods: With RT-DC large populations of cells can be analyzed 
regard cytoskeletal alterations. Cells are flowed through a micro-
fluid channel constriction and deformed by shear stress and pres-
sure gradients. First, deformation of different immune cell 
subtypes was evaluated. By in vitro analyses changes in deforma-
tion of different lymphocyte subtypes and antigen-presenting cells 
upon maturation and activation were investigated. Additionally, 
differences in cell mechanical properties between MS patients and 
healthy controls were evaluated. Impact of monoclonal-antibody 
therapies were assessed.
Results: There are distinct differences in deformation between 
lymphocytes and monocytes/granulocytes in investigated blood 
samples. Upon stimulation and maturation T cell subtypes pre-
sented increased deformation compared to immature state. 
Additional analyses over time as defined by time kinetic meas-
urements presented selective changes in degree of deformation 
with development and selection of different subgroups defined 
by various degrees in deformation. There were distinct changes 
in deformation of peripheral immune cell subtypes directly 
after monocloncal-antibody application including natalizumab, 
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alemtuzumab and ocrelizumab treatment in MS patients. Impact 
on deformation differed between acute versus long-term effects 
during monoclonal antibody therapy.
Conclusion: Here we present distinct patterns of cell mechanical 
characteristics of different peripheral immune cell subtypes and 
its modulation during maturation and activation. First data indi-
cate selective impact on cell mechanical properties during treat-
ment. Further studies will elucidate how cell mechanical 
phenotyping can act as biomarker in clinical practice.
Disclosure
K. Thomas received personal compensation for from Novartis, 
Biogen Idec and Roche for consulting service. Ziemssen received 
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Background: Fingolimod (FTY720) is one of the first-line thera-
pies for relapsing-remitting multiple sclerosis (RRMS), which 
sequesters T-cells to lymph nodes through functional antagonism 
of sphingosine-1-phosphate 1 receptor, thereby reducing the num-
ber of potential autoreactive cells migrating to the central nervous 
system.
Objective: To evaluate an extensive panel of leukocyte subpopu-
lations in peripheral blood as potencial biomarkers of therapeutic 
response to fingolimod.
Methods: Longitudinal analysis of T, B, NK, monocyte and den-
dritic-cell subpopulations was performed by multiparametric 
flow-cytometry in 45 RRMS patients at baseline and after +1, +3, 
+6 and +12 months of fingolimod treatment. Data were analyzed 
using Kolmogorov-Smirnov test. In case of no-normal distribu-
tion, Wilcoxon, U-Mann Whitney or Kruskal-Wallis test were 
used, as appropriate.
Results: Fingolimod treatment induced a severe lymphopenia 
affecting mainly T and B cells. However, an relative increase of 
Tregs (memoryTreg: baseline: 3.8 ± 1.0 % vs month +1: 8.8 ± 4.4 
% and activatedTreg: baseline: 1.5 ± 0.7 % vs month +1: 3.7 ± 2.1 
%, p < 0.001) and transitional B- cells (baseline: 10.5 ± 12.3 % vs 
month +1: 18.7 ± 14.6 %, p < 0.001) was observed. Interestingly, 
lymphocyte subpopulations were significantly different in 
responder patients already at baseline, highlighting a lower 
percentage of Recent Thymic Emigrants (responder: 4.0 ± 1.4 % 
vs non-responder: 7.4 ± 1.9 %, p < 0.000).
Patients that suffered clinical relapses during follow-up had higher 
percentage of CM CD4+ (relapsed: 36.1 ± 8.8 % vs non-relapsed: 
27.2 ± 5.2 %, p < 0.05) as well as Th1Th17 (Th1Th17 TCM: 
relapsed: 15.4 ±6.2% vs non-relapsed; 10.5 ± 4.1%, p < 0.05) at 
baseline compared to relapse-free patients.
Conclusions: These results support that immune-monitoring of 
minor lymphocyte subpopulations in peripheral blood is a power-
ful tool for the management of patients under fingolimod treat-
ment that may be extrapolable to other immunotherapies.
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Cerebrospinal fluid B-cell phenotype and intrathecal IgG 
synthesis suggest a local on-going follicular reaction in mul-
tiple sclerosis at clinical onset
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Background: Multiple sclerosis (MS) is characterized by multi-
ple immunological dysfunctions that lead to the expansion of T 
and B autoreactive clones and to intrathecal anti-central nervous 
system (CNS) antibody production. Although cerebrospinal fluid 
(CSF) B cells are easily accessible and may reflect relevant 
immune-pathological events within meninges and brain paren-
chyma, they have been poorly studied so far.
Aim: To characterize CSF B-cell subsets at clinical onset in order 
to evaluate their diagnostic and prognostic value.
Methods: Paired CSF and serum samples were obtained from 17 
patients (13 RRMS, 4 CIS) and 20 individuals affected by not-
inflammatory neurological diseases (NIND). The intrathecal IgG 
synthesis was evaluated by means of quantitative formulae and the 
demonstration of IgG oligoclonal bands (IgGOB). B cell subsets in 
the CSF were analyzed by Flow-Cytometry and classified in naive B 
cell (CD19+CD20+CD27-), memory B-cells (CD19+CD27+), plas-
mablasts (PB, CD19+CD27++CD38++CD138-) and plasmacells 
(PC, CD19+CD27++CD38++CD138+).
Results: Mild CSF pleocytosis (8.9cell/ul± 6.9) and detectable 
B-cells (2.0%± 0.5 of nucleated CD45+ cells) were found in 
RRMS patients but not in NIND (1.1cell/ul± 0.8) B cell (0.2±0.0). 
Memory B cell significantly varied among patients (60.7%±20.3 
of CD19+), as well as PB (35.2 ± 15.1 of CD19+CD27+) and PC 
(64.1±14.7 of CD19+CD27+). Of note, no PB or PC could be 
detected in CIS patient. A mild correlation was observed between 
whole B cell and quantitative indexes of intrathecal IgG synthesis 
(r:0.6, p< 0.05 for both IgG Index and IgGIF). Further correlation 
analysis between quantitative indexes of intrathecal IgG synthesis 
and single B-cell subsets disclosed a strong correlation with PC (r: 
0.89, p< 0.05 and r: 0.90, p< 0.05, respectively), and a correlation 
trend, even if not statistically significant, with PB (r: 0.80, p=0.055 
and r: 0.68, p=0.137, respectively).
Conclusions: The correlation between CSF PC/PB and quantita-
tive indexes of intrathecal IgG production supports an on-going 
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follicular reaction. Whether this phenomenon is intrathecally-
exclusive or occurs in the periphery as well, will need coupled 
analysis of CSF and blood samples investigations. Even though 
preliminary, the absence of PB and PC in CSF of CIS patients 
could suggest a role of these subsets in the conversion to clinically 
defined MS. Larger population and long-term follow-up will help 
to evaluate their diagnostic and prognostic values in MS.
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Disturbance of human brain endothelial barrier function via 
chemokine receptor CXCR2
A. Haarmann1, M. Schuhmann1, G. Stoll1, M. Buttmann1,2
1Department of Neurology, University of Würzburg, Würzburg, 
2Department of Neurology, Caritas Hospital Bad Mergentheim, 
Bad Mergentheim, Germany
Background: Recruitment of myelin-reactive CD4+ T cells to the 
CNS across the blood-brain barrier (BBB) is considered critical in 
the pathophysiology of multiple sclerosis (MS). There is emerg-
ing evidence, however, that also innate immune cells contribute to 
MS pathophysiology. Levels of the neutrophil-attracting 
chemokines CXCL5 and CXCL8 are elevated in plasma and cer-
ebrospinal fluid of patients with MS and CXCL5 levels positively 
correlate with disease activity. Interestingly, CXCR2, a high affin-
ity receptor for CXCL5 and CXCL8, is not only expressed on 
leucocytes, but also on non-hematopoietic cells including 
endothelium. This prompted us to evaluate the expression and 
function of CXCR2 in human brain endothelium.
Methods and results: Here we demonstrate that resting human 
brain endothelial cells (hCMEC/D3 cell line) express low levels 
of CXCR2. Both in response to inflammatory stimulation with 
TNFα, IL1β or TNFα + IFNγ as well as after hypoxia (1% O2), 
CXCR2 protein expression is up-regulated, as demonstrated by 
Western blot analysis. This is preceded by a corresponding 
increase in CXCR2 mRNA levels. For label-free real-time assess-
ment of transendothelial resistance, cells were cultivated in an 
ACEA xCELLigence DP system, until they formed a confluent 
monolayer with tight junction formation, as indicated by a stable 
plateau of the cell index. Physiologically relevant, low nanomolar 
concentrations of recombinant CXCL5 and CXCL8 caused a 
dose-dependent and long-lasting decrease in transendothelial 
resistance of resting cells. This barrier-perturbing effect was fur-
ther pronounced under inflammatory conditions and attenuated by 
pre-incubation with a specific CXCR2 inhibitor, suggesting a 
CXCR2-dependent mechanism.
Conclusions: CXCR2 is expressed on human brain endothelium 
and its expression is highly inducible by inflammatory stimuli or 
hypoxia. The neutrophil-attracting CXC chemokines CXCL5 and 
CXCL8 perturb barrier function of human brain endothelial cells 
via CXCR2. This mechanism may contribute to BBB breakdown 
and lesion formation in MS and represent a novel therapeutic 
target.
Disclosure
Axel Haarmann, Michael Schuhmann, Guido Stoll and Mathias 
Buttmann have nothing to disclose.
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Fractalkine (CX3CL1) in the sera of patients with multiple 
sclerosis and Neuro-Behcet’s disease
C. Irkec1, T. Kuz1, T. Altıparmak1, I. Fıdan2
1Neurology, 2Medical Microbiology and Immunology, Gazi 
University Medical Faculty, Ankara, Turkey
Chemokines are inducible cytokines. Priorly they known as a 
chemotactic factors, but now they considered in various condi-
tions. Fractalkine (CX3CL1) is a unique chemokine that can exist 
in a soluble form, as a chemotactic cytokine, or in a membrane-
attached form that acts as a binding molecule. It is constituvely 
expressed in central nervous system (CNS).Especially on neu-
rons, endothelial cells, microglias. Microglia are the main repre-
sentatives of the immune system in the healthy brain. 
Inflammation and neuronal damage cause to increase levels of 
this chemokine. CX3CL1 can reduce neuroinflammation and has 
a neuroprotective role in CNS by reducing neurotoxicity and 
microglial activation.
The objective of this study is to analyze the link of fractalkine 
levels in NeuroBehcet’s disease and multiple sclerosis (MS) for 
examine whether this chemokine has a possible diagnostic or a 
teuropathic target. Twenty NBD, 25 relapsing- remiting MS, 15 
chronic progressive MS, 15 clinically isolated syndrome, 14 radi-
ological isolated MS patients and 30 healthy controls have been 
included in this study. Serum samples has been measured using 
enzyme-linked immunosorbent assay (ELISA) method.
As a result, serum levels of CX3CL1 were significantly high in 
RRMS than other groups. Compared with healthy control groups 
there wasn’ t any significant difference between NBD group but 
again in MS groups fractalkine levels were shown high levels.
These results suggest that, NBD is a nonspecific inflammatory 
condition compared to autoimmune mediated disorders such as 
MS. In literature fractalkine was studied especially in Alzheimer’s 
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disease and it was shown that CX3CL1 has various effects. It can 
suppres the production of nitric oxide (NO) . NO, related to the 
increased levels of IFN-γ and TNF-α. Also it released from hip-
pocampal cells after excitotoxic insult has an essential role in 
brain protection by reducing against glutamate mediated excito-
toxicity. Moreover CX3CL1/CX3CR1 regulate the activation of 
microglia by controlling the release of inflammatory cytokines 
and synaptic plasticity and cognitive functions by modulating 
receptors in neurons. Consequently in inflammatory conditions 
this chemokines has a noteworthy roles for neuroprotection and 
antiinflammation. We also shown that CX3CL1 has a possible tar-
get for monitoring the prognosis of MS patients and in future it 
will be a promissing new therapeutic target.
Disclosure
Ceyla Irkec et al.: Nothing to disclosure
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25 hydroxyvitamin D and cytokines in Bulgarian patients 
with multiple sclerosis
G.S. Slavov1, A.G. Trenova1, M.G. Manova1, I.I. Kostadinova2, 
Z.I. Zahariev1
1Department of Neurology, 2Department of Pharmacology, 
Medical University of Plovdiv, Plovdiv, Bulgaria
Background: Experimental and clinical studies have demon-
strated immunomodulatory effect of vitamin D on the risk of 
developing experimental allergic encephalomyelitis (EAE), mul-
tiple sclerosis (MS) and correlation with the neurological deficit. 
Disputable questions are: vitamin D serum concentration neces-
sary to suppress the immune response; subgroup of MS patients 
suitable for vitamin D treatment; optimal effective balance 
between and safe dosage of vitamin D.
Objective: To evaluate changes in serum concentration of 25(OH)
D, IL4, IL10, TGFB1, IL17A, IFN-gamma,TNF-alpha in MS 
relapse and remission, and their correlation with patients’ degree 
of disability.
Methods: A prospective, case-control study comprised 86 per-
sons (18-50 years age) from Caucasians community dwelling at 
41.5-42 northern latitude, who were registered during the astro-
nomical winter period (October-May). Within these: 46 patients 
with relapsing-remitting MS (RRMS) according to McDonald 
criteria(2010),mean age 37±1.83 years, mean disease duration 
7.17 ±1.17 years, Expanded Disability Status Scale (EDSS) score 
1.5-5.0; 40 healthy controls matching by age and gender. Serum 
25(OH)D and cytokine concentrations were measured by ELISA. 
Statistical methods: alternative, variance analysis, nonparametric 
test, correlation analysis and multiple linear regression analysis.
Results: RRMS patients had considerably lower serum levels of 
25(OH)D than the healthy controls (p=0.09); 25(OH)D concentra-
tions within the deficiency range for Bulgarian population (≤ 
25nmol/l) were detected in 71.7% of the patients during relapse; 
serum 25(OH)D was significantly higher in clinical remission 
than in relapse phase (p=0.024). A significant negative correlation 
was found between 25(OH)D levels and EDSS in relapse (r= 
-0.416, p=0.004); 25(OH)D deficiency increased the risk of MS 
3.43 times.
Significantly higher IL4, TGFβ1 and lower IFN-gamma levels 
were found in remission compared to relapse (p=0.006, 
p=0.009p=0.017).
Multiple Linear Regression Analysis established 25(OH)D, 
TNFalpha, IL17A as significant, independents factors determin-
ing EDSS score in relapse.
Conclusion: Our study showed a protective effect of 25(OH)D on 
the neurological deficit and the risk of developing the disease in 
Bulgarian patients with RRMS. Thus further studies are necessary 
to elucidate the therapeutic potential of 25(OH)D to modify the 
disease course.
Disclosure
Georgi S. Slavov-nothing to disclose
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Ivanka I. Kostadinova-nothing to disclose
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Vascular inflammation markers in multiple sclerosis: pos-
sible role in oligoclonal band formation
R. Türkoğlu1, E. Tüzün2, M. Kürtüncü3, M. Eraksoy3
1Neurology, Haydarpasa Numune Education and Research 
Hospital, 2Institute of Experimental Medicine, Istanbul 
University, 3Neurology, Istanbul University, Istanbul, Turkey
Vascular inflammation has been shown to be involved in condi-
tions that promote chronic systemic inflammation, such as obe-
sity, cancer, autoimmune and infectious diseases. Vascular 
inflammation is regulated by endothelial adhesion molecules, 
chemokines and inflammasome components that are expressed 
mostly by endothelial cells and pericytes. In this study, we aimed 
to analyze the significance of serum and cerebrospinal fluid (CSF) 
levels of vascular inflammation parameters in pathogenesis and 
development of multiple sclerosis (MS).
A total of 19 relapsing remitting MS (RRMS) patients, 18 clini-
cally isolated syndrome (CIS) patients and 20 healthy controls 
were recruited for this study. Patients were in remission and 
were not under immunosuppressive treatment during serum and 
CSF sampling. Disease durations, EDSS scores, relapse num-
bers and oligoclonal band (OCB) status of all patients were 
recorded. Serum and CSF levels of tissue inhibitor of metallo-
proteinases-3 (TIMP3), matrix metallopeptidase 9 (MMP9), a 
disintegrin and metalloproteinase domain-containing protein 15 
(ADAM15), platelet derived growth factor-BB (PDGF-BB), 
NOD-like receptor protein 1 (NLRP1) and NLRP3 were meas-
ured by ELISA.
There were no significant differences between serum and CSF 
levels of CIS and RRMS patients by means of vascular inflamma-
tion parameters, while both groups had higher levels of all param-
eters as compared to healthy controls. CSF but not serum 
PDGF-BB, MMP9, NLRP1 and NLRP3 levels of OCB positive 
RRMS patients were significantly higher than those of OCB nega-
tive patients. There was no correlation between serum/CSF vascu-
lar inflammation parameters and clinical-demographic features of 
RRMS patients.
Vascular inflammation appears to be activated as early as during 
the first MS attack. However, levels of vascular inflammation 
parameters are not altered in a time- or disability-dependent man-
ner and thus cannot be used as indicators of MS conversion or as 
a prognostic biomarker. Increased CSF levels of OCB positive 
patients might be due to enhanced blood-brain barrier 
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permeability and subsequently increased transport of myeloid 
cells or glial cell activation.
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Recai Türkoğlu: nothing to disclose
Murat Kürtüncü: nothing to disclose
Mefkure Eraksoy: nothing to disclose
Erdem Tüzün: nothing to disclose.
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Neuromyelitis optica spectrum disorders with aquaporin-4 
and myelin-oligodendrocyte glycoprotein antibodies in Turk-
ish population:a comparative study
E. İdiman1, F. İdiman1, M. Kaya2, O. Hasankoyoglu1, D. Kaya3, 
H. Limoncu1, O. Bulut1, Z. Altun4
1Department of Neurology, 2Department of Ophthalmology, 
3Geriatrics Medicine, 4Department of Basic Oncology, Instute of 
Basic Oncology, Dokuz Eylül University, Faculty of Medicine, 
Izmir, Turkey
Background: Most patients with NMO/ NMOSD have autoanti-
bodies against aquaporin-4 (AQP4-Ab), but recently, myelin-oli-
godendrocyte glycoprotein antibodies (MOG-Abs) have been 
found in some patients with childhood and adult demiyelinating 
diseases.
Aim: To evaluate the clinical features of patients with NMO/
NMOSD with MOG-Ab and to compare them with patients with 
AQP4-Ab-positive NMO/NMOSD, and multiple sclerosis.
Methods: This observational study was conducted at Dokuz 
Eylul Üniversity Hospital in specialist center for demiyelinating 
disease. We examined AQP4 antibody and MOG antibody in 62 
NMO/NMOSD and 33 Multiple sclerosis (MS) patients with ON. 
Groups were statistically matched age, gender, onset age, disease 
duration and disease severity. The diagnosis of NMO/NMOSD 
was made according to Wingerchuck criteria (2006). Cell-based 
assays were used to test patient serum samples for AQP4-Abs and 
MOG-Abs.
Results: None of thirty-three MS patients with ON had AQP4-Ab 
and MOG antibody. Five patients with atipic agressive demiyeli-
nating disease had both antibodies. In one of 3 ADEM patients 
with LETM, MOG-Ab was positive (all AQP4-Ab negative). In 
only one of 17 LETM patients, MOG-Ab was positive and all of 
them was NMO-IgG negative. MOG antibody was not detected in 
any of 23 NMO patients with AQP4-Ab. In 2 of 10 relapsing ON 
patients MOG antibody and in 1 of the remainig patients AQP4-Ab 
was positive. These patients presented with simultaneous/sequen-
tial severe ON. Only one of 4 patients with area postrema syn-
drome had AQP4-Ab and none of them had MOG-Ab. 
Cerebrospinal fluid characteristics were different in the MS and 
NMO/NMOSD groups. OCBs were determined in 83% of MS 
patients and none of NMO/NMOSD had OCBs.
Conclusion: Only 4.8% of all patients in NMOSD group and 
6.6% of patients in AQP4-Ab negative group had MOG-Ab. A 
higher proportion of AQP4-Ab-positive patients relapsed than 
MOG-Ab positive group despite similar follow-up durations but 
onset episode severity and outcomes from the onset episode did 
not differ between the 2 groups. MS had neither AQP4- Ab nor 
MOG-Ab.
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Carotid intima-media thickness is associated with HLA-
DRB1*15 in multiple sclerosis
A. Oterino, M. Toriello-Suárez, G. Ocejo-Vinyals, J. Irure 
Ventura, S. Gutierrez-González, S. Pérez-Pereda, F. Ausín 
Ortega, V. González-Quintanilla
Hospital Universitario Marques de Valdecilla, Santander, Spain
Background: There is a growing evidence that endothelial func-
tion could be involved in the pathogenesis of multiple sclerosis 
(MS).Previous reports have shown its role in other autoimmune 
disorders like rheumatoid arthritis.
HLA DRB1*15 induces a double risk for having MS. Furthermore, 
in relapsing-remitting MS (RRMS) several markers of inflamma-
tion have been associated with the severity of disease. We have 
investigated the endothelial damage in MS patients measuring 
carotid intima-media thickness (cIMT) and its correlation with the 
levels of inflammation biomarkers.
Methods: A total of 37 patients with RRMS, aged 40.90 ± 8.6, 
median EDSS= 2.0 (range 3.5), were recruited according to 
McDonnald´s 2010 criteria for MS diagnosis. After informed con-
sent, cIMT was measured in these patients, with no other classical 
vascular risk factors. Ultrasonografic images were obtained by a 
blind examiner with an Accuson X300 PE (Siemens) device 
according with ultrasounds protocol. IMT was determined as the 
average of at least three different measurements in the common 
carotid artery. DNA was obtained from peripheral blood by using 
a semi automated method. HLA antigens typification was per-
formed by polymerase chain reaction with sequence-specific oli-
gonucleotides (PCR-SSO) and Luminex analysis. Several 
biomarkers of inflammation were also analysed with the Milliplex 
system in a Luminex 200 platform. For the statistical analysis, 
SPSS v15 was used. Categorical variables were analyzed using 
Chi2 method, and Student T test were used for continuous varia-
bles. ROC curve was calculated to determine the sensibility and 
specificity of the cIMT in predicting those HLA-DRB1*15 posi-
tive MS patients.
Results: EDSS score and demographic features (sex) versus 
presence of HLA-DRB1*15. Patients with the HLA-DRB1*15 
allele (n=14) had cIMT 0.116 mm thicker (mean 1.044 ± 0.15) 
than those lacking this allele (mean 0.928 ± 0.15 mm; p=0.0041). 
There was no correlation between the HLA-DRB1*15 allele 
and several biomarkers of inflammation (Reactive C Protein, 
Erythrocyte Sedimentation Rate, fibrinogen or von Willebrand 
Factor).
Conclusion: For the first time, we found an association of HLA-
DRB1*15 with endothelial damage (cIMT) in patients having 
RRMS. We hypothesized that endothelial dysfunction could be 
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correlated with inflammation and disease activity. Further and 
larger studies should be performed to confirm this association.
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Idec and SANOFI-GENZYME and support for travel to medical 
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Gut microbiota alteration in Clinically Isolated Syndrome: a 
pilot study
S. Rolla1, V. Bardina1, I. Ferrocino2, S. De Mercanti1, M. 
Ferraro1, A. Cianflone3, R. Lanzillo3, L. Durelli1, L.S. Cocolin2, 
M. Clerico1
1University of Turin, Orbassano, 2University of Turin, 
Grugliasco, 3Federico II University, Napoli, Italy
Background: Relatively little is known about what might trigger 
or facilitate the first episode of demyelization in Multiple Sclerosis 
(MS); recent data indicate that the dysregulation of the immune 
system that occurs in MS could be controlled by environmental 
factors. The composition of the gut microbiota structure in terms 
of species richness and distribution, as well as the functional 
potential of the community, can greatly impact the host immune 
system; an imbalance in the gut microbiome has been shown to 
induce a profound alteration of immune responses both in the gut-
associated tissue and in the periphery and could be a risk factor for 
MS.
Aims: As the Clinically Isolated Syndrome (CIS) allows to study 
the disease processes closest to the biological onset of MS, the 
aim of this pilot project was to investigate whether alteration in 
the composition of the gut microbiota could be associated with 
CIS and its immune system alteration.
Methods: Stool and blood samples were collected from 20 CIS 
patients and 20 Healthy Volunteers (HV). DNA isolated from 
stools were subjected to shotgun metagenomic sequencing strat-
egy in order to discover the microbiota composition as well as the 
microbial function. T helper (Th)17 and T regulatory (Treg) cells 
were analyzed by FACS in the peripheral blood (PB).
Results: Our preliminary results indicate a lower abundance of 
Bacteroides and a decrease species richness in CIS patients ver-
sus HV. In the PB, CIS patients displayed an increase of phato-
genic Th17 cells expressing Toll Like Receptor 2 and a decrease 
of Treg cells producing Interleukin-10 and expressing CD39 
compared to HV.
Conclusions: These findings indicate that gut microbial dysbiosis 
could exist at the onset of MS and could be suggestive of a pro-
inflammatory milieu observed in the periphery. The analysis on 
metagenomic content and microbial gene identification will allow 
us to determined the presence/abundance of specific genes that 
can be correlated with CIS in order to design strategies to modu-
late the immune system through alteration of gut microbiome.
Disclosure
Simona Rolla had travel expenses for congress paid by Sanofi-
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Does vitamin D facilitate a chronic inflammatory response in 
multiple sclerosis
M. Lu, B. Taylor, H. Korner
Menzies Institute for Medical Research, University of Tasmania, 
Hobart, TAS, Australia
Background: Multiple Sclerosis (MS) is a chronic inflammatory 
disease of the central nerve system. Multiple types of immune 
cells have been associated with MS aetiology, including mono-
cytes, B cell and T helper (Th) cell subsets. The potential interac-
tion between peripheral immune cells, Vitamin D and MS could 
affect the pathogenic mechanisms of MS and is the focus of this 
study.
Objectives: To investigate the association between peripheral 
immune cell responses, Vitamin D and MS ex vivo and in vitro in 
a case-control study.
Methods: We collected peripheral blood mononuclear cells 
(PBMCs) from 62 people with MS and 12 healthy controls (HC), 
and determined the proportion of immune cell subsets via Flow 
cytometry ex vivo. Furthermore, we stimulated isolated PBMCs 
with ConA (10µg/ml), ConA + 25(OH)D3 (500nM) or ConA + 
1,25(OH)2D3 (100nM) for 96h in vitro. The Th cell subsets were 
analysed via Flow cytometry and the titer of cytokines in superna-
tants was determined via Cytometric Bead Array. The genotypes of 
Vitamin D-associated MS risk-SNPs (rs12368653, rs703842, 
rs2248359) were determined by 3’mismatch PCR. Data were com-
pared using nonparametric tests (i.e., Mann-Whitney, Kruskal-
Wallis and Friedman test).
Results: Ex vivo, the proportion of classic monocytes was 
decreased in monocytes (p=0.0144), while the proportion of B 
cell was increased in PBMCs (p=0.0089) in the MS cohort than in 
HC. In in vitro, for the whole samples, both 25(OH)D3 and 
1,25(OH)2D3 significantly inhibited the production of IL-6 (p< 
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0.01), IL-10 (p< 0.001), TNF (p< 0.001), IFN-gamma (p< 0.001) 
and IL-17A (p< 0.001), and promoted the production of IL-4 (p< 
0.01) by PBMCs after 96hrs of stimulation with ConA. 
Interestingly the HI PBMCs produced more IL-6 (p=0.0171), 
TNF (p=0.0001) and Th1 (p=0.0231) after stimulation with ConA 
for 96h than the MS group. The rs703842 risk allele AA was asso-
ciated with significantly reduced production of IL-2 at 96h 
(p=0.0076). For the whole samples, the rs2248359 risk allele TT 
was associated with an increased proportion of Th17 and Th1 cell 
populations within the CD4+ T cell subset ex vivo and the Th1 
population after 96h ConA stimulation (in vitro).
Conclusions: Peripheral immune cell variations and inflamma-
tory cytokine profiles are influenced by Vitamin D and the MS 
status ex vivo and in vitro supporting a potential role for vitamin D 
in the pathogenesis of MS.
Keywords: peripheral immune cell subsets, Vitamin D, cytokines.
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Osteopontin plasma levels in relapsing remitting multiple 
sclerosis
S. Allahdadian, M. Etemadifar, F. Alsahebfosul
Isfahan Multiple Sclerosis Research Center, Isfahan University 
of Medical Sciences, Isfahan, Islamic Republic of Iran
Background: Multiple sclerosis (MS) is known as a neuro-
inflammatory disease of the central nervous system (CNS). The 
neuroinflammation may induce pro-inflammatory cytokines such 
as the Osteopontin (OPN). OPN plays an important role in the 
inflammation by regulating the THelper1 and THelper17 
responses. Since diagnosis of multiple sclerosis is somewhat of a 
challenge, a reliable diagnostic biomarker that can be easily meas-
ured would be a great diagnostic method.
Objective: In this study we compared OPN plasma levels in adult 
relapsing remitting multiple sclerosis (RRMS) patients.
Method: In a case-control study, plasma was collected from the 
relapsing-remitting multiple sclerosis patients (RRMS) (n=36) as well 
as 35 age matched healthy individuals and a control group. Levels of 
OPN were measured and compared between the two groups.
Result: Mean OPN plasma levels was markedly higher in the case 
group (Mean [SEM], 4240[201.5] pg/ml) compared with the con-
trol group (3419[ 264.5])( p-value=0.008).
Conclusion: Significant higher OPN plasma levels in Relapsing-
remitting multiple sclerosis patients suggest that OPN can be used 
as a diagnostic biomarker.
Keywords: Multiple Sclerosis, Relapsing-remitting multiple 
sclerosis, Osteopontin, Plasma
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Immunity in NeuroBehcet disease
M. Kchaou1, M. Belguith2, K. Bahrini2, J. Hela1, N. Ben Ali1, F. 
Saloua1, E. Slim1, M. Fredj1
1Neurological Department, Charles Nicolle Hospital, 2Pasteur 
Institute, Tunis, Tunisia
Introduction: NeuroBehcet disease (NBD) is the most frequent 
vasculitis in our country. In presence of inaugural neurological 
forms, CSF study is systematic because of diagnosis difficulties.
Objectives: To describe the immunoelectrophoretic and cytokine 
profile in NBD
Patients: Criteria of selection: NBD according to the International 
consensus recommendation (ICR) with definite and probable 
forms including isolated neurological syndrome suggestive of 
NBD. Subjects were consecutive patients who referred to 
Neurological department of Charles Nicolle hospital since 2013. 
Blood and CSF samples are taken from all patients. Cell counting, 
protein analysis, immunoelectrophoretic profile with Ig G Index 
was performed. Cytokines levels were evaluated by PCR.
Result: From 26 NBD recruited 17 had an inaugural neurological 
form of which 15/17 had a parenchymal involvement. The IgG index 
was increased in only 2 patients (8%). At the Immunoelectrophoresis, 
the profile was type 1 in 22 patients (81%), type 2 in 1 patient (3.7%) 
and type 3 and 4 in 4 patients (11%). The study of lymphocyte popu-
lations showed an increase of IL-17, interferon gamma and IL10 lev-
els in 88% of patients.
Discussion: The profile data in CSF of NBD patients in our study 
are in line with those found in the literature. Given the limited data 
on CSF levels of cytokines in patients with NBD, our results 
showed that cytokines make a pivotal role in pathogenesis of NB, 
as evidenced by the conjoining increase of pro and anti-inflamma-
tory cytokines in our patients.
Conclusion: Activation of self-reactive T cells with involvement 
of cytokines and proinflammatory transcription factors is cur-
rently proven in NBD. Implication of B cells can be also proved 
by the presence of oligo-clonal bands.
Disclosure
Nothing to disclose
Microbiology and Virology
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HLA-DRB1*15:01 confers susceptibility to Epstein-Barr 
virus infection to B cells linking genetic and environmental 
risk factors for multiple scleros
J. Menegatti1,2, F. Grässer1, K. Ruprecht2
1Institute of Virology, Saarland University Medical 
School, Homburg, 2Department of Neurology, Charité - 
Universitätsmedizin Berlin, Berlin, Germany
Background: Whereas the exact pathogenesis of multiple sclero-
sis (MS) is still not understood, it is generally accepted that MS 
results from an interplay of genetic and environmental factors. 
The strongest genetic risk factor for MS is the human leukocyte 
antigen (HLA) class II allele HLA-DRB1*15:01. The strongest 
environmental risk factor for MS is infection with the B 
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lymphocytotropic herpesvirus Epstein-Barr Virus (EBV). 
Although it is well-known that EBV uses HLA-DQ, -DR and -DP 
as co-receptors for infection of B cells, it was hitherto unknown 
whether HLA-DRB1*15:01 may act as a co-receptor for EBV 
infection.
Objective: To investigate whether HLA-DRB1*15:01 confers 
susceptibility to EBV infection to a B cell line in vitro.
Methods: We transfected the HLA-DR deficient B lymphoblas-
toid cell line 721.174 (LCL721.174) with plasmids expressing 
HLA-DRB1*15:01, HLA-DRB1*13:03, HLA-DRB1*11:01 and 
DRB1*01:01 and subsequently infected these cells with a recom-
binant EBV encoding green fluorescent protein (EBV-GFP). The 
percentage of EBV-infected cells (i.e. GFP-positive cells) among 
HLA-DR expressing cells was determined by flow cytometry.
Results: While untransfected LCL721.174 and LCL721.174 trans-
fected with an empty vector were not infectable with EBV-GFP, 
transfection with HLA-DRB1*15:01 conferred susceptibility to 
EBV infection to LCL721.174. There was a trend for a higher per-
centage of EBV-infected LCL721.174 among HLA-DRB1*15:01 
compared to HLA-DRB1*13:03, HLA-DRB1*11:01 and 
DRB1*01:01 expressing LCL721.174 (p=0.2, Kruskal-Wallis test).
Conclusion: Our findings show that EBV uses HLA-DRB1*15:01 
as a co-receptor for infection of B cells in vitro, pointing towards 
a potential mechanistic link between the strongest genetic and 
environmental risk factors for MS. Future studies should clarify 
how different HLA class II alleles influence the susceptibility of B 
cells to EBV infection in vivo.
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EP1500
Herpes virus and varicella zoster virus antibodies Index in 
the cerebrospinal fluid of patients with multiple sclerosis 
patients and clinically isolated syndrome
M.E. Evangelopoulos1, G. Karagiorgis1, F. Boufidou2, G. 
Koutsis1, P. Koutsoudaki1, J. Tzartos1, D. Tzanetakos1, E. 
Andreadou1, M. Anagnostouli1, C. Nikolaou2, K. Kilidireas1
1Neutology, 2Department of Clinical Microbiology, Eginition 
University Hospital, Athens, Greece
Varicella Zoster Virus (VZV) and Herpes Virus (HSV) are pro-
posed to play a role in the pathogenesis of Multiple Sclerosis. The 
presence of virus-specific antibodies in the CSF suggests that 
demyelination in MS is accompanied by antiviral immune 
responses mounting an altered immune response against viruses, 
in CNS. The purpose of the study was to evaluate the presence of 
VZV and HSV antibodies in patients with Multiple Sclerosis 
(MS) and Clinically Isolated Syndrome (CIS) both in serum and 
cerebrospinal fluid.
Methods: Ninenty four patients with Multiple Sclerosis were 
studied. Fifty seven patients had relapsing remitting MS (RRMS), 
37 patients had clinically isolated syndrome (CIS) and two with 
radiologically Isolated Syndrome. The presence of VZV and HSV 
antibodies was tested in the serum and cerebrospinal fluid (CSF) 
of all patients
Results: HSV IgG and VZV IgG were detected at increased levels in 
serum in patients with RRMS (HSV IgG 132.8±44.8, VZV IgG 
488.4±165.8) and CIS (HSV IgG 105.2±54.67, VZV IgG 489±165.7). 
However, the VZV IgM and HSV IgM levels in serum were low.
In CSF, IgG values >1.5 were considered to be indicative of 
intrathecal IgG production against the respective pathogen. IgG 
index of HSV and VZV in RRMS was marginally positive in low 
levels (1.4±0.9 and 0.8±0.9 respectively). IgG index of HSV and 
VZV in patients with CIS was 1.1±0.9 and 0.6±0.4 respectively. 
No patient had indication of viral infection in CSF. No HSV IgG 
was detected in CSF of RIS patients
However, increased ΗSV ΙgG index in CSF (>2) was found in 
12/57 patients with RRMS. PCR for VZV and HSV in CSF was 
negative. 5/12 (41%) had negative oligoclonal bands while from 
RRMS patients with negative HSV and VZV index in CSF only 
4/45 (9%) had negative oligoclonal bands, p=0.01. Five patients 
with CIS had increased HSV IgG index. 3/5 CIS patients and 7/12 
RRMS patients with positive HSV IgG index in CSF were in 
relapse with gadolinium enhancement in MRI.
Conclusion: The positivity of HSV and VZV IgM antibodies in 
CSF of MS patients without any sign of infection, might support a 
role of immune response against viruses in disease pathogenesis.
Disclosure
Dr. M.E.Evangelopoulos has received travel grants and consult-
ing fees from Biogen, Novartis, Teva
Dr.E. Andreadou has received travel grants and consulting fees 
from Biogen, Novartis, Teva and Merck-Serono
Dr. G.Koutsis has received travel grants and consulting fees from 
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Dr.M.Anagnostouli has received travel grants and consulting fees 
from Biogen, Novartis, and Merck-Serono
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Environmental factors
EP1501
Dietary intakes of minerals and disability in multiple sclero-
sis; is there any association?
S.P. Moosavian1, M.B. Maljaei2, O. Mirmosayyeb2, V. 
Shaygannejad2, Patients with diagnosed MS
1Neuroscience Research Center | Department of community 
nutrition, 2Isfahan University of Medical Sciences, Isfahan, 
Islamic Republic of Iran
Introduction: Multiple sclerosis (MS) is a chronic demyelinating 
disease of the nervous system which is the most common cause of 
neurological irreversible disability in young adults who are pro-
fessionally and socially active persons. It expresses itself in three 
clinical forms: relapsing remitting MS (RRMS), secondary pro-
gressive MS (SPMS) and primary progressive MS (PPMS). 
Assessment of dietary intakes of mineral is an approach that has 
been used to evaluate diet-disease and diet-disability association.
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Method: 126 patients with diagnosed MS (84 RRMS, 21 PPMS 
and 21 SPMS) with MRI assessment of brain and spinal cord were 
recruited from multiple sclerosis clinic in Kashani Hospital of 
Isfahan University of Medical Sciences, Isfahan, Iran include 
from present cross-sectional study. A 168-item semi-quantitative 
food frequency questionnaire was used for assessment of dietary 
intakes of minerals. Medical history questionnaire, Expanded 
Disability Status Scale (EDSS) and Fatigue questionnaire record 
from all participants.
Results: Mean ± SD of EDSS and fatigue scale in SPMS and PPMS 
groups was significant higher than RRMS group. In addition, there 
was a negative significant association between magnesium and phos-
phorous with fatigue scale among all participants; (r=-0.684; p< 
0.001) for magnesium and (r=-0.792; p< 0.001) for phosphorous, as 
well as calcium and fatigue scale in RRMS (r=-0.921; p< 0.001). In 
addition there was a negative significant association between sele-
nium with EDSS in RRMS (r=-0.490; p< 0.001) and PPMS (r=-
0.896; p< 0.001). Age, gender and blood pressure were not confounder 
variables. In addition, we adjusted energy intakes in subgroups.
Conclusion: Our study demonstrated that there is a negative sig-
nificant correlation between intakes of magnesium and phospho-
rous with fatigue scale among all participants that may due to the 
role of this mineral in energy metabolism. In addition dietary 
intakes of selenium can decrease EDSS in RRMS and PPMS. 
Further studies with larger sample sizes and other population 
needed to prove this correlation.
Keywords: multiple sclerosis, mineral, disability
Disclosure
The authors declared no conflict of interest.
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Clinical relevance of Vitamin D and cholesterol serum levels 
in multiple sclerosis: a real-word data study
J. Pérez-Lucas1,2, S. Fuller2, C. Abhijit2, M. Mattoscio2
1Neurología, Hospital Universitario La Paz, Madrid, Spain, 
2Barking, Havering and Redbridge University Hospitals Trust, 
Queen´s Hospital, Romford, United Kingdom
Objective: Vitamin D(VitD) is known to influence immune sys-
tem function and multiple sclerosis(MS) susceptibility. 
Modulation of serum cholesterol (Chol) level has been shown to 
impact on brain atrophy in MS. This study wanted to investigate 
correlation between VitD and Chol in MS and their association 
with MS activity and disability progression(DP).
Methods: We reviewed medical records, laboratory data and MRI 
of subjects newly diagnosed with MS at our specialist center 
between January2014 and February2017.
We analyzed association between hypovitaminosis D(HypoD) 
and hypercholesterolemia(HyprCh) with MRI activity (MRIa) 
when blood sampling and imaging acquisition were less than 120 
days(d) apart, and between HypoD or HyprCh less than 120d 
apart from 1stclinic assessment with occurrence of relapses, MRIa 
and DP at follow up (mean 492d,range0-2260d).
Finally, we evaluated correlation between VitD and Chol meas-
ured in the same sample at all time-points.
We defined HypoD as VitD< 30nmol/L, HyprCh as Chol>5mmol/L, 
DP as increase of EDSS≥1point after up to 2years and MRIa as 
presence of T1 gad-enhancement and/or new T2lesions.
Results: 72 patients were included (71% female, mean age 
44±14years): 30% were receiving disease modify treatment, 15% 
statins and 70% VitD supplements (VitDs).
Baseline MRI was performed ≈ 120d before 1st clinic attendance 
(Median -123d, -2937d-239d); 2nd MRI was performed a median 
of 364d (41d-2652d) after 1st MRI; 3rdMRI was done a median of 
392d (50d-1344d) after 2nd MRI.
Baseline HypoD significantly associate with occurrence of 
relapses during follow up (χ²,p< 0,05). HypoD does not associate 
significantly with MRIa at any time-point nor with DP at 2 years; 
a trend was observed for association between HypoD and new 
T2lesions in 2ndMRI( χ²,p=0,08). MS patients who had 3rdMRI 
had normal VitD (69% on VitDs).
HyprCh at baseline and follow up did not associate with MRIa, 
occurrence of relapses or DP at any time point; a trend was 
observed for association of HyprCh and new T2lesions in 
3rdMRI(χ²,p=0,06).
Serum VitD inversely correlate with Chol (Pearson´s r-0.22, p< 0.01).
Conclusion: HypoD impacts on early MS clinical activity and 
VitD and Chol serum levels are inversely correlated. This evi-
dence support the need for further studies looking at the effect of 
VitD and Chol on MS pathophysiology and clinical course.
Disclosure
Dr Josefa Pérez Lucas: nothing to disclosure.
Mrs Sarah Fuller has nothing to disclose.
Dr Chaudhuri has received speaker honoraria from Biogen Idec, 
Genzyme and Novartis.
Dr Mattoscio has received speaker honoraria form Novartis and 
Merk Serono and travel support from Biogen Idec, Novartis, 
Genzyme and Teva.
EP1503
Fats and multiple sclerosis; association between fats/oils 
intake and disability in patients with MS
M.B. Maljaei1, O. Mirmosayyeb2, V. Shaygannejad2, S.P. 
Moosavian2
1Isfahan Neuroscience Research Center, 2Isfahan University of 
Medical Sciences, Isfahan, Islamic Republic of Iran
Introduction: Multiple sclerosis (MS) is a chronic demyelinat-
ing disease of the nervous system which is the most common 
cause of neurological irreversible disability in young adults who 
are professionally and socially active persons. Due to the variable 
clinical course of MS, it is classified into relapsing and progres-
sive phases and three phenotypes of relapsing remitting MS 
(RRMS), primary progressive MS (PPMS), and secondary pro-
gressive MS (SPMS ). Assessment of dietary intakes of fats is an 
approach that has been used to evaluate diet-disease and diet-
disability association.
Method: 126 patients with diagnosed MS (84 RRMS, 21 PPMS 
and 21 SPMS) with MRI assessment of brain and spinal cord were 
recruited from multiple sclerosis clinic in Kashani Hospital of 
Isfahan University of Medical Sciences, Isfahan, Iran include 
from present cross-sectional study. A 168-item semi-quantitative 
food frequency questionnaire was used for assessment of dietary 
intakes of fatty acids. Medical history questionnaire, Expanded 
Disability Status Scale (EDSS) and Fatigue questionnaire record 
from all participants.
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Results: Mean ± SD of EDSS and fatigue scale in SPMS and 
PPMS groups was significant higher than RRMS group. There 
was a negative significant correlation between intakes of Polly 
Unsaturated Fatty Acids (PUFAs) including Linolenic 
Acid(r=-0.418, p=0.018), Linoleic Acid(r=-0.312, p=0.031) with 
EDSS in all participants. In addition, There was a negative signifi-
cant correlation between intakes of Mono Unsaturated Fatty Acids 
(MUFAs) (r=-0.348, p=0.028) with EDSS in all participants. 
Correlation between Saturated Fatty Acids(SFAs) with EDSS 
(r=0.465, p=0.009) and fatigue scale (r=0.298, p=0.043) was sig-
nificantly positive in all participants. Although correlation 
between total dietary fats with EDSS and fatigue scale in all par-
ticipants and subgroups were positive, but was not significant. 
Age, gender and blood pressure were not confounder variables. In 
addition, we adjusted energy intakes in subgroups.
Conclusion: Our study demonstrated that there is a positive sig-
nificant correlation between intakes of SFAs with EDSS and 
fatigue scale in all participants. In addition dietary intakes PUFAs 
and MUFAs can decrease EDSS in all patients with MS. Further 
studies with larger sample sizes and other population needed to 
prove this correlation.
Keywords: Expanded Disability Status Scale, Fatigue, Polly 
Unsaturated Fatty Acids, Mono Unsaturated Fatty Acids, Saturated 
Fatty Acids
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The authors declared no conflict of interest.
EP1504
Vitamin D level and quality of life in patients with multiple 
sclerosis
Y. Beckmann, S. Türe, C. Uzunköprü, Y. Seçil, T.K. Incesu
Izmir Katip Celebi University, Izmir, Turkey
Object: Vitamin D status is associated with the incidence and 
prevalence of a variety of neurologic disorders, including multi-
ple sclerosis. Several studies suggest or support that multiple 
sclerosis has increased prevalence in geographic areas with 
lower sunlight levels. We aimed to investigate the correlation 
between vitamin D level and quality of life in patients with mul-
tiple sclerosis who were exposed to sunny seasons within one 
year in western Turkey.
Method: This follow-up study included 200 MS patients with a 
serum baseline 25(OH)D3 level, Expanded Disability Status 
Scale (EDSS) and multiple sclerosis quality of life questionnaire 
(MSQOL-54) with a follow-up of one year. Serum 25(OH)D was 
classified into the following categories: less than 25, 25-50, and 
50 nmol/L or greater. Patients with vitamin D levels less than or 
equal 30ng/ml were administered vitamin D supplementation with 
an average weekly dose of 50.000 IU until vitamin D levels 
became normal, and then maintance daily dose of 4000 IU. All 
patients underwent interview and MSQOL-54was evaluated at 
baseline, 1 month, 3 months, 6 months, and 12 months after the 
beginning of vitamin D administration.
Results: Of 200 multiple sclerosis patients, 185 (92.5%) had 
lower vitamin D level. Patients reported no side effects during the 
study. The increase in Vitamin D level from baseline to 12 months 
was significant (p < 0.0001). The improvements remained signifi-
cant in all categories of MSQOL-54 after the vitamin D 
administration (p< 0.001). According to our results, the longer 
vitamin D use the higher improvement of quality of life.
Conclusion: Little is known regarding the effect of vitamin D 
supplementation on quality of life. Also, the evidence for a benefi-
cial effect of long-term vitamin D supplementation on health-
related quality of life is lacking. This study showed that the 
prevalence of vitamin D level is still low in geographic areas with 
higher sunlight levels, and also, when vitamin D deficiency or 
insufficiency was corrected, there was indeed a positive effect on 
quality of life of patients.
Disclosure
nothing to disclose
Neurobiology
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Moving from systemic to central nervous system inflamma-
tion: the role of A20 in the neuropathology of multiple scle-
rosis
S. Perga1, F. Montarolo1, S. Martire1, B. Bonaldo1, G. Bono1, G. 
Panzica2, A. Bertolotto1
1Neurobiology Unit and Neurologia 2 - CReSM (Regional 
Referring Center of Multiple Sclerosis), Neuroscience Institute 
Cavalieri Ottolenghi (NICO) University of Turin & AOU San 
Luigi Gonzaga, Orbassano (TO), 2Neuroscience Institute 
Cavalieri Ottolenghi (NICO), Laboratory of Neuroendocrinology 
and Department of Neuroscience, University of Torino, 
Orbassano, Italy
Multiple sclerosis (MS) is a chronic demyelinating disease of 
the central nervous system (CNS) in which inflammation plays 
a key pathological role. The anti-inflammatory enzyme A20 is 
considered a central gatekeeper in inflammation and immunity 
through the inhibition of NF-kB. Polymorphisms in A20 
genomic-region has been recently associated to MS and we 
observed an A20 down-regulation in peripheral blood cells of 
MS patients, mainly due to monocytes, correlated to a worst 
clinical course.
Recent evidences showed that systemic inflammation induces 
increasing cell infiltration within the brain parenchyma, triggering 
resident microglial ad astrocytic activation. Considering the criti-
cal role of A20 in systemic inflammation regulation, a function of 
A20 in the CNS was hypothesized. Supporting this, the presence 
of A20 transcript and proteins belonging to A20-complex were 
newly demonstrated in control human brain. Moreover, A20 dele-
tion in neuroectodermal cells worse the clinical course of the MS 
murine model. From this picture, clearly emerges a double role of 
A20 in central nervous and immune system.
Here we aimed to unveil the contribution of A20 to the CNS MS 
pathology, studying for the first time A20 expression in human 
post-mortem MS brain tissues.
We demonstrated that A20 is present in control human brain tissues 
in both white matter, mainly in parenchymal astrocytes and in grey 
matter, in neuronal cells. In MS brain, we observe a massive A20 
expression in the lesions in both perivascular infiltrates and rami-
fied cells. In particular, in active and pre-active lesions, A20 is 
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expressed in the active core, whereas in chronic active lesions, A20 
is mainly expressed on the active-margin. Preliminary double 
immunofluorescence staining unveiled that A20 is expressed in 
both AL and CAL by infiltrating macrophages and by resident acti-
vated astrocytes and a subpopulation of microglial cells. Coherently, 
chronic activation of NF-kB pathway in infiltrating and resident 
CNS seems an hallmark of the neurodegenerative process occurring 
in MS patients. In this view, the massive A20 activation in the active 
plaques could represent a defensive mechanism contributing to the 
inflammation resolution and the regeneration processes.
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The unglycosylated KIR4.1 extracellular domain constitutes 
an autoimmune target in multiple sclerosis and can promote 
demyelinating encephalomyelitis in mice
A.B. Nicot1, J. Harb1, F. Guillot1, B. Nicol1, A. Garcia1, L. 
Leberre1, H.L. Mai1, S. Wiertlewski2, V. van Pesch3, J.-P. 
Soulillou1, S. Brouard1, L. Berthelot1, D.A. Laplaud1,2
1INSERM U 1064, Université de Nantes/CRTI, 2Neurology, CHU 
de Nantes, Nantes, France, 3Neurochemistry Unit, Université 
Catholique de Louvain, Institute of Neurosciences, Brussels, 
Belgium
Background: Multiple sclerosis (MS) involves immune cells 
including B and T cells but the actual targets of the immune 
response are still undefined. The ATP-sensitive inward rectifying 
potassium channel KIR4.1 expressed by glial cells is suspected as 
an autoantigen since high seric levels of IgG against its extracel-
lular peptide sequence (e1) were reported in half of MS patients. 
Yet, high discrepancies in frequencies (0-28 %) exist among labo-
ratories raising concerns about KIR4.1 as a valid marker and 
autoantigen candidate for MS. They may result from technical 
pitfalls or different protein conformations differentially recog-
nised by the antibody. 
Methods and results: Using ELISA with the synthetic e1 sequence 
as coating peptide, we obtained very high seric levels of anti-e1 
IgG from e1-immunised mice with no signal from control mice. 
Concomitantly, we screened human sera for the presence of anti-e1 
hIgG from 71 patients diagnosed for a Clinically Isolated Syndrome 
(CIS), 193 untreated MS patients and 130 Healthy Volonteers 
(HV). We found that 5.3 % of CIS/MS patients exhibit high levels 
of KIR4.1 antibodies (defined as high responders - HR - using a 
threshold of 2.5 SD above HV mean) vs. 0.7% in HVs (p< 0.02). 
Moreover, the anti-e1 mouse serum labeled scarce astroglial cells 
and slightly white matter glial fibers in the normal rodent and 
human brain, with increased labeling in MS brain. Specific immu-
nolabeling using anti-e1 mouse serum or a HR serum was obtained 
on cultured human astrocytoma, particularly when glycosylation 
was inhibited in vitro. Western Blot of astrocytoma extracts showed 
that the anti-e1 serum recognised the unglycosylated form of 
KIR4.1 but not higher molecular weight forms. Immunisation with 
e1 peptide results in the late development of experimental autoim-
mune encephalomyelitis in 1/3 of the mice.
Conclusions: These data demonstrate in a subset of MS patients 
the presence of anti-Kir4.1 auto-antibodies directed against the 
unglycosylated protein, which is increased in MS lesions. The 
development of demyelinating neuroinflammation in e1-immu-
nised mice supports KIR4.1 as an autoantigen. Our results favor 
the heterogeneity in the autoimmune aspect of the disease, in 
which subgroups with discrete IgG autoreactivites for CNS anti-
gens may be further delineated in the MS spectrum.
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Tart cherry extract as a powerful substance to ameliorate 
oxidative stress in the cuprizone model
N. Behrangi1,2, M. Kipp2, N. Namvar Asl3, M. Ataei4, S. Dizaji3, 
G. Javdani3, M.H. Sanati4
1University of Science and Culture, Tehran, Islamic Republic 
of Iran, 2Ludwig-Maximilians-Universität, Munich, Germany, 
3Pasteur institute, Production & Research Complex, Karaj, 
4National Institute of Genetic Engineering and Biotechnology, 
Tehran, Islamic Republic of Iran
Myelin sheaths of central nervous system (CNS) are multilayered 
and are enriched in lipids and proteins. Any perturbation in myelin 
protein expression or structure might contribute to disassembly of 
the myelin sheath. It is speculated that specific chemicals found in 
cherries could reduce pain, modulate inflammation, and exert 
antioxidative effects. The aim of the current study was to evaluate 
the effect of pure p-coumaric acid as a potent antioxidant agent, 
and tart cherry extract ingestion on the expression of the oxidative 
stress sensor Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
and the myelin homeostasis factor myelin basic protein (MBP) 
during cuprizone-induced de- and remyelination.
Acute demyelination was induced by feeding young mice for 6 
weeks with cuprizone mixed into ground rodent chow. At week 6, 
animals were returned to normal chow for up to 6 weeks to allow 
endogenous remyelination. Animals were sacrificed after acute 
demyelination as well as after 3 and 6 weeks of recovery. Mice 
were categorized into three groups: normal chow, tart cherry or 
p-coumaric acid. HPLC was used to quantify p-coumaric acid lev-
els in entire tart cherry extracts. To estimate levels of oxidative 
stress and myelin recovery, we quantified Nrf2 and MBP gene 
expression levels by means of rt-PCR in the isolated brains. Results 
were compared to control animals not intoxicated with cuprizone.
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In male mice, Nrf2 expression was induced at week 6 and 9, and 
thereafter was found to be downregulated. Recovery of Nrf2 expres-
sion was accelerated in tart cherry treated groups. p-coumaric acid 
had an intermediate effect on Nrf2 expression. Amelioration of Nrf2 
expression in tart cherry treated groups was paralleled by a pro-
nounced induction of MBP expression. This was not observed in 
p-coumaric acid treated groups. Interestingly, these effects were spe-
cific for male mice, and were not observed in female mice.
In summary, this study clearly illustrates a potent anti-oxidative 
effect of tart cherry extracts in a model for de- and remyelination. 
Beyond, remyelination might be accelerated by tart cherry extract 
treatment. Future studies now have to show which pathways and 
cell types are involved in this protective effect.
Disclosure:
This research was done by personal funding
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The effect of simvastatin on autophagy in mammalian cells
E. James1, P. Dua1, G. Warnes2, U.C. Meier1
1Department of Neuroscience and Trauma, Neuroinflammation 
and Psychoneuroimmunology Group, Blizard Institute, Queen 
Mary University of London, 2Flow Cytometry Core Facility, 
Blizard Institute, Queen Mary University of London, London, 
United Kingdom
Background: Multiple sclerosis (MS) is a chronic autoimmune 
condition of the central nervous system associated with demyeli-
nation and neurological impairment. Autophagy is a mechanism 
of intracellular lysosomal degradation of dysfunctional cytoplas-
mic components. It plays a critical role in the functioning of the 
immune system and failures in autophagic processes have been 
implicated in neurodegeneration. As such, dysregulation of 
autophagy may play a role in the pathophysiology of MS. Recent 
evidence suggests that Simvastatin (a HMG-CoA reductase inhib-
itor) induces autophagy in a variety of mammalian cells, and there 
is growing interest in the therapeutic potential of statins in the 
treatment of MS. Following promising results from a phase 2 trial, 
a phase 3 trial of Simvastatin treatment in secondary progressive 
MS is due to be conducted.
Objective: To evaluate the autophagy-modulating effects of 
Simvastatin in a variety of cell types, using flow cytometry.
Methods: LC3B immunofluorescence labelling was used to meas-
ure autophagy in Simvastatin-treated K562 (human erythroleukae-
mia cells) and Jurkat cells (human acute T cell leukaemia), as well 
as PC12 cells (rat neuroblastic cells). PC12 cells resemble neuronal 
cells when differentiated with nerve growth factor. Fluorescent 
labelling of organelles was used to analyse organelle-specific 
autophagic processes in mitochondria and lysosomes, and a 
Proteostat assay detected protein aggregation in PC12 cells. Two 
time points were analysed: 24 and 48 hours.
Results: Simvastatin induced autophagy in a dose-dependent 
manner in Jurkat (at 24h; p< 0.05) and K562 cells (at 48h; p< 
0.05) treated at the following concentrations: 0µM, 0.1µM, 1µM 
and 10µM. The greatest upregulation of LC3B expression was 
seen at 1µM Simvastatin in both Jurkat (p=0.032) and K562 
(p=0.0432) cells. Simvastatin-treatment also slightly upregulated 
mitochondrial mass in Jurkat and K562 cells; increased lysosome 
expression in K562 cells, and upregulated LC3B and Proteostat 
expression in PC12 cells at 48 hours.
Conclusion: These preliminary findings suggest that Simvastatin 
influences autophagy, and this could be one mechanism by which 
Simvastatin may have therapeutic potential in the treatment of 
neurodegenerative diseases, such as MS. Further investigation is 
merited.
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EP1509
Axonal damage and motor impairment correlate with glial 
cell senescence in a model of multiple sclerosis
M. Karamita1, D. Papadopoulos1,2, D.D. Mitsikostas3, V. 
Gorgoulis2, L. Probert1, R. Nicholas4
1Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 
2Laboratory of Histology and Embryology, 31st Department of 
Neurology, National Kapodistrian University of Athens, Athens, 
Greece, 4Imperial College London, London, United Kingdom
Background: Cell senescence (CS) is an age-dependent process, 
promoted by a number of factors including oxidative stress and 
chronic inflammation. Typically, senescent cells undergo a num-
ber of changes such as division arrest and pro-inflammatory 
cytokine production. CS is thought to prevent damaged cells from 
becoming neoplastic, but evidence suggests that accelerated CS 
also contributes to loss of function associated with aging and neu-
rodegenerative disease. The mechanisms that drive disability in 
the progressive forms of MS are not fully understood but age-
related neurodegenerative processes are thought to play a key 
role.
Aim: To test the hypothesis that axonal damage and motor impair-
ment in chronic demyelinating disease are associated with glial 
cell senescence.
Methods: We used the cuprizone model of demyelination in 
C57BL/6 mice. Immunohistochemistry for MBP, Iba-1 GFAP, 
APP were used to quantify demyelination, microglial/macrophage 
activation, astrogliosis and acute axonal damage, respectively. 
γH2AX was used as a marker of DNA damage response (DDR). 
Senescent glial cells were detected with senescence-associated 
β-galactosidase (SA-β-Gal) histochemistry and p16INK4A immu-
nohistochemistry. The rotarod test and four-limb grip strength 
were used to assess motor performance.
Results: Chronic cuprizone feeding for 16 weeks led to callosal 
demyelination and astrogliosis with extensive acute axonal dam-
age. In the corpus callosum of cuprizone-treated, but not naïve 
mice, γH2AX immunohistochemistry was present in glial cell 
nuclei. There was also a significant increase in SA-β-Gal and 
P16INK4A positive senescent glial cells in the corpus callosum, 
compared to naïve controls (P< 0.001 and P< 0.05, respectively). 
Brain atrophy in cuprizone-treated mice was attested by decreased 
brain weight (8%, P< 0.001), and performance using the rotarod 
test and four-limb grip strength (P< 0.01), compared to naïve 
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controls. Correlation analysis revealed a significant association 
between the senescent glial cell load and four-limb grip strength 
(rp= -0.867, P< 0.01), and between the senescent glial cell load 
and the extent of acute axonal damage (rp= 0.92, P< 0.01).
Conclusions: Our study provides evidence of an association of 
axonal damage and motor impairment with the extent of glial cell 
senescence in a model of chronic demyelination. These data indi-
cate that glial cell senescence might contribute to disability pro-
gression under conditions of chronic demyelination.
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This work is supported by a research grant by the Multiple 
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EP1510
Brain volume loss in neuromyelitis optica spectrum disorder
J. Miguez1, J.I. Rojas1, F. Sanchez1, L. Patrucco1, N. Quiroz2, G. 
Guzman2, V. Burgos2, E. Cristiano1
1Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos 
Aires, 2Instituto de Investigación y Ciencias Básicas, Area LBAL, 
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
There are few studies regarding brain volume loss in Neuromyelitis 
optica spectrum disorder (NMOSD) with contradictory results. 
Our aim was to describe longitudinaly brain volume in a cohort of 
NMOSD patients compared to multiple sclerosis (MS) patients
Methods: Patients with diagnosis of NMOSD who had at least 
two MRI with a two year interval were included. MS patients 
matched by age and sex were included. SIENA and SIENAXr 
were used to measure brain volume.
Results: 20 NMOSD patients were included, 15 women (75%). 
Median age 39±12. The first symptom was longitudinally exten-
sive transverse myelitis (LETM) in 9 (45%), optic neuritis (ON) 
in 7 (35%), LETM plus ON in 1, brainstem in 1, cerebral in 1, 
brainstem plus LETM in 1. 9 patients (45%) were AQP4 positive. 
43 matched MS patients were included. In the baseline analysis 
grey matter volume was significantly lower in the MS group 
0.55±0.1 (x106 mm3) compared to the NMO group 0.66±0.08 (p< 
0.01). Whole brain volume (WBV), whole white matter volume 
(WWMV), left thalamic volume (LTV), right thalamic volume 
(RTV) and brainstem volume (BV) was similar in both. In the two 
year follow-up percent brain volume change (PBVC) was signifi-
cantly higher in the MS group -0.88±0.2 (%) vs the NMO group 
-0.55±0.12 (p< 0.01). WBV was lower in the MS group 1.5±0.1 
(x106 mm3) vs 1.6±0.13 (p< 0.01), GMV was also lower in the MS 
group 0.51±0.11 vs 0.65±0.09 (p< 0.01) as LTV 7±0.11 vs 7.5±0.4 
(p< 0.01). There was no difference between BV or WVMV 
between groups. In the two year follow-up of the NMO patients 
there was a significant reduction in the BV 19.1±1.2 (cm3) in 
baseline vs 17.2±0.1 in follow-up (p< 0.01). There was no differ-
ence in the other variables.
Conclusion: MS patients showed significantly higher brain atro-
phy in baseline and follow-up. In NMOSD patients there was a 
significant reduction of brainstem volume in follow-up. These dif-
ferences between groups may reflect different physiopathological 
mechanisms.
Disclosure
nothing to disclosure
EP1511
Increased glutamate is the dominant cause of deep brain 
atrophy and multiple sclerosis severity
E. Kantorova1, H. Poláček2, M. Grendár3, P. Hnilicová3, E. 
Baranovičová3, K. Zeleňák4, Š. Sivák1, D. Dobrota5, E. Kurča1
1Clinic of Neurology, 2Clinic of Nuclear Medicine, 3Biomedicine 
Centrum, 4Clinic of Radiodiagnostics, 5Department of 
Biochemistry, Jessenius Faculty of Medicine in Martin, 
Comenius University Bratislava, Martin, Slovakia
Objective: In multiple sclerosis (MS), deep grey matter (DGM) 
atrophy has been recognised as a crucial component of the dis-
ease, presenting early and being associated with disability. 
Although the precise mechanism underlying grey matter atrophy 
is unknown, several hypotheses have been postulated. As our pre-
vious study found that hypothalamic alterations correlate with 
clinical outcomes, we decided to further test the hypothesis that 
hypothalamic metabolism is related to DGM atrophy.
Methods: We used 1H - Magnetic Resonance spectroscopy 
(1HMRS) of hypothalamus via 1.5T to test its metabolites in 26 
patients with RRMS and 22 healthy age-matched controls. 
DGM atrophy was evaluated via the third ventricular widths 
(3VW) in T1 weighted MRI pictures. Metabolites of N-acetyl 
aspartate (NAA), Choline (Cho), Glutamate and Glutamine 
(Glx), myo-Inositol (mIns) and Creatine (Cr) and their ratios 
were correlated with Multiple Sclerosis Severity Scale (MSSS) 
and 3VW.
Results: In linear regression, for each log unit increase in 3VW, a 
0.35 increase in MSSS was identified (P = 0.0039); whereas for 
each log unit increase in Glx/NAA, a 0.93 increase in MSSS was 
identified (P = 0.090).
Conclusions: In our study, we found that both NAA and Glx are 
associated with neurodegeneration of DGM, but Glx was found to 
be superior in determining both atrophy of DGM and disease 
burden.
This work is supported by Project APVV-15-0107, and VEGA 
1/0287/16
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Repairing mechanisms
EP1512
Factors that regulate endogenous expression of the myelinat-
ing protein Gas6 in the brain
S. Goudarzi1, N. Aydin2, S. Hafizi1
1School of Pharmacy and Biomedical Sciences, 2School of 
Pharmacy and Biomedical Sciences | St. Michael’s Building, 
University of Portsmouth, Portsmouth, United Kingdom
Receptor tyrosine kinases of the TAM (Tyro3, Axl, Mer) subfam-
ily are expressed in the CNS, and a number of reports have shown 
that their activation via their common ligand Gas6 has a positive 
effect on (re)myelination as well as on glial cell development. 
Gas6 undergoes post-translational processing, and thereby func-
tional activation, through vitamin K (Vit K)-dependent gamma-
carboxylation of a number of glutamic acid residues within the 
protein. However, little is currently known about the expression of 
Gas6 in the brain or the factors that regulate its expression and/or 
its post-translational activation state. Such knowledge can lend 
support to strategies aimed at activating Gas6-TAM signalling in 
the brain as a means of promoting remyelination in MS.
The study presented here is aimed at investigating the effects of 
various candidate molecules on the levels of endogenous Gas6 
gene expression in the mouse brain. Molecules were administered 
in vivo or in vitro using an organotypic brain slice culture model. 
C57/BL6 mice were injected with Vit K1 intraperitoneally, and 
after 24 hours samples from brain and liver were harvested for 
gene and protein expression analyses. In addition, cultured brain 
slices from mice at postnatal day 8-12 were treated with the fol-
lowing agents: Vit K1, Vit K2, Vit D3, dexamethasone and IL-10. 
Samples were incubated with the tissues for four days, and tissues 
were analysed by qPCR for gene expression, and in addition the 
culture medium was assayed by ELISA for presence of released 
Gas6 protein. Results so far show that Vit D3 caused an increase 
in expression of the gas6 gene in cultured mouse brain tissues. In 
addition, western blot analysis showed that in vivo administration 
of Vit K1 to mice caused an increase in the levels of gamma car-
boxylated proteins in the liver; brain analysis is ongoing.
These results show that Vit K administration can stimulate gamma-
carboxylation of Vit K-dependent proteins in vivo and, furthermore, 
that the steroid hormone Vit D3 is able to upregulate Gas6 expres-
sion in brain tissue in vitro. Therefore, Vit D3 could be a potential 
promoter of remyelination during the course of MS through induc-
tion of endogenous Gas6-TAM signalling in the CNS.
Disclosure
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In vivo validation of chemical compounds with remyelinating 
potential
C. Costa, H. Pohl, H. Eixarch, C. Matute-Blanch, C. Espejo, X. 
Montalban, M. Comabella
Vall Hebron University Hospital | Multiple Sclerosis Centre of 
Catalonia, Cemcat-Vall Hebron University Hospital, Barcelona, 
Spain
Background: Remyelination occurs in patients with multiple 
sclerosis (MS), though it often fails or is incomplete. Therapies 
that favour endogenous oligodendrogenesis and promote 
remyelination may become attractive neuroprotective strate-
gies for MS patients. In a previous study based on a 
Connectivity Map approach, we defined a gene expression 
signature of mature myelinating oligodendrocytes and identi-
fied five drugs (perhexiline, deptropine, picrotoxinin, pimoz-
ide, valproic acid) with potential to enhance remyelination. 
Three out of the five drugs (deptropine, pimozide, valproic 
acid) showed the ability to induce in vitro oligodendrocyte 
maturation in oligodendrocyte progenitor cells cultures, and 
were further selected for in vivo validation of their remyeli-
nating potential in two animal models.
Methods: Experimental autoimmune encephalomyelitis 
(EAE) was induced in C57BL/6J mice with MOG35-55 peptide. 
At day 12 post-immunization, once the EAE clinical sings 
were detected, animals were randomized and treated with the 
compounds for 21 days. A lysolecithin mouse model was 
induced by injecting lysolecithin in the spinal cord. Animals 
were randomised and treated for 10 or 24 days. Deptropine, 
pimozide, valproic acid or vehicle (DMSO) were administered 
intraperitoneally daily to both mouse models. Spinal cords 
were removed and sectioned for immunostaining with MBP 
and Olig2. The demyelinated lesion area was measured and 
Olig2+ cell density assessed.
Results: Administration of selected compounds in a therapeu-
tic setting did not result in an improvement of the EAE clinical 
course, which was similar in mice treated with deptropine, 
pimozide, valproic acid compared with the vehicle group. In 
the EAE model an autoimmune response against myelin is 
induced, which could mask a positive effect of the drugs on 
remyelination. In order to avoid the effect of the immune sys-
tem, we also tested the selected compounds in a lysolecithin 
model in which focal demyelination is due to a secondary 
toxic effect in oligodendrocytes. In the lysolecithin model, we 
observed that the density of Olig2+ cells was comparable in 
all groups, albeit showing a tendency to slight increase in ani-
mals treated with valproic acid, although statistically not 
significant.
Conclusions: Although deptropine, pimozide, valproic acid 
showed good remyelinating capacity in vitro, they failed to 
enhance remyelination in immune-mediated and toxic-induced 
demyelination experimental models.
Disclosure Disclosure of conflict of interest:
CC, HP, HE, CM and CE declare no competing financial interests.
XM has received speaking honoraria and travel expenses for sci-
entific meetings, has been a steering committee member of clini-
cal trials or participated in advisory boards of clinical trials in the 
past with Bayer Schering Pharma, Biogen Idec, EMD Merck 
Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva 
Pharmaceuticals and Almirall.
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Imaging
EP1514
Classifying multiple sclerosis lesions with T1-weighted MR 
and myelin imaging
C. Köhler1, H. Wahl1, J.C. Eisele2, T. Ziemssen2, J. Linn1, H.H. 
Kitzler1
1Institut für Diagnostische und Interventionelle Neuroradiologie, 
Universitätsklinikum Dresden, 2Multiple Sklerose Zentrum, 
Klinik und Poliklinik für Neurologie, Universitätsklinikum 
Dresden, Dresden, Germany
Introduction: Myelin imaging is a potential tool to parse differ-
ences in focal myelin loss in T1 isointense and hypointense 
Multiple Sclerosis (MS) lesions. Since conventional magnetic 
resonance imaging (MRI) is unspecific to myelin we applied the 
in vivo whole-brain myelin imaging technique multi-component 
Driven Equilibrium Single Pulse Observation of T1 and T2 
(mcDESPOT) that allowed the evaluation of relative myelination 
by means of measuring the volume fraction of myelin water 
(VFM), a parameter related to brain white matter (WM) 
myelination1.
Purpose: To investigate the variation in VFM in individual 
FLAIR hyperintense MS lesions which are either isointense or 
hypointense to WM in T1-weighted images.
Methods: MRI data of 12 clinically isolated syndrome (CIS) 
patients were acquired at baseline and at 3, 6 and 12 months. 
T1-weighted and 3D-fluid attenuated inversion recovery 
(FLAIR) images were obtained and WM lesions were segmented 
as separate volumes of interest. VFM maps were derived using 
the established mcDESPOT processing method [1]. Selective 
lesion VFM read out enabled to address myelination differences 
in individual lesions. A matched control group was acquired. 
The significance of differences in VFM of T1 isointense and 
hypointense MS lesions was determined with an unpaired two-
sided t-test (P< 0,05).
Results: A total of 259 WM FLAIR lesions were examined, whereas 
157 of them were isointense (VFMmean=0,185; VFMSD=0,045) and 
102 hypointense (VFMmedian=0,156; VFMSD=0,040 ) on T1-weighted 
images. VFM in WM of healthy controls was 0,23. Significant dif-
ferences (P=0,7*10-8) were found for the groups.
Conclusion: Lesions isointens to WM exhibited higher VFM val-
ues than lesions that were hypo intense. Our findings demonstrate 
varying degrees of demyelination rejecting conventional MRI 
appearance in CIS/early MS.
References
1 Deoni et al., Magn Reson Med. 2008 Dec; 60(6):1372-87;
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Optimal timing of gadolinium-enhanced 3D FLAIR MRI for 
detection of leptomeningeal enhancement in multiple sclero-
sis
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Background: B-cell lymphoid aggregates have been impli-
cated in meningeal inflammation, microglial activation, corti-
cal grey matter demyelination, and disability progression in 
multiple sclerosis (MS) (1). Gadolinium-enhanced 3D-FLAIR 
(Gd-3D-FLAIR) MRI has recently been shown to identify 
foci of leptomeningeal enhancement (LME) in MS (2), 
thought to be an imaging biomarker for leptomeningeal 
inflammation. In order to determine disease modifying ther-
apy (DMT) efficacy in controlling LME, it will be necessary 
to control for timing of image acquisition following gadolin-
ium administration.
Goals: To identify the optimal timing of Gd-3D-FLAIR acquisi-
tion following gadolinium administration to identify LME in MS.
Methods: 8 foci of LME in 3 different MS patients were imaged 
by Gd-3D-FLAIR at 4 successive time points following injec-
tion spanning 4-45 minutes. Enhancement intensity was quanti-
fied by region-of-interest (ROI) measurements, averaged in 
sagittal and axial planes, with generation of time-intensity 
curves.
Results: Lesions were heterogeneous without definable optimal 
time for image acquisition. Mean time to peak enhancement = 
23.8 min (standard deviation = 15 min, range 2-42 min). Rough 
guidelines for optimal timing of image acquisition suggest 10-25 
min as reasonable parameters. Additionally, enhancement curves 
exhibited 3 different variations, remarkably similar to those 
described by Tofts (3): 3 lesions revealed prolonged wash-in 
curve; 2 lesions revealed slow wash-in/slow wash-out; and 3 
lesions revealed rapid wash-in/rapid wash-out.
Conclusions: 
1) While 10-25’ post-injection acquisition seems appropri-
ate, accurate assessment of DMT efficacy in modulating 
LME will require rigorous controlling of timing of image 
acquisition following gadolinium administration.
2) LMEs in MS are heterogeneous revealing 3 different 
types of wash-in/wash-out curves, suggesting a new ave-
nue for investigation of DMT modulation of LME.
References: 
1. Howell OW, Reeves CA, Nicholas R, et al. Meningeal 
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in multiple sclerosis. Brain 2011; 134:2755-2771.
2. Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI 
characterization of leptomeningeal inflammation in multiple 
sclerosis. Neurology 2015; 85:18-28.
06_MSJ731285.indd   793 13/10/2017   11:10:58 AM
794 ePosters 23(S3)
Multiple Sclerosis Journal 2017; 23: (S3) 680–975 journals.sagepub.com/home/msj
3. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR 
imaging. JMRI 1997; 7:91-101.
Disclosure
David S. Titelbaum, M.D.: nothing relevant to disclose
Renate Engisch, M.D.: nothing relevant to disclose
Eric D. Schwartz, M.D.: nothing relevant to disclose
Salvatore Q. Napoli, M.D.: nothing relevant to disclose
Jacob Sloane, M.D.: nothing relevant to disclose
EP1516
Supervised detection of newly appearing T2-w multiple scle-
rosis lesions with subtraction and deformation fields features
M. Salem1, M. Cabezas1, S. Valverde1, D. Pareto2, A. Oliver1, J. 
Salvi1, À. Rovira2, X. Llado1
1ATC, University of Girona, Girona, 2Magnetic Resonance 
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Background: MRI has become one of the most important clinical 
tools for longitudinal analysis of multiple sclerosis (MS). Newly 
appearing lesions are indicative of the disease progression. 
Several automatic approaches have been proposed for the detec-
tion of newly appearing lesions, which can be classified as either 
supervised approaches that use intensity-derived features from the 
subtraction images or unsupervised approaches that use also 
deformation fields information.
Aim: We present here a supervised approach for detecting newly 
appearing MS lesions that combines both subtraction and defor-
mation field features. Specifically, we use a logistic regression 
classifier trained with features from the baseline and follow-up 
intensities, subtraction values, and deformation field operators to 
provide a final segmentation.
Materials and methods: One year apart multi-channel brain MRI 
were scanned for 60 patients with a 3T magnet, including trans-
verse T2-FLAIR, PD-w, T2-w and T1-w images. 36 of these 
patients presented new T2-w lesions that were semi-automatically 
annotated by expert neuroradiologists. The rest had no new lesions 
in the follow-up scans. All images were pre-processed and co-
registered by multi resolution-multi stage affine registration, and 
a deformation field was also obtained using the Demons non-rigid 
registration algorithm.
Results: We performed a leave-one-out cross-validation strategy 
using the 36 patients with new T2-w lesions. In terms of detection, 
we obtained a 74.30% true positive fraction and 11.86% false posi-
tive fraction with a mean Dice similarity coefficient of 0.77. In 
terms of segmentation, we obtained a mean Dice coefficient of 
0.56. We compared these results with those obtained with state-of-
the-art methods such as Sweeney et al. (2013), Ganiler et al. (2014), 
and Cabezas et al. (2016), and our model had significantly better 
results (p< 0.05). When testing the model with the 24 patients with 
no new T2-w lesions, only 5 false positives were found in 4 cases.
Conclusion: The proposed model decreases the number of false 
positives while increasing the number of true positives. The study 
also proves the benefits of using deformation field operators as 
features to train a supervised learning model. Our approach is 
simple and fully automated and reduces user interaction and inter- 
and intra-observer variability.
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Spinal cord pathology and MS phenotypes - lesions, diffusion 
changes and spinal cord atrophy in 1036 multiple sclerosis 
patients
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1MR Unit, Department of Radiology, 2Department of Neurology 
and Center of Clinical Neuroscience, Charles University and 
General University Hospital, 3Department of Statistics and 
Probability, University of Economics, 4Department of Radiology, 
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Czech Republic
Background: Abnormal MRI findings in spinal cord (SC) fre-
quently occur in multiple sclerosis (MS). However, the relation-
ship between lesions, diffuse pathology and SC atrophy in 
different MS phenotypes remains poorly understood.
Objective: To investigate spinal cord pathology in different MS 
phenotypes with 3T MRI.
Methods: We evaluated cervical and upper thoracic SC of 
1,036 MS patients (739 women, 295 men) using the uniform 
MRI protocols: T2-weighted image with fat suppression (T2WI- 
Fat- Sat) in sagittal (slice thickness 2.0/0 mm) and 3D-T2WI-
Fat-Sat in transversal plane 3D. There were 169 patients with 
clinically isolated syndrome (CIS), 743 relapse remitting 
(RRMS) patients and 124 secondary progressive MS (SPMS). 
The spinal cord volume (SCV) was measured semi automati-
cally in 21 slices centered at intervertebral disc C3/C4. Lesion 
number and location (between craniocervical junction and ver-
tebral body Th4) and presence of diffuse changes were evalu-
ated by a neuroradiologist.
Results: Normally appearing SC was present in 33.7% (347 
patients: CIS 45%, RRMS 33%, SPMS 19%). Diffuse abnormali-
ties were present in 48 CIS (28%), 307 RRMS (41%) and 66 
SPMS patients (54%). Focal lesions were described in 110 CIS 
(35%), 454 RRMS (39%) and 67 SPMS patients (54%). The mean 
of SCV (between vertebral body C3-C4): was 1.84 cm3 (SD 0.18) 
in CIS, 1.76 cm3 (SD 0.20) in RRMS and 1.64 cm3 (SD 0.21) in 
SPMS. Statistically significant differences in SCV and type of SC 
pathology were found among all three groups (p< 0.001) (adjusted 
for gender, age, disease duration). The maximum effect size was 
0.15 for combination of diffuse changes and lesions and 0.14 for 
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whole diffuse changes. The mean of SCV differed significantly 
between men (1.83 cm3) and women
(1.74 cm3). Interestingly, this effect declined with disability and 
men with SPMS had even smaller SCV (1.63 cm3) than women 
with SPMS (1.64 cm3).
Conclusions: This large dataset of 3T MRI derived from an aca-
demic MS clinic represents well a variety of SC abnormalities 
present in different MS phenotypes. Incidence of diffuse abnor-
malities in spinal cord on MR increases with severity of the dis-
ease. Diffuse abnormalities may be an important discriminator 
between disease phenotypes, which should be evaluated in longi-
tudinal studies. In SPMS, SC atrophy was more pronounced in 
men, suggesting sex differences in pathophysiology of SCV loss.
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Periventricular lesions and 2016 MAGNIMS criteria for 
dissemination in space in patients with clinically isolated 
syndromes
M. Díaz Sánchez, R. Lamas Pérez, L. Lebrato Hernández, P. 
Baena Palomino, J.L. Casado Chocán, A.J. Uclés Sánchez
Neurology, Hospital Universitario Virgen del Rocío, Sevilla, 
Spain
Background: The Magnetic Resonance Imaging in Multiple 
Sclerosis (MAGNIMS) group recently proposed new 
dissemination in space (DIS) criteria that include lesions in the 
optic nerve, cortex and symptomatic region. In addition, these 
new magnetic resonance imaging (MRI) criteria for DIS raised the 
number of periventricular (PV) lesions from 1 to 3. We aim to 
investigate the performance of ⩾1, ⩾2 and ⩾3 PV lesions in the 
2016 MAGNIMS DIS criteria in predicting the conversion to 
clinically definite multiple sclerosis (CDMS) in patients with 
clinically isolated syndromes (CIS).
Method: Inclusion criteria:
1) CIS suggestive of central nervous system demyelination 
(since 2008);
2) clinical assessment and baseline brain MRI within 6 
months of CIS onset;
3) spinal cord MRI available if patients presented with spi-
nal cord syndrome; and
4) clinical follow-up of at least 24 months.
Results: We studied 161 CIS patients, 113 (70.2%) women, 
with a mean age at onset of 34 years. After a mean follow-up 
of 58 months, 102 (63.4%) patients were diagnosed as having 
MS according to the McDonald 2010 criteria. Seventy-eight 
(48.4%) patients converted to CDMS after a mean of 33 
months from CIS onset, despite 46 (45%) patients underwent 
disease-modifying treatment (DMT) before the second clini-
cal event. The sensitivity, specificity, and positive and nega-
tive predictive values of original 2016 MAGNIMS criteria 
requiring ⩾3 PV lesions were 75.6%, 56.6%, 62.1%, and 
71.2%; those for 2016 MAGNIMS criteria requiring ⩾2 PV 
were 80.7%, 56.6%, 63.3%, and 75.6%; and finally, those for 
2016 MAGNIMS criteria requiring ⩾1 PV were 85.8%, 
51.8%, 62.6% and 79.6%.
Conclusions: 2016 MAGNIMS DIS criteria requiring ⩾1 PV 
lesion had a higher sensitivity but lower specificity than requiring 
⩾2 or ⩾3 PV lesions. We found that the best combination of spec-
ificity and sensitivity for CDMS was seen for ⩾2 PV lesions using 
MAGNIMS 2016 criteria. Because DMT can delay or prevent the 
conversion to CDMS, the high proportion of patients that under-
went these therapies before a second attack, would explain the 
specificity values obtained.
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Iron deposition and volumes determination of subcortical, 
cerebellar and brain stem deep gray matter in multiple scle-
rosis: correlations
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Background: Increased iron deposition in subcortical deep gray 
matter structures is explained by the blood-brain barrier dysfunc-
tion, decreased iron clearance induced by axonal degeneration and 
inflammation or dysfunction of iron transport proteins induced by 
inflammation. Atrophy of the thalamus and basal ganglia nuclei 
have been established in multiple sclerosis, but the correlation 
between iron deposition and the loss of volume of the deep gray 
matter is limited studied. The aim of this study was to determine 
the presence of iron deposition and determinate the volumetric 
measurements in subcortical, cerebellar and brain stem deep gray 
matter structures in Multiple sclerosis, to compare them with the 
healthy control subjects.
Methods: Sixteen MS patients (9 RRMS and 7 SPMS), 8 CIS and 
17 age- and sex-matched control subjects were included in this 
study. Region of interest (ROI) analysis on T2* relaxation time 
maps was used to estimate T2* values for deep grey structures. 
Regionas were manually outlined for head of nucleus caudatus, 
putamen, globus pallidus, pulvinar nucleus, remaining structure 
of thalamus, subthalamic nucleus, nucleus dentatus, nucleus fas-
tigii, substantia nigra, and red nucleus and values averaged for left 
and right. The volumes of all these deep gray matter structures 
were also measured.
Results: Trends for T2* relaxation times were reduced going 
from healthy controls to CIS and then to RRMS; however the T2* 
values increased in SPMS relative to RRMS. Statistically signifi-
cant differences were identified for MS patients less than healthy 
controls in left putamen (p=0,015), left red nucleus (p=0,006), left 
remaining thalamus (p=0,032), right putamen (p=0,002) and sple-
nium (p=0,010). There was no any correlation between T2 star 
and volumes values in all anatomic structures p>0,05).
Conclusions: This study suggests the increased iron deposition as 
indicated by decreased T2* relaxation times in subcortical and 
brain stem deep gray matter structures in Multiple Sclerosis as of 
the early stage of the disease. However, increased T2* from 
RRMS to SPMS may reflect the influence of neuronal loss.
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Normative data of MRI-derived hippocampal volume from a 
large dataset of healthy subjects
L. Luchetti, G. Gentile, A. Giorgio, M. Battaglini, N. De Stefano
Department of Medicine, Surgery and Neuroscience, University 
of Siena, Siena, Italy
Background: Hippocampal atrophy occurs in Multiple Sclerosis 
(MS) patients since the early disease stages and has been associ-
ated with the impairment of episodic, visuospatial and verbal 
memory. Despite the growing clinical interest, Magnetic 
Resonance Imaging (MRI) derived measures of the hippocampal 
volume (HipV) from large datasets are missing, with important 
limitations for the implementation of this measure in large clinical 
studies.
Objective: To assess normative data of the HipV in healthy sub-
jects (HS) on a large cross-sectional MRI dataset to be used as a 
reference in clinical studies.
Materials: The HipV of 727 HS was assessed from freely avail-
able MRI datasets. The age at scan-time ranged from 20 to 80 
years. Data were stratified for gender and magnetic field strength 
(1.5 and 3 T). Volumes were obtained using a semi-automated 
approach, based on the manual editing of the masks obtained with 
FIRST (fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST). In 100 MRI scans, 
the accuracy of the method was compared with a fully manual 
segmentation output and with the fully automated outputs from 
FIRST and FreeSurfer. Finally, a multivariate regression using 
HipV corrected for head size as dependent variable and gender 
and age and their interactions as predictors was performed.
Results: Volume masks from our semi-automated approach were 
very similar to those obtained with the fully manual approach 
(7.1±0.7 cm3 vs 7.1±0.6 cm3, p=0.98; DICE=0.92) and significantly 
lower than those obtained fully automatically with FreeSurfer 
(8.5±0.94 cm3, p< 0.001; DICE=0.8) and FIRST (8.2±0.83 cm3, p< 
0.001; DICE=0.88). Age, quadratic age and gender were the predic-
tors better fitting HipVs (R2=0.164, p< 0.001). Due to the depend-
ence on gender, females showed constantly larger HipV with 
respect to males (0.44 cm3, p< 0.0001). Due to the dependence on 
age, HipV decreased by 0.07% per year between 25 and 55 years of 
age (Hip female at 25 years: 9.9 cm3; at 55 years: 9.7 cm3), with an 
apparent acceleration (0.51% per year) between 55 and 85 years of 
age (Hip female at 85 years: 8.2 cm3).
Discussion: The study provides normative data of HipV over the 
adult life-span for males and females to be used as reference in 
MS studies at group and individual levels.
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Accelerated myelin water imaging for assessment of cervical 
spinal cord demyelination in multiple sclerosis and neuromy-
elitis optica spectrum disorder
A. Dvorak1, E. Ljungberg2, I.M. Vavasour3, H. Liu4, A. 
Rauscher3,5, J. Kramer4, C. Laule1,3,6, A.L. MacKay1,3, A.L. 
Traboulsee7, P. Kozlowski1,3, S.H. Kolind1,3,7
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Introduction: Myelin water fraction (MWF) is an imaging bio-
marker for myelin, acquired by an advanced MRI technique 
known as myelin water imaging (MWI) and traditionally derived 
using a lengthy multi-echo T2 sequence. Spinal cord (SC) appli-
cation of MWI has been hindered by difficulties intrinsic to cord 
imaging. GRASE, a MWI acquisition technique accelerated by a 
factor of 3, has recently been implemented with high resolution 
and low acquisition time in healthy and injured SC.
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Objective: Investigate the myelin content in the cervical SC of 
patients with multiple sclerosis (MS) and neuromyelitis optica 
spectrum disorder (NMOSD) using GRASE MWI.
Methods: GRASE data centred at the C2/C3 disk level was col-
lected from 8 healthy controls and 4 patients (1 relapsing-remit-
ting MS (RRMS, EDSS=2.0); 1 primary-progressive MS (PPMS, 
EDSS=6.0); 2 NMOSD (EDSS=2.0 and 1.0)). Conventional ana-
tomical MRI images facilitated analysis of MWF within regions 
of interest (ROI): whole cord (WC), white matter (WM), gray 
matter (GM), dorsal column (DC) and lateral funiculi (LF). Due to 
the exploratory, case study nature of the project, MWF results dif-
fering by >1 standard deviation (σ) from HC mean were termed 
either high or low.
Results: Two patients had cervical SC lesions in the MWI field 
of view; RRMS had a small eccentric cord lesion and one of the 
NMOSD had a large transverse myelitis (TM) lesion. HC showed 
MWF variations between ROIs and agreement with literature 
(WC mean/σ=24.3/1.9%, WM=26.4/1.9%, GM=16.0/2.5%, 
DC=28.2/2.5%, LF=25.4/1.8%). NMOSD #1 with TM had dras-
tically reduced MWF in all ROIs (WC=12.8, WM=14.0, GM=6.3, 
DC=6.9, LF=16.0%). NMOSD #2 had low MWF in all ROIs 
except the LF (WC=22.1, WM=23.9, GM=12.7, DC=24.1, 
LF=24.5%) despite lack of lesions. The MWF for the RRMS 
patient was similar to HC in WC, WM and GM ROI (WC=24.4, 
WM=25.9, GM=17.5%), but high in the DC (DC=31.0%) and 
low in the LF corresponding to lesion location (LF=23.1%). 
MWF values for the PPMS patient were similar to HC in all ROI 
(WC=25.1, WM=27.4, GM=16.8, DC=29.3, LF=25.5%).
Conclusion: GRASE MWI characterized healthy SC myelin 
content in agreement with literature values, and demonstrated 
reduced myelin water in TM lesion tissue. MWF values were 
reduced in NMOSD, regardless of visible lesions on conven-
tional MRI, and suggested focal demyelination in RRMS lesion. 
These results support the clinical feasibility of using GRASE SC 
MWI as a potential quantitative measure of disease related mye-
lin changes.
Disclosure
A. Dvorak: has nothing to disclose.
E. Ljungberg: has received PhD funding from GE Healthcare.
I. Vavasour: has nothing to disclose.
H. Liu: has nothing to disclose.
A. Rauscher: has nothing to disclose.
J. Kramer: has nothing to disclose.
C. Laule: has nothing to disclose.
A. MacKay: has nothing to disclose.
A. Traboulsee: has received research support from Biogen, 
Chugai, CIHR, Roche, Michael Smith Foundation and MS Society 
of Canada, and has consulted for Biogen, Roche, EMD Serono 
and Teva Pharmaceuticals.
P. Kozlowski: has nothing to disclose.
S. Kolind: has received research support from Roche and MS 
Society of Canada, and has consulted for Acorda, Genzyme.
EP1522
Demographic analysis and lesion characterization of lepto-
meningeal enhancement in multiple sclerosis
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Background: B-cell lymphoid aggregates have been implicated 
in meningeal inflammation, cortical grey matter demyelination, 
and disability progression in multiple sclerosis (MS) (1). 
Gadolinium-enhanced 3D-FLAIR (Gd-3D-FLAIR) MRI has 
recently been shown to identify foci of leptomeningeal enhance-
ment (LME) in MS (2), thought to be an imaging biomarker for 
leptomeningeal inflammation. Awareness of demographics and 
lesion characteristics will facilitate determining if LME is a poten-
tial biomarker for anti-B cell therapies.
Goals: To analyze LME in MS patients in community-based 
practice by determining demographic and lesion characteris-
tics, including relative frequency of LME by MS-subtype and 
disease modifying therapy (DMT), and correlation with dis-
ease activity.
Methods: MRI exams in MS patients showing LME were 
reviewed for demographics, disease subtype, and DMT, and 
lesions were analyzed for concurrent disease activity, location and 
morphology, and stability over time.
Results: 18 MS patients revealed 34 LMEs (mean 1.9, range 
1-4), including 15 (83%) with relapsing remitting (RR), and 3 
(17%) with secondary progressive (SP) MS. LME was seen 
with various DMTs and in patients receiving no treatment. 1 
patient had imaging signs of active disease. Lesions were 
equally distributed between right and left, with 9 frontal, 13 
parietal, 8 occipital, 3 temporal, and 1 cingulate lesions. Lesion 
morphology showed 11 rounded dots, 21 curvilinear lesions, 
and 1 globular lesion. 7 patients had prior exams ranging from 
6-21 months, with 1 patient revealing 1 new lesion over a 10 
month follow up.
Conclusions: 
1) In the community outpatient setting, LME is more likely 
to be seen in RRMS.
2) LME can be seen with a variety of DMTs.
3) LME is generally stable and unrelated to white matter 
disease activity.
References: 
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Regional distribution of cortical and subcortical damage in 
CIS patients: a study of first-year changes with clinical, CSF 
and radiological correlations
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Background: Grey matter (GM) damage is a well-known phe-
nomenon in the early stages of multiple sclerosis (MS), but its 
specific spatial distribution, clinical and cerebrospinal fluid (CSF) 
correlates are not well known.
Objective: To evaluate the regional distribution of cortical and 
subcortical GM damage in patients with clinically isolated syn-
dromes (CIS) and to investigate whether clinical, CSF and radio-
logical features are associated with specific damage in certain GM 
regions, both at baseline and during the first year of follow-up.
Materials and methods: From an ongoing longitudinal CIS cohort 
121 patients with 3T magnetic resonance imaging (MRI) scans per-
formed at baseline (3 months) and follow-up (12 months) were 
included. The selected cohort was classified according to their clini-
cal, CSF and radiological correlates as follows: (1) clinical topogra-
phy as optic neuritis (ON)(n=53) or OTHER (n=68); (2) presence or 
absence of oligoclonal bands (OCB) (n=107) as OCB+ (n=56) or 
OCB- (n=51); (3) number of Barkhof criteria fulfilled at baseline 
MRI as 3-4 criteria fulfilled, named Barkhof High (BH) (n=37) or 
0-1-2 criteria fulfilled, named Barkhof Low (BL) (n=84). The scans 
were analyzed using the longitudinal stream included in the 
FreeSurfer software package. Baseline values and yearly change 
rates for lobar cortical thickness as well as for volumes of relevant 
subcortical structures were compared between subgroups adjusting 
for age and gender; results were corrected for multiple comparisons.
Results: At baseline significant cortical thinning was observed in 
patients with BH compared to BL in the parietal and occipital 
lobes bilaterally, in the left lateral and medial temporal lobe, and 
in the left cingulum, whereas no significant differences were 
observed between the other subgroups. At baseline, OCB+ 
patients showed lower volumes in bilateral thalami compared to 
OCB-, and BH patients showed lower volumes in the left putamen 
and bilaterally in thalami and brainstem compared to BL patients; 
no differences were observed between ON and
Conclusions: The spatial distribution of cortical and subcortical 
damage is influenced by the clinical, CSF and radiological charac-
teristics of CIS patients.
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Does frequent MRI scanning improve accuracy of evaluation 
of brain atrophy in individual multiple sclerosis patients?
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Background: A relatively high intra-individual variability of lon-
gitudinal MRI of brain volume loss measurements over time ren-
ders challenging its application to individual multiple sclerosis 
(MS) patients.
Objective: To investigate if frequent brain MRI monitoring can 
improve the accuracy in identifying abnormal brain volume loss 
in an individual patient.
Methods: 157 relapsing-remitting MS patients had 7 MRI scans 
over 12-months follow-up. Of these,
81 patients had 13 bimonthly MRI scans available over 24-months 
follow-up. All 1585 MRI scans were performed on the same 1.5-
Tesla scanner using an identical scanning protocol. Volumetric 
analysis of brain volume loss was performed by validated 
ScanView and SIENA software. Linear regression analysis was 
used for estimation of annualized brain volume loss, with a value 
greater than 0.4% defined as the pathological cut-off. We com-
pared proportions of patients with abnormal brain volume loss 
obtained by analysis of different number of MRI time-points.
Results: An analysis of 2 MRI scans (month 0 and 12) showed 
abnormal brain volume loss in 93 (59.2%) of patients. When 3 
MRI scans were included (month 0, 6 and 12), we found only 1 
(0.6%) false negative and 5 (3.2%) false positive results compared 
with the analysis of 2 MRI scans, used as a reference for assess-
ment of abnormal brain volume loss. Analysis of 7 MRI time-
points showed 10 (6.4%) false negative and 13 (8.3%) false 
positive results compared with analysis of 2 MRI time-points. 
Change in the predictive accuracy of abnormal brain volume loss 
between results obtained by analysis of 2 and 7 time-points was 
14.6%. Our results were confirmed in 103 patients analyzed by 
SIENA software and in 81 patients re-baselined at 12 months. We 
found no significant differences in predictive accuracy, neither 
between clinically stable and active patients, nor between patients 
with greater or lower brain volume loss rates. Various cut-offs of 
pathological brain volume loss (-0.34% and -0.6%) with different 
specificity and sensitivity provided very similar results.
Conclusions: Identification of individual patients with abnormal 
brain volume loss based on assessment of two MRI time-points 
over 12 months is associated with only 10-20% accuracy change 
compared with bimonthly MRI scan monitoring. Increased num-
ber of brain MRI time-points has only a moderate effect on the 
potential improvement more accurately identifying abnormal 
brain volume loss in individual MS patients.
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Comparison of methods for brain atrophy assessment in mul-
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Background: Neurodegeneration, in particular of the grey matter 
(GM), is one of the pathological hallmarks of multiple sclerosis 
(MS) and it represents one of the target outcomes of current thera-
peutic strategies for these patients. Several software tools for GM 
and brain atrophy measurement on MRI are currently available.
Aims: The aim of this study was the comparison of different 
methods [Advanced Normalization Tools (ANTs) version 1.9, 
FSL-SIENAx/SIENA 5.0.1, Icometrix-MSmetrix 1.7, and SPM 
version 12] currently used for GM and brain atrophy estimation 
on MR images of MS patients.
Methods: The dataset arranged consisted of 3D-T1 and 
3D-T2FLAIR sequences of in-house simulated data, healthy con-
trols’ longitudinal data, test and retest MRI of MS patients 
acquired at different MR scanner field strengths and manufactur-
ers, and MS patients’ longitudinal data (1 year follow-up). Cross-
sectional and longitudinal GM and brain atrophy estimation were 
tested for each software, with and without T1-hypointense lesion 
filling. Accuracy and precision between the pipelines were com-
pared. Paired t-tests were used to statistically compare the differ-
ent results.
Results: The mean accuracy in GM and brain volume estimation 
for each method was: ANTs=0.96-0.96, FSL-SIENAX=0.95-0.96, 
MSmetrix=0.87-0.89 and SPM=0.97-0.96. The mean error in GM 
and brain atrophy measure was respectively: ANTs=0.52-0.11%, 
FSL-SIENAX=0.11%, MSmetrix=0.16-0.15% and SPM=0.09-
0.1%. Except for ANTs (p< 0.001), all softwares showed signifi-
cant precision in GM and brain volume estimation between scan 
and rescan on both 1.5T and 3T scanners (p>0.05). However, all 
methods showed significant differences (p< 0.05) when compar-
ing tissue volume measurements between 1.5T and 3T scanners, 
and, except for SPM pipeline, among 3T manufacturers. For lon-
gitudinal atrophy, only ANTs was sensitive to different manufac-
turers and field strength acquisitions. Lesion filling significantly 
influenced longitudinal assessment of GM and brain atrophy for 
ANTs (p< 0.05), while for SPM and MSmetrix it only affected 
GM atrophy measure.
Conclusions: Accuracy and precision between available software 
were evaluated and compared for different settings. The results of 
this work could help in the selection of the suitable pipeline among 
the available ones, according to the need of the analysis framework 
(research center, clinical setting or clinical trial), privileging in one 
case high accuracy rather than high reliability or vice versa.
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EP1526
The cytoarchitectonic anterior-posterior subdivision of BA4 
reveals different resting state networks suggestive of mal-
adaptive mechanisms in MS
A.A.S. Alahmadi1,2, R.S. Samson1, M. Pardini1,3, E. D’Angelo4,5, 
K.J. Friston6, A.T. Toosy1, C.A.M. Gandini Wheeler-
Kingshott1,5,7
1Queen Square MS Centre, NMR Research Unit, Department 
of Neuroinflammation, UCL Institute of Neurology, University 
College London, London, United Kingdom, 2Department of 
Diagnostic Radiology, Faculty of Applied Medical Science, 
King Abdulaziz University, Jeddah, Saudi Arabia, 3Department 
of Neurosciences, Ophthalmology and Genetics, University 
of Genoa and IRCCS AOU San Martino-IST, Genoa, 4Brain 
Connectivity Center, C. Mondino National Neurological 
Institute, 5Department of Brain and Behavioural Sciences, 
University of Pavia, Pavia, Italy, 6Wellcome Centre for Imaging 
Neuroscience, UCL Institute of Neurology, University College 
London, London, United Kingdom, 7Brain MRI 3T Research 
Center, C. Mondino National Neurological Institute, Pavia, Italy
Background: Cytoarchitectonically, Brodmann area 4 (BA4) 
has been subdivided into two sub-regions: Anterior (BA4a) and 
posterior (BA4p). FMRI studies have shown that each sub-
region contributes to different functions: BA4p activity is 
modulated by attention, fine forces, and imagined forces, 
whereas BA4a is related to force production. What are the 
healthy functional connectivity (FC) rsfMRI network of BA4a 
and BA4p, and how are these networks modulated by patholo-
gies such as MS?
Methods: 26 subjects (10 HS: 5F; mean (std) age 30 (3.65) yrs 
and 16 relapsing-remitting MS (RRMS) patients: 8F; mean (std) 
age 34 (2.13) yrs; median (range) 9-hole peg test (9-HPT)=20.8 
(14.7-33.1) were assessed with fMRI whilst resting. Region of 
interest (ROI)-to-ROI connectivity matrices were calculated for 
each subject. The left (dominant) hemisphere BA4 sub-divisions 
were defined according to a cytoarchitectonic probability atlas. 
The whole brain grey-matter areas were used as target regions. At 
the second level, FC measures were calculated and compared at 
group level using ANOVA, one or two sample t-tests, as appropri-
ate. ROIs’ FC measures were then correlated with the 9-HPT. 
Results were corrected with an FDR (p< 0.05).
Results:
1. Individual groups: Both sub-regions in both groups dis-
play different rsfMRI connectivity networks. In MS, the 
BA4p network includes additional areas (e.g. posterior 
cerebellum, visual and inferior frontal regions).
2. A direct comparison of the networks in both groups shows 
that both BA4a/p sub-regions in MS have reduced FC to 
the right hemisphere. In the left hemisphere, MS exhibit 
higher FC than HS in motor and associative areas.
3. In MS, exploring correlations of the FC with the 9-HPT 
showed: i) worse performance in the 9-HPT was associ-
ated with reduced FC of BA4a with the right anterior cer-
ebellum and the thalamus; ii) worse 9-HPT performance 
was also associated with greater FC of BA4a/p with the 
right hemisphere.
Discussion: The observation that BA4p is mainly connected to 
associative and higher order functional areas while BA4a is con-
nected to motor-related areas supports previous findings. Also, the 
correlation of the FC with the 9-HPT indicates that the increased 
FC may be either an unsuccessful compensatory attempt or even a 
maladaptive mechanism of disease. Multi-modal protocols may 
enable the investigation of the pathophysiology of these changes, 
which could derive from axonal loss and demyelination, but also 
perfusion or synaptic activity impairment.
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EP1527
Lower arterial cross-sectional area of carotid and vertebral 
arteries and higher frequency of secondary neck vessels are 
associated with multiple sclerosis
D. Jakimovski1, P. Belov1, J. Krawiecki1, C. Magnano1, J. 
Hagemeier1, B. Weinstock-Guttman2, R. Zivadinov1,3
1Buffalo Neuroimaging Analysis Center, Department of 
Neurology, Jacobs School of Medicine and Biomedical Sciences, 
University at Buffalo, State University of New York, 2Jacobs 
Comprehensive MS Treatment and Research Center, Department 
of Neurology, Jacobs School of Medicine and Biomedical 
Sciences, University at Buffalo, 3Translational Imaging Center 
at Clinical Translational Science Institute University at Buffalo, 
Buffalo, NY, United States
Background: Arterial and secondary neck vessel system charac-
teristics of multiple sclerosis (MS) patients were not previously 
investigated.
Objectives: To examine the frequency of neck vessels and their 
cross-sectional areas (CSA, in mm2) between MS patients and 
healthy controls (HCs).
Methods and materials: In this study, 193 MS patients and 193 
age- and sex-matched HCs underwent two-dimensional (2D) 
time-of-flight (TOF) angiography at 3T. The main arterial (carotid 
and vertebral), venous (internal jugular), and secondary neck ves-
sels were examined at 4 separate cervical levels (C2/3, C4, C5/6 
and C7/T1). The analysis of covariance (ANCOVA) adjusted for 
age, body-mass-index, smoking status, hypertension, and heart 
disease was used to compare the differences between MS patients 
and HCs.
Results: After controlling for all confounding factors, MS patients 
had significantly lower CSA of the carotid arteries at C2/3 
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(p=0.03), C5/6 (p=0.026) and C7/T1 (p=0.005) levels, as well as 
of vertebral arteries at C2/3 (p=0.02), C4 (p=0.012) and C7/T1 
(p=0.006) levels, compared to HCs. Higher frequency of second-
ary neck vessels was found at all 4 levels in MS patients: C2/3 
(12.9 vs. 10, p< 0.001), C4 (9.1 vs. 7.5, p< 0.001), C5/6 (7.8 vs. 
6.8, p=0.012) and C7/T1 (8.8 vs. 6, p< 0.001). The total CSA of 
secondary neck vessels was also significantly lower at all 4 levels 
(p< 0.03). In a subgroup of subjects without cardiovascular risk 
factors (>70% of the study sample), similar differences were 
found for arterial and secondary neck vessels between MS patients 
and HCs. No significant differences in the CSA of jugular veins 
was found between MS and HCs.
Conclusion: MS patients showed lower CSA of carotid and verte-
bral arteries and higher frequency of secondary neck vessels and 
their CSAs compared to HCs, independently of the presence of 
cardiovascular risk factors.
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EP1528
Correlation between cognitive dysfunction and the corpus 
callosum index, brain atrophy, lesion load in multiple sclero-
sis
L. Immich Gonçalves1, G. Rodrigues dos Passos2, L. Piccoli 
Conzatti2, J. Luiz Palmeiro Burger3, G. Henrique Tomasi2, 
M. Edler Zandona2, L. Schermann Azambuja3, I. Gomes3, A. 
Franco3, D. Kazutoshi Sato1,2,3, J. Becker1,2,3
1School of Medicine of Pontifical Catholic University of Rio 
Grande do Sul, 2São Lucas Hospital, Neurology Service, 3Brain 
Institute (BraIns), Pontifical Catholic University of Rio Grande 
do Sul, Porto Alegre, Brazil
Background: Cognitive dysfunction is associated with brain atro-
phy in multiple sclerosis (MS). The brain and lesion volumetric 
measurements are time and resource consuming and they are still 
not available in routine practice. The corpus callosum index (CCI) 
is measured using conventional magnetic resonance imaging 
(MRI) and it may be a surrogate marker of brain atrophy in MS. 
However, no study evaluated the correlation between cognitive 
dysfunction and CCI.
Objective: To assess the correlation between the cognitive dys-
function and the CCI, brain and MS lesion volumes in MS.
Methods: This study was a cross-sectional, exploratory study with 
relapsing-remitting MS using clinical and neuropsychological 
assessments and MRI scans using a GE 3T scanner. The CCI 
is calculated measuring anterior, medium and posterior seg-
ments of CC adjusted to its greatest anteroposterior diameter. 
Automated total and segmented brain volumetric measurements 
were performed with the FreeSurfer software. MS lesion load 
volume was calculated using Freesurfer. The correlations were 
adjusted for age, disease duration and educational level as 
appropriate.
Results: Twenty-four patients were included. They were in their 
majority women (58.3%) and Caucasians (87.5%). The mean age 
was 28.8 (SD 7.9) years and the median disease duration was 17.5 
months (IQR 7 - 79.5). The median EDSS score was 2.5 (range 0 
- 5). The CCI correlated with the scores on the MS Functional 
Composite - MSFC (R=0.457, p=0.037). The CCI correlated with 
individual scores from 9-Hole Peg Test (R=-0.463, p=0.030), 
Paced Auditory Serial Addition Test - PASAT (R=0.461, p=0.035), 
but has no correlation with the Timed 25-Foot Walk test. The CCI 
correlated well with the corpus callosum volume - CCV (R=0.798, 
p< 0.001), white matter fraction - WMF (R=0.615, p< 0.003), 
brain parenchymal fraction - BPF (R=0.489, p=0.024) and MS 
lesions volume (R=-0.704, p< 0.001). There were no correlations 
between the CCI and gray matter fraction, as well as with the 
Expanded Disability Status Scale scores.
Conclusion: The cognitive dysfunction tests requiring hand func-
tion and auditory processing correlates with the CCI. The CCI 
correlates with brain volumetric measurements (CCV, WMF, 
BPF) and MS lesion load. The CCI is a practical surrogate marker 
of neurodegeneration in patients with MS.
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EP1529
Pathophysiology of MS tremor: an fMRI study
F.M.C. Boonstra1, G. Noffs2,3, T. Perera4,5, C.J. Shanahan1, A.P. 
Vogel3,4,6, A. Evans2, H. Butzkueven2,7, A. van der Walt2,7, S.C. Kolbe1
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1Anatomy & Neuroscience, University of Melbourne, 
2Neurology, Royal Melbourne Hospital, 3Centre for 
Neuroscience of Speech, University of Melbourne, 4The Bionics 
Institute, 5Medical Bionics, University of Melbourne, Melbourne, 
VIC, Australia, 6Neurodegeneration, University of Tübingen, 
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Introduction: Tremor is a disabling movement disorder in 
Multiple Sclerosis (MS) that has no effective treatment and 
poorly understood pathophysiology. Understanding the brain 
regions involved in MS tremor could advance treatment 
development.
Aim: To understand the functional brain abnormalities associated 
with upper limb tremor in MS.
Methods: Twenty-three MS patients with unilateral upper limb 
tremor (MST) and twenty MS patients without tremor (MSC) 
underwent 3T magnetic resonance imaging (MRI) (MPRAGE, 
DIR and task fMRI) and a clinical tremor assessment. Tremor 
was quantified using the Bain score (0 to 10) for overall sever-
ity, writing and Archimedes spiral drawing. Cerebellar function 
was quantified using the Scale for the assessment and rating of 
ataxia (SARA). The fMRI tasks included a ‘brick-breaker’ joy-
stick game that aimed to isolate tremulous movement by con-
trasting two conditions: ‘play’ (playing the game) and ´move´ 
(rhythmic left/right movement of joystick without game). Task 
fMRI was analysed using FSL FEAT. Lesions were automati-
cally segmented using LST toolbox version 2.0.15 for SPM. 
Regions of interest (ROI) were identified from FEAT analyses 
for correlation with tremor scores. Statistical analyses were per-
formed in SPSS.
Results: MST (47.6±12.9y, Expanded Disability Status Scale 
(EDSS) 4.1±1.7) and MSC (46.2±11.0y, EDSS 3.4±1.6) groups 
were well matched. MST showed significantly higher activation 
in ‘play’ vs ‘watch’ in the bilateral sensorimotor cortex compared 
to MSC. Furthermore, activation within bilateral sensorimotor 
cortex significantly correlated with Bain tremor severity (p< 
0.001), handwriting (p< 0.000), Archimedes spiral (p< 0.000), and 
SARA (p< 0,005). Ipsilateral sensorimotor cortex activation cor-
related with lesion load (p< 0.010).
Conclusion: This study demonstrates a strong involvement of the sen-
sorimotor cortex in the pathophysiology of upper-limb tremor in MS.
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Quantum - Value and feasibility of standardised, quantitative 
MRI analyses of MS patients in routine clinical practice
S. Schippling1, A.-C. Ostwaldt2, L. Spies2, R. Opfer1,2, K. Schuh3
1Department of Neurology, University Hospital of Zurich, 
Zurich, Switzerland, 2Jung Diagnostics GmbH, Hamburg, 
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Background: Magnetic resonance imaging (MRI) analyses play a 
key role both in the diagnosis and in treatment monitoring of 
patients with multiple sclerosis (MS). While reliable, quantitative 
analyses of highly standardised MRIs are carried out in clinical 
trials, comparable standards are yet to be implemented in clinical 
routine.
Aim: The data collection QUANTUM aims to evaluate if access 
to standardised quantification of MRI data and visualisation in 
reports, in addition to radiological findings provides additional 
benefit for neurologists working in day-to-day MS patient 
management.
Methods: Approximately 3,000 MRI analyses will be per-
formed in 200 participating centres in Germany . The standard-
ised MRI data (3D T1 gradient-echo sequence and 2D/3D 
FLAIR) are analysed by means of a centralised automatic pro-
cessing pipeline (Biometrica MS®, jung diagnostics GmbH). 
The analysis comprises of a volumetric quantification of brain 
volume, as well as T2 lesion load and number. Percentage brain 
volume change is computed (using optimized SIENA pipeline) 
after the availability of follow-up scans. Scanner specific 
effects are accounted for using normative data sets for healthy 
controls generated for each individual MRI platform. The 
results are visualised and provided to the participating physi-
cians as a report. The value and feasibility are evaluated using 
a questionnaire.
Results: QUANTUM started in June 2016. 60 radiological cen-
tres across Germany built-up scanner-specific data sets of healthy 
controls. By mid-2017, approximately 100 neurological centres 
would participate in the project and up to 1,000 MRIs would be 
analysed. The design used in data collection,
the MRI protocol, and details of the centralised processing pipe-
line as well as baseline data from the first 100 centres will be 
presented.
Conclusion: In the course of the QUANTUM study, standard-
ised MRI and MRI evaluations that were previously restricted to 
the clinical trial setting or expert sites were broadly made avail-
able. The optimisation of MRI protocols, the correction for scan-
ner effects by means of scanner-specific control data and 
visualised reports could help to overcome limitations of compa-
rable but less systematic approaches in routine clinical MS care. 
In addition and when fully initiated, data collected in the context 
of QUANTUM carries unique potential to improve the quality of 
imaging data collected in so-called “real-world registries” in the 
future.
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Accuracy and reliability of manual versus automated thala-
mus segmentation in patients with MS
A.-C. Ostwaldt1,2, R. Opfer1,2, C. Egger2, P. Manogaran2,3, L. 
Spies1, S. Schippling2
1Jung Diagnostics GmbH, Hamburg, Germany, 
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Department of Neurology, University Hospital Zurich and 
University of Zurich, 3Department of Information Technology 
and Electrical Engineering, Swiss Federal Institute of 
Technology, Zurich, Switzerland
Background: Atrophy of the thalamus in multiple sclerosis (MS) 
is associated with cognitive malfunctioning and disability pro-
gression. An accurate and reliable volumetric analysis of the thal-
amus is hampered by low contrast between the thalamus and 
surrounding tissue on T1 MR images.
Methods: We analysed 3D T1 images from two independent data-
sets. Dataset 1 contained 30 MS patients, scanned on a 3 Tesla 
Philips scanner. Dataset 2 was publicly available (Biberacher et al. 
2016) and contained a single MS patient, scanned 5-6 times on 3 
different MR scanners (GE, Philips, and Siemens) within a few 
weeks. Thalamus volumes were determined manually using the 
annotation tool itk-SNAP (www.itksnap.org), along with anatomi-
cal atlases and under the supervision of an expert neurologist. For 
automated thalamus segmentation, we used a previously pub-
lished (Opfer et al. 2016) atlas based volumetry approach built on 
SPM12 (Statistical Parametric Mapping), and volumetry with 
FSL FIRST (FMRIB Software Library).
Results: In dataset 1 (mean age 33 years, 70% females) the mean 
thalamus volume was 11.5 ml, 14.3 ml, and 9.9 ml for SPM, FSL, 
and manual segmentation, respectively. Mean volumetric off-set 
was 1.6 ml between manual and SPM derived volumes, and 4.5 ml 
between manual and FSL. Manually derived volumes correlated 
slightly higher with SPM volumes (r=0.77) than with FSL vol-
umes (r=0.71, difference not significant).
For all repeated scans of the 29-year-old female in dataset 2, mean 
thalamus volumes were 9.2 ml (SPM), 11.2 ml (FSL) and 6.5 ml 
(manual). Coefficient of variance was highest for manual segmen-
tations (8.1%, 3.2% and 3.3% for GE, Philips and Siemens), and 
similar for SPM (0.98%, 0.81% and 1.0% for GE, Philips and 
Siemens) and FSL volumes (1.3%, 0.84% and 1.2% for GE, 
Philips and Siemens). The mean off-set between manual and SPM 
derived volumes was 3.4 ml, 2.6 ml and 2.2 ml for GE, Philips, 
and Siemens data, respectively. The off-set between manual and 
FSL derived volumes was 5.2 ml, 4.5 ml, and 4.3 ml (for GE, 
Philips, and Siemens).
Conclusion: In our study, SPM and FSL thalamus volumes were 
larger than manually derived volumes. For FSL, this has been 
shown previously in healthy controls. The off-set was similar in 
dataset 1 and 2, and largely independent of the scanner. SPM 
derived volumes were closer to manual volumes than volumes 
assessed by FSL. Manual segmentations had a higher variability 
in the test-retest data than automatically derived volumes.
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Impact of 3 Tesla MRI on lesion detection in clinically iso-
lated syndrome: a MAGNIMS multicentre study
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Vos2, N. Cawley4, E. Sbardella5, M. Andelova6, M. Amann6,7,8, 
J.M. Lieb8, P. Pantano5,9, B.I. Witte10, J. Killestein1, C. Oreja-
Guevara11, O. Ciccarelli4, C. Gasperini12, C. Lukas13, M.P. 
Wattjes2, F. Barkhof2,14, MAGNIMS
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Madrid, Spain, 12Department of Neurosciences, San Camillo-
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Background and purpose: Increased signal-to-noise ratio has 
improved the image quality of 3 Tesla (T) MRI in comparison to 
1.5T. This allows an improved detection of multiple sclerosis 
(MS) lesions. However, to date it remains unclear if this is clini-
cally relevant in the diagnosis and follow-up of clinically isolated 
syndrome (CIS) suggestive of MS. The purpose of this multi-cen-
tre study was to investigate whether 3T MRI affects lesion detec-
tion and diagnosis in CIS.
Materials and methods: We recruited 66 CIS patients and 26 
healthy controls in 6 European MS centres. All subjects received 
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baseline 1.5T and 3T brain and spinal cord MRI. Patients who had 
not converted to MS during follow-up also received brain MRIs at 
3-6 months and at 12-15 months. The number of lesions per ana-
tomical region was scored separately on 1.5T and 3T images by 
three raters in consensus and subsequently dissemination in space 
and time (DIS and DIT) were determined according to the 2010 
revision of the McDonald criteria. Statistical analysis was per-
formed using the Wilcoxon signed-rank test for continuous varia-
bles and the McNemar test for dichotomous outcomes in SPSS 
22.0.
Results: Interim analysis of 32 patients (age 34.8±9.0 years) and 
12 controls (age 36.2±8.1 years) showed a trend towards a differ-
ence in the total number of lesions per patient, with a mean num-
ber of lesions per patient of 12.8 on 1.5T and 14.4 on 3T (p=0.088). 
This was mainly due to a significant difference in detection of 
periventricular lesions at baseline, with a mean per patient of 3.5 
on 1.5T and 4.5 on 3T (p=0.018). For healthy controls no signifi-
cant difference was seen between the two field strengths. DIS and 
DIT, and with that the diagnoses of MS, were similar between 3T 
and 1.5T (DIS p=1.00, DIT p=0.625, MS p=0.375). Full analysis 
will be presented.
Conclusion: We have extended previous findings obtained in 
single-centre studies by showing that 3T increases lesion detec-
tion in CIS suggestive of MS, but does not significantly influence 
the fulfilment of the criteria for DIS and DIT.
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Comparison of MRI findings in progressive multifocal leu-
coencephalopathy among HIV-positive patients and patients 
treated by immunosuppressive drugs, natalizumab or ritux-
imab
M. Alleg1, M. Solis1, S. Fafi-Kremer1, S. Kremer1, G. Ahle2, 
H. Oesterle2, J. De Seze1, J. Hodel3, J.P. Pruvo4, X. Leclerc4, P. 
Vermersch4, F. Bonneville5, D. Brassat5, D. Biotti5
1Hôpitaux Universitaires de Strasbourg, Strasbourg, 2Hôpitaux de 
Colmar, Colmar, 3Hôpital Henri Mondor, Assistance Publique - 
Hôpitaux de Paris, Paris, 4Hôpitaux Universitaires de Lille, Lille, 
5Hôpitaux Universitaires de Toulouse, Toulouse, France
Purpose: Progressive multifocal leucoencephalopathy (PML) is a 
demyelinating disease of the central nervous system caused by 
reactivation of the JC polyomavirus. PML is most frequently asso-
ciated with AIDS and emerges as a complication of Natalizumab 
(NAT) treatment of multiple sclerosis (MS). MRI presentation dif-
fers between HIV-positive individuals and MS patients treated 
with NAT. Rituximab (RITUX), a monoclonal antibody currently 
used for hematological malignancies and autoimmune disorders, 
is also associated with a moderately increased risk of PML. We 
compare the MRI presentation of RITUX-associated PML to NAT 
or HIV-associated PML.
Materials and methods: Brain MRI exams from 29 patients with 
a definite PML diagnosis including 12 after NAT treatment, 7 
after RITUX treatment and 10 HIV-positive patients were ana-
lyzed using the following key MRI features: aspect in T1/T2/DWI 
and T2* weighted images, location of the lesion, enhancement, U 
fibers and cortex involvement.
Results: The three PML entities show hyperintensities on T2 
weighted sequence with lesions affecting U fibers associated to 
low signal intensities in U fibers on T2* weighted sequence. Only 
NAT-associated PML shows a punctuate microcystic appearance 
in or in proximity to the lesion with a potential involvement of the 
cortex on T2, T2* and on diffusion weighted sequence and in 
some cases an early contrast enhancement. Similarly to HIV-
associated PML, RITUX-associated PML shows a rim of hyperin-
tensity on diffusion weighted sequence and no early enhancement. 
However, we observed no punctuate appearance and no cortex 
involvement.
Conclusion: Imaging features of RITUX-associated PML are dif-
ferent from those of NAT-associated PML and are close to those 
observed in HIV-associated PML. These differences may be due to 
the higher level of immunosuppression in HIV patients and patients 
treated with RITUX compared to patients treated with NAT.
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Retinal vessel oxygen saturation in multiple sclerosis
A.B. Einarsdottir1, T.L. Torp2, J. Grauslund2, H.H. Nielsen1
1Neurology, 2Ophthalmology, Odense University Hospital, 
Odense, Denmark
06_MSJ731285.indd   804 13/10/2017   11:10:59 AM
ePosters 23(S3) 805
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Introduction: Optical coherence tomography studies have previ-
ously demonstrated structural retinal changes in patients with 
Multiple Sclerosis (MS). Retinal oximetry is a non-invasive meas-
urement of retinal metabolism and studies have shown changes in 
retinal oxygen saturation in another central nervous system 
disease.
Objective: To compare oxygen saturation in retinal blood vessels 
in MS patients with or without optic neuritis (ON) and healthy 
controls.
Method: Oxygen saturation of hemoglobin was measured in reti-
nal blood vessels, with spectrophotometric noninvasive retinal 
oximeter. 29 MS patients, 12 with and 17 without history of ON 
were compared to 24 healthy individuals in a case-control study.
Results: Retinal arteriolar oxygen saturation was significantly 
higher in MS patients compared to healthy controls (96.6 ± 3.2% 
vs. 94.1 ± 4.0%; p=0.02, mean±SD). There was an increased reti-
nal arteriolar oxygen saturation in MS patients without ON com-
pared to healthy controls (96.6 ± 2.7% vs. 94.1 ± 4.0%; p=0.03 
mean±SD) and a trend towards an increase in MS patients with 
ON compared to healthy controls (p=0.08). Retinal oxygen satu-
ration in retinal venules was not significantly increased in MS 
patients compared to healthy controls (60.2 ± 5.4% vs. 57.9 ± 5.8; 
p=0.15, mean±SD). There were no significant changes in retinal 
venule saturation between MS patients with ON (p=0.12) or MS 
patients without ON (p=0.37) compared to healthy controls. 
Retinal arteriovenous difference was not significantly changed in 
MS patients compared to healthy controls (36.4 ± 5.5% vs. 36.2 ± 
4.4%; p=0.87). There was no significant difference measured in 
retinal vessel saturation when MS patients with ON and without 
ON were compared.
Conclusion: These results show metabolic changes in MS patients 
compared to healthy cohort. If confirmed in prospective studies, 
non-invasive retinal oxygen imaging may be a promising bio-
marker for MS.
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Stratifying FLAIR-hyperintense white matter lesions in a 
pilot study of MS, CIS, dementia and concussion using mag-
netic susceptibility mapping
V. Wiggermann1,2,3, C. Kames1,2, R. Hsiung4,5, L.M. Metz6, 
D.K.B. Li3,4,7, A. Traboulsee4,5, A. Rauscher1,2,8
1Physics and Astronomy, 2Pediatrics, 3UBC MRI Research 
Centre, 4Medicine (Neurology), 5Centre for Brain Health, 
University of British Columbia, Vancouver, BC, 6Clinical 
Neurosciences, University of Calgary, Calgary, AB, 7Radiology, 
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Background: In multiple sclerosis (MS), FLAIR or T2 magnetic 
resonance images (MRI) are used to identify new white matter 
hyperintensities (WMH) as an important measure of treatment 
efficacy. However, WMH detected with these techniques are path-
ologically non-specific and can appear independent of demyeli-
nating processes due to hypertension or aging. Quantitative MRI 
may help to differentiate lesions that look identical on FLAIR but 
differ pathologically.
Goal: To investigate the magnetic susceptibility (QSM) and R2* 
of WMH in relapsing-remitting MS, clinically isolated syndrome 
(CIS), concussion (CC) and dementia (DEM).
Methods: 3T QSM MRI data, together with FLAIR or T2, were 
acquired in 3 patients each of the 4 cohorts. QSM and R2* were 
estimated from the phase and magnitude of multi-echo gradient 
scans. After Laplacian unwrapping and V-SHARP, QSM maps 
were created using in-house software. R2* maps were obtained by 
linear fitting to the logarithmic data. WMH were manually defined 
on registered FLAIR or T2 scans. To establish the lesion contrast 
(iso/hypo/hyper-intensity), peri-lesional WM masks were defined 
by mask-dilation and subtraction of the original mask. Average 
ΔQSM-χ and ΔR2* values for each WMH were assessed.
Results: 19/43/30 and 38 lesions were identified in CC, DEM, 
CIS and MS(median age=20/82/19/62yrs). QSM-hypointensities 
were present across disorders, with increasing hypointensity, 
reflective of iron loss, in CIS and MS lesions (ΔχCC=-5.3/
ΔχMS=-18.7ppb).
CC-WMH presented as predominantly QSM-isointense (57.9%, 
Δχ=-0.3ppb), in agreement with an inflammatory response, com-
pared to DEM-WMH, which appeared equally iso- and 
hyperintense
(39.5% both,Δχ=0.6/9.7ppb) in response to a dilation of perivas-
cular spaces and the development of mild myelin pallor (Udaka 
2002,Ann NY Acad Sci).
R2*-hypointensities dominated DEM and MS (79%/84.2%,ΔR2*=-
4.6/-6.8Hz), confirming that MS lesions largely represent myelin 
and iron loss.
In contrast, iso- and hypointense WMH were similarly found in 
CC and CIS (42%/52%,ΔR2*=-1.9/-3.7Hz; 48/51%,ΔR2*=-0.5/-
4.6Hz), suggestive of lesser damage and possibly greater capabil-
ity to repair in these younger cohorts.
The majority of CIS and MS lesions was QSM-hyperintense (55% 
both,Δχ=14.2/21.3ppb), in line with the presence of edema, axonal 
and myelin damage (Li 2016,JMRI).
Conclusion: With its sensitivity to microstructure, QSM differen-
tiates MS lesions from other FLAIR-WMH, while the comple-
mentary, less-specific R2* is reduced in most WMH.
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Myelin and total water content show similar distributions in 
neuromyelitis optica and multiple sclerosis lesions
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Purpose: To use advanced magnetic resonance imaging (MRI) to 
determine whether neuromyelitis optica (NMO) brain lesions 
exhibit different distributions of myelin damage or water content 
compared to multiple sclerosis (MS).
Introduction: MS and NMO are distinct inflammatory diseases 
that are similar in clinical presentation. NMO and MS lesions can 
appear similar on conventional MRI. Aquaporin channels are pri-
marily affected in NMO, thus water distributions may differ 
between diseases. Due to different mechanisms of inflammation, 
the patterns of demyelination may also diverge in NMO lesions 
compared to MS. An advanced MRI technique, multi-echo T2 
relaxation imaging, was used to quantify the total water content 
(WC) and myelin (myelin water fraction (MWF)) in NMO and 
MS lesions.
Methods: Ten NMO (mean age: 42y, median EDSS: 2.5), 13 MS 
(41y, EDSS: 2.5), and 15 healthy controls (41y) underwent MRI 
on a Philips 3T scanner. The healthy control data was used to cre-
ate normative 3D atlases of the means and standard deviations of 
WC and MWF. The atlases were used to calculate Z-score maps 
for each MS and NMO patient, indicating how many standard 
deviations away from the mean each value is for an individual 
patient compared to controls. NMO and MS lesions were identi-
fied on conventional images by a radiologist. The areas within 
lesions were analysed on the Z-score maps and histogram analysis 
was performed.
Results: The histograms for WC and MWF Z-scores were visu-
ally similar for NMO (average of Z-score means: WC: +3.2; 
MWF: -0.8) and MS lesions (WC: +2.3; MWF: -1.2). There was 
no difference between NMO and MS average Z-scores for WC 
(Student’s t-test) (p=0.30) or MWF (p=0.31). The distribution of 
values within lesions was visualized using heat maps. The WC 
values were distributed with higher values near the centre of the 
lesions, while the MWF values had lower values near the centre. 
This pattern held true for both diseases.
Discussion: While the pathophysiology of MS and NMO are dif-
ferent, the lesions appear to be very similar in terms of their WC 
and MWF values. WC was higher, while MWF was lower in 
lesions when compared to the same regions in healthy controls. 
The distribution of values within lesions was also similar, where 
there is higher WC and lower MWF towards the centre of a lesion. 
This suggests that there is less myelin in the middle of lesions 
compared to the periphery. Overall, our results show that NMO 
and MS lesions are similar in terms of WC and MWF.
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The corticospinal tract in relapsing-remitting multiple scle-
rosis: a pilot tractography and fixel-based MRI analysis at 
ultra high-field
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Background: Multiple sclerosis (MS) is a progressive neurologi-
cal disorder of the central nervous system associated with demy-
elination and axonal loss, leading to permanent disability. Mobility 
impairment is the most disabling symptom in MS. Changes to 
lower limb disability in MS are likely related to axonal damage in 
the corticospinal tract (CST), the main motor pathway.
Using the high SNR afforded by ultrahigh field (7T) MRI, diffu-
sion MRI can be acquired with spatial resolution approaching ana-
tomical imaging, with high angular resolution, and within 
clinically feasible scan times (~10mins). This allows for analysis 
using higher order diffusion models such as constrained spherical 
deconvolution that can estimate the fibre orientation distribution 
(FOD) in each voxel, together with associated axonal damage 
markers such as fibre density (FD) and fibre cross-section (FC) 
that can be analysed using “fixel-based analysis”1.
Objective: This preliminary study aimed to compare the degree of 
CST degeneration (loss of FD and FC) to clinical motor disability.
Methods: Eleven relapsing-remitting MS patients (1 male and 10 
females, 42 ± 12.4 years) were tested. All had minimal or no lower 
limb dysfunction (EDSS < 4, pyramidal and cerebellar Kurtzke’s 
Functional System (KFS) ≤ 2).
Diffusion weighted MRI was acquired using 7T MRI and a simul-
taneous multi-slice 2D spin-echo EPI sequence2 (TR=7000ms, 
TE=72.4ms, multiband factor=2, GRAPPA=3, slices=128, 
1.24mm isotropic resolution, whole brain coverage, 3 b-shells: 
1000, 2000, 3000 s/mm2, 103 directions, 6 b0 images).
FODs were estimated for each voxel for each subject using 
MRtrix 3.0, and a population FOD template was generated. 
Probabilistic tractrography was used to identify the CST (Fig. 1). 
FC and FD were computed from the CST and compared to pyram-
idal KFS scores for each subject.
Results: Loss of FD (but not FC) in the subcortical white matter 
of the CST was associated with increased pyramidal dysfunction 
(puncorrected < 0.05) (Fig. 2).
Conclusion: Using ultra-high field 7T diffusion MRI we detected 
loss of FD in the CST that was associated with pyramidal disabil-
ity. FD could provide a useful marker of disease progression lead-
ing to loss of mobility. Future studies will aim to replicate this in 
a larger cohort.
References: 1. Raffelt, D.A. et al. Neuroimage 144,58-73 (2017)
2. Vu, A.T. et al. Neuroimage 122, 318-331 (2015)
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MRI-based measures for quantifying treatment efficacy in 
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Background: Magnetic resonance imaging (MRI) plays a key 
role in tracking disease activity, evaluating treatment efficacy, and 
predicting long-term disability in multiple sclerosis (MS) patients. 
Natalizumab (henceforth NA) has been shown to reduce the rate 
of clinical relapse compared to placebo and slow accumulation of 
new lesions that appear hyperintense on T2-weighted MRIs. It 
remains unknown whether NA has quantifiable effects on MRI 
lesional intensities that could be used as potential markers for 
therapeutic response or tissue repair.
Objectives: This study assessed differences in MRI intensity 
within new lesions appearing before and after NA initiation. 
Secondary objectives tested for intensity changes in chronic 
lesions that may reflect repair.
Methods: Relapsing remitting MS patients were retrospec-
tively identified who initiated NA at the University of 
Pennsylvania between 2009-2014. Fluid attenuated inversion 
recovery (FLAIR) and T1-weighted sequences from two pre-
NA scans and one post-NA scan were obtained from a common 
protocol and preprocessed. Manual segmentations identified 
chronic lesions, defined by their presence on earliest MRI (1.3 
years before NA on average), and acute lesions, defined by first 
appearance on the MRI immediately prior to NA initiation (0.4 
years before NA on average) or after NA initiation (0.6 years 
after on average). The mean and quartiles of normalized MRI 
intensities from 214 chronic and 229 acute lesions were ana-
lyzed using linear mixed models to estimate changes in lesional 
intensities after NA initiation.
Results: Although not statistically significant, mean (25th, 50th, 
75th quartile) normalized FLAIR intensity decreased by 0.8 (0.5, 
1.2, 1.1) units in post-NA new lesions compared to lesions that 
formed prior to NA, suggesting therapeutic response. Similarly, 
mean (25th, 50th, 75th quartile) normalized T1 lesional intensity 
increased by 0.7 (1.0, 0.2, -0.2) units. In chronic lesions, mean 
(25th, 50th, 75th quartile) normalized FLAIR intensity decreased 
by 1.0 (0.6, 1.0, 1.2) units and mean (25th, 50th, 75th quartile) 
normalized T1 intensity increased by 1.4 (2.0, 1.5, 0.7) units, sug-
gesting possible tissue repair after NA initiation.
Conclusions: Natalizumab may lead to decreases (increases) in 
normalized FLAIR (T1) intensities in new lesions. Lesion-based 
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analyses may provide a useful measure of treatment efficacy. 
Further investigation using a larger study cohort is warranted.
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Purpose: Our aim was to use a novel time-resolved magnetic 
resonance (MR) technique, for high contrast enhanced venogra-
phy with high temporal resolution, as an objective method for the 
assessment of cerebral venous hemodynamics in patients with 
multiple sclerosis (MS), their healthy siblings, and unrelated 
healthy controls.
Materials and methods:39 patients with clinically definite 
MS, 31 siblings and 31 unrelated controls were recruited and 
imaged between January and December 2011. Dynamic mag-
netic resonance angiography data were acquired using 
4D-TRAK on a 3T Philips Achieva scanner. Two blinded read-
ers assessed contrast arrival times over 68 time points while 
reviewing the upper and lower cross sections of the carotid 
arteries and the internal jugular veins (IJV) for maximum con-
trast. We further computed the cerebral circulation times 
(CCT) as the arrival time to the IJV minus the arrival time to 
the arteries based on the two manually defined landmarks. 
Statistical analysis was done using Kruskal-Wallis and 
ANCOVA, taking the age as a covariant.
Results:The median left and right CCTs were 6.14s for patients, 
6.24s for siblings, and 6.14s for unrelated controls for the upper 
landmarks and 7.80s for patients, 7.60s for siblings, and 7.80s for 
unrelated controls for the lower landmark. No significant differ-
ences in the CCTs were found between the three groups (p > 0.2). 
Furthermore, no correlations were found between the CCTs and 
the brain volumes, expanded disability status scale (EDSS) or dis-
ease duration.
Conclusion:The lack of significant differences in venous flow 
between patients with MS, their siblings and unrelated controls on 
MR venography suggests that flow abnormalities are not charac-
teristic for MS. Our results directly contradict previous findings 
obtained using ultrasound but agree with results obtained with 
catheter venography.
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EP1540
Functional brain network stability in natalizumab treated 
multiple sclerosis patients: a one year follow-up study
K.A. Meijer1, O. Wiebenga2, A.J. Eijlers1, M.D. Steenwijk1, J.J. 
Geurts1, M.M. Schoonheim1
1Anatomy and Neurosciences, 2Radiology, MS Center 
Amsterdam, Amsterdam Neuroscience, VU University Medical 
Center, Amsterdam, The Netherlands
Introduction: Natalizumab treatment is highly effective in limit-
ing the formation of new white matter (WM) lesions in multiple 
sclerosis (MS). It is currently unknown, however, in which way 
natalizumab influences the functional brain network. In this study, 
we longitudinally examined the severity of functional network 
changes in MS patients treated by either interferon-β/glatiramer 
acetate (IFNb/GA) or natalizumab over a period of one year.
Methods: For a period of one year, we followed relapsing-remit-
ting MS patients initiating natalizumab at baseline (N=20), con-
tinuing IFNb/GA (N=17) and healthy controls (HC; N=13). All 
participants underwent resting-state fMRI and structural MRI, as 
well as cognitive and clinical assessments. For each subject, a 
whole-brain functional network was constructed by calculating 
the functional connectivity between all pairs of brain regions in 
the automated anatomical labeling (AAL) atlas. For each network 
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connection a Z-score was calculated relative to HC and the aver-
age increase or decrease in Z-scores at baseline and after one year 
were defined as the severity of functional network change. 
Progression in severity of functional network changes was related 
to lesion load, whole-brain WM integrity and deep grey matter 
volume, as well as longitudinal changes in average cognition, 
nine-hole peg test (9-HPT) performance and EDSS.
Results: At baseline, only significant increases in connectivity 
were observed in MS compared to HC (p< 0.05), without differ-
ences between the natalizumab and IFNb/GA groups. After one 
year, functional connectivity levels further increased, but only in 
patients treated with IFNb/GA (24%; p< 0.05), whereas functional 
connectivity levels remained stable in the natalizumab and HC 
group. In MS, this change in functional connectivity was associ-
ated with increasing lesion load and loss of WM integrity (resp. 
rho=0.408 and rho=-0.383) and a decline in performance on the 
9-HPT (rho=0.419).
Conclusion: In MS patients initiating natalizumab treatment, the 
severity of functional network changes remained stable in the first 
year of treatment, while the functional connectivity of those 
patients treated with IFNb/GA therapy increased over a 1-year 
period. These findings indicate that natalizumab may stabilize the 
functional network in MS.
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EP1541
Resting State in relapsing-remitting MS patients with verbal 
episodic memory or social cognition impairment and low 
level of motor disability
E. Ciampi1,2, T. Labbe1, R. Uribe-San-Martin1,2, J.P. Cruz1, M. 
Vasquez1, A. Reyes1, C. Carcamo1, Á. Rovira3, D. Pareto3
1Neurology, Pontificia Universidad Católica de Chile, 2Hospital 
Sotero del Rio, Santiago, Chile, 3MR Unit and Section of 
Neuroradiology (Department of Radiology), Vall d’Hebron 
University Hospital, Barcelona, Spain
Background: Functional MRI (fMRI) provides information 
about the plasticity of the human brain. Special interest has arisen 
from the study of cognitive impairment and Resting State (RS) 
fMRI in MS.
Objective: To investigate RS differences in MS patients with low 
level of motor disability with and without cognitive impairment 
and to correlate these findings with clinical and neuropsychologi-
cal measures.
Methods: Cross-sectional study including RS fMRI and structural 
images (3D T1/FLAIR) acquired from a 3T scanner (Philips 
Ingenia). Clinical evaluations and a complete neuropsychological 
battery were also performed on the same day ± 2 weeks. Verbal 
Episodic Memory (VEM-California Verbal Learning Test VIII-
CVLT) and Social Cognition (SOC-Mini Social and Emotional 
Assessment-miniSEA) were assessed creating groups (normalVEM 
vs. impairedVEM and normalSOC vs. impairedSOC) according to Z 
score with a cut-off ≤ -1.5. RS studies were analysed with 
MELODIC/FSL. After concatenating all studies, RS networks were 
visually identified. Then, a dual regression analysis was performed 
to assess the differences between normalVEM vs. impairedVEM, 
and normalSOC vs. impairedSOC. Finally, the mean value for each 
subject in the clusters that showed significant differences (p< 0.05 
threshold free cluster enhancement images) was extracted to corre-
late with the clinical and neuropsychological measurements.
Results: We included 37 relapsing-remitting MS patients, 65% 
women, mean age 36.2 ± 9 years, mean disease duration 6.4 ± 4 
years, median EDSS 1.0 (range 0 - 6). Verbal Episodic Memory 
was impaired in 45.9% and Social Cognition in 24.3%. RS showed 
significant differences (decreases and increases) in networks 
including sensory-motor, visual, executive, default network and 
cerebellum for both group comparisons. In addition, differences 
found in the VEM group comparison were correlated with CVLT 
Z score and EDSS (normalVEM median EDSS 1.0 vs. impaired-
VEM median EDSS 2.0, p=0.04); while differences found in the 
SOC group comparison, were correlated with miniSEA Z score. 
The direction and magnitude of the correlations were dependent 
on the region.
Conclusion: When MS patients were classified according to their 
VEM or SOC impairment, RS showed significant differences in 
brain synchronization. Interestingly, RS was sensitive to mild dif-
ferences of EDSS in the VEM group. Results suggest that RS 
could reflect the cognitive status of MS patients within plausible 
neurocognitive networks.
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A deep-learning method for tissue volumetry from multi-
spectral magnetic resonance imaging in multiple sclerosis
R. McKinley1,2, F. Wagner1, F. Aschwanden1, A. Salman3, A. 
Chan3, M. Reyes4, R. Wiest1
1Neuroradiology, University Hospital and Inselspital, 
2Department of Clinical Medicine, University of Bern, 
3Neurology, University Hospital and Inselspital, 4Institue for 
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Surgical Technology and Biomechanics, University of Bern, 
Bern, Switzerland
We present a method (DeepSCAN-MS) for automated volumetry 
of healthy appearing and white-matter lesion tissue from multi-
spectral magnetic resonance imaging in multiple sclerosis. The 
method, which is an application of deep learning, is trained on a 
combination of automated tissue classification and manual lesion 
delineation, and provides a method for tracking the two of the 
NEDA-4 biomarkers for disease activity. These biomarkers cannot 
be adequately tracked manually, either because they are infeasible 
(atrophy) or time consuming and non-repeatable (lesion load)
FLAIR imaging of 123 MS patients from the Inselspital were 
examined by two raters, who delineated the FLAIR hyperintense 
lesions on each axial slice. The delineations from the first rater 
were superimposed on segmentations obtained from FSL FAST 
(2) (showing WM, GM and CSF) and Freesurfer (subcortical grey 
matter). The fused segmentations from 80 randomly selected 
cases, together with the FLAIR, T1-weighted and T2-weighted 
images were, after rigid registration, used to train an ensemble of 
deep learning classifiers (variations on the recently introduced 
Densenet architecture) The method was then applied to the 
remaining 43 cases. Segmentations of intracranial volume, white 
matter, grey matter and lesion tissue were signficantly correlated 
with ground truth volume (p< 0.001) in each case. A Bayesian 
method for providing confidence intervals for volumes allows to 
track significant volume change over time.
Disclosure
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EP1543
3T-PET/MRI discloses different metabolic states of cortical 
lesions in multiple sclerosis
D. Poggiali1, D. Cecchin2, A. Favaretto1, A. Lazzarotto1, M. 
Margoni1, A. Riccardi1, F. Anna Chiara3, P. Zucchetta2, F. 
Causin4, F. Bui2, P. Gallo1
1Department of Neuroscience DNS, Università degli Studi di 
Padova, 2Nuclear Medicine Unit, Department of Medicine 
DIMED, 3Department of Cardiac, Thoracic and Vascular 
Sciences, 4U.O.C. Neuroradiology, Azienda Ospedaliera di 
Padova, Padua, Italy
Background: Cortical lesions (CL) are believed to play a role in 
the accumulation of physical and cognitive disability in multiple 
sclerosis (MS). Up to date, no study has investigated the meta-
bolic behavior of CL.
Aim: To analyze the absolute 18F-FDG metabolism of CL in MS 
patients by means of a fully integrated 3T-Positron Emission 
Tomography/Magnetic Resonance Imaging (3T 18F-PET/MRI) 
system.
Methods: Fifteen early relapsing remitting MS (eRRMS) with no 
sign of cognitive impairment (CI) and fifteen RRMS with signifi-
cantly longer disease duration and clinical evidence of CI 
(CI-RRMS) were enrolled in the study. Physical and cognitive 
evaluations were done by EDSS and Rao´s BRB. Dynamic 
18F-FDG-PET/MRI (Siemens Biograph 3TMRI/PET System) data 
were analyzed with Patlak plot method to obtain absolute meta-
bolic rate of glucose (aMRglu). CL and white matter (WM) lesions 
were identified on 3DFLAIR and 3DDIR images, respectively.
Results: eRRMS had lower CL volume and number than 
CI-RRMS and, despite the limited number of patients, the differ-
ences were significant (p=0.02 and p=0.01, respectively). The 
great majority of CL (68.0%) showed aMRGlu values in the range 
of the surrounding apparently normal cortex, but 17.8% had sig-
nificantly increased aMRGlu values and 14.2% were hypometa-
bolic. aMRGlu inversely correlated with CL number and volume 
in both left (p=0.01, r=-0.49 and p=0.02, r=-0.42) and right pari-
etal (p=0.02, r=-0.43 and p=0.03, r=-0.39) lobes.
Interpretation: CL were found to differ in aMRGlu values. 
Whether the metabolic state of CL reflects their evolution from an 
initial hypermatabolic inflammatory phase (potentially excito-
toxic) to a final hypo-metabolic neurodegenerative phase merits 
to be investigated. Indeed, the metabolism of CL might be the link 
between inflammation and neurodegeneration in MS.
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EP1544
Neuropsychological correlations differ according to the 
spatial distribution of corpus callosum atrophy in multiple 
sclerosis
B.K. da Costa1,2, M.E. Zandoná1,2, G.R. dos Passos1,2, L.S. 
Azambuja2, L.I. Gonçalves2,3, J.L.P. Burger2, A. Franco2, I. 
Gomes2, D.K. Sato1,2,3, J. Becker1,2,3
1Neurology Department, Pontifical Catholic University of Rio 
Grande do Sul, 2Brain Institute of Rio Grande do Sul, 3School of 
Medicine, Pontifical Catholic University of Rio Grande do Sul, 
Porto Alegre, Brazil
Introduction: Corpus callosum (CC) measurements have been 
shown to correlate with brain volumes and disease severity in 
multiple sclerosis (MS). While most CC measurements are per-
formed taking that structure as a whole, it is worth noting that the 
origin of the fiber across the CC segments is heterogeneous. This 
study was done to assess whether different spatial distributions of 
atrophy across the CC could be associated with impairment in 
specific parameters of disability and cognitive dysfunction in MS.
Methods: Patients with relapsing-remitting MS underwent 3.0 T 
brain MRI. The FreeSurfer© software was used to estimate the CC 
volume, segmented by regions (anterior, mid-anterior, central, 
mid-posterior, and posterior). Clinical assessment included the 
Expanded Disability Status Scale (EDSS), the MS Functional 
Composite (MSFC), the Brief Repeatable Battery of 
Neuropsychological Tests, the Wechsler Memory Scale III 
(WMS), the Stroop test, and the Boston Naming Test (BNT).
Results: Twenty-one patients with relapsing-remitting MS were 
included. Moderate to strong correlations were seen between the 
PASAT (attention, working memory and information processing) 
and almost all of the CC segments (r=0.529 to 0.647, p< 0.01), 
except the anterior one, as well as between the BNT (semantic 
memory) and the central, mid-posterior, and posterior segments of 
the CC (r=0.479 to 0.550, p< 0.03). Only the mid-posterior CC cor-
related with tests of verbal memory, namely WNS - subtests Logical 
Memory I and II, and Free and Cued Selective Reminding Test - 
delayed recall (r=0.452 to 0.515, p< 0.04). The anterior CC did not 
correlate with any tests. None of the CC segments correlated with 
EDSS, other MSFC subtests, or other neuropsychological tests.
Conclusion: In line with pathological and advanced MRI studies, 
this study with conventional MRI supports different patterns of 
neuropsychological dysfunction according to the topographic dis-
tribution of atrophy across the CC in patients with MS.
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Comparison of automated brain atrophy and lesion volume 
quantification tools in multiple sclerosis patients
J. Albright, A.M. Ulug, W. Luo, K.M. Leyden, S.W. Magda, 
R.K. Haxton, C.N. Airriess
CorTechs Labs, San Diego, CA, United States
Introduction: This study used the commonly available auto-
mated tools of SIENAX from FSL, Lesion Segmentation tool 
(LST) for SPM, and NeuroQuant including its lesion segmenta-
tion module LesionQuant, from CorTechs Labs, Inc. to determine 
lesion and brain volumes in a group of MS patients. These results 
were compared to expert manual lesion segmentations. SIENAX 
and LST are research tools, widely used in the research commu-
nity. NeuroQuant is an FDA cleared, fully automated brain seg-
mentation and volume measurement tool for clinical use.
Methods: T1-weighted and FLAIR images from 24 MS (19F, 
5M, 42 ± 12 yo) patients were included in the study. Total brain, 
gray matter and white matter volumes were measured using 
SIENAX and NeuroQuant. The lesion volumes were calculated 
using LST and the LesionQuant module of NeuroQuant. Lesions 
were also manually segmented for each patient. Manually deter-
mined lesion volumes were compared with the results of the auto-
mated tools. The Pearson correlation coefficient was used in 
comparing brain volume measurements of SIENAX and 
NeuroQuant, as well as comparing the lesion volumes from LST, 
LesionQuant and manual segmentation.
Results: The total brain volumes calculated with SIENAX and 
NeuroQuant were correlated (R=0.83). LST and LesionQuant 
lesion volume determinations were highly correlated with each 
other and with manually determined lesion volumes (all R=0.97).
Conclusions: The two automated lesion determination tools, LST 
and LesionQuant, have comparable performances and their results 
are highly correlated with the manually segmented lesion vol-
umes. The whole brain volume determinations using SIENAX 
and NeuroQuant also produced results similar to each other and 
can be used to quantify brain atrophy in MS patients.
Disclosure
Authors are the employees of CorTechs Labs, Inc.
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A comparison of spinal cord grey and white matter atrophy 
in MS and healthy controls with clinical correlations
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Radiology Dept, Vall d’Hebron University Hospital, Barcelona, 
Spain
Background: Several studies have indicated the relevance for 
multiple sclerosis (MS)-related disability of spinal cord grey mat-
ter atrophy, which can now be estimated using appropriate MRI 
sequences.
Objective: To further evaluate the feasibility and clinical rele-
vance of MRI-derived estimations of spinal cord grey matter 
atrophy.
Material and methods: A convenience sample of MS patients and 
healthy controls (HC) was scanned using brain 3D T1w (MPRAGE) 
and T2-FLAIR, and spinal cord 2D heavily T1w (PSIR) sequences 
on a 3T magnet. MPRAGE and T2-FLAIR sequences were used to 
obtain whole brain parenchymal, grey and white matter fractions 
(BPF, GMF and WMF) using the automatic Lesion Segmentation 
Tool and filling implemented in Statistical Parametric Mapping. 
An experienced technician with neuroradiological supervision 
used a semiautomated method implemented in JIM software on 
MPRAGE sequences to obtain cord length, volume and mean area 
from medulla oblongata to C3 (CLmo, CVmo, CMAmo), and cord 
length and volume from C1 to C3 (CLc1, CVc1). PSIR sequences 
were used to obtain whole cord, grey and white matter areas 
(CMAc2, CGMA, CWMA) at C2-C3. Appropriate statistical tests 
were used before and after age-adjustment.
Results: 49 patients (32 female / mean age 43,0 years -SD:11.0- / 
median EDSS 4.0 - range: 0 - 7.5 / mean brain lesion volume 17,9 
ml -SD:18,4-) and 13 HC (7 female / mean age 37,8 years 
-SD:9.7-) were included. CGMA and CWMA could only be reli-
ably obtained in 17 patients and 12 controls mostly due to lesion-
related segmentation difficulties. Before and after age adjustment, 
patients with MS had significantly lower BPF, WMF, CLmo, 
CVmo, CMAmo, CLc1, CVc1, CMAc2 and CGMA than HC. 
Significant negative associations with EDSS were observed for 
BPF, GMF, CVmo, CMAmo, CVc1, CMAc2 and CGMA, but 
only CMAmo (standardized beta coefficient (sbc)=-0,254; 
p=0,091), CVc1 (sbc=-0,244; p=0,072) and CMAc2 (sbc=-0,244; 
p=0,072) survived age-adjustment.
Conclusion: Due to lesion artefacts two thirds of patients cannot 
have their spinal cord grey matter areas reliably estimated but, in 
spite of lower sample sizes, significant findings can still be 
observed.
Disclosure
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Genzyme, Celgene and Novartis
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Magnetic resonance imaging in the NMO seropositive and 
seronegative for AQP4
N.E. Araújo1, A.C. Koifman2, L.C. Thuler1, P.R. Bahia3, R. 
Alvarenga1
1Neurologia, 2Radiologia, UNIRIO/ HUGG, 3Radiologia, 
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
OBJETIVE: To describe the radiological characteristics of the 
NMO and to evaluate differences between the AQP4 positive and 
negative groups.
Methods: Patients with NMO (2006) followed between 1999 and 
2015 at Hospital da Lagoa (RJ) who dosed anti-AQP4 by IFF and 
/ or cellular methods, with at least two available skull and spinal 
MRI scans were selected for this study . The NMO complex syn-
dromes (NMO-CS) criteria of 2015 were applied to these patients. 
The MRI analysis was performed by two specialists who investi-
gated the typical radiological signs for NMO-CS. The frequency 
and characteristic of the lesions were compared in the serum posi-
tive and negative AQP4 groups.
Results: The 38 patients with NMO included in the study fulfilled 
the diagnostic criteria of NMO-CS (2015). The radiological crite-
rion was filled with the initial MRI in 60% of the cases consider-
ing specific supratentorial, infratentorial lesions, in the optic 
nerve and medulla lesions. The most frequent lesions in the AQP4 
positive patients in the order of frequency were: 1st - Cervical 
myelitis, 2nd - Bilateral or unilateral optic neuritis and 3rd - 
Brainstem lesions. In the negative AQP4 the order was: 1st - 
Dorsal myelitis, 2nd - Unilateral optic neuritis and 3rd - Brainstem 
lesions.
Conclusion: (1) The features found in the NMO were: extensive 
lesion of the optic nerve until the chiasm, Peri-chiasmatic regions 
and extensive atrophy of the optic nerve; Extensive longitudinal 
uni or bilateral lesion of the spinal cortical tract from the origin to 
the brainstem; Cervical myelitis with extension to the bulb and 
extensive atrophy of the spinal cord; Large coalescing lesions on 
the trunk and brainstem with ependymal lesions; Extensive lesions 
in the cerebral hemispheres in continuity with supratentorial 
ependymal lesions. (2) There was no significant difference in the 
brain lesions according to AQP4 status.
Key words: Optic neuromyelitis, Multiple sclerosis. Magnetic 
Resonance Imaging
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MRI in transverse myelitis: correlation with expanded dis-
ability status scale
K. Schwartz, M. Levy
Johns Hopkins University School of Medicine, Baltimore, MD, 
United States
Background: Magnetic resonance imaging is used as a diagnostic 
tool to detect spinal cord lesions.
Objective: The objective of this paper is to examine cross-sec-
tional correlations of MR images with EDSS. Limited number of 
studies examined EDSS and MRI correlations in patients with 
Transverse Myelitis. MRI images can help predict recovery pro-
gress based on lesion characteristics.
Methods: We conducted a retrospective review of the last 42 
monophasic TM admissions to the Johns Hopkins Hospital. 
Inclusion criteria included a single inflammatory attack localizing 
to the spinal cord presenting with a change in neurological exami-
nation and a new MRI lesion. Subjects were excluded if their TM 
was part of a recurring disease or if they tested positive for the 
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NMO-IgG blood test. Extended Disability Status Scale (EDSS) 
score was calculated at baseline, at presentation, at discharge, and 
on follow-up. MR images were examined and broken down by
1. Number of Vertebral Bodies
2. Lesion Location
3. Length of the lesion (cm or mm?)
Results of the MRI were compared to the EDSS scores to evaluate 
outcome based on lesions characteristics.
Results: Of the 42 subjects enrolled, 37% with Long Lesion 
(more than 4 vertebral bodies) showed improvement by at least 1 
point at one year follow up on EDSS exam. Whereas 19% with 
Short Lesion (3 or less vertebral bodies) show improvement from 
admission to one year follow up.
Conclusions: Longer lesion on MR images from admission to 
follow up resulted in better long term recovery outcome.
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Nothing to disclose
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Resting state functional networks and cognitive performance 
in clinically isolated syndromes
M. Batlle1, A. A.S. Alahmadi1, S. Collorone1, F. Prados1,2, B. 
Kanber2, S. Ourselin2, A. T. Toosy1, C.A.M. Gandini Wheeler-
Kingshott1,3,4, O. Ciccarelli1,5, C. Tur1
1UCL Institute of Neurology, University College London (UCL), 
2Translational Imaging Group, Centre for Medical Image 
Computing, Department of Medical Physics and Biomedical 
Engineering, University College London, London, United 
Kingdom, 3Department of Brain and Behavioural Sciences, 
University of Pavia, 4Brain MRI 3T Mondino Research Centre, 
C. Mondino National Neurological Institute, Pavia, Italy, 
5National Institute for Health Research University College 
London Hospitals Biomedical Research Centre, London, United 
Kingdom
Introduction: Cognitive impairment in multiple sclerosis (MS) 
has been related to structural brain damage, but the mechanisms 
linking these two phenomena are unclear. Resting-state functional 
MRI (rsfMRI) is a promising method to evaluate this link, since 
abnormal functional connectivity (FC) patterns may reflect either 
maladaptive or compensatory mechanisms, favouring or limiting 
clinical consequences of structural brain damage even from early 
stages of MS. Independent component analysis (ICA) is a tool to 
study FC by decomposing within-voxel BOLD signal into differ-
ent components. Voxel clusters with temporally correlated com-
ponents form the specific resting-state functional networks (RSN), 
with clearly defined cognitive roles.
Aims: To characterise, in patients with a clinically isolated syn-
drome (CIS), the different RSN and the association between FC 
within the RSN and cognitive performance.
Methods: We included 19 CIS patients (9 female, mean age 
36±9 years) and 12 healthy controls (HC, 8 female, 35±8 years). 
All subjects were scanned (T1- and T2-weighted images, 
rsfMRI) in a 3T scanner. Patients underwent cognitive assess-
ment (Symbol Digit Modalities Test, SDMT). CONN-FC tool-
box was used to extract RSN with ICA and to perform statistical 
analyses: generalised linear models adjusted for age and 
gender. P-value thresholds to define significance were < 0.001 
(uncorrected) at the voxel level and < 0.05 (FDR-corrected) at 
the cluster level.
Results: None of the RSN showed significant differences in 
within-network FC between groups. Yet using a more liberal 
threshold (p< 0.05 at voxel level), patients showed a trend towards 
higher FC in the default mode (b=0.82, p< 0.0001) and frontopa-
rietal (b=0.54, p< 0.01) RSN, and lower FC in the dorsal-attention 
network (b=-0.73, p< 0.01) than controls. In patients, lower FC in 
several RSN (including frontoparietal and dorsal-attention RSN) 
was associated with worse cognitive performance (b=0.04, 
p=0.004). Instead, higher FC in the salience RSN (precuneus) was 
associated with lower cognitive performance
(b=-0.06; p=0.006).
Conclusions: In early CIS, FC within RSN is relatively intact. 
However, a trend towards altered FC in areas strongly associated 
with cognition was observed in patients. Longitudinal studies will 
address whether these findings indicate an incipient FC deteriora-
tion in the CIS, therefore reflecting both maladaptive and com-
pensatory mechanisms leading to or limiting cognitive decline in 
MS.
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Information processing and brain flexibility in multiple scle-
rosis: the relevance of state-contrast
Q. van Geest1, L. Douw1,2, C. Leurs3, H.M. Genova4,5, G.R. 
Wylie4,5, M.D. Steenwijk1, J. Killestein3, J.J.G. Geurts1, H.E. 
Hulst1
1Anatomy & Neurosciences, VU University Medical Center, 
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3Neurology, VU University Medical Center, Amsterdam, The 
Netherlands, 4Neuropsychology & Neuroscience Laboratory, 
Kessler Foundation, West Orange, 5Physical Medicine and 
06_MSJ731285.indd   813 13/10/2017   11:10:59 AM
814 ePosters 23(S3)
Multiple Sclerosis Journal 2017; 23: (S3) 680–975 journals.sagepub.com/home/msj
Rehabilitation, Rutgers New Jersey Medical School, Neward, NJ, 
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Background: Information processing (IP) problems are prevalent 
in MS, and might be related to changes in dynamic functional con-
nectivity (flexibility) of the default mode network (DMN) and 
fronto-parietal network (FPN). We explored DMN and FPN flex-
ibility during IP, during rest and in relation to each other with 
respect to IP. Additionally, we explored differences between 
patients switching to fingolimod treatment (FT) and patients on 
standard (first-line) treatment (ST), in order to investigate whether 
the decision to change medication might be reflected by changes 
in flexibility.
Methods: Thirty-two MS patients (14 FT and 18 ST patients), and 
18 healthy controls (HCs) were included. The Letter Digit 
Substitution Test (LDST) was used to assess IP performance. 
Lesion load, gray matter volume (GMV) and white matter volume 
were measured using magnetic resonance imaging (MRI; 3T). 
Functional MRI was obtained during an IP-task (Symbol Digit 
Modalities Test) and during rest. Using a sliding window approach 
DMN and FPN flexibility in both states were calculated, and the 
flexibility ratio between states for each network (IP-task/resting-
state (RS) flexibility) was explored using Pearson correlation 
coefficient. LDST performance was predicted using forward lin-
ear regression analysis.
Results: No differences in age, sex, and educational level 
were found between MS patients and HCs. Compared to HCs, 
MS patients performed worse on the LDST and had lower 
GMV (P< 0.01). No differences in flexibility were found. The 
relationship between IP-task and RS flexibility of the DMN 
was positive (r=0.40, P=0.10) in HCs, but negative in MS (r=-
0.44, P=0.01) and driven by FT patients (no difference was 
found for the FPN). Better LDST performance in MS could be 
predicted by a larger IP-task/RS flexibility ratio of the DMN 
(β=0.53, P< 0.001) and larger GMV (β=0.39, P< 0.01). FT and 
ST patients did not differ on demographic or MRI measures. 
In FT patients, 77% of variance in IP performance could be 
explained by the IP-task/RS flexibility ratio of the DMN 
(β=0.76, P< 0.001) and GMV (β=0.37, P=0.02), whereas in ST 
patients, 27% of IP performance could be explained by lesion 
load (β=-0.56, P=0.02).
Conclusion: Next to GMV, greater IP-task/RS flexibility contrast 
of the DMN is important for IP in MS. This might suggests that if 
the DMN is better able to switch flexibility between states, it will 
benefit IP. Future studies should explore if this contrast is an indi-
cation for switching therapy.
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Longitudinal variation in structural and diffusion param-
eters of fatigue patients in multiple sclerosis
K. Yarraguntla, F. Bao, S. Razmjou, S. Lichtman-Mikol, R. 
Sood, C. Santiago, N. Seraji-Bozorgzad, E. Bernitsas
Neurology, Wayne State University School of Medicine, Detroit, 
MI, United States
Objective: To investigate the relation between volumes of sub-
cortical structures, diffusion properties of cortical lobes and 
fatigue score variation between two time points in Multiple 
Sclerosis.
Background: Fatigue affects 80-90% of Relapsing Remitting 
Multiple Sclerosis patients (RRMS). However, consistent longitu-
dinal imaging correlates to changes in severity of fatigue remain 
elusive. Prior studies have implicated the role of thalamus, frontal 
and parietal lobes, corpus callosum and various white matter 
tracts in pathogenesis of fatigue in RRMS patients. The thalamic 
volume variation was reported to be significant in longitudinal 
studies on fatigue in MS.
Methods: 46 RRMS patients who reported MS-related fatigue 
(Fatigue Severity Scale (FSS) mean score: 1 - 7) were involved in 
this longitudinal retrospective imaging study at baseline and year 
one. Other causes of fatigue were excluded. Patients were relapse-
free and not on steroid treatment within the last 3 months prior to 
screening. All patients had T2, MPRAGE and DTI images using 
the same MRI protocol. Using FreeSurfer program, we calculated 
the deep gray matter volumes and cortical thickness. Cross-
modality technique was used to measure the DTI parameters of 
cortices. Pearson correlation was used to test the relationship 
between the variables.
Results: The pallidal volume (r2=0.292, p< 0.04) and right tem-
poral cortex radial diffusivity (r2=0.314, p< 0.02) variation 
between two time points had significant inverse correlation with 
baseline fatigue score.
Conclusion: The changes in pallidal volume and radial diffusivity 
of right temporal cortex between the two time points reflects prog-
nosis of fatigue in RRMS. Future research will focus on the asso-
ciation between volumetric changes of specific structures in 
RRMS population and fatigue score at the above time points, 
using tract based spatial statistics of structural and diffusion data.
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Magnetic resonance fingerprinting indicates thalamic atro-
phy in multiple sclerosis and reflects extrinsic pathology
D. Ontaneda1, K. Nakamura2, K. Sakaie1, B. Thoomukuntla2, 
K.R. Mahajan1, M. Dan3, A. Shah3, O. Kilinic3, J.A. Cohen1, 
M.J. Lowe1, V. Gulani3, M.A. Griswold3
1Mellen Center, 2Biomedical Engineering, Cleveland Clinic, 
3Radiology, Case Western Reserve University, Cleveland, OH, 
United States
Introduction: Thalamic atrophy, a prominent feature in multiple 
sclerosis (MS), may occur as a consequence of intrinsic thalamic 
pathology and/or due to distant injury in white matter tracts. 
Magnetic resonance fingerprinting (MRF) is a new MRI approach 
that provides direct estimates of quantitative relaxation times 
from fast acquisition.
Objectives: To investigate quantitative MR properties using MRF 
in the thalamus of MS patients compared with controls, and to 
correlate extrathalamic involvement with quantitative changes in 
thalamic tissue.
Methods: Nine patients with relapsing remitting (RR) MS 
(disease duration [DD] ≤ 5 years, EDSS ≤ 2), 9 patients with 
secondary progressive (SP) MS (DD ≥10 years, EDSS ≥ 4.0), 
and 8 age/gender matched controls were recruited. Clinical 
measures included EDSS, MSFC, and neurocognitive testing. 
MRI of the brain was conducted with FISP-MRF protocol 
(1000 images, 1.2 x 1.2mm, 20 slices, 5mm slice thickness) 
and conventional MRI (T1-weighted MPRAGE, 3D FLAIR, 
and 3D T2). Thalami were segmented using an atlas-based 
approach. Lesions (T1/T2) and white matter structures were 
segmented. Mean T1 and T2 relaxation times were measured 
within each region of interest (thalamus, frontal normal 
appearing white matter, corpus callosum, caudate, T1 lesions, 
and T2 lesions). Differences between controls, RRMS, and 
SPMS were analyzed by ANCOVA with age as covariate. 
Correlations were assessed between MRI and clinical meas-
ures using Pearson test.
Results: Thalamic volumes were significantly different between 
controls (20.5 ml, SD: 0.7), RRMS (20.2 ml, SD: 1.4), and SPMS 
patients (16.6 ml (1.7ml) (p< 0.001). Thalamic T1 and T2 relaxa-
tion did not show consistent differences in controls, RRMS and 
SPMS. There was no correlation between thalamic volume and T1 
and T2 relaxation times from the thalamus. In contrast, significant 
correlations were found between thalamic volume and T1 relaxa-
tion times from white matter T2 lesions (r=-0.74, p< 0.001) and 
T1 lesions (r=-0.61, p=0.01). Significant correlations were found 
between thalamic volume and SDMT (r=0.78, p< 0.001) and 
EDSS (r=-0.67, p< 0.002).
Conclusions: Thalamic volume distinguishes MS from controls, 
RR from SPMS, and correlates with both physical and cognitive 
measures of impairment. Thalamic atrophy reflects extrathalamic 
injury measured in T1 and T2 lesions with no clear relationship 
between thalamic volume and intra-thalamic T2 and T1 relaxation 
times.
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Intracranial volume as a surrogate for maximal lifetime 
brain growth in adult-onset multiple sclerosis: comparison 
with healthy controls
S. Suthiophosuwan1,2, I. Cheema2, C. Casserly3, S. Sankar4, G. 
Leung1, A. Bharatha1, A. Bar-Or5, J. Oh4,6
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Health Sciences Center, London, 4University of Toronto/
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Introduction: Overall intracranial volume (ICV), which in part 
reflects maximal lifetime brain growth (MLBG), has been 
reported to be decreased in pediatric multiple sclerosis (MS) 
patients in comparison to age- and sex-matched healthy controls 
(HCs), suggesting that the pediatric-onset MS may affect primary 
brain and skull development. In adults, MS clinical symptom-
onset typically occurs between the ages of 20-30; however, the 
majority of patients already have evidence of brain atrophy on 
MRI at diagnosis, suggesting that biological disease onset started 
at an earlier timepoint. We previously demonstrated that head cir-
cumference (as a surrogate of ICV) was decreased in adult-onset 
MS patients vs. HCs. To our knowledge, ICV, as an assessment of 
MLBG, has not been compared between adult-onset MS patients 
and HCs.
Objective: To compare ICV (as an assessment of MLBG) in MS 
patients with disease onset in adulthood vs. HCs.
Methods: MRI measures, including ICV and brain parenchymal 
fraction (BPF), were assessed in 106 MS patients and 112 HCs 
balanced for age and sex using Voxel-based Morphometry 8 
(VBM8) toolbox for SPM8. Student’s t-tests compared ICV in 
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MS vs. HCs. Multivariable linear regression was performed to 
compare ICV in MS vs. HCs while controlling for potentially con-
founding covariates of age and sex.
Results: MS patients were a mean age of 43 years, 69% female, 
and had a mean age at clinical diagnosis of 32 years. HCs were a 
mean age of 45 years, and 63% female. Mean ICV was lower in 
MS (1395.66±14.67 mm3) vs. HCs (1426.52±14.98 mm3); but this 
result did not reach statistical significance (p=0.14). In MS patients 
with earlier clinical disease onset (≤ 40 years; n=79), mean ICV 
(1387.33±16.73 mm3) was even lower, with a trend towards sig-
nificance (p= 0.08), particularly when controlling for potentially 
confounding variates of age and sex (p=0.05). As expected, there 
was also clear evidence of brain atrophy in MS vs. HCs as meas-
ured by BPF (0.816±0.002 vs. 0.834±0.001; p< 0.001).
Conclusion: MS patients with clinical disease-onset in adulthood 
show trends towards having smaller ICVs in comparison to HCs, 
particularly when clinical symptom onset is before the age of 40. 
If confirmed in larger cohorts, these findings suggest that even 
when MS clinically manifests in adulthood, pathologic processes 
affecting MLBG may begin during periods of brain and skull 
growth in childhood or early adolescence, which is substantially 
earlier than expected.
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Verbal memory and brain micro-structural changes in mul-
tiple sclerosis
S. Miron1, A. Abramovitz2, O. Levy2, A. Achiron1
1Multiple Sclerosis Center, Sheba Medical Center, Ramat Gan, 
2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 
Israel
Background: Multiple sclerosis (MS) is a chronic demyelinating 
disease of the central nervous system involving both white and 
grey matter. Brain diffusion tensor imaging (DTI) enables in vivo, 
detection of pathological micro-structural changes that are not 
recognized in conventional MRI scans.
Aim: To identify brain areas with altered micro-structure that cor-
relate with verbal memory impairment in relapsing remitting MS 
patients (RRMS).
Methods: A retrospective cross sectional study was conducted in 
63 RRMS patients who completed:
1) Mindstream computerized cognitive evaluation tests 
(MCCT);
2) EDSS evaluation;
3) an MRI scan including diffusion tensor imaging (DTI).
All data were obtained within three months. Quantitative param-
eters as fractional anisotropy (FA) were derived from the DTI 
scans using in house developed Matlab software. Image process-
ing and statistical analysis were based on voxel based analysis 
(VBA) using Statistical parametric mapping (SPM 8) and brain 
visualization performed with the xjView toolbox.
Results: 63 RRMS patients were included in the study {F/M 
45/18; age 31years (21-46); disease duration 5.2±3.1 years; EDSS 
2.0±1.7}. Six statistically significant clusters were identified 
(family wise error corrected for multiple comparisons, p< 0.005), 
in which FA correlated with verbal memory MCCT scores (96.8 ± 
16.2). The clusters included: right hippocampus, right and left 
para-hippocampus, right and left cerebellum, right and left thala-
mus, right fusiform gyrus and right insula (xjView toolbox).
Conclusions: Lower FA values and micro-structural changes in 
specific brain areas were significantly correlated with a decline 
in verbal memory scores on MCCT. We describe specific changes 
in brain microstructure which cannot be seen in anatomical brain 
MRI. The VBA-DTI methodology could be used in cognitively 
affected MS patients, to identify changes in brain regions related 
to cognitive tasks.
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OFSEP MRI protocol: the need of good practice’s standard-
ization from clinicians to scientists
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OFSEP (Observatoire Français de la Sclérose en Plaques) is a 
national cohort of patients with MS and related disorders, set up in 
2010 from a rich historical background use of EDMUS in France. 
It aims at collecting standardized, high-quality, longitudinal data, 
including clinical, biological and imaging follow-up of patients 
with MS and makes it available to the research and industrial 
community and health authorities. In December 2016, more than 
54.000 clinical files were available, progressively enriched with 
biological and imaging data. Over the past two decades, the clini-
cal use of MRI in patients with MS has considerably impacted the 
diagnostic procedure as well as prognostic indicators, including 
evaluation of the treatment-response up to the concept of “No 
Evidence of Disease Activity”. Therefore, standardized MRI 
examinations only can allow a reliable comparison of successive 
MRIs over time that will guide therapeutic decision. The OFSEP 
imaging group designed a consensus standardized MRI protocol 
that could fulfil the needs of clinician in their decision-making 
process but also be available for research purpose. The group 
worked closely with main MRI companies to promote the MRI 
“OFSEP protocol” in an “exam card” available on all new system 
(see ofesp.org). MRI data are transferred and stored onto a cen-
tralized national facility, Shanoir, with respect to privacy protec-
tion in agreement with French national authority (CNIL). All the 
data are pseudonimized locally on the hospital computer priory to 
the transfer; this step allows inter-operability with biological and 
clinical databases for research. We are currently in the process of 
spreading the MRI protocol across French MRI centres. 18 cent-
ers started to export MRI data mainly through PACS connection to 
load their data retrospectively. All the data collected will be then 
available to the research community as well as the biological and 
clinical databases.
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[18F]-Florbetaben-PET/MRI as myelin-specific molecular 
imaging: a pilot study in patients with different white matter 
diseases
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Background: PET imaging with tracers such as [18F]Florbetaben 
(FBB) allows the in vivo visualization of cortical β amyloid (Aβ) 
depositions as occurring in Alzheimer’s disease. FBB also - inde-
pendently from Aβ - binds to brain white matter (WM) myelin, 
suggesting a potential value in imaging multiple sclerosis (MS). 
After promising preliminary results, further studies employing 
this tracer in other WM diseases are currently missing.
Objectives: To assess in vivo quantification of FBB uptake in 
patients with different WM diseases in comparison to non-WM 
diseased controls. We hypothesized a decreased WM tracer accu-
mulation in the patient group as a surrogate of myelin loss.
Methods: We examined 13 patients with pathophysiologically 
distinguishable WM diseases (MS [n=4]; progressive multifocal 
leukoencephalopathy [PML, n=3]; adult-onset leukodystrophy 
[genetically determined, n=3]; cerebral autosomal dominant arte-
riopathy with subcortical infarcts and leukoencephalopathy 
[CADASIL, n=3]) and concurrent mild cognitive impairment 
using FBB-PET/MRI. 13 age- and gender-matched patients with 
cognitive impairment but without WM disease served as controls. 
PET data were acquired 90-110min after injection of FBB using a 
simultaneous PET/MR System (Biograph mMR, Siemens). 
Segmentation of WM and generation of standard volumes of 
interests (Automated Anatomical Labeling atlas) was performed 
in PMOD 3.5. WM lesions were segmented by the lesion predic-
tion algorithm as implemented in the LST toolbox for SPM. We 
determined the WM standardized uptake value (SUV) ratio 
(SUVRWM) using the cerebellar cortex as reference region. For 
WM diseases, the WM lesion SUV Ratio (SUVRWML) was calcu-
lated using the same reference.
Results: SUVRsWM were significantly lower in patients than con-
trols (1.78±0.32 vs.1.90±0.14, p=0.04). Within the patient group, 
WM lesions showed an even lower tracer retention than normally 
appearing WM (SUVRWML vs. SUVRWM: 0.98±0.22 vs. 1.78±0.32, 
p< 0.001). These findings were independent of the cortical tracer 
uptake. An additional subgroup analysis regarding WM uptake 
degree and distribution between the different WM diseases is 
planned after recruitment of a larger cohort.
Conclusion: Patients with pathophysiologically different WM 
diseases show decreased FBB WM binding, especially in WM 
lesions, compared to non-WM-diseased controls. Further research 
in larger cohorts is justified to investigate the potential of FBB 
PET/MRI in evaluating demyelinating diseases.
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Basal ganglia volume and cognitive function in newly diag-
nosed and untreated multiple sclerosis patients
M. Cortese1, Ø. Bergmann1, D. Carlucci2, Ø. Torkildsen1, 
S. Wergeland1, A.G. Beiske3, H. Hovdal4, R. Midgard5, T. 
Pedersen6, K.-M. Myhr1, The OFAMS Study Group
1Norwegian Competence Center for Multiple Sclerosis, 
Haukeland University Hospital, Bergen, Norway, 2Department 
of Neurology, University of Ferrara, Ferrara, Italy,  
3The Neurology Group, Oslo, 4St. Olavs Hospital, Trondheim, 
5Department of Neurology, Molde Hospital, Molde, 6Unilabs, 
Drammen, Norway
Background: Cognitive impairment is frequent, debilitating and 
can be present early in the disease course of multiple sclerosis 
(MS). The basal ganglia are deep grey matter structures involved 
in cognitive tasks, and frequently affected in MS patients. 
Abnormal basal ganglia activation on functional MRI has been 
observed during cognitive testing and lower volume has been 
associated with cognitive dysfunction. However, these studies 
were mainly conducted in treated patients and associations may 
differ in newly diagnosed treatment-naïve patients.
Objectives: To assess the relationship between basal ganglia vol-
ume and cognitive function in untreated MS patients.
Methods: In total 68 untreated relapsing-remitting MS patients 
with short disease duration underwent brain MRI in the context of 
a previously reported randomized clinical trial (OFAMS) Their 
mean age was 38 years, mean time from diagnosis 1.7 years and 
mean EDSS 1.9±0.8. MRI scans were pre-processed using 
FreeSurfer-software estimating automatically total and constitu-
ent basal ganglia volume, including caudate nucleus, putamen, 
pallidus, and nucleus accumbens. Manual verification/editing fol-
lowed. Cognitive function was assessed within ± 7 days of the 
MRI examination by Paced Auditory Serial Addition Test 
(PASAT), a validated tool, especially sensitive to MS-related pro-
cessing speed and attention deficits. We estimated Pearson’s cor-
relation coefficients between basal ganglia and specific nuclei 
volumes and PASAT.
Results: We observed a statistically significant relationship of 
moderate strength between the basal ganglia volume and PASAT 
score. The correlation coefficient was strongest for total volume 
(r=0.28; p=0.027), but of similar magnitude for the single nuclei: 
putamen (r=0.26, p=0.043), caudate nucleus (r=0.25; p=0.040), 
pallidus (r=0.22; p=0.089), and nucleus accumbens (r=0.25; 
p=0.048).
Conclusions: In this untreated MS patient population with short 
disease duration and low physical disability, we observed that 
basal ganglia volume was significantly associated with cognitive 
function as measured by PASAT. Basal ganglia volume may be an 
early indicator of cognitive impairment and its use could be con-
sidered in prognostic scores at the first MRI in a clinical setting.
References: Torkildsen O, Wergeland S, Bakke S, et al. ω-3 fatty 
acid treatment in multiple sclerosis (OFAMS Study): a 
randomized, double-blind, placebo-controlled trial. Arch Neurol 
2012;69:1044-51.
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EP1558
Clinicoradiological correlation revisited in relapsing onset 
North African multiple sclerosis
M. Hamed, H.M. Metwally, M. Al-Bahay, M. Abdelsayed, A. 
Metwally, M. Aboulwafa, M. Atallah, Al-Azhar MS Unit
Neurology Department, Faculty of Medicine Al-Azhar 
University, Cairo, Egypt
Multiple sclerosis (MS) shows variable disease characteristics at 
different ethnicities and geographical regions. Magnetic reso-
nance imaging (MRI) features of MS are not adequately described 
in African Mediterranean region. We aimed to describe main clini-
cal and MRI features of MS in Egyptian patients.
Relapsing onset MS patients (n=47) and a group of age and sex 
matched healthy controls (n=20) were recruited. All subjects had 
a standardized clinical evaluation, and an MRI examination (1.5 
Tesla scanner, FLAIR and T2 for lesion load (LL) estimation and 
a sagittal 3D-T1 for volumetric assessment). Analysis included 
LL estimation (MIPAV software), whole brain atrophy (SIENAX 
method), subcortical segmentation (FIRST part of FSL software) 
and mean upper cord cross-sectional area CSA. Correlation 
between clinical and MRI parameters were done using partial 
correlation.
Mean disease duration was 5.8 (4.96) years (SD), only 10 patients 
were under any of the disease modifying treatments. Normalized 
Whole brain volume (NWBV) was significantly lower in MS 
group compared to controls (p=0.008), and the thalamic fraction 
(volume of both thalami divided by total intracranial volume) 
(p=0.001), right and left hippocampi (P=0.006 and 0.06 respec-
tively), but not with the normalized grey matter volume or the 
cord cross-sectional area (CSA).
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EDSS correlated well with lesion load (p=0.005, r=0.44), NWBV 
(p=0.01, r=0.48), normalized cortical volume (p=0.001, r=0.58), 
thalamic fraction (p=0.03, r=0.36), caudate fraction (p=0.001, 
r=0.43) and cord CSA (p=0.03, r=0.43).
MRI features of MS in North African population appear to be rep-
licating what has been known from other MS studies elsewhere. 
However smaller intracranial volume and cord CSA even in 
healthy controls compared to available data from western and 
European countries. We postulate that these smaller values repre-
sent a smaller tissue reserve that might interpret the relatively bet-
ter correlation between lesion load and clinically disability 
compared to other studies, and might also explain the relatively 
more aggressive nature of the disease in Africa.
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EP1559
New and enlarging lesion location for different MS clinical 
phenotypes
D.M. Sima1, S. Jain1, E. Roura1, A. Maertens1, D. Smeets1, D. 
Sappey-Marinier2, F. Durand-Dubief2, W. Van Hecke1
1Icometrix, Leuven, Belgium, 2CREATIS UMR 5220 CNRS & 
U1206 INSERM, Université de Lyon, Lyon, France
Purpose: Evaluate the location of lesion evolution for different 
MS clinical phenotypes using MSmetrix.
Materials and methods: Longitudinal MRI follow-up of 12 clin-
ically isolated syndrome (CIS), 30 relapsing remitting (RR), 17 
primary progressive (PP) and 28 secondary progressive (SP) MS 
patients was conducted using a 1.5 Tesla MR system (Sonata 
Siemens). For each patient, two time points at least 2 years apart 
were selected in order to estimate medium-term lesion evolution.
MSmetrix employs T1-weighted and FLAIR images at two time 
points to estimate brain tissue and lesion segmentations and 
volumetry, as well as volume changes in time. Moreover, the 
lesions are classified according to brain location. Volumes of 
new or enlarging lesions classified by MSmetrix as juxtacorti-
cal lesions, periventricular lesions or deep white matter lesions, 
were compared between the four patient groups (CIS, RR, PP 
and SP).
Results: CIS patients showed the largest volume of new lesions 
(i.e., lesions not touching any older lesion), with an average vol-
ume of only 0.1 ml in each of the three locations (juxtacortical, 
periventricular, deep white matter). PP and SP patients had on 
average lower new lesion volumes (< 0.06 ml), with almost no 
new lesions in the periventricular region. This was compensated 
by large volumes for lesion enlargement, especially in the perive-
ntricular region. Although all groups show lesion enlargement 
mostly in the periventricular regions compared to other regions, 
some significant differences between groups were observed: PP 
patients showed the most enlargement in the periventricular 
region (median 3.8 ml), significantly higher than for CIS and RR, 
but comparable to the SP group. The RR group showed more 
enlargement of deep white matter lesions compared to the other 
groups, with a median of 0.1 ml. There were no significant differ-
ences between clinical groups in the volumes of enlarged juxta-
cortical lesions (median value 0.05 ml for all groups).
Conclusion: MSmetrix found a location-dependent evolution of 
new and enlarging lesions for different MS clinical phenotypes. 
Some of the findings can be explained by disease duration: more 
advanced MS forms (PP and SP patients) show significant enlarge-
ment of existing periventricular lesions instead of new lesion for-
mation. Compared to other groups, RR patients had more 
enlargement of the deep white matter lesions, and for CIS patients 
there seemed to be no location prevalence in the appearance of 
new lesions.
Disclosure
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Can MR permeability and contast enhanced (CE)-FLAIR 
demonstrate AQP4 channel dysfunction in NMOSD patients? 
Work in progress
S.V. Okar1, R. Göçmen2, K. Karlı-Oğuz2, M.A. Tuncer1, Ş.E. 
Erdener3, R. Karabudak1
1Department of Neurology, 2Department of Radiology, Hacettepe 
University Faculty of Medicine, Ankara, Turkey, 3Martinos 
Center for Biomedical Imaging, Massachusets General Hospital, 
Harvard Medical School, Boston, MA, United States
Objective: NMO spectrum disorders [NMOSD] are putatively 
accepted as inflammatory autoimmune diseases of the CNS.
Imaging findings in NMOSD are distinct from MS. We previ-
ously observed leptomeningeal (LM) contrast enhancement in 4 
of our 46 NMOSD patients during their attack. Recently imaging 
findings consistent with LM blood-CSF barrier disruption and 
transient leakage of contrast agent into the subarachnoid space 
was shown in NMOSD patients during attack.AQP4 is highly 
expressed throughout the CNS including grey matter. Aquaporin 
channels are considered to have essential functions in glymphatic 
system. The anatomical integrity of this pathway has been sup-
ported by astrocytic end-foot with AQP 4 water channels. These 
findings suggest that AQP channel pathology might be more 
spread than restricted to typical parenchymal areas.Our aim is to 
evaluate further AQP4 channel dysfunction leading to LM blood-
CSF barrier disruption by studying dynamic contrast-enhanced 
(DCE) MR perfusion and contrast enhanced (CE)-FLAIR in clin-
ically stable NMOSD patients.
Material and method: 19 patients were diagnosed as NMOSD 
according to the new diagnostic criteria.All patients were in 
remission under treatment.We evaluated dynamic contrast-
enhanced (DCE) MR perfusion and contrast enhanced (CE)-
FLAIR in addition to routine brain MRI from 19 NMOSD patients 
with no disease activity.
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Results: Median age of our patients was 44,1 years old.15 of 
them were female,4 of them were male.12 of patients were posi-
tive for AQP4 antibody,3 were positive for MOG antibody,one of 
them was positive for both.3 of them were seronegative.Mean 
disease duration was 6,9 years. 5 of our patients had other auto-
immune diseases.All of our patients were under immunesupres-
sive/modulatory treatment.We identified 2 patients with NMOSD 
who have LM contrast enhancement in post-contrast (PC) FLAIR 
series while PC T1W images were normal and had no evidence of 
disease activity .First patient was 41 years old female.She dis-
played both aquaporin and MOG antibodies.CE-FLAIR revealed 
abnormal LM and sulcal enhancement.Second patient was 53 
years old female.She was seronegative for both antibodies.She 
also had Sjögren’s.CE-FLAIR revealed abnormal LM and sulcal 
enhancement. Our DCE-MR permeability data from our patients 
is being processed.
Conclusion: We propose that AQP4 channels may contribute to 
the brain microcirculation in glymphatic pathway therefore 
related sequences of MRI can be used to prove this hypothesis.
Disclosure
Nothing to disclose
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Racial and environmental influences on North African multi-
ple sclerosis, application of global and regional brain atrophy 
measures
F.M. Afifi, M. Aboulwafa, S. Al-Hagen, M.I. Seddik
Faculty of Medicine | Neurology Department, Al-Azhar 
University, Cairo, Egypt
Well validated methods has been used to evaluate brain atrophy in 
multiple sclerosis (MS) patients, however to our knowledge these 
methods has not been well applied to African multiple sclerosis 
patients which are expected to have different profile of genetic 
and environmental factors that influence brain volume.
We aimed to evaluate the SIENAX method application among 
North African patients with MS. Three groups were recruited; a 
group of relapsing onset Egyptian MS patients (n=47), a group 
of Egyptian healthy controls (n=30), and a third group of 
healthy controls from the publicly available OASIS MRI data-
base (n=181) for comparing the possible influence of racial and 
environmental factors. The three groups were matched for both 
age and sex.
We used a 1.5T Philips scanner for acquisition of a 3D T1 volume 
of the brain, and a FLAIR sequence for lesion load. Analysis 
included Lesion Load (LL) estimation (MIPAV software), 
Normalized Brain Volume (NBV) (SIENAX method) after per-
forming adequate lesion masking in the MS patient group, subcor-
tical segmentation (FIRST part of FSL software).
For MS patient group mean disease duration was 5.8 (4.96) years 
(SD), only 10 patients were under any of the disease modifying 
treatments. Total intracranial volume was highly significantly 
lower at the Egyptian Population (1245.07 (SD 115.72)) ml 
(patients and controls) compared to OASIS database (1480.50 
(SD 158.30)) ml (p< 0.001). Normalized brain volume was also 
highly significantly lower between Egyptian healthy controls 
(76.7% of intracranial volume SD 0.05%) and OASIS database 
(84.1% of intracranial volume SD 0.02%) (p< 0.00.1).
NBV was significantly lower among MS Patients 1427.35 (SD 
97.45) ml compared to Egyptian healthy controls 1494.2 (SD 
72.21) ml (p=0.008). Thalamic fraction was significantly lower 
(calculated as the volume of both thalami divided by intracranial 
volume) in patients compared to controls (p=0.001), hippocampi 
(P< 0.002 and P< 0.01 right and left), but were not different in 
normalized cortical volumes or cord cross-sectional area.
Racial and environmental factors appears to clearly influence 
brain volume in health and disease conditions. SIENAX and FIRT 
methods for evaluation of global as well as regional brain atrophy 
were able to demonstrate differences between healthy controls 
and north African MS patients. Careful consideration of general-
izing the brain atrophy measurements across different geographi-
cal, environmental as well as racial factors.
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EP1562
OCT in familial and sporadic MS patients: correlation 
between RFNL and macular volume
M. Siger, M. Grudziecka, K. Selmaj
Neurology, Medical University of Łódź, Lodz, Poland
Goal: The aim of this study was to determined correlation between 
retinal nerve fiber layer (RNFL) thickness and the macula volume 
(MV) measured by spectral- domain OCT (SD-OCT) in familial 
(fMS) and sporadic (sMS) multiple sclerosis patients.
Background: . There is unresolved issue whether sMS differs 
from familial form of disease. Optical coherence tomography 
(OCT) allows quantification of retinal structures, such as RNFL 
thickness and MV. RNFL thickness is considered as a marker of 
axonal loss and MV as a marker of neuronal integrity.
Patients and method: 71 RR MS patients (31 fMS, 40 sMS) 
age and gender matched were included in the study. Familial 
MS was defined based on whether or not the probant case had 
a first-degree relatives with MS. Both MS groups were matched 
according to neurological status measured by EDSS, annual 
relapse rate in previous 2 years and disease duration. All 
patients underwent SD-OCT examination (Spectralis, 
Heildelberg Engineering). Total RNFL thickness and MV were 
assessed in right and left eyes and were expressed as a mean 
value for each patients.
Results: RNFL thickness in fMS was lower than in sMS but this 
difference was not significant (94.90±10.8 vs 97.2±8.4 p=0.4). 
Mean MV was lower but not significantly in fMS compared to 
sMS (8.2±1.0 vs 8.4±0.3 p=0.08). There was a correlation between 
mean RNFL thickness and MV in both forms of MS (fMS r=0.4, 
p=0.01and sMS r=0.5, p=0.0001) however the this correlation 
was stronger in sMS patients.
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Evaluation of the neurodegeneration processes in dynamics 
in multiple sclerosis
D.S. Korobko1, N.A. Malkova1,2, E.M. Didrikh3, D.M. 
Pervoykin2
1Centre for MS and other AID of NS, State Novosibirsk Regional 
Clinical Hospital, 2Novosibirsk State Medical University, 
3Medical Center ‘Avicenna’, Novosibirsk, Russian Federation
The retina is a unique part of the CNS that contains glia and axons 
devoid of myelin in the retinal nerve fiber layer (RNFL), which makes 
them ideal for evaluation of neurodegeneration and neuroprotection.
The aim: to study the possibilities of the optical coherent tomog-
raphy (OCT) method in the neurodegeneration processes monitor-
ing in patients with MS.
Material and methods: 145 patients (285 eyes) were examined. 
OCT was carried out with the Cirrus 500 HD. The main group con-
sisted of 114 patients (223 eyes) with MS according to McDonald 
criteria (2005, 2010). Most of the patients included in the study had 
relapsing-remitting course, 10.5% - secondary-progressive. For 46 
patients (40% of the total), at least 2 OCT studies were obtained at 
an interval of about 12 months (352±152 days). Exclusion criteria: 
high degree of myopia, glaucoma, diabetes mellitus, other CNS dis-
eases. The control group is 31 healthy volunteers (62 eyes).
Results: The mean macular volume in MS patients (9.8 ± 0.5 
mm3), the average thickness of the macula (248 ± 26 µm) were 
significantly lower in comparison with the control. The average 
thickness of the RNFL in the main group was 85.6 ± 11 µm (in the 
control group - 96±8 µm), and RNFL was minimal in the temporal 
sector (56±12 µm). The highly sensitive and specific marker of 
neurodegenerative changes in the retina in MS are the temporal 
segments of RNFL (T, TI, TS). The thickness of the ganglion cells 
layer (GCL) of the retina was significantly lower in MS (72±9 µm 
versus 83 ± 5 µm, p< 0.05). Significant negative correlations 
between the dynamics of thinning of the GCL and an increase in 
the EDSS during the observation period were observed. The most 
significant correlations were revealed in the temporal and upper 
sectors of GCL (r = -0.44...r = -0,58, p< 0.05). These sectors can 
be considered promising markers of MS progression. The change 
in the GCL in dynamics was in the temporal segments mostly: the 
average thickness decreased by 0.35 µm during observation, and 
the thickness of the temporal and upper sectors decreased on aver-
age by 0.74 µm and 0.37 µm, respectively.
Conclusions: The dynamics of thinning of the GCL and RNFL in 
patients with MS correlates with an increase in neurological defi-
cit and disease progression. Evaluation of OCT in dynamics every 
12 months allows to objectify and monitor the neurodegenerative 
process in MS, which is necessary for predicting the course and 
selection of adequate therapy.
Disclosure
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Retinal optical coherence tomography in chronic relapsing 
inflammatory optic neuropathy: a retrospective analysis of 
distinctive features
M. Eslami Farsani, S. Razmjou, S. Lichtman-Mikol, S. Reed, M. 
Gilroy, C. Santiago Martinez, A. Tselis, N. Seraji-Bozorgzad, E. 
Bernitsas
Wayne State University School of Medicine, Detroit, MI, United 
States
Objective: To assess the distinctive features of retinal structure in 
chronic relapsing inflammatory optic neuropathy (CRION) as 
compared to other optic neuropathies in neuromyelitis optica 
(NMO) and relapsing remitting multiple sclerosis (RRMS).
Background: CRION is a recurrent, steroid responsive optic neu-
ritis without any additional neurological deficits. Diagnosis is 
made clinically, after recurrent attacks and exclusion of other 
demyelinating pathology. We used optical coherence tomography 
(OCT) to assess potential retinal features that may distinguish 
CRION from NMO and RRMS.
Design/methods: Spectral domain OCT was used to evaluate and 
compare the retinal layers of 35 eyes with optic neuritis in patients 
with CRION (8 eyes), NMO (13 eyes), RRMS (14 eyes) and 10 
eyes of healthy controls (HC). The subjects were adjusted for age, 
disease duration and number of relapses. Peripapillary retinal 
nerve fiber layer (p RNFL) within superior, inferior, temporal, 
nasal and total macular volume (TMV) and papillomacular bundle 
(PMB) were measured and intra-retinal segmentation was per-
formed to obtain retinal nerve fiber (RNFL), ganglion cell (GCL), 
inner plexiform (IPL), inner nuclear (INL), outer plexiform (OPL) 
and outer nuclear (ONL) layer thickness.
Results: pRNFL thinning was demonstrated in patients with 
CRION (52.46±8.3µm) as compared to HC (86.8±7.6µm, 
P-value=0.021) and RRMS (75.2±4.5µm, P-value=0.009) but not 
NMO patients (69.15±5.03µm, P-value=0.13). Within quadrants 
analysis, inferior quadrant was statistically thinner in CRION 
(69.31±11.3µm) when compared to RRMS patients (101.8±4.8, 
P-value=0.007). GCL thickness in macula was significantly thin-
ner in CRION patients (0.69±0.07µm) when compared to HC 
(0.86±0.07µm, P-value=0.043).
Conclusion: pRNFL thickness globally and within inferior quad-
rant may be used as surrogates to distinguish CRION from other 
optic neuropathies in particular RRMS. Further longitudinal stud-
ies are warranted to confirm these findings.
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EP1565
Neurophysiological correlates of anxiety and depression 
symptoms in patients with multiple sclerosis: a transcranial 
magnetic stimulation study
S.S. Ayache1,2,3, J.-P. Lefaucheur1,2, A. Créange1,4, M.A. 
Chalah1,2
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Objectives: Anxiety and depressive complaints are frequently 
encountered in patients with multiple sclerosis (MS). Despite their 
prevalence, no single neurophysiological study has addressed this 
issue. The main purpose of this work was to assess the relation-
ship between anxiety and depressive symptoms on one side, and 
cortical excitability measures on the other side.
Methods: 50 consecutive MS patients were included in the study. 
Anxiety and depressive symptoms were scored by the means of 
Hospital Anxiety and Depression Score. Cortical excitability meas-
ures consisted of the following: resting motor threshold, motor 
evoked potentials amplitudes and latencies, contralateral silent 
period, short-interval intracortical inhibition, intracortical facilita-
tion and interhemispheric inhibition as previously described [1]. 
Clinical and socio-demographic data were collected. Correlation 
analysis was performed to assess the relationship between anxiety 
or depression and each of the cortical excitability measures.
Results: The cohort consisted of 26 men and 24 women. Their 
mean age was 51.82 ± 12.72 years. Their mean physical disability 
score was 5.52 ± 1.64; their mean disease duration was 11.88 ± 
6.03 years. Their mean anxiety score was 5.82 ± 3.42 (range: 
1-15); their mean depression score was 6.08 ± 3.66 (range: 0-14). 
Regarding anxiety scores, they were directly correlated with the 
mean (r=0.43, p=0.003) and the maximal values (r=0.35, 0.017) 
of interhemispheric inhibition. As for depression scores, no cor-
relation was found with any of the neurophysiological measures. 
No other significant correlations were observed.
Conclusion: These results are in line with previous studies done 
in other populations and highlight the relationship between anxi-
ety and callosal transfer [2]. In other words, it seems that MS 
patients with relatively more efficient callosal transfer tend to 
have higher stress level and thus higher anxiety scores than those 
with less efficient callosal function.
Keywords: transcranial magnetic stimulation; anxiety; depres-
sion; interhemispheric inhibition; hospital anxiety and depression 
scale.
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Cortical excitability and alexithymia in multiple sclerosis: a 
transcranial magnetic stimulation study
M.A. Chalah1,2, J.-P. Lefaucheur1,2, A. Créange1,3, S.S. 
Ayache1,2,4
1EA 4391, Excitabilité Nerveuse et Thérapeutique, Université 
Paris-Est-Créteil, 2Service de Physiologie - Explorations 
Fonctionnelles, 3Service de Neurologie, Hôpital Henri Mondor, 
Assistance Publique - Hôpitaux de Paris, Créteil, France, 
4Neurology Division, Lebanese American University Medical 
Center Rizk Hospital, Beirut, Lebanon
Objectives: Alexithymia is frequently encountered in patients 
with multiple sclerosis (MS). It is a multicomponent personality 
construct featuring difficulty in identifying feelings or describing 
them, and an externally oriented thinking. Recent evidence pro-
poses defective GABAergic transmission and deficits in inter-
hemispheric transfer behind its occurrence. Such mechanisms 
could be explored using transcranial magnetic stimulation (TMS). 
To the best of our knowledge, no single TMS study has been per-
formed in the context of alexithymia in MS patients.
Methods: 10 alexithymic and 12 non-alexithymic patients with 
progressive MS were enrolled based on the 20-item Toronto 
Alexithymia Scale score (TAS). TMS was used to record the corti-
cal silent period (CSP) and interhemispheric inhibition at different 
inter-stimulus intervals. Clinical (i.e. Expanded Disability Status 
Scale, disease duration, progressive phase duration), socio-demo-
graphic (age, gender, education level, marital status), and neu-
ropsychological data (i.e. Fatigue Severity Scale, Symbol Digit 
Modalities Test, Hospital Anxiety and Depression Scale, Epworth 
Sleepiness Scale) were collected. Group comparison was done 
using the Mann-Whitney and Fisher’s exact tests. In addition, 
Spearman rank correlation coefficient was used to assess the rela-
tionship between TAS scores and each of the cortical excitability 
measures.
Results: Compared to non-alexithymic patients, alexithymic 
ones had significantly shorter CSP duration (mean: 159.33 ± 
76.96, median: 148.50, vs. mean: 84.34 ± 49.73, median: 91.50, 
respectively; p=0.03), but did not differ with regards to the 
remaining excitability data, or clinical, socio-demographic and 
neuropsychological variables. In addition, a significant inverse 
correlation was found between TAS scores and CSP (r= -0.59; 
p= 0.004).
Conclusion: This study offers for the first time insights into the 
neurophysiological mechanisms of alexithymia in MS. Defective 
GABAergic transmission, particularly that mediated by GABA 
receptors type B, seems to be associated with alexithymia. 
Although interesting, these findings warrant further screening in 
large-scale studies.
Keywords: Multiple sclerosis, alexithymia, Toronto alexithymia 
scale, cortical silent period, cortical excitability, transcranial mag-
netic stimulation.
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EP1567
Cerebral vascular reactivity in multiple sclerosis
G. Tekgol Uzuner, N. Uzuner
Eskisehir Osmangazi University, Eskisehir, Turkey
Background: Some studies have suggested that impaired vascu-
lar endothelial cell activation might be an early event in multiple 
sclerosis (MS). Hypercapnia caused by breath holding (BH) 
results in autoregulatory vasodilatation and an increase in CBF to 
the cortex. The changes of the CBF can be indirectly assessed by 
transcranial Doppler (TCD). In this study, we aimed to test the 
cerebral vascular reactivity of MS patients in response to BH 
using TCD.
Methods: We studied 30 patients with clinically diagnosed 
relapsing-remitting (RR) MS. The first TCD examination was 
performed in the relapse (acute exacerbation) phase of the disease 
and the second test was carried out at least one month later when 
the patient was in the remission phase. Blood flow velocities were 
recorded during 30 seconds of normal breathing and subsequently 
15 seconds BH. Vascular reactivity was calculated as a ratio of the 
difference of cerebral flow velocities during BH. Normalisation of 
the blood flow velocities (decrease to the basal levels after breath 
holding) and blood flow velocity changes per second were also 
calculated. Since there was no significant difference between 
blood velocity parameters recorded on the left and right-hand 
side, the data were pooled. Thus, 30 patients with 60 vessels were 
analysed.
Results: There were non-significant values between vascular 
reactivity during relapse (40.5% vs. 36.9%, p=0.3) and remission 
periods. The time to peak velocity (12.5 sec vs. 13.4 sec, p=0.3) 
and the normalisation time (13.8 sec vs. 12.4 sec, p=0.15) was 
quite similar. Also, velocity changes per second were not different 
between relapse and remission periods (3.4 cm/s vs. 3.0 cm/s, p= 
0.15) for the velocity rise and (5.0 cm/s vs. 4.9 cm/s, p= 0.8) for 
velocity decline.
Conclusion: This observation suggests that cerebrovascular reac-
tivity is normal in patients with MS during relapse or remission 
period.
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Electrophysiological study of cognitive function through 
working memory in patients with multiple sclerosis
A. Figueroa
Universidad del Desarrollo, Santiago, Chile
Multiple sclerosis (MS) is a neurological disorder characterized 
by progressive and extensive lesions in the brain and spinal cord, 
contemplating motor, cognitive and neuropsychiatric symptoms. 
Cognitive symptoms comprise between 40 and 70% of MS 
patients, affecting their functionality in both early and late stages 
of the disease. Memory impairment is one of the most common 
cognitive deficits in these patients. This cognitive ability is essen-
tial to guide behavior toward achieving goals. As part of short-
term memory; Working Memory (WM) plays an important role in 
the cognitive process of multiple cognitive functions. The 
evidence about MS is scarce and contradictory regarding the 
nature of its cognitive impairment and its evolution.
The aim of the present research is to study the WM using the modi-
fication of the Steinberg Paradigm and electrophysiological 
recording during the requested tasks. Two groups were measured; 
one of MS patients without the manifest of cognitive alteration and 
another controlled group of well-matching healthy people. 
Participants watched arrays of 2, 4 or 6 consonants that had to be 
memorized. Then a black screen was shown and finally an objec-
tive stimulus was displayed (a consonant). The subjects had to 
respond quickly whether the consonant in the objective stimulus 
was either present on the array initially shown. We found signifi-
cant differences in the reaction timing and correct responses in 
relation to the load of working memory for both the control group 
and the MS group. However, no significant differences between 
both groups were found. Regarding to Event-Related Potencials 
(ERPs), we found modulation in amplitudes of late potentials by 
memory load in both groups; showing significantly higher ampli-
tudes on the control group. In time-frequency analyses, the both 
groups showed a reduction in the alpha activity in the end of codi-
fication and the beginning of the maintenance. This alpha activity 
modulation was significantly higher for control group. Furthermore, 
MS patients showed increased alpha and beta activity in the main-
tenance stage while, in the recovery stage, patients demonstrated 
an increase in alpha activity for higher load conditions. Differences 
in late potentials and in cortical oscillations alfa y beta, electro-
physiological variables would be useful in early detecting of alter-
ations in the WM in patients with MS.
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EP1569
Correlation between visual evoked potentials and cognitive 
impairment in multiple sclerosis patients
T. Erol Yilmaz1, N. Bilge1, E. Özyildirim2
1Neurology, 2Public Health, Erzurum Atatürk University, 
Erzurum, Turkey
Multiple Sclerosis (MS) affects young adults within a heterogene-
ous clinical spectrum and it is one of the significant causes of 
disability in young adults. Cognitive impairment obstructs daily 
activities of MS patients as much as physical disability causes. 
This study aims to find out correlation between visual evoked 
potentials (VEP) and cognitive impairment in MS patients. In this 
study, cognitive impairment and visual evoked potentials (VEP) 
are evaluated in 35 RRMS patients who have been followed in 
neurology outpatient clinic at Ataturk University, Faculty of 
Medicine and 30 healthy control cases. Wide range of neuropsy-
chometric test battery is applied to patient and control groups 
including Faces-Symbol Test (FST), Rey Auditory Verbal 
Learning Test (RAVLT), Digit Span Test (DST), Paced Auditory 
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Serial Addition Test(PASAT), Face Symbol Test (FST), Clock 
Drawing Test, Trail Making Test (TMT) and Stroop Test. It was 
identified that there is impairment in verbal memory processes, 
attention, retain of attention, working memory, visuospatial func-
tions, executive functions and construction ability in RRMS 
patients according to healthy controls. In correlation analysis, 
there is statistical positive correlation between left eye P100 
latency and TMT Part B time of completion (p= 0.046) besides, 
there is statistical negative correlation between right eye P100 
latency and forward DST (p= 0.04). In conclusion, RRMS patients 
are encountering impairments in verbal memory processes, atten-
tion, retain of attention, working memory, visuospatial functions, 
executive functions, and construction ability. Although it is diffi-
cult to make any interpretation about whether there is any associa-
tion between VEP abnormalities and cognitive disorder or not, the 
presence of a correlation between P100 latency and impairment in 
attention, short-term memory and executive functions are remark-
able. Further studies about this subject are needed to encourage 
these findings.
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Visual evoked potentials with low-contrast stimuli in the 
evaluation of optic neuritis
J.-Y. Cho1, S.-H. Park2, N.-H. Kim2
1Neurology, Ilsan Paik Hospital, Inje University College of 
Medicine, 2Neurology, Dongguk University Ilsan Hospital, 
Goyang-si, Republic of Korea
Background: Contrast vision is known to be more sensitive to 
detect optic neuritis (ON) in patients with multiple sclerosis 
(MS). Even in the absence of a history of ON or decrease of 
visual acuity (VA), low-contrast VA may appear to be abnormal. 
Thus, we investigated if VEPs using low contrast stimuli which 
can reflect low-contrast VA would help to identify optic nerve 
involvement.
Methods: We studied 9 patients with demyelinating diseases (5 
male, 4 female; 15-51 years old). We included patients with 
demyelinating diseases which were ON, MS, or neuromyelitis 
optica spectrum disorders. Patients who had an episode of ON 
within the last 6 months were excluded to minimize the effect of 
optic disc swelling by acute ON. Clinical characteristics includ-
ing disease duration, history of ON, number of ON episodes, and 
Expanded Disability Status Scale (EDSS) scores were obtained. 
Monocular VEPs were induced using pattern-reversal checker-
board stimuli with 100% and 10% contrast at check size of 33 
minute. For 10% contrast VEPs, a prolonged absolute latency 
(more than 130 ms which was a limit obtained from the previous 
literature) or absence of the P100 component was considered 
abnormal.
Results: Eleven eyes with ON and seven eyes without ON were 
evaluated. VEP latencies were significantly increased in response 
to low-contrast stimuli compared with high-contrast stimuli in 
both groups; low-contrast and high-contrast VEPs were 
136.1±19.5 ms and 115.3±14.4 ms in the eyes of ON (p=0.004) 
and 134.5±12.4 ms and 103.3±4.6 ms in the eyes without ON 
(p=0.001), respectively. Low-contrast and high-contrast VEPs 
were abnormal in 66.7% (n=12) and 27.8% (n=5), respectively in 
all eyes (n=18). Low-contrast and high-contrast VEPs were 
abnormal in 63.7% (n=7) and 45.5% (n=5) of ON eyes (n=11). In 
the eyes without ON (n=7), low-contrast VEPs detected subclini-
cal involvement in 71.4% (n=5), but high-contrast VEP did not 
find any abnormalities. Thus, low-contrast VEPs proved to be 
more sensitive to detect optic nerve involvement than high-con-
trast VEPs (McNemar p=0.016) in the eyes of demyelinating dis-
eases. Low-contrast VEPs latencies seems to be correlated with 
average RNFL thickness (ρ=-0.49, p=0.063), but not with VA 
(ρ=0.59, p=0.833).
Conclusions: In our study, we identified abnormal low-contrast 
VEPs in patients with demyelinating diseases, even when high-
contrast VEPs is normal or no history of ON exists.
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Neuropsychology
EP1571
Validation of the French version of the BICAMS and com-
parison with the MACFIMS
M. Deloire1, A. Saubusse1, J. Charré-Morin1, M. Barbaud1, T. 
Loock1, N. Ehrlé2, A. Ruet1,3, B. Brochet1,3, BICAFMS Study 
Group
1Neurology, CHU Bordeaux, Bordeaux, 2Neurology, CHU 
de Reims, Reims, 3INSERM U 1215, University of Bordeaux, 
Neurocentre Magendie, Bordeaux, France
Background: The Brief International Cognitive Assessment for 
Multiple Sclerosis (BICAMS) requires proper validation in each 
country.
Objectives: To establish French normative values in healthy sub-
jects (HS) for the tests of the BICAMS and the Minimal Assessment 
of Cognitive Function in Multiple Sclerosis (MACFIMS) and to 
determine the predictive value of the BICAMS to impairment at the 
MACFIMS in persons with multiple sclerosis (PwMS).
Methods: PwMS were recruited in several French centers. 
Healthy women and men, aged 18-64, without any known chronic 
systemic, psychiatric or neurologic disease or current dependence 
on alcohol or drugs, were recruited. All subjects were evaluated 
by trained neuropsychologists using the BICAMS and MACFIMS 
tests. The BICAMS includes the Symbol Digit Modalities Test 
(SDMT) and the first learning trials of the Brief Visual Memory 
Test Revised (BVMT-R) and the California Verbal Learning Test 
second edition (CVLT_II). A new form of the CVLT developed by 
Ehrlé et al. has been used. The MACFIMS included the SDMT, 
the BVMT-R, the CVLT, the Paced Auditory Serial Addition Task 
(PASAT 3s), the Judgment of line orientation test (JLOT) the 
Controlled Oral Word Association Test (COWAT) and a French 
adaptation of the Dellis-Kaplan sorting test, the “Epreuve de 
Classement des Cartes de Champagne” (ECCC, developed by 
Ehrlé et al). ANOVAs were used to study the effects of age, educa-
tion and gender for each test. Cognitive impairment (CI) was 
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diagnosed for each test and battery for patients with < 1.5 standard 
deviation (SD) of the HS group. The predictive value of CI at the 
BICAMS to CI at the MACFIMS was calculated using Bayesian 
statistics.
Results: 81 PwMS (27 primary progressive, 18 relapsing-remit-
ting and 36 secondary progressive) and 253 HS have been 
included so far. Enrollment will end in June 2017. Normative val-
ues were calculated according to age, gender and education. 
ANOVA showed an effect of age on all tests except PASAT, 
COWAT and ECCC, an effect of education on all tests except 
BVMT-R and an effect of gender on CVLT, PASAT and JLOT. In 
this preliminary analysis, 59% of 81 PwMS had CI at one test at 
least of the BICAMS and 37% at two tests at least of the 
MACFIMS. CI at the BICAMS (at least 1 test) predicts with a 
sensitivity of 93%, a specificity of 61% and accuracy of 73% CI 
at the MACFIMS (at least 2 tests).
Conclusion: The BICAMS could be more considered as a short 
cognitive assessment rather than a screening tool.
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EP1572
Association between cytokine gene polymorphisms and cog-
nitive functions in relapsing-remitting multiple sclerosis
A.G. Trenova1, G.S. Slavov1, M.G. Manova1, Z.I. Zahariev1, 
L.D. Miteva2, S.A. Stanilova2
1Department of Neurology, Medical University of Plovdiv, 
Plovdiv, 2Department of Molecular Biology, Immunology and 
Medical Genetics, Trakia University, Stara Zagora, Bulgaria
Background: Cognitive impairment is a common feature of mul-
tiple sclerosis (MS). There are still disputable questions about its 
morphological substrate and causation. The type and degree of 
cognitive dysfunction is not highly associated with disease course 
and physical disability, which emphasizes the need of disclosing 
the factors that determine the development of cognitive deficit.
Objective: The objectives of this study is to investigate the rela-
tionship between promoter polymorphisms -308A/G TNF-alpha, 
-1082A/G IL10 and -607C/A IL-18 and cognitive functioning in 
patients with relapsing-remitting MS (RRMS).
Methods: The study comprised 159 patients with RRMS, diag-
nosed according to McDonald’s criteria (2010) in remission phase 
(mean age 40.08±8.48years, mean disease duration 10.60±5.70years) 
and 154 healthy controls matching by age, gender and education. 
Paced Auditory Serial Addition Test (PASAT), Symbol Digit 
Modalities test (SDMT) and Isaacs test were used for assessment of 
working memory, attention, visuo-perceptual abilities, information 
processing speed, verbal fluency and executive functions. 
Genotyping of the promoter polymorphisms in IL-10 and IL-18 
was performed using ARMS-PCR assay, while polymorphism in 
TNF-alpha was genotyped by RFLP-PCR assay.
Results: Patients had lower mean score on all three neuropsycho-
logical tests than the controls (p< 0.0001). In the patients’ group the 
following significant associations were found: AG genotype of 
-308A/G TNF-alpha was associated with higher serum TNF-alpha 
concentration than GG genotype (p=0.04), higher serum TNF-alpha 
levels correlated with poorer attention and visuo-perceptual abili-
ties (SDMT) (p=0.033); CC genotype of -607C/A IL-18 was related 
to lower score on the test for verbal fluency and executive functions 
(Isaacs test) as compared to AC variant (p=0.04).
The test result was considered abnormal when the patient scored 2 
standard deviations below the average performance of the control 
group. Carriers of AA genotype of -1082A/G IL-10 from the 
patients’ group showed significantly higher risk for abnormally low 
performance on PASAT than GG carriers (OR=10.0; p=0.0471).
Conclusion: The results of our study suggest that cytokine gene 
polymorphisms are one of the factors that affect cognitive functions 
in patients with RRMS. In Bulgarian population two promoter 
polymorphisms in pro-inflammatory cytokine genes - IL-18 and 
TNF-alpha, are associated with cognitive decline in RRMS patients.
Disclosure
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EP1573
The executive component of naming ability in multiple scle-
rosis
H. Joly, M. Cohen, C. Lebrun
Neurology Department, MS Clinic, CHU Pasteur 2, Nice, France
Background: Recent studies show language dysfunctions in 
Multiple Sclerosis (MS) at the level of the lexical access to the 
word in naming tasks. The presence of executive dysfunctions in 
MS has been demonstrated and confirmed through many studies. 
The link between executive component and the lexical access in 
naming task remains to be demonstrated.
Objective: Investigate the role of executive dysfunctions on nam-
ing abilities in MS.
Method: 105 patients ran the Boston Naming test (BNT) and the 
BCCog (a French short cognitive battery specific to MS). They 
were 2 Clinically Isolated Syndrome (CIS), 1 Radiologically 
Isolated Syndrome (RIS), 68 Relapsing Remitting, 28 Secondary 
Progressive (SP), and 6 Primary Progressive (PP) forms of MS. 68 
women, 37 men, with a mean age of 46 years (ET: 13.24, 19-80), 
a mean study level of 12 years (ET: 3.6), and a median EDSS 
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score of 3.5 (0-8). 48 out of these patients also ran the Trail 
Making Test (TMT) and the Stroop test in order to evaluate 
respectively mental shifting and inhibitory control (2 CIS, 37 RR, 
5 SP,4 PP): 36 women, 12 men, with a mean age of 43 years 
(ET:14.1, 19-74), a mean study level of 11 years (ET: 1.9), and a 
median EDSS of 3 (0-7.5).
Results: The results from the whole cohort confirm a lexical 
access deficit in MS on naming task. In the line of previous 
research the total score at the BNT is normal (mean: 53.57, SD: 6), 
but the patients need high number of phonological clue (mean 6, 
SD: 4) in order to normalize their scores. They were no significant 
correlation between the BNT and the BCCog scores. The lexical 
access deficit was stronger in the SP than in the RR forms of MS 
(ANOVA: f=4.4, p < 0.5). On the smaller cohort, linear regression 
analysis showed a significant impact of the speed processing at 
the TMTA (f=5, p< 0.5), the TMTB (f=13, p< 0.001), and of the 
mental shifting TMTB-A (f=9, p=0.005) on the lexical access. 
The production of phonological and semantic paraphasias was 
also impacted by the mental shifting (f=6, p=0.02). No naming 
score were linked to the inhibitory control score.
Conclusions and perspectives: The impact of executive dysfunc-
tion in MS on naming ability is enlightened through this study 
specifically at the level of mental shifting. It suggests the neces-
sity to take executive dysfunction into account in order to permit 
an adequate reeducation of naming abilities in MS. Further studies 
will investigate the naming and executive functions at earlier state 
of the disease.
Disclosure
Joly, Cohen & Lebrun: Nothing to disclose
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Cognitive profiles in multiple sclerosis: beyond information 
processing speed
A. Cortés-Martínez1, V. Pytel1,2, J. A. Matias-Guiu1,2, M. 
Valles-Salgado1, C. Oreja-Guevara1,2, P. Montero1,2, T. Moreno-
Ramos1,2, J. Matías-Guiu1,2
1Neurology, San Carlos Institute for Health Research (IdISSC), 
2Neurology, Hospital Clínico San Carlos, Madrid, Spain
Background: Changes in information processing speed (IPS) 
constitute the most important cognitive alteration in multiple scle-
rosis (MS). However, given the clinical and topographical varia-
bility of the disease, cognitive alterations may vary greatly and 
appear in other forms in addition to slower IPS. Our aim was to 
determine the principal cognitive domains and components 
involved in MS and identify factors associated with presence of 
cognitive impairment in these patients.
Methods: Cross-sectional study of 311 patients with MS (236 
with relapsing-remitting MS [RRMS],
52 with secondary progressive MS [SPMS], and 23 with primary 
progressive MS [PPMS]). Patients’ cognitive function was 
assessed with a comprehensive neuropsychological assessment 
protocol. We conducted a principal component analysis to detect 
different cognitive patterns by identifying clusters of tests highly 
correlated to one another.
Results: Cognitive impairment was detected in 41.5% of the 
sample and more frequent in patients with SPMS and PPMS 
(P = 0.002). EDSS scores and education were independent predic-
tors of cognitive impairment. Principal component analysis iden-
tified 7 clusters: attention and basic executive function (including 
IPS), planning and high-level executive function, verbal memory 
and language, executive and visuospatial performance time, 
fatigue-depression, visuospatial function, and basic attention and 
verbal/visual working memory. Mean scoring of components 2 
and 3 was higher in patients with RRMS than in those with PPMS 
(component 2) and SPMS (component 3).
Conclusions: MS is linked to multiple cognitive profiles and 
alterations in different domains. This suggests that cognitive alter-
ations in MS are heterogeneous and affect other domains in addi-
tion to IPS.
Disclosure
Ana Cortés-Martínez: nothing to disclose
V. Pytel: nothing to disclose
Jordi A. Matias-Guiu: nothing to disclose
María Valles-Salgado: nothing to disclose
C. Oreja-Guevara: nothing to disclose
P. Montero: nothing to disclose
T. Moreno-Ramos: nothing to disclose
J. Matias-Guiu: nothing to disclose
EP1575
The relationship between attention impairment and informa-
tion processing speed in patients with multiple sclerosis
M. Schmoeger, K. Zebenholzer, M. Deckert, G. Lindinger, C. 
Schmied, B. Bajer-Kornek, E. Arndorfer, P. Rezwanpanah-
Poshteh, T. Schneider, E. Auff, U. Willinger
Department of Neurology, Medical University of Vienna, Vienna, 
Austria
Multiple sclerosis (MS) is the most common autoimmune disor-
der in adulthood affecting the central nervous system which leads 
to significant physical disabilities (e.g. Noseworthy et al., 2006) 
and diverse cognitive deficits with respect to memory, processing 
speed, executive functions or attention and concentration (e.g. 
Ferreira, 2010). Due to the fact that attention impairment in MS 
seems to be related to the slowing down of information processing 
(Balsimelli et al., 2007) the aim of the present study is to examine 
this relationship using three different psychometric tests of selec-
tive attention.
The sample consisted of 38 patients with MS (42% men, 58% 
women) aged between 22 and 65 years (M=40.6; SD=9.7), and 38 
age, gender and education matched healthy controls. Mean dis-
ease duration was 11.2 years (SD=6.2), the type of MS was relaps-
ing remitting in 92% and secondary progredient in 8% of the cases 
(EDSS-M=1.5).
Results showed a significantly lower performance of patients with 
MS (M=34.63, SD=16.22) than healthy controls (M=27.26, 
SD=10.49; t=2.44, df=37, p=.019) regarding basic selective atten-
tion skills in terms of psychomotoric speed (Trail Making Test - 
A). However, no significant differences between MS-patients and 
control subjects with respect to the number errors were found. 
With respect to selective attention in terms of discrimination of 
similar visual stimuli under time pressure (d2-Test of attention) a 
significant difference regarding concentration performance (t=-
2.57, df=37, p=.014) in terms of lower performance scores of 
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MS-patients (M=142.84, SD=36.08) than controls (M=162.26, 
SD=38.43) was found. No significant differences were found with 
respect to error rates. Significant differences (t=2.16, df = 37, 
p=.037) were found in selective attention ability in terms of inhi-
bition of dominating stimuli (Color Word Interference Test) with 
MS-patients (M=77.47, SD=16.92) showing longer response 
times than controls (M=69.97, SD=13.14). Error rates did not dif-
fer significantly between MS patients and controls.
MS-patients showed lower performances than healthy controls 
with respect to different selective attention indices that rely on 
information processing speed. However, performance accuracy in 
terms of error rates did not differ between patients and controls. 
This result supports the suggestion that attention impairment in 
MS is mainly related to the slowing down of processing speed 
(Balsimelli et al., 2007).
Disclosure
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Deckert, M´.: nothing to disclose
Lindinger, G.: nothing to disclose
Schmied, C.: nothing to disclose
Bajer-Kornek, B.: nothing to disclose
Arndorfer, E.: nothing to disclose
Rezwanpanah-Poshteh, P.: nothing to disclose
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EP1576
Adaptive coping interventions should be a priority for people 
with multiple sclerosis and cognitive impairment
L.B. Grech1, L. Kiropoulos1, K. Kirby1, E. Butler2, M. Paine3, R. 
Hester1
1Melbourne School of Psychological Sciences, University of 
Melbourne, Parkville, 2Neurology, Monash Health, Clayton, 
3Neurology, St Vincent’s Hospital, Fitzroy, VIC, Australia
Background: Lower quality of life (QoL) experienced by people 
with multiple sclerosis (PwMS) may be influenced by their cop-
ing style. Coping has been shown to provide an indirect link 
between cognition and stress, depression and anxiety in MS. This 
research extends this to the assessment of coping as a moderator 
or mediator between executive function and QoL in PwMS.
Methods: Participants were 107 people with relapsing remit-
ting (83) or secondary progressive (24) MS (mean age: 
48.8±11.1 years), administered executive function tasks 
(Symbol Digit Modalities Test, Word List Generation, Reading 
Span, Trail Making Test [TMT], Elevator Counting with 
Distraction, Visual Elevator, Modified 6 Elements, Zoo Map, 
Action Programming), transformed into Z-scores and totalled to 
provide an executive function index. Self-reported dispositional 
coping (COPE) and QoL (MS Quality of Life-54) inventories 
were also administered.
Results: Coping strategies mediated (behavioural disengagement, 
acceptance, growth and religion) and moderated (denial, active 
and total coping) the relationship between executive function and 
QoL in PwMS. Lower executive function indirectly increased 
mental health and overall QoL through acceptance, growth and 
religion coping (SD range between .06 and .24 increase for each 
unit decrease). Whereas mental health QoL decreased with each 
executive function unit decrease, through the indirect effect of 
behavioural disengagement coping (SD=.14 ). In participants who 
endorsed high denial coping, lower executive function was related 
to lower mental health and overall QoL (ΔR2=.07 and .04 respec-
tively), while this was not the case in participants who endorsed 
no-to-low use of denial coping. A relationship between lower 
executive function and lower physical health QoL was shown for 
participants who endorsed no-to-low active and total coping 
(ΔR2=.07 and .04 respectively), which was not seen in moderate-
to-high users of these coping strategies.
Conclusion: These results imply that in PwMS who have reduced 
executive function, less cognitively demanding adaptive coping 
strategies: acceptance, growth and religion, are related to increased 
QoL, while maladaptive strategies: behavioural disengagement 
and denial, are associated with poorer QoL. Interventions aimed at 
reducing avoidant coping strategies and increasing less cogni-
tively demanding adaptive coping strategies in PwMS who expe-
rience deficits in executive function are required as a priority.
Disclosure
The authors have nothing to disclose.
EP1577
Interpretability of the patient-reported multiple sclerosis 
neuropsychological screening questionnaire: a cognitive 
screening tool?
I.M. Nauta, L.J. Balk, J.M. Sonder, B.M.J. Uitdehaag, B.A. de Jong
Department of Neurology, MS Center Amsterdam, VU University 
Medical Center, Amsterdam, The Netherlands
Background: Detecting cognitive impairment among patients with 
multiple sclerosis (MS) is relevant, given the profound impact of 
cognitive impairment on quality of life. A potential screening tool for 
cognitive impairment is the Multiple Sclerosis Neuropsychological 
Screening Questionnaire (MSNQ). However, the interpretability of 
its patient-reported version (MSNQ-P) is unclear.
Objectives: This study aimed to increase the interpretability of 
the MSNQ-P by (1) determining the optimal cut-off score to pre-
dict cognitive impairment among MS patients, and by (2) investi-
gating which factors predict patient-reported cognitive problems.
Methods: A cohort of 335 MS patients completed the Dutch version 
of the MSNQ-P and a neuropsychological examination. Patients 
were classified into cognitively impaired (CI; n = 87), mildly cogni-
tively impaired (MCI; n = 107) and cognitively preserved (CP; n = 
141), based on the scores of 88 healthy controls. The optimal cut-off 
score to detect CI and MCI was considered the value for which [sen-
sitivity + specificity] was highest. Furthermore, backward prediction 
models were used to determine which factors (cognition, depression, 
anxiety, fatigue, age, disease duration, education and physical disa-
bility) predict the MSNQ-P scores. Patients with scores on each fac-
tor were included in these analyses (N = 244).
Results: Preliminary results demonstrated a value of 20 as the 
optimal cut-off score to detect MS patients with CI (sensitivity = 
.60, specificity = .57, accuracy = .58), and 12 to detect MS patients 
with MCI (sensitivity = .82, specificity = .41, accuracy = .59). The 
MSNQ-P was predicted by the following factors: cognition, 
depression, anxiety, fatigue, education and physical disability, of 
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which fatigue was the strongest predictor. The model explained 49 
percent of the variance on the MSNQ-P.
Conclusion: Due to low psychometric properties, the MSNQ-P 
cannot solely be used as a screening tool to detect cognitive 
impairment among MS patients, which is in line with previous 
studies. Multiple factors influenced patient-reported cognitive 
problems, including fatigue, depression, anxiety, cognition, edu-
cation and physical disability.
Disclosure
I.M. Nauta has received a grant from the Dutch MS Foundation.
L.J. Balk reports no conflict of interests.
J.M. Sonder has received a grant from the Dutch MS Foundation.
B.M.J. Uitdehaag has received personal compensation for con-
sulting from Biogen Idec, Genzyme, Merck Serono, Novartis, 
Roche en TEVA.
B.A. de Jong has received speaker and consulting fees from 
Merck-Serono, Biogen, TEVA, Genzyme and Novartis.
EP1578
Cognitive-motor interaction in patients with multiple sclerosis
M.B. Eizaguirre, A. Merino, C. Yastremiz, N. Cabral, B. Silva, 
R. Alonso, S. Vanotti, O. Garcea
J.M. Ramos Mejía Hospital, Buenos Aires, Argentina
Background: Multiple Sclerosis (MS) patients, usually show 
cognitive and motor deficits. These deficits are regularly assessed 
separately, however recent studies have found an interaction when 
these tasks are performed simultaneously (Cognitive-Motor 
Interaction, CMI). The research in CMI allows a more ecological 
approach to the description of MS symptoms.
Objectives: 
1) To compare performance in CMI between MS patients 
and healthy controls.
2) To analyze the relationship between CMI and clinical 
variables and cognitive impairment.
Methods: Forty patients with relapsing-remitting MS and 20 
healthy controls were included. Patients age: 38.03 ± 11.26; edu-
cation: 13.55 ± 2.74; Expanded disability status scale (EDSS): 
2.02 ± 0.93; Disease evolution: 10.81 ± 11.19. Controls age: 34.00 
± 14.25; education: 14.92 ± 2.15
Outcome measures:
Clinical variables: EDSS; Fatigue Severity Scale; Beck’s 
Depression Inventory II.
Cognitive variables: BICAMS Battery;
Dual tasks: Two cognitive -motor interaction tasks (walking while 
performing verbal fluency/counting). The measure of the differ-
ence between subject performance in the simple task and in the 
situation of dual task was obtained. It was quantity: time, number 
of steps and cognitive performance.
Results: No significant differences were found between patients 
and controls in age (p=.268) and education (p= .083). Significant 
differences were found between patients and controls in CMI, 
in the time (fluency: p=.027; counting: p=.038), the steps of 
the counting task (p=.029) and in the performance of both 
cognitive tasks (fluency: p= .040; counting: p=.001). Significant 
correlations were found between CMI time and disease evolution 
(p=.025), number of steps and physical disability (p=.042), and 
between fluency and fatigue (p=.026). No correlations were found 
between CMI and depression. There were no differences in CMI 
between patients with and without cognitive impairment.
Conclusions: Patients with MS show alterations in cognitive-
motor tasks. Patients with more years of evolution, disability and 
fatigue evidence a worse performance.
Disclosure
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Yastremiz C.: Nothing to disclose
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Garcea O.: Nothing to disclose
EP1579
Functional MRI of the symbol digit modalities task in relaps-
ing remitting multiple sclerosis
K. Hoffeld1, M. Domin2, M. Opolka1, J. Berneiser1, M. Lotze2, 
M. Grothe1
1Neurology, 2Radiology, University Greifswald, Greifswald, 
Germany
Background: The symbol digit modalities task (SDMT) is rec-
ommended for assessing cognitive disabilities in multiple sclero-
sis (MS). There is a broad literature about adaptations of cognitive 
tasks (like the paced auditory serial addition task) for functional 
MRI, but only a few studies investigated the SDMT in both 
patients and healthy controls (HC).
Here, we adapted an oral version of the SDMT for fMRI to study 
the cognitive networks involved in the SDMT in both patients and 
healthy controls.
Methods: In total, 20 patients with relapsing remitting MS (EDSS 
1-8; median 2.0) and 20 healthy controls, matches due to age 
(mean 41y) and gender (10 female) were investigated. Study 
design was an oral version of the SDMT with 30 sec blocks of 
assigning numbers to symbols.
Results: Both patients and healthy controls had strong functional 
activation in areas involved in language processing (Brodmann 
area (BA) 22), working memory (BA9), motor (BA4, BA6), visu-
omotor (BA7) and visual function (BA17-19) at p(FWE)< 0.05. 
Patients did not have any increased activation compared to healthy 
controls (MS>HC). Interestingly, HC had increased activation in 
BA 22 and in the insula (BA13) compared to the patients group 
(HC>MS).
Discussion: Here we could demonstrate a robust fMRI adaptation 
of the SDMT task. In our data, controls had an increased activa-
tion in language processing areas, indicating a disrupted network 
in MS-patients involved in this task.
Disclosure
MG has received research grants and travel support from TEVA 
pharma, Biogen Idec, Sanofi genzyme and Novartis.
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EP1580
Cognitive impairment in neuromyelitis optica and multiple 
sclerosis
E. Fernández Díaz, I. Diaz-Maroto, M. Fernández Valiente, M. 
Gomez Hontanilla, J. Gracia Gil
Neurology, Complejo Hospitalario Universitario de Albacete, 
Albacete, Spain
Introduction: Cognitive impairment (CI) has a growing interest 
among multiple sclerosis (MS) yet cognitive dysfunction is not as 
well characterized in neuromyelitis optica (NMO) seropositive for 
APQ4-IgG, even less is known for the MOG-IgG seropositive 
group. Our aim is to investigate the prevalence and patterns of 
cognitive impairment in our NMO and MS patients compared to 
matched healthy controls (HC).
Methods: We included 68 subjects in the study (5 NMO-AQP4, 4 
NMO-MOG, 37 MS and 22 HC in a single centre. Cognitive func-
tion was evaluated with the Brief Neuropsychological Battery for 
MS, a Spanish validated battery for MS. Depression and fatigue 
assessments were conducted. Clinical and MRI data was also col-
lected for the NMO/MS patients. CI was considered when a 
patient had 2 or more tests with a score under fifth percentile of 
HCs.
Results: Both NMO and MS groups performed worse than HC in 
all cognitive functions evaluated (p< 0.05) including verbal mem-
ory, information memory speed, complex attention and verbal flu-
ency. CI was detected in 22.2% of NMO and 13,5% of MS 
patients. Any abnormal test was observed in 22.2% of NMO and 
40,5% of MS patients. CI in MS was related to EDSS score >4 and 
higher T2 load in brain MRI. The NMO patients with CI were 1 
NMO-AQP4 and 1 NMO-MOG, no relation with clinical or radio-
logical variables. No differences were found across 3 groups in 
terms of age, sex, education, depression or fatigue. We neither 
found differences in disease duration, time to treatment, time from 
last relapse, EDSS score or percentage of DMT between NMO 
and MS patients.
Conclusions: Both NMO and MS have worse cognitive perfor-
mance than matched healthy controls. Our results support the 
need to evaluate cognitive function in both NMO-AQP4 and 
NMO-MOG patients to define the CI profile in these patients.
Disclosure
The authors of this study have nothing to disclose.
EP1581
Executive functioning and delayed verbal memory retrieval 
in patients with multiple sclerosis
F. García-Vaz1,2, V. Meca-Lallana3, I. Palmi3, B. del Rio3, J.A. 
Vivancos-Mora3, R.G. Gonzalez-Cuenca2, A. Meldaña-Rivera4, 
M.L. Martinez-Gines5, J.M. Garcia-Dominguez5, J.P. Cuello5, F. 
Romero-Delgado5, Y. Higueras4
1Fundacion Investigacion Biomedica, Hospital Universitario de 
la Princesa, 2Universidad Complutense de Madrid, 3Hospital 
Universitario de la Princesa, 4Instituto de Investigación 
Sanitaria del Gregorio Marañón, 5Hospital Gregorio Marañón, 
Madrid, Spain
Introduction: It has been postulated that 40% to 60% of people 
with multiple sclerosis (MS) have memory and learning problems. 
Training of executive functions has demonstrated to be effective 
for memory and learning rehabilitation (Mitolo, 2015).
Objectives: We aim to analyse differences between immediate 
recall and long term retrieval in patients with (MS) using Spanish 
Version of California Verbal Learning Test (TAVEC) and its rela-
tionship executive functioning (EF).
Method: 143 patients with remitting-relapsing MS (RRMS) were 
recruited from the clinic ( mean age: 42,39 y.o.) and a sample of 
35 healthy controls (HC) of the same age and educational level. A 
complete neuropsychological assessment was administered to 
both groups. MS sample was classified in three groups: no cogni-
tive impairment, mild cognitive impairment and moderate cogni-
tive impairment. We analyse differences between immediate and 
delayed retrieval in TAVEC in the HC and MS and the relation-
ship with verbal fluency as a measure of EF.
Results: All MS groups obtained significant better (p< 0.01) out-
comes in long term retrieval than in short term retrieval; no sig-
nificant differences were found in HC (p< 0.05). A positive 
correlation (p< 0.01) was found between phonological verbal flu-
ency and memory in TAVEC for patients group.
Conclusions: MS patients obtain better delayed retrieval out-
comes than in immediate memory. Verbal fluency is related to 
short and long term verbal memory in patients with multiple 
sclerosis and could explain the findings in TAVEC results . We 
suggest that patients with deficit in executive functioning take 
benefit of the semantic classification provided by this test what 
facilitates coding. Our results support previous research sug-
gesting that EF are related to memory outcomes in patients 
with MS.
Disclosure
García-Vaz, F; Meca-Lallana, V; Palmi-Cortés, I; del Río Muñoz, 
B; Vivancos, J ; Martínez-Ginés , M.L; García-Domínguez , J.M; 
Cuello, J.P ; Romero-Delgado, F ; Higueras, Y . have received 
speaker honoraria and/or travel grants from Novartis, Biogen, 
Gencyme, Almirall, Bayer, Teva, Roche. A. . Rafael G. Gonzalez-
Cuenca and Ariana Maldaña-Rivera has nothing to disclosure
EP1582
Cognition and the cerebellum in multiple sclerosis (MS)
J.C. Hinchliffe1, K. Abdel-Aziz2, K. Parmar3, D.W. Langdon4
1Department of Clinical Psychology, Royal Holloway, 
University of London, 2Department of Neurology, Ashford & 
St. Peter’s NHS Foundation Trust, London, United Kingdom, 
3Neurological Clinic and Policlinic, University Hospital Basel, 
Basel, Switzerland, 4Psychology, Royal Holloway, University of 
London, London, United Kingdom
Background: Cerebellar motor symptoms mean poor prognosis 
in MS and have been associated with a specific cognitive profile. 
A few studies have reported further dysfunction in the domains of 
reduced information processing speed (IPS), impairments in visu-
ospatial functions and verbal fluency deficits associated with cer-
ebellar damage. The cerebellum can encode models of sensory 
stimuli, providing mental representations of the world used to 
plan motor actions. Motor planning may be a key factor in the dis-
ability that cerebellar involvement imposes.
Aim: To explore how the cognitive profile of those with cerebel-
lar motor symptoms (RR-MSc) differs from those without 
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cerebellar symptoms (RR-MSnc), and how this relates to motor 
function and motor planning.
Method: RR-MSc allocation was based on the NARCOMS 
tremor and coordination scale (≥4). 21 HC
(10 males, x̅ age: 37.1), 21 RR-MSnc (6 males, x̅ age: 39.8) and 
14 RR-MSc (7 males, x̅ age: 40.6) completed BICAMS (CVLT-II, 
SDMT, BVMT-R), PASAT3, and word list generation (WLG). We 
computed a cognitive impairment index (CII), and designated 
“widespread cognitive impairment” (x̅- (>1.5SD) on three or 
more tests). The 9-hole peg-test (9-HPT, as a sensorimotor con-
trol) and grooved pegboard test (GPT, more motor planning 
demands) were subtracted to compute a motor planning index 
(MPI).
Results: One-way ANCOVAs, covarying premorbid IQ revealed 
differences: SDMT (F(3,52) = 7.81, p < .001), CVLT-II (F(3,52) = 
3.42, p = .0024), BVMT-R (F(3,52) = 2.93, p = .0042), PASAT3 
(F(3,52) = 12.89, p < .001), CII (F(53,2) = 8.85, p < .001), 
9HPT(F(3,52) = 20.04, p < .001), GPT (F(3,52) = 20.15, p = 
.001), MPI (F(3,52) = 16.75, p = < .001). No differences were 
found for WLG (F(3,52) = 2.55, p = .07). SDMT, GPT, 9HPT and 
MPI were the only tests to differentiate RR-MSnc and HC, and all 
tests differentiated RR-MSnc and RR-MSc other than WLG (not 
significant) and BVMT-R (just HC from RR-MSc). CII differed 
significantly between RR-MSc and all groups, but not between 
RR-MSnc and HC. RR-MSc showed significantly greater CII. 
Frequency of widespread cognitive impairment was 4.8% for HC, 
28.6% for RR-MSnc and 57.1% for RR-MSc.
Conclusion: RR-MSc had more significant and widespread 
impairments than RR-MSnc, specifically with IPS, visual/verbal 
memory, and motor planning and function. These findings have 
clinical implications for those with cerebellar symptoms. MPI has 
potential as a clinical and research measure of motor planning.
Disclosure
JH: none
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KP: Holds a grant of the Baasch-Medicus-Foundation and has 
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EP1583
Resilience matters in multiple sclerosis: the independent con-
tribution of psychological resilience to disability
S. Klineova, M.T. Fabian, G. Pelle, C. Lewis, J.F. Sumowski
CGD Center for MS at Mount Sinai, New York, NY, United States
Objective: To identify relationship between psychological resil-
ience and measures of disability in patients with Multiple Sclerosis 
(MS).
Background: Resilience is a dynamic process encompassing 
positive adaptation within the context of significant adversity. 
Resilience facilitates healthy coping skills and thus improves 
quality of life. Despite the importance of this concept, resilience 
has been understudied in patients with MS. In this project we 
analyzed whether greater resilience is associated with lower MS 
disability, independently of demographics (age, sex, education), 
cerebral atrophy, anxiety and depression.
Methods: Patients with early MS (87 RRMS, 18 CIS; < 5 years 
diagnosed; median EDSS = 1.0) completed the Connor-Davidson 
Resilience Scale 10 item (CD-RISC-10): a well-established meas-
ure of psychological resilience. Disability was assessed with the 
MS Functional Composite (MSFC), which assesses upper extrem-
ity function (Nine Hole Peg Test, NHPT), gait (Timed 25 Foot 
Walk, T25FW), and cognition (Symbol Digit Modalities Test, 
SDMT). Cerebral atrophy was estimated with normalized brain 
volume and thalamic volume from 3D T1 3.0T MRIs. Mental 
Health Inventory assessed anxiety and depression. Any outliers 
were winsorized. We evaluated partial correlations between resil-
ience and disability (MSFC, NHPT, T25FW, SDMT), controlling 
for demographics and cerebral atrophy. We then repeated analyses 
also controlling for anxiety and depression.
Results: Higher resilience was linked to lower disability on the 
MSFC (rp=.281, p=.005), and components SDMT (rp=.279, 
p=.005) and NHPT (rp=.252, p=.012), but not T25FW (rp=.037, 
p>.50). The independent contributions of resilience to lower dis-
ability on MSFC (rp=.222, p=.028), SDMT (rp=.224, p=.026), and 
NHPT (rp=.236, p=.019) remained when also controlling for anxi-
ety and depression. In contrast, MSFC was unrelated to anxiety 
(rp=.071, p=.487) and depression (rp=.069, p=.500) when control-
ling for aforementioned covariates and CD-RISC-10. Resilience 
was unrelated to all demographics (e.g., education) and cerebral 
atrophy (Ps>.10).
Discussion: We report a contribution of higher resilience 
(CD-RISC-10) to lower disability in MS, even independently of 
anxiety and depression. Lack of association between CD-RISC 10 
and potentially confounding factors (cerebral atrophy, education 
as a proxy for socioeconomic status) strengthen our findings. 
Further studies are needed to examine whether higher resilience 
protects longitudinally.
Disclosure
S. Klineova has given non-promotional lectures with Biogen 
Idec.
M. Fabian, G. Pelle, C. Lewis and J.F Sumowski have nothing 
to disclose.
EP1584
The brief international cognitive assessment for multiple 
sclerosis (BICAMS): normative values with gender, age and 
education corrections in the Portuguese population with mul-
tiple sclerosis
C.S. Sousa1, M. Neves2, T. Miranda1, P. Alegria3, J. Vales3, A. 
Passos2, M.J. Sá1
1MS Clinic, Neurology, Centro Hospitalar de São João, Porto, 
2BRU-IUL Instituto Universitario de Lisboa (ISCTE-IUL), 
Lisboa, 3Neurology, Hospital Beatriz Ângelo, Loures, Portugal
Background: The Brief International Cognitive Assessment for 
Multiple Sclerosis (BICAMS) is an international assessment tool for 
monitoring cognitive function in multiple sclerosis (MS) patients. 
BICAMS consist of three tests: the Symbol Digit Modalities Test 
(SDMT), the California Verbal Learning Test - Second Edition 
(CVLT II) and the Brief Visuospatial Memory Test - Revised 
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(BVMT-R). Our objective was to validate and assess the reliability 
of BICAMS to obtain normative data in Portuguese population.
Method: The sample composed of 107 MS patients and 62 healthy 
controls (HC). In order to test its reliability, BICAMS was re-
administered in a subset of 25 patients after 3 month later. 
Depression, anxiety and fatigue were assessed by Hospital Anxiety 
and Depression Scale and Modified Fatigue Impact Scale (MFIS).
Results: The sample comprises a control group (n=62, age: M = 
37,00; DP = 12,74, education:
M = 14,53; DP = 3,44) and a clinical group (n=107, age: M = 
38,50; DP = 11,34, education: M = 13,51; DP = 3,82). About 64% 
of the participants were women. The groups did not differ for age, 
education, or gender. The MS group performed significantly 
worse than the control group across the three neuropsychological 
tests, yielding the following values: SDMT: t(167) = 3.71, p = 
.000; CVLT-II: t(167) = 2.69, p = .008; and BVMT-R: t(167) = 
2.33, p = .021. The mean raw scores for Portuguese normative 
data were as follows: SDMT: 58.18 ± 10.25; CVLT-II: 59.65 ± 
10.96; and BVMT-R: 24.05 ± 6.47. Finally, test-retest reliability 
coefficients for each test were as follows: SDMT: r = .92; CVLT-II: 
r = .48; and BVMT-R: r = .86.
Conclusion: This BICAMS version is reliable and useful as a 
monitoring tool for identifying MS patients with cognitive 
impairment.
Disclosure
Funding: This project was partially funded by a research grant 
from Bayer AG. The authors would like to thank Dr. Dawn Langdon 
for her advice and support during the course of this study.
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Visual perceptual organization ability in multiple sclerosis
S. Demirci, M.D. Unlu
Neurology Department, Suleyman Demirel University School of 
Medicine, Isparta, Turkey
Objectives: Cognitive impairment is recognized as a core feature 
of multiple sclerosis (MS).Mostly memory, attention, and execu-
tive functions are affected.This study aims to compare visual 
information processing between multiple sclerosis(MS) patients 
and controls.
Methods: A case-control study was conducted in 30 MS 
patients(22female) and 30 (21female) age-, gender- and education 
level-matched healty subjects.All subjects were administered a 
detailed neuropsychological evaluation. Visuospatial information 
processing was evaluated with Hooper visual organization test 
(VOT),that requires perceptual and mental reorganization of parts 
of an object into an identifiable whole. The patients and controls 
were also administered Beck Depression Inventory and Mini-
MentalState Examination.
Results: Patient and control groups did not differ in means of gen-
der, age and education levels.BDI scores were similar in both 
groups and general cognitive functioning of patients were much 
the same.
MS subjects performed more poorly on the TMT part A and B 
than the control group.Mean scores obtained in PASAT were 
also lower in MS patients in comparison to healthy subjects.
Visual perceptual organization ability of multiple sclerosis 
patients were much the same as controls’ (MS:22.0+4.1,Contro
l:23.6+2.7;p=0.080).In order to evaluate whether the progress-
ing age does load any burden to visual perception organization 
ability, patient and control groups were categorized into three 
age groups(those younger than 25 years old, those between 
25-35 years old, and those older than 35 years).Though, healthy 
controls showed no statistically significant difference between 
groups(F=1.559;p=0.229); a significant difference was observed 
in MS group (F=4.670;p=0.018). Especially those older than 35 
years had a poor performance in comparison to younger 
patients. VOT performance showed a moderate inverse correla-
tion with disease duration and total attack number(r:-
0.471,p=0.009;r:-0.451,p=0.012;respectively) but no significant 
correlation with EDSS(r:-0.276;p=0.140). VOT performance 
correlated moderately with PASAT score(r:0.529;p=0.005) and 
showed an inverse correlation with TMA-A,-Bscores(r:-
0.535,p=0.002;r:-0.421,p=0.021; respectively).
Conclusions: Visual information processing ability is unimpaired 
in MS patients.
Disclosure
Serpil Demirci:nothing to disclose
EP1586
Neuropsychological Management of multiple sclerosis: Eval-
uation of the added value of a supervised and customized 
cognitive rehabilitation program for self-used at home
C. Harand, F. Daniel, A. Mondou, D. Chevanne, P. Branger, N. 
Derache, G. Defer
Neurology Unit, CHU Caen, Caen, France
Background: Cognitive and affective dysfunction negatively 
impact daily living of patients, particularly quality of life (QoL). 
Pharmacological treatment did not demonstrate any effect on cog-
nition compared to cognitive rehabilitation (CR) programs that 
show promising results but are less consistent concerning affec-
tive and QoL domains.
Objective: We developed a randomized controlled study to dem-
onstrate the interest of a patient’s tailored computerized CR pro-
gram, conducted at home, on QoL and self-esteem (SE).
Methods: This project comprises two phases. First, we con-
ducted a pilot study on 10 multiple sclerosis (MS) patients to 
assess the feasibility and acceptance of this project. 41 comput-
erized exercises were further selected according to the specific-
ity of MS cognitive difficulties and appropriate recommendations 
of patients. The second step will consist of the randomized study 
conducted with two groups (the experimental group and the con-
trol group). The experimental group will benefit for the CR pro-
gram and a psychological support at home during eight weeks (3 
sessions exercises of 45 minutes per week) whereas the control 
group will only receive psychological support. QoL and SE, 
respectively assessed by the MUSIQOL and the SE-inventory 
questionnaires, will be evaluated three times (at baseline, after 
the CR program and 6 months after the CR program). Given the 
expected MUSIQOL score variation, inclusion of 18 patients per 
group will be required.
Results: Pilot-study showed high acceptance and feasibility of 
exercises as well as improved subjective QoL. Preliminary results 
of the randomized study will be presented at the meeting.
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Conclusion: As QoL and SE are poorly evaluated in CR studies, 
we believe that this original customizeed CR program will high-
light the benefits on both parameters over short and longer delays 
in patient’s daily life.
Disclosure
C. Harand: nothing to disclose
F. Daniel: nothing to disclose
A. Mondou: nothing to disclose
D. Chevanne: nothing to disclose
P. Branger received funding for speaker honoraria from Novartis 
and Sanofi-Genzyme.
N. Derache received funding for speaker honoraria from Merck-
Serono, Biogen-Idec, Novartis, Teva and Sanofi-Genzyme.
G. Defer received personal compensation for serving on scientific 
advisory boards for Biogen Idec, Merck-Serono, Novartis, Sanofi 
Aventis, Genzyme and Teva Pharmaceutical Industries Ltd. He 
has received funding for travel and/or speaker honoraria from 
Merck Serono, Biogen, Guerbet, Sanofi Aventis, Novartis, 
Genzyme and Teva Pharmaceutical Industries Ltd. His institution 
received grants supporting research in his department from Merck 
Serono, Biogen, Sanofi Aventis and Novartis.
EP1587
Cortical lesions correlate with cortical atrophy and drive 
cognitive impairment in multiple sclerosis
T. Kunchev1, N. Fileva2, M. Petrova1, D. Zlatareva2, L. Traykov1
1Department of Neurology, 2Department of Diagnostic Imaging, 
University Hospital Alexandrovska, Sofia, Bulgaria
Background: There is increasing scientific data that cortical 
lesions (both number and size) are an independent factor in the 
pathogenesis of cognitive impairment in multiple sclerosis (MS). 
Several studies have also linked cortical lesions with disability 
and evolution to secondary progressive phase of the disease.
Objective: Our study aims to investigate the role of cortical 
lesions, cortical atrophy and white matter lesions in cognitive 
decline in patients with MS.
Methods: Fifteen patients with MS underwent clinical, detailed 
neuropsychological and neuroimaging examination. We per-
formed a 3 Tesla magnetic resonance imaging with three-dimen-
sional double inversion recovery in the sagittal plane added to the 
standard protocol. The images were reviewed and compared by 
two radiologists. Lesions were divided into 6 groups and the stage 
of cortical atrophy was assessed on a scale of 0-4.
Results: Cortical lesion pathology positively correlated with the 
severity of cortical atrophy (p=0.05) and periventricular white 
matter lesion load (p< 0.05). Cortical lesions correlated with some 
cognitive scores including Mini-Mental State (p< 0.05), informa-
tion processing, measured by Symbol Digit Modalities Test 
(p=0.05) and verbal fluency (p< 0.05). White matter lesion load 
correlated with executive functioning, measured by the number of 
hits (p=0.001) and omissions (p< 0.05) in the Paced Auditory 
Serial Addition Test and reached near statistical significance for 
recognition in the Free and Cued Selective Reminding Test 
(p=0.06). Physical disability, measured by the Expanded Disability 
Status Scale, correlated with cortical atrophy (p< 0.05).
Conclusion: Our results show that cortical lesion pathology is 
one of the most sensitive imaging correlates of cognitive 
dysfunction in MS. Specific tests measuring executive dysfunc-
tion may correspond to the different types of imaging pathology 
and their underlying pathogenic processes.
Disclosure
T. Kunchev: nothing to disclose
N. Fileva: nothing to disclose
M. Petrova: nothing to disclose
D. Zlatareva: nothing to disclose
L. Traykov: nothing to disclose
EP1588
Subjective versus objective cognitive screening of patients 
with multiple sclerosis
L. Kadrnozkova, J. Motyl, J. Blahova Dusankova, M. Andelova, 
B. Benova, K. Novotna, K. Kucerova, J. Lizrova Preiningerova, 
E. Havrdova, D. Horakova, T. Uher
Department of Neurology and Center of Clinical Neuroscience, 
First Faculty of Medicine, Charles University and General 
University Hospital in Prague, Prague, Czech Republic
Background: Cognitive impairment occurs frequently in the 
patients with multiple sclerosis (MS). However, the accuracy rate 
of subjective cognitive complaints for predicting of abnormal 
objective cognitive performance is lacking.
Objectives: To investigate the relationship between subjective 
cognitive complaints assessed by the Multiple Sclerosis 
Neuropsychological Questionnaire (MSNQ) and objective cogni-
tive performance evaluated by the Brief International Cognitive 
Assessment for Multiple Sclerosis (BICAMS).
Methods: A total of 1052 patients (70% females, at baseline: 
mean age: 38.1±8.8; mean disease duration: 9.6±7.1) after the first 
demyelinating event suggestive of MS or with clinically definitive 
MS were included in this 2-years longitudinal study. The MSNQ, 
the BICAMS battery and the Beck Depression Inventory (BDI) 
were evaluated at baseline and at 24 months. Pearson´s and 
Spearman´s correlation analyses were performed to evaluate the 
relationships among absolute values of the MSNQ, the BICAMS 
subtests and the BDI score. Sensitivity, specificity, accuracy and 
positive predictive value were used to assess agreement between 
the subjective and objective screening methods.
Results: At baseline, we observed a weak negative correlation 
(r=-0.273 to -0.134; p< 0.001) between absolute values of the 
MSNQ and the BICAMS subtests. The abnormal MSNQ (cut-off 
value >24) at baseline identified patients with the abnormal 
BICAMS (≥1 abnormal subtest) at baseline with 69% accuracy 
(sensitivity=33%, specificity=83%, positive predictive value 
[PPV]=41%). The MSNQ was also associated with the BDI 
(r=0.540; p< 0.001). We observed a weak negative correlation 
between absolute values of the MSNQ at baseline and the 
BICAMS subtests at 24 months (r=-0.259 to -0.117; p< 0.001). 
The abnormal MSNQ at baseline identified patients with the 
abnormal BICAMS at 24 months with 64% accuracy (sensitiv-
ity=30%, specificity=82%, PPV=46%).
Conclusion: Subjective evaluation of cognitive performance 
assessed by the MSNQ predicted the abnormal outcome of objec-
tive cognitive screening by the BICAMS with only 64-69% accu-
racy. On the other hand, the abnormal MSNQ was associated with 
abnormal cognitive screening with a relatively high specificity 
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(82-83%). MSNQ is not suitable cognitive screening tool due to its 
low sensitivity (30-33%), however, subjective cognitive complaints 
of MS patients need to be taken seriously, because they are often 
associated with cognitive impairment or depressive symptoms.
Disclosure
The project was supported by the Czech Ministry of Education 
project Progres Q27/LF1.
Lucie Kadrnozkova received compensation for conference travel 
from Roche.
Jiri Motyl: nothing to disclose.
Jana Blahova Dusankova: nothing to disclose.
Michaela Andelova has received travel and conference fees sup-
port from Novartis and Biogen Idec.
Barbora Benova received compensation for travelling and confer-
ence fees from Novartis and Sanofi Genzyme and Biogen Idec.
Klara Novotna received compensation for travel and speaker hon-
oraria from Merck, Novartis and Teva
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Jana Lizrova Preiningerova has received speaker and consulting 
fees from Biogen,
Novartis, and Teva.
Eva Havrdova received speaker honoraria and consultant fees 
from Biogen Idec, Merck Serono, Novartis, Genzyme and Teva, 
as well as support for research activities from Biogen Idec and 
Merck Serono.
Dana Horakova received compensation for travel, speaker hono-
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research activities from Biogen Idec.
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EP1589
A cognitive occupation-based programme for people with 
multiple sclerosis (COB-MS): a study to test feasibility and 
clinical outcomes
S. Reilly1, S.M. Hynes2
1National University of Ireland Galway, 2NUIG, National 
University of Ireland Galway, Galway, Ireland
Introduction: Difficulties with cognition have been reported to 
be present in 50-60% of people with MS. Despite the high preva-
lence little has been done to address these difficulties and more 
importantly the impact that they have on a person’s everyday life. 
The Cognitive Occupation Based Programme for People with MS 
(COB-MS) was developed to address this. The COB-MS focuses 
on rehabilitation that is measured by and taught through focusing 
on occupational participation.
Objectives: This feasibility study assessed the following out-
comes -eligibility criteria, recruitment and retention, participant 
acceptability and; administration protocol.
Method: This feasibility study used an experimental, pre-test/
post-test design with eight-week follow-up. Participants were 
recruited from MS networks using convenience sampling. Twelve 
participants (1 male) were recruited to two COB-MS groups, 
which consisted of eight sessions (2 individual, 6 group). 
Participants were asked to complete various homework activities 
throughout the week in order to practice strategies learned and 
solidify learning.
Results: Results, from this modestly-sized sample, are promising 
with significant improvements seen in everyday life goal attain-
ment [Goal Attainment Scaling; GAS (z = -2.67, p < .008)], and 
memory, including verbal memory, visuospatial memory and self-
reported everyday memory [CVLT-II (c² (2, n = 9) = 13.89, p < 
.001), BVMT-R (c² (2, n = 9) = 11.09, p < .004), and EMQ-R (c² 
(2, n = 9) = 7.00, p < .030)]. It was also well-received and adhered 
to by participants. Recruitment methods were explored and the 
protocol followed by three facilitators.
Conclusion: Significant improvements were observed in all daily 
life measures and most cognitive measures. Limitations include 
selection bias and subtle practice effects in cognitive measures. 
Preliminary data from a small sample looks promising and is 
encouraging to test the COB-MS on a larger sample of people 
with MS.
Disclosure
Sean Reilly: Nothing to disclose
Sinéad M Hynes: Nothing to disclose
EP1590
Cognitive disorders in multiple sclerosis: a screening tool 
proposed in current practice. The experience of the Rhône-
Alpes SEP Network
L. Guilloton1, D. Latombe2, J.P. Camdessanché3, C. Thomas 
Anterion2, B. Mercier4, S. Roggerone5, S. Jacquin-Courtois6
1Neurologie, Cabinet Médical, Mornant, 2Cabinet Médical, 
Lyon, 3Loire, CHU Saint-Etienne - Hôpital Bellevue,  
Saint-Etienne, 4Réseau SEP Rhône Alpes, Bron, 5CHU Lyon 
Hôpital Edouard Herriot, Lyon, 6CHU Lyon Hôpital Henry 
Gabrielle, St Genis Laval, France
Introduction: Cognitive disorders are common in Multiple 
Sclerosis (MS) and can be present at any stage of the disease, 
affecting attention, concentration, planning, memory. Their func-
tional impact can alter quality of life. They are often associated 
with confounding factors: fatigue, anxiety, depression. The ques-
tion of the optimal time for a more complete neuropsychological 
assessment remains to be asked, this assessment being most often 
carried out before a spontaneous cognitive complaint with the dif-
ficulty of determining the weight of any associated factors.
Objectives: The aim was to assess the feasibility and relevance of 
a rapid, comprehensive and functional cognitive screening bat-
tery, which could be carried out during an usual consultation.
Methods: 73 MS patients reporting a cognitive complaint bene-
fited from cognitive explorations. Seven themes were studied 
through Visual Analogue Scales (VAS), quantified on 10 points: 
fatigue, fitness, pain, thymic state, attention, memory, organiza-
tion. The cognitive study involved the realization of the SDMT 
and the story of Barbizet, completed by a fatigue scale (FSS score) 
and an anxiety and depression scale (HADS).
Results: A good feasibility of the evaluation was validated with a 
duration of 15 to 20 minutes, allowing a realization in common prac-
tice. Among the different dimensions explored through the VAS, a 
score>5 was identified for fatigue, fitness and memory. Fatigue was 
also underlined by the average FSS score (5.1/7). The HADS did not 
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appear pathological. As for the analytical evaluation, the mean score 
of SDMT was pathological at 38.9 (SD:13.6). The story of Barbizet 
showed an average score of 11.3 (SD:4.4). Interestingly, double dis-
sociation was found for some patients between SDMT and recall 
performances, proving interest of both tests. Spearman´s correlation 
found a modest correlation for pain, memory, state of mood and 
organization; on the contrary, the use of a purely analytical balance 
appeared insufficient. These results underline the value of jointly 
realizing these personal feelings scales and cognitive tests.
Conclusion: This work validates the use of a simple and repro-
ducible tool in common consultation, in the detection of cognitive 
disorders and possible confounding factors, in the MS patients. 
These tests allow to refer patients for further explorations, to 
adjust the management of confounding factors and thus to opti-
mize the management, in particular for fatigue and anxiety.
Disclosure
Any disclosure for this work.
EP1591
No evidence of disease activity and cognition in relapsing-
remitting multiple sclerosis
R. Alonso, B. Eizaguirre, C. Pita, L. Zavala, B. Silva, A. 
Marinangeli, S. Vanotti, O. Garcea
Hospital Ramos Mejía, Buenos Aires, Argentina
Background: The term “No evidence of disease activity” (NEDA) 
means no relapses or disability progression and no new/enlarging 
MRI lesions in relapsing-remitting multiple sclerosis (RRMS). 
Cognitive progression in these patients has been poorly studied.
Objective: Determine the cognitive evolution in NEDA patients.
Method: RRMS patients were examined at baseline and in the 
second evaluation (after a one to three years period) with neuro-
logical, neuropsychological and structural MRI examinations. 
Outcomes measures: Neuropsychological assesment: Selective 
Reminding Test (SRT), 7/24 Visuospatial Test, SDMT and Verbal 
Fluency, Beck Depression Inventory II (BDI II); Clinical meas-
ures: Expanded disability status scale (EDSS).
Results: 15 NEDA patients were described. Age: 37.5 13.9; 
Female: 8; education: 12.7 2.7 years; EDSS: 3.21.5; disease evo-
lution: 9.18.3 years. When compare cognitive function between 
both neuropsychological evaluations, NEDA patients show sig-
nificant low scores in verbal memory (p= .026 and a trend toward 
worsening in verbal fluency (p= .056).
Conclusions: In our work we have found cognitive changes in 
NEDA patients. Based on these results, the relevance of cognitive 
assessment as a marker of disease activity is reaffirmed.
Disclosure
Nothing to disclose
EP1592
Characteristics of verbal strategies used in semantic and 
phonemic fluency in patients with multiple sclerosis
E. Tyburski1, A. Potemkowski1, A. Sołtys1, M. Chęć1, M. 
Kowalewski2, A. Samochowiec1
1Department of Clinical Psychology, University of Szczecin, Szczecin, 
2Centre of Rehabilitation for MS Patients, Borne Sulinowo, Poland
Background: Patients with multiple sclerosis (MS) exhibited 
deficiencies in the performance of verbal fluency tasks. However, 
most studies analysed mainly the number of correctly produced 
words in particular tasks’ variants. Little is known about verbal 
strategies applied by patients that facilitate the performance of the 
described test.
Objectives: The characteristics of semantic and phonemic flu-
ency as well as verbal strategies adopted by MS patients.
Methods: The study embraced 30 patients with diagnosed relaps-
ing-remitting MS as well as 30 people without neurological dis-
eases or mental disorders. Both groups matched for age, sex or 
number of years of education. Two versions of the Verbal Fluency 
Test were applied: semantic (names of animals) and phonemic 
(words beginning with K).
Results: In semantic fluency test MS patients obtained signifi-
cantly lower results compared with the control group with regard 
to the following indicators: the number of correct answers, the 
number of clusters, the number of switches as well as the ratio of 
the number of switches to the number of correct answers. 
Similarly, patients demonstrated worse results in phonemic vari-
ant in the following parameters: the number of correct answers, 
the number of switches and the ratio of the number of switches to 
the number of correct answers. In turn, in semantic fluency 
patients obtained better results than healthy individuals for clus-
ter’s size and in phonemic variant in the ratio of the number of 
clusters to the number of correct answers. Medium effect sizes 
were demonstrated for three indicators and large ones for the other 
indicators. No significant inter-group differences were found for 
other measures.
Conclusions: Patients’ lower results demonstrated in the ratio 
of the number of switches to the number of correct answers in 
both variants of the test as well as no differences found in the 
ratio of the number of clusters to the number of correct answers 
in semantic variant and, at the same time, better results of 
patients in this component in phonemic variant could suggest 
the dominance of disturbances in executive functions over the 
problems in the scope of semantic memory in these patients. 
However, the performance of both tasks could also be hindered 
by deficiencies in language functions and slower information 
processing.
Disclosure
E. Tyburski: the research was supported by 5043000240764/2011 
(Faculty of
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Adiponectin as a possible biomarker in multiple sclerosis
E. Signoriello1, E. Nigro2, R. Polito2, S. Casertano1, M. Coletta1, 
F. Rossi1, M.L. Monaco2, O. Scudiero2,3, G. Lus1, A. Daniele2,4
1Multiple Sclerosis Center, Second Division of Neurology, 
Department of Surgical and Medical Sciences, Neurological, 
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Metabolic and Aging, University of Campania “Luigi Vanvitelli’, 
2CEINGE-Biotecnologie Avanzate, 3Dipartimento di Medicina 
Molecolare e Biotecnologie Mediche, Università di Napoli 
Federico II, 4Dipartimento di Scienze e Tecnologie Ambientali 
Biologiche Farmaceutiche, University of Campania “Luigi 
Vanvitelli’, Naples, Italy
Background: Among adipokines, adiponectin plays important 
roles in the regulation of energy homeostasis and insulin sensitiv-
ity, enough to be considered a marker for obesity and related dis-
eases as type II diabetes. Moreover, an immunomodulatory action 
in several sistemic inflammatory disorders has been demostrated. 
Adiponectin is produced as a monomer that circulates in serum as 
different oligomers (LMW, MMW, HMW). Few studies analyzed 
the adiponectin role in a neuroinflammatory disorders as Multiple 
Sclerosis (MS) with controversial results. In this study, we ana-
lyzed serum adiponectin levels in MS patients and investigated 
the potential relationships with disease features.
Methods: 99 unrelated MS patients, diagnosed according to Mc 
Donald Criteria, from University of Campania “Luigi Vanvitelli”, 
and 87 age-and sex-matched controls were recruited. 
Anthropometric and biochemical features of MS patients and con-
trols were evaluated and compared. In serum, adiponectin levels 
were measured by ELISA. Adiponectin oligomeric profile was 
characterized by Western blot.
Results: Serum adiponectin levels analyzed by ELISA assay were 
higher in MS patients compared to matched controls (12,18 vs 
10,02 µg/ml) (p< 0,001). A negative correlation was found between 
adiponectin levels and BMI in controls while a positive correlation 
was present in patients. No difference in adiponectin was found 
between active/no active patients and between forms of disease. 
Western blotting analysis performed on serum demonstrated that 
the HMW adiponectin oligomers are increased in MS patients.
Discussion and conclusions: Our study demonstrated a strong 
modulation of adiponectin and its HMW oligomers in MS. The 
positive correlation of adiponectin with BMI in MS patients sug-
gests that adiponectin plays a role in the regulation of neuroin-
flammatory conditions as MS, probably acting towards 
pro-inflammatory pathways at the basis of MS. Further studies are 
required to better understand the biological role of adiponectin 
and its possible usefulness as a biomarker of MS.
Disclosure
Elisabetta Signoriello has received personal compensation for 
activities with Biogen Idec, Roche, Merck Serono, Novartis as a 
consultant; has received support for travelling from Biogen Idec, 
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EP1594
Cerebrospinal fluid oligoclonal IgM bands and prognosis in 
multiple sclerosis patients: pooled long-term follow-up data
D. Ferraro1, A.M. Simone1, R. Bedin1, F. Vitetta2, V. Camera1, 
P.F. Nichelli1, P. Sola2
1Department of Biomedical, Metabolic, University of Modena 
and Reggio Emilia, 2Department of Neurosciences, Azienda 
Ospedaliero-Universitaria, Modena, Italy
Background: Cerebrospinal fluid (CSF) oligoclonal IgM bands 
(IgMOB) have been linked to a shorter first-inter attack interval and to 
a more aggressive disease course in Multiple Sclerosis (MS) patients. 
Some recent studies [1-2], however, did not confirm this data.
Objective: Aim of the study was to assess the prognostic role of 
CSF IgMOB over time and in relation to the introduction of dis-
ease-modifying drugs (DMD).
Methods: We pooled and updated information on patients included 
in previous studies on CSF IgMOB and divided them in two groups, 
depending on whether the disease onset had occurred before or in/
after 1995, year in which the first DMD became available in Italy.
Results: We studied 336 patients (220F) who had carried out a spinal 
tap between 1984 and 2011 and who were followed up for a median of 
13 years (IQR: 8-19) from onset. Ninety-one percent of patients with 
disease onset prior to 1995 (63/69) had not been treated in the first two 
years as opposed to 49% (131/267) of those with onset in/after 1995 
(p< 0.001). The presence of CSF IgMOB significantly increased the 
odds of reaching an EDSS of 3, 4 and 6 (OR: 4.7, 5.7 and 7.1, respec-
tively) only in patients with disease onset prior to 1995.
Discussion: Our results may be explained by the efficacy of DMD 
in modifying the disease course, although we must point out that 
the older cohort carried out the spinal tap after a longer median 
interval from onset (12 months versus 1 month). IgMOB-positive 
patients in the older group may, therefore, hypothetically, be more 
likely to have persistent IgM responses (associated with lipid-
specific IgMOB and a more aggressive disease course), while in 
the more recent cohort we may have included more IgMOB-
positive patients with transient IgM responses.
Conclusion: CSF IgMOB were predictive of higher long-term 
disability only in patients with MS onset prior to the treatment era 
and with a longer onset-spinal tap interval.
1. Ferraro D, Galli V, Vitetta F, et al. (2015) Cerebrospinal fluid 
CXCL13 in clinically isolated syndrome patients: Association 
with oligoclonal IgM bands and prediction of Multiple Sclerosis 
diagnosis. J Neuroimmunol 283:64-9.
2. Frau J, Coghe G, Lorefice L, et al. (2016) Intrathecal IgM syn-
thesis: is really a prognostic factor? Neurol Sci 37:S260-1.
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CSF neurofilament light chain provides a valuable prognostic 
tool in multiple sclerosis
M.J. Leitao1, R. Pascoal2, M.H. Ribeiro2, I. Correia3, S. Batista3, 
L. Sousa3, I. Baldeiras1,2,4
1Center for Neuroscience and Cell Biology, University of 
Coimbra, 2Neurochemistry Laboratory, 3Neurology Department, 
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University Hospital of Coimbra, 4Faculty of Medicine, 
University of Coimbra, Coimbra, Portugal
The presence of elevated levels of neurofilament light chain 
(NFL) in the cerebrospinal fluid (CSF) is an indicator of axonal 
damage in the Central Nervous System (CNS) and has been tested 
as a biomarker in Multiple Sclerosis (MS). However, its value to 
predict disease course and to assist in therapeutic management 
still needs further confirmation.
In this study, our goal was to evaluate the usefulness of CSF NFL 
to predict disease severity in Relapsing-Remitting MS (RRMS) 
patients followed up to 10 years (6.5±3.3 years).
The study population comprised 39 RRMS patients and a control 
group consisting of 17 patients with non-inflammatory neurologi-
cal diseases. In RRMS patients, evidence of active disease during 
follow-up (EDA) was evaluated through the occurrence of 
relapses, brain magnetic resonance imaging MRI activity or EDSS 
worsening. All patients received immunomodulatory treatment 
during follow-up: 20 underwent first line treatments (β-Interferon 
and Glatiramer Acetate); while 19, with a more aggressive disease 
course, were submitted to second line therapies (Natalizumab, 
Rituximab and Fingolimod). CSF samples were collected at time 
of diagnosis and NFL baseline levels were measured using an 
ELISA kit (Uman Diagnostics AB, Sweden).
There were no significant differences between RRMS patients 
and controls neither regarding age nor gender, but NFL levels 
were significantly higher in patients (2532±2237 vs. 896±932 pg/
mL; p=0.0011). Regarding RRMS patients, no correlation was 
found between baseline NFL levels and EDSS score at lumbar 
puncture (LP) or at follow-up. However, we found increased base-
line CSF NFL levels in patients with EDA compared to those not 
showing signs of active disease (3129±2061 vs. 2048±2440 pg/
mL, p=0.038). Moreover, patients submitted to second line treat-
ment during follow-up, had significantly higher baseline CSF 
NFL levels than patients that only underwent first line treatment 
(3305±2496 vs. 1759±1680 pg/mL, p=0.022). In fact, in a logistic 
regression analysis (including age of onset, gender, IgG oligo-
clonal bands, disease duration, EDSS at LP), baseline NFL levels 
was the only variable that could significantly predict, with 84% 
accuracy, the need for undergoing second-line therapy (p=0.022).
This study demonstrates the potential prognostic value of baseline 
CSF NFL in RRMS baseline CSF and supports its use as a guiding 
tool for long-term management of the disease.
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Principal component analysis of intrathecal chemokine 
expression in multiple sclerosis and other neurological dis-
eases
F. Gilli1, D.B. Royce1, K.D. DiSano1, M.A. Lane2, A.R. Pachner1
1Dartmouth Hitchcock Medical Center | Neurology, Geisel 
School of Medicine, Lebanon, NH, 2Neurology, Oregon Health 
& Science University, Portland, OR, United States
Background/goals: Chemokine dysregulation contributes to 
immune dysfunction, inflammation and central nervous system 
(CNS) damage in multiple sclerosis (MS). Chemokines have 
diverse interactions with other chemokines and immune cells. We 
used principle component analysis (PCA) to unravel the interplay 
of a selection of chemokines for MS vs. other neurological dis-
eases (OND).
Materials/methods: Matched serum and cerebrospinal fluid 
(CSF) samples from the Dartmouth Neurological specimen bank 
were obtained on 33 patients. Patients were chosen based on their 
diagnosis of MS (n=8), other neuroinflammatory diseases (OND-
I, n=8), idiopathic intracranial hypertension patients felt to be 
negative controls (IIH, n=8), and a variety of other non-inflamma-
tory OND (OND-NI, n=9). Forty chemokines were measured in 
CSF and serum samples using a multiplex bead array assay 
(BioPlex Pro-Human Chemokine Panel, BioRad). In order to 
compare intrathecal production of chemokines, CSF chemokines 
were normalized to serum chemokines by calculating a CSF/
Serum ratio, which accounts for individual variability in serum 
concentrations as well as blood/CSF barrier integrity. Ratios were 
compared non-parametrically among groups. PCA was then used 
to summarize the overall patterns in chemokine expressions in 
MS vs. OND.
Results: We found differences in the average ratio of 6 of the 40 
analyzed chemokines: MS patients had elevated CSF/Serum 
ratios of CXCL13, CXCL10, CXCL9, CCL1, CCL22, and MIF. 
However, the PCA revealed only increased CXCL13, CXCL10, 
CXCL9, CCL22, and CCL1 concentrations to be significantly 
associated with MS. Overall, 5 principal components (PC) were 
generated, with the first 2 PCs explaining 99.6% of the total vari-
ance in the chemokine data. PC1 reflects an activation of cell-
mediated immunity due to its positive loading with both CXCL10 
and CXCL9; conversely, PC2 reflects an activation towards 
humoral immunity due to its positive loading with CXCL13, 
CCL1, and CCL22.
Conclusions: Our findings suggest that mutually interacting cel-
lular and humoral immune components modulate MS pathology 
and may contribute to the differential diagnosis of MS among 
patients with neurological conditions.
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Lactate, beta2-microglobulin and ACE in cerebrospinal fluid 
as markers of clinical disease course and severity in patients 
with multiple sclerosis
A. Haarmann1, L. Hähnel1, M. Schuhmann1, G. Stoll1, M. 
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Background: The increasing armamentarium of immunothera-
peutics for multiple sclerosis (MS) calls for reliable biomarkers to 
better monitor disease activity, predict progression and evaluate 
treatment response in individual patients. CSF lactate, beta2-
microglobulin and angiotensin converting enzyme (ACE) levels 
were all reported to reflect various aspects of MS disease activity 
which we validated in a large cohort of MS patients.
Methods and results: An automated search identified 554 
patients with MS who received an analysis of CSF lactate, beta2-
microglobulin and ACE levels as part of their routine diagnostic 
workup in our department between 2005 and 2012. Manual chart 
review allowed their classification as purely relapsing-remitting 
MS including cases of clinically isolated syndrome (RRMS, 
n=321), secondary progressive MS (SPMS, n=170) or primary 
progressive MS (PPMS, n=63) according to the 2010 revision of 
the McDonald diagnostic criteria. Patients were further character-
ized by EDSS score, disease duration, Multiple Sclerosis Severity 
Score (MSSS) and current relapse activity. We found that beta2-
microglobulin was significantly elevated in CSF of patients with 
PPMS (mean 1.42 mg/l, p< 0.05) and SPMS (mean 1.59 mg/l, p< 
0.01) compared to those with RRMS (mean 1.17 mg/l), while CSF 
levels of lactate and ACE did not differ between these three 
groups. In patients with stable but not in those with active RRMS 
(n=104 and n=217, respectively), we found a moderate positive 
Spearman correlation between both MSSS (r=0.39, p=0.0023) or 
EDSS (r=0.41, p=0.0015) and beta2-microglobulin in CSF. In 
contrast, CSF lactate weakly correlated with MSSS and EDSS in 
patients with active, but not in those with stable RRMS (r=0.21, 
p=0.0035; r=0.16, p=0.026, respectively).
Conclusions: In our cohort, CSF beta2-microglobulin but not lac-
tate or ACE levels were higher in chronic progressive than in 
relapsing-remitting MS patients, in whom in currently relapse-
free patients a higher CSF beta2-microglobulin level correlated 
with higher disease severity and disability.
Disclosure
Axel Haarmann, Luzia Hähnel, Michael Schuhmann, Guido Stoll 
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Cerebrospinal fluid levels of neurofilament light chain, 
C-X-C ligand motif 13, and chitinase-3-like protein 1 reflect 
distinct pathological processes in multiple sclerosis
M. Zanoni, M. Bongianni, E. Poletto, M. Turatti, M. Calabrese, 
A. Marangi, F. Gobbin, S. Monaco, M.D. Benedetti, A. Gajofatto
Neurology Section; Department of Neurosciences, Biomedicine 
and Movement Sciences, University of Verona, Verona, Italy
Background: Analysis of cerebrospinal fluid (CSF) biomarkers 
has the potential of clarifying the interplay between the inflamma-
tory and degenerative components of multiple sclerosis (MS). The 
main goal of the study was to determine whether CSF concentra-
tion of neurofilament light chain (Nf-L), C-X-C ligand motif 13 
(CXCL13), and chitinase-3-like protein 1 (CHI3L1) were associ-
ated with MRI measures of disease activity and grey matter 
pathology.
Methods: Consecutive patients with clinically isolated syndrome 
(CIS) or MS according to 2010 McDonald criteria, and a CSF sam-
ple stored at Verona Laboratory of Neuropathology were eligible 
for the study. All cases had a brain MRI performed at the time of 
lumbar puncture with a 1.5 Tesla scanner and a standardized proto-
col, including Double Inversion Recovery sequences. Brain vol-
ume analysis was performed using SIENAX software. CSF 
standard analysis, including IgG index and oligoclonal bands 
(OBs), was done at the time of sample collection. Commercial 
ELISA kits were used to determine Nf-L, CXCL13 and CHI3L1 
levels on stored CSF samples. The distribution of CSF biomarker 
levels according to presence of enhancing and cortical lesions on 
brain MRI and the correlation between biomarkers CSF concentra-
tion, brain volumes and number of cortical lesions were analysed.
Results: As of May 2017, 78 patients (50 females) have been 
included in the study, with mean age at CSF collection of 
38.3±12.5 years. 48 patients had relapsing-remitting MS, 15 a 
CIS, and 15 progressive forms of MS. Median disease duration at 
inclusion was 0.6 years (range 0-31). Mean Nf-L concentration 
was 4215 ng/L in patients with at least one enhancing lesion on 
MRI compared to 2043 ng/L in patients with no enhancing lesions 
(p=0.002). Mean Nf-L concentration was greater in patients with 
OBs or increased IgG index in CSF compared to cases without 
such findings (3795 vs. 1856 ng/L, p=0.002). Mean concentration 
of CXCL13 was 53.4 pg/mL in patients with OBs or increased 
IgG index in CSF, compared to 11.4 pg/mL in patients with no 
such evidence (p< 0.001). Finally, CHI3L1 level was inversely 
correlated to total cerebral volume (r= -0.317, p=0.018) and white 
matter volume (r= -0.279, p=0.039).
Conclusions: Nf-L and CXCL13 levels in the CSF of MS patients 
are associated with MRI and CSF measures of inflammatory 
activity, while CHI3L1 CSF concentration is correlated to brain 
volume loss. Implications for prognosis and treatment deserve 
further investigation.
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CSF cell signature and biomarkers of neuroinflammation 
and neurodegeneration in MS: preliminary results of the 
OBOE study
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Background: Development of cerebrospinal fluid (CSF) bio-
markers, such as neurofilament light chain (NfL) and/or lympho-
cyte cell signatures, may improve current understanding of 
multiple sclerosis (MS) pathogenesis and the therapeutic mecha-
nism of action (MOA) of disease-modifying treatment (DMT). 
Ocrelizumab is a humanised monoclonal antibody that selectively 
targets CD20, a cell-surface antigen expressed on pre-B cells, 
mature B cells and memory B cells but not lymphoid stem cells or 
plasma cells. The Ocrelizumab Biomarker Outcome Evaluation 
study (OBOE; NCT02688985) aims to further elucidate the MOA 
of ocrelizumab in patients with relapsing MS (RMS) and primary 
progressive MS (PPMS) by examining potential biomarkers of 
neuronal or glial injury, B-cell antigen presentation, immunoglob-
ulin production, cytokine secretion and meningeal inflammation.
Objective: To elaborate on the blood and CSF biomarkers being 
studied and the methodology for determining CSF cell signatures 
in OBOE.
Methods: The open-label OBOE study is enroling treatment-
naive or previously treated patients with RMS or PPMS. All 
patients initially receive two intravenous (IV) infusions of ocreli-
zumab 300 mg separated by 14 days; at Weeks 24 and 48, patients 
with PPMS repeat this regimen, while patients with RMS receive 
single 600-mg infusions. Lumbar punctures to obtain CSF are per-
formed prior to and at Month 3, 6 or 12 of ocrelizumab treatment; 
longitudinal CSF samples are also being collected from a subset 
of RMS patients while on DMT prior to receiving ocrelizumab. 
Freshly isolated CSF cells are examined using a standardized cell-
surface phenotyping flow cytometry assay. Primary endpoints 
include changes in NfL, CD19+ B cells and CD3+ T cells in the 
CSF over 3, 6 and 12 months of ocrelizumab treatment.
Results: Planned enrolment includes 88 patients with RMS and 
16 with PPMS; updated information on patient disposition will be 
presented. Assay development and approach to standardization of 
the multicenter CSF flow cytometry assay to limit analytical vari-
ability will be discussed.
Conclusions: OBOE will provide important information on puta-
tive disease biomarkers in the blood and CSF of patients with 
RMS and PPMS and the effects of selectively depleting CD20+ B 
cells on those markers. Findings are expected to improve under-
standing of the MOA of B-cell depletion in patients with MS.
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Neuronal and glial CSF biomarkers in patients with second-
ary progressive multiple sclerosis treated with dimethyl 
fumarate
K.R. Edwards1, J. Siuta1, J. Button1, B. Zhu2, T. Plavina2, J.P. 
Mendoza2, N. Penner2
1Multiple Sclerosis Center of Northeastern New York, Latham, 
NY, 2Biogen, Cambridge, MA, United States
Background: Dimethyl fumarate (DMF) has been approved for 
the treatment of patients with relapsing forms of multiple sclerosis 
(MS). Investigation of DMF in secondary progressive MS (SPMS) 
is supported by its mechanism of action, which appears to be 
mediated, at least in part, through activation of the nuclear factor 
(erythroid derived 2)-related factor 2 (Nrf2). Nonclinical studies 
have shown DMF to have both cytoprotective and antiinflamma-
tory effects. Studies in SPMS patients and pre-clinical models 
show that the active metabolite of DMF, monomethyl fumarate 
(MMF), penetrates the CNS; however, the effect of DMF on neu-
ronal and glial CSF biomarkers is unknown.
Objectives: To explore the effect of DMF on neuronal and glial 
biomarkers in the CSF of SPMS patients.
Methods: Sixteen SPMS patients were treated with oral DMF 
120 mg twice daily (BID) for 4 weeks, followed by oral DMF 240 
mg BID for 24 weeks. CSF levels of neurofilament light (NfL), 
tau, glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-
terminal hydrolase isozyme L1 (UCH-L1) were measured by the 
Single Molecule Array (SIMOA) assay at baseline, week 6 and 
week 28. CSF samples from four healthy controls were also 
analyzed.
Results: At baseline patients had a mean EDSS of 4.4, disease 
duration of 22.5 years, and no Gd+ lesions. Baseline CSF NfL 
levels (mean±SD) in SPMS patients were 572±296 pg/mL and in 
healthy subjects 303±193 pg/mL. Mean EDSS decreased to 3.4, 
reflecting clinical improvement in 9 of 13 patients; NfL remained 
stable over the course of DMF treatment to week 28 (569±316 pg/
mL), except for one patient who had disease exacerbation at week 
18 when NfL levels increased to 1950 pg/mL and then decreased 
to 823 pg/mL by week 28. Levels of tau, GFAP and UCH-L1 
remained stable over the 28 weeks.
Conclusions: In this small group of SPMS patients, baseline CSF 
NfL was relatively low, consistent with absence of Gd+ lesions, 
remained stable during DMF treatment, and increased upon exac-
erbation in one patient. These data are consistent with the pro-
posed value of NfL as a marker of MS disease activity and 
treatment monitoring.
Supported by: Biogen.
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Translational multi-omics identifies four peptides differen-
tially regulated in the CSF of relapsing and progressive MS
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Biomarkers may predict the natural disease course in relapsing-
remitting MS (RRMS), identify patients with need of early aggres-
sive treatment, and may help in determining transition from 
RRMS to progressive disease early.
Here we used a translational multi-omics approach to identify poten-
tial biomarkers in the cerebrospinal fluid (CSF) of patients with 
RRMS, and secondary/primary progressive MS (SPMS/PPMS).
Demyelination was induced in mice by cuprizone (CPZ) adminis-
tration for 4 weeks, while acute and full remyelination was induced 
by suspending CPZ for 2 and 14 days. The 4x44K Agilent Whole 
Mouse Genome Microarray detected 1239 differentially expressed 
genes in the de- and remyelinated corpus callosum. Comparison of 
these genes to the transcriptome of MS lesions identified 91 over-
lapping homologous genes and 7 susceptibility genes. By liquid 
chromatography mass spectrometry (LC-MS/MS), we detected 19 
proteins of these 98 genes in pooled CSF of PPMS, RRMS and 
SPMS, respectively. We selected additional 32 out of the 98 genes 
based on biological function, and designed 132 peptides represent-
ing these 51 homologous proteins. In 97 individual CSF samples of 
30 PPMS, 27 SPMS and 41 RRMS, we measured the levels of the 
132 peptides by targeted proteomics, i.e. parallel reaction monitor-
ing (PRM). Four proteins were differentially regulated among MS 
subgroups: tyrosine protein kinase receptor UFO (UFO-Axl), 
TIMP-1, apolipoprotein C-II (APOC2), and beta-2-microglobulin 
(B2M). Their genes were up-regulated during acute remyelination 
in the mouse brain. Immunohistochemistry indicated TIMP1 
expression by oligodendrocyte precursor cells, while UFO-Axl 
and APOC2 by macrophages/microglia within demyelinating 
lesions. By using MesoScale, we correlated the concentration of 36 
inflammatory molecules, neurofilament light chain (NF-L) and the 
4 peptides in the CSF of 17 RRMS patients. The level of UFO-Axl 
and TIMP-1 negatively correlated with the concentration of IL-6; 
UFO-Axl also negatively correlated with concentration of MCP-1. 
B2M negatively correlated with the concentration of TARC. In 
contrast, APOC2 showed positive correlation with the concentra-
tion of IL-16, IL-2 and eotaxin-3.
This proof of concept study suggests that pathology-based trans-
lational multi-omics may identify potential biomarkers in MS.
Supported: Lundbeckfonden R118-A11472, OTKA-NN109841, 
OTKA-K77892, Region of Southern Denmark 14/24200, Jascha 
Fonden 5589, Direktør Ejnar Jonasson kaldet Johnsen og hustrus 
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Disease modifying therapies alter microRNA expression pat-
terns in distinct immune cell subsets in relapsing-remitting 
multiple sclerosis
D. Galloway1, K. Murphy-Peddle2, M. Stefanelli2, C.S. Moore1
1Division of Biomedical Sciences, 2Discipline of Medicine, 
Memorial University of Newfoundland, St. John’s, NL,  
Canada
Background: MicroRNAs are small non-coding RNA molecules 
that regulate the expression of genes post-transcriptionally. In the 
context of MS, several microRNAs are dysregulated in both 
immune cells and plasma. Identifying altered microRNA expres-
sion patterns between MS patient prescribed various disease-mod-
ifying therapies (DMTs) may further elucidate the mechanism(s) 
of action for DMTs and assist in predicting an individual’s immune 
and clinical response to a particular therapy.
Objective: The objective of this study was to identify whether 
DMTs influence the dysregulated microRNA expression that is 
observed in the immune cells (T cells, B cells and monocytes) of 
MS patients. Furthermore, microRNA expression in both plasma 
and specific immune cell subsets will be correlated with clinical 
disability.
Methods: Plasma and peripheral blood mononuclear cells were 
collected from age and sex-matched healthy controls and relaps-
ing-remitting MS patients, including both treatment naïve 
and patients prescribed specific DMTs. Isolation of CD19+ B 
cells, CD14+ monocytes, CD8+ T cells and CD4+ T cells was 
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performed by magnetic-activated cell sorting. RNA was isolated 
from plasma and individual cell subsets. qPCR was used to quan-
tify the expression of miR-223, -155, -146a, -146b, -19a and -365. 
Expression was correlated with EDSS.
Results: A significant decrease in miR-19a was observed in the 
plasma of MS patients vs healthy controls and was independent 
of treatment. Compared to healthy controls, analysis of CD14+ 
microRNA demonstrated increases in mir -146b, -223 and -365a 
in MS patients; teriflunomide normalized the expression of all 
microRNAs within the CD14+ population. In CD4+ and CD8+ 
T cells from RRMS patients, mir-155 was increased, however 
teriflunomide and dimethyl fumarate only normalized miR-155 
expression within helper, but not cytotoxic, T cells. No signifi-
cant differences were found between healthy control and MS 
patient B cells, however miR-223 was upregulated by treatment 
with DMF. No microRNAs were significantly correlated with 
EDSS.
Conclusion: Our results indicate that microRNAs are dysreg-
ulated in several immune cell subsets of RRMS patients and 
can be significantly altered by DMTs. Unique cellular micro-
RNA expression patterns may therefore serve as potential dis-
ease biomarkers and/or elucidate further mechanism(s) of 
action.
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Autoantibodies in neuromyelitis optica spectrum disorder 
and clinical characteristics
E.-J. Lee, Y.-M. Lim, J. Lee, H. Kim, J.Y. Jin, Y.J. Oh,  
K.-K. Kim
Neurology, Asan Medical Cente, University of Ulsan, Seoul, 
Republic of Korea
Background: Multiple sclerosis with antinuclear antibody (ANA) 
has been reported to demonstrate more benign disease course than 
the disease without ANA. In neuromyelitis optica spectrum disor-
der (NMOSD), it is unclear whether autoantibodies including 
ANA are protective or toxic markers. We aimed to compare clini-
cal characteristics and prognosis between NMOSD patients with 
and without ANA.
Methods: We reviewed the Asan Medical Center registry between 
January 2007 and June 2015 retrospectively, and analyzed data of 
patients who were diagnosed of seropositive NMOSD. Patients 
were classified into two groups according to the presence of ANA. 
The frequency of autoantibodies, annual relapse rates, spinal and 
orbital magnetic resonance imaging (MRI) findings during attacks 
were compared between the groups. The presence of poor func-
tional outcome, defined by Expanded Disability Status Scale 
score ≥6 or visual acuity ≤0.1, was also compared. For the MRI 
findings, numbers of vertebral segments and optic nerve segments 
(retrobulbar/canalicular/intracranial/optic chiasm/tract) involved 
during attacks were investigated for myelitis and optic neuritis, 
respectively.
Results: A total of 63 patients with NMOSD was identified, and 
the median follow-up duration from the disease onset was 7 
(IQR 3−11) years. Of them, 26 patients had ANA in their disease 
courses. The ANA-positive group demonstrated more frequent 
autoantibodies such as SSA/Ro, SSB/La, and double stranded 
DNA antibody. Clinically, however, between the ANA-negative 
and ANA-positive groups, annual relapse rates (median [IQR], 
0.6 [0.4−1] vs. 0.5 [0.3−0.8], p=0.321) and average lesion 
extents of myelitis (vertebral segments: 8 [5−12] vs. 7 [4−12], 
p=0.421) and of optic neuritis (optic nerve segments: 2 [1−3] vs. 
2 [1−2], p=0.477) on MRI during attacks were comparable. The 
presence of poor functional outcome (17 [45.9%] in the ANA-
negative group vs. 13 [50.0%] in the ANA-positive group) also 
did not differ.
Conclusions: In our NMOSD cohorts, patients with ANA showed 
more frequent autoantibodies than those without. However, these 
autoantibodies were not associated with benign or malignant dis-
ease characteristics. Autoantibodies other than aquaporin-4 anti-
body are commonly observed, but may be a bystander in NMOSD 
patients.
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The role of metabolomics in multiple sclerosis sub-classifica-
tion and clinical course
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Elucidating potential biomarkers in autoimmune neuroinflamma-
tory diseases, is important to identify disease specific metabolic 
signatures. This is particularly relevant to complex diseases such 
as Multiple Sclerosis (MS). Studying specific metabolomic path-
ways in MS patients provide valuable clinical information to 
monitor the disease progression and guide therapeutic decisions.
The authors attempted to quantify low molecular weight potential 
biomarkers for MS progress monitoring, by developing and vali-
dating a novel fast and sensitive analytical method in patients’ 
serum.
Pre-treatment sera were obtained from 30 Relapse Remit MS 
patients (RRMS) (18 females-12 males) during a clinical relapse. 
Serum samples were also collected from 20 patients with Clinical 
Isolated syndrome (CIS) (11 females-9 males) and 20 healthy 
individuals (13 females-7 males) matched for age and gender. 
Disease duration, relapse rate (rr for RRMS group), number of 
Gadolinium enhanced lesions (GdE+) and EDSS score were 
recorded for each MS patient.
High performance liquid chromatography coupled to tandem mass 
spectrometry (HPLC-MS/MS) was applied for the simultaneous 
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detection and quantification of the following suspected biomark-
ers: Choline, Acetyl-choline, Histidine, Histamine, Imidazoleacetic 
acid, Arginine, Citrulline and 3-Nitro-Tyrosine.
Acetyl-choline (Ach) was not detected in CIS and RRMS groups 
(Limit of Detection, LOD: 100pg/ml) while Choline was signifi-
cantly reduced in RRMS and CIS groups (F(2,67)=11,392, 
p=0.001). Histamine was not detected in RRMS group (LOD: 
1ng/ml) while Imidazoleacetic acid was quantified in all groups 
(Limit of Quantification, LOQ: 500pg/ml). Citrulline was signifi-
cantly elevated in the RRMS group (F(2,67)=5.811, p=0.005) and 
3-nitrotyrosine (product of NOx) was detected in RRMS group 
only (LOQ: 10ng/ml). In addition, Citrulline was correlated with 
rr, EDSS score and GdE+ lesions in RRMS participants (r=0.620, 
p=0.001 r=0.447, p=0.05 r=0.599, p=0.001) and Histidine was 
correlated with EDSS only (r=0.620, p=0.001).
Our results highlight the importance of the correlation of specific 
metabolomic signatures with certain clinical MS profiles, as it 
can provide valuable information regarding the progress of the 
disease. This is a preliminary report of an ongoing research pro-
ject regarding the screening and quantification of potential MS 
biomarkers.
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EP1605
NFL and CXCL13 reveal disease activity in clinically and 
neuro-radiologically stable MS
L. Novakova1, M. Axelsson1, C. Malmeström1, A. 
Svenningsson2, H. Zetterberg3, K. Blennow3, J. Lycke1
1Clinical Neurocience, Sahlgrenska Academy at Gothenburg 
University/ Institute of Neuroscience and Physiology, 
Göteborg, 2Karolinska Institute, Stockholm, 3Psychiatry 
and Neurochemistry, Sahlgrenska Academy at Gothenburg 
University/ Institute of Neuroscience and Physiology, Göteborg, 
Sweden
Background: Increased levels of Neurofilament light protein 
(NFL) in cerebrospinal fluid (CSF) indicate axonal degeneration 
and are associated with disease activity in MS. The concentration 
of CSF-CXCL13 has strong association with neuroinflammation 
and B-cell infiltration. In MS, CSF-CXCL13 levels correlate to 
CSF-NFL levels, supporting a connection between inflammation 
and axonal injury in the pathogenesis of MS.
Objective: To investigate the degree of inflammation and axonal 
injury in patients of different MS phenotypes MS by comparing 
the changes in the CSF levels of NFL and CXCL13 in patients 
with relapsing-remitting (RRMS) and progressive multiple scle-
rosis (PrMS) during disease activity and during disease modifying 
treatments (DMTs).
Methods: We included 202 RRMS and 84 PrMS patients, of those 
95 RRMS and 47 PrMS were followed for 12 months. CXCL13 
and NFL were determined by ELISA. Disease activity was defined 
as a relapse within 3 months prior to sampling and/or one or more 
gadolinium (Gd) contrast enhancing lesions on MRI. The 
increased levels of NFL and CXCL13 were defined as levels 
above the following reference values: CSF-NLF reference range 
for different ages are < 30 years: < 380ng/L; 30-40 years: < 560 ng 
/ L; 40 years- < 60 years: < 890 ng / L; > = 60 years: < 1850 ng / 
L. CSF-CXCL13 reference value is > 7.8 ng / L.
Results: In RRMS and PrMS with disease activity, NFL levels 
were increased in 63.6% and 64.5%, and CXCL13 levels were 
increased in 53.3% and 58.1%, and both were increased in 34.1% 
and 45.2%, respectively. In RRMS and PrMS without disease 
activity, NFL levels were increased in 34.1% and 34.7%, and 
CXCL13 levels were increased in 14.1% and 17%, and both were 
increased in 8% and 11.9%, respectively. In 4.5% RRMS and 
9.1% PrMS with low CSF levels of NFL and CXCL13 had signs 
of ongoing disease activity.
The treatment with various DMTs decreased the levels of NFL 
and CXCL13 in 78% RRMS (p< 0.001 and p< 0.001) and in 64% 
PrMS (p=0.014 and p=0.063), respectively.
Discussion: The increased CSF levels of NFL and CXCL13 in 
MS patients without a recent relapse and without contrast enhanc-
ing lesions on MRI indicate a residual disease activity not detected 
clinically or by MRI. Further, DMTs reduced NFL and CXCL13 
levels supporting treatment effects on both inflammation and 
degeneration. Thus, CSF biomarkers add information that might 
facilitate the monitoring of disease activity and therapeutic deci-
sion in MS patients.
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A comprehensive in silico analysis of transcripts upregulated 
in multiple scleroses patients and ZIkV infection: identifica-
tion of similar pathways
F. Fontes-Dantas1, A. Araújo1, L. França1, J. Farinhas1, I. 
Paschoal1, R. Barbosa1, B. Nogueira1, F. Abboud1, C. Rêgo2, V. 
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Pereira2, F. Malfetano2, S. Scherpenhuijzen2, A. Oliveira2, V. 
Neri1, C. Vasconcelos1, S. Alves-Leon1,2
1Pós-Graduação em Neurologia, Hospital Universitário 
Gaffrée e Guinle/ UNIRIO, 2Neurology, Hospital Universitário 
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Increasing reports link recent ZIKV infections to various forms of 
neuropathology, including microcephaly and Guillain-Barré syn-
drome (GBS). The pathogenesis viral infections and the develop-
ment of autoimmune diseases may have viral trigger and are 
linked to disturbances in immune response. Here we compared 
upregulated transcript profile of multiple scleroses (MS) patients 
and infection by ZIKV (human neural progenitor cells, human 
maternal decidual tissues and human fetal brain neural stem cells, 
all exposed to ZIKV) using bioinformatics tools. In lists available 
in online databases, we found a total of 593 genes upregulated in 
MS and 534 in ZIKV infection, 36 genes were shared between 
them. To further understand the impact of MS and ZIKV infec-
tions on the biological processes, we used Gene ontology (GO). 
Several biological processes were similarly significantly enriched 
for both MS and ZIKV transcriptomes, these terms include mainly 
the cell proliferation, response to stress and immune response. In 
comparative analyses of protein-protein interactions (PPI) net-
work design we observed network with 289-261 nodes and 878-
778 connectors in ZIKV and MS network, respectively. Centrality 
parameters (Node degree and Betweenness) of each node were 
analyzed. These pathways obtained statistical significance (p < 
0.05). STAT1, ISG15, HERC5, OAS1, IFIT3, IRF7, IFIT1, MX1, 
IFI35 and IFIT2 were the 10 top hub genes in ZIKV network. In 
MS network, JUN was the gene capable of making the largest 
numbers of connections with other genes and joining several sub-
networks, thus being considered the hub-bottleneck, which con-
trols the most of the information of a network. The 10 top hub in 
this network were JUN, CDC20, FOS, TOP2A, AURKB, KIF2C, 
RRM2, CREBBP, IL8 and CDC45. We also did an analysis of the 
two networks together to identify molecular signatures similar in 
MS and ZIKV infection. The main functional enrichment catego-
ries in this analysis were regulation of apoptosis, chemotaxis, 
regulation of JAK-STAT cascade, immune response, positive 
regulation of cell proliferation and signal transmission. The 
approaches employed in this study enabled us to report sets of 
genes that according to their physical interactions are predicted to 
be molecular signatures similar in MS and ZIKV infection, 
improving the understanding of this new outbreak and, in the 
future, may support a new proposal of prognostic and treatments.
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The authors declare that they have no competing interests.
EP1608
CSF interleukin 6 concentrations in pseudotumoral inflam-
matory CNS lesions suspicious of CNS lymphoma
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Raysz1, S. Baetz1, C. Gaultier1, R. Hurstel3, F. Sellal1, M. Le 
Garff-Tavernier2, G. Ahle1
1Service de Neurologie, Hôpitaux Civils de Colmar, Colmar, 
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Pitié-Salpêtrière, Paris, 3Hôpitaux Civils de Colmar, 
Laboratoire d’Hématologie, Colmar, France
Background: Interleukin (IL)-6 is a cytokine with a wide range 
of biological functions. Its upregulation in the cerebrospinal fluid 
(CSF) is considered as a marker of central nervous system (CNS) 
inflammation.
Objective: Our aim was to analyse the diagnostic significance of 
CSF IL-6 levels among various CNS pseudotumoral inflamma-
tory lesions (PIL) and primary CNS lymphoma (PCNSL).
Methods: We retrospectively analysed the CSF IL-6 concentra-
tion in 43 patients admitted for suspected primary CNS lymphoma 
between February 2014 and march 2017. 28 patients were posi-
tively diagnosed with PCNSL, 15 with various inflammatory 
CNS disorders. We correlated the results with CSF IL-10, a 
recently established diagnostic biomarker of PCNSL.
IL concentrations were measured by FCM using the cytometric 
bead array (CBA) technique (BD Biosciences) with a detection 
limit set at 2.5 pg/ml.
Results: In the PCNSL group, the median CSF IL-6 concentration 
with interquartile range (IQR) was 8 pg/ml IQR (5 - 18.5). For the 
patients with other PIL the median concentration was of 70 pg/ml, 
IQR (5 - 1368). A group comparison showed significantly higher 
CSF IL-6 levels in patients with PIL compared to PCNSL (p=0.032). 
Moreover, IL-6 was correlated with CSF cell count for the whole 
cohort (r=0.45, p=0.002), as well as for the PIL group (r=0.56, 
p=0.028), but not in PCNSL group (r=0.3, p=0.13). There was no 
correlation between CSF IL-6 in the two groups (r=0.023, p=0.9). 
Moreover, we found significantly higher CSF IL-10 levels in 
patients with PCNSL compared to the group with PIL (p< 0.001).
Conclusion: Our study suggests that CSF IL-6 levels could repre-
sent, in addition to CSF IL-10, a useful biomarker in the diagnosis 
of CNS PIL that may mimic PCNSL.
Disclosure
Nothing to disclose
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Ozanimod (RPC1063) reduces the plasma biomarker neuro-
filament light chain in preclinical rodent models of multiple 
sclerosis
K.R. Taylor Meadows, F.L. Scott, C. Villescaz, B. Clemons, C. 
Lopez, S. Sawa-Ballweber, K. Dines, G.J. Opiteck
Receptos, a wholly owned subsidiary of Celgene, San Diego, CA, 
United States
Background: Ozanimod (RPC1063) selectively targets S1P1R 
and S1P5R and has shown therapeutic benefit in clinical trials of 
relapsing multiple sclerosis (RMS). S1P1R and S1P5R expression 
on T and B cells as well as glial cells provides a series of critical 
control points by which ozanimod can disrupt the inflammatory 
cascade of MS. Furthermore, ozanimod penetrates the blood-brain 
barrier and potentially promotes CNS-tissue preservation. 
Neurofilament light chain (NfL) is released into the cerebrospinal 
fluid and serum/plasma following axonal injury and degeneration. 
It may serve as a biomarker for monitoring neurological damage 
in RMS.
Methods: The concentration of NfL was measured in the plasma 
of experimental autoimmune encephalomyelitis (EAE) and cupri-
zone-induced demyelination mouse models. Blood was isolated 
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from mice via terminal cardiac puncture and plasma NfL was 
measured at Quanterix (Lexington, MA) using the Simoa technol-
ogy platform. In EAE, mice were therapeutically dosed with oza-
nimod for 14 days and then spinal cords were assessed for 
inflammation by H&E staining and demyelination by Luxol Fast 
Blue at termination. In the cuprizone model, mice were treated 
with an ozanimod surrogate (RP-101074) for six weeks concur-
rently with cuprizone and corpus callosum sections at termination 
were stained with SMI-32 to evaluate neuronal breaks.
Results: Plasma NfL was significantly elevated in EAE and cupr-
izone-treated mice over naïve controls. Elevated plasma NfL lev-
els correlated with spinal cord inflammation and demyelination in 
EAE and with neuronal breaks in the corpus callosum of mice 
treated with cuprizone. Ozanimod treatment in EAE significantly 
reduced plasma NfL levels correlating with a significant reduction 
in clinical scores and spinal cord inflammation and demyelina-
tion. Mice treated with RP-101074 in the cuprizone model had 
significantly reduced plasma NfL and neuronal breaks, supportive 
of a neuroprotective effect.
Conclusion: Plasma NfL was significantly elevated in EAE 
mice and in the cuprizone-treated mice compared to naïve, non-
diseased induced animals. Elevated plasma NfL correlated with 
clinical scores and spinal cord inflammation and demyelination in 
EAE as well as with neuronal breaks in the cuprizone model. In 
both of these preclinical studies, plasma NfL served as a bio-
marker indicative of CNS injury, inflammation and demyelina-
tion. These observed effects indicate a potential positive and 
direct CNS effect of ozanimod.
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JCPyV microRNA in plasma inversely correlates with 
JCPyV seropositivity among long-term natalizumab-treated 
relapsing-remitting multiple sclerosis patients
P. Basnyat1, E. Virtanen2, I. Elovaara1,3, S. Hagman1, E. 
Auvinen2
1Neuroimmunology Unit, School of Medicine, University of 
Tampere, Tampere, 2Department of Virology, Medicum, and 
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Background: Sensitive biomarkers are needed to better detect or 
evaluate the multiple sclerosis (MS) patients for natalizumab 
(NTZ)-associated risk of progressive multifocal leukoencepha-
lopathy (PML). Currently used risk stratification algorithm, 
mainly based on JC polyomavirus (JCPyV) serology, has not led 
to a reduction of PML incidence. JCPyV encoded microRNAs 
(miRNAs) could serve as sensitive biomarkers for PML risk 
because these miRNAs are frequently detected in plasma, urine 
and CSF of immunosuppressed and healthy individuals, both 
JCPyV seropositive and seronegative.
Objective: To evaluate the presence and prevalence of JCPyV miR-
NAs in plasma of NTZ-treated MS patients, and to explore their bio-
marker potential for NTZ-associated PML risk assessment.
Methods: Altogether 102 plasma samples from 49 NTZ-treated 
and 28 interferon-beta (IFN-b)-treated relapsing-remitting MS 
patients, and 25 healthy controls (HCs) were analysed for jcv-
miR-J1-5p (5p miRNA) and jcv-miR-J1-3p (3p miRNA) 
expression.
Results: The overall detection rate of 5p miRNA was 80.5 % 
(62/77) among MS patients and 92% (23/25) in HCs. When the 
patients were grouped based on current medication, the overall 
detection rate for 5p miRNA was 84% (41/49) among NTZ-
treated patients, and 75% (21/28) among IFN-b-treated patients. 
However, the differences in detection rates were not statistically 
significant (p>0.5). Further, in groups based on the presence of 
JCPyV antibodies, 5p miRNA detection rates were similar among 
JCPyV seropositive and seronegative patients. Relative 5p 
miRNA expression levels were lower in NTZ-treated patients as 
compared to patients treated with IFN-b (p=0.027) but not to HCs. 
Moreover, 5p miRNA expression inversely correlated with anti-
JCPyV antibody index among JCPyV seropositive long-term 
NTZ-treated patients (r=-0.756; p=0.002). The overall detection 
rate of 3p miRNA was low.
Conclusion: Our results suggest that JCPyV miRNA in plasma 
may be linked to the reactivation of persistent JCPyV, enhanced 
virus replication, and eventually to the risk of developing PML 
among NTZ-treated MS patients. However, further study is war-
ranted in a larger data set including samples from PML patients to 
confirm the clinical relevance of JCPyV miRNA as a sign of/in 
viral reactivation, and to identify its potential to predict develop-
ing PML risk.
Disclosure
The authors have no conflict of interests to declare.
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Comparing the CSF proteome of neuromyelitis optica 
patients with and without anti-AQP4 antibodies - prelimi-
nary data
Y.Y.M. Wong1, M. Stoop1, R.M. Van der Vuurst de Vries1, C. 
Stingl1, B. Hemmer2,3, T.M. Luider1, R.Q. Hintzen1,4
1Neurology, Erasmus MC, Rotterdam, The Netherlands, 
2Department of Neurology, 3Munich Cluster of Systems 
Neurology (SyNergy), Technical University of Munich, 
Munich, Germany, 4Department of Immunology, Erasmus MC, 
Rotterdam, The Netherlands
Background: Neuromyelitis optica (NMO) is an inflammatory 
and demyelinating auto-immune disease of the central nervous 
system. Subgroups of NMO patients have been identified, includ-
ing anti-AQP4 seropositive and anti-AQP4 seronegative patients. 
We aim to gain insight in the pathophysiology of NMO, in patients 
with and without anti-AQP4 antibodies, using CSF proteomic 
analysis.
Methods: CSF was enzymatically digested and analysed by high 
resolution mass spectrometry (Orbitrap QX+) after separation 
using a 90 minute LC gradient on a C18 column. The resulting 
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spectra were analysed using specialized software (Progenesis 
LC-MS) and differentially abundant proteins between the groups 
were identified. Subsequently the differentially abundant proteins 
were submitted to Ingenuity Pathway Analysis (IPA) for assess-
ment of their connection and roles in biological pathways that 
might be relevant to disease pathology.
Results: CSF of 12 anti-AQP4 positive NMO patients and 16 
anti-AQP4 negative patients were available and analysed. The 
anti-AQP4 group consisted of more females (75% vs 52%) and 
were older at onset (median 46 years vs median 38 years). In total, 
we identified 6595 peptides belonging to 725 proteins, with a pep-
tide false discovery rate (FDR) of 0.02% and a protein FDR of 
0.8%. These proteins were analysed with stringent criteria to 
detect the significantly differentially abundant proteins between 
the groups. Six proteins were significantly higher in abundance in 
the AQP4-ab positive patients than in the APQ4-ab negative 
patients. These proteins are involved in biological processes, 
including neurogenesis, synaptogenesis, cell adhesion properties 
and cell proliferation.
Conclusion: This preliminary data shows that the CSF proteome 
of anti-AQP4 positive patients has higher abundance for six pro-
teins involving in neuro-regenerative processes. Further analyses 
are needed to confirm these findings.
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OFSEP biobank: high quality samples for powerful research 
on MS biomarkers
N. Dufay1, R. Casey2, B. Britsch-Fayet1, S. Lehmann3, G. 
Gallot4, P. Gelé5, B. Fontaine6, E. Thouvenot7, R. Marignier8, H. 
Zephir5, D. Laplaud4, on behalf of the OFSEP Investigators
1OFSEP, Hospices Civils de Lyon, 2OFSEP, Université Claude 
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The Observatoire Français de la Sclérose En Plaques (OFSEP) is 
a French national cohort of patients with multiple sclerosis (MS), 
granted in 2011 for a ten-year tenure by the French National 
Research Agency. The OFSEP’s biobank aims to provide research 
high quality biological samples from MS patients, associated to 
clinical data.
Selected groups of patients only are currently sampled: Clinical 
Isolated Syndromes (CIS), Radiologically Isolated Syndromes 
(RIS), primary progressive MS (PPMS), NeuroMyelitis Optica 
Spectrum Disorders (NMOSD), Acute Disseminated 
EncephaloMyelitis (ADEM) and multifocal leukoencephalopa-
thy (PML). Blood and urine collection are mandatory, CSF and 
stool are optional.
To achieve high quality samples, OFSEP relies on 13 French 
biobanks certified with the NF S96-900 norm.
Samples of serum, plasma, DNA, PBMC (Peripheral Blood 
Mononuclear Cells), urine, CSF, CSF cells and stool are condi-
tioned in sterile conditions and rapidly stored in a highly secured 
manner. According with international recommendations, delay 
between sampling and freezing is less than 4h (24h for PBMC).
More than 15 000 biological samples are now available for MS 
research, corresponding to 241 CIS patients, 36 RIS patients, 108 
PPMS patients, 148 NMOSD patients, 11 patients with ADEM 
and 4 PML. Diagnosis and respect of inclusion criteria were con-
trolled by using EDMUS clinical data and when necessary by 
expert groups (RIS and NMOSD).
OFSEP’s biobank associated with clinical data from EDMUS 
software provides the opportunity to achieve high level research 
on MS biomarkers. Biological samples and associated data are 
open to academic and industrial research. In a near future, collec-
tion will extend to relapsing-remitting and atypical forms of MS.
Disclosure
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Serum Neurofilament light chain as a predictor of long-term 
outcomes in patients with CIS in the BENEFIT 11 trial
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Background: Serum Neurofilament light chain (sNfL) is a prom-
ising biomarker of neuro-axonal injury. Recent studies have 
shown associations with clinical and MRI disease activity and sig-
nificant predictive value for relapses and worsening of disability. 
Follow up from patients with clinically isolated syndrome (CIS) 
who were enrolled in BENEFIT and had comprehensive assess-
ments after 2, 5 and 11 years provides an opportunity to study the 
short- and long-term predictive value of sNfL.
Objective: To analyse the predictive capacity of baseline and year 
1 sNfL measurements for outcomes at 2, 5 and 11 years. Further, 
to investigate associations between clinical and imaging variables 
and sNfL levels measured at baseline, 1 and 11 years.
Methods: Patients with CIS within 60 days were randomized to 
initial treatment with interferon beta-1b or placebo for 2 years or 
until diagnosis of clinically definite MS (CDMS). After conver-
sion to CDMS or 2 years, patients on placebo could switch to 
interferon beta-1b or another treatment. Prospective follow up 
rater-blinded to initial randomization continued to year 5. Eleven 
years after randomization, patients were asked to participate in a 
comprehensive re-evaluation including clinical, imaging and 
blood laboratory tests. sNfL was measured by Single Molecule 
Array (Simoa) assay. The relation of sNfL to relapse-, disability- 
and MRI related endpoints at Years 2, 5 and 11 is investigated by 
uni- and multivariate regression analyses. Baseline covariates 
include sex; age; lowest EDSS up to Month 6 visit; mono/multi-
focal onset; presence of optic nerve, brainstem, or spinal cord 
lesions; PASAT3; Timed 25-Foot Walk and 9-Hole Peg test 
scores; number and volume of hypointense T1, gadolinium-
enhancing T1, and T2 lesions; cerebral volume; and initial treat-
ment assignment.
Results: sNfL was measured in 1018 samples (BL n=463; year 1, 
n=330, and year 11, n=225). Results of uni- and multivariate anal-
yses will be presented.
Conclusions: Using the Simoa technology that allows highly sen-
sitive and robust quantitation of sNfL levels our study will pro-
vide insights into the predictive value of sNfL for mid and 
long-term outcomes in patients with a first clinical inflammatory 
demyelinating event.
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EP1614
mTOR signaling plays a crucial role in IFN-β non-respon-
siveness in MS patients with high serum Sema4A levels
A.H. Namba1, T. Okuno1, T. Koda2, K. Yamashita1, M. 
Shimizu1, M. Kinoshita3, A. Kumanogoh4, Y. Miyazaki5, M. 
Niino5, K. Miyamoto6, Y. Nakatsuji7, H. Mochizuki1
1Department of Neurology, Osaka University Graduate 
School of Medicine, Suita, 2National Center of Neurology and 
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Psychiatry, Kodaira, 3Department of Neurology, Osaka General 
Medical Cente, Osaka, 4Department of Respiratory Medicine, 
Allergy and Rheumatic Diseases, Osaka University Graduate 
School of Medicine, Suita, 5Department of Clinical Research, 
Hokkaido Medical Center, Sapporo, 6Department of Neurology, 
Kinki University, Sayama, 7Department of Neurology, Toyama 
University Hospital, Toyama, Japan
Background: Interferon-beta (IFN-β) is one of the first-line ther-
apies in relapsing-remitting multiple sclerosis (RRMS) and one-
third of patients are poor responders to this therapy. We previously 
reported that a class IV semaphorin (Sema4A) is increased in the 
sera of MS patients, those with high Sema4A do not respond well 
to IFN-β therapy. Although Correlation between Sema4A and 
Mammalian target of rapamycin (mTOR) signaling in CD8+ T 
cells has been shown recently, the relationship in CD4+ T cells 
has not been unknown.
Goals: In this study, we confirmed reproducibility of our previous 
study in larger cohort and evaluate new outcome measure of MS. 
In addition, we tried to reveal the mechanism by which Sema4A 
inhibits the therapeutic effect of IFN-β.
Methods: This study examined 201 RRMS patients (58 facilities 
in Japan) who met the MacDonald criteria 2010. Serum Sema4A 
levels were examined using sandwich ELISA. We also evaluated 
clinical severity of 48 RRMS patients receiving IFN-β therapy. To 
analyze the effect of Sema4A in CD4+ T cell differentiation, we 
stimulated coculture of human CD4+ and CD14+ cells with 
recombinant Sema4A.
Results: MS patients with high serum Sema4A tended to have 
earlier age of onset, higher annual relapse ratio, and more severe 
EDSS score change than those with low Sema4A. No significant 
differences were found in positive ratio of oligoclonal immuno-
globulin G bands and distribution of brain MRI lesions. A total of 
9 of 28 (32.1%) patients with low Sema4A achieved remission 
status after 5 years from start IFN-β therapy, but only 1 of 12 
(8.3%) patients with high Sema4A did. When we differentiated 
human CD4+ T cells, Sema4A promoted phosphorylation of 
mTOR (Ser2448) and ribosomal protein S6 kinase beta-1 (S6K1) 
which acts downstream of mTORC1 pathway. Moreover, Sema4A 
increased the proportion of both Th1 and Th17 cells, which was 
canceled by rapamycin, mTOR inhibitor.
Conclusion: Our results suggest that high serum Sema4A corre-
lates with IFN-β resistance in RRMS patients by activation of 
mTOR signaling.
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EP1615
Intrathecal IgM synthesis is associated with conversion of 
CIS patients to definite MS
A. Huss1, A. Abdelhak2, F. Bachhuber1, S. Halbgebauer1, M. 
Senel2, M. Otto2, H. Tumani2,3
1Experimental Neurology, University Ulm, 2Neurology, 
University Hospital Ulm, Ulm, 3Specialty Hospital of Neurology 
Dietenbronn, Schwendi, Germany
Background: Detection of intrathecal immunoglobulin G (IgG) 
synthesis indicated by oligoclonal bands (OCBs) or in the Reiber 
diagram are well established markers for acute and chronic 
inflammation in the central nervous system (CNS). Especially 
OCBs are connected to a more severe disease course in multiple 
sclerosis (MS). In the last years also IgM OCBs gained impact and 
were associated with a worse clinical outcome if present, particu-
larly in the progressive forms of MS. However, the detection of 
IgM OCBs is challenging and conformation of those findings by 
several independent groups is still pending. In this study we com-
pared the predictive values of IgG OCBs, intrathecal IgG and IgM 
production towards conversion of CIS patients to definite MS.
Methods: We retrospectively collected data of IgG OCBs, intrathe-
cal IgG and IgM production as indicated by the Reiber diagram of 
CIS patients who attended university hospital of Ulm during their 
very first relapse as well as clinical data such as extended disability 
status scale (EDSS) and time to conversion to MS (CTM) in months.
Results: 50 patients were included of whom 60 % were female and 
the median age was 34 (IQR 23-45). The median follow up time was 
35 months (IQR 24-46), whereas in this time 48 % converted to clini-
cal definite MS. 80 % of the patients showed a positive OCB finding, 
28 % an intrathecal IgG and 18 % an intrathecal IgM production.
There was no correlation of the numerical quotients for IgG and 
IgM to EDSS (p= 0.43 and 0.37, respectively) but EDSS levels 
were significantly higher in IgG OCB positive compared to OCB 
negative patients (p= 0.016).
The hazard ratio for conversion was highest for patients showing 
an intrathecal IgM production (HR 2.5 compared to 2.1 for intrath-
ecal IgG production and 2.0 for OCB positivity). Furthermore, 89 
% (8 of 9) patients with an intrathecal IgM production did convert 
to a definite MS, whereas the conversion prevalence for OCB 
positive subjects was 64 % and 75 % for patients with an intrathe-
cal IgG production according to the Reiber diagram.
Discussion: Our data suggest that an intrathecal IgM production 
indicated by the Reiber diagram is a more specific risk marker for 
conversion than e.g. OCBs, nevertheless OCBs are still superior 
concerning sensitivity and are related with a higher EDSS in our 
study. This finding has to be confirmed by a larger study and 
should also be compared to IgM OCBs to see whether those two 
findings are comparable or independent of each other.
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EP1616
Determination of the altered metabolome as an expected 
biomarker of active plaques in relapsing-remitting multiple 
sclerosis patients
N. Niedziela1, K. Osadnik2, T. Osadnik3,4, J. Kasperczyk2,5, K. 
Kubicka-Bączyk1, M. Adamczyk-Sowa1
1Department of Neurology, School of Medicine with the 
Division of Dentistry in Zabrze, Medical University of Silesia, 
2Centre of Polymer and Carbon Materials, Polish Academy 
of Sciences, 3IInd Department of Cardiology and Angiology 
Silesian Centre for Heart Diseases, 4Third Department of 
Cardiology, School of Medicine with the Division of Dentistry, 
Medical University of Silesia, Zabrze, 5School of Pharmacy with 
the Division of Laboratory Medicine in Sosnowiec, Medical 
University of Silesia, Katowice, Poland, Chair and Department 
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Background: Despite the establishment of some well-known fac-
tors invloved in MS pathology, no specific biomarker of the dis-
ease is currently available. The cerebrospinal fluid (CSF) 
metabolome, defined as the set of all CSF metabolites might be 
important for MS diagnosis and management.
Goals: To assess differences in the CSF metabolite profiles 
between
relapsing-remitting MS patients (RRMS) and healthy controls 
(HCs) according to the presence of active inflammatory plaques in 
the brain or cervical spinal cord on magnetic resonance imaging 
(MRI).
Methods: 14 RRMS patients and 12 HCs were included in the 
study. Patients were divided into 2 groups: MS-I group: 6 
patients without disease modyfing therapy (DMT) who showed 
active inflammatory plaques in the brain or cervical spinal cord 
on MRI and 8 MS patients lacking such plaques on MRI (MS-II 
group). To evaluate metabolome of CSF, 1H NMR spectroscopy 
was used. The comparison of metabolic profile between MS-I, 
MS-II and HCs was conducted and the pathway analysis was 
performed.
Results: The CSF metabolome did not significantly differ 
between MS patients and HCs (R2Y=0.09, Q2Y=-0.17 - single-
component score; permutation test statistic for separation dis-
tance: p=0.46). The results of partial least square discriminant 
analysis (PLS-DA) indicated significant discrimination between 
the MS-I group and the MS-II group (R2Y=0.70, Q2Y=0.56 - 
single-component model; permutation test statistic for separation 
distance: p=0.024). The variables predominantly responsible for 
the distinction between the MS-I and MS-II groups were spectral 
regions corresponding to lactate, creatine, L-glutamine, acetic 
acid, and D-glucose which revealed that concentrations of the 
identified metabolites were used to perform enrichment analysis 
that revealed that changes in CSF metabolite profiles in MS 
patients with active plaques on MRI primarily affected the pyru-
vate metabolism pathway.
Conclusions: Distinct metabolite profiles between RRMS 
patients with and without active inflammatory plaques in the brain 
or cervical spinal cord on MRI was found. The CSF metabolome 
was comparable between healthy individuals and MS patients 
which suggests that the metabolite profile is altered only during 
active MS processes. 1H NMR spectroscopy is an analytical tool 
for metabolome determination and seems to be helpful in MS bio-
marker estimation.
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EP1617
Towards personalized dosing of natalizumab in multiple scle-
rosis: an ongoing multicentre trial in the Netherlands
Z.L.E. van Kempen1, D. Doesburg1, N.F. Kalkers2, J.P. Mostert3, 
E.L.J. Hoogervorst4, R.Q. Hintzen5, H.C. Weinstein2, M.P. 
Wattjes1, B.M.J. Uitdehaag1, T. Rispens6, J. Killestein1
1VU University Medical Center, 2OLVG, Amsterdam, 3Rijnstate 
Hospital, Arnhem, 4St Antonius Hospital, Utrecht, 5Erasmus MC, 
Rotterdam, 6Sanquin, Amsterdam, The Netherlands
Background: Natalizumab is an efficacious drug in the treatment 
of relapsing-remitting multiple sclerosis (RRMS). Despite the 
knowledge of a large variation in pharmacokinetics and patient 
characteristics, every patient receives the same treatment regimen 
of 300mg intravenously administered natalizumab every four 
weeks. We believe that a natalizumab concentration based treat-
ment schedule may result in fewer hospital visits and lower costs, 
without decreasing drug efficacy.
Objective: To prove that extending dose intervals guided by 
serum concentrations of natalizumab will not result in radiologi-
cal and clinical disease activity in completely stable RRMS 
patients treated with natalizumab.
Study design: A prospective multicentre, single arm trial.
Study population: Adult patients with RRMS with no evident 
disease activity during the last 12 months of natalizumab infu-
sions with a minimum treatment duration of 12 months. Only 
patients with natalizumab trough concentrations of ≥15µg/ml can 
enter the study.
Intervention: Before subsequent natalizumab infusions, serum 
natalizumab concentrations will be evaluated. If the concentration 
exceeds 15µg/ml the dose interval will be extended with one week 
to a maximum of eight weeks. If serum concentration falls between 
10-15µg/ml patients will remain on their current schedule. If serum 
concentration drops below 10µg/ml the infusion schedule will be 
put back with one week with a minimum of a four week interval.
Patients will undergo 3 monthly brain MRI’s with gadolinium and 
3 monthly neurological testing, i.e. expanded disability status 
scale (EDSS). Furthermore, at baseline and at 12 months, patients 
will complete questionnaires including Short form-36 and 
Multiple Sclerosis Impact Scale-29.
Main study parameters/endpoints: The primary endpoint is the 
number of patients developing gadolinium enhancing lesions on 
brain MRI. Secondary endpoints are new or enlarging T2 lesions 
on brain MRI, clinical relapses, progression on EDSS and changes 
of subjective health measured with the questionnaires.
Preliminary trial results: The first patient was included in 
November 2016. So far, 30 patients have been included and >50% 
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of patients are treated with an interval ≥6 weeks. MRI follow-up 
showed no gadolinium enhancing lesions in included patients. 
Furthermore, no new/enlarging T2 lesions were found at MRI 
follow-up and no patient experienced a clinical relapse so far.
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Two-year follow-up of 19 patients treated with alemtuzumab 
for active relapsing-remitting MS: the Lyon’s experience
F. Durand-Dubief1,2, R. Marignier1, I. Ionescu1, J. Pique1, C. 
Lavie1, S. Vukusic1,3,4
1Service de Neurologie, Sclérose en Plaques, Pathologies de la 
Myéline et Neuro-Inflammation, Hôpital Neurologique, Hospices 
Civils de Lyon, Bron Lyon Cedex, 2Bâtiment Blaise Pascal, 
CREATIS (CNRS UMR 5220 & INSERM U 1206), Université 
de Lyon, Villeurbanne, 3Centre des Neurosciences de Lyon, 
INSERM 1028 et CNRS UMR 5292, Lyon, 4Université Claude 
Bernard Lyon 1, Faculté de Médecine Lyon-Est, Villeurbanne, 
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Background: Alemtuzumab has been approved by the European 
Medicines Agency as a treatment of relapsing-remitting multiple 
sclerosis (RRMS). However, with regards to its safety profile, 
French regulators have limited its use to radiologically and clini-
cally active and severe cases only.
Objectives: To describe the efficacy and safety profile of alemtu-
zumab in a monocentric cohort of patients.
Methods: We prospectively collected clinical and radiological 
data of RRMS patients treated with alemtuzumab since January 
2015.
Results: 19 RRMS patients (16 women/3 men) received alemtu-
zumab (mean age at treatment: 34.5 years). Mean disease dura-
tion was 11.5 years (range: 2.5-26) and mean EDSS was 4.8 
(range 0-8) at treatment onset. In the year before, mean number 
of relapses was 1.6 (range 1-5). Pre-treatment MRI showed 
new T2 lesions in 91% and Gadolinium-enhancing lesions in 
82% of patients. Mean number of previous disease modifying 
treatments (DMT) before alemtuzumab was 4 (2-7). Among 18 
patients followed for at least one year, 15 did not relapse and 
mean EDSS decreased by 0.5. New T2 lesions and new 
Gadolinium-enhancing lesions were found in 40 % (from 1 to 30 
G + lesions / patient). At two years, 9/11 patients had no relapse 
and mean EDSS decreased by 0.7. New T2 lesions and new 
Gadolinium-enhancing lesions were found in respectively 36 % 
and 18 % of the patients (from 8 to 14 G + lesions/patient). 
Infusion-related reactions were found in 85% of the patients 
(mainly rash and headache/pyrexia). Noteworthy, 8 patients pre-
sented short-term moderate to severe adverse events: 4 episodes 
of bradycardia (25-45 pulses/mn), 1 pleural and pericardial effu-
sion associated to hepatic cytolysis, 1 pericarditis, 1 spontane-
ous multiple cervical artery dissection complicated by ischemic 
stroke and 1 intra alveolar haemorrhage. After 2 years, 1 patient 
had severe immune thrombocytopenia and neutropenia and 2 
patients developped thyroid disorders.
Conclusion: Our experience emphasizes the possible modified 
efficacy and safety profile of alemtuzumab when used as a rescue 
therapy, rather than in its original early indication, in patients pre-
viously exposed to many other DMTs. Further evaluations are 
warranted to support this assumption.
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EP1619
Impact of dimethyl fumarate (DMF) treatment on immune 
tolerance during multiple sclerosis
G.T. Maniscalco
Neurological Clinic, A Cardarelli Hospital, Naples, Italy
Background: Dimethyl fumarate (DMF) is a first line oral treat-
ment of relapsing-remitting multiple sclerosis (RR-MS) patients. 
Recent data have shown that DMF inhibits immune cells and 
inflammation, and may have antioxidant properties protective 
against damage to the brain and spinal cord during MS. However, 
the precise molecular mechanism of action of DMF, particularly in 
the context of its impact on cells involved in immune tolerance such 
as FoxP3+ regulatory T cells (Treg cells), remains speculative.
Objectives: The aim of this study is to evaluate the capacity of 
DMF to modulate the peripheral blood immune phenotype and the 
proliferation and suppressive function of conventional T (Tconv) 
and Treg cells in RRMS patients.
Methods: We obtained blood samples from 22 naïve-to-treat-
ment and 72 previously treated with IFN-beta-1a RRMS 
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patients and performed an ex vivo immune-phenotyping before 
and after treatment with DMF. In addition, we analyzed isolated 
Tconv and Treg cells from RR-MS subjects before and after 
DMF treatment.
Results: We observed that DMF treatment was able to reduce the 
number of total lymphocytes and of CD3+, CD4+ and CD8+ T 
cells. The analysis also revealed that DMF treatment resulted in a 
specific decrease of cells of the memory compartment 
(CD3+CD45RO+ and CD4+CD45RO+). The analysis of prolifera-
tion and suppressive function of Treg cells showed that DMF is 
able to increase the suppressive function of Treg cells with little 
impact on their proliferative capacity.
Conclusions: Our data suggest that DMF could be involved in the 
control of immune tolerance during MS by reducing the compart-
ment of memory T cells that likely contain the self-reactive fraction 
of cells, and by increasing the suppressive capacity of Treg cells.
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Inhibition of mitochondrial respiration with teriflunomide 
modulates antigen-specific immune responses in an affinity-
dependent fashion
M. Eschborn1, L. Klotz1, M. Lindner1, M. Liebmann1, 
B. Torres Garrido1, J. Breuer1, N. Schwab1, C. Gross1, 
A. Schulte-Mecklenbeck1, P. Hundehege1, G. Nebel2, S. 
Glander2, K. Busch2, M. Stoll2, M. Eveslage2, S.G. Meuth1, 
D. Zehn3, T. Turner4, A. Bar-Or5, H. Wiendl1, on behalf of the 
TERIDYNAMIC Study Group
1University Hospital Münster, 2University of Münster, 
Münster, 3Technical University of Munich, Munich, Germany, 
4Sanofi Genzyme, Cambridge, MA, United States, 5Montreal 
Neurological Institute and Hospital, McGill University Health 
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Teriflunomide (TF) is an immunmodulatory drug used for treat-
ment of T cell mediated autoimmune diseases e.g. rheumatoid 
arthritis and multiple sclerosis. Its capacity to inhibit the mito-
chondrial enzyme dihydroorotate dehydrogenase (DHODH) of 
the de novo pyrimidine synthesis pathway results in a reduced 
proliferation of activated immune cells. Pharmacological 
DHODH inhibition via TF interferes with mitochondrial respira-
tion and glycolysis in T cells. Here, we provide first evidence that 
TF suppresses
T cell proliferation and metabolism in an affinity dependent man-
ner as high affinity T cells were more susceptible towards 
DHODH inhibition than low affinity T cells. Kinetics of high 
affinity T cell activation revealed that they increase mitochon-
drial respiration more rapidly than low affinity T cells in the early 
phase of activation which explains their enlarged susceptibility 
towards DHODH inhibition. In an antigen-driven mouse model 
for central nervous system (CNS) autoimmunity we could illus-
trate that leflunomide (precursor of TF) treatment results in a 
preferential reduction of high-affinity T cells and hence in a 
reduction in mean T cell receptor (TCR) affinities. We therefore 
hypothesize that DHODH inhibition in vivo results in an altered 
T cell clonal repertoire, a concept which is further supported by 
recent data from a clinical trial employing the DHODH inhibitor 
teriflunomide in relapsing-remitting multiple sclerosis (RRMS) 
patients (TERIDYNAMIC trial). Taken together, our data sug-
gest that the affinity of the peptide-TCR-interaction directs the 
mode of energy production in T cells and can hence be specifi-
cally targeted via DHODH inhibition.
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EP1621
Should lesions enhanced by gadolinium injection predict effi-
ciency of first line therapies?
P. Labauge1, X. Ayrignac1, N. Collongues2, L. Kremer2, S. 
Kremer3, J.C. Ongagna2, L. Corti1, C. Carra Dalliere1, F. Pinna1, 
C. Theis1, J. de Seze2
1Neurology, CHU Montpellier, Montpellier, 2Neurology, 
3Neuroradiology, Strasbourg, Strasbourg, France
Background: Immunomodulatory treatments are indicated as 
first line therapy in MS patients after the first demyelinating 
event. Correlation of MR activity in such patients especially 
enhanced lesions and response to 1st line therapies is not known.
Objectives: To evaluate correlation of MR activity and response 
to first line therapies in MS patients.
Material and methods: Based on EDMUS data bank, we retro-
spectively included MS patients treated by a first line treatment 
followed during 2 years. Criteria analysis were annual rate of 
relapses (ARR) and EDSS score at year 1 and 2, compared 
between patients without (Gd- ) and with (Gd+) activity at the 
baseline MR examination. Extensive follow at 5 years was avail-
able in a part of the patients.
Results: From 2180 MS patients included in our MS base 
(EDMUS), 149 MS had inclusion criteria: 91 Gd- and 58 Gd + . 
Group Gd - characteristics were: sex ratio (M 19 / F 72), mean age 
of onset: 32.3, mean follow-up : 72 months. Mean EDSS score at 
the beginning of therapy was 0.7. Most of them (94 %) had an 
EDSS score below 2. Mean duration of first line therapy was 39. 
6 months. Gd+ group consisted of 58 patients (M12 / F 46), mean 
age of onset 31.3 yo, mean follow-up: 60 months, mean EDSS 
score at the prescription : 0.9 (91 % < 2), duration of treatment: 
32.1 months.
At year 1 , ARR was 0.35 in Gd - and 0.49 in Gd + group, mean 
EDSS score 0.7 and 0.87 (not statistically significant) . At year 2, 
ARR was 0.25 in Gd - and 0.35 in Gd + patients, mean EDSS 
score 0.7 and 1.06 (NS). At year 5, EDSS score was available for 
54 patients of Gd - group and 29 from Gd +. It was respectively 
0.6 and 1.6 (p < 0.05).
Conclusions: Occurrence of enhanced lesions on MR at the onset 
of the first line therapy, suggests a more severe evolution. ARR and 
mean EDSS score is slightly more important at year 1 and 2 in Gd 
+ patients. Long term EDSS score is worst in Gd + patients treated 
by first line therapy. These results could suggest to treat some MS 
patients with GD + lesions directly by a 2nd line therapy.
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EP1622
Comparative efficacy of teriflunomide versus dimethyl-
fumarate: a French multicenter observational study from the 
french national OFSEP cohort
D.A. Laplaud1,2, L. Barbin3, R. Casey4,5,6, M. Debouverie7, S. 
Vukusic5,6, P. Labauge8, D. Brassat9, S. Wiertlewski3, J. De 
Sèze10, G. Edan11, B. Brochet12, T. Moreau13, E. Berger14, P. 
Clavelou15, G. Castelnovo16, J. Ciron17, J. Pelletier18, B. Bourre19, 
C. Lubetzki20, A. Al-Khedr21, P. Vermersch22, C. Lebrun-
Frenay23, G. Defer24, A. Tourbah25, J.-P. Camdessanché26, B. 
Stankoff27, C. Labeyrie20, I. Patry28, A. Creange29, O. Gout30, 
O. Heinzlef31, O. Casez32, L. Magy33, A.-M. Guennoc34, T. 
Debroucker35, C. Nifle36, C. Dupel-Pottier37, E. Leray38, F. 
Rollot4,5,6, Y. Foucher2,39, SFSEP, OFSEP
1CRTI, Neurology, CHU Nantes, 2Université de Nantes, 3CHU 
Nantes, Nantes, 4OFSEP, 5UCBL, 6HCL, Lyon, 7CHU Nancy, 
Nancy, 8CHU Montpellier, Montpellier, 9CHU Toulouse, 
Toulouse, 10CHU Strasbourg, Strasbourg, 11CHU Rennes, 
Rennes, 12CHU Bordeaux, Bordeaux, 13CHU de Dijon, Dijon, 
14CHU Besançon, Besançon, 15CHU de Clermont Ferrand, 
Clermont-Ferrand, 16CHU Nîmes, Nîmes, 17CHU Poitiers, 
Poitiers, 18CHU Marseille, Marseille, 19CHU de Rouen, Rouen, 
20Pitié-Salpêtrière Hospital, Paris, 21CHU Amiens, Amiens, 
22CHU de Lille, Lille, 23CHU de Nice, Nice, 24CHU de Caen, 
Caen, 25CHU de Reims, Reims, 26CHU Saint-Etienne, Saint-
Etienne, 27Saint-Antoine, Paris, 28CH Corbeil-Essonne, Corbeil-
Essonne, 29CHU Créteil, Créteil, 30Foundation A de Rothschild, 
Paris, 31CH Poissy-Saint-Germain, Poissy, 32CHU Grenoble, 
Grenoble, 33CHU Limoges, Limoges, 34CHU Tours, Tours, 
35CH Saint-Denis, Saint-Denis, 36CH Versailles, Versailles, 
37CH Pontoise, Pontoise, 38EHESP, Rennes, 39Inserm U 1246 - 
Sphere, Nantes, France
Background: Both Teriflunomide (TRF) and Dimethyl-Fumarate 
(DMF) have been approved as first line treatments for patients 
with relapsing-remitting multiple sclerosis (RRMS). However, to 
date, neither randomized controlled nor observational studies 
have compared their relative efficacy.
Objective: To compare TRF and DMF efficacy on both clinical 
and MRI outcomes in RRMS patients from the national french 
OFSEP cohort.
Methods: RRMS Patients were included if aged 18 to 65 with an 
EDSS score of 0 to 5.5 at baseline and an available brain MRI 
performed within the year before treatment initiation. Data were 
collected prospectively for 585 patients treated with TRF and 
890 with DMF. The main outcome was the proportion of patients 
with at least one relapse in the year following TRF or DMF ini-
tiation. Three secondary endpoints were studied: the proportion 
of patients with at least a new T2 lesion, the proportion of 
patients with at least one gadolinium positive (gado+) lesion and 
the proportion of patients with an increased EDSS score after 
one year of treatment. Outcomes were modeled using propensity 
scores (Inverse Probability Weighting) and logistic regressions 
by using weighted likelihood maximization and robust variance 
estimator.
Results: Baseline comparison revealed that patients treated with 
DMF were significantly younger with shorter disease duration, 
increased percentage of patients with at least one relapse in the 
year and the two years preceding treatment initiation and increased 
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percentage of patients with at least one gado+ lesion on baseline 
MRI scans. However, the confounder-adjusted proportion of 
patients with at least one relapse within the first year of treatment 
was similar in TRF-treated patients compared to DMF group 
(20.1% versus 20.4%). On the same way, analyses of the MRI and 
EDSS secondary endpoints revealed similar efficacy of the treat-
ments at one year after initiation.
Interpretation: In France neurologists preferentially choose 
DMF as a first-line treatment for patients with objective clinical 
and radiological signs of activity. However, after one year of treat-
ment and after correction for confounders, the efficacy of DMF 
and TRF was similar in terms of prevention of relapse and occur-
rence of new T2 or gadolinium-positive lesions.
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EP1623
Real clinical experience in multiple sclerosis patients treated 
with alemtuzumab in the Northwest of Spain
A.M. Lopez Real1, J. Peña Martinez2, A. Rodriguez Regal3, A. 
Oterino Durán4, D.M. Solar Sanchez5, A. Pato Pato6, I. González 
Suárez7, A. García-Pelayo Rodríguez1, E. Costa Arpin8, M.Á. 
Llaneza González9, M.D. García Bargo10, M. Rodríguez 
Rodríguez11, J.M. Prieto González8
1Complejo Hospitalario Universitario de A Coruña, A 
Coruña, 2Hospital Universitario San Agustin, Avilés, 
3Complejo Hospitalario de Pontevedra, Pontevedra, 
4Hospital Universitario Marques de Valdecilla, Santander, 
5Hospital Universitario de Cabueñes, Gijón, 6Hospital de 
POVISA, 7Complejo Hospitalario Universitario de Vigo, 
Vigo, 8Complejo Hospitalario Universitario de Santiago de 
Compostela, Santiago de Compostela, 9Complejo Hospitalario 
Universitario de Ferrol, Ferrol, 10Complejo Hospitalario 
Universitario de Ourense, Ourense, 11Hospital Universitario 
Lucus Augusti, Lugo, Spain
Background: In pivotal studies alemtuzumab have demonstrated 
a marked reduction of relapse rates and improved on MRI out-
comes. Different results were obtained about disability.
Objectives: To describe “real-world” experience of the use of 
alemtuzumab in a multicentre cohort of patients.
Methods: Patients from 11 centres from the Northwest of Spain 
who received first dose Alemtuzumab were included. Baseline 
and prospective data were obtained. Previous disease-modifying 
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treatment (DMT) use and reason for changing to Alemtuzumab, 
relapse rate, EDSS change and magnetic resonance imaging 
(MRI) are described. EDSS were performed at baseline and every 
6 months. The reported cranial MRI scans were performed at 
baseline and annually.
Results: Eighty three patients: 55 (66%) females and 28 (34%) 
males, were included. Mean of age was 39.4±8.27 years. Mean 
duration of follow up was 11.0±5.88 months; 30 patients received 
the second course. Mean MS duration was of 10.8±6.86 years. 
Annualized relapse rate (ARR) in the previous year was 1.3±1.13 
and mean baseline EDSS was 3.5±1.66 (median 3.5). The mean 
number of previous DMT was 2.5±1.51. The main reason for 
switching to alemtuzumab was lack of efficacy (80%). The 28 
patients who was followed for 12 months, showed an important 
reduction of ARR, from 1.82±1.36 to 0.07±0.26 (U=319.5; p< 
0.001); and mean EDSS did not change. From baseline to 12 
months, there was a reduction from 58% to 15% (n=26) in the 
number of patients with gadolinium-enhancing lesions on 
T1-wheighted MRI and there were 23% of patients with new 
T2-hyperintense lesions (n=26). Infusion-related reactions were 
registered in 67 (81%) patients (all were mild-moderate). Infections 
were detected in 33% of patients; the most common were urinary 
tract infections. Thyroid disease was the only observed secondary 
autoimmune disorder (6% of patients). No serious adverse events 
(AE) occurred.
Conclusions: This study confirms a positive effect on clinic 
(relapses, EDSS) and radiological measures. AE are predictable 
and treatable. Thyroid disease was the only autoinmune disorder 
observed.
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EP1624
Comparison of the B-cell recovery time following discontinu-
ation of anti-CD20 therapies
M. Savelieva1, J. Kahn2, M. Bagger1, D. Piani Meier1, D. 
Tomic1, D. Leppert1, E. Wallström1
1Novartis Pharma AG, Basel, Switzerland, 2Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, United States
Background: The success of anti-CD20 monoclonal antibodies 
(mAbs) in clinical trials highlights a key role for B-cells in driving 
multiple sclerosis (MS) pathology and disease activity. Anti-CD20 
mAbs differ in terms of epitope binding, potency and dosing regi-
men. Due to its unique biological properties, the fully human mAb 
ofatumumab (OFA) is given as subcutaneous (s.c.), low dose, 
monthly injections as maintenance therapy in ongoing Phase 3 
studies.
Objective: To evaluate the B-cell recovery time after discontinu-
ation of OFA compared with other anti-CD20 therapies.
Methods: We used the MIRROR Phase 2 dose-ranging study of 
s.c. OFA in relapsing−remitting MS (RRMS), which included a 
24-week treatment phase and a 24-week follow-up, to describe 
B-cell repletion for OFA at different doses and administration fre-
quencies in comparison with previously published results for 
intravenous (i.v.) ocrelizumab (OCR) and i.v. rituximab (RTX). In 
addition, we used a population kinetics-pharmacodynamic model 
developed using MIRROR data to predict time to B-cell repletion 
after OFA treatment stop. These predictions were done under con-
ditions of the current OFA Phase 3 trials and compared with the 
published OCR data.
Results: The successful depletion of peripheral CD19+ B-cell 
counts by OFA, OCR and RTX has been reported previously. For 
OFA, median time to repletion (CD19+ B-cell count above the 
lower limit of normal or ≥baseline value) in weeks from last active 
dose was 36.7 (7.6, 97.1) for 30 mg every 12 weeks (Q12W), 36.1 
(12.1, 111.0) for 60 mg Q12W, and 49.0 (14.4, 101.9) for 60 mg 
Q4W. For the humanised mAb OCR, median time to B-cell reple-
tion was 71.0 weeks (95% CI: 59-76 weeks). Repletion of imma-
ture B-cells (CD19+CD27-IgD+CD38+bCD10+) to baseline 
occurred within 4 weeks with OFA. For RTX, a chimeric mAb, 
the naïve B-cell population (CD27-IgD+) slowly increased, reach-
ing baseline only after 12-16 months. Our model-based predic-
tions showed that by week 38 since last dose of OFA (loading of 
20 mg three times weekly followed by 20 mg Q4W), 50% of 
patients repleted to either ≥110 B-cells/µl or baseline compared 
with 11% for OCR 600 mg.
Conclusions: OFA differs from other anti-CD20 therapies as it 
achieves faster post-treatment B-cell repletion. Faster repletion 
may be beneficial in the management of adverse events or in treat-
ment sequencing. As the present analysis is based on a 24-week 
OFA treatment duration, B-cell recovery times may need to be 
confirmed after longer-term dosing.
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Lymphocyte recovery in real life clinical practice after dis-
continuation of fingolimod in patients with multiple sclerosis
S. Nagy, J. Kuhle, L. Kappos, T. Derfuss
University Hospital Basel, Basel, Switzerland
Background and aims: Fingolimod induces a fast reduction of 
lymphocyte counts in the blood, however, less is known about 
the recovery of immune cells after treatment discontinuation in 
real life clinical practice, especially in patients who begin with 
a new immunomodulatory treatment shortly after cessation of 
fingolimod. Therefore, we aimed to analyze the course of lym-
phocyte recovery and its potential influencing factors in the 
first year after fingolimod discontinuation in patients with mul-
tiple sclerosis.
Methods: We examined leukocyte, lymphocyte and neutrophil 
counts of 58 patients with multiple sclerosis, 3 (mean 79.1 ± 31.6 
days), 6 (mean 193.3 ± 35.7 days) and 12 (mean 368.6 ± 48 days) 
months after cessation of fingolimod. Blood tests were available in 
55 patients for the baseline (prior fingolimod), in 47 patients for the 
3 months, in 46 for the 6 months and in 48 for the 12 months time-
point. Leukopenia was defined as ≤3500, lymphopenia as ≤900, 
neutropenia as ≤1300 cells per microliter. We included age, sex, 
EDSS and disease duration at fingolimod start, fingolimod treat-
ment duration, transition time before therapy switch, lymphocyte 
baseline prior fingolimod and at start with a following medication, 
and previous immunomodulatory regimens into our analysis.
Results: All patients showed a drop of lymphocyte count under 
fingolimod with no relevant leukopenia or neutropenia. Three 
months after fingolimod discontinuation 11 patients showed 
decreased lymphocyte levels (23.4%), while six and twelve 
months later still 10 patients were lymphopenic (21.7%). 8 out of 
these 10 patients received rituximab as a follow-up treatment. 
47% (8 out of 17) patients that switched to rituximab and 3 out of 
4 patients pretreated with mitoxantrone showed delayed lympho-
cyte recovery. Patients with prolonged lymphopenia had a longer 
treatment duration of fingolimod and tended to have lower lym-
phocyte counts at baseline and at therapy switch.
Conclusion: Only 42% of patients reached their baseline lympho-
cyte levels, while 21.7% stayed lymphopenic after one year of 
cessation of fingolimod. Longer treatment duration of fingolimod, 
low lymphocyte counts at baseline and at therapy switch, succes-
sive treatment with rituximab, and pretreatment with mitox-
antrone might contribute to a prolonged immune cell recovery and 
should be considered when changing treatment regimens.
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Real world effectiveness and safety of alemtuzumab in MS 
patients
S. Eichau1, R. Lopez Ruiz1, J.L. Ruiz Peña1, G. Navarro1, N. 
Becerril1, M. Rus Hidalgo2, G. Izquierdo1
1Hospital Universitario Virgen Macarena, 2Hospital Universitari 
Germans Trias i Pujol, Sevilla, Spain
Background: Alemtuzumab has shown high efficacy in decreas-
ing relapse rates in patients with active relapsing MS in clinical 
trials, but data from real world clinical practice is needed to con-
firm these findings.
Goal: To study efficacy and safety outcomes in real world patients 
treated with alemtuzumab.
Methods: Patients with highly active RRMS treated with alemtu-
zumab since March 2015 at Virgen Macarena Hospital, Sevilla, 
Spain. Baseline, MS characteristics, relapses, change in disability, 
and adverse event data in alemtuzumab-treated patients were 
collected.
Results: 65 patients (43 females, 66%) were identified with a 
mean follow-up of 13.3 months (28-3). 31 (48%) have received 
their second course of treatment.
Average age was 39.4 years (range 20-60) and the mean years 
since MS diagnosis was 15.2 (range 3-30). Patients had been 
treated with a mean of 2.3 disease modifiying therapies prior to 
alemtuzumab treatment. Following alemtuzumab treatment, the 
annualized relapse rate (ARR) decreased from 1.6 to 0.09, and 
EDSS decreased from a mean of 4.6 to 4.0. 34 (59.6%) patients 
showed lower EDSS values, 22 (38.6%) patients showed stable 
EDSS, and 1 (1.7%) showed an increase in EDSS. 3 patients 
(4.6%) had relapses after receiving the first course of alemtu-
zumab (with active MRI), and one of them was treated with the 
second course 10 months after the first. This patient is currently 
the only candidate for re-treatment.
All patients were treated with the second course of alemtuzumab 
when their lymphocyte counts were normal, with a mean of 12.7 
months post first course (10-16). 89% had mild to moderate infu-
sion reactions during the first course, with 77% experiencing mild 
infections within the first year on treatment. One patient suffered 
a severe cytomegalovirus and pneumocystis jirovenci pneumonia 
infection, but recovered following antibiotic treatment. 13% of 
patients developed thyroid disorders between the two courses; 3 
cases of hypothyroidism and 5 cases of hyperthyroidism, 2 of 
which required a thyroidectomy.
Conclusions: Our data shows that MS patients treated with alem-
tuzumab in a real world clinical setting show significant decreases 
in ARR and the majority mantain or improve their disability. Mild 
to moderate infusion reactions and manageable adverse events 
were observed.
Disclosure
Sara Eichau received speaker honoraria and consulting fees from 
Genzye, Biogen, Merck Serono, Teva and Novartis
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EP1627
Baseline characteristics and safety profile of patients in the 
first interim analysis of the peginterferon beta-1a Phase IV 
POP study
A. Pachner1, M. Salvetti2, J. Yun3, D. Appiah-Badu4, G. 
Sabatella3, M.L. Naylor3
1Geisel School of Medicine, Dartmouth College, Hanover, 
NH, United States, 2Sapienza University, S. Andrea Hospital, 
Rome, Italy, 3Biogen, Cambridge, MA, United States, 4Biogen, 
Maidenhead, United Kingdom
Background: Subcutaneous peginterferon beta-1a 125 mcg every 
2 weeks is approved for the treatment of relapsing-remitting mul-
tiple sclerosis (RRMS). The 5-year observational Phase IV 
Plegridy Observational Study (POP) provides an opportunity to 
explore the long-term safety and effectiveness of peginterferon 
beta-1a in a real-world setting.
Objectives: Report interim data on baseline, adverse events 
(AEs), and clinical effectiveness from the POP study.
Methods: The POP study is ongoing in over 150 sites in 14 coun-
tries. Patients who initiated peginterferon beta-1a treatment either 
after or within 31 days prior to date of consent (Naïve subgroup) 
and patients treated with peginterferon beta-1a more than 31 days 
prior to date of consent (Experienced subgroup) will be followed 
for up to 5 years.
Results: Data from 467 patients treated with peginterferon beta-
1a were analysed. At the time of this first interim analysis, 409 
patients (88%) had been followed for 12-24 months. A total of 
153 patients (31%) discontinued treatment, primarily due to AEs 
(55%) and lack of efficacy (13%). At on-study baseline, mean 
age was 44.9 years, 76% were female, and the mean Expanded 
Disability Status Scale (EDSS) score was 1.9. Of the 370 patients 
(79%) previously treated with a disease-modifying therapy, 217 
(46%) had been treated with intramuscular interferon beta-1a. 
There were more patients in the Naïve subgroup than in the 
Experienced subgroup (60% vs 40%, respectively). Overall, 
AEs were more common in the Naïve subgroup compared with 
the Experienced subgroup (35% vs 20%). Serious AEs were 
reported in 5% and 9% of the Naïve and Experienced subgroups, 
respectively. AEs leading to treatment discontinuation were also 
more common in the Naïve subgroup (29% vs 15%). The most 
commonly reported AEs leading to treatment discontinuation in 
both groups were injection-site erythema and influenza-like ill-
ness. A high proportion of patients in both groups were reported 
to be relapse-free (84.4% and 81.5%; Naïve and Experienced, 
respectively).
Conclusions: The safety profile reported in this first interim anal-
ysis of the POP study was consistent with that observed in the 
pivotal Phase 3 trial of peginterferon beta-1a. No new safety sig-
nals were observed. Patients who had been naïve to peginterferon 
beta-1a were more likely to experience AEs and discontinue treat-
ment due to injection site reactions and flu-like symptoms, high-
lighting a need for prophylactic mitigation strategies.
Disclosure
Marco Salvetti has received grant support and speaker honoraria 
from Biogen.
Andrew. Pachner has been a PI on clinical trials funded by: 
Biogen, EMD Serono, Genzyme, Novartis, Genentech, and 
Roche; as well as a PI on basic research studies funded by: Acorda, 
Biogen, EMD Serono and Genzyme. He has received consulting 
fees for participation in advisory boards from Biogen, Genzyme, 
and Novartis.
Jang Yun, David Appiah-Badu, Guido Sabatella, and Maria L. 
Naylor are employees and stockholders of Biogen.
EP1628
Halting disability progression in multiple sclerosis with 
immunomodulatory injectable treatments: Is it achievable?
Y.D. Fragoso1, T. Spelman2, P. Duquette3, M. Girard3, M. 
Trojano4, G. Izquierdo5, P. Grammond6, A. Lugaresi7, V. Van 
Pesch8, F. Grand’Maison9, C. Oreja-Guevara10, G. Iuliano11, 
R. Bergamaschi12, M.E. Rio13, R.F. Bolaños14, M. Terzi15, H. 
Butzkueven16, MSBase
1Neurology, Universidade Metropolitana de Santos, Santos, 
Brazil, 2Department of Medicine and Melbourne Brain Centre 
at the Royal Melbourne Hospital, Melbourne, VIC, Australia, 
3CHUM - Hopital Notre Dame, Quebec, QC, Canada, 
4University of Bari, Bari, Italy, 5Hospital Universitario 
Virgen Macarena, Sevilla, Spain, 6Centre de Réadaptation 
Déficience Physique Chaudière-Appalache, Charny, QC, 
Canada, 7Ospedale Clinizzato ‘Ss. Annunziata’, Chieti, Italy, 
8Cliniques Universitaires Saint-Luc, Brussels, Belgium, 
9Neuro Rive-Sud, Hôpital Charles LeMoyne, Quebec, 
QC, Canada, 10Hospital Universitario La Paz, Madrid, 
Spain, 11Ospedali Riuniti di Salerno, Salerno, 12National 
Neurological Institute C. Mondino, Mondino, Italy, 13Hospital 
São João, Porto, Portugal, 14Hospital Universitario Virgen 
de Valme, Sevilla, Spain, 1519 Mayis University, Medical 
Faculty, Samsun, Turkey, 16The Royal Melbourne Hospital, 
Melbourne, VIC, Australia
Introduction: The introduction of newer therapies for the treat-
ment of multiple sclerosis (MS) is based upon the need to control 
neurological disability. Halting disability progression is a chal-
lenge for therapy since permanent neurological impairment is the 
most worrisome aspect of MS for patients and their doctors. The 
objective of this study was to identify whether “older” injectable 
treatments can lead to MS-related disability control over at least 
seven years.
Materials and methods: Data were sourced from the MSBase 
Registry Patients with at least seven years of continuous treatment 
with any formulation of interferon beta or glatiramer acetate were 
analyzed. Disability control was defined as no increase in the 
expanded disability scale score (EDSS) >1-point from baseline. 
Time to event by index DMT product was analysed via Cox pro-
portional hazards regression.
Results: Of the 546 eligible patients, 379 (69.4%) were female 
with a mean (SD) age and disease duration at index DMT start of 
38.2 years (10.3) and 7.3 years (7.2) respectively. Median (IQR) 
EDSS at baseline was 2. A total of 225 patients (41.2%) recorded 
a minimum greater than 1-point increase from their baseline 
EDSS, sometime during their on-index treatment follow-up. The 
remaining 321 patients (58.8%) maintained the “disability con-
trol” state during follow-up. Median time to event (>1-point 
increase from baseline) was 12.3 years. There were no significant 
differences in time to EDSS increase among the different formula-
tions of interferon beta and/or glatiramer acetate.
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Conclusion: Patients with MS who respond well to immunomod-
ulatory injectable treatments may exhibit satisfactory control of 
neurological disability over long-term follow-up.
Disclosure
Yara Dadalti Fragoso, Tim Spelman, Pierre Duquette, Marc 
Girard, Maria Trojano, Guillermo Izquierdo, Pierre Grammond, 
Alessandra Lugaresi, Vincent Van Pesch, Francois Grand´Maison, 
Celia Oreja-Guevara, Gerardo Iuliano, Roberto Bergamaschi, 
Maria Edite Rio, Ricardo Fernández Bolaños, Murat Terzi, and 
Helmut Butzkueven, have no particular conflicts of interest to 
declare for this abstract. The work was carried out on behalf of 
MSBase study group, which receives unconditional grants from 
pharmaceutical industries (Biogen Idec, Novartis, MerckSerono, 
Genzyme) to support the existence of the database.
EP1629
Effectiveness of fingolimod in Spanish patients with relaps-
ing-remitting multiple sclerosis in the clinical practice
V. Meca-Lallana1, S. Martinez Yélamos2, J. Mallada3, J. Meca-
Lallana4, M. Martínez5, E. Marzo6, C. Durán7, T. Ayuso8, F. 
Barrero9, R. Romero10, R. Guillen10, J. Ricart10, E. Garcia10, MS 
NEXT and MS SECOND LINE GATE studies
1Hospital La Princesa, Madrid, 2Hospital de Bellvitge, 
barcelona, 3Hospital de Elda, Alicante, 4Hospital Virgen de 
la Arrixaca, Murcia, 5Hospital Gregorio Marañón, Madrid, 
6Hospital San Pedro, Logroño, 7Hospital Infanta Cristina, 
Madrid, 8Hospital de Navarra, Pamplona, 9Hospital San Cecilio, 
Granada, 10Novartis Farmacéutica S.A., Barcelona, Spain
Background: Fingolimod is a sphingosine 1-phosphate receptor 
modulator for relapsing-remitting multiple sclerosis RRMS treat-
ment. Continuous collection and analysis of real world effective-
ness and safety data is key to making accurate treatment decisions.
Objective: To describe baseline characteristics at fingolimod 
treatment initiation and effectiveness of fingolimod in RRMS 
patients in clinical practice.
Methods: Pooled analysis of 2 observational, retrospective, mul-
ticentre studies conducted in Spain: MS SECOND LINE GATE 
and MS NEXT. Both studies were carried out in RRMS patients, 
≥18 years, treated with 0.5mg/day of fingolimod and followed for 
≥1 year after treatment initiation.
Results: 988 patients were included (post first-line injectable 
disease-modifying treatment [iDMT]: 666 patients, post-natali-
zumab [NTZ]: 252, treatment-naïve: 70; 69% female, mean [SD] 
age: 40 [9] years). At year 1, 2 and 3 after treatment initiation, 
mean annual relapse rate (ARR) decreased by 77%, 82% and 86% 
compared to the year prior to treatment initiation (p< 0.0001 all). 
At year 3, mean ARR significantly decreased in iDMT and treat-
ment-naïve subgroups by 91% and 96%, respectively, and 
remained stable in NTZ patients. At year 1, 90% of patients had 
stable or improved EDSS that was maintained in 84% of patients 
at year 2. Mean number of T1 Gd+ lesions decreased significantly 
in the overall population: 69% (year 1) and 80% (year 2) (p< 
0.0001). At year 1 and year 2, 72% and 58% of patients did not 
show new/increased T2 lesions respectively, and 78% and 69% 
were relapse-free.
Conclusions: Fingolimod is an effective treatment for RRMS 
in the clinical practice. At year 3, there was a decrease in the 
mean ARR of treatment-naïve and iDMT patients, and stabili-
zation in NTZ patients. After fingolimod treatment initiation, 
RRMS patients significantly improved clinical disease activity 
and most of the patients had a stable EDSS after one year of 
treatment.
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V. Meca-Lallana: has received honoraria and travel expenses for 
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past years with: Almirall, Biogen Idec, Genzyme, Merck Serono, 
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S. Martinez Yélamos: received honoraria compensation to partici-
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travel and congress expenses from Biogen Idec, Novartis, TEVA, 
MerckSerono, Genyme and Almirall
J. Mallada: recived honoraria from Merck, Bayer, Teva, Sanofi, 
Novartis, Biogen andRoche
J. Meca-Lallana: Nothing to disclose
M. Martínez: Nothing to disclose
E. Marzo: has received compensation for travel expenses and 
speaking honoraria from Biogen Idec, Novartis and Genzyme.
C. Duran: I’ve received honoraria from Abbvie, Biogen, Novartis, 
Merck y Sanofi Genzyne
T. Ayuso: has received compensation for travel expenses, speak-
ing honoraria and consultation fees from Almirall, Biogen, 
Genzyme, Merck Serono, Novartis and Teva
F. Barrero: has received consulting/speaker fees from and advi-
sory board for Bayer HealthCare, Biogen, Genzyme, Merck 
Serono, Novartis, Roche, Sanofi-Aventis, and Teva, and been 
involved with clinical trials for Novartis.
R. Romero: Novartis employee
R. Guillen: Novartis employee
J.Ricart: Novartis employee
E. Garcia: Novartis employee
EP1630
Delayed-release dimethyl fumarate demonstrated no differ-
ence in clinical outcomes versus fingolimod in patients with 
relapsing-remitting multiple sclerosis: results from the real-
world EFFECT study
J. Sloane1, J.T. Phillips2, J. Calkwood3, A. Van der Walt4, J. 
Min5, M. Okwuokenye5, C. Taylor5
1Beth Israel Deaconess Medical Center, Boston, MA, 2Multiple 
Sclerosis Program, Baylor Institute for Immunology Research, 
Dallas, TX, 3Schapiro Center for Multiple Sclerosis, Minneapolis 
Clinic of Neurology, Golden Valley, MN, United States, 4Royal 
Melbourne Hospital, Parkville, VIC, Australia, 5Biogen, 
Cambridge, MA, United States
Background: In real-world comparative effectiveness studies of 
relapsing-remitting multiple sclerosis (RRMS) patients, including 
claims data and registries, treatment with delayed-release dime-
thyl fumarate (DMF) compared with fingolimod (FTY) for up to 
2 years was associated with no statistically significant differences 
in relapse outcomes.
Objectives: To report the real-world effectiveness of DMF com-
pared with FTY in RRMS patients (pts) at 12 months.
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Methods: EFFECT (NCT02776072) was an observational, multi-
centre, international, retrospective, single time point, medical 
record review study undertaken to evaluate the effectiveness of 
DMF and other disease-modifying therapies (DMTs). Pt eligibil-
ity criteria included: age ≥18 years, diagnosis of RRMS, treatment 
naïve or 1 prior DMT (interferon or glatiramer acetate [GA]), ini-
tiation of DMT treatment after December 2010, and ≥12 months 
of medical record data following DMT initiation. Endpoints 
included Kaplan-Meier estimated proportion of pts relapsed at 12 
months and annualized relapse rate (ARR). Substantive baseline 
covariates were used in estimating propensity score. The data 
were divided into
4 strata using quartiles of propensity score. After assessing for 
balance in baseline covariates between treatment groups, Kaplan-
Meier estimates and estimate of treatment effects were pooled 
across strata of propensity score.
Results: Of the 826 DMF and 785 FTY pts enrolled at sites in 17 
countries, 816 and 781 pts, respectively, were included in the full 
analysis set. Treatment groups were balanced after propensity 
score stratification. At 12 months, 86% of DMF-treated patients 
and 94% of FTY-treated patients remained on therapy. In the 
trimmed full analysis set, the estimated proportion of DMF pts 
that relapsed at 12 months was 12% compared with 13% for FTY 
pts; hazard ratio (95%, CI) 1.07 (0.78, 1.46; p=0.6926). At 12 
months after treatment initiation, the adjusted ARR ratio (95% CI) 
was 1.09 (0.80, 1.49; p=0.5754) for pts treated with DMF com-
pared to FTY.
Conclusions: Over 12 months, treatment with DMF versus FTY 
was associated with no statistically significant difference on 
relapse outcomes.
Supported by: Biogen
Disclosure
Sloane J: Consulting fees: Biogen, Genentech, Genzyme, Teva
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Roche, and Teva. Research grants: Biogen, Celegene, Genzyme, 
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EP1631
Delayed-release dimethyl fumarate significantly reduced 
relapse based outcomes vs. interferon, glatiramer acetate, 
or teriflunomide: pairwise propensity-matched comparative 
effectiveness analyses of the German NeuroTransData regis-
try
S. Braune1, S. Grimm2, P. van Hövell2, U. Freudensprung3, R. 
Hyde3, A. Bergmann4, NeuroTransData Study Group
1NeuroTransData Study Group, Prien, Germany, 2PwC Digital 
Services, Zürich, 3Biogen International GmbH, Zug, Switzerland, 
4NeuroTransData Study Group, Neuburg a.D., Germany
Background: There are currently no head-to-head, randomized 
controlled trials comparing efficacy outcomes between delayed-
release dimethyl fumarate (DMF) vs interferon (IFN), or teriflu-
nomide (TERI) in patients with relapsing-remitting multiple 
sclerosis (RRMS) whilst evidence for comparison vs GA is lim-
ited to the CONFIRM study (Fox et al. N Engl J Med. 2012).
Objective: To assess the comparative effectiveness of delayed-
DMF vs IFN, GA, or TERI in a pair-wise propensity-score-
matched (PSM) cohort of patients with RRMS as measured by the 
primary outcome of time to first relapse (TTFR) and the second-
ary outcomes of annualized relapse rate (ARR), time to treatment 
discontinuation (TTD), and time to 3- and 6-months expanded 
disability status score (EDSS) confirmed disability progression 
(TTCDP3, TTCDP6).
Methods: Data were sourced from the NeuroTransData (NTD) 
MS registry, a German network of >130 practice-based neurolo-
gists and including ~25,000 MS out-patients. As of 01 October 
2016, patients with RRMS aged ≥18 years at therapy initiation 
with ≥1 relapse or EDSS assessment on-therapy were included; 
1:1 PSM was used to match DMF to comparator cohorts. TTFR, 
TTD and TTCDP3/6 were analyzed using a Kaplan-Meier 
approach and Cox-marginal-regression-model. ARR was ana-
lyzed using a GEE Poisson-regression-model. The clustered 
nature of the matched design was taken into account. Non-
pairwise censoring was applied with a pre-defined sensitivity 
analysis using pairwise censoring.
Results: DMF patients were matched 1:1 to IFN (n=439), GA 
(n=535), and TERI (n=388) patients; more than 75%, 61%, and 36% 
were treatment-naïve, respectively. Time-to-first relapse was signifi-
cantly reduced for DMF vs IFN (hazard ratio [HR] 0.59; 95% confi-
dence interval [CI] 0.44, 0.79; p=0.0004), GA (HR 0.65; 95% CI 0.50, 
0.84; p=0.0011) and TERI (HR 0.53; 95% CI 0.38, 0.75; p=0.0003). 
ARR was significantly reduced for DMF vs IFN (Rate ratio (RR) 
0.71; 95% CI 0.53, 0.94; p=0.017), GA (RR 0.76; 95% CI 0.59, 0.98; 
p=0.035) and TERI (RR 0.55; 95% CI 0.39, 0.77; p=0.001). A sensi-
tivity analysis using pairwise censoring was conducted demonstrating 
consistent results with the primary analyses. No differences in time to 
TTCDP3/6 and TTD were evident for any comparison.
Conclusions: Time-to-first relapse and ARR were significantly 
reduced in patients treated with DMF vs IFN, GA, and TERI in 
pairwise propensity-score matched populations from the NTD 
network.
Disclosure
Braune S, Bergmann A and most of the members of NTD study 
group receive royalties from many pharmaceutical companies for 
participation in clinical trials, lecturing, consultancy. For this 
NeuroTransData own project there is no conflict of interest.
van Hövell P, Grimm S are fulltime employees of PwC and have 
no conflict of interest.
Hyde R and Freudensprung U are fulltime employees and stock-
holders in Biogen.
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Comparison of natalizumab vs fingolimod and dimethyl 
fumarate in the treatment of multiple sclerosis: two year 
experience
B.L. Vollmer1, K.V. Nair2, S. Sillau1, J. Corboy1, T. Vollmer1, E. 
Alvarez1
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Objective: Compare two year discontinuation rates and efficacy 
of fingolimod (FTY) and dimethyl fumarate (DMF) to natali-
zumab (NTZ).
Background: FTY and DMF are the most common MS oral ther-
apies becoming available in 2010 and 2013, respectively. Limited 
comparative effectiveness data exists.
Methods: Patients prescribed FTY, DMF or NTZ at the Rocky 
Mountain MS Center at University of Colorado between January, 
2010 and October, 2013 were identified. Clinician-reported data 
including demographics, disease history, relapses, MRI outcomes, 
and adverse events(AEs), were retrospectively collected. Primary 
outcome was the probability of discontinuing drug within two 
years, which is presented here. Data was analyzed with logistic 
regression controlling for age, disease duration, type of MS, gen-
der, and presence of enhancing lesions on baseline MRI to esti-
mate differences in the primary outcome.
Results: 271, 342 and 451 patients were evaluated on FTY, DMF 
and NTZ over two years. Patients had a mean age of 42.5 (FTY), 
45.8 (DMF) and 39.8 (NTZ) years; were predominantly female 
(72.0% FTY; 69.6% DMF; 76.7% NTZ); and had a mean MS dis-
ease duration of 11-12 years for all groups. At ≤24 months, 93 
(34.3%), 161 (47.1%) and 147 (32.6%) discontinued FTY, DMF 
and NTZ, respectively. FTY versus NTZ had an adjusted OR of 
1.18 (95%CI: 0.85 - 1.65,p= 0.315) for discontinuation at ≤24 
months. DMF versus NTZ had adjusted OR of 2.06 (95%CI: 1.50 
- 2.83, p < 0.001). Primary reason for discontinuation: NTZ - 
+JCV antibodies (12.6%), FTY and DMF - adverse events (17.0% 
and 24.0%). The most common adverse events leading to discon-
tinuation were gastro-intestinal related issues for FTY and DMF, 
and a rash at time of infusion for NTZ. Respectively for FTY, 
DMF and NTZ - 24 (8.9%),
44 (12.9%) and 27 (6.0%) had a clinical relapse, 28 (13.1%), 26 
(10.0%) and 17 (5.8%) had gadolinium-enhancing lesions and 75 
(35.1%), 82 (31.5%) and 74 (25.3%) had new T2 lesions.
Conclusions: There were fewer discontinuations with DMF vs. 
NTZ. Discontinuation rates in the first two years were driven by 
AEs and being positive for JC virus antibodies. Further analyses 
will investigate NTZ superiority in efficacy outcomes using pro-
pensity matching and ATT doubly robust weighting methods.
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Teriflunomide inhibits activation and proliferation of 
B-cells in patients with relapsing remitting multiple sclerosis 
(RRMS)
M. Thamilarasan1, X. Zhang1, S. Markovic-Plese2
1University of North Carolina at Chapel Hill, 2University of 
North Carolina at Chapel Hill, Neurology, Microbiology and 
Immunology, UNC, Chapel Hill, NC, United States
Objective: To investigate the effect of teriflunomide, an approved 
therapy for RRMS, on the activation and proliferation of B-cells.
Background: Teriflunomide is a high affinity inhibitor of dihy-
droorotate dehydrogenase (DHODH), a key enzyme in pyrimi-
dine synthesis. De-novo pyrimidine synthesis is required by 
rapidly proliferating cells, such as activated lymphocytes to pro-
gress through the cell cycle.
Methods: Peripheral blood mononuclear cells (PBMC) were iso-
lated from 20 untreated RRMS patients. Teriflunomide effects on 
B-cells were studied using in-vitro assays. PBMC were stimulated 
with anti-IgG/IgM and rCD40L in the absence or presence of 100 
µM teriflunomide and exogenous uridine. Proliferation and sur-
face markers expressions of CD19+ B-cells were measured using 
flow cytometry and teriflunomide effect on the signalling path-
ways in B-cells were analysed using western blotting.
Results: In proliferation assay, anti-IgG/IgM and rCD40L treat-
ment for 4 days induced a significant proliferation of CD19+ 
B-cells (p< 0.001, fold change: 1.83), which was inhibited by 
teriflunomide treatment (p< 0.001, fold change: 0.87). The addi-
tion of exogenous uridine reversed inhibition of CD19+ B-cell 
proliferation. Stimulation of CD19+ B-cells increased the expres-
sion of CD25, OX40, CD80, CD5, CD24, and CD20. 
Teriflunomide treatment down-regulated the expressions of acti-
vation markers CD25 (p< 0.05) and IgD (p< 0.05), B-cell 
chemokine receptor CCR2 (p< 0.01), costimulatory molecule 
CD80 (p< 0.001), and CD5 (p< 0.05), which are all reversed in 
the presence of exogenous uridine. Teriflunomide treatment of 
activated B-cells inhibited the phosphorylation of p65 (p< 0.001), 
IKKα (p< 0.001), pERK 1/2 (p< 0.001), pSTAT1 (p< 0.001) and 
pSTAT3 (p< 0.001) .
Conclusion: Teriflunomide inhibits activation and proliferation 
of B-cells derived from RRMS patients. Inhibition of pSTAT1, 
pSTAT3, and NF-kappa B signalling, and CD5 and CD80 costim-
ulatory molecule expression may inhibit B-cell cytokine secretion 
and antigen presenting capacity, while inhibition of CCR2 may 
decrease B-cell migration to the CNS.
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Laquinimod protects optic nerve and retina in an experimen-
tal autoimmune encephalomyelitis model
S.C. Joachim, A.T. Wilmes, S. Kuehn, X. Pedreiturria, S. 
Reinehr, I. Ayzenberg, G. Stute, R. Gold, H.B. Dick, I. Kleiter
Ruhr University Bochum, Bochum, Germany
Background: The oral immunomodulatory agent laquinimod is 
currently evaluated for multiple sclerosis (MS) treatment. The 
phase III ALLEGRO study demonstrated a reduction of lesion 
development, brain atrophy, relapse rate and progression of disa-
bility with(under?) laquinimod therapy. In addition to anti-inflam-
matory effects, laquinimod might have neuroprotective properties. 
However, its impact on the visual system, which is often affected 
by MS, is unknown.
Objective: To investigate a potential protective effect of laquini-
mod on optic nerve and retina in an experimental autoimmune 
encephalomyelitis (EAE) model.
Methods: We immunized wild-type C57/BL6 mice with MOG35-55 
to induce EAE. Five groups were investigated: an untreated EAE 
group, three EAE groups receiving laquinimod in doses of 1, 5, or 
25 mg/kg daily, starting the day post-immunization, and a healthy 
control group without EAE. Neurological impairment was evalu-
ated via scoring. 30 days post-immunization, scotopic electroreti-
nograms were carried out and mice were sacrificed for 
histopathology, immunohistochemistry, and qRT-PCR. In the 
optic nerve, the extent of cellular infiltration (HE) and demyelina-
tion (LFB, MBP) was monitored. Microglia (Iba1) with mac-
rophage function (F4/80) and macroglia (astrocytes, GFAP), 
including retinal Müller glia (vimentin), were examined in retina 
and optic nerve. Moreover, we investigated retinal ganglion cells 
(Brn-3a) and their rates of apoptosis (cleaved caspase-3).
Results: Laquinimod significantly reduced clinical EAE symp-
toms in a dose-dependent manner. In electroretinogram measure-
ments, a protection of neurons in the inner nuclear layer could be 
noted. Laquinimod decreased signs of cellular infiltration (25 mg: 
p=0.002) and demyelination (25 mg: p< 0.001) in the optic nerve. 
Numbers of microglia, also with macrophage function, in optic 
nerves and retinas, were reduced. Retinal macroglial signal was 
diminished under treatment, whereas in the optic nerve more 
GFAP signal was found. Furthermore, laquinimod protected reti-
nal ganglion cells (25 mg: p< 0.001) and lowered their apoptosis 
rate (25 mg: p< 0.029).
Conclusion: From our study, we deduce neuroprotective and anti-
inflammatory effects of laquinimod on optic nerve and retina in 
EAE mice. Given the fact that the visual system is frequently 
affected by MS, the agent might be an interesting subject of fur-
ther neuro-ophthalmic investigations.
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Acceptability of first-line disease-modifying drugs in relaps-
ing-remittingmultiple sclerosis: a real-life multicenter study
D. Ferraro1, V. Camera1, E. Baldi2, V. Vacchiano3, E. Curti4, 
A. Guareschi5, S. Malagù6, S. Montepietra7, S. Strumia8, M. 
Santangelo9, L. Caniatti2, A. Lugaresi3, F. Granella4, I. Pesci5, 
L. Motti7, W. Neri8, P. Immovilli10, E. Montanari11, F. Vitetta12, 
A.M. Simone1, P. Sola12
1Department of Biomedical, Metabolic and Neurosciences, 
University of Modena and Reggio Emilia, Modena, 2Azienda 
Ospedaliera-Universitaria S. Anna, Ferrara, 3University 
of Bologna, Bologna, 4University of Parma, 5Vaio-Fidenza 
Hospital, Parma, 6Bufalini Hospital, Cesena, 7Arcispedale Santa 
Maria Nuova-IRCCS, Reggio Emilia, 8Ospedale G.B. Morgagni 
- L. Pierantoni, Forlì, 9Ramazzini Hospital, Carpi, 10G. da 
Saliceto Hospital, Piacenza, 11Polo Neurologico Interaziendale, 
Parma, 12Department of Neurosciences, Azienda Ospedaliero-
Universitaria, Modena, Italy
Multiple sclerosis (MS) first-line disease-modifying drug (DMD) 
treatment options now include oral drugs in addition to injectable 
therapies. Purpose of this multicenter real-life prospective study 
was to assess the proportion of patients discontinuing a newly ini-
tiated first-line treatment, for any reason, during a one-year fol-
low-up period.
Nine MS centres in Emilia-Romagna, Italy, enrolled consecutive 
MS patients starting any first-line DMD during 2015, and recorded 
data on treatment discontinuation throughout a one-year period.
Five-hundred patients were enrolled in the study (353F, 147M; 
mean age: 43 years; mean baseline EDSS: 1.8 +/- 1.3), and fol-
lowed up for at least one year or until the DMD was discontinued 
(mean: 13 +/-5 months). An injectable drug (beta-interferon 1a/b, 
glatiramer acetate) was started in 246 patients (49%) and an oral 
one (dimethylfumarate, teriflunomide) in 254 (51%); 155 (31%) 
were treatment-naïve. A total of 113 (23%) patients discontinued 
the drug, mostly due to adverse events/tolerability issues (54% of 
cases) or ongoing disease activity (33%). There was no difference 
in a) the proportion of patients on oral or injectable DMD discon-
tinuing treatment (22% and 24%, respectively), b) the reason for 
treatment discontinuation, and c) in the time to treatment discon-
tinuation between the two groups. Patients starting oral drugs had 
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higher basal EDSS values (2.1 versus 1.5, p< 0.001), as had treat-
ment-naïve patients (1.9 versus 1.6; p=0.02). Treatment-naïve 
patients started injectable therapies, as opposed to oral drugs, more 
frequently (117/155 versus 129/345; p< 0.001), and were more 
likely to discontinue treatment (45/155 versus 68/345, p=0.02).
There was no difference in the acceptability of injectable versus 
oral first-line DMD in MS patients, as measured by the proportion 
of patients discontinuing the drug for any reason during the first 
year of treatment.
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Characterizing temporal pattern of alemtuzumab infusion-
associated reactions: experience in clinical practice in a mul-
ticentre study of the Northwest of Spain
A.M. Lopez Real1, J. Peña Martinez2, V. González Quintanilla3, 
D.M. Solar Sánchez4, I. González Suárez5, A. Pato Pato6, M.D.C. 
Amigo Jorrin7, M. Aguado Valcárcel5, E. Álvarez Rodríguez5, 
M. Arias Gomez8, J.R. Lorenzo González6, L. Álvarez 
Fernández9, C. Lema Devesa1, P. Cacabelos Pérez8, A. Oterino 
Durán3
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2Hospital Universitario San Agustin, Avilés, 3Hospital 
Universitario Marqués de Valdecilla, Santander, 4Hospital 
Universitario de Cabueñes, Gijón, 5Complejo Hospitalario 
Universitario de Vigo, 6Hospital Povisa, Vigo, 7Complejo 
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Background: In pivotal studies, Alemtuzumab infusion-associ-
ated reactions (IARs) occurred in a majority (>90%) of patients 
despite using of prophylactic treatment; 3% were serious.
Objectives: To describe the most relevant IARs and its temporal 
pattern in routine clinical practice in 11 centres of the Northwest 
of Spain.
Methods: Eighty three patients: 55 (66%) females and 28 (34%) 
males, who received first dose Alemtuzumab were included. 
Mean age was 39.4±8.27 years. The median duration of follow up 
was 11.0±5.88 months; 30 patients received the second course.
Alemtuzumab infusion was given over approximately 5 hours. 
Patients received daily previous standarized pre-medication regi-
men: antihistamines, proton-pump inhibitors, diphenhydramine, 
acetaminophen and methylprednisolone (MP). 1g MP was admin-
istered on infusion day 1-3 of each course and 500 mg on day 4-5. 
IARs was observed and managed with symptomatic treatments as 
needed during and post-infusion. All IARs and its severity were 
collected.
Results: IARs occurred in 67 (81%) patients and all were mild to 
moderate in severity.
The 1st infusion day pyrexia and headache were the most frequent 
IARs. On infusion days 3rd to 5th, the most prominent IARs were 
rash and urticaria, being observed until 72 hours after the last infu-
sion day. Similar temporal pattern of IARs was observed in the 
first and the second courses. IARs were less frequent during 
course 2 (mean 2.3±2.33 events/patient) than during course 1 
(mean 3,4±3.45 events/patient).
Conclusions: In our clinical experience, IARs were less frequent 
that in clinical trials and no serious IARs occurred.
It is interesting to observe that IARs have a characteristic tempo-
ral pattern of presentation. Pyrexia and headache were typically 
observed on the first day. Rash and urticaria were more frequent 
on infusion days 3rd to 5th.
It is remarkable that rash and urticaria persisted even for 72 hours 
after the last infusion day; therefore, it is important to inform to 
the patient about this; it will improve patient care.
Disclosure
López Real A.M. has served as speaker for Biogen Idec, Merck 
Serono, Genzyme, Novartis and TEVA;
Peña Martínez J. has served as speaker for Sanofi Genzyme, 
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Effectiveness of fingolimod in Spanish patients with relaps-
ing-remitting multiple sclerosis (RRMS) in daily clinical 
practice: fingoview study multivariate analysis
S. Martínez Yélamos1, J. Mallada2, V. Meca-Lallana3, J. Meca-
Lallana4, M. Martínez5, E. Marzo6, C. Durán7, T. Ayuso8, F. 
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Pedro, Logroño, 7Hospital Infanta Cristina, Madrid, 8Hospital 
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Background: Fingolimod has been used in ~204,000 RRMS 
patients (pts) having a total pt exposure >424,000 pt-years. 
Analysis of clinical practice data is key to make accurate treat-
ment decisions.
Objective: To describe effectiveness variables according to clini-
cal and demographic characteristics in RRMS pts.
Methods: Pooled analysis of 2 observational, retrospective, mul-
ticentre Spanish studies (MS-Second Line Gate and MS-Next) in 
≥18 years RRMS pts treated with fingolimod 0.5mg/day and ≥1 
year follow-up after treatment initiation in clinical practice 
(Nov2014-Dec2015). Regression models were performed to iden-
tify potential predictive variables of the number of relapses and 
Expanded Disability Status Scale (EDSS) score after 1 year of 
fingolimod treatment using clinical and demographic characteris-
tics at treatment initiation.
Results: 988 pts (MS-Next=804,MS-Second Line Gate=184) 
were analyzed: 69% female, mean age=40 years, post first-line 
injectable disease-modifying treatment (iDMT)=666, post-
natalizumab (NTZ)=252, treatment-naïve=70. The independent 
predictors of the number of relapses were prior treatment (50% 
lower in post-iDMT/post-NTZ pts; 65% lower in treatment-
naïve/post-NTZ pts), number of relapses in the previous year 
(32% higher per each additional relapse in the previous year), 
number of prior treatments (35% lower in pts with ≤1/>1) and 
number of T2 lesions (34% lower in pts with 9-20/>20 T2 
lesions)(p< 0.05 all cases). The independent predictors of EDSS 
score were prior treatment (-0.39 points in post-iDMT/post-NTZ 
pts; -0.34 points in treatment-naïve/post-NTZ pts), age (+0.008 
points per each additional year), EDSS score at treatment 
initiation (+0.89 points per each additional EDSS point) and 
time from RRMS diagnosis (+0.02 points per each additional 
year)(p< 0.05 all cases).
Conclusions: The prior treatment, number of relapses in the pre-
vious year, number of previous treatments, number of T2 lesions, 
age, RRMS evolution and EDSS score at treatment initiation 
should be taken into account before fingolimod treatment initia-
tion since they might predict the clinical disease activity during 
the first year of treatment.
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EP1638
Tocopherol-based emulsions as functional vehicles for anti-
gen-specific immunotherapy ameliorate experimental auto-
immune encephalomyelitis in vivo
J.D. Griffin1, M.A. Christopher2, C.J. Berkland1,2,3
1Bioengineering Graduate Program, 2Department of 
Pharmaceutical Chemistry, 3Department of Chemical and 
Petroleum Engineering, University of Kansas, Lawrence, KS, 
United States
Currently approved therapeutics for Multiple Sclerosis compro-
mise the entire immune system, leading to a susceptibility to 
severe side effects such as opportunistic infections. Co-delivery 
applications of antigens with immunomodulatory drugs have 
shown unique potential to overcome global immunosuppression 
through their ability to skew immunity with antigen-specificity. 
Historically, the necessity of a spatially associative vehicle has 
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been viewed as a setback to co-delivery approaches due to fac-
tors such as the immunogenicity of nanoparticles or clinical 
incompatibility of Freund’s adjuvants. Development of a func-
tional vehicle capable of substantially contributing to desired 
tolerogenic outcomes would be of great value in the advance-
ment of co-delivered antigen-specific immunotherapies (ASITs). 
In this work, antioxidant tocopherol-based emulsions were 
selected and evaluated for their functional utility as ASIT vehi-
cles. 4-5 week old SJL/J female mice were induced with experi-
mental autoimmune encephalomyelitis (EAE) and treated with 
either PBS, tocopherol emulsion alone (ETPGS), or tocopherol 
emulsion plus 200 nmol PLP139-151 (ETPGS+PLP, n=3/group) on 
days 4, 7 and 10. Mice treated with ETPGS alone exhibited a 
delayed clinical onset, but fully severe disease while 
ETPGS+PLP-treated mice showed an even further delayed onset 
with significantly suppressed symptoms. On day 25, splenocytes 
were harvested and incubated with and without 25µM PLP 
rechallenge for 120 hours. Following the incubation period, a 
multiplexed cytokine panel, ELISPOT and flow cytometry were 
conducted. Significantly increased Il-10 (p< 0.01) and Il-4 (p< 
0.05) were observed in the ETPGS+PLP group over both the 
PBS vehicle and ETPGS alone, suggesting antigen-specific tol-
erance. These data, when combined with the clinical effective-
ness of ETPGS+PLP show that tocopherol vehicles can serve as 
potent antigen delivery systems. Further investigation of these 
formulations may elucidate their utility as functional co-delivery 
vessels for autoimmune applications.
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Acute tumefactive demyelination in a patient on rituximab; a 
case report
B. Chaudhry1,2, M.A. Willis1, J.A. Cohen1
1Cleveland Clinic Neurological Institute, Cleveland, OH, 
2Tulane University Medical Center, New Orleans, LA, United 
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Introduction: Recent clinical trials demonstrating the efficacy 
ofCD20-depleting agents like rituximab, ocrelizumab, and ofatu-
mumab have highlighted the importance of B cells in MS patho-
genesis. Although rituximab has extensive use in other 
autoimmune disorders, relatively limited data exist regarding 
rituximab real world MS use. We report a case of tumefactive 
inflammatory demyelination in a relapsing remitting multiple 
sclerosis (RRMS) patient during rituximab therapy.
Case report: A 55 year old man with RRMS, diagnosed in 2013, 
was started on rituximab 1000mg IV every 6 months after having 
continued activity despite treatment with IV methylprednisolone, 
glatiramer acetate, natalizumab, and cyclophosphamide. He 
remained stable clinically and radiographically for 2.5 years. Six 
weeks after his fifth cycle, he developed urinary urgency, left 
hemiplegia and ataxia. Brain MRI demonstrated a large right pari-
etal lobe lesion with incomplete ring enhancement, surrounding 
edema, and mild mass effect. His cervical and thoracic spine MRI 
showed several enhancing lesions. Due to the concern for progres-
sive multifocal leukoencephalopathy, as he was JCV antibody 
positive, and lymphoma, he was hospitalized. CSF demonstrated 
signs of active inflammation but was negative for infectious 
causes including JCV PCR. Flow cytometry revealed no repopu-
lation of B cells. After failing to improve with 5 days of IV meth-
ylprednisolone, 5 plasma Exchange resulted in improvement in 
his clinical symptoms and improvement of his lesion on neuroim-
aging. Subsequent therapy currently is under consideration - 
alemtuzumab, adding an immunosuppressant agent to rituximab, 
or autologous hematopoietic stem cell transplantation.
Discussion: Extensive literature review did not yield any previous 
reports of tumefactive lesion in a rituximab treated patient. Rather, 
rituximab is sometimes listed as a potential treatment for this con-
dition. This report calls for need for heighten surveillance of MS 
patient with highly active MS on B cell modulation and raises 
questions on the best approach going forward.
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Effectiveness and safety of fingolimod in Spanish relapsing-
remitting multiple sclerosis patients in clinical practice (Fin-
goview study): subanalysis of patients previously treated with 
first line injectable disease-modifying treatment
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Durán5, T. Ayuso6, F. Barrero7, V. Meca-Lallana8, S. Martínez-
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Background: Fingolimod is a sphingosine 1-phosphate receptor 
modulator approved for relapsing-remitting multiple sclerosis 
(RRMS). Continuous collection and analysis of real world data is 
key to make accurate treatment decisions.
Objective: Fingoview study aimed to describe the effectiveness 
of fingolimod in Spanish RRMS patients in clinical practice. Here 
we present the results of the subpopulation previously treated with 
first line injectable disease-modifying treatment (iDMT).
Methods: Fingoview is a pooled analysis of two observa-
tional, retrospective and multicentric studies (MS-SECOND 
LINE GATE + MS-NEXT) including patients ≥18 years, 
treated with fingolimod and followed up for ≥12 months 
(Nov2014-Dec2015).
Results: Fingoview study included 988 patients (MS-Next: 804, 
MS-2nd-Line GATE: 184). 666 patients were post-iDMT (1 
iDMT=382, >1 iDMT=284): 71% female, mean age=40 years, 
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and mean time from first diagnosis to fingolimod treatment initia-
tion=8 years. The mean annual relapse rate (ARR) of the whole 
post-iDMT subpopulation decreased by 82%, 88% and 91% at 
year 1, 2 and 3 after treatment initiation respectively (p< 0.0001 
all), with decrease in both 1 iDMT and >1 iDMT subgroups (p< 
0.0001 all). The ARR decrease was higher in 1 iDMT than >1 
iDMT cohorts (85% vs 78%, 90% vs 84% and 93% vs 87%, years 
1, 2 and 3 respectively) with statistically significant difference at 
year 1 (p< 0.05). At year 1, 90% (1 iDMT=91%, >1 iDMT=90%) 
of patients had stable or improved EDSS that was maintained in 
85% (1 iDMT=84%, >1 iDMT=87%) of patients at year 2. There 
was no significant difference between cohorts. At year 1 and 2, 
73% (1 iDMT=69%, >1 iDMT=78%; p=0.0696) and 55% (1 
iDMT=50%, >1 iDMT=63%; p=0.2370) of iDMT patients did not 
show new/increased T2 lesions respectively, and the mean num-
ber of T1 Gd+ lesions decreased by 72% (1 iDMT=74%, >1 
iDMT=70%) and 80% (1 iDMT=76%, >1 iDMT=89%) respec-
tively (p< 0.0001). At year 1, 83% of 1 iDMT patients and 76% of 
>1 iDMT were relapse-free (p< 0.05). This difference was main-
tained at year 2 (75% and 67% respectively).
Conclusions: Fingolimod is an effective treatment for RRMS 
patients previously treated with iDMT in clinical practice. For the 
first 3 years, there was a decrease in the ARR in both 1 iDMT and 
>1 iDMT cohorts, with a higher reduce in 1 iDMT cohort at year 
1. After fingolimod treatment initiation, most than 80% of post-
iDMT patients improved or had stable EDSS without differences 
between 1 iDMT and >1 iDMT cohorts.
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Unexpected systemic reactions following glatiramer acetate 
40 mg injections. Experience at 2 multiple sclerosis cCenters
C. Zecca1,2, G. Bellavia2, L. Brambilla2, L. Pareja Gutierrez2, C. 
Gerardi3, A.M. Fiori2, L. Bernardini2, G. Camera2, G. Disanto4, 
J. Perugini2, C. Antozzi2, P. Confalonieri2, V. Torri Clerici2, C. 
Gobbi4, R. Mantegazza2, S. Rossi2
1Neurology, Neurocenter of Southern Switzerland, Ospedale 
Regionale di Lugano, Lugano, Switzerland, 2Neuroimmunology 
and Neuromuscular Diseases Unit, IRCCS Fondazione 
Istituto Neurologico Carlo Besta, 3IRCCS- Istituto di Ricerche 
Farmacologiche ‘Mario Negri’, Milan, Italy, 4Neurocenter of 
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Background: Glatiramer acetate 40 mg 3 times a weeks (GA40) 
has been approved as an alternative treatment schedule to glati-
ramer acetate 20 mg daily (GA20). Albeit similar on a weekly 
basis, a GA40 dose and concentration are twice as high as a GA20 
one, and systemic reactions (SR) following each injection might 
differ.
Aim: To investigate unexpected SR (USR) following GA40.
Methods: Prospective, observational study performed at 2 ter-
tiary Multiple Sclerosis (MS) Centers between February and May 
2017. Consecutive MS patients treated with GA40 for at least 3 
months were administered a semi-structured, face to face ques-
tionnaire on frequency and characteristics of USR, defined as SR 
other than chest pain, palpitations, dyspnoea and constriction of 
the throat following injections. Treating neurologists evaluated 
USR as mild, moderate or severe. Descriptive statistics were used 
to describe patients’ characteristics and logistic regression was 
used to evaluate predictors of USR under GA40.
Results: 162 patients were included [n=119 (73.4%) females; 
median (interquartile range, IQR) age 41.5 (35.4-49.3) years; 
median disease duration 3.4 (1.4-8.9) years; median treatment 
duration 9(5-12) months; patients previously on GA20 n=96 
(59.6%)].Thirty-seven patients on GA40 (22.8%) had ≥1 USR: of 
these, 22 (13.5%) had ≥1 gastrointestinal symptoms (diarrhea, 
abdominal cramps, nausea/vomiting), 26 (16.0%) fever and/or 
shivering, and 11 (6.8%) both. A single patient reported abdomi-
nal cramps also during previous GA20 exposure. USR were 
severe in 7(4.3%) patients, and 12(7.4%) patients discontinued 
GA40 because of SR. Age, gender and previous exposure to GA20 
were not related to different risk of USR under GA40.
Conclusion: Gastrointestinal symptoms and fever are unexpected 
SR following GA40 injections and were reported by approxi-
mately one quarter of patients. Preliminary data do not support a 
protective role of previous treatment with GA20.
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Neurology, Regional Hospital Lugano, Switzerland, receives 
financial support from TEVA, Merck Serono, Roche, Biogen 
Idec, Genzyme, and Novartis. None of these agreement was 
related to the present work.
Rossi S acted as an Advisory Board member of Biogen Idec, 
Bayer Schering, Merck Serono, Teva, Novartis and Genzyme, and 
received funding for traveling and honoraria for consultancy, 
speaking or writing from Biogen Idec, Merck Serono, Teva, 
06_MSJ731285.indd   862 13/10/2017   11:11:02 AM
ePosters 23(S3) 863
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Novartis, Bayer Schering, Genzyme, Almirall. She received sup-
port for research project by Teva, Merck Serono and Bayer 
Schering and is involved as principal investigator in clinical trials 
for Teva, Novartis and Roche.
Mantegazza R acted as an Advisory Board member of Biomarin, 
received Funding for Travel or Speaker Honoraria from Sanofi-
Aventis, Biomarin, Grifols, Teva, Bayer, Alexion, Argenx; he is 
is involved as principal investigator in clinical trials for Alexion, 
Merck Serono, Hoffman-La Roche, Teva, Besta-Azienda 
Ospedaliera San Gerardo, Biogen, Biomarin, Almirall, Novartis, 
Genzyme Corporation, Catalyst.
Brambilla L received honoraria for speaking from Novartis.
Antozzi C received funding for travel and congress attendance 
from Biogen, Merck Serono and Teva
Pareja-Gutierrez L, Camera G, Bellavia G, Bernardini L, Perugini 
J, Gerardi C have nothing to disclosure
Confalonieri P acted as Board member for Biogen-idec and 
Roche, received support for conference travel from Sanofi-
Aventis, Biogen Dompé AG, Merk Serono anf Novarrtis; received 
support for scientific projects from Merk Serono and Novarstis
Torri Clerici V acted as an Advisory Board member of Merck and 
Genzyme, and received funding for traveling and honoraria for 
speaking or writing from Biogen, Merck and Almirall. She 
received support for research project by Almirall.
EP1642
Real life efficacy and safety of fingolimod: a french southwest 
and center cohort
A. Roux1, N. Simeoni2, J. Thomas3, D. Brassat4, A.-M. 
Guennoc2, B. Brochet5, P. Clavelou1
1Neurology, CHU Clermont Ferrand, Clermont Ferrand, 
2Neurology, CHU Tours, Tours, 3CHU Bordeaux, Bordeaux, 
4CHU Toulouse, Toulouse, 5Neurology, CHU Bordeaux, 
Bordeaux, France
Background: Fingolimod is a disease modifying drug used as a 
second line treatment in very active relapsing remitting multiple 
sclerosis (MS). It has been used in France since 2011 and we now 
can provide data about its efficacy and safety in real life.
Objectives: This study describes the real life data of efficacy and 
safety in patients treated with oral Fingolimod from 2011 to 2017 in 
the cities of Bordeaux, Tours, Toulouse and the Auvergne region.
Methods: We retrospectively collected data from the EDMUS 
database and from patient’s medical files in the universities hospi-
tals of Bordeaux, Toulouse, Tours and Clermont-Ferrand, general 
hospitals and neurologists in Auvergne.
We focused on the population characteristics, efficacy (Annualized 
Relapse Rate (ARR), MRI and the Expanded Disability Status 
Scale (EDSS) evolution) and safety of Fingolimod.
Results: Baseline characteristics of the 432 patients : mean age 
39.9 ± 10 years; sex ratio women/men 3.8; duration of MS when 
Fingolimod is introduced 10.28 ±7.8 years, numbers of relapses 
during the past two years 1.5 ±1.3; ARR during the past two years 
0.76; mean EDSS 2.68 (0-8.5); 29% MRI contrast enhancing.
6.25% received Fingolimod as a first line treatment, 36,8% after a 
natalizumab cure. ARR was decreased by 67,1% after a two years 
following. Mean EDSS was slightly increased after 1 year of 
treatment (2,7) and stable after 2 years (2,6). 78,7% patients were 
free from MRI progression the first year.
27% of patients interrupted the treatment, mainly because of a 
lack of efficacy or severe adverse events.
Severe infections were the reason for the interruption for 10 
patients.
The others adverse events for which Fingolimod was stopped are: 
4 atrioventricular block during the first introduction ,16 severe 
lymphopenia, 7 hepatitis , 4 macular oedema, 3 severe asthenia, 3 
cancers ( 1 tongue epidermoid carcinoma, one basocelular carci-
noma, one uterine cancer ), 2 headaches, 3 vomitings/diarrhea, 1 
interstitial pneumoniae, 1 autoimmune hemolytic anemia. We did 
not report any case of progressive multifocal leukoencephalopa-
thy in our cohort.
Conclusions: Fingolimod shows efficacy on the ARR with an 
important reduction during the first two years. In our cohort, most 
of the patients were also free from disability progression during 
these two years.
Fingolimod is overall well tolerated, even if it was stopped 
because of severe adverse events in 12,5% of patients.
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The efficacy and safety of the biosimilar interferon beta-1a 
Teberif® in patients with relapsing-remitting multiple scle-
rosis: data from a comparative international multicenter 
double-blind placebo-controlled randomized phase III study
A. Boyko1, L. Volkova2, M. Zakharova3, F. Khabirov4, 
S. Kotov5, E. Parshina6, O. Patrusheva7, S. Prokopenko8, 
D. Sazonov9, L. Timchenko10, L. Chichanovskaya11, Y. 
Trinitatsky12, M. Sherman13, A. Zinkina-Orikhan14, C. 
Tursunova14
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Background: Biosimilars of interferon beta-1a are being intro-
duced in clinical practice in patients with relapsing-remitting mul-
tiple sclerosis (RRS).
Objectives: To demonstrate the equivalence of the biosimilar 
interferon beta-1a Teberif® and the originator Rebif® in the treat-
ment of RRS.
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Materials and methods: The study involved 163 patients with 
RRS, duration of the disease ≥12 months and EDSS score of 
0-5.5. Randomization: 1:1:1 - Group 1 (Teberif®), Group 2 
(Rebif®) for 52 weeks and Group 3 (placebo) for 16 weeks then 
Teberif® for 1 year. 137 patients completed the study. The primary 
end point was assessment of MRI outcomes - CUA (combined 
unique active lesions).
Results: After 16 weeks of the study, Teberif® and Rebif® showed 
equivalent efficacy and were superior to placebo.
Groups 1 and 2 did not differ by the number of CUA (p=0.898). 
The pair-wise comparison of groups 1 and 2 with placebo showed 
statistically significant differences (p=0.038 and p=0.024 
respectively).
After one year of the treatment, CUA in Groups 1 and 2 (mean ± 
standard deviation) was 0.727±1.042 and 0.652±1.059 (p = 
0.735). The percentage of patients without Gd+ lesions was 
75.00% and 80.43% (Groups 1 and 2, respectively) (p=0.718). 
Similar data (without significant differences between the groups) 
were obtained for all other MRI outcomes. During the year of the 
treatment, most patients did not have relapses (89.1% vs. 91.7%, 
Groups 1 and 2, р=0.737). Baseline EDSS scores at screening 
were 2.5 in both groups, while after one year of therapy - 2.0 
(p=0.546).
Groups did not differ by the frequency, nature, and severity of 
adverse events. No serious adverse events were reported during 
the entire period. The drugs had similar immunogenicity; they 
rarely induced the development of neutralizing antibodies (in 10 
and 9 patients in Groups 1 and 2, p=0.928). The final assessment 
of immunogenicity will be performed after 2 years of treatment.
Patients who received placebo during the first 16 weeks com-
pleted their one-year course of treatment with Teberif®. In this 
Group mean values of CUA before the treatment were 3.286±5.216, 
after one year of the treatment - 1.048±2.083 (p=0.0001). The per-
centage of patients without contrast-enhancing lesions was 
80.95%, without confirmed relapses - 90.74%.
Conclusions: Biosimilar Teberif® showed the equivalence to 
Rebif® by all parameters of efficacy, safety, and immunogenicity 
in patients with RRS.
Disclosure
This study was sponsored by JSC Biocad.
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Real world data on teriflunomide and dimethyl fumarate 
treatment of multiple sclerosis
H. Norborg, P. Strauss, K.-M. Myhr
Department of Clinical Medicine, University of Bergen, Bergen, 
Norway
Background: Multiple Sclerosis (MS) is characterized by inflam-
matory demyelinating lesions in the central nervous system and a 
heterogeneous clinical course. No curative treatment exists, but 
various disease modifying therapies are available. Teriflunomide 
(Aubagio®) and dimethyl fumarate (Tecfidera®) are two oral 
first-line therapies that since 2013/2014 have been approved for 
the treatment of MS in Norway. Oral medications have several 
advantages compared to injection therapies, especially side effects 
related to injections. However, it is still unknown if there are dif-
ferences in efficacy and side effects influencing compliance and 
adherence to therapy between these oral agents. We have therefore 
examined real world data of teriflunomide and dimethyl fumarate 
treatment in a population of Norwegian MS patients.
Methods: We examined the 237 MS patients at Haukeland 
University Hospital, Western Norway, who were treated with 
either dimetylfumarat (N=109) or teriflunomide (N=130) during 
May 1st 2014 to November 1st 2016. We recorded the frequency of 
attacks before, during and after the use of the oral medication, side 
effects, duration of the treatment and the reason for switching 
therapy among several other factors. We performed a Kaplan 
Mayer analyses of time to switching therapy during the first 52 
weeks of therapy.
Results: The mean observation period on teriflunomide therapy 
was 57 weeks (range: 1 - 154), and 71 weeks (range: 1 -142) on 
dimetylfumarat. A total of 74% of the patients receiving dimethyl 
fumarate experienced side effects, while only 44% of the patients 
using teriflunomide did. Flushing and gastrointestinal side effects 
were most frequent in dimethyl fumarate treated patients, and hair 
thinning and gastrointestinal side effects most frequent in teriflu-
nomide treated patient. A total of 29 (22 %) patients that received 
teriflunomide, and 35 (32 %) patients that received dimethyl 
fumarate switched therapy during the observation period. Kaplan 
Mayer analyses of time to switching therapy during the first 52 
weeks showed that patients on dimethyl fumarate had a shorter 
time to switching therapy compared to those that received teriflu-
nomide (p=0.07).
Conclusion: Side effects were more frequent in patients that 
received dimethyl fumarate compared teriflunomide. Although 
not statistically significant different, patients on dimethyl fuma-
rate therapy had a shorter time to switching therapy compared to 
those that received teriflunomide.
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Hilde Norborg reports no disclosures
Philipp Strauss reports no disclosures
K.-M. Myhr has received research support, speaker honoraria or 
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Comparing efficacy between natalizumab and fingolimod: 
radiological findings from BEST-MS study
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S. Wiertlewski5, L. Michel5, B. Brochet6, A. Ruet6, G. Defer7, 
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Objective: To compare efficacy between natalizumab (NTZ) and 
fingolimod (FTY) in active relapsing remitting multiple sclerosis 
(RRMS)
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Methods: BEST-MS was a French multicentric study 
(ClinicalTrials.gov Identifier: NCT01981161) with prospective 
data collection involving patients with active RRMS who started 
either NTZ or FTY. Treatment choice was patient’s and physi-
cian’s discretion. Last patient was recruited by September 2016.
Efficacy was assessed by clinical (EDSS, relapses) and MRI 
parameters (number of new T2 lesions, number of gadolinium 
enhancing lesions) after 12 months of therapy, and compared 
between treatment groups. We present data about MRI findings.
Results: 224 patients were included in 10 MS centers (NTZ : 111; 
FTY : 113). Sex ratio was 3.15, mean age was 30 [12-62]. Mean 
disease duration was 6 years. Baseline EDSS was 2.4 [0-6.5] and 
mean number of relapses during the 12 months preceding initia-
tion of treatment was 1.4 [0-3]. To date, we collected both initial 
and 1-year MRI data for 66 patients.
Comparison between treatment groups showed that NTZ patients 
had a shorter disease duration (3.4 vs 7.4 months; p< 0.05) and a 
higher relapse rate before treatment initiation (1.6 vs 1.1; p< 
0.05). Regarding MRI, there was no significant difference between 
groups at baseline.
After 12 months, mean number of new T2 lesions was 0.45 [0-5], 
without any difference between treatment groups. Mean number 
of gadolinium enhancing lesions was 0.1 [0-3]. There was a sig-
nificant lower number of gadolinium enhancing lesions in patients 
treated with NTZ (0.06 vs 0.18; p< 0.05).
Discussion: Regarding MRI parameters, NTZ seems to be more 
effective than FTY in reducing the number of gadolinium enhanc-
ing lesions.
Further analysis will be performed to compare clinical efficacy 
between treatment groups
Conclusion: We present MRI results of BEST-MS study. Results 
suggest a higher efficacy of NTZ compared to FTY on radiologi-
cal parameters.
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A novel case of autoimmune myositis after alemtuzumab 
therapy for multiple sclerosis
P. Aouad1,2, C. Yiannikas1, S. Fernando1,2, J. Parratt1,2
1Royal North Shore Hospital, St Leonards, 2University of 
Sydney, Sydney, NSW, Australia
Objectives: We describe the case of a 44-year-old female who 
developed a previously unreported, corticosteroid-responsive, 
autoimmune, non-necrotising myositis after receiving alemtu-
zumab for relapsing remitting multiple sclerosis (RRMS).
Case report: A 44-year-old female with a 13-year history of RRMS 
was treated with alemtuzumab without any immediate complica-
tions in November of 2015. Her baseline EDSS at the time of treat-
ment was 2.0, with MRI showing widespread demyelination 
affecting the deep white matter of the brain, optic nerves and spinal 
cord. Seven months later she developed myalgia affecting the arms 
and legs in a proximal distribution. Clinical assessment and MRI 
excluded progression of multiple sclerosis (MS). Blood tests showed 
a grossly elevated creatine-phosphokinase level (CK) of 11015 U/L 
(< 211 U/L). Hepatic transaminase levels were also elevated at 322 
U/L and 129 U/L (< 30 U/L) for AST and ALT respectively.
Electromyography demonstrated myopathic units in keeping with 
a mild generalized non-necrotizing process. A muscle biopsy was 
obtained from the left quadriceps. Occasional lymphocytes were 
seen but there was neither necrosis nor a significant inflammatory 
infiltrate. Rare fibers were positive for C5b9, the terminal compo-
nent of complement.
Corticosteroid therapy was started and weaned to 5mg over a 
3-month period. The patient’s symptoms resolved completely and 
correlated with decreases in serum CK levels.
Discussion and conclusion: Secondary autoimmunity affecting 
the thyroid, platelets and rarely the kidneys is well described fol-
lowing immune reconstitution after alemtuzumab. Each of these 
complications involves antibody-dependent immunity. This case 
of myositis also appears to be autoimmune and involves humoral 
immunity. A cellular infiltrate could not be shown on muscle 
biopsy, but complement activation was present and steroids were 
highly effective. In the absence of histopathological evidence of 
T-cells, macrophages or necrosis, we propose this form of myosi-
tis may be a unique entity and term the condition, pauci-immune 
myositis. This case highlights the importance of reporting novel 
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adverse events with emerging immune therapies for MS. Further 
research is required to understand the mechanisms underlying 
secondary autoimmunity after alemtuzumab treatment.
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Background: The AMS3 study tracked the development of a sys-
tem to improve pathology monitoring and alerting of abnormali-
ties in patients treated with alemtuzumab for MS.
Aims: To report the clinical & MRI outcomes of 10 patients with 
very active relapsing remitting MS treated with alemtuzumab and 
followed for 2 years.
Methods: Ten patients selected by rank order of need from 30 
nominated by neurologists from Australia, with highly active MS 
and failure or unsuitability for other therapies. Clinical and MRI 
measures are reported given the unique severe nature of this 
cohort. The endpoints of the study are reported separately.
Results: At baseline (BL), mean age = 36 (24 - 57), disease dura-
tion = 5.3Y (2 - 10), relapses prior 12 months = 2.3 (1-5), EDSS = 
3.05 (2 - 4). Mean prior MS therapies = 2.9 (1-6 - all had prior 
natalizumab, 9 JC+). The reason for alemtuzumab given was: 
relapse on fingolimod (6) or DMF(2); relapse on natalizumab, JC- 
(1); relapse while pregnant, JC+ (1).
During the study, 3/10 patients had relapses. One patient had 4, 
without change in exam or MRI. Two other patients had 2 relapses 
each, with new features and MRI lesions. The annualised relapse 
rate declined to 0.4 (from 2.9), an 86% ARR reduction. The mean 
EDSS declined from BL=3.05, to Y1=2.25, and Y2=2.22. Seven 
patients had confirmed disability improvement, 2 unchanged, 1 
confirmed disability worsening. That patient had cord relapses with 
pial spinal cord enhancement and cerebral Gd+ lesions unchanged 
over 2 years suggesting a non-MS disease such as sarcoid.
On completion, mean MRI-T2-hyperintense lesion volume 
increased 3.6% BL-Y1, then declined -3.1% Y1 - Y2. Atrophy 
(SIENA): average -0.97% (SD 0.68%) brain atrophy BL-Y1 and 
-0.29% (SD 0.53%) Y1-Y2. Both suggest a contribution of active 
disease and subsequent pseudoatrophy in the first year with brain 
volume changes approximately normal in the second year. The 
mean Gd lesion number at entry was 9.2 (0-26), Y1 1.9 (0-13), Y2 
0.11 (0-1). Conversion of enhancing lesions to T1-black holes: 4 
patients at BL (n lesions = 1,1,2,2), no Y1 Gd lesions converted to 
black holes.
Conclusions: Alemtuzumab is a highly effective treatment for 
MS, even in a highly active cohort with considerably more pre-
treatment than patients in the pivotal trials. Careful review of the 
diagnosis is needed in atypical cases before alemtuzumab treat-
ment. Marked improvement in relapse rates, new Gd lesions, and 
second year brain atrophy occurred.
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EP1648
Observational study of the factors leading to the switch to 
fingolimod after first-line therapy in patients with relapsing-
remitting multiple sclerosis in France: interim analysis 
ESGILE study
A. Tourbah1, C. Mekies2, C. Papeix3, P. Tourniaire4, K. Rerat5, 
M. Meite5, I. Chouette5, ESGILE Study Group
1Maison Blanche Hospital, Department of Neurology, Reims, 
2Polyclinique du Parc, Toulouse, 3Pitié-Salpêtrière Hospital, 
Paris, 4Henri Duffaut Hospital, Avignon, 5Novartis Pharma 
S.A.S, Rueil-Malmaison, France
Background: Fingolimod, a sphingosine 1-phosphate receptor 
modulator, was the first approved oral disease-modifying therapy 
(DMT) in patients with multiple sclerosis (MS). In France, it is indi-
cated in patients with high disease activity despite previous treat-
ment with at least one DMT or patients with rapidly evolving severe 
relapsing remitting MS (RRMS). Retrospective database studies of 
patients with MS disease have demonstrated the superiority of 
switching to more efficacious therapy such as fingolimod compared 
to cycling between first-line DMTs. However, factors supporting 
the switch decision to fingolimod are not yet understood.
Objective: The objective of this study is to describe the factors 
leading to the switch to fingolimod after initial DMT in patients in 
clinical practice and to follow up with clinicians and patients on 
their treatment satisfaction after 1 year.
Methods: ESGILE is an observational, non-interventional, multi-
centric, 12-month, prospective study conducted in France in 
patients with RRMS. Included patients should have started fin-
golimod no longer than 4 weeks before baseline visit in line with 
its approved indication. Visits were scheduled at 6 and 12 months. 
This interim analysis describes the baseline characteristics of the 
patient population and the reasons for switching to fingolimod as 
a second-line treatment. Other outcomes will include clinical and 
patient global impression changes, and quality-of-life question-
naire (ACCEPT).
Results: Between November 2015 and March 2016, 35 centers 
included 87 patients with mean age of 40.3 years, 79.3% females, 
MS diagnosis of 5.8 ±6.2 years, Expanded Disability Status Scale 
(EDSS) average score of 2.1±1.3. The main reason for therapeutic 
change was the disease progression (74.7%), followed by admin-
istration modalities (34.5%), patient choice (14.9%), and tolera-
bility (6.9%).
Conclusion: The change in treatment is mainly motivated by the 
progression of disease activity. This study also revealed a high 
occurrence for therapeutic change from other DMT to fingolimod 
that is linked to the administration modalities.
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EP1649
Efficacy and safety of daclizumab beta in patients with 
relapsing-remitting MS switching from natalizumab: ratio-
nale and study design of the phase 3b SUSTAIN study
G. Giovannoni1, V. Bhan2, D. Centonze3,4, S. Cohan5, T. 
Ziemssen6, J. Easter7, L. Chiodo8, X. Jiang9, S. Fam9, G. 
Giannattasio9
1Barts and The London School of Medicine and Dentistry, 
Queen Mary University of London, London, United Kingdom, 
2Department of Medicine, Division of Neurology, Dalhousie 
University, Halifax, NS, Canada, 3Department of Systems 
Medicine, Tor Vergata University of Rome, Rome, 4IRCCS 
Neuromed, Pozzilli, Italy, 5Providence Multiple Sclerosis Center, 
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Background: Treatment sequencing of disease-modifying thera-
pies (DMTs) is a key consideration in the management of relaps-
ing MS. Natalizumab is a highly effective DMT. However, some 
patients stop treatment with natalizumab because of reasons other 
than efficacy, primarily due to concerns about the risk of develop-
ing progressive multifocal leukoencephalopathy (PML). 
Identifying DMTs that can be effectively and safely used in the 
post-natalizumab treatment setting is a key unmet medical need. 
Daclizumab beta (DAC BETA) is a once monthly subcutaneous 
(SC) DMT for relapsing MS that offers high efficacy and a man-
ageable safety profile through routine monitoring with no 
increased risk of opportunistic infections versus placebo or IM 
interferon beta-1a, and no cases of PML to date.
Objectives: To evaluate the efficacy and safety of DAC BETA in 
subjects who switch from natalizumab to DAC BETA.
Methods: SUSTAIN (NCT02881567) is a 12-month (mo), open-
label, multicentre phase 3b study. Eligible adult relapsing-remit-
ting MS (RRMS) subjects have: EDSS score 0-5.5; been treated 
with natalizumab for ≥12 months prior to screening without miss-
ing ≥2 consecutive doses; no relapse, increase in EDSS, Gd+ or 
new/newly enlarging T2 lesions in the last ≥6 months; and been 
enrolled within 28(+3) days of last natalizumab dose. At the end 
of the 28(+3) day period, subjects receive DAC BETA 150mg 
once monthly SC using a pre-filled pen during 12 mo of follow 
up. Study assessments occur at enrolment, baseline, and 1, 3, 4, 6, 
9 and 12 mo with a safety follow-up visit 4 (EU sites) or 6 (US/
Canada sites) mo after the last dose; brain MRI scans are per-
formed at enrolment and 1, 4, 6 and 12 mo (all time points: pre-
contrast T1, T2, PD, FLAIR; enrolment and 1, 4 and 6 mo: DWI; 
enrolment and 6 and 12 mo: post-contrast T1). The primary end-
point is the proportion of subjects relapse free at 6 mo; secondary 
endpoints include: incidence of AEs/serious AEs, proportion of 
subjects relapse free and annualised relapse rate at 12 mo; number 
of new Gd+, new T1 hypointense, and new/newly enlarging T2 
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hyperintense lesions at 6 and 12 mo; and rate of permanent dis-
continuation of DAC BETA at 12 mo.
Results: SUSTAIN is expected to enrol ~100 subjects. Enrolment 
is ongoing. Estimated study completion is early 2019.
Conclusions: Results from SUSTAIN will provide information 
about the efficacy and safety of DAC BETA in RRMS patients 
initiating this therapy after discontinuation of treatment with 
natalizumab.
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Real-world treatment satisfaction with teriflunomide: results 
from the European cohort of the phase 4 Teri-PRO study
P. Vermersch1, J. Meca Lallana2, E. Maida3, V. van Pesch4, H. 
Kuusisto5, G. Comi6, R. Johansson7, W. Rashid8, N. Fakas9, P. 
Rufi10, E. Poole11, R. Gold12
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Saint-Luc, Université Catholique de Louvain, Brussels, 
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Finland, 6University Vita-Salute San Raffaele, Milan, Italy, 
7Centralsjukhuset, Karlstad, Sweden, 8Royal Sussex County 
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Background: Teriflunomide is a once-daily oral immunomodula-
tor approved for the treatment of relapsing-remitting MS. The 
Teri-PRO study (NCT01895335) previously reported high levels 
of treatment satisfaction with teriflunomide in routine clinical 
practice. The global nature of Teri-PRO allows for an assessment 
of the influence of different treatment practices on outcomes 
among participating countries.
Objective: To report treatment satisfaction with teriflunomide in 
the European cohort of the Teri-PRO study.
Methods: Patients in Europe received teriflunomide 14 mg, 
according to local labelling. The primary outcome was Global 
Satisfaction with treatment at Week (W) 48, measured using the 
Treatment Satisfaction Questionnaire for Medication (TSQM, 
version 1.4). TSQM scores were measured at baseline (patients 
switching from a prior disease-modifying therapy [DMT] 
within the previous 6 months), and at W4 and W48/end of treat-
ment (all patients). In this post hoc analysis, patients in Europe 
were stratified into 4 regions: Nordics (Norway, Finland, and 
Sweden), Southern Europe (SE; Greece, Italy, and Spain), 
Central Europe (CE; France, Belgium, Austria, and Germany), 
and the UK.
Results: Mean (SD) age (years) was 43.8 (9.3) in the Nordics 
(n=63), 41.7 (9.3) in SE (n=121), 42.5 (10.6) in CE (n=205), and 
45.3 (9.1) in the UK (n=44); baseline EDSS score was 1.8 (1.4), 
2.3 (1.5), 2.1 (1.3), and 3.2 (1.9), respectively. TSQM Global 
Satisfaction remained high over the study period in all regions 
(mean [95% CI]; Nordics: W4 73.1 [68.0,78.1], W48 71.9 
[65.6,78.2]; SE: W4, 68.7 [65.6,71.7], W48 64.2 [59.8,68.5]; CE: 
W4 72.2 [69.2,75.3], W48 66.8 [63.1,70.6]; UK: W4 80.4 
[74.5,86.4], W48 76.2 [68.1,84.2]). In patients switching from 
another DMT, Global Satisfaction significantly improved from 
baseline to W4 (Nordics: baseline 57.3 [50.5,64.2], W4 75.7 
[70.1,81.2], P=0.0192; SE: baseline 52.9 [47.7,58.0], W4 72.0 
[68.3,75.6], P< 0.0001; CE: baseline 56.7 [51.9,61.5], W4 75.4 
[71.7,79.0], P< 0.0001; UK: baseline 43.5 [31.0,55.9], W4 80.0 
[71.0,89.1], P=0.0003) and remained high to W48 (Nordics: W48 
75.3 [68.2,82.3], P=0.0840 vs baseline; SE: W48 64.2 [58.9,69.4], 
P=0.0335; CE: W48 69.9 [65.2,74.6], P< 0.0001; UK: W48 72.2 
[59.1,85.3], P=0.0209).
Conclusions: High levels of treatment satisfaction were observed 
in Europe regardless of region, including significant improve-
ments in patients switching from another DMT. These results are 
consistent with the full study population.
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Surface charge distribution, an attribute linked with 
immunogenicity of nanoparticles, is different for follow-on 
glatiramer acetate products approved in EU, Russia, Latin 
America and USA compared with Copaxone
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Background and objectives: Given its structural and composi-
tional complexity, Copaxone (Teva, glatiramer acetate) cannot be 
fully characterized using current state-of-the-art methodologies. 
As studies indicate a correlation between surface charge and 
immunogenicity of polypeptides (Foged C Int J Pharm 2005; 
Bhattacharjee S Part Fibre Toxicol 2010; Fromen CA 
Nanomedicine 2016), Teva employed a gold standard for charge-
sensitive antibody analysis, Cation Exchange Chromatography 
(CEX), to further assess the surface charge attributes of Copaxone 
and compare them to follow-on glatiramer acetate (FOGA) prod-
ucts marketed in Europe, the USA, Russia and Latin America.
Methods: CEX is based on a non-destructive separation of poly-
peptide mixtures into subgroups according to their average overall 
surface charge. Copaxone samples consistently comprise of three 
subpopulations represented by distinct peaks on CEX chromato-
grams: weak negatively charged, weak positively charged, and 
strong positively charged polypeptide subpopulations.
Results: The charge distribution for the marketed batches of 
FOGAs differed from that of Copaxone batches in terms of the 
distribution of the typical three distinct subpopulations. Charge 
distribution values of Polimunol (Argentina), Axoglatiran 
(Russia), and Synthon’s European FOGA (Europe) were outside 
the Copaxone range of values for the negatively charged subpopu-
lation and weak positively charged subpopulation. For the strongly 
positively charged distribution, all of Polimunol and Axoglatiran 
batches and 4 of 6 batches of the Synthon European product were 
above the Copaxone range. Glatopa batches demonstrated incon-
sistent results with the negative subpopulation varying from 
higher to significantly lower values than Copaxone thresholds; 
weak positive distributions were lower than Copaxone in all 
batches; and strongly positive subpopulation were higher than the 
Copaxone range in six out of eight batches.
Conclusion: All tested FOGA products demonstrated varying 
degrees of altered surface charge relative to Copaxone. Since this 
hypothesis has already been confirmed for Polimunol and Glatopa, 
showing robust differences in gene expression profiles of immune-
mediated inflammatory pathways (Laifenfeld Ectrims 2016; 
Kolitz Ectrims 2016, respectively), further investigation of 
FOGA-induced immunogenicity is warranted.
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copaxone
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Objective: Copaxone (Teva, glatiramer acetate), has provided a 
safe and effective treatment option for multiple sclerosis for 20+ 
years. The European regulatory assessment of follow-on-glati-
ramer acetate (FOGA) relied on establishing similarity rather than 
sameness of the active substance, and followed a biosimilar type 
approach. Copaxone release tests, high resolution physicochemi-
cal tests and biological assays were employed to evaluate compo-
sitional characteristics and their associated and functional 
ramifications, when comparing European FOGA relative to 
Copaxone specifications or inherent variability ranges.
Methods: The characterization methods included molecular weight 
distribution (MWD), Coomassie Brilliant Blue G-250 (CBBG), 
Viscotek TDAmax, cation exchange chromatography (CEX), Atomic 
Force microscopy (AFM), 2D-RPLC MALLS, cell-based potency, 
cytotoxicity, and ELISA assays using monoclonal (MAb) and poly-
clonal (PAb) antibodies for bio-recognition of glatiramer acetate.
Results: The FOGA batches (n=6) were within the Copaxone 
specification or variability ranges for the following methods; 
MWD, CBBG, AFM, 2D-RPLC MALLS, potency, and bio-rec-
ognition by MAb and PAb antibodies. Several compositional 
attributes were consistently different between the FOGA and 
Copaxone, including molecular size, hydrodynamic radius, and 
intrinsic viscosity (Viscotek). Charge distributions of the FOGA 
batches were outside the Copaxone value range for negatively 
charged and weak positively charged subpopulations, and for 4 
out of 6 batches, also for the strongly positively charged subpopu-
lation (CEX). Biological tests showed distinctly higher potency of 
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all FOGA batches as compared to Copaxone although results were 
within the potency specification range. Furthermore, a third of the 
FOGA batches demonstrated higher in vitro cytotoxicity activity 
than the established Copaxone specification range.
Conclusion: When applying state-of-the-art methodologies, con-
sistent differences were observed in compositional characteristics 
of the European FOGA product. Altered surface charge distribu-
tion has previously been associated with cytotoxicity and potency 
alterations (Bhattacharjee et al. 2010; Fromen et al. 2016) and was 
confirmed herein experimentally. Associated immunogenicity 
risks warrant investigation.
Disclosure
All authors are employees of Teva Pharmaceutical Industries who 
sponsored the research described in this report
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Background: Fingolimod (FTY) is a well-known and effective 
Sphingosine-1-phosphatase receptor immunomodulator to treat 
patients with Multiple Sclerosis (MS). Hispanic MS patients com-
prise less than 3% of the patient population in major clinical trials. 
Therefore, clinical data regarding treatment efficacy in controlling 
disease burden via MRI parameters is vastly limited.
Aim: FTY efficacy in Hispanic MS patients by MRI outcomes on 
T1 gadolonium enhancing lesions (GAD+), new/enlarging T2 
lesions (T2), T1 hypointense lesions (T1BH).
Methods: Single-center, open label, non-comparative, 2-year 
observational longitudinal follow-up study from 2012-2014. All 
patients were diagnosed by the 2010 McDonald Criteria and 
treated by a MS specialized neurologist at the largest nationally 
accredited MS center in Puerto Rico (PR). All patients had pre and 
post treatment imaging at a designated center with 1.5T MR and 
interpreted by a Neuroradiologist trained in MS imaging protocol. 
Patients were imaged at 1 year intervals. IRB approval and 
informed consent was obtained.
Results: 150 patients were enrolled and 81.5% (119) patients 
completed the 2 year trial. Females represent 78.1%(114) of origi-
nal patient population. Mean age of diagnosis was 40.8 ±10.9 and 
mean duration of disease (years) 6.6 ± 6.0. 13%(19) of the patient 
population was treatment naive. 2.6%(4) of patient population 
were lost to follow up and 18.4%(27) discontinued treatment. 
Reasons for discontinuation include 11.1%(3) experienced 
adverse events (AE), 2 macular edema and 1 arrhythmia, and 
25.9%(7) were non-responders. At baseline, 22%(31) of patients 
had GAD+ lesions. At 1 year and
2 years, 8.6%(9) and 5.2%(4) of patients had T1GAD+ lesions, 
respectively. This means at year 1 and year 2 there was a 91.3% 
and 94.5% reduction in T1GAD+ lesions. At baseline, 24.5%(34) 
had T2 lesions. At 1 year and 2 years, 78.9%(82) and 77.9%(60) 
of patients showed a reduction of T2lesions. At baseline, 
44.6%(62) of patients had T1BH. Of the T1BH negative patients, 
at 1 and 2 year follow up, 3%(3) and 0% (0) developed T1BH 
lesions, respectively.
Conclusion: FTY showed a great response in MRI outcomes in 
PR Hispanic population. Specifically, in patients with active dis-
ease. The authors recommend the inclusion of Hispanic popula-
tion in future clinical trials.
Disclosure
Angel Chinea: consultant and speaker for Novartis, BIOGEN, 
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8Neurología, Hospital Universitario Marques de Valdecilla, 
Santander, Spain
Introduction: Teriflunomide (TER) has been effective and secure 
in multiple sclerosis (MS) clinical trials (CTs) recruiting mainly 
naïve patients. Some real-world evidence is now available sug-
gesting TER is even effcient for patients who differ mostly from 
CTs, but the follow-up is still too short.
Objective: To analyze the efficacy and tolerability of TER with 
respect to previous disease modifiyng therapy (DMT).
Methods: We retrospectively recorded clinical and radiological 
data from 255 patients who underwent teriflunomide. Comparisons 
were made using t test or sign test for numerical variables, and χ2 
for categorical variables.
Results: A total of 255 patients´ records (mean of age=45.27±11.5y) 
who were on treatment (13.1±6.7mo) from december 2014 to 
march 2017; 184 females) were reviewed. MS types (n=242) were 
classified as relapsing-remiting, and 13 as progressive forms 
(mean disease duration=10.92±8.5y). Most (n=171) were on at 
least one DMF (43.13% from IF), 37 patients switched to TER 
because of inefficacy, and 134 for intolerance. Annual relapse rate 
(ARR) was significatively reduced in 191 patients completing at 
least 1y on treatment (basal ARR=0.950±0.7; 1y ARR=0.246±0.5; 
p< 0.0001), 2ndy ARR=0.5±0.6 (n=37; p=0.006). Multivariate 
regression, adjusted for sex, and age, disclosed no differences for 
TER response after 12 mo by previous treatment (absolute ARR 
reduction=0.588±0.09 for naïve patients, and 0.673±0.1 for 
switchers). After 1y, basal EDSS (mean=1.992±1.4) remained sta-
ble in 73.71% (p=0.093), and in 84.12% in the 2ndy (p=0.028). 
MRI scans (basal n=236; 1sty n=77) showed no new T2 lesions in 
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61.44%. Number of Gd+T1 lesions decresed after 1y (p=0.066). 
No serious adverse events were recorded.
Conclusions: In real word, most patients switched from other 
therapies to TER, and they were older. than in CTs. Even in this 
scenario, TER was clinical and radiologically effective. We 
observed a further potential benefit for those swhitching from 
other therapies, mainly IFB and GA, independently of the reason 
for switching.
Disclosure
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EP1655
Efficacy and safety of natalizumab extended interval dosing
M. Zeineddine1, N. Ayyoubi1, H. Tamim2, J. Nicolas3, S. 
Khoury1, B. Yamout1
1Nehme and Therese Tohme Multiple Sclerosis Center, American 
University of Beirut Medical Center, 2Clinical Research 
Institute, 3American University of Beirut, Beirut, Lebanon
Objective: Natalizumab is highly effective in MS but carries the 
risk of progressive multifocal leukoencephalopathy (PML). It is 
postulated that extending the dosing interval from 4 to 5-8 weeks 
might decrease this risk by decreasing the α4 integrin saturation 
on the surface of mononuclear cells. The aim of this study was to 
assess the effect of extended interval dosing (EID) on the thera-
peutic efficacy of natalizumab.
Methods: We reviewed all patients treated in our MS center with 
natalizumab for at least 6 months using EID. A total of 55 patients 
were shifted after an initial treatment period at standard interval 
dosing (SID) to an EID ranging from 5 to 8 weeks. All patient had 
a baseline MRI before initiating therapy and a follow-up MRI 
every 6 months thereafter.
Results: The mean treatment duration on SID and EID was 
16.7±13.0 and 9.1±6.4 months respectively. The mean age of our 
patients was 35.9±11.7 years, mean disease duration 5.4±6.4 years, 
79.5% were females, and 94.5% had relapsing remitting MS as 
opposed to 5.5% with secondary progressive MS. Before initiating 
therapy, annualized relapse rate (ARR) was 0.83, mean EDSS 
2.52±1.5, and 63.6% of patients were JCV antibody positive 
(Antibody index ≤0.9 in 72.5% and ≥1.5 in 25.5% of cases). By the 
end of SID and EID treatment 92.7% and 93.3% of patients were 
free of relapses (P=NS) and the ARR decreased to 0.05 and 0.06 
respectively (P=NS). The mean EDSS at the end of SID and EID 
periods was 1.7±1.4 and 1.8±1.3 respectively (P=NS). A total of 
72.7% and 92.7% of patients were free of any new T2 or enhancing 
lesions on MRI during the SID and EID periods respectively 
(P=0.011). It is of note that in the SID group the baseline MRI was 
performed before starting natalizumab. The overall incidence of 
adverse events was 51% vs 31% during SID and EID periods 
respectively. Specifically the rate of infections was higher during 
SID compared to EID (42% vs 20%). There were no cases of PML.
Conclusion: In patients treated with natalizumab, shifting from 
SID to EID has no negative effect on efficacy as evidenced by 
relapse rate, disability progression and MRI activity. The EID 
regimen is associated with a lower rate of infections and might 
potentially decrease the risk of PML.
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Nabil Ayyoubi: nothing to disclose
Hani Tamim: nothing to disclose
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Samia J. Khoury: nothing to disclose
Bassem I. Yamout: nothing to disclose
EP1656
A case of Legionnaires’ disease in a patient on dimethyl 
fumarate therapy for relapsing-remitting multiple sclerosis
R. Brandstadter, I. Katz Sand
CGD Center for MS at Mount Sinai, Neurology, Icahn School of 
Medicine at Mount Sinai, New York, NY, United States
Objective: We present a case of Legionnaires’ disease in a patient 
on dimethyl fumarate (DMF) with lymphopenia.
Background: Lymphopenia is a well-established consequence of 
DMF therapy. A myriad of infections have been reported in lym-
phopenic patients on DMF including respiratory, urinary tract, 
herpes virus, and gastrointestinal infections. Special attention has 
been paid to the risk of progressive multifocal leukoencephalopa-
thy in patients on DMF with very low or rapidly dropping lym-
phocyte counts. To our knowledge there are no reported cases of 
Legionnaires’ disease in a patient on DMF.
Discussion: The patient was diagnosed with relapsing-remitting 
multiple sclerosis (RRMS) in September 2013 after an episode of 
right arm numbness in in September 2012 followed by right leg 
weakness in May of 2013 and MRI consistent with MS. He began 
on DMF as disease-modifying therapy in October 2013. His abso-
lute lymphocyte count (ALC) dropped to 600 in July 2014 and 
reached a nadir of 400 in February 2014. Potential change in ther-
apy was discussed however ALC stabilized at 500 in December 
2015 and April 2016. He reported no infections during this time.
In August of 2016 the patient developed rigors with fever to 102 
Fahrenheit. He had intractable cough, myalgias, and malaise. 
Chest x-ray revealed bilateral patchy infiltrates concerning for 
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pneumonia. He received an intramuscular injection of ceftriaxone 
with little response after which he was started on an oral course of 
levofloxacin and began to improve. Urine antigen test for 
Legionella was positive. Investigation revealed no report of any 
outbreak of Legionnaires’ disease at the patient’s home, work or 
fitness center. He reported no atypical exposures. He fully recov-
ered with completion of the course of levofloxacin.
Conclusion: We present this case of Legionnaires’ disease in a 
patient with RRMS on DMF therapy to add to the body of litera-
ture on infections encountered in lymphopenic patients on this 
medication.
Disclosure
Dr. Rachel Brandstadter: nothing to disclose
Dr. Ilana Katz Sand: nothing to disclose
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Brain atrophy and disease free status over 3 years in multiple 
sclerosis patients under interferon beta 1a subcutaneous 
treatment
J.I. Rojas1, F. Sanchez1, F. Caro2, L. Patrucco1, J. Miguez1, E. 
Cristiano1
1Centro de Esclerosis Multiple de Buenos Aires, Hospital 
Italiano, 2Cemka-Eval, Buenos Aires, Argentina
Percentage of brain volume change (PBVC) has been suggested as 
a potential marker of MS disease progression, however, no clear 
relationship between PBVC and disease free status was clearly 
described yet. The objective of the study was to evaluate the rela-
tionship of PBVC and disease free status in MS patients under 
interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 
years of follow up.
Methods: RRMS patients, with less than three years from disease 
onset, EDSS ≤3 and in which IFN beta 1-a 44 mcg was indicated 
were included. MR scans were acquired 3 to 6 months after the 
initiation of IFN beta 1-a treatment and every 12 months after dur-
ing 3 years. Demographic, clinical and structural parameters from 
the MR scan, during the 3 years of follow up were analyzed and 
compared between patients with disease free status and no disease 
free status patients. Disease free status was defined as the absence 
of a) three month confirmed disability progression defined as an 
increase in EDSS score of 1.0; b) confirmed relapses; c) new/
enlarged T2 lesions. PBVC from baseline to months 12, 12 to 24, 
24 to 36 was compared between groups.
Results: 87 patients, mean age 33 ± 6 years, 57 (65.5%) women 
were included. The mean EDSS of the population was 2.1±0.5, 
follow up time 40 ± 4.3 months. Disease free status was reached 
by 31 patients at year 3. PBVC from baseline to months 24 in 
disease free status patients was -1.1 % vs. -1.54 % in no disease 
free status patients (p< 0.001) and from baseline to month 36 it 
was -1.43% vs. -2.1%
(p< 0.001) in disease free and no disease free status respectively.
Conclusion: At 3 years follow up, patients who received IFN beta 
1a and were disease free had lower PBVC compared to patients 
with disease activity.
Disclosure
This research was partially supported by Merck S.A. (Argentina), 
an affiliate of Merck KGaA, Darmstadt, Germany.
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Characterising properties of dimethylfumarate on innate and 
adaptive immunity: longitudinal data from MS patients
M. Diebold, C. Sievers, N. Sanderson, L. Kappos, R.L.P. 
Lindberg, T. Derfuss
Laboratory of Clinical Neuroimmunology, Neurologic Clinic and 
Policlinic, Departments of Biomedicine and Clinical Research, 
University Hospital and University of Basel, Basel, Switzerland
Introduction: The mode of action of dimethylfumarate (DMF), 
an immunomodulatory treatment for relapsing-remitting multiple 
sclerosis (RRMS), has not yet been fully elucidated. While in-
vitro experiments and animal studies suggest effects on immune 
cell survival, cytokine secretion and oxidative stress response, a 
proof from human ex-vivo studies is lacking.
Methods: Blood samples were collected from twenty well-char-
acterized RRMS patients at baseline and after 3, 6 and 12 months 
of DMF treatment and an age- and gender-matched cohort of 
healthy individuals at 0 and 3 months. Peripheral blood mononu-
clear cells (PBMCs) were separated and cryopreserved for flow 
cytometry and immunoassays. Leukocyte subpopulations and 
cytokine secretion ex-vivo and upon in-vitro stimulation were 
recorded. T cells were assessed for their levels of reactive oxygen 
species (ROS) and their proliferative capacity. Response of mono-
cyte activation markers as well as NFkB and MAPK pathways to 
DMF was analysed.
Results: Upon DMF treatment all lymphocyte subpopulations 
dropped significantly over the course of 12 months with cytotoxic 
and effector T cells being affected most drastically. In vitro DMF 
treatment lead to increased lymphocyte cell death which was 
potentiated by oxidative stress. In line with this result a significant 
increase of cytosolic ROS levels after 3 months treatment was 
detected. DMF inhibited proliferation of T cells in-vitro 
(CD8>CD4).Interestingly, this anti-proliferative effect decreased 
under treatment. While in-vitro stimulation with DMF resulted in 
an increased secretion of pro- and anti-inflammatory cytokines, 
no according longitudinal effects were observed. In-vitro DMF 
treatment reduced NFkB (p65) translocation to the nucleus. 
Consistent with this result the activation of antigen presenting 
cells (APCs) was decreased both in-vitro and ex-vivo.
Conclusion: This study translates knowledge from in-vitro and 
animal studies on DMF into the clinical setting. Our data suggest 
that DMF not only alters lymphocyte composition but also has 
profound effects on proliferation. In addition it also acts on innate 
immunity by reducing the activation status of APCs by reducing 
NFkB activation.
Disclosure
This study was supported by an Investigator Initiated Trial grant 
from Biogen.
Tobias Derfuss received speaker fees, research support, travel sup-
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EP1659
RAM-589.555 induces B-cell apoptosis during acute multiple 
sclerosis relapse: in-vitro study
A. Feldman, M. Gurevich, A. Achiron
Sheba Medical Center, Ramat Gan, Israel
Background: Acute multiple sclerosis (MS) relapses are a major 
factor that contributes to permanent neurological disability in MS 
patients. The current use of corticosteroids in the treatment of acute 
relapse has no effect on the sustained residual disability. Therefore, 
there is a need for a better treatment of acute MS relapses to reduce 
relapse residual disability. Recently, we have designed an innova-
tive Polymerase1 inhibiting compound, RAM-589.555, that sup-
presses ribosomal biogenesis and activates apoptosis as an 
innovative therapeutic approach to ameliorate MS relapse.
Objective: To evaluate effect of RAM-589.555 on B-cell apopto-
sis in-vitro during acute MS relapse as compared with methyl-
prednisolone (MP).
Design and methods: CD19+ B-cells lymphocytes were obtained 
from relapsing-remitting (RRMS) patients during acute MS 
relapse. Cells were incubated for 72h with RAM-589.555 in con-
centration of 50 and 100 nM or with 400 mg/ml MP. Thereafter, 
cells were stained with Annexin V for early and Annexin/PI for 
late apoptosis level (MBL). Samples were analyzed by FACS 
Calibur (BD, Germany) and data were evaluated using FLowJo 
software (USA).
Results: Five RRMS patients, age 40.8±3.1 years, disease dura-
tion 9.1±1.6 years and EDSS increase during relapse >=2.0 were 
included in the study. Incubation of B-cells with 50 and 100 nM 
RAM-589.555 or 400 mg/ml MP increased early apoptosis by 2.6 
(p=0.002), 3.5 (p=0.001) and 2.5 (p=0.01) folds, respectively. 
Late apoptosis of B-cells were increased by 7.5 (p=4.69E-06) and 
8.9 (5.73E-06) times using 50 and 100 nM RAM-589.555 respec-
tively, and significantly less by MP (p=0.01).
Conclusion: As compared to MP, RAM-589.555 significantly 
increased late apoptosis of B-cells obtained from RRMS patients 
in acute relapse. These findings suggest RAM-589.555 as a poten-
tial treatment for acute MS relapse.
Disclosure
Michael Gurevich: contracted research (Biogen Idec, Teva, 
Merck)
Anat Achiron: Consulting fees (EMD Serono, Genzyme, Roche); 
contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, 
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Is brain atrophy of multiple sclerosis patients treated with 
fingolimod different from those treated with interferon at 
high doses?
J.L. Ruiz Peña1, G. Navarro Mascarell1, P. Sau2, L. Dinca1, S. 
Eichau1, R. Lopez Ruiz1, E. Pacheco1, M.D. Paramo Camino1, G. 
Izquierdo Ayuso1
1Hospital Universitario Virgen Macarena, 2CERCO, Sevilla, 
Spain
Background: SIENA is a free algorithm, part of the FSL toolkit 
(www.fmrib.ox.ac.uk) that allows the direct quantification of 
brain atrophy from serial MR images. It has been applied in 
numerous studies of MS, investigating brain atrophy in people 
who have experienced a CIS and patients with RRMS, SPMS and 
PPMS.
Purpose: To determine and to compare the Percentage of Brain 
Volume Change of two groups of MS patients treated on Interferon 
B1a sc or Fingolimod.
Methods: 63 patients (16 male and 47 female) with Relapsing 
Remitting MS and a Kurtzke Expanded Disability Scale Score 
(EDSS) of 0-5.0 were included in a prospective study of Fingolimod 
(36 patients) or Interferon B1a sc (27 patients) in RRMS. All 
patients were followed up for a minimum period of 1 year. Every 
three months disability was assessed by different neurological 
scale. Percentage of Brain Volume Change (PBVC) was measured 
by an automated segmentation of SIENA (ABACUS).
Results: Patients on Fingolimod 0.5 mg achieved a Percentage of 
Brain Volume Change of -0.48±0.6%. Patients on Rebif achieved 
a Percentage of Brain Volume Change of -0,30±0.9%. There was 
no statistical difference between these two groups.
Conclusions: Although the drugs are positioned at different lev-
els of effectiveness, this measure of whole-brain atrophy provided 
similar data regarding these two inmunomodulators. Further 
investigations are required.
Disclosure
JLRP nothing to disclose
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Lymphocytes subsets after one year of dimethylfumarate 
treatment in multiple sclerosis: a real life study
S. La Gioia, V. Barcella, M.Z. Conti, B. Frigeni, C. Zanchi, M. 
Rottoli
USC Neurologia, ASST Papa Giovanni XXIII, Bergamo, Italy
Objectives: Dimethylfumarate (DMF) is used to treat relapsing 
multiple sclerosis and causes lymphopenia in a subpopulation of 
patients. Much remains to be understood about how the drug 
affects lymphocyte subsets. Our objective was to characterize 
changes in lymphocytic phenotype induced by DMF and if these 
changes are transient or persistent after 1 year of treatment.
Materials and methods: Peripheral blood samples were col-
lected from 38 consecutive DMF-12 months-treated patients at 
our multiple sclerosis center at 3 different time points: before 
treatment start, after 6 months and 12 months of DMF treatment. 
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Leucocytes count, lymphocytes count and lymphocyte subsets 
(CD3+, CD4+, CD8+, C20+ and NK cells) were analyzed by flow 
cytometry, CD4/CD8 ratio was also evaluated.
Results: The total leucocytes count resulted unaffected by treat-
ment. Lymphocyte count was significantly lower after 6 months 
of DMF treatment with persistent lower levels after 12 months 
(mean: 1.83 10^9/L pre-treatment, SD 0.46; 1.31 after 6 months, 
SD 0.51; 1.21 after 12 months, SD 0.40; p< 0.001). All lympho-
cytes subsets, apart from NK cells, resulted significantly affected 
by treatment. CD3+ cells were significantly lower after 6 and 12 
months of DMF (1448 cells/mmc, SD 569; 848, SD 311; and 810, 
SD 325; p=0.002). CD4+ cells were significantly lower after 6 
and 12 months of DMF as well (922 cells/mmc, SD 352; 606, SD 
207; 567, SD 201; p=0.006). CD8+ cells were the more affected 
subset, significantly lower at 6 and 12 months (481 cells/mmc, SD 
239; 229, SD 130; 229, SD 140; p< 0.001). C20+ cells were also 
mildly affected (290 cells/mmc, SD 181; 189, SD 107; 191, SD 
83; p=0.044). A significantly higher CD4/CD8 ratio at 6 and 12 
months (2.16, SD 0.74; 3.3, SD 1.6; 3.3, SD 1.8;
p< 0.001) was detected.
Discussion and conclusions: The results of our real life study, 
though small, are consistent with those previously reported at 6 
months and confirm the lowering of lymphocyte levels as an 
effect of DMF. CD8+ cells seem to be the more affected subset. 
Lymphocytes subsets changes are confirmed at 12 months, impli-
cating a persistent alteration of the immune cellular profile under 
DMF treatment, which may be clinically relevant. Much remains 
to understand if these changes may be considered surrogate mark-
ers for efficacy and if safety implications have to be raised due to 
relative immunosuppression.
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EP1662
Real Life comparative evaluation of dimethyl fumarate effi-
cacy and tolerability in relapsing remitting multiple sclerosis 
patients switching from other treatments
B. Forci, A. Mariottini, C. Mechi, E. Magnani, A. Barilaro, L. 
Massacesi, A. Repice
Department of Neuroscience (NEUROFARBA), Careggi 
University Hospital, Florence, Italy
Introduction: Dimethyl fumarate (DMF) is an oral medication 
effective as a first-line treatment of relapsing-remitting multiple 
sclerosis (RRMS). However efficacy and safety profile of DMF as 
a second-line treatment is controversial. In this study DMF admin-
istration was compared in naïve patients and in patients switching 
from another first line therapy.
Methods: MS patients with relapsing remitting MS consecutively 
treated for at least 8 months with dimethyl fumarate at the Multiple 
Sclerosis Regional Reference Center of the Careggi University 
Hospital, were included and followed for a median time of 15 
months. For the analysis the patients were stratified in three groups:
1) treatment naïve;
2) switching from another treatment because of:
a) low efficacy;
b) adverse events.
The primary end-point of the study was DMF efficacy in terms of 
annualized relapse rate (ARR). Others end points were EDSS 
score change over 12 months, safety and tolerability.
Results: The patients included were n= 81: 19 naïve (group 1) 
and 62 switching from other treatments (group 2) .Out of 
these, 20 switched for efficacy failure (group 2a) and 42 
because of adverse events (group 2b). Group 1 had a ARR in 
the year before therapy higher than Group 2a and Group 2b 
(p=0,027 and p=0,03), lower disease duration (p=0,003 and 
p=0,01) and EDSS (p=0,001 and p=0,0001). During treatment 
ARR was 0,06, 0,04 and 0,13 respectively in each group (p= 
0,78.; p= 0,29; p= 0,44); the median EDSS change after 12 
months of treatment was 0,16, 0,06 and 0,10 respectively in 
each group (p= 0,448); the percentage of patients showing a 
progression of disability was very similar between group 1 
and 2b (10,5% vs 9,5%), but tended to be lower in group 2a 
(5%, not significant).
Adverse events occurred in 36% of the patients. The most com-
mon were leucopenia, flushing or gastrointestinal disorders, 
mainly of mild entity and without difference among groups. The 
percentage of patients who interrupted the treatment because of 
adverse events was 9%.
Discussion: DMF seems effective in naive as well as in patients 
switching from other treatments; the type and number of adverse 
events are consistent with previous data.
Disclosure
This study received no funding.
Benedetta Forci received funding travel from Novartis, Biogen 
and Genzyme
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Alessandro Barilaro has nothing to disclosure
Luca Massacesi received educational grants for participation in 
international meetings from Biogen, Teva, Merk-Serono, 
Novartis, Genzyme, Roche; honoraria for symposia, advisory 
boards, preceptorship, consultation from Biogen, Teva, Merk-
Serono, Novartis, Genzyme, Roche, Mylan.
Anna Repice received consulting fees by Merk-Serono, Biogen, 
Novartis and Genzyme, and funding travel from Teva, Biogen and 
Novartis.
EP1663
Radiological and cognitive outcomes among patients ran-
domized to interferon beta, glatiramer acetate or fingolimod 
in PREFERMS
S.F. Hunter1, B.A.C. Cree2, X. Meng3, L. Schofield3, S. 
Kolodny3, N. Tenenbaum3, F.P. Thomas4, on behalf of the 
PREFERMS investigators
1Advanced Neurosciences Institute, Franklin, TN, 2UCSF, School 
of Medicine, San Francisco, CA, 3Novartis Pharmaceuticals 
Corporation, East Hanover, 4Seton Hall Hackensack Meridian 
School of Medicine, Hackensack, NJ, United States
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Background: PREFERMS was a 12-month, phase 4, open-
label study comparing treatment retention on fingolimod and on 
injectable disease-modifying therapy (iDMT: interferon [IFN] 
beta or glatiramer acetate [GA]) in patients with relapsing mul-
tiple sclerosis. One treatment switch was allowed for any rea-
son after ≥3 months, or before for efficacy or safety. At end of 
randomized treatment (EoRT), patients had received only rand-
omized therapy. At end of study (EoS), randomized groups were 
a mix of patients exposed only to randomized treatment and 
those who had switched. In total, 58.1% of patients switched to 
fingolimod from IFN or GA and 6.2% switched to iDMT from 
fingolimod.
Objective: To compare patient outcomes on fingolimod and on 
different iDMT classes before (EoRT) and after (EoS) any treat-
ment switches.
Methods: In PREFERMS (N=875), patients who were treatment-
naïve or previously treated with iDMT were randomized 1:1 to 
fingolimod or to preselected IFN or GA. Exposure-adjusted per-
cent brain volume loss (BVL) and percent cortical grey-matter 
volume loss (cGMVL) and change in oral Symbol Digit Modalities 
Test (SDMT) scores were analysed post hoc at EoRT and at EoS 
by treatment assignment at randomization (fingolimod, n=433; 
GA, n=231; IFN, n=197). Analyses were for hypothesis genera-
tion only.
Results: At EoRT, median BVL from baseline in the fingolimod 
and GA groups was 0.37% (n=370) and 0.46% (n=127), and at 
EoS was 0.40% (n=382) and 0.40% (n=194). Greatest BVL was in 
the IFN group at EoRT (0.85% [n=119]) but had reduced by EoS 
(0.59% [n=167]). At EoRT, median cGMVL from baseline in the 
fingolimod and GA groups was 0.02% (n=327) and 0.12% (n=53), 
and at EoS was 0.03% (n=348) and 0.12% (n=160). Greatest 
cGMVL was in the IFN group at EoRT (0.48% [n=56]) but had 
reduced by EoS (0.28% [n=137]). At EoRT, least-squares (LS) 
mean oral SDMT scores (95% confidence interval [CI]) had 
increased more in the fingolimod than in the GA group (3.5 [1.7, 
5.2; n=73] vs 1.0 [−1.6, 3.6; n=35]) but were closer by EoS (3.2 
[1.3, 5.1; n=73] vs 2.7 [0.0, 5.4; n=37]). At EoRT, LS mean score 
(95% CI) had decreased in the IFN group (−0.7 [−4.0, 2.6; n=30]) 
but had increased by EoS (2.5 [−1.0, 6.1; n=30]).
Conclusions: In PREFERMS, patients on fingolimod tended to 
have less BVL and cGMVL, and better cognitive scores than 
those on iDMT. At EoS, improved BVL and cGMVL in the IFN 
group, and cognition in the IFN and GA groups, might be due to 
the high proportion of switches to fingolimod.
Disclosure
Samuel F Hunter has received consulting fees and/or research 
support from and/or served on speakers’ bureau for Acorda 
Therapeutics, Avanir, Bayer, Genentech-Roche, Sanofi Genzyme, 
Novartis, Osmotica and Teva Neuroscience.
Florian P Thomas has served as a speaker and/or consultant for 
Acorda Therapeutics, Biogen, Genzyme, Novartis and Teva 
Neuroscience, and has received research support from Biogen and 
Teva Neuroscience.
Bruce AC Cree has received personal compensation for consult-
ing from Abbvie, Biogen, EMD Serono and Novartis.
Xiangyi Meng, Lesley Schofield, Scott Kolodny and Nadia 
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Profile of MS patiens treated with alemtuzumab in real 
world
E. Miñano-Guillamón1, E. Guerra-Schulz1, I. Gonzalez-Suarez2, 
M. Ortiz-Pica3, A. Arenaza-Peña4, C. Oreja-Guevara1
1Neurology, Hospital Clinico San Carlos, Madrid, 2Neurology, 
Hospital Alvaro Cunqueiro, Vigo, 3Hospital Clinico San Carlos, 
4Pharmacy, Hospital Clinico San Carlos, Madrid, Spain
Introduction: Alemtuzumab is a monoclonal antibody approved 
for the treatment of RRMS with clinical or radiological active dis-
ease. Alemtuzumab could be used as induction therapy or as sec-
ond line treatment in the same way as in the clinical trials. But, it 
seems that the profile of patients treated with alemtuzumab in real 
world is quite different as in the clinical trials. The objective is to 
analyze the characteristics of patients who have started alemtu-
zumab in real life and the causes of switching.
Methods: Retrospective observational study including patients 
diagnosed with RRMS who received alemtuzumab in the last two 
years. Clinical examination and EDSS were performed before the 
treatment and every three months.
Results: We studied 20 RRMS patients of our MS center, 4of 
them were men. The average age was 43 years old (32-57), and 
the time from the first symptom of MS was 14 years. The average 
EDSS before treatment was 5.5 (2.5-7.0). All had previously been 
treated modifying treatment of the disease:25% with2treatments, 
35% with 3 and 40% with4or more treatments.95% had previ-
ously received Natalizumab and in 40% it was the previously 
treatment to Alemtuzumab (In 35% was Fingolimod and in 20% 
Tecfidera). 84.2% of patients have switched due to an increase of 
clinical and radiological activity; 32% only due to clinical activity 
and 10.5% radiological activity. 35.7% had 2 relapses in the previ-
ous year, and 28.6%had more than3 relapses. 30% presented > 5 
new hyperintense lesions in T2 and 50% had 2or more contrast-
detecting lesions.
Conclusions: The profile of MS patient starting Alemtuzumab in 
our center is very different from the clinical trials. In real life they 
are very active patients with a longer disease duration, higher 
EDSS and treated with two or more therapies before alemtu-
zumab. It was not used as induction therapy.
Disclosure
Elena Miñano-Guillamón: nothing to disclose.
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Switching from fingolimod to alemtuzumab in patients with 
active relapsing multiple sclerosis
A. Carroll1, A. Shields1, W.J. Brownlee1,2, J. Chataway1,2
1National Hospital for Neurology and Neurosurgery, 2Queen 
Square Multiple Sclerosis Centre, UCL Institute of Neurology, 
London, United Kingdom
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Background: Alemtuzumab has been shown to be efficacious in 
trials of early relapsing remitting multiple sclerosis (RRMS) in 
treatment naïve populations, and in those who have relapsed on 
injectable drugs. Despite limited clinical trial data, alemtuzumab 
is often used as a second or third-line agent in patients with longer 
disease durations and more established disability. A recent case 
series suggested a high risk of early relapses in patients switching 
from fingolimod to alemtuzumab.
Objectives: To investigate the frequency and predictors of relapse 
in RRMS patients switching from fingolimod to alemtuzumab.
Methods: We retrospectively analysed patients switching from 
fingolimod to alemtuzumab at the National Hospital for Neurology 
and Neurosurgery, London between 2015- 2017. Patient charac-
teristics (age, sex, duration of RRMS, sequence of prior disease 
modifying therapies, relapses in the last 2 years, Extended 
Disability Status Scale (EDSS), and reason for switching treat-
ments) and fingolimod treatment characteristics (duration of treat-
ment, lymphocyte count, and wash out period) were collected.
Results: Fifteen patients were identified (mean age 38.5 (SD 
8.75) years, 10 (66.7%) female, Mean EDSS 5.3 (SD 0.98), mean 
disease duration 10.2 (SD 6.34) years). The annualized relapse 
rate in the 2 years prior to switching to alemtuzumab was 1.07 
(SD 0.59). The mean washout period between fingolimod and 
alemtuzumab treatment was 138 days. The mean follow-up on 
treatment with alemtuzumab was 9 months (range 0-18). 4/15 
patients (26.7%) had relapses after a mean of 3.75 months after 
dosing (range 1-6). There was no difference in the annualized 
relapse rate, disease duration, lymphocyte count while on fingoli-
mod or on starting alemtuzumab, or duration of the wash out 
period in patients with and without relapses after switching to 
alemtuzumab. Follow-up of the cohort is ongoing.
Conclusion: In this small case series of patients with active 
RRMS switching from fingolimod to alemtuzumab, one quarter 
had a relapse in the first year of treatment. Larger studies are 
required define risk factors for disease activity after switching 
from fingolimod to alemtuzumab.
Disclosure
A Carroll: Nothing to disclose.
A Shields: Nothing to disclose.
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J Chataway has support from the National Institute of Health 
Research (NIHR) University College London Hospitals 
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Teriflunamide and dimethyl fumarate: results from clinical 
practice
C. Cunha1, D. Gabriel2, R. Samões3, M. Calejo4, A. Bettencourt5, 
A.P.S. Sousa3, E. Santos3, A. Martins Silva3
1Neurologia, Centro Hospitalar do Porto, Serviço de 
Neurologia, Hospital de Santo António, 2Neurologia, Serviço 
de Neurologia, Centro Hospitalar do Porto, 3Neurologia, 
4Centro Hospitalar do Porto, Hospital de Santo António, 
5Unidade Multidisciplinar de Investigação Biomédica, Instituto 
de Ciências Biomédicas Abel Salazar, Universidade do Porto, 
Porto, Portugal
Introduction: Teriflunamide (TRF) and dimethyl fumarate 
(DMF) are first-line oral immunomodulators approved for replas-
ing-remitting multiple sclerosis (MS) treatment. They have com-
parable efficacy with injectable drugs and are more convenient for 
patients.
Aim: To compare demographic and clinical characteristics 
between MS patients under TRF and DMF and to compare toler-
ability and efficacy.
Results: Clinical data from 30 MS patients under TRF and 50 MS 
patients under DMF was reviewed. All had relapsing-remitting 
type except for 2 patients under TRF who had secondary progres-
sive type. MS patients under TRF were older (46.9 ± 10.3 vs 36,5 
± 9.4, p< 0.001) with no difference in gender (p=0.49). MS 
patients under TRF presented superior baseline EDSS (4 vs 1, p< 
0.001) but no difference in relapse rate for the last 12 months was 
found (0.5 vs 1, p=0.98). The mean follow-up time was 14.5±10.7 
months for DMF group and 8.3±5.7 months for TRF group. DMF 
and TRF were equally chosen for naïve patients. Treatment was 
changed to TRF or DMF due to adverse events in 55% and due to 
therapy failure in 26%. DMF had to be stopped in 7 patients (14%) 
due to intolerance (gastrointestinal symptoms, recurrent infec-
tions and lymphopenia) and in 3 patients (6%) due to clinical fail-
ure. TRF was stopped in 4 patients (13%) due to intolerance (toxic 
hepatitis, pancytopenia, epilepsy and recurrent infection) and in 1 
patient (3%) due to severe alopecia and failure to prevent relapse. 
In those with more than 6 months of follow-up, the average 
relapse rate (p=0.77) and EDSS progression (p=0.29) were not 
different between groups.
Conclusion: TRF was the drug of choice for older and more disa-
bled patients. Tolerability and efficacy were similar for both 
drugs.
Disclosure
Nothing to declare.
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Multiple sclerosis outcome determination evaluating real 
differences after TimE (MODERATE): treatment variations 
and outcomes in Scotland
P.J. Gallagher1, M. Hair2, A. Macleod3, J. Overell1, 
MODERATE
1Neurology, NHS Greater Glasgow and Clyde Institute of 
Neuroscience, 2Statistics Consultant, Glasgow, 3Division of 
Applied Health Sciences, University of Aberdeen, Aberdeen, 
United Kingdom
Introduction: The long-term impact of Disease Modifying 
Treatments (DMTs) for people with Relapsing Remitting 
Multiple Sclerosis (pwRRMS) remains poorly characterised. 
Published data suggest considerable variation in DMT use, but 
suffer from numerous sources of bias. By identifying patients 
with similar disease severity in Scotland who are treated differ-
ently, MODERATE aims to compare outcomes in patients with 
and without DMTs, using Propensity Score Matching (PSM) to 
account for indication bias.
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Methods: The Scottish Multiple Sclerosis Register was used to 
identify all pwRRMS diagnosed in 2010-2011 in 2 regional cen-
tres. PSM was used to identify DMT treated and untreated sub-
jects with similar baseline characteristics. Nine covariates were 
used to calculate propensity scores for DMT initiation: age, gen-
der, ethnicity, disease duration, initial relapse symptoms, number 
of relapses, first inter-attack interval and number of MRI lesions. 
Calliper distance was 0.2 for matching. Retrospective outcomes 
were collected, comparing pwRRMS who started a DMT within 1 
year and remained on treatment versus pwRRMS never treated 
over 4 years.
Results: After exclusions for incomplete data, 245 patients were 
identified. 130(53%) had DMT started within one year of diagno-
sis, while 115(47%) did not. There was considerable overlap in 
propensity scores: 41% of untreated and 58% of treated pwRRMS 
were within the middle two quartiles for the whole cohort. PSM 
identified 62 matched pairs with similar disease severity at diag-
nosis, one of whom was treated and one of whom was untreated 
within 1 year of diagnosis.
Detection bias and missing data influenced outcome assessments, 
with treated patients being reviewed more frequently. Over 3 
years, mean relapse number and severity in the treated and never 
treated group (39 pairs) showed no significant differences and 
17.9%(treated) vs. 10.3%(untreated) pwRRMS had documented 
disability worsening. Over 5 years, 17.9% of the treated group and 
5.1% of the never treated group were diagnosed with progressive 
disease (p=0.07).
Conclusions: The initial decision to treat approximately half 
(124/245) of pwRRMS with DMTs in Scotland depends on factors 
unrelated to their disease or demographics. Propensity matched 
pairs have been generated for detailed outcome assessments eval-
uating the effects of DMT initiation and escalation. Initial retro-
spective analysis of the effect of early DMT initiation on disability 
has not demonstrated benefit over 5 years.
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Paul Gallagher has received research funding from Sanofi 
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Experience with tocilizumab in treatment of neuromyelitis 
optica
V. Meca-Lallana, P. Sanchez, J. Dotor, C. Aguirre, B. del Río, 
M. Rabadan, J. Vivancos
Demyelinating Disorders Unit, Neurology Department. Instituto 
de Investigación Sanitaria, Hospital Universitario de la 
Princesa, Madrid, Spain
Objective: To communicate our experience with the use of tocili-
zumab, a humanized monoclonal antibody against the interleu-
kin-6 receptor (IL-6R) , in a neuromyelitis optica (NMO) patient.
Material and methods: We present a 53-year-old patient diag-
nosed with seronegative neuromyelitis optica after an optic neuri-
tis, a medulla oblongata lesion relapse and a longitudinally 
extensive transverse myelitis over 8 vertebral segments. The 
patient was initially treated with azathioprine but it had to be with-
drawn due to severe pancytopenia. He was then treated with ritux-
imab but developed a probable serum sickness reaction, so no 
consecutive dosing was administered. The patient had a medulla 
oblongata lesion relapse, requiring high dose methylprednisolone 
and plasma exchange for recovery. Treatment with tocilizumab 
was initiated as compassionate use at a dose of 8mg/Kg/month.
Results: The patient showed a good clinical response after 3 infu-
sions. There were no new relapses or Magnetic Resonance 
Imaging inflammatory activity. He didn’t develop cytopenia or 
any other associated complications.
Conclusions: Treatment with anti-IL-6 might be a safe and effec-
tive treatment option in NMO patients who don’t respond or don’t 
tolerate other traditionally used therapies.
Disclosure
Virginia Meca-Lallana has received consulting or speaking fees 
from Almirall, Biogen, Genzyme, Merck Serono, Novartis, 
Roche, Terumo, Sanofi and Teva.
Virginia Meca-Lallana disclose neither conflict of interest in the 
elaboration of this abstract
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Safety and efficacy of dimethyl fumarate in a real-world 
relapsing-remitting multiple sclerosis population
A. Barros, J. Sequeira, A. Sousa, C. Capela, R. Pedrosa
Centro Hospitalar Lisboa Central, Lisboa, Portugal
Background: Dimethyl fumarate (DMF) is an oral immunomod-
ulator approved for the treatment of relapsing-remitting multiple 
sclerosis (RRMS) and available in Portugal since April 2015, 
based on two phase III clinical trials demonstrating its efficacy.
Objectives: The aim of this study is to evaluate post-marketing 
DMF safety and effectiveness in a real-world clinical population.
Methods: Observational study of patients with RRMS treated 
with DMF in our centre with at least 6 months of follow-up. 
Demographic and clinical characteristics, including Annual 
Relapse Rates (ARR), Expanded Disability Status Score (EDSS), 
previous treatments, change in Magnetic Resonance Imaging 
(MRI) lesion load, adverse effects (AE), treatment duration and 
reason for discontinuation were examined.
Results: Eighty-four patients were included, 57 (67.9%) females. 
Mean age and mean disease duration were 41.5±11.9 years and 
8.9±7.2 years, respectively. Mean baseline EDSS was 1.7±1.7. 
Seventy (84.5%) patients received prior first-line disease modify-
ing therapies (DMT), 2 (2.4%) patients received prior second-line 
DMT and 12 (14.3%) were treatment naïve. Mean follow-up was 
15.1±7.8 months; 48 (57.1%) patients with at least 12 months of 
DMF treatment. Most frequent AE were flushing (n=45, 53.5%) 
and gastrointestinal symptoms (n=47, 55.9%). Lymphopenia was 
present in 22 (26.2%) patients (11 grade I, 6 grade II and 5 grade 
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III). Eleven (13.1%) patients experienced infections. Ten (11.9%) 
patients discontinued therapy due to AE (n=7), disease activity 
(n=2) and own initiative (n=1).
In total, 74 (88.1%) patients were relapse free at the end of follow-
up. Mean interval between DMF start and first relapse was 2.2±1.4 
months.
Considering the population with at least one year of follow-up 
(n=48), there was a 62.1% decrease in the ARR (0.58±0.94 vs 
0.22±0.55, p=0.002), but no effect was observed regarding mean 
EDSS (1.92±1.76 vs 1.96±1.91, p=0.667). Among these patients, 
27 (56.3%) performed a control MRI, 18 (66.7%) achieved No 
Evidence Disease Activity (NEDA), 9 (33.3%) had new MRI T2 
lesions and 3 (11.2%) had new MRI T1-gadolinium-enhancing 
lesions.
Conclusions: Despite the incidence of some AEs (such as 
flushing and gastrointestinal side effects) was mildly increased 
than that reported in clinical trials, our observational data con-
firm the good tolerability and safety of DMF. This audit of 
DMF showed it significantly reduced relapse rates in this 
RRMS population.
Disclosure
Ariana Barros: nothing to disclose;
João Sequeira: nothing to disclose;
Ary Sousa: nothing to disclose;
Carlos Capela: nothing to disclose;
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Disease modifying therapy use in multiple sclerosis patients 
with comorbidities
D.S. Conway, S.M. Planchon, D. Ontaneda
Mellen Center for MS, Cleveland Clinic Foundation, Cleveland, 
OH, United States
Introduction: Pivotal trials of multiple sclerosis (MS) disease 
modifying therapies (DMTs) typically exclude patients with sig-
nificant comorbidities. This leads to uncertainty about the safety 
of DMTs in patients with comorbidities. Several studies have sug-
gested that comorbidities negatively impact MS disease course, 
meaning patients with comorbidities may need to switch DMTs 
more frequently.
Methods: A database query for relapsing-remitting MS patients 
visiting the Mellen Center after 1 January 2010 was conducted. 
Chart review was completed to determine each patient’s DMT his-
tory and whether or not they have hypertension (HTN), hyperlipi-
demia (HLD), diabetes (DM), or obstructive lung disease (OLD). 
A linear regression model was used to determine associations 
between comorbidities and the total number of DMTs used by a 
patient. Covariates used for adjustment included age, race, gender, 
disease duration, insurance type, median household income by zip 
code, depression, and smoking status. A parsimonious model 
using only significant predictors from the larger model was also 
constructed and tested for interactions.
Results: The analysis included 2,702 patients. The mean age was 
47.9 years, mean disease duration was 11.2 years, and the mean 
number of DMTs was 2.1. In the larger model, male gender was 
significantly associated with a higher number of DMTs used (β= 
.131, p=0.03), while disease duration
(β= -0.016, p< 0.001), HTN (β= -0.129, p=0.02), and HLD (β= 
-0.13, p=0.03) were significantly associated with fewer DMTs 
used. The results from the parsimonious model were similar and 
no statistical interaction was found with disease duration. When 
the model was applied to those with disease duration < 10 years 
only, the relationship between disease duration and number of 
DMTs disappeared.
Conclusions: Patients with HTN and HLD used fewer DMTs, 
whereas DM and OLD had no association with the number of 
DMTs used. This may be because of concern about the safety of 
certain DMTs in patients with HTN and HLD. Interestingly, male 
gender was associated with more DMTs used. This may be due to 
a more aggressive disease among men requiring more treatment 
escalation. Alternatively, men may be less cautious and willing to 
try DMTs with more inherent risk. The inverse relationship 
between disease duration and number of DMTs used was unex-
pected. We theorize that this may be related to individuals diag-
nosed when fewer DMT options were available who never went 
on to change treatments.
Disclosure
Devon Conway has received research support paid to his institu-
tion by Novartis Pharmaceuticals.
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Daniel Ontaneda has received grant support from the NIH, NMSS, 
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Infusion-related reactions with ocrelizumab in phase III 
studies
J. de Seze1, S.L. Hauser2, L. Kappos3, X. Montalban4, C. 
Pozzilli5, C. Chognot6, L. Julian7, H. Koendgen6, H. Zheng7, J.S. 
Wolinsky8
1University Hospital of Strasbourg, Strasbourg, France, 
2University of California, San Francisco, CA, United States, 
3University Hospital Basel, University of Basel, Basel, 
Switzerland, 4Vall d’Hebron University Hospital, Barcelona, 
Spain, 5Sapienza, University of Rome, Rome, Italy, 6F. 
Hoffmann-La Roche Ltd, Basel, Switzerland, 7Genentech, 
Inc, South San Francisco, CA, 8McGovern Medical School, 
UTHealth, Houston, TX, United States
Background: Ocrelizumab (OCR) is an FDA-approved, human-
ised, CD20+ B cell-selective monoclonal antibody for the treat-
ment of relapsing (RMS) and primary progressive (PPMS) 
multiple sclerosis. Infusion-related reactions (IRRs) in OCR 
Phase III studies, including the separate double-blind, double-
dummy OPERA I and II studies (RMS; OCR N=825; comparator: 
interferon β-1a 44 µg three times weekly; NCT01247324 and 
NCT01412333) and ORATORIO (PPMS; comparator: placebo; 
NCT01194570) have been reported.
Objective: To define the pattern and characteristics of OCR IRRs 
in the prespecified pooled analysis of OPERA I and OPERA II, 
and ORATORIO.
Methods: OCR was given as 600 mg infusions every 24 weeks in 
OPERA I and OPERA II (96-week controlled period; 1st infusion: 
2 × 300 mg infusions split by 14 days) and ORATORIO (at least 
120 weeks’ controlled treatment until a set number of disease 
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progression events was seen; 2 × 300 mg infusions split by 14 
days). Pretreatment per protocol was methylprednisolone (MP) 
100 mg intravenous (or equivalent); antihistamines and analge-
sics/antipyretics were recommended. Populations of interest were 
those with an IRR (≥1 or >1), a Day 1 IRR (with/without ≥1 later 
IRRs) and those without Day 1 IRRs with a later IRR. Subgroups 
were also analysed by pretreatment.
Results: Overall, 283 of 825 (34.3%) of OCR recipients in the 
pooled OPERA analysis had ≥1 IRR; of these, 123 patients 
(14.9%) had >1 IRR. 227 patients (27.5%) had an IRR on Day 1, 
of which 106 patients (12.8%) had a further IRR; 56 patients 
(6.8%) had an IRR after not having an IRR on Day 1. Most IRRs 
were mild to moderate in severity and generally manageable 
including by infusion adjustments; one life-threatening IRR (Day 
1; bronchospasm; MP alone pretreatment) and no fatal IRRs 
occurred. 11 patients (1.3%) discontinued due to IRRs. Fewer 
IRRs were seen in patients pretreated with MP + antihistamines 
(N=120; ≥1 IRR, 29.2% [n=35]; >1 IRR, 9.2% [n=11]; Day 1 
IRR, 19.2% [n=23]) vs other pretreatment groups (≥1 IRR, 31.2-
52.6%; >1 IRR, 14.5-21.6%; Day 1 IRR, 24.9-49.5%). 
ORATORIO study results will be presented.
Conclusions: IRRs were a common adverse event experienced by 
34.3% of patients (≥1 IRR) and most frequently occurred at the 
first vs later infusions. IRRs were generally mild to moderate in 
severity, manageable (including infusion adjustments) and less 
frequent with a combination of premedication with MP + antihis-
tamines before each infusion vs other pretreatment groups.
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Research Foundation.
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reimbursement for participation in scientific meetings, has been a 
steering committee member of clinical trials or participated in 
advisory boards of clinical trials in the past years with Actelion, 
Almirall, Bayer, Biogen, Genzyme, Merck, Novartis, Octapharma, 
Receptos, F. Hoffmann-La Roche Ltd, Sanofi, Teva and Trophos.
C. Pozzilli has served on scientific advisory boards for Actelion, 
Biogen, Genzyme, F. Hoffmann-La Roche Ltd, Merck Serono, 
Novartis, Sanofi and Teva, and has received consulting and/or 
speaking fees, research support and travel grants from Allergan, 
Almirall, Biogen, Genzyme, F. Hoffmann-La Roche Ltd, Merck 
Serono, Novartis, Sanofi and Teva.
C. Chognot is an employee of F. Hoffmann-La Roche Ltd.
L. Julian is an employee and shareholder of Genentech, Inc.
H. Koendgen is an employee and shareholder of F. Hoffmann-La 
Roche Ltd
H. Zheng is an employee of Genentech, Inc.
J.S. Wolinsky has served on advisory boards, data monitoring or 
steering committees, has consulting agreements, or received 
speaker honoraria from the following entities: AbbVie, Academic 
CME, ACTRIMS, Alkermes, Bayer HealthCare, Biogen, Bionest, 
Celgene, Clene Nanomedicine, CMSC, ECTRIMS, Forward 
Pharma A/S, MedDay Pharmaceuticals, Novartis Pharmaceuticals, 
PRIME, Roche Genentech, Sanofi Genzyme, Strategic 
Consultants International, Takeda, Teva Pharmaceuticals and 
WebMD; royalties are received for outlicensed monoclonal anti-
bodies through UTHealth from Millipore Corporation.
EP1672
Cyclophosphamide in the treatment of multiple sclerosis. 
Can the “elders” protect against neurodegeneration?
M. Anagnostouli, G. Karagiorgis, A. Artemiadis, P. 
Dimopoulou, P. Katsika, P. Koutsoudaki, G. Koutsis, M.-E. 
Evangelopoulos, E. Andreadou, K. Kilindireas
1st Department of Neurology, Athens National and Kapodistrian 
University, ‘Aeginition’ Hospital, Athens, Greece
Background: Cyclophosphamide(Cy) is used as an induction ther-
apy for aggressive relapsing-remitting multiple sclerosis(RRMS) 
and possibly for progressive types of the disease(primary or sec-
ondary progressive - PP or SP). The aim of this observational study 
was to identify determinants of disability improvement in patients 
receiving monthly(MO) infusions of Cy.
Methods: 91 MS patients (57 females and 34 males, mean age: 
47.9, range: 26-75, mean duration of disease: 14.2 years, range: 
0-46, median Expanded Disability Status Scale-EDSS: 6.0, 
range: 1.5-8.0), 7 (7.7%) with RRMS, 56 (61.5%) with SPMS, 
22 (24.2%) with PPMS and 6 (6.6%) with relapsing progressive 
MS (RPMS) were included. The median number of MO Cy 
infusions was 3 (range: 1-21). The median MO Cy dose was 
700mg/m2BSA (range: 500-1,500mg). Previous therapy (i.e. 
none, disease modifying drugs, immunosuppressive drugs or 
both) and the presence of 1 or more Gd+ lesions before treat-
ment was recorded. Disability improvement(DI) was defined as 
one point change in EDSS at the time of each patient´s evalua-
tion after the last infusion. Univariate tests (Student´s t-test and 
chi-square test) and a Cox proportional hazard model was 
employed to ascertain determinants of improvement with 
Cy-therapy.
Results: 63 patients (69.2%) were identified with DI. The 
response rate across MS types was RRMS/RPMS: 69.2%, SPMS: 
69.6% and PPMS: 68.2% (p=0.99). Univariate test revealed that 
gender, age, duration of MS, EDSS at Cy onset, previous therapy 
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and Cy cumulative dose did not affect Cy response. The number 
of patients with DI was significantly higher in patients with no 
Gd+ lesions at Cy commencement than patients with at least one 
Gd+ lesion (77.5% vs. 40%, p=0.003). Absence of Gd+ lesions 
was significantly related to disability improvement after 
Cy-therapy(HR: 2.56, 95%CI 1.16-5.66, p=0.02), after control-
ling for age, gender, duration of disease, EDSS, previous therapy 
and disease type. Three patients on Cy-therapy developed urinary 
tract infection.
Conclusions: This study provides evidence for the significant DI 
of Cy-therapy even in MS patients with less neuroinflammatory 
types of the disease. Presumably, the ability of Cy to cross blood-
brain barrier may account for the neuroprotective properties docu-
mented in this study. In an era of ongoing development of newer 
neuroprotective drugs, older and low cost treatments (i.e. Cy) may 
still confer significant DI in less neuroinflammatory or progres-
sive types of MS.
Disclosure
Dr. Maria Anagnostouli has received honoraria and research sup-
port from all pharmaceutical companies involved in MS therapeu-
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Severe acute non-immune thrombocytopenia during the first 
cycle of treatment with alemtuzumab
E. Carreon Guarnizo1,2, R. Hernández Clares1,2, F. Iniesta 
Martínez1,2, A.E. Baidez Guerrero1, E. García Molina1, G. Valero 
López1, J. Zamarro Parra3, J.E. Meca Lallana1,2
1Unidad de Neuroinmunología Clínica y Esclerosis Múltiple, 
Servicio de Neurología, Hospital Clínico Universitario Virgen de 
la Arrixaca, 2Cátedra de Neuroinmunología Clínica y Esclerosis 
Múltiple, Universidad Católica San Antonio (UCAM), 3Servicio 
de Neurradiología, Hospital Clínico Universitario Virgen de la 
Arrixaca, Murcia, Spain
Objective and background: Alemtuzumab (ALZ) is a monoclo-
nal antibody approved for the treatment of Multiple Sclerosis 
(MS). Severe Immune Thrombocytopenia (ITP) has been reported 
as a side effect up to 1% within 14-36 months after the first dose 
of ALZ. It has also been reported a decrease in the platelet count 
during the infusion, but always within normal limits. The objec-
tive of this paper is to report a case of severe acute non-immune 
thrombocytopenia during the first cycle of treatment with ALZ.
Methods: We present a case of severe acute non-immune throm-
bocytopenia, reversible and self-limiting, after the first dose on 
the first cycle of treatment with ALZ.
Results: 54-year-old woman with Relapsing-Remitting MS and 15 
years evolution that despite receiving different treatments, has con-
tinued to present outbreaks; finally opting for ALZ treatment. After 
the first infusion, platelets 48000 UL were observed (201000 UL 
levels prior to treatment), no bruising and no evidence of bleeding. 
Treatment was suspended and platelets normalized, 155000 UL 72 
hours later; so ALZ treatment was completed with good tolerance.
Conclusions: In the light of the approval of new MS treatments, 
it is important to pay attention to the potential onset of new side 
effects in our patients, as is our case, a severe non-immune throm-
bocytopenia during ALZ infusion.
Disclosure
Authors: Nothing to disclose
Neuroprotection and Repair
EP1674
Contribution of K+ channels and P2X7 receptor in 7-keto-
cholesterol - induced lipotoxicity on 158N murine oli-
godendrocytes: new pharmacological targets to prevent 
oligodendrocytes dysfunctions in multiple sclerosis
M. Bezine1,2, T. Nury3, R. Ben Khalifa2, A. Vejux3, J. De Seze4, 
M. El Ayeb2, T. Moreau3,5, G. Lizard6
1Lab. Bio-PeroxIL / EA 7270, Univ. de Bourgogne Franche-
Comté, Dijon, France, 2Lab. ‘Venoms & Therapeutic 
Biomolecules’, Pasteur Institut, Tunis, Tunisia, 3Lab. Bio-
PeroxIL / EA 7270, Univ. Bourgogne Franche-Comté, Dijon, 
4Dept. Neurology, Hôpital de Hautepierre, Strasbourg, 5Dept. 
Neurology, Univ. Hospital of Dijon, Univ. Bourgogne Franche-
Comté, 6Lab. Bio-PeroxIL / EA 7270, Univ. Bourgogne Franche-
Comté / Inserm, Dijon, France
Aims: Imbalance in the homeostasis of K+ ions contributes to the 
pathogenesis of multiple sclerosis (MS). 7-ketocholesterol (7KC) 
often found at increased levels in patients with MS is able to trig-
ger numerous oligodendrocyte dysfunctions. We therefore studied 
the impact of 7KC on 158N murine oligodendrocytes, and deter-
mined its effect on the P2X7 ATP-dependent receptor channel, 
and on the Kv3.1 potential dependent-channel, which are involved 
in K+ homeostasis.
Methods: 158N murine oligodendrocytes were cultured with 7KC in 
the absence or in the presence of 4-aminopyridine (specific K+ chan-
nel blocker), diazoxide (ATP sensitive K+ channel activator), or glib-
enclamide (ATP sensitive K+ channel blocker). The activation of 
P2X7 was measured by flow cytometry with YOPRO1. Kv3.1b 
expression was determined by flow cytometry and western-blotting 
with a mouse monoclonal antibody (Sigma-Aldrich; ref: SAB5200030 
(anti-kv3.1b)). The intracellular concentration of K+ ([K+]i) was 
determined by flame photometry and the ratiometric approach using 
the PBFI-AM fluorescence indicator. 7KC-induced cell death was 
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evaluated by the crystal violet test as well as by mitochondrial depo-
larization and enhancement of the cytoplasmic membrane permeabil-
ity measured by flow cytometry after staining with DiOC6(3) and 
propidium iodide, respectively. Overproduction of reactive oxygen 
species (ROS) was quantified with dihydroethidium.
Results: Positive correlations were found between P2X7 activa-
tion, Kv3.1b expression and intracellular K+ level, overproduction 
of ROS, loss of transmembrane mitochondrial potential and 
increased plasma membrane permeability in 158N cells. The cor-
relations were determined with the Spearman correlation test: r 
was in the range of 0.8 and p ≤ 0.005.
Conclusion: Our data support that the lipid environment affects 
P2X7 activity and Kv3.1b channel expression and/or functional-
ity, and that the subsequent rupture of K+ homeostasis as well as 
enhanced [K+]i is relied with oligodendrocytes damages. It is sug-
gested that the ability to modulate K+ homeostasis with drugs 
capable to modulate ATP and voltage dependent K+ channels 
could constitute new pharmacological targets to prevent oligoden-
drocytes dysfunctions in multiple sclerosis.
Disclosure
Maryem BEZINE, Thomas NURY, Rym BEN-KHALIFA, Anne 
VEJUX, Jérôme de SEZE, Mohamed EL-AYEB, Thibault 
MOREAU and Gérard LIZARD have nothing to disclose.
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The Australian Alfred Alemtuzumab Experience
C.S. Nesbitt, L. Rath, O. Skibina
Alfred Hospital, Neurology and Neuroscience, MS Services and 
Neuroimmunology, Alfred Health, Melbourne, VIC, Australia
Relapsing Remitting Multiple Sclerosis (RRMS) is an increas-
ingly prevalent condition. Treatments to date have focused on sta-
bilising the inflammatory aspect of disease and maintaining 
current level of function. Alemtuzumab (Lemtrada®) an anti-
CD52 monoclonal antibody is known to reduce disease activity 
and disability accumulation in primary drug trials. The Australian 
MS population is a unique demographic to study as there are no 
barriers to access or funding for any of the highly effective thera-
pies at any stage of the MS disease process.
Aim: To assess the treatment effect of Alemtuzumab for RRMS in 
an Australian centre, and ascertain if patient outcomes are 
improved with this new aggressive therapy.
Hypothesis: Patients with an EDSS (Expanded Disability Scoring 
Status) of 3-4.5 are likely to develop increasing disability from 
RRMS and will benefit most from new aggressive treatments.
Methods: 15 patients were treated for RRMS at Alfred Health with 
Alemtuzumab and followed up between 2 and 15 months (average 8 
months) with clinical review and EDSS assessment. There were 11 
females and 4 males with an average MS disease duration of 7 years.
Results: The average EDSS score prior to commencement of 
Alemtuzumab was 6.1. The average EDSS following treatment was 
2.73 revealing that patients treated with Alemtuzumab had an average 
EDSS reversal of 3.4. All the patients were treated with highly effec-
tive MS therapies prior to Alemtuzumab treatment. Most patients 
changed to Alemtuzumab due to long term safety concerns with their 
previous therapies and not because of ongoing MS disease activity.
Additional sub-group analysis determined that patients with a pre-
treatment EDSS between 3 and 4.5 had the greatest EDSS reversal 
compared to those with a pre-treatment EDSS < 2.5 or >6 where 
there was no significant change in EDSS. All patients had EDSS 
stabilisation following treatment.
Conclusion: All patients in this study received highly effective 
MS treatment prior to Alemtuzumab. This new therapy not only 
stabilised EDSS scores, but in several cases lead do EDSS rever-
sal. Our single centre experience suggests patients with EDSS 
scores of 3-4.5 are most at risk of accumulating disability and the 
most likely to positively respond to this new aggressive therapy.
Disclosure
Dr Skibina and Dr Nesbitt have both previously received sponsor-
ship from Genzyme to attend educational meetings
There are no additional meaningful disclosures
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Attenuation of 7-ketocholesterol and 7β-hydroxycholesterol - 
induced lipotoxicity by dimethylfumarate, monomethylfuma-
rate and biotin on 158N murine oligodendrocytes
R. Sghaier1,2, A. Zarrouk2,3, T. Nury1, A. Vejux1, A.S. 
Masmoudi4, T. Moreau1,5, G. Lizard6
1Lab. Bio-PeroxIL / EA 7270, Univ. Bourgogne Franche-Comté, 
Dijon, France, 2Laboratory of Biochemistry, Faculty of Medicine, 
Univ. Sousse, Sousse, 3LR 12 ES 05, Lab-NAFS ‘Nutrition - 
Functional Food & Vascular Health’, Faculty of Medicine, 
4Lab. Biotechnology, Univ. Monastir, Monastir, Tunisia, 5Dept. 
Neurology, Univ. Hospital of Dijon, 6Lab. Bio-PeroxIL / EA 7270, 
Univ. Bourgogne Franche-Comté / Inserm, Dijon, France
Aims: Mitochondrial dysfunctions and oxidative stress are 
involved in multiple sclerosis (MS) associated with lipid peroxida-
tion leading to increased levels of 7-ketocholesterol (7KC) and 
7β-hydroxycholesterol (7β-OHC). These compounds induce oxi-
dative stress, inflammation and cell death. Therefore, it is impor-
tant to identify natural and synthetic compounds to counteract their 
side effects. So, the eventual protective effects of dimethylfuma-
rate (DMF) and biotin (Vit B8), used for the treatment of MS, and 
of monomethylfumarate (MMF), the main metabolite of DMF, 
were evaluated on 7KC- and 7β-OHC-treated oligodendrocytes.
Methods: Murine oligodendrocytes 158N were exposed to 7KC or 
7β-OHC (50 µM, 24 h) without or with DMF, MMF (25 µM) or 
biotin (10-100 nM). The activities of 7KC and/or 7β-OHC without 
or with DMF, MMF and biotin were evaluated by complementary 
methods: phase contrast microscopy, crystal violet test (quantifica-
tion of adherent cells), MTT test (measurement of succinate 
dehydrogenase activity), flow cytometry (measurement of the mito-
chondrial potential (ΔΨm), O2●- and H2O2 production, with 
DiOC6(3), dihydroethidine and dihydrorhodamine 123, respec-
tively; measurement of plasmic membrane integrity with propidium 
iodide (PI) and fluoresceine diacetate (FDA)). Apoptosis and 
autophagy were evaluated with Hoechst 33342 and acridine orange, 
respectively, and by Western blotting with specific antibodies 
against uncleaved and cleaved caspase-3 and PARP, and LC3-I/II.
Results: The cytotoxic effects of 7KC were attenuated by DMF 
and MMF: cell growth inhibition, loss of cell adhesion, decrease 
of ΔΨm, O2●- and H2O2 overproduction, PARP and caspase-3 
cleavage, nuclear condensation and fragmentation, and activation 
of LC3-I into LC3-II. Biotin attenuates 7β-OHC-induced cell 
death: the number of non-adherent cells is decreased as well as the 
number of cells with damaged membranes and/or dead cells iden-
tified with PI and FDA; the number of cells with depolarized 
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mitochondria is reduced, and the decrease of mitochondrial suc-
cinate dehydrogenase activity is attenuated. The side effects of 
7KC and 7β-OHC were significantly reduced (Mann Whitney 
test, P< 0.05) with DMF, MMF and biotin.
Conclusion: Major side effects of MS, oxidative stress and mitochon-
drial dysfunctions leading to cell death of oligodendrocytes, are attenu-
ated by DMF, MMF and Biotin. These data support that these molecules 
could be of interest to prevent oligodendrocyte dysfunctions in MS.
Disclosure
Randa SGHAIER, Amira ZARROUK, Thomas NURY, Anne 
VEJUX, Ahmed Slaheddine MASMOUDI, Thibault MOREAU 
and Gérard LIZARD have nothing to diclose
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Modifying the migration velocity of oligodendrocyte progeni-
tors by altering the expression of PDGFRα via CRISPR-Cas9
M.J. Ulloa Navas, M.C. Gonzalez Calixto, J.M. Garcia Verdugo, 
V. Herranz Perez
Laboratory of Comparative Neurobiology-CIBERNED, 
Universidad de Valencia-Instituto Cavanilles, Valencia, Spain
Oligodendrocyte progenitor cells (OPCs) are capable of remyelinat-
ing injured axons caused by multiple sclerosis (MS). Demyelinated 
axons secrete PDGF-AA to direct chemotactic migration of PDGFRα-
expressing OPCs. Still, this mechanism is not sufficient to achieve 
robust remyelination given that inflammation and demyelination 
activate fibrous astrocytes and microglia. Fibrous astrocytes and 
microglia generate a glial scar, which obstructs OPCs to contact with 
the axon thereby, blocking remyelination. Here, we demonstrate that 
by modifying the expression levels of PDGFRα in OPCs migration 
velocity can be altered. We transfected vectors based on CRISPR-
Cas9 system targeting PDGFRα gene promoter to alter protein 
expression. CRISPR-Cas9 stimulates genome editing by creating a 
double strand break (DSB) in a precise locus, thereby inducing DNA 
repair by either non-homologous end joining (NHEJ) or homology 
directed repair (HDR). Transfection of two different constructs 
directed to PDGFRα promoter into mouse derived OPCs resulted in 
efficient expression of GFP reporter protein. We did not observe sig-
nificant ultrastructural differences between transfected and non-
transfected cells in transmission electron microscopy (TEM). By 
means of immunogold TEM, we observed GFP bound to the plasma 
membrane and to intermediate filaments as well as, inside the 
nucleus. We next sought to assess the effect of our approach on OPC 
migration efficiency by chemotaxis assays. Transfected cells exhib-
ited a significant reduction in terms of migration velocity. This effect 
was more evident in OPCs transfected with PDGFRα1 promoter-
Cas9, suggesting that regulation of PDGFRα-mediated signalling via 
CRISPR-Cas9 is a promising tool for the treatment of demyelinating 
lesions. Our current efforts are focused on transfecting a linear DNA 
sequence containing a strong promoter flanked by homologous arms 
together with the PDGFRα promoter-Cas9 plasmids. We expect that 
these genomic editions might increase OPC chemotactic migration 
efficiency and eventually, modified cells could be engrafted into 
lysolecithin injected mice to assess remyelination efficiency.
Disclosure
This research was supported by grants from the Spanish Network 
for Cell Therapy (ISCIII2012-RED-19-016) and the Spanish 
Ministry of Economy and Competitiveness (SAF2012-33683).
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Effect of erythropoietin on disease activity and conversion 
into multiple sclerosis after optic neuritis
K.-W. Sühs1, P. Papanagiotou2, K. Hein3, R. Pul4, K. Scholz5, C. 
Heesen6, R. Diem7
1Medical School Hannover, Hannover, 2Hospital Bremen Mitte, 
Bremen, 3Georg-August University, Göttingen, 4Essen University 
Hospital, Essen, 5Lüneburg Hospital, Lüneburg, 6University 
Hospital Hamburg-Eppendorf, Hamburg, 7University Clinic 
Heidelberg, Heidelberg, Germany
Introduction: In the EAE model of optic neuritis, erythropoietin 
was particularly effective when given in combination with meth-
ylprednisolone, and proved to exert neuroprotective effects in 
humans, too. Yet it is unknown if erythropoietin has any effects on 
MRI activity in MS patients
Methods: We analyzed changes in cerebral lesion load by mag-
netic resonance imaging (MRI) in 35 patients from a double-blind, 
placebo-controlled, phase II study on erythropoietin in clinically 
isolated optic neuritis (ClinicalTrials.gov, NCT00355095). In the 
trial patients with acute optic neuritis were assigned to receive 
either 33,000IU recombinant human erythropoietin i.v. daily for 
three days, or placebo, as an add-on to methylprednisolone. MRIs 
were recorded at baseline and at weeks 4, 8, and 16.
Results: During the observation period there was no significant 
difference between the groups with respect to the change in abso-
lute numbers of periventricular, juxtacortical, and infratentorial 
lesions including gadolinium-enhancing lesions. In ten of thirty-
five patients we found MRI disease progression already within the 
observation period of 16 weeks. In 5 (14%) patients, we found a 
conversion into multiple sclerosis (MS) based on MRI progres-
sion only. These patients all received placebo. Another 5 patients 
showed MRI progression together with relapses. Three of these 
patients had received erythropoietin, two placebo.
Conclusions: After isolated optic neuritis erythropoietin treat-
ment did not change MRI progression. However during follow-up 
early conversion to CDMS seemed to occur more frequently in the 
placebo-treated group.
Disclosure
KW.S: no conflict of interest
R.D.: no conflict of interest
K.H.: no conflict of interest
C.H.: no conflict of interest
P.P.: no conflict of interest
K.S.: no conflict of interest
R.P.: no conflict of interest
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Mapping proteomics changes induced by fingolimod in dif-
ferent regions of the brain and retina
V.K. Gupta1, M. Mirzaei2, A. Klistorner1,3, S. Graham1,3
1Faculty of Medicine and Health Sciences, 2Department of 
Chemistry and Biomolecular Sciences, Macquarie University, 
3Save Sight Institute, Sydney University, Sydney, NSW, Australia
06_MSJ731285.indd   882 13/10/2017   11:11:03 AM
ePosters 23(S3) 883
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Purpose: Fingolimod (FTY720) is widely used in the manage-
ment of multiple sclerosis and is known to upregulate Akt and Erk 
neuroprotective survival signalling pathways in the neurons and 
astrocytes. The drug protects neurons against ischemic stroke and 
has also been shown to protect the retina against damage caused 
by experimental glaucoma. In this study, we aimed to investigate 
the molecular changes caused by fingolimod in the retina and dif-
ferent regions of the brain under normal conditions.
Methods: CBA/CaHArc mice were treated with the FTY720 drug 
(7.5 mg/kg i.p weekly) or vehicle control for 2 months. Retina and 
brain tissues (frontal cortex, hippocampus, cerebellum) were har-
vested and examined from drug treated and control mice (n=10). A 
multiplexed proteomics using chemical isobaric tandem mass tags 
(TMTs) using LC/MS was carried out. Detailed functional and pro-
tein-protein interaction analyses were performed using Ingenuity 
pathway analysis, STRING and Panther computational tools.
Results: FTY720 administration lead to differential proteomics 
changes in various regions of the central nervous system (CNS) 
particularly in the frontal cortex and cerebellum. Mass spec-
trometry revealed 29, 10, 1272 and 667 upregulated and 16, 22, 
1361, 1265 downregulated proteins in the retina, hippocampus, 
frontal cortex and cerebellum respectively out of a total of 
>6000 proteins identified in each case. Computational analysis 
demonstrated several of the proteins associated with neuropro-
tective signalling were upregulated (e.g; Sphingosine 1 phos-
phate receptor 1 (S1PR1) p< 0.0001; phosphatidylinositol 
3-Kinase < 0.02; insulin receptor < 0.001; serpin a3k < 0.00001) 
while markers associated with pro-inflammatory and apoptotic 
pathways (Caspase 1< 0.007; caspase 3 < 0.01; Tumour necro-
sis factor (TNF) alpha < 0.0001; tissue plasminogen activator 
(tPA) < 0.02; interleukin 1R < 0.001; interleukin enhancer bind-
ing factor 2 (ILF2) < 0.03) were downregulated.
Conclusions: This study for the first time provides a compre-
hensive profile of proteomics changes in different CNS 
regions under normal conditions upon chronic fingolimod 
treatment. Protein quantification and computational analysis 
highlight that fingolimod not only promotes suppression of 
pro-inflammatory pathways, but also up-regulates neuropro-
tective pathways.
Disclosure
Vivek Gupta: Nothing to disclose.
Mehdi Mirzaei: Nothing to disclose.
Alexander Klistorner: Nothing to disclose.
Stuart Graham: Nothing to disclose.
Source of funding: Novartis Pharmaceuticals Australia.
Long-term treatment monitoring
EP1680
Observational study to evaluate real-world effectiveness in 
multiple sclerosis patients treated with alemtuzumab in Ger-
many: TREAT-MS study preliminary results
K. Thomas1, A. Leptich2, R. Kern1, U. Engelmann3, R. Haase1, 
T. Ziemssen1, on behalf of the TREAT-MS Study Group
1Center of Clinical Neuroscience, Carl Gustav Carus University 
Hospital, Dresden, 2Clinical Study Unit, Sanofi Deutschland 
GmbH, Frankfurt am Main, 3Medical Affairs, Sanofi 
Deutschland GmbH, Neu-Isenburg, Germany
Background: Alemtuzumab, a humanised anti-CD52 monoclonal 
antibody, is approved in >60 countries for patients with RRMS. In 
2 phase 3 studies, alemtuzumab administered in 2 annual courses 12 
months apart had improved efficacy versus SC IFNB-1a over 2 
years. In an extension, efficacy was durable over 6 years in the 
absence of continuous treatment, with manageable safety; long-
term evaluation is ongoing (TOPAZ; NCT02255656). Real-world 
data on alemtuzumab use in clinical practice are limited.
Goal: Report preliminary real-world safety and effectiveness 
results from the ongoing TREAT-MS study (non-interventional 
long-Term study foR obsErvAtion of Treatment with alemtu-
zumab in active relapsing-remitting MS) of alemtuzumab in 
RRMS patients in Germany.
Methods: TREAT-MS is a 5-year, observational, longitudinal study 
of patients (max: 3200) treated with alemtuzumab according to 
German prescribing information, with prospective and retrospective 
data collection. Follow-up will continue for 48 months post last dose. 
Assessments: change from baseline (BL) in EDSS score; Physicians’ 
Clinical Global Impression (PCGI) score; adverse events (AEs).
Results: As of April 27, 2017, 566 patients were screened; 547 
(96.6%) were treated (537 received Course 1). BL characteristics: 
71.0% female; mean (SD) age 35.5 (9.0) years (range, 16-62 years); 
time since first MS symptoms 7.7 (6.6) years; time since MS diagno-
sis 7.1 (6.3) years; relapses in 12/24 months before inclusion 1.7 
(1.2)/2.3 (1.9). Immediate prior medication: fingolimod (23.4%); 
natalizumab (20.8%); interferon beta preparations (10.5%); glati-
ramer acetate (5.5%); others (15.8%); none (15.8%); unknown 
(7.8%). After alemtuzumab, mean (SD) and median EDSS estimates 
were stable from BL (3.0 [1.8], 2.5) to Month 12 (2.8 [1.8], 2.5) and 
Month 24 (2.7 [1.7], 2.5); mean PCGI score improved from 3.9 (1.3) 
at BL to 3.6 (1.2) at Month 12 and 3.4 (1.2) at Month 24 (P< 0.001). 
Median PCGI was constant (4.0). Percentage rated slightly, border-
line, or not ill: 33.9% (BL); 43.7% (Month 12); and 48.5% (Month 
24). Safety profile was similar to previous clinical trials.
Conclusion: Patients in TREAT-MS have different BL characteris-
tics compared with those in the registration studies (due to different 
prior medications), and showed stable EDSS and stable/improved 
PCGI scores through 2 years. TREAT-MS data will help provide 
additional guidance for optimising sequencing to/from alemtu-
zumab and monitoring of alemtuzumab-treated RRMS patients.
Study support: Sanofi.
Disclosure
KT: Personal compensation for consulting services (Biogen, 
Novartis, and Roche). 
AL and UE: Employees of Sanofi.
RK: Compensation for consulting services (Bayer HealthCare, 
Biogen, Novartis, Sanofi Genzyme, and Teva).
RH: Nothing to disclose.
TZ: Consulting and/or speaking fees (Almirall, Bayer, Biogen, 
Merck, Novartis, Roche, Sanofi Genzyme, and Teva); grant/
research support (Biogen, Novartis, Sanofi Genzyme, and Teva).
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A retrospective claims analysis: compliance and discontinua-
tion rates among anadians MS patients treated with disease-
modifying therapies at 6, 12 and 24-months - Canadian real 
world experience
P. Duquette1,2, M. Yeung3, R. Schecter4, P. Haddad4, K. Jobin 
Gervais4
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Montréal, QC, 3Multiple Sclerosis Clinic, University of Calgary, 
Calgary, AB, 4Novartis Pharmaceuticals Canada Inc, Dorval, 
QC, Canada
Background: Compliance to therapy has been associated with a 
reduced risk of relapse, reduced healthcare resource utilization 
and improved health-related quality-of-life in patients with multi-
ple sclerosis (MS).
Objective: To assess compliance and discontinuation rates with 
Disease-Modifying Therapies (DMTs) in Canadian patients with 
Relapsing-Remitting MS (RRMS).
Methods: In this Canadian retrospective claims analysis based on 
Rx Dynamics® data from IMS Health Canada Inc., patients had 
≥1 prescription filled for each DMT (oral: fingolimod, dimethyl 
fumarate (DMF), teriflunomide; injectable (BRACE): interferon 
beta-1a, interferon beta-1b, glatiramer acetate; infusible: natali-
zumab). Patients were considered compliant if the medication 
possession ratio (MPR) was ≥80%. Discontinuation rates were 
calculated based on patients who stopped therapy (60 day win-
dow) or who were switched to another DMT. Compliance and 
discontinuation rates were collected 6, 12 and 24-month periods 
(cohorts from 2013-2017, rolling 36 months total).
Results: Compliance and discontinuation data was collected after 
6 month (n=12543, n=9460 respectively), 12 month (n=7665, 
n=7234) and 24 month (n=6047, n=6030) periods. The percentage 
of patients deemed compliant after 6, 12- and 24-months across 
Canada was higher for fingolimod (75%, 76%, 71% respectively), 
compared to natalizumab (72%, 73%, 56%), DMF (71%, 68%, 
55%), and BRACE (52%, 46%, 35%) and comparable to teriflu-
nomide (76%, 77%, 68%). Patients on fingolimod had the lowest 
discontinuation rate after 6, 12 and 24-month periods (26%, 25%, 
29% respectively) compared to: BRACE (48%, 35%, and 55%); 
natalizumab (34%, 29%, and 49%) and DMF (31%, 30% and 
43%); and similar to teriflunomide (26%, 25%, 31%).
Conclusions: The percentage of patients deemed compliant and 
treated with fingolimod was higher than for other DMTs but was 
similar to teriflunomide. Unlike other DMTs, the discontinuation 
rate with fingolimod did not significantly increase and the compli-
ance rate with fingolimod remained stable over the 24-month 
period. The discontinuation rate of fingolimod was lower com-
pared to other DMTs at all time points and was similar to terifluno-
mide. This analysis provides insight into short and medium term 
compliance and discontinuation of DMTs in a Canadian real-world 
setting. These findings may inform MS management strategies 
which may lead to improved clinical and economic outcomes.
Disclosure
Pierre Duquette: has received honoraria for advisory boards, for 
CMEs from Novartis, Biogen-Idec, Genzyme, EMD Serono and 
Teva Neurosience. He has taken part in Investigator-initiated tri-
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and has received funding from peer-reviewed agencies such as the 
Canadian Institutes for Health Research (CIHR) and the MS 
Society of Canada.
Michael Yeung: has received honoraria for consultation fees 
from EMD-Serono, Genzyme and Novartis, and the Canadian 
Agency for Drugs and Technologies in Health (CADTH/Health 
Canada), and research support from Biogen-Idec, Genzyme, 
Hoffmann-La Roche, Novartis, and Teva Canada Innovation.
Robyn Schecter: is an employee of Novartis Pharmaceuticals 
Canada Inc.
Paola Haddad: is an employee of Novartis Pharmaceuticals 
Canada Inc.
Katherine Jobin Gervais: is an employee of Novartis 
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A Swedish nationwide pharmaco-epidemiological study of 
the long-term safety and effectiveness of dimethyl fumarate 
(IMSE 5)
L. Forsberg1, S. Kågström1, Å. Leandersson1, A. Berglund1,2, J. 
Hillert1, P. Nilsson3, C. Dahle4, A. Sveningsson5, J. Lycke6, A.-
M. Landtblom7, J. Burman7, F. Walentin8, C. Martin5, F. Piehl1, 
T. Olsson1
1Department of Clinical Neuroscience, Karolinska Institutet, 
Stockholm, 2Medical Department, Biogen, Upplandsväsby, 
3Department of Neurology, Lund University, Lund, 4Department 
of Clinical and Experimental Medicine, Linköping University, 
Linköping, 5Department of Clinical Science, Danderyd 
Hospital, Stockholm, 6Department of Clinical Neuroscience 
and Rehabilitation, University of Gothenburg, Gothenburg, 
7Department of Neuroscience, Uppsala University, Uppsala, 
8Örebro University Hospital, Örebro, Sweden
Background: Dimethyl fumarate (DMF) is an oral therapy for 
relapsing-remitting multiple sclerosis (RRMS), the efficacy of which 
has been shown in phase II and III studies. However; post-marketing 
surveillance is important to determine the long-term safety and effec-
tiveness in a real-world setting. DMF has therefore been included into 
the Swedish post-market surveillance study “Immunomodulation and 
Multiple Sclerosis Epidemiology” (IMSE).
Objectives: To follow-up the long-term safety and effectiveness 
of DMF in a real-world setting.
Methods: MS patients in Sweden are registered into the nation-
wide web-based Swedish Neuro registry (Neuroreg). The IMSE 
study includes descriptive data of adverse events (AEs), extended 
disability status scale (EDSS), MS severity scale (MSSS), symbol 
digit modalities test (SDMT), MS impact scale (MSIS-29), 
European quality five dimensions (EQ-5D) and Visual Analog 
scale (VAS) obtained from Neuroreg. Blood samples are collected 
at baseline and after 12 and 24 months of treatment. Drug survival 
was measured using the Kaplan-Meier curve and effectiveness 
measures were assessed using the Wilcoxon Signed Rank Test.
Results: 1820 DMF-treated patients have been included in the 
IMSE 5 study between March 25th, 2014 and April 30th, 2017 most 
of which have switched from interferons or glatiramer acetate 
(44%), 23% of the patients were treatment naïve (11% missing 
data on prior treatment). 91% of the patients have RRMS (4% 
missing data on MS phenotype). The mean treatment duration is 
18.0 ± 11.1 months, the mean age at treatment start is 40.8 ± 11.0 
years and 73% are female.
The one year drug survival was 74% and discontinuation was signifi-
cantly more common among female than male patients (p< 0.05).
In patients treated with DMF continuously for ≥24 months 
(n=669), significant improvements in mean values at 24 months 
of treatment compared to mean baseline values have been noted 
for MSSS by 24% (2.6 ± 2.4 to 2.1 ± 2.2, n=120); SDMT by 2% 
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(52.0 ± 10.8 to 53.0 ± 11.4, n=242); and MSIS-29 Psychological 
subscale by 15% (27.9 ± 23.0 to 24.3 ± 21.1, n=240). EDSS, 
MSIS-29 Physical subscale, EQ-5D and VAS did not improve 
significantly.
Conclusions: Neuroreg proves to function well as a post-market-
ing drug surveillance platform, providing data regarding drug 
effectiveness and AEs. DMF is generally well tolerated; however 
a longer follow-up period is needed to assess the real-world effec-
tiveness and safety of DMF.
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Clinical and economic evaluation of alemtuzumab compared 
to ocrelizumab in the treatment of relapsing forms of mul-
tiple sclerosis in the United States: a payer perspective
V. Chirikov1, I. Ma2, N. Joshi1, D. Patel1, A. Smith2, C. 
Giambrone2, N. Cornelio1, L. Hashemi2
1Pharmerit International, Bethesda, MD, 2Sanofi, Cambridge, 
MA, United States
Background: Alemtuzumab (ALEM) and ocrelizumab (OCR) 
each demonstrated improved clinical efficacy outcomes vs SC 
IFNB-1a in patients with active relapsing MS (RMS) in 
randomised phase 3 clinical trials over 2 years (y) (ALEM: 
CARE-MS I [NCT00530348]/CARE-MS II [NCT00548405]; 
OCR: OPERA I [NCT01247324]/OPERA II [NCT01412333]). 
ALEM demonstrated durable efficacy over 6 y in an extension 
(NCT00930553) in the absence of continuous treatment. 
OCR launched in the US at lower annual cost than other 
therapies.
Goal: To evaluate the relative clinical and economic benefit of 
ALEM vs OCR in patients with RMS in the US.
Methods: A Markov model (using British Columbia MS data to 
project disease progression) of patients transitioning in annual 
cycles through EDSS health states, was run from a US payer per-
spective. The modelled population represented demographic and 
clinical characteristics of pooled treatment-naive and -experi-
enced patients from CARE-MS I and II. ALEM and OCR effi-
cacy inputs were derived from network meta-analysis. Compared 
to no treatment, the relative risk (95% CI) for reducing relapses 
was 0.31 (0.26-0.36) for ALEM and 0.35 (0.26-0.47) for OCR. 
The hazard ratio for slowing 6-month (mo) confirmed disability 
worsening was 0.41 (0.27-0.63) for ALEM and 0.46 (0.29-0.72) 
for OCR. For ALEM (12 mg/d IV; baseline: 5 d; 12 mo later: 3 d; 
as-needed retreatment: ≥12 mo after previous course for relapse/
MRI activity), acquisition cost was $103,749 in Y1 (Course 1) 
and $62,250 in Y2 (Course 2) and all subsequent courses. For 
OCR, acquisition cost was $65,000 annually. Administration and 
monitoring costs per year were lower for OCR than ALEM. 
Safety information was extracted from FDA-approved prescrib-
ing information.
Results: Over a 20-y horizon, 8.89 quality-adjusted life y 
(QALYs) and $426,169 total costs were accumulated with ALEM 
vs 8.46 QALYs and $908,742 total costs with OCR. Patients on 
ALEM had fewer relapses (mean: 7.1) compared with those on 
OCR (mean: 8.5). QALY loss due to adverse events was -0.126 
for ALEM vs -0.006 for OCR. The OCR withdrawal rate and the 
assumption of ALEM durable efficacy over 6 y were identified as 
the most influential model parameters.
Conclusion: In this analysis, ALEM is projected to be cost-saving 
and more effective vs OCR. Results should be interpreted with 
caution as a head-to-head comparison is unavailable, but they 
offer evidence of economic and clinical benefits of ALEM vs 
OCR from a US payer perspective.
Study support: Sanofi.
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Regression of erythroblastaemia in natalizumab-treated 
patients with multiple sclerosis after drug suspension
S. La Gioia, V. Barcella, M.Z. Conti, B. Frigeni, M. Vedovello, 
C. Zanchi, M. Rottoli
USC Neurologia, ASST Papa Giovanni XXIII, Bergamo, Italy
Objectives: Erythroblastaemia has been previously reported as a 
frequent finding of natalizumab treatment in multiple sclerosis 
patients. Its long-term clinical or pathological implications are 
still to be understood. We investigated the persistence of erythro-
blastaemia after natalizumab suspension.
Materials and methods: We retrospectively evaluated the blood 
samples of 15 subjects with erythroblastaemia during natalizumab 
and who were withdrawn from treatment.
Results: All our patients had been treated with more than 12 natali-
zumab infusions and they suspended the treatment due to evidence 
of antiJCV antibodies. Erythroblastaemia was present in all cases 
at the last blood sample before the last drug administration. 
Erythroblasts were absent in all blood samples of our patients after a 
mean time of 2.8 months (range 1-4 months) after drug suspension.
Discussion and conclusions: The prevalence of erythroblastaemia 
has been previously reported to be significantly higher in patients 
treated with natalizumab compared to patients on other multiple 
sclerosis treatments. These previous data raised some issues on 
long term pathological implications. Our last findings support the 
hypothesis of erythroblastaemia as a transient phenomenon during 
natalizumab treatment: it appears then acceptable to refrain from 
further diagnostic procedures during treatment in the absence of 
any other laboratory results suggesting underlying disorders. A 
larger sample of patients is needed to confirm our data.
Disclosure
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Case series: a specialty center 10 year experience with use 
of azathioprine in neuromielytis optica spectrum disorders 
(NMOSD)
A.B. A G R Gomes1, A. de Moura Brasil Matos1, L.M. Gomes 
de Brito Ventura1, M. Sales Pitombeira1, R. Barbosa Paolilo1, 
P.H. Bruel Torretta1, F. Menucci de Haidar Jorge1, D. Kazutoshi 
Sato2, D. Callegaro1, S.L. Apóstolos Pereira1
1Neurology, Universidade de Sao Paulo, São Paulo, 2Neurology, 
Pontifical Catholic University of Rio Grande do Sul, Porto 
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Introduction: The therapy of neuromielytis optica spectrum dis-
orders (NMOSD) targets early treatment and prevention of 
relapses as well as improvement of relapse-associated symptoms. 
Without adequate relapse prevention most patients will present a 
devastating stepwise accumulation of disability. Azathioprine was 
historically used for the management of multiple sclerosis and it is 
currently widely used in the treatment of NMOSD. An increase in 
risk of cancer has been reported in patients with long term use of 
azathioprine for intestinal and rheumatologic diseases. There is no 
such description for patients with NMOSD. We report our experi-
ence with the long term use of azathioprine in NMOSD patients.
Methods: We conducted a retrospective medical record review of 
all Hospital das Clínicas da Universidade de São Paulo - Brazil- 
patients who filled NMOSD 2015 criteria and were treated with 
azathioprine for at least 10 years.
Results: Of 375 reviewed records, 18 patients met inclusion crite-
ria (4.8%); 17 were female and 1 was male, 17 were NMO-IgG 
seropositive. Median age was 44 years (27-56). Median time of 
disease was 15 years (10-39). Mean duration of treatment was 
12.43 (SD = 3.16). Mean relapse/year rate prior and post introduc-
tion of azathioprine was 0.928 (SD = 0.478) and 0.131 (SD = 
0.115) with a statistically significant reduction (p < 0.001) on 
analysis. Eleven of the patients (61.1%) had been free of relapses 
for at least 5 years. Three patients (16.6%) had records of adverse 
events during the follow up: chronic B12 deficiency, pulmonary 
tuberculosis and breast cancer. At the time of the review 13 of the 
18 patients (72%) were still receiving azathioprine, 1 had been 
switched methotrexate due to long exposure to azathioprine, 1 to 
rituximab due to failure of therapy and the remainder 3 had immu-
nosuppression discontinued due to stability of disease.
Discussion: Adverse events are a concern for patients undergoing 
long term use of azathioprine; therefore screening is warranted. In 
our sample, azathioprine was considered relatively safe with only 
one report of malignancy (5.5 %) and effective in relapse preven-
tion (p < 0.001) at a 10 year follow up.
Conclusion: We believe the risks of adverse events are surpassed 
by the clinical benefits of azathioprine use, therefore we suggest a 
vigilant maintenance of therapy for responding patients with long 
use of the drug.
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Real World Evidence (RWE) on long-term persistence 
to medications for relapsing-remitting multiple sclerosis 
(RRMS) in the Australian community (REALITY)
M. Schulz1, B. Arora1, E. Chung2, P. Juneja2, R. Walker1, S. 
Verhaeghe1, T. Spelman3, S. Broadley4
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Background: This study aimed to examine and compare patient 
persistence to all publicly-funded disease modifying therapies 
(DMTs) for relapsing-remitting multiple sclerosis (RRMS) in 
Australia.
Method: The Australian Government Medicare Database was 
used in this study. For patients to be eligible for the study they 
needed to have received a script for a reimbursed MS disease 
modifying therapy between September 2011 and February 2016. 
Patient demographics were summarized using mean and standard 
deviation or frequency percentage. Persistence was defined as a 
patient that remained on a DMT with a gap in scripts of no longer 
than 4 months. Individual patients could be included multiple 
times if they initiated a new DMT during the study period. 
Persistence was derived using the Kaplan-Meier method and haz-
ard ratios (HR) calculated to compare persistence rates between 
different treatments; p-values were based on the log-rank test.
Results: A total of 720 unique patients were eligible for the study. 
The majority were female (73.5%) and aged between 36-65 
(64%). These patients contributed 1827 observations that were 
used for analysis (i.e. 2.5 new initiations/patient). Overall the 
median persistence to therapy was 29.6 months with 67.7% of 
patients remaining on therapy for 12 months. The only DMT that 
had significantly better persistence compared to the overall aver-
age, was fingolimod (HR 0.65 (95%CI: 0.57-0.73; p< 0.001)). 
Patients had a median persistence of 60 months on fingolimod and 
79.5% of patients were persistent at 12 months. Patients were sig-
nificantly less persistent to interferon Beta-1a, interferon Beta-1b, 
glatiramer acetate and dimethyl fumarate (hazard ratios above 
1.27 (p values all ≤ 0.001) whilst the remaining DMTs, terifluno-
mide and natalizumab, showed no significant difference from the 
average persistence.
Conclusion: In Australia, reimbursed MS patients were most persis-
tent to fingolimod treatment amongst all DMTs. The implications of 
this superior persistence and how it may translate to differences in 
clinical effectiveness will be the subject of future studies.
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Long-term real-life retrospective analysis on interferon β1-a 
use in RRMS patients in Finland
A. Murtonen1, J. Vuorio1, E. Järvinen2, A. Wiksten3, M.-L. 
Sumelahti1
1University of Tampere, Tampere, 2Merck Finland, 3StatFinn, 
Espoo, Finland
Objective: To study the long-term real-life use of interferon β1-a 
sc tiw in relapsing remitting multiple sclerosis (RRMS) patients, 
and to investigate the duration of the treatment periods, the causes 
of treatment cessation, and changes in expanded disability status 
scale (EDSS).
Methods: Clinical data was drawn in two population based 
cohorts diagnosed for RRMS during 1990 to 2010 and 2010 to 
2014. Patients treated with interferon β1-a sc tiw at the Tampere 
District University Hospital in Finland were included in the study. 
Baseline characteristics and study endpoints were summarized 
using descriptive statistics.
Results: Of the 680 patients diagnosed during 1990-2010, a total of 
293 initiated with interferon β1-a sc tiw. The average first treatment 
period lasted 2.9 years (standard deviation SD 2.89). The EDSS at 
treatment start was 1.7 (mean, SD 1.56) and 3.4 at the follow up of 
6.8 years (mean, SD 4.1).Of the 209 patients diagnosed during 2010-
2014, a total of 68 initiated with interferon β1-a sc tiw. The average 
first treatment period lasted 2.1 years (SD 1.55). The EDSS at treat-
ment start was 0.9 (mean, SD 1.08) and 1.3 at the follow up of 2.2 
years (mean, SD 1.3).Of the 361 patients in both cohorts, 39.1 % of 
the patients did not switch treatment. A total of 36.1% switched treat-
ment once. The activation of the disease was the most common cause 
for cessation of the treatment (24.1%). Other factors were low MXA 
titer (12.2%) and side effects (11.9%).A total of 53.7% did not have 
any treatment interruptions, 32.4% had one interruption.
Conclusions: Long-term compliance to treatment was observed 
in patients treated with interferon β1-a sc tiw.
Disclosure
Annukka Murtonen: Nothing to disclose
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Elina Järvinen: employee of Merck Finland, an affiliate of Merck 
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The burden of treatment monitoring in disease modifying 
therapies in Europe and the United States
J.L. White1, S. Gabriele1, R. Hooper1, H. Brown1, M. 
Dibonaventura2, B. Shah-Manek3
1Ipsos Healthcare, London, United Kingdom, 2Ipsos Healthcare, 
New York, NY, 3Ipsos Healthcare, San Francisco, CA, United 
States
Background: Increasingly, high efficacy infusion and oral dis-
ease modifying therapies (DMTs) possess extensive monitoring 
requirements during both treatment initiation and throughout the 
course of therapy.
Objective: To assess perceptions of the burden of monitoring 
requirements for multiple sclerosis (MS) treatments among 
healthcare professionals (HCPs) in both the 5EU (UK/Germany/
France/Italy/Spain) and the United States.
Methods: The Ipsos Healthcare Global MS Therapy Monitor, a 
multi-centre cross-sectional survey of HCPs (mainly Neurologists; 
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MS nurses included in UK) is run on a bi-annual basis in 5EU and 
US since 1997 to collect de-identified perceptions and barriers to use 
of DMTs. HCPs are recruited from a large panel to be geographically 
representative within respective countries. HCP perceptions from 
Q4 (September through December) in 2013, 2014, 2015, and 2016 
were analysed.
Results: 270 HCPs in 5EU (2013: N=265, 2014: N=275; 2015: 
N=269, 2016: N=275) and 100 HCPs in the US (2013: N=100, 
2014: N=100; 2015: N=111, 2016: N=99) were included. 58.4% 
and 60.3% of HCPs in the 5EU and US, respectively, associated 
high efficacy DMTs (natalizumab, alemtuzumab, fingolimod, 
daclizumab) with initial and on-going monitoring. The strength of 
this perception decreased over time (68.9% and 80.5%, respec-
tively in 2014 to 58.4% and 60.3% in 2016). Platform orals (terif-
lunomide, BG-12) were also frequently perceived to have 
monitoring requirements (46.9% and 55.6%, respectively). 11.5% 
(5EU) and 17.2% (US) of HCPs also perceived the monitoring of 
platform orals to be a barrier to prescribing; 19.8% (5EU) and 
33.1% (US) perceived the monitoring of high efficacy DMTs to be 
a barrier. In comparison, very few HCPs in both regions consid-
ered monitoring as a barrier to use of the platform injectables 
(Interferon beta-1a and 1b, Glatiramer Acetate); 2.3% (5EU) and 
1.4% (US).
Conclusions: HCPs in both the 5EU and US report that required 
monitoring programs for infusion and oral DMTs can be a signifi-
cant issue in comparison to traditional injectable treatments, that 
can often influence prescribing decisions. Although the perceived 
monitoring burden is declining over time, further research into 
how much this monitoring burden impacts HCP prescribing and 
also patient experience may be beneficial to improving access to 
these therapies.
Disclosure
Joanna White: nothing to disclose
Simone Gabriele: nothing to disclose
Rachael Hooper: nothing to disclose
Hannah Brown: nothing to disclose
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EP1689
A Swedish nationwide pharmaco-epidemiological study 
of the long-term safety and effectiveness of alemtuzumab 
(IMSE 3)
Å. Leandersson1, S. Kågström1, L. Forsberg1, J. Hillert1, P. 
Nilsson2, C. Dahle3, A. Svenningsson4, J. Lycke5, A.-M. 
Landtblom6, J. Burman6, F. Walentin7, C. Martin4, F. Piehl1, T. 
Olsson1
1Department of Neuroscience, Karolinska Institutet, Stockholm, 
2Department of Neurology, Lund University, Lund, 3Department 
of Clinical and Experimental Medicine, Linköping University, 
Linköping, 4Department of Clinical Sciences, Danderyd 
Hospital, Stockholm, 5Department of Clinical Neuroscience 
and Rehabilitation, University of Gothenburg, Göteborg, 
6Department of Neuroscience, Uppsala University, Uppsala, 
7Örebro University Hospital, Örebro, Sweden
Background: Alemtuzumab (ALZ) is a modulatory drug for 
patients with relapsing-remitting multiple sclerosis (RRMS). 
Post-marketing surveillance is important to assess the long term 
safety and effectiveness in a real-world setting. ALZ has therefore 
been included into the Swedish post-market surveillance study 
“Immunomodulation and Multiple Sclerosis Epidemiology 
Study” upon launch in Sweden (March 2014).
Objective: To follow up the effectiveness and long-term safety of 
ALZ in a real-world setting.
Methods: Swedish MS patients are registered into the nationwide 
web-based Swedish neuro registry (neuroreg). Before ALZ initia-
tion, patients are asked to participate in the IMSE 3 study. Adverse 
events (AEs) and clinical measures; extended disability status 
scale (EDSS), multiple sclerosis severity scale (MSSS), symbol 
digit modalities test (SDMT), multiple sclerosis impact scale 
(MSIS-29), European quality of life - 5 dimension test (EQ-5D), 
are obtained from neuroreg. The Wilcoxon signed-rank test was 
used to assess changes in effectiveness.
Results: Between March 2014 and April 2017, 104 patients (63% 
female; 95% RRMS) were included in the IMSE 3 study. Mean 
age at treatment start was 34 years. Mean number of drugs used 
before ALZ was 2.8 and most patients switched from Natalizumab 
(NTZ) (39%). In patients treated with Fingolimod (FGL) before 
ALZ (n=15), 47% were temporarily (≤ 5 months) treated with 
NTZ between FGL and ALZ start. 15% had ALZ as their very 
first disease modifying treatment. Six patients had discontinued 
ALZ treatment, of which five patients switched to another dis-
ease modifying therapy, and one patient died in association with 
the first ALZ treatment cycle due to fulminant viral hepatitis 
(Cytomegalovirus, Epstein-Barr Virus). 17 AEs were reported to 
the Swedish Medical Products Agency, 12 events were classified 
as non-serious. 97 patients had been treated for at least 12 months 
and 87 patients for at least 24 months. In patients treated at least 
12 months significant improvements were seen for EDSS 
(2.10±1.57 - 1.67±1.54, n=55), MSSS (3.43±2.76 - 2.64±2.42, 
n=47), VAS (66.8±21.9 - 73.2±17.7, n=63) and EQ5D (0.67±0.30 
- 0.76±0.25, n=70).
Conclusions: Neuroreg proves to function well as a post-marketing 
drug surveillance platform, providing data regarding drug effective-
ness and AEs. A longer follow-up period is needed to assess the 
real-world effectiveness and safety of ALZ.
Disclosure
The IMSE 3 study has received unrestricted grants from Sanofi 
Genzyme.
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for Biogen, Sanofi-Genzyme and Novartis and speaker’s fees 
from Biogen, Novartis, Merck-Serono, Bayer-Schering, Teva and 
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EP1691
A 8-year retrospective cohort study comparing Interferon-β 
formulations for relapsing-remitting multiple sclerosis
M. Moccia1, R. Palladino2, A. Carotenuto1, F. Saccà1, C.V. 
Russo1, R. Lanzillo1, V. Brescia Morra1
1Department of Neuroscience, Federico II University, Napoli, 
Italy, 2Department of Primary Care and Public Health, Imperial 
College London, London, United Kingdom
Objective: Interferon-β has been approved for the treatment of 
relapsing-remitting (RR) multiple sclerosis (MS), whereas its effi-
cacy in preventing long-term disability and conversion to second-
ary progressive (SP) MS is still debated. We aim to compare the 
long-term clinical evolution of newly-diagnosed RRMS patients 
treated with different Interferon-β formulations.
Methods: 507 patients were included in the analysis and fol-
lowed-up for 8.5±3.9 years. 37.6% were treated with subcutane-
ous Interferon-β1a (Interferon-β1a 44mcg), 33.4% with 
intramuscular Interferon-β1a (Interferon-β1a 30mcg), and 29.0% 
with subcutaneous Interferon-β1b (Interferon-β1b 250mcg). 
Relapse occurrence, 1-point EDSS progression, reaching of EDSS 
4.0 and conversion to SP were recorded as outcome measures. To 
reduce the selection bias, we calculated the propensity score of 
receiving the specific treatment considering age (32.7±8.3 years), 
gender (female 63.1%), disease duration (2.7±2.8 years), and 
baseline EDSS (1.5, range 1.0-3.5). Propensity score and covari-
ates (age, gender, disease duration and EDSS) were included in 
the statistical models.
Results: At Cox regression models, the reaching of EDSS 4.0 was 
20% higher for Interferon-β1b 250mcg (HR=1.207; p=0.063), and 
30% higher for Interferon-β1a 30mcg (HR=1.363; p=0.095), 
when compared with Interferon-β1a 44mcg. The rate of SP con-
version was 100% higher for Interferon-β1b 250mcg (HR=2.054; 
p=0.042), and 80% higher for Interferon-β1a 30mcg (HR=1.884; 
p=0.081), when compared with Interferon-β1a 44mcg.
Conclusion: Patients treated with Interferon-β1a 44mcg pre-
sented with a marginally reduced risk of disability accrual in the 
long-term, when compared with Interferon-β1b 250mcg and, at 
least in part, with Interferon-β1a 30mcg. Formulation, frequency 
of administration and dose of Interferon-β might affect the long-
term clinical evolution of RRMS.
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Adherence, cognition and behavioral performance in relaps-
ing-remitting MS (RRMS) patients using the electronic auto-
injector RebiSmart: 1 and 2 year follow-up from the German 
multicenter RebiSmart study
D. Rau1, F. Roßnagel1, J. Gössling1, R. Hartmann1, K. Gehring1, 
K. Gößwein1, C. Bischoff1, A. Kornhuber1, M. Lang1, S. 
Braune1, M. Tünnermann2, M. Hommen2, A. Bergmann1, H. 
Schreiber1
1NeuroTransData (NTD) Study Group, Neuburg/Do, Germany, 
2Europa Apotheek Venlo B.V, LV Venlo, The Netherlands
Background and aims: Adherence is crucial for therapeutic suc-
cess in chronic diseases. The electronic autoinjector RebiSmartTM 
is a unique device allowing objective assessment of interferon 
(IFN)β-1a sc administration. Our study investigated adherence 
pattern and cognitive-behavioral variables in RRMS patients 
using this device.
Methods: Prospective, 24-month, non-interventional, multi-
centre study assessing quantitative (percentage of administered 
relative to prescribed injections) and qualitative adherence 
(percentage of weeks with three evenly-timed injections) in 
RRMS patients (18-65 yr) at months 3/6/12/18/24 after base-
line (BL). EDSS, clinical self-rating/NRS, quality of life/
MusiQoL, fatigue/FSMC, depression/BDI, information pro-
cessing/SDMT and word fluency/RWT were assessed at 
months 3/6/12/18/24 and at BL. 188 patients entered the study 
(intent-to-treat group/ITT), 129 provided complete adherence 
data over 12 months (per-protocol study group1 ST1) and 62 
over 24 months (ST2). 42 discontinued therapy within 12 
month, another 50 within 2nd year, 34 without clear data. 
67/188 patients entered an additional support program of the 
Europa Apotheek Venlo (EAV).
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Results: In ST1-group quantitative and qualitative adherence was 
96,3% and 88,9%, respectively, and in ST2-group 93,4 and 84,6%. 
82% of patients in ST1 and 74% in ST2 reached qualitative adher-
ence of at least 80%. Adherence did not significantly differ in the 
EAV-group. EDSS, NRS, QoL, depression and cognition (verbal flu-
ency, SDMT) remained stable within normal ranges throughout the 
observation period. FSMC motor and cognitive score increased by 
9.4% and 10.0%, respectively, across 12 months (ST1: p< 0.002; p< 
0.035), and only cognitive fatigue by 8,4% (p< 0,038) in the ST2 
group. ANCOVA indexed fatigue at baseline as a significant predic-
tor of fatigue increase, but not the factors sex, premedication, age, 
disease duration or EDSS. Dropout analysis revealed no significant 
differences between adherent and non-adherent patients; dropout in 
the EAV-group was non significantly lower than that in non-EAVs. 
Possible predictors of non-adherence will be validated.
Conclusion: 
(1) Autoinjector RebiSmartTM proves high adherence for injecta-
ble DMTs in RRMS patients.
(2) High adherence results in stable clinical, cognitive and behav-
ioral parameters.
(3) Causes of fatigue increase are to be further explored.
(4) Findings might indicate an advantage of a support-programm 
concerning persistence.
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Real-world changes in immunological and routine lab 
parameters of multiple sclerosis patients in 72 months long-
term follow up
M. Kaufmann1, K. Thomas2, R. Haase2, T. Ziemssen2
1Klinikum für Neurologie, 2Universitätsklinikum Dresden, 
Dresden, Germany
Background: Natalizumab (NAT) prevents the transmigration of 
immune cells across the blood-brain barrier thus inhibiting CNS 
inflammation.
Objectives: In this study we present real world laboratory data of 
123 NAT treated patients up to 72 months follow up.
Methods: 123 patients diagnosed with relapsing-remitting multi-
ple sclerosis (RRMS) and highly active disease course were 
included. Monitoring of distinct lymphocyte subtypes and stand-
ardized lab testing were realized before and every third infusion in 
72 months’ follow-up. Generalized linear mixed models were 
used to assess the significance of the results.
Results: At every evaluation the lymphocyte count during NAT 
therapy was significantly higher compared to baseline for all 
patients (on average 1,8-fold, p< 0,001). Although 31% of patients 
presented lymphocyte count lower than normal limit at treatment 
initiation, lymphocytes count increased higher than the reference 
range in 14 % of the patients 6 months after start of NAT. B cells, 
T cells and NK cells increased significantly (2.6-, 1.6- and 2.0-
fold, each p< 0,01) after three months and remained stable up to 
72 months follow up. Within CD3+ T cells the increase upper nor-
mal limit was primarily evoked by CD8+ T cells (increase about 
1.8 fold, p< 0.01) whereas CD4+ T cells varied in normal range 
(increase about 1,5- fold, p< 0,01). No significant changes were 
detectable in CD4+/CD8+ ratio, neutrophils or in routine com-
plete blood count. No changes were detectable in serological 
parameters including creatinine, CRP or liver enzymes.
Conclusions: In order to improve decision-making and thus to 
optimize treatment management long-term monitoring of real 
world data is notably important. In our present report we observed 
no relevant immunological effects accompanied with the changes 
in peripheral immune cell subtypes or standard lab testing of NAT 
treatment in a 72 months’ long-term follow-up.
Disclosure
K. Thomas received personal compensation for from Novartis, 
Biogen Idec and Roche for consulting service. Ziemssen received 
personal compensation from Biogen Idec, Bayer, Novartis, 
Sanofi, Teva, and Synthon for consulting services. Ziemssen 
received additional financial support for research activities from 
Bayer, Biogen Idec, Novartis, Teva, and Sanofi Aventis.
M. Kaufmann und R. Haas have nothing to disclose.
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Hands on experience in therapy management and challenges 
addressed in an individualized patient support program of 
three different therapeutic disease-modifying approaches to 
treat multiple sclerosis in Germany
Y. Begus-Nahrmann1, G. Niemczyk2, M.-T. Baugut2, B. 
Schmid2, M. Mäurer3
1Konzept Pharma Service GmbH, Elze, 2Biogen GmbH, 
Ismaning, 3Juliusspital, Würzburg, Germany
Background: The complex nature of Multiple Sclerosis (MS) 
creates a need for different therapeutic options. The oral 
delayed-release dimethyl fumarate (DMF; also known as gas-
tro-resistant DMF) reduces inflammation and oxidative stress, 
peginterferon beta-1a (PEG) optimizes interferon-related sign-
aling by reduced injection interval and daclizumab beta (DAC 
BETA) modulates interleukin-2 signaling by blocking CD25. In 
addition to MS related adherence barriers, each therapy is 
accompanied by different challenges based on application route 
and side effects. Patient support programs (PSPs) optimized for 
each therapy were thus developed. The objective of this retro-
spective cohort study is to evaluate the real-life situation for MS 
patients. Furthermore, the potential benefit of individual patient 
coaching is analysed. 
Methods: From February 2014, September 2014 and August 
2016 patients were recruited for DMF, PEG and DAC BETA, 
respectively. All patients signed a written consent form and were 
provided with a smartphone application with reminder function. 
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Contents and coaching frequency were adapted according to chal-
lenges and patient needs.
Results: As of April 2017, 16480 patients were recruited. Data for 
9561 and 4619 MS patients including 1472 and 1142 dropouts 
could be analyzed for DMF and PEG, respectively. Overall, gas-
trointestinal issues (GI) (24.6%) for DMF and flu-like symptoms 
(FLS) (36.6%) for PEG were reported as the most frequent drop-
out reason of the discontinuers. While GI was most frequent in the 
first three therapy months, FLS were consistently the main reason 
for PEG therapy discontinuation. Time to therapy discontinuation 
was differentiated for more intensively and less intensively 
coached patients. 5.9%, 10.4% and 18.0% of more intensively 
coached DMF patients stopped therapy after 3, 6, and 12 months 
compared to 10.4%, 15.9% and 25.3%, respectively. PEG therapy 
discontinuation after 6 months was reduced for more intensively 
coached patients by 4.1% (p=0.0003) compared to the less inten-
sively coached group. The preliminary result for DAC BETA 
therapy discontinuation after 6 months is 4.3% (n=139, 6 
dropouts). 
Conclusion: Side effects reported in the phase III studies are the 
main reasons for discontinuing MS therapy. Patient coaching pro-
vides an essential contribution effectively address preventable or 
manageable side effects and promotes regular treatment monitor-
ing, leading to supervised therapy continuation and treatment 
satisfaction.
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Bayer Healthcare, Merck Serono, Genzyme, Sanofi Aventis, 
Talecris, Teva, Novartis.
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Effectiveness and safety of long-term fingolimod treatment 
in relapsing-remitting multiple sclerosis patients with highly 
active disease
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and Biomedical Engineering, University Hospital Basel, 
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Background: Fingolimod treatment improved the clinical and 
MRI outcomes over 12 months in relapsing-remitting MS (RRMS) 
patients with highly active disease (HAD) after an exposure to pre-
vious disease-modifying therapies (DMTs)1.
Objective: To evaluate the long-term effectiveness and safety of 
fingolimod in RRMS patients with HAD after an exposure to previ-
ous DMTs.
Methods: LONGTERMS is a single-arm, open-label extension 
study of phase 2/3/3b trials of fingolimod in relapsing MS. Two 
cohorts of patients who received fingolimod 0.5 mg as the only 
dose in the core phase of three phase 3 trials were analysed: 
Highly active disease cohort (HADC, N=463) and overall core 
cohort (CC, N=1212). HADC included patients who received any 
DMT during the year before study entry and either (1) had as 
many or more relapses in the year before study entry than 2 years 
before study entry or (2) had ≥1 relapse in the previous year and 
≥1 Gd+ T1 lesion or ≥9 T2 lesions at baseline (BL). Effectiveness 
evaluations included relapse (annualised relapse rate [ARR], esti-
mated by negative binomial regression) and disability outcomes 
(Kaplan-Meier [KM] estimates for patients not reaching Expanded 
Disability Status Scale (EDSS) of ≥4, ≥6, or ≥7). Incidence rate 
ratios (IRRs; IR for HADC/CC) were reported for any adverse 
events (AEs) and serious AEs (SAEs).
Results: BL demographics and disease characteristics of patients 
in the HADC and CC cohorts were: women, 74% and 70%; mean 
age (years), 38.6 and 37.9; mean number of relapses in the year 
prior to enrolment in the core studies, 1.5 and 1.5; mean EDSS, 
2.5 and 2.3. The median (range) exposure to fingolimod was: 
HADC, 1361 (2-3546) days and CC, 1545 (2-3619) days. From BL 
to Month (M)120, 46% and 53% of patients remained relapse free 
in the HADC and CC, respectively. The ARR (95% CI) remained 
low during M0-6 to M0-120 (HADC, 0.46 [0.38; 0.56] to 0.27 [0.24; 
0.31]; CC, 0.36 [0.32; 0.41] to 0.21 [0.19; 0.23]). At M96, most 
patients in both HADC and CC did not reach an EDSS score of ≥4
(64% and 71%), ≥6 (83% and 86%) or ≥7 (98% and 97%). The 
IRs for any AE or SAE were higher in the HADC vs CC: IRR (95% 
CI) for AEs was 1.37 (1.23; 1.53) and SAEs was 1.26 (1.02; 1.54).
Conclusions: For patients remaining on long-term fingolimod 
treatment, those with HAD after an exposure to previous DMTs 
showed benefits in terms of low ARR, delayed EDSS progression 
and no new safety concerns. The intrinsic limitation of the open-
label extension study cannot be excluded.
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Interim data from the Hungarian fingolimod registry 
(CFTY720DHU01)
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12Department of Neurology, Bács-Kiskun County Teaching 
Hospital, Kecskemét, 13Medical Department, Novartis Hungary 
Ltd, Budapest, 14Neuroscience Research Group, MTA-SZTE, 
Szeged, Hungary
Background: Fingolimod is a sphingosine 1-phosphate receptor 
modulator approved by the European Medicines Agency (EMA) 
in 2011. Fingolimod has been reimbursed in Hungary since 2014 
for second-line and for first-line treatment of patients (by refer-
ence to the summary of product characteristics ) with relapsing-
remitting multiple sclerosis (RRMS) to reduce disease activity.
Objective: This non-interventional study aims to collect long 
term data on real-world effectiveness in patients treated with fin-
golimod in Hungary.
Design and methods: This study combines retrospective and pro-
spective methods from fingolimod treated patients in order to 
obtain long term 5 year datasets from 21 multiple sclerosis cent-
ers. The interim analysis on the dataset was available on 31 
October 2016.
Results: 475 patients were entered in the registry until 31 October 
2016; 70% of patients were female. The mean disease duration of 
total patients is 10.56±6.69 years. 92.10% patients were treated 
with previous immunomodulatory therapy. 276 (58.10 %) and 177 
(37.26 %) patients had received fingolimod for at least 1 or 2 
years, respectively. The annual relapse rate (ARR) of patients 
treated with fingolimod was substantially reduced from 0.90±0.75 
(baseline) to 0.21±0.55 (p< 0.001) during the first year of treat-
ment and to 0.36±0.69 (p< 0.001) by the end of the second year. 
The mean baseline Expanded Disability Status Scale (EDSS) 
score was 2.82±1.58 at baseline. The EDSS score did not change 
substantially over time, by the end of the first year the mean score 
was 2.84±1.68 (p=0.423), by the end of the second year it was 
2.97±1.80 (p=0.423).
Conclusions: The results of the 2 year interim analysis of 
Hungarian fingolimod registry support the positive effectiveness 
profile of fingolimod demonstrated in phase III clinical trials with 
real world evidence data.
Disclosure
K. Bencsik: This study was sponsored by Novartis Hungary Ltd.
T. Biernacki: This study was sponsored by Novartis Hungary Ltd.
J. Füvesi: This study was sponsored by Novartis Hungary Ltd.
Cs. Rózsa: This study was sponsored by Novartis Hungary Ltd.
S. Komoly: This study was sponsored by Novartis Hungary Ltd.
L. Bors: This study was sponsored by Novartis Hungary Ltd.
P. Ács: This study was sponsored by Novartis Hungary Ltd.
A. Trauninger: This study was sponsored by Novartis Hungary 
Ltd.
E. Dobos: This study was sponsored by Novartis Hungary Ltd.
B. Cseh: This study was sponsored by Novartis Hungary Ltd.
J. Nikl: This study was sponsored by Novartis Hungary Ltd.
Sz. Péntek: This study was sponsored by Novartis Hungary Ltd.
J. Kasza: This study was sponsored by Novartis Hungary Ltd.
G. Rum: This study was sponsored by Novartis Hungary Ltd.
L. Jávor: This study was sponsored by Novartis Hungary Ltd.
A. Csányi: This study was sponsored by Novartis Hungary Ltd.
G. Tóth: This study was sponsored by Novartis Hungary Ltd.
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K. Kovács: This study was sponsored by Novartis Hungary Ltd.
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M. Simó: This study was sponsored by Novartis Hungary Ltd.
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EP1697
Long-term safety profile of fingolimod in the treatment of 
multiple sclerosis: Results of the ‘DIAMOND’ non-inter-
ventional, prospective, observational study conducted in the 
routine care of Greece
D.D. Mitsikostas1, E. Zafeiropoulou2, E. Dardiotis3, A. 
Orologas4, V. Mastorodimos5, I. Markakis6, K. Karageorgiou7, 
N. Grigoriadis4
1Athens National and Kapodistrian University, “Aeginition” 
Hospital, 2Novartis, Novartis Hellas S.A.C.I, Athens, 3University 
General Hospital of Larissa, Larissa, 4University General 
Hospital of Thessaloniki “AHEPA’, Thessaloniki, 5General 
University Hospital of Crete, Heraklion, 6General Hospital of 
Nikaia “St. Panteleimon”, Piraeus, 7Athens Medical Center, 
Athens, Greece
Background: This study aimed to further characterise the safety 
profile of fingolimod, the first approved oral therapy for multiple 
sclerosis (MS), by generating real-world evidence on its long-
term (2-year) safety.
Methods: A total of 506 patients (498 eligible) were enrolled in 
this non-interventional, observational study between 20-Feb-2012 
and 13-Jan-2014 at 40 study sites across Greece. Patients were 
followed over a period of 24 months. Fingolimod (0.5 mg) had 
been initiated 0 to 15 days prior to enrolment (median: 0.0 days).
Results: Over a median of 23.6 months of fingolimod exposure, 
20.5% (n=102) patients experienced 233 fingolimod-related 
adverse events (AECommon AEs (i.e. frequency ≥1%) included 
‘lymphopenia’ [45 events by 8.8%; exposure-adjusted incidence 
rate (EAIR): 5.3 cases per 100 patient-years; 95%CI: 3.8-7.1]; 
‘leukopenia’ (21 events by 4.2%; EAIR: 2.4; 95%CI: 1.5-3.7); 
‘hepatic enzyme increased’ (31 events by 3.4%; EAIR: 2.0; 
95%CI: 1.1-3.1), ‘headache’ (9 events by 1.8%; EAIR: 1.0; 
95%CI: 0.5-2.0); ‘dizziness’ (7 events by 1.2%; EAIR: 0.7; 
95%CI: 0.3-1.5), ‘bradycardia’ [6 events (five on the day of fin-
golimod onset) by 1.2%; EAIR: 0.7; 95%CI: 0.3-1.5]; and ‘her-
pes viral infections’ (5 events by 1.0%; EAIR: 0.6; 95%CI: 
0.2-1.3). Overall, infections (19 AEs) were reported by 3.0% 
(EAIR: 1.7; 95%CI: 1.0-2.8) of the patients. Among other events 
of interest, malignant neoplasms (one event each of B-cell lym-
phoma and intestinal adenocarcinoma) were reported in 0.4%, 
while there was a single event of a first degree atrioventricular 
block. Serious AEs were reported by 9.6%; ‘lymphopenia’ (5.0%; 
EAIR: 2.9; 95%CI: 1.9-4.3), ‘leukopenia’ (1.6%; EAIR: 0.9; 
95%CI: 0.4-1.8), and ‘hepatic enzyme increased’ (1.4%; EAIR: 
0.8; 95%CI: 0.3-1.6) were the only common serious AEs. No 
cases of macular oedema were reported. Overall, 5.6% of the 
patients permanently discontinued fingolimod treatment due to 
AE occurrence. At the end of the study, 57.1% of the AEs had 
recovered, 32.6% were ongoing, 8.2% had fatal outcome, while 
the outcome was unknown in 2.1%.
Conclusions: The study yielded real-world data on the well-
established safety profile of fingolimod in a representative MS 
population. No new safety signals were identified.
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Novartis, Merck-Serono, Teva and Bayer I. Markakis has nothing 
to disclose
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fees from Biogen Idec, Novartis, Bayer, Merck Serono, Genesis 
Pharma, ELPEN and Sanofi - Aventis
N. Grigoriadis received honoraria, travel support, consultancy and 
lecture fees from Biogen Idec, Novartis, TEVA, Bayer, Merck 
Serono, Genesis Pharma, Sanofi - Aventis and Research grants 
from Biogen Idec, Novartis, TEVA, Merck Serono, Genesis 
Pharma
All authors, except of E.Z are Principal Investigators of the study.
EP1698
Discontinuation of dimethyl fumarate in relapsing multiple 
sclerosis in a single centre
R. Dorsey-Campbell, B. Esfahani Motlagh, T. Quinn, D. 
Delacruz, T. Felongco, P. Walters, A. Scalfari, V. Singh-Curry, 
O. Malik, R. Nicholas
Pharmacy, Imperial College Healthcare NHS Trust, London, 
United Kingdom
Introduction: Dimethyl fumarate (DMF) is an oral disease modi-
fying therapy (DMT) licensed to treat relapsing multiple sclerosis 
(RMS). The rate of discontinuation due to adverse effects in the 
pivotal trials was 12-16%. We aimed to determine the stopping 
rate at Imperial College Healthcare NHS Trust (ICHNT) and the 
reasons for its discontinuation.
Method: Patients who discontinued DMF were identified from a 
local database. These patients were interviewed using a telephone 
questionnaire. The reasons for stopping treatment were recorded. 
Patients who had stopped due to side effects were asked to iden-
tify which health care professional they had contacted prior to this 
decision. Information on subsequent treatment choices was also 
obtained.
Results: ICHNT recorded 352 patients being treated with DMF. 
142 (29%) patients were identified as having stopped treatment. 
Excluding those stopping for progression the discontinuation rate 
was 20%.
39 patients (28%) stopped due to disease progression, 14 patients 
(10%) due to lymphopenia, and 55 patients (39%) due to side 
effects, with the remaining 33 (23%) stopping for a range of other 
reasons.
The peak period for discontinuation due to side effects was 3-5 
weeks after starting treatment. Discontinuation due to lymphope-
nia peaked at 7-12 months, and for disease progression was after 
more than 1 year on treatment. 73% of patients who experienced 
06_MSJ731285.indd   893 13/10/2017   11:11:04 AM
894 ePosters 23(S3)
Multiple Sclerosis Journal 2017; 23: (S3) 680–975 journals.sagepub.com/home/msj
side effects were offered an alternative drug. 17% were given a 
temporary dose reduction. The majority of patients discussed their 
side effects with either their neurologist or their MS nurse. 26% of 
patients stopped with no discussion with a health care 
professional.
Conclusion: This real world data shows the rate of discontinua-
tion of DMF due to side effects to be greater than that reported in 
clinical trials. A significant number of patients are stopping treat-
ment with DMF due to side effects and being switched to alterna-
tive therapy. This has implications both for the patient & the MS 
service. By identifying the peak time for discontinuation due to 
side effects the MS team can target follow up with these patients 
at 2 weeks & offer telephone counselling from an appropriately 
trained pharmacist or MS nurse to improve management of side 
effects & adherence to therapy.
Disclosure
Esfahani Motlagh B Nothing to declare
Quinn T Nothing to declare
Dorsey-Campbell R Educational meetings honorarium , advisory 
board or conference attendance sponsored by Biogen Idec, Roche, 
Sanofi Genzyme & Novartis
Delacruz D Nothing to declare
Felongco T Nothing to declare
Walters P Nothing to declare
Scalfari A Nothing to declare
Singh-Curry V
Malik O
Nicholas R. Novartis, Genzyme, Biogen Idec honorarium for 
speaking, advisory boards, Roche - advisory boards, CASTINGS 
committee member
EP1699
Retrospective longitudinal analysis of cognition and clinical-
behavioral parameters (PRO) in relapsing-remitting mul-
tiple sclerosis (RRMS) patients treated with Teriflunomide 
- results from a 12 month registry study in German practice 
centers
H. Schreiber1,2, F. Roßnagel1, K.-H. Gößwein1, S. Braune1,3, A. 
Bergmann1,4, for the Neuro Trans Data (NTD) Study Group
1Neuro Trans Data (NTD) Study Group, Neuburg, 2Neurological 
Practice, Ulm, 3Neurological Clinic, Medical ParkPractice, 
Prien, 4Neurological Practice, Neuburg, Germany
Background: There is limited experience about how the new oral 
MS drugs influence non-motor symptoms of MS and cognition 
over time, especially under real-life conditions.
Objectives: To longitudinally assess
(1) the evolution of cognition, course and PROs in RRMS patients 
on teriflunomide as first-line therapy (de novo) or changing from 
other MS therapies (switchers)
(2) outcomes between de novos and switchers,
(3) differences in re-test effects between RRMS and controls.
Methods: Retrospective, multicenter, open-label registry data 
analysis of 35 German MS practices (NTD network) with respect 
to teriflunomide therapy in RRMS. Data were available at base-
line (T0) and after 12 months (T12) identifying 246 RRMS 
patients on teriflunomide (Mc Donald; mean age: 45.8 yr, 67.5% 
female, mean EDSS 2.2) having completed a 12-month treatment 
period. Among them were 81 (32,9%) de-novos and 165 (67,1%) 
switchers.
Outcomes: clinical status, EDSS, IQ (MWT-B), cognition 
indexed by information processing, verbal and visuo-spatial 
memory (SDMT, CVLT,BVMT-R) from BICAMS battery, (2) 
interference control (Stroop), (3) fluency (RWT), and PROs rep-
resented by motor and cognitive fatigue (FSMC), depression 
(BDI, fast screen) and QoL (EQ-5D).
Results: At baseline (T0), RRMS patients performed below nor-
mal controls in most cognitive tests. Motor fatigue scored at a 
medium, cognitive fatigue at a low level, depression in the normal 
range. Across time (T12 vs. T0), 86,4% of patients remained 
relapse-free and EDSS stable (2.3 vs. 2.2), as did BICAMS 
parameters (SDMT, CVLT, BVMT-R) and 3 dimensions of flu-
ency, i.e. semantic, formal-lexical and semantic category change 
(RWTsf, RWTflcc, RWTscc). Significant cognitive improvement 
was found for formal-lexical word fluency (RWTflw: 17.7 vs. 
19.7, p< .000) and interference processing
(2 Stroop runs; p< 0.03, p< 0.04). Depression scored normal (2.5 
vs. 2.7). Motor FSMC subscore persisted at medium level (29.4) 
whereas cognitive fatigue augmented significantly (25.8 vs. 27.1,
p< 0.049). Outcomes were not significantly different between de 
novo and switchers. Cognitive evolution was less positive, but 
insignificantly different, in RRMS vs. controls.
Conclusion: 
(1) Teriflunomide is effective stabilizing or improving cogni-
tion and most clinical-behavioral outcomes in RRMS.
(2) Switchers take comparable benefit from therapy as de 
novo patients
(3) Positive cognitive dynamics around re-test effects is less 
expressed in RRMS patients than controls.
Disclosure
The study was funded by Genzyme
HS: Research grants from Bayer, Biogen and Teva. Honoraria 
(speaker fees, symposia, adboards) and travel grants from Biogen, 
Genzyme, Merck, Novartis and Teva.
FR, KKG: nothing to disclose
SB: research grants and honoraria from Bayer, Biogen, Genzyme, 
Merck, Novartis and Teva
AB: resarch grants from Novartis, Biogen, Genzyme.
EP1700
The inclusion of cognitive evaluation into NEDA-3 (NEDA-3/
Co) further confirms the high efficacy of natalizumab in mul-
tiple sclerosis
L. Federle, M. Puthenparampil, C. Cazzola, A. Riccardi, P. 
Perini, P. Gallo
Department of Neuroscience DNS, Università degli Studi di 
Padova, Padua, Italy
Background: Natalizumab (NTZ) has proved to be highly effective 
in MS, arresting inflammation and improving clinical outcomes. 
However, its effect on cognition has been poorly investigated.
Aim of the study: To evaluate the efficacy of natalizumab (NTZ) 
by incorporating cognitive outcomes (Co) into NEDA (no evi-
dence of disease activity)-3 criteria (NEDA-3/Co). To evaluate at 
therapy initiation the presence of clinical and neuropsychological 
parameters that may influence NTZ efficacy.
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Methods: NTZ-treated patients were enrolled in a two-year longi-
tudinal study. At therapy initiation, brain MRI, neurological 
examination by means of the expanded disability status scale 
(EDSS) and neuropsychological assessment by means of the Brief 
Repeatable Battery of Neuropsychological Tests (BRB-NT) were 
performed. Thereafter, EDSS evaluation was performed every 6 
months, brain MRI every year and neuropsychological assess-
ment at the end of the follow-up. NEDA-3 was evaluated at the 
end of follow up and was defined as no evidence of clinical activ-
ity (i.e., no relapse and no increase in EDSS= clinically silent 
patient, CS) and no evidence of MRI activity (i.e., no evidence of 
new/enlarging T2 lesions, no evidence of gadolinium enhancing 
lesions= MRI silent patient, MRIS). MS patients with no evidence 
of cognitive decline (no evidence of cognitive impairment in at 
least one further item) at year 2 were defined as neuropsychologi-
cal silent (cognitive silent, CoS) patients.
Results: On May 2017, 123 patients concluded the two-year fol-
low-up: 83% were CS, 80% were CoS and 73% were MRIS. 77 
patients (63%) were NEDA-3, and 80.5% of these (62 patients= 
50% of the total number) were also NEDA-3/Co. CS, MRIS, CoS 
and NEDA-3 percentages did not differ between treatment-naïve 
and previously-treated patients. CoS rates did not matched to CS 
or MRIS rates. No clinical parameter at baseline was found to 
predicted NEDA-3/Co. However, normal Word List Generation 
test at therapy initiation was mildly associated to a higher proba-
bility of NEDA-3/Co (OR 4.95, IC95% 1.3-18.8, p< 0.05).
Conclusion: The inclusion of cognitive evaluation into NEDA-3 
further proved the high efficacy of NTZ in MS patients. Since 
cognitive decline in MS is mainly related to cortical grey matter 
damage, the incorporation of cognitive impairment into NEDA-3 
may help to monitor the effect of therapies on the neurodegenera-
tive component of MS.
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advisory board member of Biogen-Idec and has received funding for 
travel and speaker honoraria from Merck Serono, Biogen Idec, Sanofi-
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Idec, Sanofi-Aventis, and Bayer Schering Pharma and has been 
consultant for Merck Serono, Biogen Idec and Teva; Gallo Paolo has 
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Pharma and Bayer-Schering Pharma, Teva; has received research sup-
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EP1701
Real-world evidence of patients treated with alemtuzumab in 
Canada
A. Smith1, L. Hashemi1, E. Poole1, A. Gehchan2
1Sanofi, Cambridge, MA, United States, 2Sanofi, Mississauga, 
ON, Canada
Background: Alemtuzumab is approved in Canada for the 
treatment of adult patients with RRMS with active disease as 
defined by clinical and imaging features, and an inadequate 
response to interferon-β or other disease-modifying therapies 
(DMTs). In the CARE-MS II study (NCT00548405), alemtu-
zumab (12 mg/day IV; 5 consecutive days at baseline, 3 con-
secutive days 12 months later) significantly improved clinical 
and MRI outcomes vs SC IFNB-1a (44 µg; 3 times weekly) in 
patients with active RRMS who had an inadequate response to 
prior therapy.
Goal: To describe real-world evidence (RWE) demographic and 
clinical characteristics of patients treated with alemtuzumab in 
clinical practice in Canada relative to the CARE-MS II study 
population.
Methods: MS One-to-One is a patient support program for 
patients with RRMS, facilitating access to alemtuzumab and 
ensuring monitoring during treatment. In this retrospective, 
descriptive analysis, demographic and clinical characteristics of 
real-world Canadian patients, who were previously treated with 
other DMT(s) and who received alemtuzumab between 1 Jan 
2014 and 1 May 2017, were assessed and compared with baseline 
characteristics of patients who participated in CARE-MS II. 
Consent was provided by neurologists and patients for the use of 
all clinical information from MS One-to-One.
Results: A total of 494 patients were enrolled in the Canadian MS 
One-to-One program and had received at least 1 course of alemtu-
zumab and ≥1 prior DMT. Of these, 33.0% had been treated with 
1 prior DMT, 30.2% had 2 prior DMTs, and 36.8% had >2 prior 
DMTs. The majority of patients were switched from either fingoli-
mod (32.6%), dimethyl fumarate (22.5%), natalizumab (19.8%), 
or glatiramer acetate (13.4%). Reasons for switching included 
lack of effectiveness (45.7%), tolerability (17.2%), and physician 
choice (7.5%). In comparison to the CARE-MS II population at 
study baseline, the Canadian real-world alemtuzumab-treated 
patient population was older (38.9 years [y] vs 34.8 y), included a 
greater percentage of females (74% vs 66%), had a longer dura-
tion of disease (8.0 y vs 4.5 y), and had a similar mean EDSS 
score at baseline (3.0 vs 2.7).
Conclusion: This analysis represents RWE of previously treated 
patients receiving alemtuzumab in Canada. As RWE is gained, the 
use and sequencing of alemtuzumab may evolve.
Study support: Sanofi.
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EP1702
Illness- and medication-perceptions are key predictors of 
adherence in patients with MS
A. Wolkovich1,2, S. Ratzabi1, E. Neter3, L. Glass-Marmor1,2, S. 
Dishon1,2, I. Lavi4, A. Miller1,2
1Multiple Sclerosis & Brain Research Center, Carmel Medical 
Center, 2Rappaport Faculty of Medicine, Technion - Israel 
Institute of Technology, Haifa, 3Ruppin Academic Center, Emek 
Hefer, 4Department of Community Medicine and Epidemiology, 
Carmel Medical Center, Haifa, Israel
Background: Adherence to medication is the extent to which a 
patient acts in accordance with the prescribed interval and dose of a 
medication regimen. Adherence comprises of implementation and 
persistence of habit and is estimated to be around 50% in chronic 
illnesses as MS. Existing evidence indicates that improved medica-
tion adherence could have a major effect on disease progression and 
overall health in patients with MS. There’s scarce knowledge about 
perception- related aspects as predictors of non-adherence to medi-
cations among people with Multiple Sclerosis (PwMS).
Aim: To identify prospective indicators of non-adherence to med-
ication in MS.
Methods: Participants were 96 relapsing-remitting PwMS 
treated at our MS Center. Questionnaires assessing adherence, 
demographic data, illness and medicine perceptions, health-
related quality of life (HRQoL), habits, and emotional factors 
were filled by participants. Physical disability (EDSS) was 
evaluated by the treating neurologist. The questionnaires and 
physical evaluation were administered at baseline and 6 months 
later. Adherence was defined using the Probabilistic Medication 
Adherence Scale (ProMAS) and participants were divided to 2 
levels of adherence.. Univariate analysis was conducted to 
assess the association between background, perceptual and 
medical variables with adherence.
Results: Participants´ adherence rates were divided into 2 sub-
groups: 67 (69.8%) participants reported high adherence and 29 
(30.2%) reported medium-low adherence.
Pearson correlations indicated that illness- and medications-per-
ceptions are key predictors of adherence 6 months later. The 5 
predictors were:
Illness perception, understanding the illness, (OR=3.062, 
p=0.045); Health perception (OR=6.667, p=0.012); Satisfaction 
with care (OR=5.25, p=0.012); Medication erception -overuse 
(OR=3.422, p=0.011); Medication perception -harm (OR=3.030, 
p=0.009).
Demographic data, physical disability status, HRQoL, habits, 
depression and anxiety had no significant predictive value.
Conclusions: Our study suggests that illness- and medication-
perceptions, malleable constructs, are key predictors of adherence 
among PwMS. Interventions should be developed to improve 
medication adherence among these subgroups so that patients can 
achieve the full benefits of prescribed pharmaco-therapies.
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The 20-year history: change of multiple sclerosis patient pro-
file over 20 years
S. Ozakbas1, B. Piri Cinar2, T. Kahraman3, G. 
Kosehasanogullari4
1Department of Neurology, Dokuz Eylül University, Izmir, 
2Samsun Education and Research Hospital, Samsun, 3Katip 
Celebi University, Izmir, 4Usak State Hospital, Usak, Turkey
The first disease modifying treatment (DMT) option for multiple 
sclerosis (MS) was started to be used at the end of 1996, in Turkey. 
The aim of this study was to investigate the effect of the develop-
ment of treatment options on the MS patient profile, comparing 
1996, when no DMT was available, and 2016, when almost every 
treatment options were available.
This study was conducted retrospectively examining the patient 
records of Dokuz Eylul MS Clinic. The patient records (all clinic 
days throughout the year) in 1996 were compared to those in 
2016. Patients who applied to the clinic for routine control, and 
having a clinically isolated syndrome (CIS), relapsing-remitting 
MS (RRMS), secondary progressive MS (SPMS), or primary pro-
gressive MS (PPMS) were included. Patients applied to the clinic 
for a suspected relapse were excluded.
The records including 1929 visits in 1996 were compared to 2245 
visits in 2016. The mean frequency of visits were significantly 
higher in 1996 compared to 2016 (once in 3.7 vs. 5.8 months, 
p=0.003). No significant difference was found in age and disease 
duration of the patients visited in 1996 and 2016. There were sig-
nificantly more number of patients with clinically isolated syn-
drome (8.2 vs. 3.6%, p=0.004) and SPMS (36.3 vs. 21.4%, p< 
0.001) in 1996; however, significantly less number of patients 
with RRMS (51.4 vs. 70.4%, p< 0.001). The number of patients 
with the Expanded Disability Status Scale (EDSS) scores of ≤3 
were significantly higher in 2016 (68.7 vs. 44.5%, p< 0.001). On 
the other hand, the number of patients with the EDSS scores of 
6-6.5 and ≥7 were significantly less in 2016
(9.2 vs. 21.0% and 3.7 vs. 12.8%, respectively, p< 0.001). 
Significantly more patients with SPMS, EDSS scores of 6-6.5 and 
≥7 (wheel-chair dependent patients) came to the clinic in 1996 
compared to 2016 (14.3 vs. 10.0%, 0.006; 8.4 vs. 4.3%, p< 0.001; 
5.1 vs. 1.7%, p< 0.001, respectively).
The emergence of treatment options in MS and the increasing 
availability of new treatment options for patients with no/inade-
quate treatment response have changed the MS patient profile over 
the 20 years. The proportion of patients with SPMS and higher 
EDSS scores reduced. Thus, the number of wheelchair-dependent 
patients also dramatically reduced. The reduction in the proportion 
of patients diagnosed with clinically isolated syndrome seems to 
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be related to the narrowing of the clinical definition of clinically 
isolated syndrome with new diagnostic criteria.
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EP1704
Safety and efficacy of long-term treatment with daclizumab 
beta: 6-year results from the SELECTED extension study
R. Gold1, E.-W. Radue2, G. Giovannoni3, K. Selmaj4, E. 
Havrdova5, X. Montalban6, D. Stefoski7, T. Sprenger8, R.R. 
Robinson9, J. Smith10, B. Parks11, G. Giannattasio11, S. Eraly11, 
G. Lima11
1St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany, 
2Medical Image Analysis Center, University Hospital Basel, 
Basel, Switzerland, 3Barts and The London School of Medicine 
and Dentistry, Queen Mary University of London, London, 
United Kingdom, 4Medical University of Lodz, Lodz, Poland, 
5Department of Neurology, Charles University in Prague, 
Prague, Czech Republic, 6Hospital Vall d’Hebron University, 
Barcelona, Spain, 7Rush University Medical Center, Chicago, 
IL, United States, 8DKD HELIOS Klinik Wiesbaden, Wiesbaden, 
Germany, 9AbbVie Inc, Redwood City, CA, United States, 
10Biogen, Maidenhead, United Kingdom, 11Biogen, Cambridge, 
MA, United States
Background: SELECTED (NCT01051349) was an open-label 
extension study that evaluated treatment with daclizumab beta 
(DAC BETA) for up to 6 additional years in patients with 
relapsing MS (RMS) who completed the randomized SELECT/
SELECTION studies. A previous interim analysis of 
SELECTED showed that efficacy was maintained over 3 years 
of continuous treatment and adverse events (AEs) did not 
increase over time.
Objective: To report the long-term safety and efficacy outcomes 
in RMS patients treated with DAC BETA in SELECTED.
Methods: Patients who completed 1-2 years of treatment with 
DAC BETA in SELECT/SELECTION were eligible to receive 
open-label DAC BETA 150mg subcutaneous every 4 weeks for up 
to 6 more years in SELECTED. To consolidate extension studies, 
SELECTED was stopped early and patients transitioned to the 
open-label EXTEND (NCT01797965) study that also includes 
patients from DECIDE and OBSERVE.
Results: 90% (410/455) of patients who completed treatment in 
SELECT/SELECTION enrolled in SELECTED. The mean 
(median) time on treatment in SELECTED was 40.2 (45.1; 
range:0-66) months; 69% of patients received DAC BETA for 
>3 years, 39% for >4 years and 9% for >5 years. The incidence 
of AEs in Years 1, 2, 3, 4 and ≥5 was 60%, 60%, 57%, 56% and 
51%. 87% of patients experienced an AE; 26%, a serious AE 
excluding MS relapse. Most patients (75%) had AEs that were 
mild/moderate in severity. There were no deaths during the 
study. Incidence of alanine transaminase and/or aspartate 
transaminase elevations >5x upper limit of normal was 9% and 
6%, respectively.The adjusted annualised relapse rate (95%CI) 
in Years 1, 2, 3, 4 and ≥5 was 0.150 (0.111, 0.205), 0.122 (0.087, 
0.170), 0.105 (0.074, 0.148), 0.133 (0.084, 0.211) and 0.087 
(0.054, 0.140). The incidence of 24-week confirmed disability 
progression was low (17.4%) with a stable rate of occurrence 
over the study period. The mean numbers of new Gd+ and new/
newly enlarging T2 hyperintense lesions occurred at rates simi-
lar to the reduced rates in SELECT/SELECTION. The percent-
age change in whole brain volume was −0.4%, −0.4%, −0.2%, 
−0.5%, −0.2% and 0.1% for Years 1, 2, 3, 4, 5 and 6, 
respectively.
Conclusions: Results from SELECTED extend those from 
SELECT/SELECTION and together show that the effects of DAC 
BETA on clinical and radiologic outcomes and the favourable 
benefit/risk profile of DAC BETA were sustained over up to ~8 
years of treatment, with no new safety concerns identified in the 
SELECTED study population.
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Real world lab data: Intra- and inter-individual changes in 
fingolimod treated MS patients
M. Kaufmann, K. Thomas, R. Haase, T. Ziemssen
Universitätsklinikum Dresden, Dresden, Germany
Background: As a disease modifying therapy fingolimod (FTY) 
prevents lymphocytes egress into peripheral blood which results 
in peripheral lymphopenia. So accurate monitoring of lab data is 
necessary. In this real world study we analysed laboratory data 
of 128 FTY treated patients up to 36 months follow up.
Methods: 128 patients diagnosed with relapsing-remitting 
multiple sclerosis and highly active disease course were 
included. Real world monitoring of lab testing was performed 
before and every third months up to 36 months’ follow-up. 
Generalized linear mixed models were used to assess the sig-
nificance of the results.
Results: We analyzed peripheral immune cell populations 
including T, B, NK cells and granulocytes. Leukocyte pre-
sented at a significantly lower level compared to baseline in 
each analysis (p< 0,001) and remained stable after the 1st 
application. After FTY start, leukocytes decreased by approx-
imately 40% during the entire observation period and 
decreased below 3.8 GPt/L in one-third of the treated patients. 
Within first month of therapy, lymphocytes declined by about 
70%. Within treated patients, 98% presented lymphocyte 
count < 1,5 GPt/L, 93.7% < 1,0 GPt/L, 55.8% < 0.5 GPt/L and 
2.1% < 0,2 GPt/L. During period of observation, levels of 
leukocyte respective lymphocyte counts fluctuated about 0.8 
respectively 0.14 in FTY treated patients. Compared with the 
intra-individual variability of patients treated with natali-
zumab (fluctuation leukocytes 1.5 and lymphocytes 0.6), 
FTY treated patients demonstrated a narrow deviation range 
and more stable values. No significant changes were detecta-
ble in triglycerides, cholesterol, high and low-density lipo-
protein. After first application aspartate-aminotransferase 
(ASAT) levels increased in 25%, alanine-aminotransferase 
(ALAT) in 22% and γ-glutamyl transferase (γGT) in 26% of 
patients higher than upper limit.
Conclusions: Although it is widely known that FTY induces lym-
phopenia, we have shown that as well in the real world the lym-
phocyte counts decreased in only a small number of patients under 
a critical limit of 0,2 GPt/L in a real-world cohort. Additionally we 
present stable levels in lymphocyte count and only small intra- 
and inter-individual fluctuations in treated patients during long-
term follow up evaluation.
Disclosure
K. Thomas received personal compensation for from Novartis, 
Biogen Idec and Roche for consulting service. Ziemssen received 
personal compensation from Biogen Idec, Bayer, Novartis, 
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Analysis of the effectiveness of natalizumab through non-
evidence of disease activity (NEDA-3) criteria in real world 
practice in a tertiary hospital in Asturias Spain
P. Suárez-Santos, P. Oliva-Nacarino, A. García-Rúa, E. 
Ameijide-Sanluis, M. Castañón-Apilánez, J. Villafani
Neurology, Hospital Universitario Central de Asturias, Oviedo, 
Spain
Introduction: Natalizumab (NTZ) is used in patients with high 
active disease or a severe and rapid onset. The efficacy of NTZ 
has originated the concept of NEDA. The concept of NEDA-3, 
“no evidence of disease activity” is based on the absence of 
relapses, progression of disability and activity on MRI. The major 
limitation for the use of NTZ is the development of progressive 
multifocal leukoencephalopathy (PML).
Objectives: Our objective is to analyze the percentage and the dura-
tion over time patients meet NEDA-3 criteria in real world clinical 
practice in multiple sclerosis (MS) under treatment with NTZ.
Methods: We retrospectively reviewed the clinical records of 97 
MS patients who have received NTZ therapy for at least one year 
at the Neurology Service of Hospital Universitario Central de 
Asturias (Oviedo, Spain) since year 2008 to present.
Results: We analyzed 97 patients, 75.3% women, 93.8% with 
relapsing-remitting MS. The median age of the patients at the 
beginning of treatment was 41,1 years old. The baseline EDSS 
was 3.3. The time from diagnosis to the onset of NTZ was 5.84 
years. The annualized relapse rate (ARR) in the year prior to treat-
ment was 1,91. The reason for initiating NTZ was the lack of effi-
cacy of prior treatment in 83.5% and 8.24% for an aggressive 
onset of the disease. The mean treatment time was 4.24 years. At 
the beginning of treatment 60% of the patients had anti-JCV posi-
tive antibodies. 25% of patients with negative anti-JCV antibodies 
become positive in the course of treatment. In 74.4% the reason 
for withdrawal of NTZ was the risk of PML.
In the case of NEDA-3 after one year of treatment, 66.7% of the 
patients fulfilled the criteria, after two years 54.7%, after three 
50.7%, after four 44.4%, after five 40.5%, after six 34, 4%, after 
seven 39.1%, after eight 53.8% and after nine 60%. The ARR 
reduction was 87.44% that was maintained over the years.
Conclusion: NTZ is used in patients with high clinical and MRI 
activity. In our series, a high percentage of patients treated with 
NTZ met NEDA-3 criteria and maintained over the years. One of 
the major limitations of treatment is the risk of PML, which is the 
most frequent reason for withdrawal.
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Six year prospective immunological study of alemtuzumab 
treated patients: identification of markers of the clinical 
response
L. Durelli1, S. Rolla1, S. De Mercanti1, V. Bardina1, A. Cucci1, 
D. Taverna2, F. Novelli2, E. Cocco3, A. Vladic4, M. Habek5, I. 
Adamec5, P. Annovazzi6, D. Horakova7, M. Clerico1
1University of Turin, Orbassano, 2University of Turin, Torino, 
3University of Cagliari, Cagliari, Italy, 4Klinička bolnica ‘Sveti 
Duh’, 5University Hospital Center Zagreb, Zagreb, Croatia, 
6Multiple Sclerosis Study Center, Gallarate Hospital, Gallarate, 
Italy, 7Charles University in Prague, Prague, Czech Republic
Background: Alemtuzumab is a highly effective treatment for 
relapsing remitting multiple sclerosis (RRMS) that selectively tar-
gets the CD52 antigen, with consequent profound T and B lym-
phocyte depletion. In particular alemtuzumab induced a CD4+ T 
cells lymphopenia, a decrease of Th17 and Th1 cells and pro-
inflammatory molecules and a restored Treg suppressor function 
that long last for years. 25-30% MS patients, however, relapse 
after alemtuzumab treatment.
Aims: Long-term immunological study of RRMS patients after 
alemtuzumab treatment to identify markers that could help to pre-
dict the clinical response to the drug.
Methods: Multicenter follow-up of 29 alemtuzumab-treated 
RRMS patients from 6 European sites in the CARE-MS I and 
CARE-MS II trials. Patients received two courses of alemtu-
zumab at Month 0 and 12. Further courses have been repeated in 
non responders. Clinical and immunological evaluation were per-
formed at Months 0, 6, 12, 18, 24, 36, 48, 60 and 72. CD4+ T 
cells, Treg, Th1 and Th17 cells were evaluated in the peripheral 
blood mononuclear cells by FACS analysis. mRNA levels of 
cytokines, chemokines, chemokine receptors and transcriptional 
factors with pro-inflammatory (IL-1β, IL-2, IL-6, IL-12, IL-17A, 
IL-17F, IL-21, IL-22, IL-23, IL-26, IFN-γ, T-bet, RORC, TNF-α, 
CCR3, CCR4, CCR5, CCR6, CXCR3, CXCL10, CCL20, VLA4) 
or anti-inflammatory function (IL-10, IL-27, TGF-β, FoxP3) were 
quantified by TaqMan® low density array real-time polymerase 
chain reaction in whole blood.
Results: Nine patients had a clinical or MRI disease activity 
resumption between Month 20 and 32. At Month 18 they had a 
higher Th17/Treg ratio and increased IL-1β mRNA levels com-
pared to patients that remained stable. Two patients continued 
to present evidence of disease activity despite repeated alemtu-
zumab courses. They display an atypical CD4+ T population 
behaviour different from the other patients. Despite that lym-
phocyte count strongly decreased after the first administration 
of alemtuzumab and then fluctuated accordingly to alemtu-
zumab administration, the percentage of CD4+ cells was not or 
just mildly affected.
Conclusions: An increase of Th17/Treg ratio and of the pro-
inflammatory cytokine IL-1β mRNA level after alemtuzumab 
could be an early marker of MS disease activity resumption sug-
gesting alemtuzumab retreatment. Furthermore, the evaluation of 
the CD4+ cell percentage could represent a helpful tool to address 
the individual clinical response to the drug.
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Adherence to oral versus injectable disease-modifying thera-
pies for multiple sclerosis using French national health insur-
ance databases
J. Roux1,2,3, A. Guilleux1,2, E. Leray1,2,3
1EA 7449 REPERES, EHESP / Rennes 1 University, 2METIS 
Department, EHESP French School of Public Health, 3INSERM 
CIC-P 1414, University Hospital of Rennes, Rennes, France
Background: Twelve disease-modifying therapies (DMTs) spe-
cific for multiple sclerosis (MS) are now available in France, 
whom three are oral medications (fingolimod, dimethyl fumarate, 
teriflunomide).
A higher adherence to oral drugs may be expected compared to 
injectable ones. To our knowledge, no study has compared adher-
ence in patients who received both types of DMTs over time.
Objective: From administrative databases we aimed to compare 
adherence to DMTs according to their route of administration - 
oral vs injectable - within a unique group of patients, who switched 
from injectable to oral drugs. 
Methods: People with MS were identified between 2011 and 
2015 in a random sample of French healthcare insurance system 
thanks to a three-criterion algorithm using diagnoses of hospital 
admissions, DMTs and MS long disease duration status. Only 
patients who went from an injectable to an oral DMT over the 
study period (2011 to 2015) were selected (all duration between 
the two DMTs were considered). Adherence was estimated using 
the medical possession ratio (MPR), a threshold of ≥0.8 being 
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considered as optimal adherence. For each DMT it was calculated 
from the date of first dispensation (index date) to either estimated 
end of treatment or the end of follow-up on 31st December 2015. 
Differences between injectable and oral DMTs regarding MPR 
and proportion of optimal adherence were tested with a paired 
sign rank test and a McNemar’s test respectively.
Results: A switch from an injectable to an oral DMT was identi-
fied for 100 out of 1,153 patients with MS. Median age was 45 
years and 67% were female. Median treatment duration was 846.5 
and 296.0 days for injectable and oral DMTs respectively. Mean 
MPR was higher for oral compared to injectable DMTs (0.97 vs 
0.89, p< 0.001). The proportion of optimal adherence differed sig-
nificantly between oral and injectable (93% vs 76%, p< 0.001). 
Results were consistent when selecting a minimum of 6-month 
DMTs duration (97% vs 75%, p< 0.001).
Conclusion: In patients who switched from injectable to oral 
DMTs, we found higher adherence for oral DMTs than injectable 
ones. It may reveal that reason for switching was lack of adher-
ence or injections’ weariness. However, high adherence to oral 
DMTs may also be linked to the limited treatment duration and 
may decrease over time. We plan to assess adherence also in non-
switchers (only oral or only injectable), and for each DMT sepa-
rately. Comprehensive results will be available in October 2017.
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Long-term effectiveness of fingolimod in multiple sclerosis 
patients treated in the routine care of Greece: results of the 
‘DIAMOND’ non-interventional, prospective, observational 
study
D.D. Mitsikostas1, E. Zafeiropoulou2, I. Iliopoulos3, N. Fakas4, 
T. Thomaides5, M. Maltezou6, N. Grigoriadis7
1Athens National and Kapodistrian University, ‘Aeginition’ 
Hospital, 2Novartis, Novartis Hellas S.A.C.I, Athens, 3University 
General Hospital of Alexandroupolis, Alexandroupolis, 
4401 General Army Hospital, 5Hellenic Red Cross General 
Hospital of Athens, 6General Oncological Hospital of Kifisia 
‘Ag. Anargyroi’, Athens, 7University General Hospital of 
Thessaloniki ‘AHEPA’, Thessaloniki, Greece
Background: This non-interventional, prospective observational 
study aimed to provide real-world data to complement pre-author-
ization evidence on fingolimod’s effectiveness in relapse rate, dis-
ability progression and MRI measures in multiple sclerosis (MS) 
patients.
Methods: 498 adult MS patients, who had recent (up to 15 days) 
treatment initiation with, or had been prescribed 
fingolimod,according to the approved label prior to enrolment, 
comprised the eligible study population. Data were collected over 
a median follow-up of 23.6 months, during 7 visits occurring at 
enrolment and at approximately 1, 3, 6, 12, 18 and 24 months 
post-enrolment. 25.3% of the patients prematurely discontinued 
study participation at a median of 12.8 months, mainly due to loss 
of follow-up (9.0%), adverse events (6.8%), and patient decision/
non-compliance/consent withdrawal (4.6%).
Results: Eligible patients (age: 41.2±9.8 years; 63.7% females) 
had been diagnosed with MS a median of 7.5 years prior to fin-
golimod onset. All patients had experienced at least one relapse 
over 12 months prior to treatment onset [total 803 (mean: 1.6±0.8); 
675 treated with corticosteroids]. 95.8% of patients had received 
prior MS-related treatment; 73.8% of these patients had discontin-
ued their most recent prior medication within the 6-month period 
prior to fingolimod treatment onset treatment. The median base-
line EDSS score of 3.2±1.9 significantly decreased to 3.1±1.9 (p< 
0.001), 3.0±1.9 (p=0.003), 3.1±1.9 (p=0.020) and 3.0±1.9 
(p=0.010) point at 6,12,18 and 24 months post-treatment, respec-
tively .Brain MRI among patients with available data demon-
strated significant decreases from baseline in gadolinium-enhancing 
lesion count at 6, 12, 18 and 24 months (p< 0.001 for all) and in 
T1 lesion count at 12 (p=0.006) and 24 months (p=0.046), while 
the T2 lesion counts remained unchanged. The 12- and 24-month 
annualised relapse rates were 1.81 and 1.85 per patient-year, 
respectively, prior to fingolimod onset, and 0.10, and 0.09, respec-
tively, post-treatment onset. Median decreases of 1 and 3 relapses 
were noted from the 12- and 24-month periods prior to fingolimod 
onset to the respective periods post-treatment onset (p< 0.001 for 
both).
Conclusions: Fingolimod displays beneficial effects on disabil-
ity progression, relapse rate and brain MRI outcomes of MS 
patients in routine clinical practice in Greece. Also, this study 
supports data of relevant international literature and phase III 
studies.
Disclosure
Novartis Hellas S.A.C.I is the sponsor of the study
D.D. Mitsikostas has received grants and honoraria from: 
Allergan, Amgen, Biogen, Genesis Pharma, Electocore, Eli Lilly, 
Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Teva
E. Zafeiropoulou is currently a Novartis (Hellas) S.A.C.I 
employee
I. Iliopoulos received personal compensation from Genesis, 
Merck Serono, Novartis and Sanofi as member of scientific advi-
sory boards, steering committees or independent data monitoring 
boards in clinical trials, or as speaker at meetings
N. Fakas has received honoraria from Novartis as a member of 
scientific advisory boards or, as a speaker in congresses
T. Thomaides and M. Maltezou have nothing to disclose
N. Grigoriadis received honoraria, travel support, consultancy and 
lecture fees from Biogen Idec, Novartis, TEVA, Bayer, Merck 
Serono, Genesis Pharma, Sanofi - Aventis and Research grants 
from Biogen Idec, Novartis, TEVA, Merck Serono, Genesis 
Pharma
All authors, except of E.Z are Principal Investigators of the 
study.
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EP1710
Biomarkers for monitoring natalizumab treatment in mul-
tiple sclerosis
G.H. Bringeland1,2, C.A. Vedeler1,2, K.M. Myhr1,2, S. Gavasso1,2
1Department of Clinical Medicine, University of Bergen, 
2Department of Neurology, Haukeland University Hospital, 
Bergen, Norway
Background: Natalizumab is one of the therapeutic monoclonal 
antibodies developed for prevention of inflammatory attacks in mul-
tiple sclerosis (MS). It blocks integrins on leukocytes from adhering 
to the blood brain barrier, thereby hindering migrating into the cen-
tral nervous system. All treated patients receive the same dose, but 
the clinical response is variable and saturation of natalizumab on 
integrins differs substantially between patients. Natalizumab satura-
tion has been proposed as a biomarker to monitor and patient-tailor 
treatment, and different methods to measure this on a single-cell 
level have been proposed in previous flow cytometry studies. We 
have compared three of these methods, using a new technology for 
single-cell analysis: mass cytometry by time-of-flight (CyTOF), 
where antibodies are labelled with metal isotopes instead of fluoro-
chromes, allowing analysis of over 50 parameters in a single cell.
Methods: Peripheral blood leukocytes from MS patients receiv-
ing natalizumab therapy (n=9) were labelled with antibodies 
against natalizumab, integrin and cell subtype markes prior to 
CyTOF analysis. Natalizumab saturation calculated by three pre-
viously described methods were compared: 1) natalizumab level 
compared to a reference sample in vitro saturated with natali-
zumab, 2) ratio natalizumab/integrin and 3) quantitation of rela-
tive numbers of natalizumab and integrin molecules on single 
cells using beads with known amounts of bound antibodies against 
natalizumab and integrin as a reference.
Results: Numbers of bound natalizumab was positively corre-
lated to numbers of integrin on single cells. After a natalizumab 
infusion, numbers of both natalizumab and integrin molecules 
decreased, but the ratio natalizumab/integrin increased. Measuring 
natalizumab levels alone, therefore gave a false impression of 
decreasing natalizumab levels after infusion.
Conclusions: The method that best reflects saturation of natali-
zumab on target cells is a combination of previously described 
techniques: using beads for quantitation of natalizumab and inte-
grin to calculate a ratio natalizumab/integrin. This approach will 
be of interest for monitoring other therapeutic antibodies.
Disclosure
Gerd Haga Bringeland: Nothing to disclose.
Christian Vedeler: Nothing to disclose.
Kjell Morten Myhr: Nothing to disclose.
Sonia Gavasso: Nothing to disclose.
EP1711
Long-term experience with natalizumab as first-line treat-
ment for highly active pediatric multiple sclerosis: a case 
report
S. Daoudi, M. Lounis
Department of Neurology, Nedir Mohamed Teaching Hospital, 
Tizi Ouzou, Algeria
Introduction: Pediatric multiple sclerosis (MS) comprises 2-5% 
of all cases of MS. Although first-line disease-modifying therapy 
(DMT) including interferons appear to be well tolerated in perdi-
atric MS, but recent publications highlight an increasing number 
of cases resistant to those first-line treatments. There is an urgent 
need for second-line treatment strategies for pediatric MS, and 
this is the case of highly active forms.
We report the case of highly active pediatric ms treated with natal-
izumab as first-line treatment over a period of 36 months.
Observation: This is a male child who was diagnosed at the age 
of 14 with highly active MS and a treatment with NATALIZUMAB 
300 mg per month was proposed to him as first intention.
At the initiation of treatment the child´s expanded disability status 
scale (EDSS) was 4, and John Cunningham virus (JCV) serology 
was negative.
At 6 months of treatment the child had an EDSS of 1 with a per-
sistent MRI activity.
At 12 months, a relapse was reported with an EDSS of 3 and cer-
ebral/medullar MRI revealed a new demyelinating lesions with no 
signs of activity.
At the 13th infusion, the child’s EDSS was 1 and a JCV serocon-
version was noted with a JCV index of 0,33. After two years treat-
ment the EDSS was 0 and the JCV index was 0,4 without any MRI 
activity. The clinical course was performed without any incident 
and the child had an MRI control and analysis of the JCV index 
every 6 months up to two years of treatment.
Following a radiological suspicion of progressive multifocal leu-
koencephalopathy (PML) the treatment was suspended at its 27 th 
infusion and levels of JCV replication in cerebrospinal fluid (CSF) 
measured via quantitative real-time PCR returned with a negative 
result. Given the child´s good tolerance and its clinical efficacy, 
the treatment was continued.
Currently the child has received a 36th infusion with a JCV index 
< 0,9 and no particular incident have been reported up to date. A 
cerebral MRI control is performed every 3 months with a JCV 
index analysis every 6 months.
Conclusion: Our case report indicate that natalizumab may be 
safe and effective against highly active MS in pediatric patients. 
Furthermore, the number of published case studies on children 
with highly active MS treated with natalizumab also rises, whereas 
long-term risks as well as therapeutic potential of this therapy in 
pediatric population have been at the centre of attention.
Disclosure
Nothing
EP1712
Optimal response to dymethyl fumarate associates in MS 
with a shift from an inflammatory to a tolerogenic blood cell 
profile
S. Medina1, S. Sainz de la Maza1, L. Costa-Frossard1, N. 
Villarrubia1, J.C. Alvarez Cermeño2, L.M. Villar1
1Hospital Universitario Ramon y Cajal, 2Hospital UNiversitario 
Ramon y Cajal, Madrid, Spain
Background: The precise mechanism of action of dimethyl 
fumarate (DMF) treatment in MS remains unknown.
Objective: To identify the changes in the blood lymphocyte pro-
file of MS patients predicting no evidence of disease activity 
(NEDA) status after DMF treatment.
Methods: We studied by flow cytometry blood lymphocyte sub-
sets of 64 MS patients treated with DMF at baseline and after six 
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months of treatment. NEDA (41 patients) or ongoing disease 
activity (ODA, 23 patients) were monitored after a year of 
follow-up.
Results: During treatment, all patients experienced an increase in 
the naïve T cells and a decrease in effector memory ones. However, 
only NEDA patients showed a significant reduction in: central 
memory CD4+ and CD8+ T cells, memory B cells, CD4+ T cells 
producing interferon-gamma, CD8+ T cells producing TNF-alpha 
and interferon-gamma and B cells producing tumor necrosis fac-
tor-alpha (TNF-alpha). Additionally, NEDA patients had an 
increase in regulatory CD56-bright cells not observed in ODA 
group. After treatment, there was a negative correlation between 
CD56-bright cells and CD8+ T cells producing IFN-gamma and 
TNF-alpha.
Conclusion: A pro-tolerogenic shift in the blood leukocyte profile 
associates with an optimal response to DMF in MS.
Disclosure
Silvia Medina, Noelia Villarrubia, and Jose LIfante have nothing 
to disclose.
Susana Sainz de la Maza received travel expenses and payment for 
lecturing from Merck, Novartis, Genzyme, Biogen. and Roche, 
Lucienne Costa-Frossard received travel expenses and payment 
for lecturing from Merck, Novartis, Genzyme, Biogen. and Roche,
José Carlos Álvarez Cermeño received travel expenses and pay-
ment for lecturing, or being part from advisory boards, or research 
grants from Merck, Novartis, Genzyme, Biogen. and Roche
Luisa Maria Villar Guimerans received travel expenses and pay-
ment for lecturing, or being part from advisory boards, or research 
grants from Merckand conference feesand from Merck, Novartis, 
Genzyme, Biogen. and Roche
EP1713
Impact of alemtuzumab on work capacity based upon evi-
dence from the CARE-MS II study
T. Ziemssen1, H. Wang1, W. Zhang2, K. Thangavelu2, M. 
Melanson2, L. Hashemi2, J. Guo2
1Center of Clinical Neuroscience, Carl Gustav Carus University 
Hospital, Dresden, Germany, 2Sanofi, Cambridge, MA, United 
States
Background: MS disease progression negatively affects employ-
ment, leading to high economic costs. Hence, therapeutic strate-
gies to reduce disease activity are recommended. In CARE-MS II 
(NCT00548405), alemtuzumab significantly improved clinical 
and MRI outcomes vs SC IFNB-1a over 2 years in patients with 
active RRMS and inadequate response to prior therapy.
Goal: To explore potential impact of alemtuzumab on work 
capacity in CARE-MS II alemtuzumab-treated patients, measured 
by the Health Resource Utilization questionnaire (HRUQ).
Methods: HRUQ evaluates patients’ use of healthcare resources, 
non-medical resources, informal care, and work capacity, and was 
completed at baseline and every 3 months during the 2-year study 
by 426 alemtuzumab- and 202 SC IFNB-1a-treated CARE-MS II 
patients. Questions related to work capacity assessed sick leave 
due to MS during the past 3 months. Primary analysis excluded 
sick leave at Months 3 and 15, as it included alemtuzumab treat-
ment at baseline (5 days) and 12 months later (3 days). Statistical 
analyses to compare alemtuzumab and SC IFNB-1a groups 
included descriptive analysis, chi-square test on cumulative 
percentages over each visit, and generalised linear mixed-effect 
model for repeated measurements.
Results: At baseline, 53.3% and 55.5% of patients randomised to 
alemtuzumab or SC IFNB-1a, respectively, reported being 
employed or self-employed. Six SC IFNB-1a and no alemtuzumab 
patients discontinued study due to lack of efficacy (LOE). During 
CARE-MS II, the cumulative percentage of alemtuzumab-treated 
patients taking sick leave due to MS was significantly lower vs SC 
IFNB-1a-treated patients at Months 6 (11.5% vs 18.8%, P=0.018), 
9 (15.3% vs 25.9%, P=0.002), 18 (24.6% vs 33.5%, P=0.023), 21 
(26.1% vs 35.1%, P=0.022), and 24 (27.7% vs 36.0%, P=0.035) 
and was numerically lower at Month 12 (21.6% vs 27.7%, P=0.1). 
In a longitudinal model over 2 years, alemtuzumab-treated patients 
took significantly less sick leave due to MS vs the SC IFNB-1a 
group (P=0.04); this finding was confirmed by sensitivity analysis 
including Months 3 and 15.
Conclusion: These exploratory analyses showed that alemtu-
zumab-treated patients took significantly reduced sick leave due 
to MS vs SC IFNB-1a over 2 years, a difference that may have 
been greater if no SC IFNB-1a patients had discontinued due to 
LOE. These findings suggest that alemtuzumab may offer a 
unique treatment approach for patients with active RRMS, poten-
tially improving work capacity.
Study support: Sanofi and Bayer HealthCare Pharmaceuticals.
Disclosure
TZ: Consulting and/or speaking fees (Almirall, Bayer, Biogen, 
Merck, Novartis, Roche, Sanofi Genzyme, and Teva); grant/
research support (Biogen, Novartis, Sanofi Genzyme, and Teva).
HW, WZ, KT, MM and JDG: Employees of Sanofi.
EP1714
Efectiveness of alemtuzumab in RRMS patients with an 
EDSS score of ≤ 5 or >5
R. López Ruiz1, S. Eichau2, J.L. Ruiz-Peña2, G. Navarro2, D. 
García Mascort2, E. Arellano2, G. Izquierdo2
1Neurology, 2Hospital Universitario Virgen Macarena, Seville, 
Spain
Background: Alemtuzumab is a disease-modifying therapy 
(DMT) for the treatment of relapsing-remitting multiple sclerosis 
(RRMS) that has shown efficacy in reducing the annualized 
relapse rate (ARR), the risk of sustained disability accumulation, 
and reduction in gadolinium-enhancing T1 lesions in cerebral 
magnetic resonance imaging (MRI) in patients with EDSS ≤ 5.
Objectives: To study effectiveness outcomes in patients with 
RRMS with EDSS scores of ≤ 5 or >5.
Methods: Retrospective observational study in patients with 
highly active RRMS treated with alemtuzumab from March 2015 
to March 2017 at Virgen Macarena Hospital, Seville, Spain. 
Demographic/disease characteristics, ARR, changes in disability, 
and cerebral MRI findings were collected at enrolment.
Results: EDSS ≤ 5: 35 patients (23 females), mean age: 36.5 
years, mean time to diagnosis 13.2 years. 16 patients have received 
two cycles of treatment. Mean EDSS score decreased from 3.4 to 
2.6 (p< 0.05). 22 (62.9%) patients showed a reduction in EDSS, 
the remaining patients showed no changes in EDSS. ARR 
decreased from 1.8 to 0.1 (p< 0.05). Two patients (5.7%) experi-
enced relapses after two cycles of treatment. T2 lesions on MRI 
showed no changes, but the mean number of gadolium enhancing 
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lesions per patient decreased from 2.7 to 0.2 post-treatment 
(p< 0.05).
EDSS > 5: 27 patients (18 females), mean age: 42.7 years, mean 
time to diagnosis: 14.6 years. 14 patients have received two 
cycles of treatment. Mean EDSS score decreased from 6.6 to 5.9 
(p< 0.05). 11 (40.7%) patients showed a reduction in EDSS. One 
patient showed an increase in EDSS of 0.5 points despite receiv-
ing the second cycle of treatment. The mean number of T2 lesions 
on MRI increased from 38.9 to 42.4, and the mean number 
of gadolinium enhancing lesions decreased from 1.2 to 0.25 
(p< 0.05).
Conclusions: Our data show that alemtuzumab is an effective 
therapy for the treatment of RRMS irrespective of the EDSS score 
status, with significant improvement in EDSS score, ARR, and 
gadolinium-enhancing lesions in patients with EDSS score ≤ 5 or 
> 5. Larger studies are needed to confirm these results given the 
relatively small size of our patient population.
Disclosure
Rocío López Ruiz received honoraria as consultant on scientific 
advisory boards from Biogen, Novartis and Genzyme.
Sara Eichau received honoraria as consultant on scientific advi-
sory boards from Biogen, Bayer-Schering, Merck-Serono, Teva 
and Novartis; has participated in clinical trials/other research pro-
jects by Biogen, GSK, Teva and Novartis.
JL Ruiz-Peña received honoraria as consultant on scientific advi-
sory boards from Biogen, Bayer-Schering, Merck-Serono, Teva 
and Novartis; has participated in clinical trials/other research pro-
jects by Biogen, GSK, Teva and Novartis.
G. Navarro received honoraria as consultant on scientific advisory 
boards from Biogen, Bayer-Schering, Merck-Serono, Teva and 
Novartis; has participated in clinical trials/other research projects 
by Biogen, GSK, Teva and Novartis.
G. Izquierdo received honoraria as consultant on scientific advi-
sory boards from Biogen, Bayer-Schering, Merck-Serono, Teva 
and Novartis; has participated in clinical trials/other research pro-
jects by Biogen, GSK, Teva and Novartis.
EP1715
Long-term disability outcomes in teriflunomide-treated 
patients in TEMSO and TOWER: an EDSS and FSS cat-
egorical analysis
F. Lublin1, A. Miller1, P. Truffinet2, K. Thangavelu3, M. 
Mandel3, M.S. Freedman4
1Icahn School of Medicine at Mount Sinai, New York, NY, 
United States, 2Sanofi Genzyme, Chilly-Mazarin, France, 
3Sanofi Genzyme, Cambridge, MA, United States, 4University of 
Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, 
Canada
Background: In both phase 3 clinical trials (TEMSO, 
NCT00134563; TOWER, NCT00751881) teriflunomide signifi-
cantly reduced the risk of disability worsening confirmed for ≥12 
weeks in patients with relapsing forms of MS (RMS).
Objective: To assess long-term disability outcomes in a pooled 
analysis of the TEMSO and TOWER core and extension studies.
Methods: In TEMSO and TOWER, patients with RMS were ran-
domized 1:1:1 to placebo, teriflunomide
7 mg, or 14 mg. Patients received treatment for 2 years in TEMSO; 
in TOWER, study duration was variable ending 48 weeks after the 
last patient was randomized. In the TEMSO extension 
(NCT00803049), patients randomized to teriflunomide 7 mg or 14 
mg continued treatment; those previously receiving placebo were 
re-randomized 1:1 to teriflunomide 7 mg or 14 mg. All patients 
received teriflunomide 14 mg in the TOWER extension. Disability 
worsening was assessed using the Expanded Disability Status 
Scale (EDSS) and Functional System Scores (FSS). In this pooled 
analysis of the TEMSO and TOWER core and extension studies 
(intent-to-treat [ITT] population), EDSS scores were categorized 
based on change over 1 year, as stable (change from baseline of 
0.5 points) or improved (reduction from baseline of 1 point or 
greater), or worsened (increase from baseline of 1 point or 
greater); change from baseline at Year 5 is reported for each FSS.
Results: The proportion of patients with stable or improved EDSS 
scores in the overall pooled ITT population remained consistently 
high over 5 years of treatment with teriflunomide 14 mg (Year 5, 
73.6%). This trend was observed in both patients with relapsing-
remitting MS (Year 5, 74.0%) and progressive forms of relapsing 
MS (Year 5, 61.5%). Consistent with these observations of EDSS 
scores, changes in individual FSS were stable over 5 years (mean 
[SD] change from baseline at Week 252: Brainstem, 0.05 [0.73]; 
Bowel & Bladder, 0.12 [0.94]; Cerebellar, 0.20 [0.88]; Cerebral, 
-0.06 [0.89]; Pyramidal, 0.12 [0.92]; Sensory, 0.18 [1.11]; Visual, 
0.01 [0.82]). Disability outcomes were consistent for patients 
treated with teriflunomide 7 mg.
Conclusions: Long-term disability remained stable or improved 
with teriflunomide in the majority of patients, regardless of MS 
subtype, which was also reflected in stability across different 
functional systems. Disability outcomes as measured by FSS were 
consistent with EDSS outcomes observed in the teriflunomide 
clinical development programme.
Disclosure
Study supported by Sanofi Genzyme.
FL: Consulting agreements, advisory board/DSMB membership 
(Abbott, Acorda, Actelion, Allozyne, Avanir, Bayer HealthCare, 
Biogen Idec, Celgene, EMD Serono, Genmab, Johnson & 
Johnson, Medicinova, MorphoSys, Novartis, Pfizer, Questcor, 
Roche, Sanofi, Teva Neuroscience); Speaker bureaus/honoraria 
(EMD Serono, Teva Neuroscience); stock ownership (Cognition 
Pharmaceuticals); research support (Acorda Therapeutics, Biogen 
Idec, Genzyme, National Institutes of Health, National MS 
Society, Novartis, Sanofi, Teva Neuroscience).
AM: Consulting fees (Accordant Health Services, Acorda 
Therapeutics, Alkermes, Biogen Idec, EMD Serono, Genentech/
Roche, Genzyme, GSK, Mallinckrodt Pharmaceuticals [Questcor], 
Novartis, Roche, Teva); contracted research (Biogen Idec, 
Genentech, Novartis, Questcor, Roche, Sanofi).
PT: Employee of Sanofi Genzyme with ownership interests.
KT and MM: Employee of Sanofi Genzyme.
MSF: Research/educational grant support (Bayer HealthCare, 
Genzyme); honoraria/consulting fees (Bayer HealthCare, Biogen 
Idec, EMD Canada, Novartis, Sanofi, Teva Canada Innovation); 
member of company advisory boards/board of directors/other 
similar group (Bayer HealthCare, Biogen Idec, Chugai, Merck 
Serono, Novartis, Opexa Therapeutics, Sanofi, Teva Canada 
Innovation).
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EP1716
Long-term efficacy, safety, tolerability and quality of life with 
fingolimod treatment in patients with multiple sclerosis in 
real-world settings in France: VIRGILE two-year results
C. Lebrun-Frenay1, C. Papeix2, G. Kobelt3,4, J.-M. Visy5, M. 
Coustans6, M. Debouverie7, F. Lamy8, I. Chouette8
1Pasteur Hospital, Nice, 2La Salpêtrière Hospital, Paris, 
3European Health Economics, Mulhouse, France, 4Lund 
University, Lund, Sweden, 5PolyClinique Courlancy, Reims, 
6Laënnec Hospital, Quimper, 7Central Hospital, Nancy, 
8Novartis Pharma S.A.S, Rueil-Malmaison, France
Background: Fingolimod 0.5 mg daily has an established effi-
cacy, safety and tolerability profile in patients with relapsing-
remitting multiple sclerosis (RRMS), with data from a large 
clinical development programme demonstrating its benefits on 
relapse rates, disability progression and imaging activity com-
pared to placebo and/or IFNB-1a IM. However, limited data are 
available in real-world settings, which include patients with a 
wide range of co-morbidities and concomitant treatments.The 
French Health Authorities (HAS, CEPS) requested a pharmacoep-
idemiological study to assess the use and impact of fingolimod in 
the treatment of highly active forms of RRMS in France. VIRGILE 
is the largest study in France to date evaluating the long-term effi-
cacy, safety, and tolerability profiles of fingolimod in real-world 
settings. A natalizumab arm was included in the study.
Objective: To assess the effect of fingolimod 0.5 mg on relapse 
activity, disability progression and quality of life in real-life prac-
tice. The study will also describe baseline characteristics of patients 
treated with fingolimod and natalizumab, and assess the impact of 
fingolimod treatment on health resource use in both groups.
Methods: This is a non-interventional, multicentre, post-authori-
sation, observational study with prospective follow up of patients 
treated with fingolimod or natalizumab for 3 years, and poten-
tially an additional 2 years for patients in the fingolimod group. 
The primary endpoint is the change in annualised relapse rate 
(ARR) at 2 years compared to baseline (relapse rate in the year 
prior to treatment). Other endpoints include Expanded Disability 
Status Scale (EDSS) and tolerability.
Results: Enrollment was completed last year, with the inclusion 
of 1114 patients in the fingolimod arm and 335 patients in the 
natalizumab arm. Primary outcome results will be presented along 
with other efficacy and safety results for patients who reached the 
two-year time point.
Conclusion: The results support the long-term efficacy and safety 
profile of fingolimod in daily clinical practice.
Disclosure
This work has been done in collaboration with the Observatoire 
Français de la Sclérose en Plaques (OFSEP), a national cohort 
supported by a public grant from the French Agence Nationale de 
la Recherche within the context of the Investments for the Future 
programme, referenced ANR-10 COHO-002; www.ofsep.org.
Funding statement: This study is supported by Novartis Pharma 
S.A.S.
CLF has received consultancy fees from Merck, Novartis, Biogen, 
MEDDAY, Roche, Teva.
CP: has received compensation as a consultant, advisory board 
member or speaker for Roche, Novartis, Biogen idec, Teva 
Aventis, Genzyme-Sanofi, Merck.
GK has received consultancy fees from Biogen, Merck Serono, 
Novartis, Genzyme, Roche, Teva
MV has received compensation from Novartis for educational 
activity and consulting
MC disclosures: Biogen, Merck, Novartis, Genzyme
MD has done consulting research and/or workshops for Biogen-
Idec, Bayer-Schering, Genzyme, Merck-Serono, Novartis, Sanofi-
Aventis and Teva Pharma.
FL and IC are employees of Novartis Pharma S.A.S
EP1717
3 year follow-up of 80 patients with RRMS: switching therapies 
between injectable therapies versus escalation to fingolimod
E. Kouremenos1, D. Naoumis1, M. Antonopoulou1, D. 
Likomanos1, S. Katsavos1, M. Maltezou2
1Neurology, 251 Hellenic Air Force General Hospital, 
2Neurology, General Oncology Hospital Agioi Anargyroi, 
Athens, Greece
Introduction: There is a great controversy in decision making 
about patients in the early phase of MS, whether to adopt escala-
tion or induction therapy. The existence of multiple injectable 
therapies (interferons, glatiramer acetate) raises the question to 
followers of escalation therapy, whether to switch between inject-
able therapies after relapse or to escalate to higher efficiency 
drugs, such as fingolimod.
Method: We followed 80 patients, 25-35 years old, with RRMS and 
starting EDSS 0, who after disease relapse EDSS increased to 1. They 
have been divided in 2 groups of 40 patients each, age and sex matched. 
The first group was treated with fingolimod 0,5mgr, while the second 
was treated with the same or other form of interferon or glatiramer.
All patients were under clinical follow up every 3 months and 
MRI imaging every 6 months.
Result: Out of the 40 that escalated to higher efficiency, 33 
(82.5%) did not present new relapse, and between the rest group 1 
patient remained to EDSS 1, 1 ascended to 1,5 and the rest 3 had 
EDSS 2. From the 33 only 5 (12,5%) presented imaging relapse.
The 2nd group, showed poorer results, as only 10(25%) did not 
present clinical relapse. Among the remaining, 7 had EDSS 1,5, 
10 EDSS 2 and 13 EDSS 3.
Discussion: It has become evident that the timely switch to higher-
efficiency drugs is beneficial to patients, preserving their good clini-
cal and imaging condition, for as long as 3 years after relapse. It 
seems that timely change of the immunomodulation mechanisms 
has a positive effect on the disease course. It is very important to note 
that the spinal cord remains intact for 3 years after escalation.
Disclosure
Nothing to disclose
EP1718
Persistent no evidence of disease activity during natalizumab 
treatment
F. Sangalli, M. Radaelli, L. Moiola, G. Dalla Costa, F. Esposito, 
B. Colombo, G. Comi, V. Martinelli
San Raffaele Scientific Institute, Milano, Italy
Background: Natalizumab (NAT) is a high effective treatment 
for relapsing-remitting multiple sclerosis (MS). Pivotal trials and 
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post-marketing studies showed prolonged disease-free status for 
patients on treatment.
Objective: To evaluate the long-term safety and efficacy of NAT 
in a monocentric real-world observational study.
Methods: We collected data of patients who underwent at least one 
course of NAT since March 2007 at the MS Centre of San Raffaele 
Scientific Institute. We analysed clinical and radiological data during 
NAT therapy. We also reviewed medical charts for side effects.
Results: Of the 555 included patients, 69% were female and mean age 
at inclusion was 33.5 years. Mean disease duration at time of inclusion 
was 8.6 years, with a mean number of 1.8 relapses in the year before 
NAT start. Median baseline EDSS was 3.0 and 88% of patients had an 
active baseline MRI. Mean follow-up on treatment was 3 years (range 
1 month-10 years). During NAT treatment annualised relapse rate 
dropped to 0.26 and only 38% of patients presented at least one active 
MRI. The probability of disability worsening was 7% at 5 years, while 
20% of patients presented a sustained reduction of disability. At 5-year 
follow-up the overall probability of “No Evidence of Disease Activity 
(NEDA 3)”was 47%. The most common adverse event was infection 
(45%) but less than 1% of the patients had to interrupt treatment due to 
the severity of infection. Seven percent of patients developed anti-
NAT antibodies, which were linked to allergic reactions and poor 
response to treatment. Unfortunately 2 patients developed progressive 
multifocal leukoencephalopathy.
Conclusions: Our data confirm that NAT is to date one of the 
most effective treatment available and that its benefits are persis-
tent throughout long-term treatment. Our study demonstrated that 
the drug is well tolerated, improving patients’ quality of life. 
These findings should be carefully pondered, together with infor-
mation on PML risk stratification, in order to evaluate a personal-
ized benefit-risk profile of NAT.
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Dr. Sangalli, Dr. Radaelli, Dr. Dalla Costa, Dr. F. Esposito have 
no conflicts of interest relevant to this submission. Dr. Moiola 
reports speaking fees and/or travel expenses from Merck Serono 
and from Biogen, outside the submitted work. Dr. Colombo 
reports speaking fees and/or travel expenses from Merck Serono 
and from Teva Pharmaceuticals, outside the submitted work. Prof. 
Comi has received compensation for consulting services and/or 
speaking activities from Biogen, Novartis, Teva Pharmaceutical 
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Martinelli reports consultancy, speaking fees and/or travel 
expenses from Biogen-Dompè SG, Merck Serono, Bayer 
Schering, Novartis, Sanofi-Aventis, Genzyme Europe, Teva 
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Risk management for disease 
modifying treatments
EP1719
An investigation into the relationship between the multiple 
sclerosis Impact Scale (MSIS-29) and Predicted Medication 
Adherence as measured by the Morisky Medication Adher-
ence Scale (MMAS-8)
M. Gudesblatt1, R. Julius1, S. Tan1, J. Underwood1, K. 
Wissemann1, L. Fafard1, B. Bumstead1, M. Buhse1,2, M. Zarif1, 
K. Blitz1, D. Golan3
1South Shore Neurologic Associates, Patchogue, 2Nursing, State 
University of Stony Brook, Stony Brook, NY, United States, 
3Faculty of Medicine, Technion Israel Institute of Technology, 
Haifa, Israel
Objective: To examine the specific relationships between global 
and subscale scores of the MSIS-29 and MMAS-8 in people with 
Multiple Sclerosis (PwMS).
Background: (PwMS) have multiple treatment choices for dis-
ease modifying therapies (DMT). DMT non-adherence and treat-
ment delay impacts outcomes and costs. Adherence can be 
measured by patient report, observation and refills. With varied 
DMT choices, routes and frequency, predicted PwMS adherence 
behavior needs exploration as this might impact choice. Non-
adherence factors (purposeful vs. accidental) remains unexplored 
in PwMS. MMAS-8, a validated 8 point questionnaire, is predic-
tive of: medication adherence, pharmacy fill data, and efficacy, 
economic outcomes, and can be graded to analyze purposeful and 
accidental sub-scores of non-adherence. This information, when 
paired with disability measures, might improve both understand-
ing and addressing PwMS non-adherence, and perhaps resultant 
related disease progression.
Methods: Retrospective reviews of PwMS who completed MSIS-
29 and MMAS-8 on the same day in the course of routine clinical 
care. Global scores for each scale, MSIS-29 physical and cogni-
tive subscales, and MMAS-8 purposeful and accidental subscales 
were included. Multivariate regression analysis was used to ana-
lyze the relationships between scales. Significance was set at p< 
0.01.
Results: 245 PwMS; average age=49.8±10.8, 73.5% female. 
Significant relationships were as follows: MSIS-29 global with 
MMAS-8 global (r=0.19, p< 0.01) and accidental (r=0.22, p< 
0.001); MSIS-29 physical with MMAS-8 accidental (r=0.17, p< 
0.01), and MSIS-29 cognitive with MMAS-8 global (r=0.24, p< 
0.001), purposeful (r=0.18, p< 0.01), and accidental (r=0.28, p< 
0.00001).
Conclusions: Factors in non-adherence in MS is complex and the 
most consistent relationships was between accidental non-adher-
ence and self-reported cognitive impairment. Providers should 
consider therapies that are not self-administered when prescribing 
DMT to cognitively impaired PwMS.
Disclosure
All authors: nothing to disclose
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TRUST - evaluation of baseline data to investigate an inte-
grated approach for optimised patient management in mul-
tiple sclerosis patients treated with natalizumab
H.-P. Hartung1, A. Gass2, J. Wuerfel3, A. Bayas4, B. 
Tackenberg5, V. Limmroth6, R. Linker7, M. Mäurer8, J. Haas9, 
M. Stangel10, T. Ziemssen11
1Department of Neurology, Heinrich-Heine-University, 
Düsseldorf, 2Department of Neurology, University Medicine 
Mannheim UMM, University of Heidelberg, Mannheim, 
Germany, 3Medical Image Analysis Center (MIAC AG), 
Basel, Switzerland, 4Department of Neurology, Hospital 
Augsburg, Augsburg, 5Department of Neurology, Philipps 
University and University Clinics Gießen and Marburg, 
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Marburg, 6Department of Neurology, Cologne General 
Hospitals, University of Cologne, Cologne, 7Department of 
Neurology, Friedrich-Alexander University Erlangen, Erlangen, 
8Department of Neurology, Caritas Hospital Bad Mergentheim, 
Bad Mergentheim, 9Department of Neurology, Jewish 
Hospital Berlin, Berlin, 10Department of Neurology, Clinical 
Neuroimmunology and Neurochemistry, Hannover Medical 
School, Hannover, 11Department of Neurology, MS Center 
Dresden, Center of Clinical Neuroscience, University Hospital 
Carl Gustav Carus, Dresden, Germany
Background: In order to improve treatment decisions in natali-
zumab-treated relapsing-remitting multiple sclerosis (RRMS) 
patients at higher risk for progressive multifocal leukoencepha-
lopathy (PML), standardised monitoring procedures may provide 
a superior basis for individual benefit/risk evaluation. However, 
management of these patients in the clinical practice in Germany 
is highly heterogeneous.
Goals: Key goals of the prospective, non-interventional TRUST 
study are to assess the course of disease over 36 months in patients 
with sustained natalizumab therapy versus those who discontinue 
natalizumab treatment and to evaluate the use and effects of an 
integrated, adaptive patient management approach.
Methods: The ongoing TRUST study enrols up to 1260 RRMS 
patients treated with natalizumab for ≥12 months. Patients are docu-
mented over 3 years irrespective of treatment changes. Endpoints 
include clinical, subclinical, and patient reported outcomes as well 
as utilisation of risk-stratification tools and expert advice in the clini-
cal routine. This interim analysis presents baseline data at the end of 
the recruitment period (cut-off date Jan 17, 2017).
Results: The full analysis set of this interim analysis comprised 
1186 patients (71.8% female, mean [±standard deviation, SD] age 
39.2±10.1 years) from 154 sites. Mean (±SD) EDSS score at start 
of natalizumab was 3.1±1.6. The pre-study annualised relapse rate 
(ARR) before and after starting natalizumab was 2.09 and 0.15, 
respectively. Patients received 43.0±29.7 (mean±SD) natalizumab 
infusions before study inclusion. At baseline, 95.5% of patients 
had John-Cunningham-virus (JCV) antibody tests and 96.9% 
patients had initial magnetic resonance imaging data available. 
Until April 20, 2017, 20 cases of suspected PML were reported (8 
were confirmed and 12 were ruled out) and expert opinion was 
requested by 13 sites (46 requests in total), mostly focusing on 
PML risk assessment. 9.4% of patients discontinued natalizumab 
after study inclusion.
Conclusion: The TRUST study examines a population of MS 
patients with high disease activity as seen by their ARR before 
natalizumab start. Compared to the first interim analysis (n=427), 
there were slight increases in the number of patients with availa-
ble JCV antibody tests. As follow-up continues irrespective of 
natalizumab discontinuation, TRUST will provide insight into 
individual benefit/risk considerations and decision making in clin-
ical routine practice.
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EP1721
severe rebound tumefactive relapse in a MS patient on Lem-
trada
S. Kumari, G. Mazibrada
New Queen Elizabeth Hospital Birmingham, Neurology, NHS, 
Birmingham, United Kingdom
Case history: A 19 year old Asian patient with known relapsing 
remitting multiple sclerosis (MS), presented with a very severe 
multifocal rebound relapse 10 months after his first Lemtrada 
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infusion. He initially presented in September 2014 with left-sided 
weakness, paraesthesia and ataxia and was started on Avonex. He 
was switched to Lemtrada in July 2015 following a brain stem 
relapse and radiological progression. His lymphocyte recovery 
started within 2 weeks and his lymphocyte levels 6 months post 
Lemtrada were near normal. In mid-April 2016 he presented with 
slurred speech and drooping on the right side of his mouth. On 4th 
May 2016 he was admitted to hospital with progressive dysarthria, 
diplopia, unsteadiness, left sided facial and lower leg numbness. He 
was given high dose intravenous methylprednisolone but continued 
to deteriorate requiring intubation and ventilatory support. Serial 
MRIs showed active tumefactive MS with almost entire brainstem 
involvement as well as large hemispheric tumefactive lesions. He 
was given a further course of steroids, plasmapheresis and six doses 
of cyclophosphamide. Following this he stabilised radiologically 
and clinically and was eventually moved back to the ward. In 
August 2016 he was discharged to a rehabilitation hospital. Seven 
months following discharge he was reviewed in MS clinic and has 
shown remarkable recovery with a jerky smooth pursuit and inabil-
ity to perform tandem gait. His EDSS is 2. His MRI of the brain 
showed almost complete resolution of the previously seen lesions.
Discussion and conclusion: Lemtrada is a humanized monoclo-
nal anti-CD52 antibody that causes rapid and prolonged pan-lym-
phocyte depletion with relatively rapid and disproportionate 
B-cell repopulation. Our patient showed rapid lymphocyte recon-
stitution starting within 2 weeks of his Lemtrada infusion which 
potentially played a role. As suggested by Gold and colleagues 
this rare rebound inflammatory phenomenon could be B-cell 
driven. Cyclophosphamide effect on T cells is to induce apoptosis 
and rapid cell death as well as to supress antibody production. Our 
patient made a remarkable clinical and radiological recovery with 
relatively little neurological sequelae. Cyclophosphamide should 
be considered as a rescue therapy in cases of rapidly progressive 
rebound inflammatory disease post-Lemtrada. The role of B-cells 
in rebound disease post-Lemtrada should be explored further.
Disclosure
Dr. Sonia Kumari: nothing to disclose
Dr. Gordon Mazibrada: has served at advisory boards for Biogen, 
Merck, Teva, Novartis, Genzyme and Roche and our MS depart-
ment has received funding from those companies for research pro-
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Secondary antibody deficiency and infection following B-cell 
depletion for CNS neuroinflammation
E.C. Tallantyre1,2, D.H. Whittam3,4, N.P. Robetson1,2, A. Jacob3,4
1University Hospital of Wales, 2Cardiff University School of 
Medicine, Cardiff, 3Walton Centre, 4University of Liverpool, 
Liverpool, United Kingdom
B-cell depleting anti-CD20 monoclonal antibody therapies have 
demonstrated promising clinical efficacy in suppressing relapses 
in individuals with neuromyelitis optica (NMO) and multiple 
sclerosis (MS). However, uncertainties remain about the optimum 
treatment schedule. In rheumatological disease, anti-CD20 agents 
are most often employed for short-term induction therapy 
and are subsequently replaced by longer-term maintenance 
therapy. In contrast, repeated cycles of anti-CD20 monoclonal 
antibody therapy are proposed as maintenance therapy for CNS 
neuro-inflammatory disorders. Post-marketing surveillance will 
be essential to fully uncover the long-term safety profile of 
repeated B-cell depletion. Hypogammaglobulinaemia is a recog-
nised consequence in a proportion of patients treated with 
medium- to long-term B-cell therapy and may play a role in the 
increased incidence of infection observed in the anti-CD20 arms 
of treatment trials. We report 5 cases of serious infection associ-
ated with hypogammaglobulinaemia occurring in patients receiv-
ing rituximab for NMO. The cases were all female, all had low 
IgG with variable reductions in IgM and IgA. The cases had a 
mean treatment duration of 3.1 years, but not all cases had had 
extensive exposure (treatment duration range 0.5 - 6.2y). We 
review the evidence relating to hypogammaglobulinaemia follow-
ing anti-CD20 treatment for neuroinflammatory disorders and 
propose an algorithm for monitoring and treatment of this recog-
nised complication.
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Progressive multifocal leucoencephalopathy in patient with 
fingolimod treatment: one-year follow-up
F. Rossi, M. Turazzini, S. Ricci, A. Polo
Neurology Dept, Mater Salutis Hospital, Legnago, Italy
Awareness of Progressive multifocal leucoencephalopathy (PML) 
has increased in recent years, with the description of cases related 
to disease modifying therapy in multiple sclerosis (MS).
We present a case of PML affecting a patient with MS treated with 
fingolimod.
A 60 year-old female patient affected by MS since 1993, pre-
sented in June 2016 subacute onset of apraxia. She took fingoli-
mod uneventfully since march 2012. She had previously received 
treatment with interferon Beta 1a for 3 years. Previous medical 
hystory was negative. Routine white blood cell count showed a 
lymphocytopenia with a variable value from to 700/mmc and 300/
mmc.
In May 2016 pts presented a minimal worsening of paraparesis 
with more fatigue and slowness . We plan a strict clinical-radio-
logical follow-up. One mounth later patient presented inability to 
control movement. Brain MRI revealed multifocal non enhancing 
white matter (WM) T2 hyperintensity, involves subcortical 
U-fibers in frontal and parieto-occipital areas. Cerebrospinal JCV 
viral load was 1000 copies/ml. White blood cell count showed a 
leucocytopenia (3600/mmc) and lymphocytopenia (400/mmc). 
Stratify JCV was positive (3,82). We immediatly stopped treat-
ment; other immunocompromission causes were excluded. 
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Neuropsycological tests revealed cognitive impairment focused 
on attentional systems and ideomotor/ideational apraxia. We 
planned monthly MRI in order to identify immune reconstitution 
inflammatory syndrome. Clinical progress was insidious and 
reached the nadir in september when patient presented construc-
tional/spatial defects, dressing apraxia, dysgraphia, dyscalculia 
and worsening of motor weakness. Serial MRI showed progres-
sion of the patchy WM lesions without enhancement; increased 
signal intensity on T2-weighted and diffusion-weighted images 
suggested an active inflammatory process. We never prescribed 
steroids. Four month after drug discontinuation cerebrospinal 
JCV viral load was negative.
Since october 2016 clinical status slowly improved and MRI 
showed stabilized lesions. Patient underwent to rehabilitation: 
now she required unilateral assistance to walk and retains most 
self-care functions.
Actually 9 cases of PML are reported in MS patients on Fingolimod 
treatment; all patients are over 50 years old, suggesting immu-
nosenescence as main promoting factor. No one has been fatal. 
MRI and neuropsycological assessment are precious tools to rec-
ognize PML in subclinical phase in order to optimize the manage-
ment of disease.
Disclosure
Francesca Rossi: nothing to disclose
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Incidence of cervical dysplasia in females receiving alemtu-
zumab: an Australian single centre observational study
C. Nesbitt, L. Rath, O. Skibina
Alfred Hospital, Neurology and Neuroscience, MS Services and 
Neuroimmunology, Alfred Health, Melbourne, VIC, Australia
Background: Cervical Dysplasia (CD) is linked to the Human 
Papilloma Virus (HPV). Immunocompromised patients are there-
fore thought to have an increased risk of CD, and to develop dys-
plastic changes faster compared to immunocompetent individuals. 
CD screening is recommended with Alemtuzumab, however there 
is no data regarding the incidence of CD in Multiple Sclerosis 
(MS) patients exposed to this treatment.
Goal: To ascertain the incidence of CD in patients receiving 
Alemtuzumab. Our secondary goal was to assess the role for HPV 
dna testing in determining patient risk.
Methods: We collected data from all 11 female patients treated 
with Alemtuzumab at the Alfred from 2014 to present. All patients 
had a pap test prior to treatment, and 3 out of 11 self funded addi-
tional HPV dna testing. Patients with abnormal pap tests or posi-
tive high risk HPV dna were referred to gynaecology for ongoing 
6 monthly follow up. Patients with normal pre-treatment tests 
were advised to have ongoing annual testing. All abnormal pap 
tests were confirmed with colposcopy.
Results: Data was collected over a crude period of 13.25 patient 
years. 2 patients with normal initial pap tests developed changes 
(1 with low grade squamous epithelial lesion LSIL, and 1 with 
high grade squamous epithelial lesion HSIL). These changes were 
identified at a 6 month follow up interval. Both patients who 
developed CD changes tested positive for high risk HPV dna.
The crude incidence of HSIL in our Alemtuzumab treated patients 
with an additional positive high risk HPV tests was 55.5 per 100 
patient-years. The population incidence of HSIL with a positive high 
risk HPV test is 0.25 per 100 patient-years suggesting a significant 
increased risk for patients who are exposed to Alemtuzumab.
Conclusion: This sample is too small to have meaningful statisti-
cal significant but does support concerns that exposure to immu-
nosupressing therapies including Alemtuzumab increases risk of 
CD.
MS patients are typically young and female who will have long 
term exposure to immunosupressants. We recommend CD screen-
ing become a part of routine clinical care and to consider closer 
surveillance than the usual population screening protocols.
All patients in this study who tested positive for high risk HPV 
dna prior to Alemtuzumab treatment developed dysplastic changes 
on follow up testing. We advocate for additional HPV dna testing 
to be performed to help identify patients who warrant closer 
surveillance.
Disclosure
Dr Skibina and Dr Nesbitt have both previously received sponsor-
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Myocardial ischemia associated with alemtuzumab infusion 
in multiple sclerosis: a case report
V. Camera1, D. Ferraro1, F. Vitetta1, M. Zennaro2, A.M. 
Simone1, P.F. Nichelli1, P. Sola1
1Neurology, University of Modena and Reggio Emilia, 
2Cardiology, Civil Hospital, Azienda Ospedaliero-Universitaria, 
Modena, Italy
Introduction: Alemtuzumab is an anti-CD52 monoclonal anti-
body widely used for the treatment of relapsing-remitting multiple 
sclerosis (RRMS) with high disease activity despite previous dis-
ease-modifying therapies.1 The most common infusion-associated 
reaction (IAR) is cytokine-release syndrome. Incidence of car-
diac-related IARs is 12.5% (tachycardia, bradycardia, palpita-
tions), of which only 0.5% are serious cardiac-related IARs such 
as atrial fibrillation, sinus bradycardia, sinus tachycardia, hypo-
tension or hypertension.2
We report a serious cardiac-related adverse event occurring during 
alemtuzumab-infusion in a RRMS patient.
Case report: A female 24-year-old RRMS patient, with an unre-
markable personal history, started treatment with alemtuzumab 
due to ongoing disease activity during treatment with natali-
zumab. On the third day of treatment, shortly after premedication 
with steroids, antihistamine drugs, paracetamol and lansoprazole, 
the patient developed severe asymptomatic sinus bradycardia, 
which was treated with intravenous atropine. Infusion of alemtu-
zumab was resumed but on the following morning she complained 
of oppressive chest-pain lasting 20 minutes associated with dysp-
noea. Blood tests showed high levels of troponin I, creatine kinase 
MB, and D-Dimer. Alemtuzumab treatment was discontinued. 
Continuous cardiac monitoring showed mild bradycardia in the 
absence of cardiac arrhythmias. Electrocardiography revealed a 
prolonged QTc interval. Echocardiography and cardiac magnetic 
resonance imaging did not detect alterations of left ventricular 
function nor the presence of regional wall-motion abnormalities. 
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Computed tomography angiography and doppler ultrasonography 
of lower limbs did not reveal signs of acute pulmonary embolism/
deep venous thrombosis. Within the subsequent week, myocardial 
cytolysis enzymes and D-dimer spontaneously returned within 
normal ranges and QTc interval normalized.
Conclusion: To our knowledge, this is the first report on a possi-
ble association between alemtuzumab treatment and acute coro-
nary syndrome in absence of cardiovascular risk factors. We 
speculate that the augmentation of endothelial and myocyte mem-
brane permeability and vasodilation induced by alemtuzumab-
related cytokine- release syndrome might determine supply/
demand ischemia of myocardic muscle defining type 2 myocar-
dial ischemia.3
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Evaluation of the benefit of an initial risk-assessment and 
individualized patient coaching for adherence for three 
different-modifying therapies
J. Abel1, Y. Begus-Nahrmann1, G. Niemczyk2, B. Schmid2, M. 
Mäurer3
1Konzept Pharma Service GmbH, Elze, 2Biogen GmbH, 
Ismaning, 3Juliusspital, Würzburg, Germany
Background: Patient support programs (PSPs) contribute to the 
adherence to prescribed multiple sclerosis (MS) therapies. Beside 
therapy-dependent side effects, conscious and unconscious fac-
tors as well as personal circumstances are crucial for therapy 
adherence. By considering these aspects, PSPs for three disease-
modifying therapies (DMTs) were established. The aim of this 
analysis is to evaluate the benefit of patient classification by risk 
factors to favour adherence through an individualized coaching. 
Methods: From February 2014 dimethyl fumarate (DMF), 
September 2014 peginterferon beta-1a (PEG) and August 2016 
daclizumab beta (DAC BETA) patients were recruited and signed 
a written consent form. Each PSP considers potential adherence 
barriers for instance prior therapies and personal circumstances. 
At therapy start patients were stratified into subgroups displaying 
high, medium and low risk for non-adherence. Contents and fre-
quency were adapted according to expected challenges and patient 
needs. 
Results: As of April 2017, 16480 patients taking any of the three 
DMTs were recruited. 4871, 2842 and 117 patients were stratified 
for DMF, PEG and DAC BETA, respectively, according to indi-
vidual adherence risks. DMF patients were stratified at therapy start 
into high (24.2%), medium (34.4%) and low (41.0%) adherence 
subgroups. PEG patients were categorized by cumulative adher-
ence risks into five subgroups from 1 for high up to 5 for low adher-
ence (14.2%, 42.4%, 40.8%, 2.2%, 0.4%). Non-adherence was 
measured by therapy discontinuation and analyzed. For DMF and 
PEG dropout rates correlated with assessed adherence risks. After 
one year DMF therapy discontinuation was 16.5%, 20.9% and 
24.7% for high, medium and low adherence subtypes, respectively. 
PEG subgroups also demonstrated more susceptibility for therapy 
discontinuation depending on the present adherence risks. One year 
dropout rates were 15.2%, 19.9%, 23.6%, 43.8% and 45.5% for 
patient subtypes 1, 2, 3, 4 and 5. For DMF, adherence subtypes were 
re-classified after 1 year of appropriate coaching displaying a shift 
of the number of patients from low to the high adherence subtype. 
Conclusion: Present data demonstrate that patient stratification 
based on identified risk factors can predict non-adherence. In 
turn, subtyping of patients can be useful to provide an adjusted 
support according to patient needs. Risk-adopted, individualized 
coaching is suitable to reduce adherence barriers and to promote 
adherence.
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JA: received funding for medical writing.
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The results of a controlled, prospective study of relapsing MS 
patients at risk for PML who switched from long term natali-
zumab to teriflunomide in a controlled, prospective study
K. Edwards1, J.T. O’Connor1, J. Siuta1, J. Thomas2, S. Cohan3, 
K. Smoot3, K. Kresa-Reahl3, C. Chen3, T. Gervasi3
1Multiple Sclerosis Center of Northeastern New York, 
2Community Care Physicians P.C, Latham, NY, 3Providence 
Multiple Sclerosis Center, Portland, OR, United States
Background: Natalizumab (NTZ) has the risk of causing pro-
gressive multifocal leukoencephalopathy (PML) in patients after 
extended use and with detectable anti-JCV-antibodies. There is a 
need for alternative disease modifying treatment (DMT) that 
would be safe and effective to prevent recurrence of MS exacerba-
tions upon discontinuation of NTZ without further risk of PML. 
Platform DMTs have been ineffective in preventing rebound of 
MS activity. Fingolimod and dimethyl-fumarate (DMF) have 
associated with PML. No cases of PML have been associated with 
teriflunomide in 70,000 patients.
Objectives: To explore the safety and efficacy of teriflunomide in 
patients switching from NTZ to teriflunomide in MS patients at 
risk for PML.
Methods: Patients with relapsing multiple sclerosis (RMS) must 
have received 12 or more NTZ treatments and be anti-JCV-ab 
positive and not have had prior immunosuppressive therapy. 
Patients had to be free of clinical relapses during prior 12 months 
of NTZ treatment. RMS patients ages 21 to 65 began terifluno-
mide at 14mg daily, within 4 weeks after last dose of NTZ. 
Relapse assessment, EDSS, 3T brain MRI, laboratory tests were 
performed at baseline and monthly for 6 months. Final assess-
ments were done at 12 months.
Results: There were 62 patients screened and 55 enrolled. Mean 
age was 47 (SD 10.16). Seventy six percent were female. The 
mean EDSS at baseline was 3.03 (SD 1.35); 47 patients completed 
12 months with mean EDSS of 2.98 (SD 1.44). The mean number 
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of NTZ treatments prior to treatment with teriflunomide was 43 
(SD 25.86).
MRI results showed 38 patients (69%) stable in all parameters 
from baseline to month 12. Seventeen patients had a new MRI 
lesion during the 12 months. There were 12 patients with Gd+ 
enhancing lesions, 13 patients with new T2 hyperintensities and 5 
patients with enlarging lesions. Most of the patients with new 
MRI lesions had no symptoms. Only three patients required 
change of DMT due to MRI progression. Seven patients dropped 
out of the study due to adverse events or lack of efficacy.
Discussion: These results show that, in the majority of patients, 
teriflunomide may be a rational choice for long term safety and 
efficacy for patients at risk for PML. Early switch, in fewer than 
4 weeks, from NTZ to teriflunomide, may be important to sup-
press ongoing ´rebound´ and recurrent MS activity after stop-
ping NTZ.
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Hepatic toxicity appears infrequently and early after initia-
tion of teriflunomide in real-world practice: a multicenter, 2 
years follow-up retrospective study
R. Suarez1, P. Oliva2, V.G. Quintanilla3, J. Peña4, D.M. Solar5, L. 
Lara6, L. Hernández6, D. Fernández-Uría5, D. Pérez7, A. Ares6, 
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1Unidad de Esclerosis Múltiple/Neurología, Hospital de 
Cabueñes, Gijón, 2Neurología, Hospital Universitario Central 
de Asturias, Oviedo, 3Neurología, Hospital Universitario 
Marques de Valdecilla, Santander, 4Neurología, Hospital San 
Agustín, Avilés, 5Unidad de Esclerosis Múltiple-Neurología, 
Hospital Universitario de Cabueñes, Gijón, 6Neurología, 
Hospital Universitario de León, León, 7Neurología, Hospital 
de Ponferrada, Ponferrada, 8Hospital Marques de Valdecilla, 
Neurology, Health Service of Cantabria, Santander, Spain
Introduction: Teriflunomide (TER) has been subjected to a spe-
cial monitoring for hepatic toxicity, as it could be observed in 
multiple sclerosis (MS) clinical trials (CTs), but it is necessary to 
investigate what happens in real-world practice, where TER has 
been used mainly after first-line disease-modifying drugs (DMD)
Objective: To analyze safety and tolerability of TER.
Methods: We retrospectively recorded clinical and biochemical 
data from MS patients who underwent teriflunomide from 6 
Spanish hospitals.
Results: A total of 255 records from MS patients (mean of age= 
45.27±11.5 y; 184 females) who initiated TER (mean on-treat-
ment time =13.1±6.7mo) from december 2014 to march 2017, 
were reviewed. Regarding the MS type, most of them (n=242; 174 
females) were classified as relapsing-remiting form, and 13 as 
progressive active forms (12 SP, 1 PP). Mean disease duration was 
10.92±8.5y ; range=0-37y). A total of 171 patients had been previ-
ously on at least one DMF (43.13% from IF, 8.23% from GA, 
2.74% from NTZ, 3.13% from FTY, and 7.45% from DMF), 37 
patients switched to TER because of inefficacy, and 134 patients 
for intolerance or side effects. A 40.8% of patients on TER expe-
rienced some adverse events (AE). Most common AEs were 
abdominal complaints (23.5%), hair thinning or decreased hair 
density (16.9%). AEs, leading to discontinuation appeared in 15 
patients (6%), mainly diarrhea (n=4; 26.7%). Serious adverse 
events accounted for 13 patients, included 5 patients with stoma-
titis (1 herpetic), 1 case with lymphopenia (< 900 cel/mm3), and 
pregnancy in 2 females. Hepatic toxicity was temporarily observed 
in 22.7%, being less than 3x normal range in 48.5% of them, and 
in only one case exceeded x3 normal range. First ALT increase 
was recorded during the first 3 months for 91.9% of patients.
Conclusions: In real word practice, teriflunomide was generally 
well tolerated. Hepatic toxicity was mild and temporarilly found in 
the first 3 months, leading to discontinuation for only one patient 
(0.4%). These results do not justify the number of blood draws 
needed for monitoring teriflunomide potential hepatic toxicity.
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Mortality from Listeria monocytogenes meningoencephalitis 
following escalation to Alemtuzumab therapy for relapsing-
remitting multiple sclerosis
L.J.W. Canham1, A. Manara2, J. Fawcett3, M. Rolinski3, A. 
Mortimer3, K. Inglis3, D.A. Cottrell3
1Bristol Brain Centre, BrAMS Service, 2Intensive Care, 3North 
Bristol NHS Trust, Bristol, United Kingdom
06_MSJ731285.indd   910 13/10/2017   11:11:05 AM
ePosters 23(S3) 911
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
A 42 year old Caucasian female died from Listeriosis a week fol-
lowing Alemtuzumab administration, one month after discontinu-
ing dimethyl fumarate.
This is the first mortality of a complication to which patients 
appear particularly vulnerable days/weeks post-administration.
Multiple Sclerosis was diagnosed in 2014. Relapse in March 2015 
lead to dimethyl fumarate initiation in July 2015.
Further relapses arose in August 2015 and April 2016. Dimethyl 
Fumarate was discontinued in July 2016. Expanded Disability 
Severity Scale score was 2.5. In August 2016 Alemtuzumab 12mg 
iv was administered for five days with 1gram Methylprednisolone 
for the initial 3 days.
At day 6 post-completion, a 3 day history of diarrhoea, vomiting 
and malaise was reported and rapid deterioration supervened. 
Paramedics found the patient comatose (GCS 7; E4, V2, M1) with 
severe tachypnoea (60 breaths/minute), high-grade pyrexia of 40C, 
tachycardic and hypertensive. She was intubated on scene.
CT head revealed reduced grey-white differentiation, diffuse cer-
ebral swelling, bilateral temporal horn distension and cisternal 
effacement consistent with severe meningoencephalitis. 
Laboratory studies demonstrated a grossly elevated C reactive 
protein in the absence of a peripheral leucocytosis.
Eight hours after admission her pupils became asymmetrically 
fixed. External ventricular drainage decompressed intracranial 
pressure >30cmCSF; the fluid was clear and colourless, yielding 
only 5 white cells and 279 red cells, protein .33g/l and a raised 
glucose gradient of 2.8mmol/l in CSF vs. 8.1mmol/l in serum.
Therapy included Ceftriaxone 2g b.d., Aciclovir 700mg t.d.s. and 
Amoxicillin 2g four hourly.
CSF PCR yielded a positive result for Listeria monocytogenes. 
Despite resolution of pyrexia and improving inflammatory indices 
a diagnosis of brain death was recorded at 60 hours following 
admission. Cultures of blood and CSF later supported the diagno-
sis of listeriosis.
There was considerable overlap with typical post-infusion 
symptoms therefore high surveillance and low threshold for 
empirical or possible prophylactic co-trimoxazole therapy is 
advocated.
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Clinical activity after fingolimod cessation: disease reactiva-
tion or rebound?
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Background: In the last years several reports about a possible 
rebound after fingolimod discontinuation in patients with Multiple 
Sclerosis (MS) were reported. On the other side, no rebound was 
found in the fingolimod randomized clinical trials, including more 
than 2000 subjects. It is still debated if the so-called rebound is 
really related to fingolimod discontinuation rather than the natural 
course of highly active MS.
Objective: The study aimed to survey the prevalence of severe 
reactivation and rebound after fingolimod discontinuation in a 
large cohort of MS Italian patients.
Methods: Patients with RRMS treated with fingolimod since at 
least 6 months, who stopped treatment for reasons not related to 
inefficacy were included in this analysis. A severe reactivation 
was defined as a relapse with an associated EDSS increase of at 
least 2 points or 2 or more relapses in the 6 months following 
fingolimod discontinuation. A severe reactivation was considered 
a rebound if these criteria have never been fulfilled in the patient’s 
previous medical history.
Results: A total of 108 patients (mean age: 37.3 (SD:10); females: 
79.6%; median EDSS: 2.5 (0-8.5); disease duration: 10.6 years) 
satisfied the inclusion criteria; we selected 90 patients with no 
relapses in the last 6 months under fingolimod. 13 out of 90 
(14.4%) patients had a relapse within 3 months after fingolimod 
discontinuation (9 without any new therapy), and further 10 
(11.1%) had a relapse within 6 months (6 without any new ther-
apy). Six out of 90 (6.5%) patients had a severe reactivation. 
Among them, 1 had a relapse associated with an EDSS increase of 
6 points, 2 had a relapse associated with an EDSS increase of 2 
points and 1 had 3 relapses over 6 months. Four patients out of 90 
(4.4%) were defined as rebound.
Conclusions: The present study showed that more than 25% of 
patients risk to have a relapse within 6 months after fingolimod 
discontinuation. This is an expected result, being fingolimod 
approved in Italy as second line therapy in MS. Nevertheless, the 
risk of severe reactivations and rebound is lower than previously 
described.
Reference
Hatcher SE, et al. Rebound syndrome in patients with multiple 
sclerosis after cessation of fingolimod treatment
06_MSJ731285.indd   911 13/10/2017   11:11:05 AM
912 ePosters 23(S3)
Multiple Sclerosis Journal 2017; 23: (S3) 680–975 journals.sagepub.com/home/msj
Disclosure
J Frau serves on scientific advisory boards for Biogen, received 
honoraria for speaking from Merck Serono, Biogen and Teva and 
received research grant from Serono.
G Fenu received consulting fees from Biogen Idec, Merck Serono, 
Teva, Genzyme, Novartis.
R Lanzillo received personal fees for public speaking or consul-
tancy from Biogen, Novartis, Teva, Genzyme, Merck, Almirall.
D Baroncini received speaking honoraria and fees for advisory 
board, travel and editorial projects from Almirall, Sanofi-
Genzyme, Merck, Novartis, Teva
P Annovazzi received speaking honoraria and/or fees for parteci-
pating to advisory boards and7or travel expenses for partecipating 
to congresses and meetings fron Teva, Biogen, Novartis, Roche, 
Almirall, Sanofi Genzyme and Merck
A Sartori received honoraria for speaking from Novartis and fund-
ing for travel from Teva, Merck Serono, Sanofi-Genzyme, 
Novartis, Almirall.
G.T. Maniscalco has received travel assistance and/or honoraria 
from, and provided advice to Biogen Idec, Novartis, Genzyme, 
Sanofi-Aventis and Merck-Serono.
MP Sormani received consulting fees from Biogen Idec, Merck 
Serono, Teva, Genzyme, Roche, Novartis.
E Cocco reports personal fees and non-financial supportfrom
Bayer, Biogen, Novartis, Genzyme, Merck Serono, Roche, and Teva.
The other authors have nothing to disclose about this work.
EP1731
Delayed lymphocyte re-population following discontinuation 
of dimethyl fumarate and after switching to other disease 
modifying drug therapies
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Background: Dimethyl fumarate (DMF) reduces absolute lym-
phocyte counts, CD4, and CD8 counts, without significantly 
affecting total white blood cell counts. However, the recovery rate 
of these cells after discontinuation of DMF is unknown. The effect 
of subsequent disease modifying therapies (DMTs) on re-popula-
tion rate is also unknown.
Objectives: First, to study the re-population rate of absolute lym-
phocytes, CD4, and CD8 counts back to baseline after discontinu-
ation of DMF. Second, to measure the effect of subsequent DMTs 
on the re-population rate of these cells after DMF therapy. Third, 
to study the effect of the duration of exposure to DMF on repopu-
lation of these cells. 
Methods: A retrospective chart review of subjects who had dis-
continued DMF and in whom, CBC with differential, CD4 and 
CD8 counts were available at baseline, discontinuation and fol-
low-up (n=113). Linear mixed models were used to analyze and 
assess linear trends in lymphocyte counts after DMF had been 
discontinued.
Results: DMF causes a significant drop in absolute lymphocyte, 
CD4, and CD8 counts. Re-population of these cells after discon-
tinuation of DMF is significantly delayed, irrespective of whether 
or not a subsequent DMT is used, although there is a difference in 
re-population rate among DMTs. Repopulation rate was the 
shortest for glatiramer acetate (or on no therapy); no recovery was 
observed with fingolimod or with alemtuzumab at the conclusion 
of our study. The re-population rate is also dependent on the dura-
tion of time patients have been exposed to DMF; longer exposure 
was associated with more delayed recovery. One extra month on 
DMF was significantly associate with a 4% decrease in the monthly 
rate of change for CD4 counts, 6% decrease in the monthly rate of 
change for CD8 counts and a 3% decrease in the monthly rate of 
change for the absolute lymphocyte count.
Conclusion: During this 30 month study period, re-population 
rates were significantly delayed post-DMF. Furthermore, no 
recovery of lymphocyte counts occurred in patients who were 
started on fingolimod or alemtuzumab after DMF was discontin-
ued; in fact there was a continued decline in all of the cell popula-
tions studied.
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Teriflunomide (Aubagio®) International Pregnancy Registry: 
enrolment update
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Truffinet3, A. Ghezzi5
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France, 4Sanofi Genzyme, Cambridge, MA, United States, 
5Ospedale di Gallarate, Gallarate, Italy
Background: Teriflunomide is a once-daily oral immunomodula-
tor approved for the treatment of relapsing-remitting MS in 70 
countries, with more than 71,000 patients currently being treated 
with teriflunomide worldwide. Teriflunomide is contraindicated 
in pregnancy based on embryo-foetal toxicity in rats and rabbits. 
Despite the requirement to use effective contraception during teri-
flunomide clinical trials, pregnancies did occur. There were no 
signs of structural or functional deficits in newborns and data 
from the clinical programme, although limited due to the low 
number of pregnancies, showed no signal for human teratogenic-
ity. It is, therefore, important to continue to collect data on teriflu-
nomide exposure in pregnancy.
Objective(s): The International Teriflunomide Pregnancy Exposure 
Registry will compare rates of birth defects (congenital malforma-
tions, foetal deaths, termination due to foetal abnormality) in terif-
lunomide-exposed pregnant women with those reported by the 
European Surveillance of Congenital Anomalies (EUROCAT).
Methods: The registry is a voluntary, multinational, prospective, 
observational, exposure-registration study. Pregnant women with 
MS with teriflunomide exposure (any dose, any time after Day 1 
of last menstrual period until pregnancy end) can enrol. National 
Coordinators will liaise with healthcare professionals to collect 
information on teriflunomide-exposed pregnancies and coordi-
nate patient enrolment in the registry. Target recruitment is 196 
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women to achieve 104 live births, providing an 80% power to 
detect a 3.95-fold increase in risk ratio of birth defects associated 
with teriflunomide exposure vs EUROCAT. Pregnancy outcome 
data including birth defects and infant characteristics during the 
first year of life will be collected.
Results: As of April 26, 2017, 14 patients have been recruited 
from 7 countries in Europe. Six healthy babies have been born 
with no abnormality reported to date. One patient had an elective 
termination that was not motivated by either an abnormal result of 
a prenatal test or by any concerns regarding potential birth defect.
Conclusions: This registry aims to provide data on pregnancy 
outcomes and infant development during the first year of life from 
teriflunomide-exposed pregnancies and will help physicians to 
provide better counselling for women exposed to teriflunomide 
during pregnancy.
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Unexpectedly high rate of discontinuation of pegylated inter-
feron beta-1a among previously stable interferon-treated 
patients due to poor tolerability and disease recurrence
P. Repovic1, K. Smoot2, C. Chiayi2, L. Grote2, M.M. Napier3, 
J.D. Bowen1
1Multiple Sclerosis Center, Neurology, Swedish Neuroscience 
Institute, Seattle, WA, 2Providence Brain and Spine Institute, 
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Background: Biweekly pegylated interferon beta-1a (PEG-IFN, 
Plegridy) is an attractive treatment option for multiple sclerosis 
(MS) patients currently treated with interferons. However, the 
efficacy and tolerability of PEG-IFN treatment in this population 
is unknown, as only 1% of the patients in the pivotal trial of PEG-
IFN were previously treated with interferons, and a subsequent 
interferon-to-PEG-IFN switch study focused primarily on flu-like 
symptoms and their management.
Objective: To evaluate the efficacy, tolerability and 12-month 
discontinuation rates of PEG-IFN among MS patients previously 
stable on another interferon.
Methods: In this retrospective two-centre study, we reviewed 
the medical records of 116 MS patients who initiated treatment 
with PEG-IFN between November 2014 and March 2016. We 
limited the analysis to 73 patients who were previously treated 
with interferons with no evidence of disease activity (as deter-
mined by the absence of relapses and/or MRI lesions) prior to 
initiation of PEG-IFN. The primary outcome was the rate of 
PEG-IFN discontinuation in the first 12 months. Secondary 
outcomes were the reasons for PEG-IFN discontinuation and 
evaluation of MS activity (relapse or new MRI lesions) during 
the initial
12 months of PEG-IFN treatment. Chi-square and t-test were used 
to assess differences between categorical and continuous varia-
bles, respectively.
Results: The study population consisted of 73 patients (85% 
female) previously treated with interferon for 7.4+/-4.7 years, 
with no evidence of relapses or MRI changes for median 18 
months (range 6-58 months from last MRI prior to PEG-IFN ini-
tiation). Within the first 12 months of switching to PEG-IFN, 29 
(40%) discontinued PEG-IFN, due to poor tolerability (n=19, 
26%) and MS relapses (n=10, 14%). Median time to discontinua-
tion was 134 days (range 21-350 days); 69 days for those who 
discontinued due to intolerability, and 179 days for disease activ-
ity. The patients with and without MS activity on PEG-IFN could 
not be distinguished in terms of age, duration of disease, or dura-
tion or type of prior interferon therapy.
Conclusion: The observed high rate of discontinuation of PEG-
IFN due to tolerability and MS relapses among previously stable 
interferon-treated patients was unexpected given the within-class 
therapy switch. These findings mandate a cautious reevaluation of 
risks and benefits of switching previously stable interferon-treated 
patients to PEG-IFN.
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Lack of clinically meaningful changes in cardiac effects from 
co-administration of ozanimod and a beta-blocker or a cal-
cium channel blocker
J.L. Boyd1, S. Walker2, P. Mccloskey1, M. Syto1, B. Darpo3, J.Q. 
Tran1
1Receptos, a wholly owned subsidiary of Celgene, San Diego, 
CA, 2Apex Biostatistics, Raleigh-Durham, NC, United States, 
3Department of Clinical Sciences, Danderyd’s Hospital, Division 
of Cardiovascular Medicine, Karolinska Institutet, Stockholm, 
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Background: Ozanimod (RPC1063) is an oral, selective sphingo-
sine 1-phosphate (S1P) 1 and 5 receptor modulator in clinical 
development for the treatment of relapsing multiple sclerosis and 
inflammatory bowel disease (Cohen, 2016; Sandborn, 2016). 
Initiation of S1P receptor modulators causes transient decreases in 
heart rate (HR) that decreases with repeat dosing (Kovarik, 2004). 
The primary objective of this study was to compare the cardiac 
effects of ozanimod initiation in combination with steady-state 
propranolol or diltiazem to that of ozanimod alone.
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Methods: In a double-blind, placebo-controlled, 3-period crosso-
ver study, 2 separate groups (propranolol and diltiazem groups) of 
18 healthy subjects each received 3 treatment arms (separated by 
7-10 days) per randomly assigned sequence: 1) placebo for 5 days 
and a single dose of ozanimod 0.25 mg on Day 5; 2) propranolol 
80 mg or diltiazem 240 mg once daily for 5 days and placebo on 
Day 5; and 3) propranolol or diltiazem for 5 days plus a single 
dose of ozanimod on Day 5. HR nadir (0-12 hours postdose) and 
maximum increase (over a 24-hour postdose) from baseline PR 
interval were evaluated using least squares mean (LSM) differ-
ences (ΔHR or ΔPR) from a linear mixed model, with fixed effects 
for sequence, treatment, period, baseline as continuous covariate 
and subject (sequence) as a random effect. The pharmacokinetics 
(PK) of individual drugs were evaluated.
Results: Administration of ozanimod alone in the propranolol 
group and diltiazem group resulted in mean (SD) HR reduction 
from 75.7 (8.12) and 73.8 (11.41) bpm at baseline to 62.7 (7.48) 
and 63.6 (7.95) bpm at nadir, respectively. Propranolol+ozanimod 
arm and diltiazem+ozanimod arm resulted in mean (SD) HR 
reduction from 65.6 (6.61) and 73.9 (9.68) bpm at baseline to 55.2 
(5.80) and 61.6 (7.63) bpm at nadir, respectively. Compared to 
ozanimod alone, a small and not clinically meaningful ΔHR (95% 
confidence interval [CI]) of 0.57 bpm (-1.95 to 3.10) for 
propranolol+ozanimod or -1.31 bpm (-3.14 to 0.52) for 
diltiazem+ozanimod was observed. Small, non-clinically mean-
ingful ΔPR (95% CI) for (propranolol+ozanimod vs propranolol) 
and (diltiazem+ozanimod vs diltiazem) were 1.65 ms (-2.98 to 
6.27) and 4.53 ms (-5.26 to 14.3), respectively. The PK of indi-
vidual drugs were not affected during co-administration.
Conclusion: Co-administration of ozanimod and propranolol or 
diltiazem did not result in further clinically meaningful changes in 
HR or PR interval.
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EP1735
Anti- JCV antibody Sero-positivity and index value among 
Iranian patients with multiple sclerosis and its correlation 
with demographic data and previous therapies
S. Koolaji1, N. Sistany Allahabadi1, A. Ahmadi1, M.A. Sahraian1, 
A.R. Azimi1, A. Naser Moghadasi1, S. Eskandarieh1,2
1MS Research Center, Neuroscience Institute, Tehran University 
of Medical Sciences, 2Brain and Spinal Cord Injury Research 
Center, Neuroscience Institute, Tehran University of Medical 
Sciences, Tehran, Islamic Republic of Iran
Background: Anti- JCV antibody index is the predicting factor of 
progressive multifocal leukoencephalopathy (PML) for multiple 
sclerosis (MS) patients treating with Natalizumab.
Objectives: To evaluate the prevalence of anti-JCV antibody pos-
itivity and high index among Iranian patients who are the candi-
date for Natalizumab to see its correlation with their demographic 
data.
Method: This cross-sectional study assessed all received anti-
JCV Antibody test result of Iranian MS patients between Jan 2014 
and Dec 2016. Demographic data and disease characteristics were 
also obtained. After data quality control, statistical analysis was 
done using logistic regression.
Results: Among 803 MS patients that were observed, prevalence of 
anti-JCV antibody positivity was 67.9% (mean of index=2.23; stand-
ard deviation (SD) =1.16) and 67.6 % of positive patients had index ≥ 
1.5. Males were more anti-JCV antibody positive than females (81.7% 
and 64% respectively; significance sig. < 0.001, crude OR =2.51, CI: 
1.65-3.81). Patients with 50 ≤ years old age (y.) comparing to patients 
with ≤18 y. had higher positivity prevalence (sig. =0.021; adjusted OR 
= 3.45, CI: 1.20-2.86). Patients who lived in cold regions had signifi-
cantly more prevalence of positivity (Number of cases=403; sig. = 
0.043 and crude OR = 1.86, CI: 1.02-3.39) and higher rate of index ≥ 
1.5 (sig. = 0.017; crude OR=3.99, CI: 1.79-8.88). Disease onset age 
between 28 to 37 y. were more positive comparing to 18 to 27 y.
(N= 480; sig. =0.02; adjusted OR=1.85, CI: 1.09-3.14) but corre-
lated reversely with index (sig. =0.01).
Conclusions: Age, male gender, onset age, cold area residency 
significantly influenced anti-JCV antibody positivity prevalence. 
Only age of onset and cold area residency related to the index. No 
significant difference observed between the previous type of dis-
ease modifying drugs, dosage and duration of treating with them 
and anti-JCV antibody positivity and its index.
Disclosure
Founding source: this study was funded by Tehran University of 
medical sciences.
Conflict of interest: authors declare no conflict of interest.
EP1736
Pregnancy outcomes with delayed-release dimethyl fuma-
rate: interim results from an international registry
N.J. Everage, S. Liu, J. Yun, C. Prada, J. Hanna
Biogen, Cambridge, MA, United States
Background: Data from clinical trials and post marketing reports 
show no safety signals with exposure to delayed-release dimethyl 
fumarate (DMF) during pregnancy; however, these data are lim-
ited and the product label recommends use during pregnancy only 
if the potential benefit justifies the potential risk to the foetus.
Objectives: To assess interim pregnancy outcomes in an interna-
tional registry (NCT01911767) of women with MS exposed to 
DMF since the first day of their last menstrual period prior to con-
ception or at any time during pregnancy.
Methods: DMF-exposed women with MS participating in the 
registry were prospectively evaluated for live births and preg-
nancy loss, defined as elective or therapeutic pregnancy termina-
tions, spontaneous abortions, and foetal death including stillbirth. 
Ectopic and molar pregnancies, birth defects, any congenital 
anomalies or infant death occurring at ≤52 wks of age, and any 
maternal death at ≤12 wks postdelivery, were reported. Baseline 
data were collected at enrolment; follow-ups were conducted at 
6-7 mos of gestation and 4 wks after the estimated delivery date, 
and 4, 12, and 52 wks after birth. Gestational size (GS) was clas-
sified as small (< 10th percentile), appropriate (10th-90th), or large 
(>90th) based on WHO or country-specific growth charts. Potential 
birth defects were adjudicated by an external teratology expert.
06_MSJ731285.indd   914 13/10/2017   11:11:05 AM
ePosters 23(S3) 915
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Results: As of 30 Sept 2016, 104 patients (pts) were enrolled in 
the registry; mean (SD) age was 31 (5) yrs. Of the 94 pts with a 
known DMF exposure date, 95% occurred in the first trimester, 
1% in the second, and 0% in the third. To date, 58 pregnancy out-
comes have been reported, including 52 pts with 54 live births and 
4 (7%) spontaneous abortions (< 22 wks). Of the 54 (93%) live 
births, 47 (87%) were full term (delivered ≥37 wks) and 4 (7%) 
premature. Two (4%) infants had adjudicator-confirmed birth 
defects: 1 with pyloric stenosis, and 1 with transposition of the 
great vessels and patent ductus arteriosus. No maternal, neonatal, 
perinatal, or infant deaths were reported. Of the 40 infants with 
GS data, 3 (8%) were classified as small, 34 (85%) as appropriate, 
and 3 (8%) as large.
Conclusions: The limited interim results from this ongoing regis-
try did not identify a safety signal for DMF exposure on preg-
nancy outcomes, consistent with previous reports. Final results 
will provide essential information for women of childbearing age 
concerning the safety of DMF during pregnancy.
Supported by: Biogen
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EP1737
Acalculous cholecystitis as an infusion-related reaction in 
alemtuzumab-treated RRMS patients. Long-term follow-up 
and conversion to chronic disease
S. Pfeuffer1, T. Ruck1, C. Beuker1, F. Lenze2, N. Melzer1, H. 
Wiendl1, S.G. Meuth1
1Institute of Translational Neurology and Neurology Clinic, 
2Medical Department B, University of Münster, Muenster, 
Germany
Alemtuzumab is an effective therapeutic option for patients with 
active relapsing-remitting multiple sclerosis (RRMS). Its adverse 
event profile mainly comprises development of secondary auto-
immune disorders and infusion-associated reactions (IARs). The 
latter mostly manifests with headache, pyrexia and rash, but also 
rarely includes hypotension, cardiac arrhythmia, and anaphylactic 
shock. IARs are usually limited to the first days of infusion and - if 
managed properly - do not cause sustained impairment.
We recently described acalculous cholecystitis (AAC) as a novel, 
but rare IAR. AAC itself is usually seen in intensive-care-unit 
(ICU) patients suffering from septicemia following surgery and in 
end-stage HIV infections. Furthermore, AAC has been a compli-
cation of infectious (e.g. Epstein-Barr virus or cytomegalovirus 
infection) or inflammatory disorders (e.g. systemic lupus erythe-
matosus, Sjögren’s syndrome). Diagnosis is often rendered 
difficult due to unspecific symptoms such as upper right quadrant 
stomach pain, pyrexia and inconclusive laboratory findings (e.g., 
often normal levels of alkaline phosphatase). Precise treatment is 
crucial given the high mortality of about one third of patients.
Among the 180 infusion courses that were administered to around 
100 patients in our department between 2015 and 2016, we 
detected 4 cases of AAC. All cases were confirmed using CT and/
or ultrasound imaging. In contrast to our previous experience, this 
condition is not always limited to the first days of infusion and 
was converted to chronic gall bladder inflammation in two cases. 
Furthermore, AAC did not occur as a single event and was detect-
able also after repetitive courses of Alemtuzumab in the three 
patients that did not undergo cholecystectomy. In one patient 
requiring cholecystectomy, histopathology demonstrated lympho-
cyte invasion in the gallbladder.
These findings require careful consideration on whether the appear-
ance of AAC in alemtuzumab patients should lead to subsequent 
cholecystectomy. Facing the potential risk of chronic gall bladder 
inflammation, monitoring should include clinical surveillance for this 
condition. Generally, physicians should be aware of this IAR and 
seek contact to gastroenterologists or surgeons in suspicious cases.
This project is supported financially by Sanofi Genzyme
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Rituximab-induced interstitial lung disease in a patient with 
neuromyelitis optica spectrum disroder: the first case report
S.H. Ahn1, S.M. Kim1, B.J. Kim2, S.H. Baek2
1Seoul National University Hospital, 2Korea University Medical 
Center, Seoul, Republic of Korea
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) 
is an inflammatory disease of the central nervous system (CNS) 
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which is predisposed to the optic nerves and spinal cord. Rituximab 
(RTX) is a chimeric monoclonal antibody to the CD20 in pre-B / 
mature B cells and has been suggested as an efficient treatment for 
NMOSD. Its common side effect incudes infusion related reac-
tions, fever/chills, infection, and respiratory complications. 
Among them, RTX-induced interstitial lung disease (ILD) is very 
rare, but potentially fatal. Herein, we report a first case of RTX-
induced ILD in a patient with NMOSD.
Case presentation: A 48-yearold woman with NMOSD with 
aquaporin-4 IgG presented to the hospital complaining of dyspnea 
and a non-productive cough for 3 weeks. Two months prior to 
symptom onset, she was treated with four cycles of rituximab 
therapy. She did not have any signs or symptoms for respiratory 
disease before RTX treatment. Physical examination showed nor-
mal breath sounds on auscultation and normal saturation at rest, 
nevertheless her pulmonary function test showed a mild restric-
tive pattern with a reduced diffusion capacity for carbon monox-
ide of 46% and forced vital capacity of 75%. Chest CT scan also 
revealed bilateral patchy ground glass opacities with subsegmen-
tal linear atelectasis on bilateral lower lobe. The diagnosis of 
rituximab induced ILD was made on clinical and radiological 
basis and her RTX treatment was discontinued. Two months after 
the diagnosis of RTX-induced ILD, her respiratory symptom was 
improved without steroid treatment and her chest CT were nor-
malized. After 8 month, her respiratory symptoms were com-
pletely recovered and the follow up pulmonary function test 
showed normal FVC and DLco.
Conclusion: This is the first report of RTX-induced ILD in 
patients with NMOSD. This rare complication should be con-
sidered in NMOSD patients under RTX treatment, who present 
with dyspnea and/or cough and without any evidence of infec-
tion. As the early diagnosis of RTX-induced ILD might pro-
duce a good prognosis, clinicians should be aware of the 
possibility of this complication in NMOSD patients under RTX 
treatments.
Disclosure
All of the authors have nothing to disclosure
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Progressive multifocal leukoencephalopathy during teriflu-
nomide in multiple sclerosis patient: a case report
L. Lorefice1, G. Fenu1, S. Gerevini2, J. Frau1, G. Coghe1, F. 
Contu3, M.A. Barracciu3, M.G. Marrosu1, E. Cocco1
1Multiple Sclerosis Center, Department of Medical Sciences and 
Public Health, University of Cagliari, Cagliari, 2Neuroradiology 
Department, IRCCS San Raffaele Hospital, Milano, 3Radiology 
Unit, Binaghi Hospital, ATS Sardegna, Cagliari, Italy
Background: Teriflunomide (TER), the active metabolite of 
leflunomide, is prescribed by few years for relapsing remitting 
MS (RR) as first line therapy (Oh J, 2014). Progressive multifocal 
leukoencephalopathy (PML) is an opportunistic infection of the 
central nervous system (CNS) caused by JC virus primarily seen 
in immunocompromised patients or associated with specific 
immunotherapies (Ferenczy MW,.2012). Any case of PML has 
been reported in patients treated with TER, but two case of leflu-
nomide-related PML has been described. Here, we reported the 
first case of PML during TER treatment.
Case report: A 36-year-old woman with multiple sclerosis, tak-
ing TER since three months, on January 30, 2017 developed an 
acute decline in speech. She was previously treated with natali-
zumab (N), discontinued after 33 infusions eight months before, 
for JCV antibodies detection. Brain MRI showed a unilobar area 
suggestive for PML; cerebrospinal fluid showed JCV DNA (11 
copies/ml). A dissemination of brain lesions with several new cor-
tical and subcortical enhancing lesions was observed, making dif-
ficult the differential diagnosis between PML-immune 
reconstitution inflammatory syndrome and new MS relapse.
Conclusions: Up to now, there is no knowledge about the possible 
risk of PML related to immunosuppressant use subsequently N 
exposure. The acute onset of symptoms, the first unilobar PML 
lesion documented by brain MRI and low number of CSF JCV 
DNA copies, support the hypothesis that in our patient PML was 
in an initial phase at diagnosis time, occurring eight moths after N 
cessation, but few months after TER initiation. However, multiple 
enhancing lesions occurring without modification of clinical 
symptoms and without any kind of response to steroid could rep-
resent a diffuse MS relapse with exaggerated inflammatory reac-
tion, perhaps related to the underlying not clear mechanism of the 
drugs. Therefore, this case highlights the debate for a more pro-
longed PML surveillance program, especially for patients exten-
sively N pre-treated with high risk for PML (Schwab N, 2017) 
that switch to therapies with an immunosuppressant effect.
Keywords: teriflunomide, natalizumab, JC virus, Progressive 
Multifocal Leukoencephalopathy, safety
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Alemtuzumab-associated anti-glomerular basement mem-
brane antibody-positive glomerulonephritis complicated by 
secondary thrombotic microangiopathy and posterior revers-
ible encephalopathy syndrome
S.M. Yap1, N. McNicholas1, S. O’Riordan1, J. Fitzgerald2, A. 
Watson3, C. McGuigan4
1Department of Neurology, 2Department of Haematology, 
3Department of Nephrology, St. Vincent’s University Hospital, 
4St. VIncent’s University Hospital, Dublin, Ireland
Background: Potential adverse events associated with alemtu-
zumab (AL) therapy for relapsing multiple sclerosis (MS) include 
secondary autoimmune disorders of which autoimmune nephropa-
thies, including anti-glomerular basement membrane (GBM) dis-
ease, have been identified in 0.3% of cases. It is unclear if 
recommended pharmacovigilance for AL involving monthly 
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blood and urine testing for 4 years from last AL infusion would 
identify anti-GBM disease in an asymptomatic state.
Objectives: To report a rare case of AL-associated anti-GBM Ab 
positive glomerulonephritis (GN) with unusual complications.
Case description: A 30-year-old female with highly active MS 
was treated first-line with two standard courses of AL (total dose 
96mg) 1 year apart. Urine testing and serum creatinine were nor-
mal 6 weeks and 3 weeks prior to symptom onset respectively. 5 
months after last AL infusion, she presented with a 5-day history 
of headache, vomiting and oliguria. There was no rash, arthralgia 
or haemoptysis. Urine showed proteinuria, haematuria and granu-
lar casts; serum creatinine was raised (492 umol/l). Renal biopsy 
showed extensive necrotising and crescentic lesions. Anti-GBM 
Ab titre was markedly raised (463 EliAu/ml). Extensive microbial 
testing was negative. Cerebrospinal fluid testing was normal.
To date, the patient has been treated with 20 sessions of plasma 
exchange, 2 courses of rituximab 375mg/m2, intravenous methyl-
prednisolone and oral prednisolone with slow taper. 3 weeks from 
symptom onset, the patient developed fever, headache, visual 
field defect, severe hypertension and seizures. Magnetic reso-
nance imaging of brain was indicative of posterior reversible 
encephalopathy syndrome (PRES). Within 24 hours, platelet 
count dropped to nadir 64X109/l with haemoglobin 8.1g/dl, schis-
tocytes on blood film, increased reticulocytes and reduced hapto-
globins, suggestive of haemolytic anaemia. Normal ADAMTS13 
activity (70iu/dl) supported a diagnosis of secondary thrombotic 
microangiopathy. She remains dialysis-dependent with persis-
tently elevated anti-GBM Ab titres
(mean 280 EliAu/ml).
Conclusion: Failure to detect imminent symptomatic manifesta-
tion of AL-associated anti-GBM disease with monthly blood and 
urine reminds us that although safety monitoring may detect other 
autoimmune complications such as thyroid disease, it may not 
identify an explosive onset disorder such as anti-GBM disease. 
New clinical symptoms should prompt consideration of these 
disorders.
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Suspected pneumocystis jirovecii pneumonia after alemtu-
zumab
E.D. Verter1, J. Hand2, B. Bagert3
1University of Queensland School of Medicine, Neurology, 
2Infectious Disease, 3Neurology, Ochsner Medical Center, New 
Orleans, LA, United States
Introduction: The Food and Drug Administration recommends 
prophylaxis against pneumocystis jirovecii pneumonia (PJP) for 
patients on alemtuzumab for B cell lymphoma, but not for patients 
on alemtuzumab for multiple sclerosis (MS). We present a case of 
suspected PJP secondary to alemtuzumab immunosuppression in 
a patient with MS.
Case report: A 37-year-old male with a history of MS presented 
to the emergency room 10/8/2016 with new symptoms of fever, 
weakness, blurry vision, and shortness of breath. The patient’s 
immunotherapy for MS had recently been switched from natali-
zumab to alemtuzumab. He received his first alemtuzumab infu-
sion 41 days prior to the onset of these new symptoms. There was 
a five week washout period between alemtuzumab and his last 
dose of natalizumab.
Initial infectious workup revealed no abnormalities. There was no 
leukocytosis, blood cultures showed no growth, and all initial 
standard viral assays were negative. Spinal fluid studies were 
within normal limits. Chest X-ray was unremarkable, and mag-
netic resonance imaging brain revealed no new lesions. The 
patient was admitted, improved with supportive care, and was dis-
charged with a proposed diagnosis of upper respiratory tract infec-
tion 10/12/2016. The patient returned to the emergency department 
on 10/18/2016 with symptoms of fever, shortness of breath, and 
non-productive cough. He was found to have exertional hypoxia 
to the 70’s and was re-admitted. Lactate dehydrogenase was ele-
vated to 345 U/L, and CD4 was found to be 36 cells/microliter.
Streptococcal culture, respiratory viral panel, and sputum culture 
were within normal limits. Computed tomography chest revealed 
bilateral ground glass opacities. Bronchoscopy was unremarka-
ble. (1→3)-β-D-glucan assay was >500 pg/ml, however gomori 
methenamine silver stain (GMS) was negative. PJP polymerase 
chain reaction was not sent. Empiric trimethoprim/sulfamethoxa-
zole (TMP-SMX) and oral corticosteroids were started, and the 
patient quickly improved. He was discharged on TMP-SMX and 
was seen as outpatient in both infectious disease and neurology 
clinic where he was observed to do very well.
Conclusion: While GMS was negative in this patient, the clinical 
picture, elevated (1→3)-β-D-glucan assay, low CD4 count, and 
improvement with TMP-SMX raise suspicion that this was a case 
of PJP secondary to alemtuzumab immunosuppression. This case 
supports the possible need for TMP-SMX prophylaxis in MS 
patients taking alemtuzumab.
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Pharmacodynamics and pharmacokinetics of natalizumab 
administered at extended interval dosing
L. Zhovtis Ryerson1, G. Zuniga-Estrada1, A. Jacob1, T. Bacon1, 
K. Pandey2, J. Mohn2, I. Kister1
1Department of Neurology, Multiple Sclerosis Center, NYU 
Langone Medical Center, New York, NY, 2Multiple Sclerosis 
Center, RWJ Barnabas Health, Livingston, NJ, United States
Objective: To evaluate α4β1 integrin saturations (SAT) and serum 
concentrations (CONC) in patients on extended interval regiments 
of Natalizumab (NTZ).
Background: NTZ is approved for every 4-week administration 
as effective therapy for multiple sclerosis (MS), but carries risk of 
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progressive multifocal leukoencephalopathy (PML). Extended 
interval dosing (EID) is being explored in attempt to decrease 
PML risk. Pharmacodynamics and pharmacokinetics of NTZ at 
EID are unknown.
Methods: Patients who consistently received NTZ on every 6 
week EID schedule (EID-6) or every 8 EID schedule (EID-8) for 
12 months or more were included. Peak and trough NTZ CONC 
and SAT were measured using ELISA (Covance) and flow cyto-
metric analysis of whole blood (LabCorp), respectively. Chart 
review was performed to evaluate disease status.
Results: 28 patients were enrolled, of whom 17 were women. 
Mean age ±SD (range) 42.2±11.5 (20-64). Peak CONC EID-6 
121.5±33.3 (82.6-203.0) and EID-8 114.3±24.1 (78.9-145.0) (p= 
0.53). Trough CONC EID-6 14.0±8.9 (0.5-28.8) and EID-8 
6.1±7.1 (0.5-22.9) (p = 0.02). In EID-6, 55% achieved ‘high’ 
CONC (defined as >10µg/mL); 39% ‘adequate’ CONC (defined 
as 2-10 µg/mL); and 8% ‘inadequate’ CONC (defined as < 2 µg/
mL). In EID-8, 21% achieved ‘high’ CONC, 38% ‘adequate’ 
CONC; and 43% ‘inadequate’ CONC. Peak SAT EID-6 91.4±4.3 
(83.8-96.0) and EID-8 92.7±4.9 (83.7-93.9) (p=0.69). Trough 
SAT EID-6 was 72.1±11.1 (45.7-87.6) and EID-8 55.0±24.2(4.5-
87.7) (p= 0.02). In EID-6, 29% achieved ‘high’ SAT (defined as 
>80%); 64% ‘adequate’ SAT (defined as 50-80%); 7% ‘inade-
quate’ SAT (defined as < 50%). In EID-8 group, 7% achieved 
‘high’ SAT; 57% ‘adequate’ SAT; 36% ‘inadequate’ SAT.
Conclusions: Majority of patients on NTZ EID maintained ade-
quate CONC and SAT through increasing dose interval resulted in 
higher number of patients with “inadequate” CONC/SAT. 
Analyses of the relationship between NTZ CONC, SAT, and clini-
cal outcomes is planned. This will help understand which CONC/
SAT of NTZ is sufficient to exclude entry of auto-reactive T cells 
into CNS and thereby achieving clinically meaningful response.
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Using lumbar puncture to exclude progressive multifocal 
leukoencephalopathy in people with multiple sclerosis on 
natalizumab: real life experience in a single centre
A. Alidina, J. Raffel, R. Nicholas
Imperial College London, London, United Kingdom
Introduction: These are the principal reasons for lumbar puncture 
(LP) in people with MS (pwMS) on NTL. Early on, progressive 
multifocal leukoencephalopathy (PML) can be difficult to 
distinguish from a MS based on symptoms and imaging but 
prompt diagnosis improves clinical outcome. In addition chang-
ing therapy from NTL to a treatment where prolonged immuno-
suppression is expected increasingly drives a need to exclude 
PML. We studied the reasons for, results from and outcome after 
LP in those on NTL in our cohort.
Methods: We collected clinical and MRI data, serum anti-JC 
Virus antibody (JCVab) titres and CSF results for pwMS who had 
LP’s performed on NTL.
Results: 58 pwMS (64% female) were identified (mean: age 
40.95±9.55, MS duration 3.91±2.24, anti-JCVab titre 2.05±1.41). 
Compared to the total cohort of pwMS on NTL the only difference 
was in the mean anti-JCVab titre (p< 0.0001). Of the three indica-
tions for LP worsening symptoms was the reason in 20 (new 
lesions: 2, PML: 2), medication change in 29 (new lesions: 6, 
PML: 0) and new lesions in 9 (PML: 0). The total number of 
patients with new lesions was 17 (29.3%), comparable to the total 
cohort (p=0.13). Worsening symptoms had a positive predictive 
value (PPV) for developing PML of 10% (95% confidence interval 
(CI) 7.06%-13.98%); new lesions PPV of PML of 5.88% (95%CI 
1.45%-20.98%) and changing medication PPV of PML of 0%. 
Analysis of the LP results found that there was an increase in white 
cell counts in JCV-DNA positive cases versus JCV-DNA negative 
cases (p=0.002). After LP, 13 remained on NTL, 30 changed medi-
cation and 13 stopped all treatment. Two pwMS developed PML 
and both survived.
Discussion: Though the emphasis on monitoring focuses on the 
specificity of new lesions in the diagnosis of PML in this cohort 
new lesions were a common finding on NTL but did not in isola-
tion have a high PPV for PML. The most important feature was 
new symptoms.
Disclosure
Abbas Alidina: nothing to disclose
Joel Raffel: nothing to disclose
Richard Nicholas: Sanofi-Genzyme, Biogen Idec honorarium for 
speaking, advisory boards, Roche - advisory boards, CASTINGS 
committee member
EP1744
Type 0 blood group associates with higher anti-JCV antibody 
levels
P. Frenken1, H.-P. Hartung2, T. Olsson3, O. Adams1, C. Warnke4
1Virology, 2Neurology, University of Düsseldorf, Düsseldorf, 
Germany, 3Karolinska Institutet, Stockholm, Sweden, 
4Neurology, University Hospital Cologne, Köln, Germany
Background: JC virus (JCV) associated progressive multifocal 
leukoencephalopathy (PML) occurs during therapy for multiple 
sclerosis (MS). Detection of anti-JCV antibodies, and the so-
called serum “index values” are accepted risk factors for the later 
development of PML. The reasons why higher antibody levels to 
JCV associate with higher risk of developing PML are not well 
understood. Host genetic factors may influence the anti-JCV anti-
body levels, and thus may be the underlying cause for such link. 
Putative host gene candidates could include those that encode the 
ABO blood groups, with the blood group 0 previously noted to 
display a trend for over-representation in cases with PML (Khoury 
et al, JAMA Neurology 2013).
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Aim: To assess if type O blood group associated with higher lev-
els of anti-JCV antibodies, and if type O blood group therefore 
was a risk factor for the development of PML.
Methods: Determination of ABO blood group antigens on blood 
samples of 62 patients with PML, and 64 controls without PML. 
Sera were tested in an enzyme-linked immunosorbent assay using 
a JCV-VP1 protein fused to GST as antigen, and anti-JCV anti-
body levels in arbitrary units (AU) were determined as previously 
published (Warnke et al, MSJ 2013).
Results: Of the patients with PML and known underlying disease, 
62% were patients with MS treated with natalizumab, 14% were 
HIV positive, and 11% had underlying malignancy. JCV antibody 
levels were higher in patients with blood group 0 compared with 
all other blood groups, irrespective of the development of PML (0: 
median AU: 136; not 0: median AU: 53; p< 0.01). This association 
was not observed for the closely related BK virus. Of the 62 
patients with PML, 29 (47%, 95% CI 35-59%) were of blood 
group 0, which showed a non-significant trend to differ from the 
expected distribution in the German population (41%), and the 
MS controls studied (23/64=36%, 95% CI 25-48%). In the natali-
zumab-associated PML subgroup, this deviation was the most 
prominent with 16 of the 29 cases having blood group 0 (55%, 
95% CI 38-71%).
Conclusion: The ABO blood group 0 antigen associates with 
higher anti-JCV antibody levels, and may impact the risk of the 
later development of PML. The non-significant over-representa-
tion of blood group 0 in cases with PML was in line with a previ-
ous publication. Larger studies are warranted to assess a potential 
value of host genetic risk factors, such as the ABO status, for PML 
risk prediction during immunotherapy.
Disclosure
PF: nothing to disclose.
HPH: consulting fees and fees for serving on steering and data 
monitoring committees from Bayer Healthcare, Biogen, GeNeuro, 
Medimmune, Merck, Novartis, Receptos / Celgene, Roche, 
Sanofi Genzyme, Teva with approval by the Rector of 
Heinrich-Heine-University.
TO: has received lecture and/or advisory board honoraria from 
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have provided unrestricted MS research grants.
OA: accepted speakers honoraria and research funding from Biogen.
CW: consulting and/or research funding: Biogen, Novartis, Teva.
Study support: grant of the European Charcot Foundation and the 
Hertie-Foundation to CW (P1150063).
EP1745
Low signal intensity rim on magnetic susceptibility imaging 
in patients from the Dutch-Belgian natalizumab-associated 
PML cohort
M.T. Wijburg1,2, J. Killestein1, M.P. Wattjes2
1Department of Neurology, Neuroscience Amsterdam, VUmc 
MS Center Amsterdam, 2Department of Radiology & Nuclear 
Medicine, Neuroscience Amsterdam, VUmc MS Center Amsterdam, 
VU University Medical Center, Amsterdam, The Netherlands
Background: Brain magnetic resonance imaging (MRI) plays a 
crucial role in the diagnosis and follow-up of natalizumab-associ-
ated progressive multifocal leukoencephalopathy (NTZ-PML) 
patients. Recent studies have demonstrated that PML lesions may 
show a low signal intensity (LSI) rim or band along the grey-
white matter junction on susceptibility weighted imaging (SWI) 
or T2*-weighted imaging (T2*WI), which is likely caused by iron 
accumulation in macrophages in the lower layers of the cortex.
Objective: 
To investigate whether the presence of a LSI rim on SWI or 
T2*WI is a reproducible finding in patients from a multi-center, 
real-world, and heterogeneous, dataset of local and referred NTZ-
PML patients.
Methods: Patients were collected from the ongoing Dutch-
Belgian NTZ-PML cohort and included in the study if a MRI with 
SWI or T2*WI sequence was available after the diagnosis of 
PML. The image acquisition was not standardized and based on 
local scanning protocols. Two raters in consensus scored the pres-
ence of a LSI rim, its location and whether it was located in, or 
adjacent to, a PML lesion.
Results: Of the 30 screened patients, 8 patients were included. A 
total of 10 MRIs (five different MR scanners; three 1.5T and two 
3.0T) with SWI (n = 7) and/or T2*WI (n = 7) were available. The 
MRIs were performed at the acute PML stage (n = 2), PML- 
immune reconstitution inflammatory syndrome (IRIS) stage (n = 
2), and chronic/follow-up stage (n=6).
In 7 of the 8 patients a LSI rim was visible (7 out of 10 MRIs): 2 
in the acute PML stage and 5 at the chronic stage. The LSI rims 
were observed in the left frontal lobe (n = 3), right frontal lobe (n 
= 4), or left occipital lobe (n = 1), and all were in or adjacent to a 
PML lesion.
Conclusion: We show that the presence of a LSI rim was observed 
in, or adjacent to, a PML lesion in 7 out of 8 patients tested. This 
suggests that SWI and T2*WI may add to the diagnosis and fol-
low-up of PML without being influenced by differences in image 
acquisition.
Disclosure
MTW does not report any potential conflict of interest.
JK has received consultancy fees from Merck-Serono, Teva, 
Biogen, Genzyme and Novartis.
MPW has received consultancy fees from Biogen, Roche, and 
Novartis.
EP1746
Understanding the treatment preferences of people with 
relapsing remitting multiple sclerosis
H. Ford1, A. Manzano2, I. Eskyte2, S. Pavitt2, G. Pepper3, K. 
Schmierer4, J. Chataway5, B. Potrata6, E. Webb2, D. Meads2, J. 
Marti7, H. Bekker2
1Leeds Teaching Hospitals NHS Trust, 2University of Leeds, 
3Shift.ms, Leeds, 4Queen Mary University London, Blizard 
Institute, Barts and the London School of Medicine and 
Dentistry, 5University College London, 6Gallup, 7Imperial 
College London, London, United Kingdom
Background: The last decade has seen a large increase in the 
number of disease modifying treatments (DMTs) for people with 
relapsing remitting multiple sclerosis (PwRRMS). There is, how-
ever, a knowledge gap as to which type of DMT people prefer, 
how their choices are related to treatment attributes (how aggres-
sive they are, risks, mode of administration, etc.), and how these 
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preferences relate to when/if treatments are started. Discrete 
choice experiments (DCEs) help to understand the relative impor-
tance of treatment attributes and the trade-offs made in decision-
making but they need to be supported by robust qualitative work.
Aim: To identify which are the attributes of DMTs attributes most 
important to PwRRMS as a first step to design a DCE.
Methods: Attribute identification included 3 phases:
1) A critical review of the literature to generate a conceptual 
framework for setting out the underlying context in which behav-
ioural decision making takes place.
2) Stakeholder focus groups (n=17 participants) with PwRRMS, 
neurologists and MS nurses to explore preferences for individual 
DMTs, their benefits and risks, and to establish a sampling 
strategy.
3) Semi-structured qualitative interviews with PwRRMS (n=30) 
to understand the main factors that discourage and encourage 
choosing, starting, switching and stopping DMTs; why such deci-
sions are taken, and how specific preferences relate to attributes of 
the DMTs. Data was analysed using a thematic analysis.
Results: Eight key interrelated attributes of DMTs were 
identified:
1) mode of administration;
2) effectiveness;
3) duration, severity, controllability and reversibility of side 
effects;
4) how treatment routine - including frequency of adminis-
tration and side effects management- fits into lifestyle;
5) practicality & transportability;
6) treatment monitoring;
7) likelihood of adherence;
8) parenthood and reproduction.
Conclusion: PwRRMS trade off a complex set of interrelated 
attributes to weigh up advantages and disadvantages of DMTs. 
Some of them are related to DMT clinical outcomes (efficacy, side 
effects) whilst others are related to how DMT outcomes and pro-
cesses can be integrated into patients’ lives.
Disclosure
Study funded by the UK Multiple Sclerosis Society (Award 
Reference: 30)
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Pavitt S: Nothing to disclose
Ford, H: In the last year HF has received consultancy/speaker fees 
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Biomedical Research Centres funding scheme and University 
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sory boards for Roche, Merck and Apitope. He is local principal 
investigator for trials in multiple sclerosis funded by Novartis, 
Biogen, and Receptos
Schmierer, K is the PI on trials sponsored by Novartis, Roche and 
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attend AAN 2014 and Novartis to attend AAN 2016. He has 
received research support from Novartis, Biogen, National MS 
Society (US), MS Society of Great Britain & Northern Ireland, 
Royal College of Radiologists, and Barts Charity.
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EP1747
Behçet’s disease following alemtuzumab treatment for mul-
tiple sclerosis
S. Luppe1, B. Wright2, J. Angus2, E. Ormerod2, K. Inglis1, D. 
Cottrell1
1Neurology, Southmead Hospital, 2Dermatology, University 
Hospitals Bristol, Bristol, United Kingdom
We report the case of a 41-year-old female with relapsing-remit-
ting multiple sclerosis. Six weeks following her second treatment 
with alemtuzumab she developed recurrent genital and mouth 
ulceration. The results of a serum auto-immune and vasculitis 
screen were unremarkable and biopsy of the lesions showed epi-
dermal ulcerations.
On the first occasion, her ulcers improved with oral steroid treat-
ment over five days. Two further recurrences responded well to 
the use of topical steroids.
The occurence of these skin manifestations appeared to be related 
to treatment with alemtuzumab and the patient met the clinical 
criteria for the diagnosis of Behçet’s disease. To our knowledge 
this is the first reported case of alemtuzumab therapy followed by 
Behçet’s disease.
Disclosure
Sebastian Luppe: has previously accepted speakers fees and/or 
hospitality from Lundbeck, Serono, and Novartis.
Beth Wright: nothing to disclose.
Janet Angus: nothing to disclose.
Emma Ormerod: nothing to disclose.
Kirsty Inglis: has previously accepted speakers fees and/or hospi-
tality from Serono, Biogen, and Novartis.
David Cottrell: has previously accepted speakers fees and/or hos-
pitality from Serono, Biogen, and Novartis.
EP1748
Safety issues in multiple sclerosis patients treated with alem-
tuzumab in real world
C. Oreja-Guevara1, E. Guerra-Schulz1, E. Miñano-Guillamon1, 
A. Carcamo Fonfria1, M. Ortiz-Pica1, A. Arenaza-Peña2, I. 
González-Suarez3
1Neurología, 2Farmacia, Hospital Clinico San Carlos, Madrid, 
3Hospital Alvaro cunqueiro, Vigo, Spain
Introduction: Alemtuzumab is a monoclonal antibody used as 
induction or escalation therapy in patients with multiple sclerosis 
(MS). The most frequent adverse events happened in the first 
months.
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Objective: To study the adverse events in the first months of treat-
ment with alemtuzumab in MS patients in real world.
Methods: Observational study. We study patients with multiple 
sclerosis, who received at least one cycle of alemtuzumab and 
were followed at least six months. Blood and urin tests were per-
formed at baseline, three and five days after the start and later 
monthly.
Results: 20 patients with RRMS (16 females, mean age 43 ) with 
and baseline EDSS of 5.5 ( 2.5-7.0) were studied.
The most frequent adverse event during the infusions was mild to 
moderate rash. Interestingly, in 80 % of the patients there was a 
transitory increase of liver enzymes (between 2- and 5-fold the 
upper limit of normal, ALT maximum 196 u/l) between the third 
and the fifth day of the infusion in 80 % of the patients. One 
patient with 10 times elevation of ALT and AST presented an 
acute abdominal pain, the treatment was discontinued and the 
liver enzymes were normalized after two weeks. Hepatitis C and 
B were discarded. Other adverse events in the first week were 
fever (40%), headache (35%), fatigue (10%).
During the first month three patients suffered from unfrequent 
infections produced by Lysteria monocytogenes, by blastocystis 
hominis and by herpes zoster. After the adequate treatment were 
solved without sequelae.
Conclusions: Most frequent adverse events with alemtuzumab 
were cutaneous rash and liver enzymes elevation in the first week. 
Some not common infections appeared in the first month. 
Monitoring of infections in the first month is needed. Vaccinations 
or antibiotics could be useful in some patients to reduce the num-
ber and severity of infections.
Disclosure
Celia Oreja-Guevara has received honoraria for speaking and/or 
consultancy from Biogen, Genzyme, Bayer, Merck, Roche, Teva 
and Novartis
EP1749
Management of infusion related reactions associated with 
alemtuzumab in patients with multiple sclerosis
S. Sega Jazbec1, B. Barun2, A. Horvat Ledinek1, M. Krbot 
Skoric2, M. Habek2,3
1Neurology, University Medical Centre Ljubljana, Ljubljana, 
Slovenia, 2University Hospital Center Zagreb, 3University of 
Zagreb, School of Medicine, Zagreb, Croatia
Background and aims: Infusion-associated reactions (IARs) 
occur in >90% patients with multiple sclerosis (MS) treated with 
alemtuzumab. We aimed to investigate modified premedication 
scheme consisting of 1g/day of IV methylprednisolone through-
out all 5 days of alemtuzumab treatment.
Methods: This was retrospective chart review of 38 consecutive 
MS patients who were treated with alemtuzumab from June 2015 
till February 2017 at Department of Neurology, University 
Hospital Center Zagreb, Croatia and Department of Neurology, 
University Medical Centre Ljubljana, Slovenia.
Results: Seventeen patients (44.7%) did not experience IARs. Skin 
reactions and fever were the most common IARs attributed to 
alemtuzumab infusions and they were most frequent on Day 5 
and Day 1, respectively. We have observed significant differences 
in the occurrence of fever (p=0.005) depending on the site of 
alemtuzumab administration which could be explained by different 
antipyretics used; fever was absent in the Slovenian cohort because 
high doseintravenous metamizole was administered. In the Croatian 
cohort, in 3 patients IARs resulted in hospitalization, in all 3 cases 
due to worsening of preexisting neurological deficits associated 
with fever (in one patient paraparesis and in 2 patients cognitive 
dysfunction). In the Slovenian cohort in one patient the 5 cycle was 
administered with a 3 days delay due to rash. Two out of 9 treat-
ments naïve, and 19 out of 29 patients who previously received 
immunomodulatory treatment had IARs (χ2=5.208, p=0.022).
Conclusion: Modified premedication scheme consisting of 1g/
day of IV methylprednisolone throughout all 5 days of alemtu-
zumab treatment leads to reduction of IARs, especially skin 
reactions.
Disclosure
SSJ: Reports no conflict of interest.
BB: Reports no conflict of interest.
AHL: Reports no conflict of interest.
MKS: Reporst no conflict of interest.
MH: Participated as clinical investigator and/or speaker for: 
Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, 
Roche, Alvogen, Actelion, Alexion Pharmaceuticals.
EP1750
Neurologists’ tolerance to risk and uncertainty in the practi-
cal management of multiple sclerosis
G. Saposnik1,2, J. Maurino3, A. Sempere4, M. Terzaghi1, X. 
Montalban5,6
1Division of Neurology, Department of Medicine, St. Michael’s 
Hospital, University of Toronto, Toronto, ON, Canada, 
2Laboratory for Social and Neural Systems Research (SNS-
Lab), Department of Economics, University of Zurich, Zurich, 
Switzerland, 3Medical Department, Roche Farma, Madrid, 
4Department of Neurology, Hospital General Universitario de 
Alicante, Alicante, 5Department of Neurology-Neuroimmunology 
and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital 
Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, 
Barcelona, Spain, 6Division of Neurology, Department of 
Medicine, St. Michael’s Hospital, University of Toronto, 
Toronto, ON, Canada
Introduction: The current treatment landscape in multiple sclero-
sis (MS) includes the acceptance of potential risks of lymphope-
nia and elevated liver transaminases with some disease-modifying 
therapies. Physicians’ tolerance to risk is a new paradigm that may 
influence therapeutic decisions under uncertainty in MS care.
Objectives: To assess physicians’ tolerance to three specific ther-
apeutic decisions under uncertainty: i) risk of lymphopenia, 2) 
risk of elevated liver transaminases, 3) willingness to discontinue 
treatment for patients who remained stable (neither clinical nor 
radiological activity) over 10 years.
Design: Overall, 25 neurologists completed a survey regarding 
the optimal management of 20 simulated case-scenarios, their 
willingness to accept risks of lymphopenia and elevated transami-
nases for effective MS therapies, and treatment discontinuation 
for longstanding stable patients. We used the ‘physicians reaction 
to uncertainty’, a validated scale to assess neurologists’ tolerance 
to uncertainty.
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Results: Overall, 60% of participants had low tolerance to uncer-
tainty (mean score 22.5+/-7.9). Participants were more likely to 
accept a 10% risk of lymphopenia (mean score 86.4+/-11.1%) 
compared to the risk of elevated transaminases (mean 28.8 +/-19) 
(p< 0.0001). Most of participants were not willing to stop MS 
treatment even when simulated-cases were stable for over 10 
years (mean score 21.2+/-23.1). Multivariable analysis revealed 
that women neurologists were less likely to accept the risks asso-
ciated with elevated transaminases (p=0.024) and treatment dis-
continuation (p=0.005) despite having similar tolerance to 
uncertainty score compared to men.
Conclusions: Neurologists caring for MS patients have low toler-
ance to the risks of transaminitis and are not willing to accept 
treatment discontinuation for longstanding stable patients.
Disclosure
The study was sponsored by the Sociedad Española de Neurologia 
(SEN) and funded by Roche Farma Spain.
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Impact of a community pharmacy-based information pro-
tocol on multiple sclerosis patients’ adherence to treatment 
with dimethyl fumarate: TECPHIE, a randomized study vs 
usual practice
Y. Michiels1, P. Tilleul2, H. Méchin3, F. Hammes4
1Pharmacie, Policlinique Médicale Lausanne, Lausanne, 
Switzerland, 2Pharmacie, Hôpital Pitié-Salpêtriere, 3Observia, 
4Biogen France, Paris, France
Introduction: Dimethyl fumarate is an oral compound indicated 
for the treatment of adult patients with relapsing remitting multi-
ple sclerosis. Adherence to treatment may be impacted by the 
route of administration as well as side effects. Although the neu-
rologist remains the primary point-of-contact for MS patients, the 
retail pharmacist has the opportunity to play a key role by provid-
ing individually tailored information at the beginning of treat-
ment. The TECPHIE study aims to assess the impact on adherence 
of motivational interviews provided by community pharmacists in 
France.
Materials and method: TECPHIE is a 12-month, randomized, 
prospective multicentre study examining two groups of pharma-
cists: one providing periodic motivational interviews in addition 
to the usual drug delivery, and one delivering drug in the standard 
manner. Motivational interviews consist of discussions of differ-
ent topics in response to patient requests (information about treat-
ment, side effects, or disease; and advice for daily living). The 
primary criteria for evaluation is the Medication Possession Ratio 
(MPR) at 12 months. Several secondary endpoints will be evalu-
ated, such as persistence to treatment, use of medical resources, 
patient satisfaction with treatment measured by the TSQM 
(Treatment Satisfaction Questionnaire for Medication), and 
patient satisfaction with pharmaceutical interviews. The required 
patient sample size of 150 (75 per group) was calculated based on 
an estimated adherence of 70% in usual care and an increase of 15 
to 20% in interview group.
Results: Recruitment began in December 2016. At present, 35 
pharmacists have been recruited and 24 patients enrolled. Baseline 
results will be presented.
Conclusion: This study will be able to rigorously assess the 
impact on adherence of information provided by pharmacists to 
adult patients with relapsing remitting multiple sclerosis treated 
by dimethyl fumarate.
Disclosure
Yves Michiels: member of the scientific committee of the 
TECPHIE study and investigator of the study, he has received 
honoraria for it from Biogen France SAS; Novartis, MSD
Patrick Tilleuk: member of the scientific committee of the 
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Listeria monocytogenes meningitis after course of alemtu-
zumab for relapsing-remitting multiple sclerosis - a case 
report
P. Hradilek, P. Hon, D. Zeman, O. Zapletalova, I. Woznicova, 
M. Cabal
Neurology, University Hospital Ostrava, Ostrava, Czech 
Republic
Background: Alemtuzumab (ALM) is a humanized monoclonal 
antibody approved for the treatment of patients with active relaps-
ing-remitting multiple sclerosis (RRMS). Treatment with this 
agent may be accompanied by some serious complications. 
Following this treatment, another autoimmune disease can 
develop and infectious complications of varying severity can also 
occur. The present case report describes the development of lis-
teria monocytogenes meningitis in a female patient following a 
course of ALM for multiple sclerosis.
Case report: A 28 year old female of Caucasian race with RRMS 
developed a fever up to 40 degrees Celsius, headache, vomiting 
and global weakness several days after a course of 5 infusions of 
ALM. At neurological exam the signs of meningeal irritation were 
found and lumbar puncture showed hyperproteinorrhachia (1,098 
g/l), elevated cells (72 in 1 ml) and also elevated level of lactate 
(6,95 mmol/l). PCR DNA of listeria monocytogenes in the CSF 
was positive. After treatment with ampicilin and cefotaxim the 
further course of this complication was favourable and patient was 
discharged home in stabilized clinical status within 17 days.
Discussion and conclusion: Listeria monocytogenes meningitis 
is a bacterial infection. Its source is usually contaminated food. 
Patients who have received ALM may be more vulnerable to this 
infection due to changes in the immune system (depletion in both 
innate and adaptive immunity, which can facilitate the break-
through of pre-existing clinically silent and CD8+ T-cells 
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modulated infection with listeria monocytogenes). Thus, increased 
clinical alertness is essential for correct diagnosis and manage-
ment of this condition. Patients should be also advised to avoid a 
“risky” food (like meat without heat adjustment, soft cheeses, 
fresh food from the market, non-pasteurised food etc.) several 
weeks before and after course of ALM.
Disclosure
none of the authors has anything to disclose
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CD62L as a PML risk stratification marker: a 4 years pro-
spective study
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Background: Progressive multifocal leukoencepahlopathy 
(PML) is a major concern when using biotherapies for multiple 
sclerosis (MS) treatment. PML is frequent with natalizumab 
(NTZ), considered as rare with fingolimod (FGL). Current guide-
lines on how and when to switch treatment in patients at high 
PML risk are expert based. They allowed to minimize PML risk 
but not to avoid new PML cases. Recent studies highlighted the 
use of the low level of CD62L (L-selectin) ( < 10%) as a predic-
tive biomarker of further PML development in NTZ-treated MS 
patients (Schwab et al., 2013; Pignolet et al., 2016).
Objectives: To evaluate and confirm the 10% threshold of CD62L 
as a PML risk stratification biomarker (PRSB) in NTZ and FGL 
treated MS patients at high PML risk.
Methods: We are using the Best-MS cohort (NCT01981161), a 
multicentre, observational prospective study conducted to evalu-
ate CD62L as a PRSB. CD62L was monitored by flowcytometry 
every 3 months for NTZ and 6 months for FGL on CD4 T cells 
derived from frozen/thawn PBMC. Patient inclusion criteria 
included: -a- more than 18 months under NTZ or FGL, positive 
for JC virus serology with -b- an index value (IV) higher than 0.9 
or -c- prior immunossupress. CD62L determination was central-
ized in only 1 laboratory (Toulouse). We proposed to stop NTZ or 
FGL only when under 10% of CD62L. A collegial decision on 
how to switch was performed. All patients signed an informed 
consent.
Results: Started in 2013 and currently by March 2017, 353 
patients have been included with 311 under NTZ and 42 under 
FGL. None of the FGL treated patients experienced a CD62L < 
10%. In the NTZ-treated group, only 3.6 % of the patients experi-
enced a low level of CD62L (< 10 %). All patients have been 
switched to another drug: mean follow-up before switch = 19.6 
months ; 9 % to FGL, 50 % to Rituximab, 35 % to Tecfidera and 
6 % to Alemtuzumab).
Currently, no PML case was observed.
Conclusions: So far, in this cohort, no new PML case was 
observed. Thus, this prospective study is a first confirmation of 
the interest of CD62L as a PRSB that may be useful in daily clini-
cal practice.
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Severe disease reactivation in two multiple sclerosis patients 
after natalizumab withdrawal was not halted by monthly 
administrations of cyclophosphamide - two case reports
A. Mariottini, B. Forci, E. Magnani, L. Massacesi, A. Repice
NeuroFARBA, Careggi University Hospital, Florence, Italy
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Background: Natalizumab (NTZ) is a highly effective disease 
modifying treatment for Relapsing Remitting Multiple Sclerosis 
(RRMS) often discontinued for safety issues. Potentially disa-
bling disease reactivations are frequently observed following its 
cessation, even beyond the pre-treatment period level. Despite 
data from small clinical studies, there is still no consensus 
regarding the best treatment strategy to be adopted in order to 
prevent such phenomenon. We present two cases of severe dis-
ease reactivation in two RRMS patients treated with monthly 
administrations of Cyclophosphamide (Cy) after NTZ 
discontinuation.
Case reports:
Patient 1: a 33 years old woman affected by RRMS since 
December 2012 started NTZ treatment in April 2013, after two 
relapses with MRI activity.
Patient 2: a 25 years old woman diagnosed with RRMS in 2009 
started NTZ therapy in April 2010, following Mitoxantrone 
treatment failure. Both patients achieved complete disease 
remission during NTZ therapy. After respectively 36 and 46 
drug administrations they discontinued NTZ due to safety 
issues and were treated with monthly administrations of Cy 
(dosage 0,75 gr/m2) after a wash-out period of 2 months. 
Following the fifth Cy administration, patient 1 developed 
numbness and hyposthenia in her right limbs. A contrast-
enhanced (ce.) brain MRI showed a new 21 mm diameter T2 
brain lesion with open-ring Gd enhancement in the white mat-
ter of left cerebral hemisphere, consistent with a tumefactive 
demyelinating lesion. Patient 2 experienced generalized sei-
zure, blurring of vision and right hemiparesis after 3 Cy admin-
istrations; ce. MRI showed several new T2 hyperintensities 
and almost 25 contrast-enhancing lesions in the subcortical and 
periventricular white matter of cerebral emispheres. Other 
potential etiologies were ruled out for both patients.
Discussion: Severe clinical and radiological disease reactivations 
were observed respectively 8 and 5 months following NTZ with-
drawal, despite Cy treatment starting after a 2 months washout 
period. Notably both patients achieved disease remission during 
NTZ treatment. In conclusion, NTZ is a very effective treatment 
but its clinical use is restricted by potentially life-threatening 
infective complications and by the risk of disease reactivation fol-
lowing its withdrawal. The latter represents a still unresolved 
clinical issue for the MS specialist, needing a safe and more “evi-
dence-based” strategy in order to prevent patient’s disability 
worsening.
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A case of listeriosis in a multiple sclerosis patient treated with 
alemtuzumab: a strict clinical and laboratory monitoring can 
help to make early diagnosis and avoid related meningitis
L. Moiola, S. Guerrieri, M. Pisa, V. Martinelli, G. Comi
San Raffaele Hospital, Milan, Italy
We report the case of a 21 years old female, affected by multiple 
sclerosis since June 2016 with a very high clinical and neuroradio-
logical disease activity in the very first months after onset. She was 
initially treated with natalizumab discontinued due to an allergic 
reaction. In February 2017 she was then switched to alemtuzumab-
ALEM, administered without any adverse event during the five 
days of infusion. Two days after she complained for fever, vomit-
ing and headache with progressive worsening. She arrived at our 
E.R. three days later with high fever (39.5 °C) and severe head-
ache. We performed blood tests finding marked leukocytosis 
(17600 - 97.1% neutrophils and 0% lymphocytes) and CRP 
increase (158 mg/L). Due to severe headache we performed spinal 
tap with normal CSF biochemistry and negative bacterioscopic 
examination. Blood cultures were also performed and empirical 
antimicrobic therapy was promptly started with a regimen includ-
ing ampicilline (2 g 6 times daily) and acyclovir (10mg/kg tid). 
Within the first 24 hours blood cultures revealed the presence of a 
Gram positive bacterium characterized as Listeria monocytogenes 
the day after. We added Gentamycine 5mg/kg with clinical 
improvement in 2 days and blood tests normalization in 7 days. 
This case underlines the importance of a strict clinical monitoring 
for infections in ALEM patients, especially in the first two months 
after drug administration. In the presence of fever with respiratory 
or gastrointestinal symptoms CMV is the most frequently involved 
pathogen. However Listeria represent another infective agent that 
should be taken into account, even in the very first days after 
ALEM infusion despite long incubation period, because of a pre-
existing colonization of the gastrointestinal tract. An element that, 
besides routinary laboratory tests, may help the diagnostic process 
is the collection of a careful history, including food habits, being 
Listeria mainly acquired from some dietary products. ALEM eligi-
ble patients should be therefore recommended to avoid, since at 
least one month before treatment is scheduled, products such as not 
pastorized milk and cheese, raw meat and fish. Furthermore they 
should be instructed to consume in a few days any prepacked and 
ready to eat food, even if kept in the fridge, and to observe com-
mon hygienic rules (such as washing carefully fruit and vegetables 
before consumption, and hands before eating or preparing meals).
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Multiple Sclerosis risk perception and risk acceptance for 
Brazilian patients
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Bichuetti1
1Neurology Discipline, Universidade Federal de São Paulo, 
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Background: although many drugs are available for treating mul-
tiple sclerosis (MS), and many guidelines published to guide phy-
sicians on the best therapeutically choice, the practice of medicine 
is still dependent on human contact and influenced by emotional 
and personal history of the individual, and thus the perception of 
disease severity and the risk-taking behavior might change from 
one culture to another.
Goals: To investigate the perception of MS severity in a cohort of 
Brazilian patients and access their knowledge of the risks associ-
ated to natalizumab (NTZ), their willingness to accept the risks 
associated with hypothetical drug’s profiles, and to compare to 
two previously presented cohorts
(Heensen 2010, Germany; Tur 2013, Spain).
Methods: We consecutively interviewed 96 patients with relaps-
ing-remitting MS from 2 centres (São Paulo and Goiás) with a 
standardized questionnaire, aiming to get their impressions about 
MS severity, the risks resulting from NTZ treatment and the fac-
tors involved in risk perception and decision making upon the 
choice of drugs with hypothetical risk profiles of severe adverse 
events from 1:2,000,000
(very low) to 1:50 (very high), as previously performed by Tur 
(Tur 2013). Answers were given as multiple choices or visual ana-
logic scale.
Results: mean age and disease duration were 39.3 and 9.1 years, 
and mean EDSS 2.6. All patients have received at least one dis-
ease modifying therapy for MS (20 used NTZ). MS was perceived 
as a very severe disease (VAS 7.3; 0=not severe, 10=most severe) 
and the risk of developing progressive multifocal leukoencepha-
lopathy due to NTZ as moderate to high (VAS 5.9, 0=very low; 
10=very high). 76% of the patients considered a risk of 1:1,000 or 
higher impeditive for the use of NTZ. Older age was the only vari-
able associated to higher risk acceptance. When comparing the 
willingness to receive a hypothetical drug, our patients disclosed 
a more conservative profile than German (Heesen) and Spanish 
(Tur) patients.
Conclusion: Brazilian patients in these centres perceive MS 
severity and PML risk associate to NTZ similarly than elsewhere, 
but their willingness to take risks is more conservative compared 
to European patients. This should be considered when discussing 
therapeutic options with the patients and might have an influence 
in guidelines adaptations to populations with distinctive cultural 
background
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Feasibility of online risk-based monitoring by patients: the 
Natalizumab case
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Introduction: In the Netherlands 11 Disease Modifying Drugs 
(DMDs) are registered for Relapsing Remitting Multiple Sclerosis 
(RRMS) and there are more to come. Some DMDs need risk-
based monitoring (RM), however uniformity is lacking. We aim to 
design one channel for all regimens, including alerts and an active 
role for the patient.
In the Netherlands 1125 multiple sclerosis (MS) patients are mon-
itored by 28 hospitals monitor via myhealthmonitor.eu/msmonitor 
(MHM), an online, modular, platform where patients receive, 
enrich and share their data.
In 2013 the Natalizumab screening APP was added to MHM. The 
The Natalizumab screening APP consists of 16 questions every 28 
days, and must be submitted 2 days prior to the infusion of 
Natalizumab, sends email reminders. The patient submits the list, 
the MSnurse can screen the answers and can timely postpone the 
infusion if needed.
Aims and objective: This study analyses the feasilbility of for 
RM in a real-life setting.
Methods: Five hospitals use the APP in MHM) in 6o RRMS patients 
since 2013. MSnurses sign up patients and activate the APP.
Patients were between 22-59 years old, 52 females, 8 males and 
gave consent.
Results: 53 patients (92%) submitted 860 screeningslists (range 1 
- 53 per individual), participated between 1 - 1561 days (mean 565 
days). In range with clinical purpose: 648 lists (75,4%) were sub-
mitted the same day or the next day.
In this real-life setting patients start and stop. At data-extraction 
(16th of May 2017), 27 patients were “on track” (last submission 
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before or after 19 April 2017). 33 patients were not “on track”. 
Reasons for were: never loged on (n=6), Natalizumab was stopped 
(n=13), personal reasons (n=2), unknown (still using natalizumab) 
(n=10).
Conclusion: This real-life setting shows that patients are capable 
of providing information on line for RM “in time” as needed for 
clinical purposes.
An APP to serve all different schedules for the different DMD’s 
seems a valuable tool to develop in risk-based monitoring in 
RRMS.
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How to treat patients after natalizumab discontinuation: the 
TY-STOP 2 study, an Italian, prospective and multicenter 
study
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M.P. Sormani2
1University of Turin, Turin, 2University of Genoa, Genoa, 
3Cardarelli Hospital, 4Federico II University, 5Vanvitelli 
University Hospital, Naples, 6University of Cagliari, Cagliari, 
7Gallarate Hospital, Gallarate, 8Città della Salute e della Vita 
Hospital, Turin, 9Besta Neurological Institute, Milan, Italy
Background: Natalizumab (NTZ) is notoriously associated with 
progressive multifocal leukoencephalopathy (PML) with a global 
incidence of 4.20 per 1000 treated patients. After 24 courses, 
patients and physicians decide whether to continue NTZ or not: a 
previous study (TY-STOP) showed a stopping rate of about 65%.
Goals: To describe study design, methods, state of enrollment, 
and preliminary results of the TY-STOP2 study, aimed to compare 
the efficacy and safety continuing versus not continuing NTZ.
Methods: An Italian, multicenter (8 centres), prospective, obser-
vational study, enrolling patients after at least 24 NTZ administra-
tions. Patients underwent clinical evaluation, magnetic resonance 
imaging (MRI) and John Cunningham virus (JCV) antibodies 
testing every three months.
Results: Recruitment is still ongoing. Up to now 138 patients 
have been enrolled: mean age at baseline 37.3 years (SD: 10.7); 
median expanded disability status scale (EDSS) 2.0 (range: 0-6.5); 
mean disease duration 8.9 years; ARR pre-NTZ: 0.94. 125 patients 
(90.6%) continued NTZ after 24 courses; 8/13 that discontinued 
were JCV-positive (on total of positive of 59/138). During the 
follow-up, 3 patients stopped NTZ after 6 months, 4 after 9 and 2 
after 12. A total of 6 patients out of 126 (4.8%) had a clinical 
relapse in the first year after 24 courses. Of these, only 1 had 
stopped NTZ. 8/87(9.2%) patients with available data had an 
EDSS increase >= 1 point in the first 12 months (delta EDSS: 
median 0 (range: -2.5 - 2)) and 1 of these have discontinued NTZ. 
5/103 patients (4.9%) showed at least an active MRI during the 
first 12 months of follow-up and 1/9 of these with available infor-
mation had stopped NTZ. 11/74 (14.9%) had an adverse event in 
the first 12 months (1 serious).
Conclusion: This descriptive analysis shows a NTZ stopping 
rate lower (10%) than in TY-STOP (65%), this is probably due 
to a better known PML management. However, PML is still a 
serious NTZ adverse event and more alternative drugs are and 
will become available. This will probably lead to a higher 
number of switching patients in our, still ongoing, recruit-
ment. Our study will try to identify a possible therapeutic 
strategy preserving disease stability and preventing the occur-
rence of PML.
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A case report of asymptomatic progressive multifocal leuko-
encephalopathy
Y. Zhang, C. Wright, A. Flores
University of Texas, Southwestern Medical Center, Dallas, TX, 
United States
We report the development of asymptomatic progressive multifo-
cal leukoencephalopathy (PML) in a 24-year-old woman with 
multiple sclerosis treated with natalizumab. The patient was diag-
nosed with PML based on characteristic MRI lesions after 27 infu-
sions of natalizumab. She had no neurologic deficits at the time of 
diagnosis and John Cunningham virus (JCV) was detected at 15 
copies/ml (NIH/NINDS, Bethesda, MD. USA). She was initially 
treated with mefloquine and mirtazapine and remained asympto-
matic for three months. The patient later developed worsening 
MRI lesions related to immune reconstitution inflammatory syn-
drome (IRIS). At that time, she received intravenous immuno-
globulin (IVIG) and high dose intravenous methylprednisone with 
radiographic improvement of the lesions. Our report illustrates 
that early detection of asymptomatic PML and its subsequent 
treatment resulted in a benign clinical course. In consideration of 
the additional small number of asymptomatic PML cases that 
have been reported, we conclude that routine MRI surveillance is 
important for MS patients that are at high risk for developing 
natalizumab-associated PML.
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Favorable evolution post hematologous stem cell transplant 
after primary central nervous system lymphoma in a mul-
tiple sclerosis under natalizumab
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The association between Primary central nervous system lym-
phoma (PCNSL) and Multiple Sclerosis (MS) treated with natali-
zumab (N) can be a coincidence. This case is the sixth known. 150 
000 MS are treated with N through the world in 2016. The preva-
lence of PCNSL is 3.3 cases for 100 000 MS treated with N. This 
number is higher than PCNSL in the general population (1.8 to 3 
for 100 000 person).
To report a new case of PCNSL in MS under N treated with hema-
tologous stem cell transplant (HSCT).
Case report: A MS was diagnosed in 1997 in a man born in 1970. 
After interferon beta-1b, N was started in November 2000. The 
Expanded Disability Status Scale (EDSS) was 3.0. In June 2011, 
he was hospitalized because of loss of weight, depression, cogni-
tive impairment and headache. Neurological exam revealed psy-
chomotor slackening, instable walking requiring a crutch (EDSS 
6.0). Brain MRI showed several flair hypersignals involving right 
internal capsule with mass effect on ventricle, corpus callosum 
and left insula, all enhanced. Standard biological exams, 
Lymphocytes T, B, blood immunofixation were normal. Serologies 
were negative except for EBV. Because of the mass effect, lumbar 
puncture was not done. Bone biopsy, thoraco abdomino pelvic CT 
scan were normal. The brain biopsy revealed PCNSL type B. In 
October 2011 he underwent HSCT. In February 2012 he was con-
sidered in remission. In May 2012 his walk was to 500 meters. 
Important asthenia persisted with hyperemotivity. At last visit, 
patient was stable without MS treatment (EDSS 4.0).
In this case, HSCT allowed not only PCNSL remission but also 
MS remission. HSCT has been proposed to control or even cure 
refractory cases of MS for several years. This transplant leads 
reset the pathogenic T cells repertoire thus renewing the immune 
system repertoire and possibly reinforcing immune tolerance 
mechanism.
Disclosure
Fromont: nothing to disclose
Casasnovas: nothing to disclose
Billy: nothing to disclose
Martin: nothing to disclose
Moreau: nothing to disclose
EP1761
Rebound of disease activity after fingolimod withdrawal: can 
we predict it?
J. Dotor García-Soto, V. Meca Lallana, S. Quintas, C. Aguirre, 
P. Sánchez, J. Vivancos
Demyelinating Diseases, Neurology Department. Instituto de 
Investigación Sanitaria, Hospital La Princesa, Madrid, Spain
Background: Although rebounds of disease activity (RA) 
after natalizumab withdrawal have been widely described, data 
about a possible reactivation of disease activity in patients 
treated with fingolimod (FTY) are limited. We analyse those 
patients of our Department that have discontinuated FTY treat-
ment, we describe rebound cases and we try to establish pos-
sible predictors.
Methods: Retrospective study including patients with Relapsing 
Remitting Multiple Sclerosis (RRMS) treated with FTY in whom 
it has been discontinuated, permanently or not. We compare 
patients with RA after FYT suspension and those with no-RA. We 
describe demographic, clinical, therapeutic and analytical features 
before and after withdrawal.
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Results: 20 patients were included, 18 women. Mean age 37.2 
years (SD:8.3). The median EDSS at diagnosis was 1 (SD:0.6) and 
mean relapse rate at first year was 1.35 (SD:0.58). The mean dis-
ease duration until FTY was 8.5 (SD:6.1), with mean time under 
FYT therapy of 33 months (SD:14.3). Mean of annualized relapse 
rate improvement was 90%. Mean of peripheral blood lympho-
cytes under FYT therapy was 300/mm3 (SD:130). Corticosteroids 
were used during washout period in 70.6% of patients. There were 
17 cases of permanent FYT withdrawal, 10 of them with RA. 
Mean time to RA was 37 days after withdrawal (DS:22.3). No RA 
was observed in temporary discontinuations. Patients with RA had 
lower peripheral blood lymphocyte. No association was found 
with age, body mass index EDSS, disease activity, immediately 
previous treatment or the reason of discontinuation.
Conclusion: RA after FYT withdrawal was common in our expe-
rience. Peripheral blood lymphocytes may be one possible predic-
tor. Future studies are needed for better defining this hypothesis 
and other intercurrent factors.
Disclosure
No author has nothing to disclose
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Central and peripheral nervous system inflammation disease 
secondary to alemtuzumab therapy
F.M.H. Jorge1,2, R. Simm1, S.L. Apóstolos-Pereira1, M.F. 
Mendes1, A.B.A.G.R. Gomes1, M. Hoshino2, M. Peterlevitz2, 
V.H.R. Marussi2, L. Amaral2, D. Callegaro1,2
1Faculdade de Medicina, Universidade de Sao Paulo, USP, 
2Hospital Santa Catarina, Sao Paulo, Brazil
Alemtuzumab is a pan-lymphocyte depleting anti-CD52 antibody 
approved as escalation therapy for patients with multiple sclerosis 
(MS) with clinically or image defined active disease. It has been 
shown effective in reducing relapse rate and brain volume loss. 
However concerns have been raised due to its numerous adverse 
effects. We report a case of severe nervous system inflammatory 
response following Alemtuzumab infusion.
On March 2017 a 31-year-old woman was referred to our service 
due to an acute deterioration of her mental status. She had been 
diagnosed with multiple sclerosis in 2007 after attacks of dizziness 
and left hemiparesis with typically disseminated T2 lesions fulfill-
ing diagnostic criteria on magnetic resonance imaging (MRI) and 
oligoclonal band (OCB) positivity on cerebrospinal fluid analysis. 
Despite the use of several immunomodulatory therapies - interferon 
beta-1a, glatiramer acetate, cyclophosphamide and natalizumab- 
the patient maintained frequent relapses and persistent disease 
activity on MRI. Alemtuzumab was first infused in January of 2017 
and in March 2017 the patient presented with severe trigeminal 
neuralgia, marked cognitive impairment including apraxia and left-
dominant tetraparesis. The MRI showed two new lesions on T1 
weighted image with ring contrast enhancement in periventricular 
white matter, thickening and enhancement of nerve roots in bulbar 
(V, VII and XI nerves) and cervical segments. Infection was ruled 
out and the patient received 5000mg of methylprednisolone which 
led to marked clinical and radiological improvement.
The reported case illustrates an exacerbated inflammatory response 
observed after Alemtuzumab infusion. The response seen in our 
patient is consistent with the time-frame in which B-cell repopula-
tion and peripheral expansion occur following alemtuzumab treat-
ment, therefore further cases might be identified. As such, we 
suggest that apparent relapses after alemtuzumab treatment should 
be promptly screened by MRI for the presence of therapy-related 
inflammation.
Disclosure
Nothing to disclose
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The first reported case of autoimmune hepatitis following 
alemtuzumab therapy for multiple sclerosis
L.J.W. Canham1, B. Mozayani2, U. Chelvaratnam3, R. 
Przemioslo3, J. Stevens4, C. Fry5, T. Batty5, K.E.A. Inglis5, D.A. 
Cottrell6
1BRAMS Service, Bristol Brain Centre, Neurosciences, North 
Bristol NHS Trust, 2Histopathology, 3Gastroenterology & 
Hepatology, 4Neurology, 5North Bristol NHS Trust, 6BRAMS 
Service, Bristol Brain Centre, Neurology, North Bristol NHS 
Trust, Bristol, United Kingdom
A 43 year old Caucasian female developed a subacute hepatitic 
illness 12 months after completion of her second course of 
Alemtuzumab for Multiple Sclerosis. This is the first reported 
incidence of this unexpected outcome.
Multiple Sclerosis was diagnosed in December 2014 following 
episodes of sensory disturbance and gait ataxia in July and 
September 2014. Paraclinical findings were typical. Past history 
included depression and Vitamin D deficiency; a broad autoim-
mune screen was initially negative.
The patient underwent her first 5 day infusion of Alemtuzumab 
(12mg/d with 1gram Methylprednisolone on d1-3) in March 2015 
without significant difficulty and had her second 3 day infusion in 
April 2016. Her neurological status only improved with therapy, 
with no further relapse and increased occupational capacity.
Post-administration the patient manifested a normal time course 
of lympho-depletion and restitution with mild persisting lympho-
penia (0.47-0.94 x109/l). In January 2017 she travelled to Southern 
India and Thailand, followed the recommended vaccination 
schedule and experienced no serious illness.
Post-infusion monitoring detected an isolated gradual rise in ALT 
(163U/l) from March onwards, reaching a peak of 2018U/l by 
early May 2017 from which time bilirubin and ALP also began 
gradually rising to peaks of 347umol/l and 269U/l respectively 
some three weeks later. Clinical features of progressive malaise, 
steatorrhea, anorexia, right hypochondrial tenderness and jaun-
dice developed contemporaneously with the hyperbilirubinaemia. 
No coagulopathy or gross encephalopathy arose. The neutrophil 
count also dropped from normal to 0.38x109/l in March, reaching 
a nadir of 0.19 x109/l in May 2017.
Broad viral screens were negative. Autoimmune serology returned 
positive for Anti-LKM. Liver Biopsy demonstrated chronic lympho-
cytic and plasmacytic infiltrate of portal tracts with interface hepatitis 
and perivenular necrosis without bilary lesions, fibrosis or cirrhosis.
A diagnosis of Autoimmune Hepatitis was made, oral predniso-
lone 40mg initiated and sustained clinical and haematobiochemi-
cal improvement observed. Follow up is ongoing.
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Tools for detecting therapeutic 
response
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Correlation of global and regional brain volume changes 
with disease activity, cognition and disability in a 2-year 
follow-up of 60 Finnish MS patients
K. Hänninen1, M. Viitala2, T. Paavilainen3, J. Karhu4, J.O. 
Rinne5, T. Aittokallio6, J. Koikkalainen7, L. Jyrki7, S.-H. Merja8
1Division of Clinical Neurosciences, 2Mathemathics and 
statistics, University of Turku, 3Medical Imaging Centre of 
Southwest Finland, Turku University Hospital, 4Medical Imaging 
Centre of Southwest Finland, University of Turku, 5PET Centre, 
Turku University Hospital, 6Department of Mathematics and 
Statisrics, University of Turku, Turku, 7Combinostics Limited, 
Tampere, 8Division of Clinical Neurosciences, Turku University 
Hospital and University of Turku, Turku, Finland
Background: Brain atrophy occurs in all clinical stages of 
untreated patients with MS and correlates with disability and cog-
nition at a group level. In clinical trials, high efficacy therapies 
have shown to reduce rate of brain atrophy. However, brain vol-
ume is routinely not measured in normal clinical practice.
Aims: To measure global and regional brain volumes in a real life 
cohort of relapsing remitting (RRMS) and secondary progressive 
(SPMS) Finnish MS patients. To analyze the correlation of vol-
ume changes during 2-years follow-up with cognition and 
achievement of no evidence of disease activity (NEDA) status.
Patients and methods: Global and regional brain volumes was 
measured from 3D T1 brain magnetic resonance images (MRI) 
using a Siemens 3.0 Tesla scanner from 24 newly diagnosed 
RRMS patients 6 months after initiating disease modifying ther-
apy (DMT), and from 36 SPMS patients. Correlation of volumes 
and volume changes with cognition and disability were analysed 
using Wilcoxon and Pearson tests with R Statistics. Baseline 
global brain volume was measured by Sienax and 2-year percent-
age of brain volume change (PBVC) using Siena. Regional brain 
volumes were measured by cNeuro (Combinostics Ltd, Finland) 
using an automated method. SDMT (symbol digit modalities test) 
was used for cognitive testing and expanded disability status scale 
(EDSS) for disability measurement. NEDA was determined by no 
relapses, no EDSS progression and no new/enlarging lesions of 
brain MRI.
Results: At baseline, mean global brain volumes in patients in 
RRMS and SPMS groups were 1509 and 1398 ml respectively 
(Wilcoxon p< 0.001). Baseline EDSS was 1.35 in RRMS and 4.61 
in the SPMS patients (Wilcoxon p< 0.001). EDSS change in 2 years 
was 0.27 in the RRMS and 0.38 in the SPMS patients. EDSS pro-
gression was not significant in either group. There was a moderate 
correlation with baseline SDMT and thalamic (Pearson r=0.42) and 
hippocampal (Pearson r=0.38) volumes. Relative change of SDMT 
at 2 years correlated with thalamic volume change (Pearson 
r=-0.24). NEDA status from the treatment epoch of 6 months after 
DMT initiation to 2 years thereafter was reached in 35% of the 
RRMS patients. SDMT worsened in patients not reaching NEDA. 
PBVC at 2 years was greater in patients not reaching NEDA com-
pared to those reaching NEDA (0.8% vs 0.5%).
Conclusions: Thalamic atrophy correlates with cognition in MS. 
Brain volume loss and cognitive deterioration are greater in 
patients not reaching NEDA.
Disclosure
The study was supported by an unrestricted research grant from 
Biogen Idec Finland to Turku University Hospital, Division of 
Clinical Neuroscience.
M Soilu-Hänninen has received honoraria for lectures, advisory 
boards or for serving as an investigator for clinical trials from 
Bayer, Biogen, Eisai, Novartis, Orion, Roche, Sanofi-Genzyme, 
Teva and UCB.
J Lötjönen is CSO and J Koikkalainen is an employee of 
Combinostics.
T. Paavilainen has received a lecture fee from Roche.
JO Rinne serves as a consultant neurologist for CRST (Clinical 
Research Services Turku). The other authors do not have 
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EP1765
Stability of maximal oxygen uptake (V̇O2max) and clinical 
symptoms over one year in multiple sclerosis
L.P. Kelly, A.J. Devasahayam, A.R. Chaves, E.M. Wallack, 
K.P. Wadden, H.D. Wiseman, M.C. Kirkland, M.E. Curtis, M. 
Stefanelli, M. Ploughman
Recovery and Performance Lab | Faculty of Medicine, Memorial 
University of Newfoundland, St. John’s, NL, Canada
Background: Assessment of maximal oxygen uptake (V̇O2max) 
during an incremental exercise test is the gold-standard measure 
of cardiorespiratory fitness (CRF). Exercise training resulting in 
improved CRF may be a viable therapeutic strategy to improve 
MS-related symptoms. Although the association between level of 
disability and V̇O2max has been established in persons with 
Multiple Sclerosis (PwMS), the long-term repeatability of V ̇O2max 
and its association with changes in other clinical measures is 
unclear.
Methods: Participants in an ongoing longitudinal study com-
pleted year 1 and year 2 physical profiles including assessment of 
EDSS by a neurologist, completion of the MS Impact Scale-29 
(MSIS), walking on an instrumented walkway (Protokinetics, 
Havertown USA) and maximal incremental exercise tests on the 
total body recumbent stepper with integrated indirect calorimen-
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try system (AEI technologies, Pittsburgh USA) to record cardi-
orespiratory parameters.
Results: Twelve (10F) PwMS aged 48±13 years completed year 1 
and 2 assessments. EDSS scores ranged from 0 to 6. At initial 
assessment: V̇O2max, EDSS, MSIS, and walking velocity were 
22.6±7.7 ml min-1 kg-1, 2±2, 38±24, 103±30 cm sec-1, respec-
tively. These values indicate low levels of CRF despite preserved 
walking speed and relatively low levels of disability. V̇O2max was 
strongly correlated with walking velocity, MSIS, and EDSS 
(r=0.87, p< 0.01; r=-0.77, p< 0.01; r=-0.60, p=0.041 respectively), 
which was maintained at 1-year follow-up (r=0.81, p< 0.01; 
r=-0.82, p< 0.01; r=-0.62, p=0.035). No significant changes in 
V̇O2max and clinical measures were observed between time peri-
ods. It is important to note that the repeatability of V ̇O2max over a 
12-month period was very high in this cohort with a correlation 
coefficient of 0.98 and a 95% CI between -0.52 and 1.58 ml min-1 
kg-1.
Conclusion: V̇O2max is associated with clinical measures of 
MS-related disability and is highly repeatable over a 12-month 
period in this population. Data collection is ongoing.
Disclosure
Nothing to disclose.
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The effect of quantitative magnetic resonance imaging 
(QMRI) on no evidence of disease activity (NEDA) status in 
multiple sclerosis clinical practice: a multicentre retrospec-
tive longitudinal study
H. Beadnall1,2, T. Billiet3, D. Horakova4, D.P. Ramasamy5, 
L. Ly6, A. Ribbens3, M.G. Dwyer5, T. Uher4, C. Wang1,6, 
N. Bergsland5, E. Havrdova4, E. Carl5, W. Van Hecke3, M. 
Vaneckova7, R. Zivadinov5,8, M.H. Barnett1,2,6
1The Brain and Mind Centre, The University of Sydney, 
2Neurology Department, The Royal Prince Alfred Hospital, 
Sydney, NSW, Australia, 3Icometrix, Leuven, Belgium, 
4Department of Neurology and Center of Clinical Neuroscience, 
First Faculty of Medicine, Charles University and General 
University Hospital in Prague, Prague, Czech Republic, 5Buffalo 
Neuroimaging Analysis Center, Department of Neurology, 
Jacobs School of Medicine and Biomedical Sciences, University 
at Buffalo, State University of New York, Buffalo, NY, United 
States, 6Sydney Neuroimaging Analysis Centre, Sydney, NSW, 
Australia, 7Department of Radiology, First Faculty of Medicine, 
Charles University and General University Hospital, Prague, 
Czech Republic, 8Translational Imaging Center at Clinical 
Translational Science Institute, University at Buffalo, State 
University of New York, Buffalo, NY, United States
Background: Quantitative magnetic resonance imaging (QMRI) 
is not used routinely in multiple sclerosis (MS) clinical practice, 
but is regularly used in clinical trials and by some imaging 
research groups. ‘No evidence of disease activity’ (NEDA) status 
is a recent concept that has been examined in few real-world MS 
cohorts.
Objectives: 
(i) To compare lesion activity and whole brain volume change 
data obtained by radiologist MRI review with data provided by 
formal QMRI analysis, performed locally and using MSmetrix;
(ii) To determine whether QMRI analysis data influences NEDA3 
and NEDA4 status in this MS cohort.
Methods: Clinical brain MRIs (3D T1 and 2D/3D FLAIR 
sequences) were acquired at baseline and follow-up (≥12 months) 
from 150 MS patients: 50 each from three centres located in 
Buffalo (USA), Prague (Czech Republic) and Sydney (Australia). 
MRIs were reviewed by expert neuroradiologists; QMRI analyses 
were performed both locally and centrally (MSmetrix). Clinical 
parameters, including relapses and Expanded Disability Status 
Scale (EDSS) scores, were recorded at both time points. Patients 
were classified as NEDA3 +/- NEDA4 based on clinical activity/
progression criteria combined with MRI activity +/- progression 
criteria. MRI progression was defined as >0.4% (annualised) 
whole brain volume loss.
Results: 150 MS patients (77.3% female; 98.0% Relapsing-
remitting MS), mean age 38.8(10.2) years, mean disease dura-
tion 9.0(7.3) years and median baseline EDSS 2.0 (range 0-7.0), 
were evaluated. Based on clinical criteria alone, 65.3% of the 
cohort were NEDA. With the addition of MRI data from radi-
ologist review, 46.3% were NEDA3 and 45.6% NEDA4. Using 
local and MSmetrix QMRI data, NEDA3/NEDA4 rates fell to 
44.9%/23.8% and 38.8%/19.7%, respectively. Comparison of 
local and MSmetrix QMRI data revealed discrepancies in the 
presence of MRI lesion activity and progression in 26.5% and 
24.5%, respectively.
Conclusions: Incorporating QMRI lesion data had only a mod-
est impact on NEDA3 status in this cohort, which was greater for 
MSmetrix. Thus QMRI only provides minor additional benefit 
in NEDA3 assessment over experienced neuroradiologists. 
However, volumetric QMRI data significantly influenced 
NEDA4 status, regardless of whether local or MSmetrix QMRI 
data was used. QMRI is critical for accurate NEDA4 assess-
ment, as relevant brain atrophy rates are not detectable by expe-
rienced neuroradiologists.
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Creating a healthcare claims-based adaptation of Kurtzke 
Functional Systems Scores for assessing multiple sclerosis 
severity and progression
C.T.L. Truong1, H.V. Le2, A.W.C. Kamauu3, J.R. Holmen4, C.L. 
Fillmore4, M.G. Kobayashi5, M. Sabidó-Espin6, S.L. Wong7
1MedCodeWorld, Mississauga, ON, Canada, 2Real World 
Evidence & Data Analytics, PAREXEL International, Durham, 
NC, 3Anolinx LLC, Salt Lake City, 4Intermountain Healthcare, 
Murray, UT, 5PAREXEL International, Durham, NC, United 
States, 6Global Biostatistics & Epidemiology, Merck KGaA, 
Darmstadt, Germany, 7Global Research & Development, EMD 
Serono Inc, Billerica, MA, United States
Background: Although the demand for observational studies in 
multiple sclerosis (MS) using real-world data has grown in recent 
years, administrative codes such as ICD-9-CM do not exist for 
results of clinical assessment instruments such as the Kurtzke 
Functional Systems Scores (KFSS). The ability to measure KFSS 
in healthcare claims databases will improve the capacity to per-
form comparative effectiveness and safety of medical products 
studies.
Objectives: To map the components of the KFSS to ICD-9-CM 
codes for identifying MS patients with disease progression and 
quantifying MS severity.
Methods: The KFSS include pyramidal, cerebellar, brainstem, 
sensory, bowel and bladder, visual, and cerebral (or mental) com-
ponents. As ICD-9-CM does not have all of the exact codes for 
KFSS signs and symptoms within each system, cross-mapping 
was performed as close as possible by an experienced clinician 
and reviewed by clinical informaticists. ‘Unknown’ (value=9) 
was not mapped for the KFSS. ‘Normal’ (value=0) was defined by 
an absence of a sign or symptom. From the assigned ICD-9-CM 
code list for KFSS, it was possible to generate Kurtzke Expanded 
Disability Status Scale (EDSS) scores for patients and to assess 
disease progression over time. Disease progression was defined 
by change between the first recorded EDSS score during the first 
7th -12th months of care coverage and the EDSS score during the 
1st -6th months of the patient’s most recent 1-year period of care 
coverage. Change was required to be ≥ 1.0 point if the baseline 
EDSS score was between 0 and 5 inclusive, or ≥ 0.5 point if the 
baseline EDSS score was ≥5.5.
Results: From a cohort of 2,960 MS patients, 608 (20.5%) were 
identified as progressive MS by change in EDSS score. Among 
these 608 patients, the mean first and second EDSS scores were 
0.49 and 4.74. Median (range) first and second EDSS scores were 
0 (0-6) and 5 (1-8), respectively. The mean change from the first 
to second EDSS score was 4.25, while the median was 5 (1 to 7.5). 
The median KFSS first score for all systems was 0. The mean 
KFSS first score varied by system, with the highest (1.06) for sen-
sory function and lowest (0.12) for cerebellar functions.
Conclusions: Mapping of KFSS using ICD-9-CM can be used to 
calculate change in EDSS score and identify patients with MS 
disease progression. Progressive MS patients had a wide range of 
EDSS score changes with a median increase of 5 during their final 
year of coverage in the IDN.
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Multiple sclerosis with pattern III lesions successfully treated 
with mitoxantrone
T. Grüter1, W. Brück2, A. Gahlen1, J. Kneiphof1, R. Gold1, I. 
Kleiter1
1Department of Neurology, St. Josef Hospital, Ruhr University, 
Bochum, 2Institute of Neuropathology, University Medical 
Center, Göttingen, Germany
Background: In multiple sclerosis (MS) treatment, a personal-
ized approach is pursued to account for the clinical and histo-
pathological heterogeneity. Four different histological patterns of 
brain lesions were identified: subtypes I and II are characterized 
by T-cell infiltration without and with antibody involvement, 
respectively, whereas subtype III and IV reveal a distal or general 
oligodendrocytopathy, respectively. Apart from pattern II lesions, 
which have been identified to be predictive for a therapeutic 
response to apheresis therapies, knowledge about the correlation 
of histological subtypes and efficacy of treatment regimens is 
sparse.
Objectives: Description of the successful treatment of a MS 
patient with pattern III lesions.
Methods: Case report. Histological and immunocytochemical 
analysis.
Results: A 53-years old male developed atactic gait disorder, dys-
arthria, and sensory disturbance. Moreover, saccadic pursuits, pall-
hypaesthesia, and pyramidal tract signs were evident. His first 
MRI exposed a large, contrast enhancing lesion in the left middle 
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cerebellar peduncle, disseminated supratentorial T2 lesions and a 
thoracic spinal lesion. Cerebrospinal fluid oligoclonal bands were 
present. Stereotactic cerebellar biopsy revealed perivascular T cell, 
macrophage, and plasma cell infiltration, along with demyelina-
tion, all compatible with MS. By evidence of oligodendrocyte 
apoptosis and a significant reduction of myelin-associated glyco-
protein (MAG) expression, the lesion was classified as pattern III 
according to Lucchinetti, Brück, and Lassmann 2000. Treatment 
with high dose intravenous steroids and 180 mg triamcinolone 
intrathecally led to recovery of the atactic gait. After immunosup-
pressive therapy with four cycles of mitoxantrone (12 mg/m² body 
surface) every 2-3 months, his clinical condition and MRI findings 
further improved.
Conclusions: Distal oligodendrocytopathy, MAG loss, and 
increased hypoxia inducible factor-1α are common findings in 
MS with pattern III lesions, but also in virus-induced demyelina-
tion and acute white matter stroke lesions. This might indicate a 
common mechanism based on hypoxia-induced metabolic injury. 
The treatment response of pattern III lesions to classical immu-
nomodulatory MS therapy is unknown. Since in pattern III lesions 
a small vessel vasculitis is suspected, immunosuppressive thera-
pies such as mitoxantrone might be more effective and should be 
considered as therapeutic option.
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EP1769
Patient reported quality of life and disability measures in the 
West Yorkshire multiple sclerosis treatment programme
M. Vinjam, M. Russell, O. Lily, H.L. Ford
Department of Neurology, Leeds Teaching Hospitals NHS Trust, 
Leeds, United Kingdom
Background: Patient reported outcome measures (PROMs) has 
been included in recent trials involving both disease modifying and 
symptom management drugs in multiple sclerosis (MS). There is 
lack of information on PROMs outside the trial setting in patients 
treated with different disease modifying treatments (DMT).
Methods: All patients with Relapsing remitting MS (RRMS) 
treated with DMT’s including newly licenced drugs prospectively 
completed Leeds Multiple sclerosis Quality of life (LMSQoL) 
scale and United Kingdom Neurological Disability scale 
(UKNDS) on an annual basis. Expanded Disability Severity Score 
(EDSS) was also assessed during these visits. LMSQoL is an eight 
item scale with resulting scores from 8 to 32, with higher scores 
reflecting higher levels of well-being. UKNDS has 12 functional 
domains with an overall score ranging between 0 (no disability) to 
60 (maximum possible disability). Mean scores for LMSQoL, 
UKNDS during their first 12 months and 24 months were com-
pared to pre-treatment baseline along with the median EDSS.
Results: In total we analysed PROMs from 962 patients. There 
were 595 patients on injectable (Beta-interferon and Glatiramer 
acetate) treatments, 92 on Natalizumab, 109 on Fingolimod, 151 
on Dimethyl fumarate, 7 on Alemtuzumab and 8 on Teriflunomide.
In the injectable group there was 2 point increase (p-0.0001) in 
LMSQol with small decrease in the mean UKNDS which is not 
statistically significant with median EDSS remaining stable at 2. In 
Natalizumab group there was increase of 3.36 points (p-0.0001) on 
LMSQoL and decrease of 4.89 points (p-0.001) on UKNDS with 
unchanged median EDSS. In Alemtuzumab group there was 5.81 
point increase from baseline (p - 0.07) in LMSQoL, 16.38 
decreased from baseline (p-0.007) in UKNDS with 1.5 point 
reduction in median EDSS. There was no statistically significant 
change in PROMs in the rest of the treatment groups over the 
observed 24 month period.
Conclusion: There was improvement in the well-being scores 
from the baseline in people who are on Natalizumab and Injectable 
treatments. Natalizumab and Alemtuzumab group also reported 
improvement in their disability.
Disclosure
Maruthi Vinjam: Has received support to attend educational meet-
ings from Merck, Biogen, Novartis, and Genzyme
Melanie Russell: nothing to disclose
Oliver Lily: Has received support to attend educational meetings 
from Biogen and Teva
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EP1770
Whole brain tract disruption better explains cognitive 
decline in multiple sclerosis than total lesion volume
T. Fuchs, K. Carolus, S. Choudhery, D. Jakimovski, N.P. 
Bergsland, B. Weinstock-Guttman, R. Zivadinov, R.H.B. 
Benedict, M.G. Dwyer
University at Buffalo, State University of New York, Buffalo, NY, 
United States
Background: Total lesion volume is commonly evaluated in mul-
tiple sclerosis (MS) as an indicator of overall disease pathology. 
However, lesion volume often correlates poorly with cognitive 
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outcomes. Newer techniques allow for the assessment of a global 
outcome measure which accounts for the number of actual region-
to-region connections impaired by individual lesions (based on 
their location). This measure can be derived from typical clinical 
MRI and may be better associated with cognitive decline than total 
lesion volume.
Objective: To determine whether whole brain tract disruption 
caused by lesions is a better predictor of cognitive decline than 
total lesion volume in MS.
Methods: The Network Modification tool was used to quantify 
tract disruption between gray matter structures caused by white 
matter lesions in 120 subjects with MS. Linear regressions were 
used to model cognitive decline with either total lesion volume or 
whole brain tract disruption, controlling for age and gender. 
Cognitive decline was assessed via consensus cognitive tests of 
processing speed, visual memory, verbal memory, and attention 
(as measured by Symbol Digit Modalities Test, Brief Visuospatial 
Memory Test-Revised total learned, California Verbal Learning 
Test total learned, and Paced Auditory Serial Addition Test).
Results: For prediction of processing speed, adjusted R2 was 
0.222 for the total lesion volume model and 0.263 for the whole 
brain tract disruption model - an 18% relative increase in explana-
tory power
(4% absolute increase). Similar increases in adjusted R2 were 
observed in models predicting visual memory (0.120 vs. 0.143), 
verbal memory (0.147 vs. 0.154), and attention (0.075 vs. 0.083).
Conclusions: Although still describing a minority of the variance 
in cognitive decline, a single measure of global tract disruption is 
more strongly related to a variety of cognitive deficits in MS than 
total lesion volume.
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Persistent total suppression of T follicular regulatory lym-
phocytes in alemtuzumab-treated multiple sclerosis patients
M. Puthenparampil1, F. Grassivaro1, F. Rinaldi2, P. Perini2, L. 
Federle1, E. Quaggia2, G. Pantano3, M. Plebani3, P. Gallo1
1Department of Neuroscience DNS, Università degli Studi di 
Padova, 2Department of Neuroscience DNS, Università degli 
Studi di Padova, Azienda Ospedaliera di Padova, 3Laboratory 
Medicine Unit, University Hospital of Padua, Medical School, 
Padua, Italy
Background: Alemtuzumab, a humanized anti-CD52 IgG1 mon-
oclonal antibody, almost completely depletes T and B cells from 
the circulation. The long-lasting clinical efficacy of alemtuzumab 
has been associated to unique modifications of the cellular 
immune network during the re-constitution phase, characterized 
by the rapid reappearance of Treg lymphocytes and by. prolonged 
suppression of Th1 and Th17 lymphocytes. However, cases of 
severely exacerbated central nervous system (CNS) inflammation 
following alemtuzumab therapy have been described and 
explained with an exaggerated B-cell activity.
Aim: On the base of these observations, we investigated TFR and 
TFH cell number and percentage at all the RRMS patients treated 
with alemtuzumab in our MS Centre.
Results: We observed two alemtuzumab-unresponsive patients 
that had a severe disease reactivation 4 and 8 months after therapy, 
respectively. In both patients, we observed the almost complete 
absence of T follicular regulatory (TFR = CD3+CD4+CD127dimCD25+ 
CXCR5+PD1+) lymphocytes in the peripheral blood, while T fol-
licular helper (TFH, CD3+CD4+CD127+CD25-CXCR5+PD1+) lym-
phocytes were detectable. In one case, it was possible to analyse 
the cerebrospinal fluid lymphocytes. B cells represented the 
12.5% of all CSF lymphocytes, 40% were CD20- (while 98% of 
peripheral blood B-cells were CD20+) and displayed high values 
of physical parameters, suggesting an active state. Moreover, 48% 
of CSF B cells expressed high levels of CD38 and 61% (versus 
4% of peripheral B cells) expressed the activation marker CD83, 
suggested to play a role in the germinal centre maturation. 
Interestingly, the complete absence of TFR was observed in all 
patients independently of the time-point of sampling. In all the 
patients, variable percentage of TFH could be demonstrated.
Conclusions: The presence of TFH along with the complete 
absence of TFR suggests an imbalanced TFH/TFR ratio and, thus, a 
dysregulated follicular reaction. However, despite the persistent 
total suppression of TFR the majority of patients benefit from 
alemtuzumab therapy. Thus the mismatched reconstitution of B 
and T lymphocytes allows CNS-autoreactive B cell clones to pro-
liferate without control only in a few patients. Whether this phe-
nomenon is related to a given threshold number of circulating TFH 
or implies the presence of other immunological abnormalities 
merits to be investigated in a large cohort of patients.
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Evaluating the association between absolute lymphocyte 
count (ALC) after 6 months of dimethyl fumarate treatment 
and risk of relapse at one year
K. Smoot, K. Spinelli, L. Lucas, C. Chen, T. Stuchiner, L. Grote, 
E. Baraban, K. Kresa-Reahl, S. Cohan
Providence Multiple Sclerosis Center, Providence Brain and 
Spine Institute, Portland, OR, United States
Objective: Examine the relationship between absolute lympho-
cyte count (ALC) and relapses in relapsing MS (RMS) patients on 
dimethyl fumarate (DMF).
Background: DEFINE and CONFIRM trials showed a 40-50% 
reduction in relapse rate in patients taking DMF 240mg twice a 
day, however about 1 in 4 patients had a relapse within two years. 
Grade III lymphopenia (ALC< 0.5x103 cells/µL) developed in 6% 
of patients in the clinical trials and 11% of DMF patients in our 
community hospital registry. A recent report showed a positive 
correlation between ALC and relapses for DMF patients. Here we 
analyzed data from the Providence DMF registry to determine if 
ALC at 6 months was correlated with relapse within the first year 
of treatment.
Methods: Patients prescribed DMF for RMS from March 2013 
to March 2016 who had ALC values at 6 (±1) months and relapse 
data within one year of starting DMF were included. Poisson 
regression with the logarithm of time on DMF as an offset was 
used to analyze the relationship between ALC and annualized 
relapse rate (ARR). Cox proportional hazards regression was 
used to estimate the relationship between ALC and risk of 
relapse. Age, gender, and disease duration were included as 
covariates in the models. For both analyses, ALC was analyzed 
as a categorical variable with patients grouped into three ALC 
tertiles (lowest 33%, middle 33%, and highest 33%) and as a 
continuous variable.
Results: Of the 412 RMS patients in our registry during the study 
period, 116 patients met the inclusion criteria. Nineteen patients 
(16.4%) had a relapse within one year of starting DMF. While 
relapses increased with ALC tertiles (lowest tertile, ARR 
(SE)=0.07 (0.05), hazard ratio (HR)=reference; middle tertile, 
ARR (SE)=0.11 (0.07), HR=1.20; highest tertile, ARR (SE)=0.18 
(0.10), HR=2.27), this trend was not significant (p=0.26 for ARR, 
p=0.128 for HR). With ALC as a continuous variable, there was 
suggestive but inconclusive evidence that higher ALC correlated 
with relapses (adjusted ARR ratio=1.06, p=0.086; adjusted 
HR=1.06, p=0.142 for every 0.1 x103 cells/µL increase).
Conclusion: Our results, although not statistically significant, 
suggest a potential relationship between higher ALC values and 
relapse. With a numerically larger cohort these differences may 
have reached statistical significance.
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Towards personalized therapy through extensive longitudinal 
follow-up using a multidisciplinary data infrastructure for 
people with MS: a-proof-of-concept study
L.M. Peeters1, I. Lamers2, D. Valkenborg3, P. Feys2, V. Somers1, 
A. Spooren4, V. Popescu5, N. Hens3, P.M. Matthews6, C. 
Thalheim7, B. Van Wijmeersch1,5, N. Hellings1
1Biomedical Research Center, 2Rehabilitation Research Center, 
Biomedical Research Center, 3Center of Statistics, Hasselt 
University, Diepenbeek, 4Expertise Center Health Innovation, 
PXL, Hasselt, 5Rehabilitation and MS Center, Overpelt, 
Belgium, 6Brain Sciences and Data Science Institute, Imperial 
College Londen, London, United Kingdom, 7European Multiple 
Sclerosis Platform, Schaarbeek, Belgium
Multiple sclerosis should be featured by an individualized and 
intense clinical follow-up and multidisciplinary treatment. The 
construction of composite MS diagnostic/prognostic models com-
bining multiple parameters and the development and evaluation of 
personalized and effective MS treatments and rehabilitation strate-
gies requires extensive longitudinal follow-up. There is an urgent 
unmet need for multidisciplinary repositories combining (para)-
clinical parameters on different levels together with individualized 
information like immunological and genetic profiles to investigate 
multidisciplinary research questions combining multiple parame-
ters. Although many, individually held clinical research databases 
have been developed over the last few decades, open access to 
them is limited. Furthermore, the interoperability between these 
data resources is inexistent, because different types of data is 
acquired in different ways using different controlled vocabularies, 
which preclude direct integration. The existing (inter) national MS 
registers and IT platforms are either strictly observational or focus 
on disease epidemiology, access to new disease modifying drugs or 
quality of life priorities of people with MS.
The overall aim of this project, “MS DATACONNECT”, is build-
ing a multidisciplinary data infrastructure for people with MS that 
allows extensive longitudinal followup. MS DATACONNECT is 
an initiative of a consortium of 5 partners involved in MS research, 
care and rehabilitation. Within this consortium, around 660 people 
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with MS have been investigated. MS DATACONNECT combines 
following data:1° patient specific data, 2° disease specific data, 
3° treatment strategies , 4° paramedical data, 5° clinical data, 6° 
patient reported data, 7° biological sample specific data, 8° 
patient and sample phenotyping.
To the best of our knowledge, a data infrastructure that combines 
as many different types of MS data and parameters is unique. The 
platform is created in collaboration with Imperial College 
London, using the OPTIMISE open source software developed 
for use with MS and integrated with the tranSMART platform. 
MS DATACONNECT focusses on interoperability with other 
international registries and is involved in the development of a 
European Network of National MS Registries.
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Lateral ventricular atrophy measurements agree better than 
whole brain measures across centers and measurement tech-
niques
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Neuroscience, First Faculty of Medicine, Charles University 
and General University Hospital in Prague, 3Department of 
Radiology, First Faculty of Medicine, Charles University and 
General University Hospital, Prague, Czech Republic, 4Sydney 
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Background: Brain atrophy is a key component of MS and an 
important predictor of disability, but translation to clinical routine 
is hindered by methodological challenges, including high varia-
bility between different centers and analysis techniques. Lateral 
ventricular volume (LVV) was recently proposed as a robust, 
clinically-feasible proxy for whole brain atrophy. However, it has 
not been established whether different methods of measuring 
LVV at different centers are more concordant than whole brain 
measures.
Objective: To compare agreement of whole brain and lateral ven-
tricular volume measurements between different sites and assess-
ment techniques.
Methods: Three sites collected baseline and one-year follow-
up clinical routine MRI for 150 patients with MS. Sites used 
local, center-specific methods to produce measures of: base-
line brain parenchymal volume (BPV), one year percent brain 
volume change (PBVC), baseline lateral ventricular volume 
(LVV), and one year percent lateral ventricular change 
(PLVVC). All scans were also sent to an independent central 
lab, where CE/FDA approved software was used to generate 
independent volume and atrophy measures. Correlation 
between the sites and the central lab was assessed both across 
and within sites for each measure. One site did not produce 
normalized baseline data, and was excluded from cross-sec-
tional analyses.
Results: Overall BPV agreement with the central lab across the 
centers was moderate (r=0.63, p=0.001). Average within-center 
BPV agreement, controlling for center-specific bias, was slightly 
higher (r=0.68, p< 0.001). In contrast, overall LVV agreement 
with the central lab across centers was very high, (r=0.968, p< 
0.001). Average within-center LVV agreement was even higher 
(r=0.981, p< 0.001). For three-center longitudinal data, overall 
PBVC agreement was moderate (r=0.52, p< 0.001), as was within-
center agreement (r=0.57, p< 0.01). PLVVC agreement was again 
higher both overall (r=0.62, p< 0.001) and within-center (r=0.68, 
p< 0.01).
Conclusions: Both cross-sectional and longitudinal ventricular 
volume measurements are more stable across centers and analysis 
methods than whole brain volume measurements.
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Real life efficacy and tolerability of teriflunomide: multicen-
tre study in Galicia (TERIGAL)
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Background: Teriflunomide is an oral formulation which was 
approved as first line option for the treatment of Relapsing-
Remitent Multiple Sclerosis. Its efficacy and adverse events have 
been described in randomized controlled trials. Data for regular 
clinical practice are need. We have been using teriflunomide since 
july 2015.
Objective: Our objetive is to describe our initial experience with 
Teriflunomide in terms of tolerance and clinical effectiveness 
after 1 year of treatment.
Patients and methods: All patients from 7 Clinical Hospitals in 
Galicia, Spain, who were prescribed Teriflunomide were 
included, regardless of time on treatment. Basics demographic, 
clinical data, disability (EDSS scale), number of relapses, adverse 
events and reasons for discontinuation under teriflunomide were 
reported.
Results: 139 patients (72,7% woman) were reviewed, 36% naive, 
average age 42,8 years old (+-9,2), average anual relapse rate 
(ARR) 0,7 (+-0,7), average EDSS 1,62 (+-1,5). 119 and 64 
patients complied 6 and 12 months of treatment. Teriflunomide 
decrease ARR at 6: 0,11 (+-0,33) and 12 months: 0,19 (+-0,79), 
p< 0,05. Disability was stable at 6: 1,61 (+-1,4) and 12 months 
1,98 (+-1,7), p>0,05. 60 patients (43,2%) experience adverse 
events, most common gastrointestinal (30,9%), 2 severe (insom-
nia, elevation ALT) in the first 6 months. 8 patients (5,7%) stopped 
the treatment in the first 6 months. In the last 6 months 14 patients 
(10,1%) related adverse events, most common hair thinning (5%), 
without severe adverse events. 6 patients stopped the treatment in 
the last 6 months.
Conclusions: The efficacy of teriflunomide in real-life setting 
was demostrate by the stability in EDSS and reduce the number of 
relapses. Teriflunomide has been well tolerated by the majority of 
patients.
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This work have not commercial support.
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Treatment of progressive MS
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MD1003 (High-Dose Biotin) for the treatment of progressive 
multiple sclerosis: baseline data and results from a cohort of 
patients included in a early access program
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1Department of Neurology, Hôpital Pierre-Paul Riquet, 
Toulouse, 2Groupement des Hôpitaux of the Catholic Institue 
of Lille, Lomme, 3Department of Neurology, Pierre Wertheimer 
Hospital, Rhone, 4Department of Neurology, Caremeau Hospital, 
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Objectives: MD1003 (biotin 100 mg three times per day) was 
granted an early access program called Qizenday® cohort 
Temporary Authorisation for Use (ATUc) in July 2016, follow-
ing a named patient use called nominative ATU (ATUn) granted 
in 2015, by the French National Agency for Medicines and 
Health Products Safety, for treatment of adult primary (P) and 
secondary (S) progressive multiple sclerosis (PMS) patients 1 
year relapse free. ATUc baseline characteristics at inclusion, 
and efficacy and safety results from both the ATUn and ATUc, 
are presented.
Methods: The ATUc included 5483 patients (61% female) 
between 13 July 2016 and 12 January 2017 (SPMS: 3080 [56%]; 
PPMS: 1524 [28%]; PMS type not reported: 880 [16%]); 2781 
patients (51%) already received MD1003 as an ATUn. Further 
patients are currently included in the ATUc. To date, mean base-
line values were: age: 57 years; time from diagnosis: 18 years 
(SPMS: 21 years; PPMS: 13 years); Expanded Disability Status 
Scale (EDSS) score: 6.1 (SPMS: 6.2; PPMS: 5.9) and walking 
distance (WD): 218.1m.
Here we report follow-up changes in EDSS, WD and clinical 
global impression (CGI) over a period of 1 year.
Further results covering the period until July 13 2017, with addi-
tional patients and a longer observation period, will be presented.
Results: To date, mean change in EDSS remained stable over 1 
year while an increase in WD related to duration of MD1003 
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exposure was observed. An increased proportion of patients had 
improved CGI related to MD1003 exposure duration.
Safety data were consistent with the MD1003 summary of prod-
uct characteristics.
Discussion: In this large cohort of patients, the efficacy and safety 
of MD1003 are consistent with the MS-SPI trial results.
Disclosure
David Brassat received honoraria, consulting fees and travel 
grants from Bayer, Biogen, Medday, Merck-Serono, Novartis, 
Sanofi-Genzyme, Roche and Teva.
Patrick Hautecoeur has received board membership fees, hono-
raria, and paid travel accommodation from Biogen, Merck and 
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Cecil Donze has nothing to disclose.
Bertrand Audouin has nothing to disclose.
Jean-Christophe Ouallet has received consultancy fees, speaker 
fees, research grants (non-personal), and honoraria from Novartis, 
Biogen, Merck, Roche, Teva and Genzyme.
Nicolas Collongues has received board membership fees, hono-
raria, and paid travel accommodation from Biogen, Merck, Roche, 
Novartis and Sanofi.
Olivier Simon is an employee of Medday.
Guillaume Brion is an employee of Medday.
Patrick Vermersch has received honoraria and consulting fees 
from Biogen, Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-
Serono, Roche, Medday and Almirall, and research support from 
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Characteristics and therapeutic management of patients with 
primary progressive multiple sclerosis - data from a French 
multiple sclerosis population-based registry (the Multiple 
Sclerosis Registry in Lorraine Region)
J. Epstein1, G. Mathey1, F. Guillemin1, M. Debouverie1, L. 
Bitoun2, P.-H. Depoortere2, D. Pau2
1CHRU - Nancy, Nancy, 2Roche France, Boulogne-Billancourt, 
France
Background: No disease-modifying treatments (DMTs) have yet 
been approved for the management of primary progressive multi-
ple sclerosis (PPMS) patients.
Objective: To describe the characteristics and therapeutic man-
agement of PPMS patients, using the French regional multiple 
sclerosis (MS) population-based registry (Registre Lorrain des 
Scléroses en Plaques, ReLSEP).
Methods: Data from patients with confirmed MS, first MS symp-
toms between 2000 and 2014, at least one medical consultation 
with a neurologist between 2007 and 2015, and without combined 
DMTs during at least 3 months were extracted from the ReLSEP 
database. Following descriptive results focused on patients with 
primary progressive multiple sclerosis.
Results: From the 6090 MS patients registered in the ReLSEP 
database, 1926 MS patients met all the predefined selection crite-
ria, including 263 (14%) patients with PPMS at initial diagnosis. 
Among these 263 PPMS patients, 190 patients (72%) received at 
least one DMT from diagnosis and 73 patients (28%) never 
received any DMTs.
The characteristics of non-treated and treated patients were 
respectively as follows: women (53% and 50%), mean age at first 
MS symptoms (48±10 and 44±11 years), mean irreversible score 
on the Kurtzke disability status scale (DSS, 2.7±1.1 and 2.7±0.7), 
and median follow-up duration of patients [8 years (Q1-Q3: 5-11) 
and 9 years (Q1-Q3: 6-12)]. Among the 190 PPMS patients hav-
ing received at least one DMT from diagnosis, the first treatments 
prescribed were mostly non-selective IV immunosuppressant 
(55%) and interferon/assimilated products (35%). Median first 
treatment duration was 2 years (Q1-Q3: 1-3).
Conclusions: Despite no approved drugs, we observe in real life 
setting that more than 70% PPMS patients received at least one 
DMT in the RELSEP population. Mainly interferons/assimilated 
products and non-selective IV immunosuppressant are prescribed.
Disclosure
Dr. Epstein : nothing to disclose.
Dr. Mathey has received paid travel accommodations from 
Biogen, Merck, Roche, Novartis, and Sanofi.
Pr. Guillemin has received grants from Roche and Merck to his 
institution, and fees for scientific advisory board from Biogen to 
his institution.
Dr. Debouverie has received consulting and lecturing fees, travel 
grants and unconditional research support from Biogen, Genzyme, 
Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma.
L. Bitoun, Dr PH. Depoortere, D. Pau are employed by Roche.
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Laquinimod regulates inflammatory gene induction in a 
human model of reactive astrogliosis
C. Chapouly1, J.N. Mariani1, J. Zhang1, N. Zach2, G. John1
1Icahn School of Medicine at Mount Sinai, New York, NY, United 
States, 2Teva Pharmaceutical Industries, Netanya, Israel
Laquinimod is an orally-delivered immunomodulator which 
includes actions on the innate immune system and is in clinical 
trials for primary progressive multiple sclerosis. Laquinimod 
crosses the blood-brain barrier and enters the CNS, and recent 
studies suggest that in addition to peripheral actions, it may also 
exert its effects via direct modulation of reactive astrogliosis, 
which increasing evidence implicates as a key regulatory mecha-
nism controlling CNS inflammation. Here, we report that laquini-
mod strongly impacts proinflammatory gene expression in a 
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primary human model of reactive astrogliosis in vitro. Interleukin-
1beta (IL-1β) is implicated in lesion pathogenesis in MS, and is a 
strong inducer of astroglial reactivity in human cultures. We exam-
ined the impact of laquinimod on human astrocytic responses to 
IL-1β treatment. Notably, we found that IL-1β 10ng/ml induced a 
pro-inflammatory transcriptional pattern in primary human astro-
cytes, which encompassed induction of inflammatory cytokines, 
reactive nitrogen species, chemokines, adhesion molecules, matrix 
metalloproteinases, and inducers of endothelial plasticity and 
blood-brain barrier permeability, as shown by microarray, QPCR 
and multiplex ELISA. Importantly, at therapeutic concentrations, 
laquinimod dose-dependently inhibited IL-1β induction of 
cytokines including TNFα, IL-6, IFNα, IL-12 and IL-23, inducible 
nitric oxide synthase, and the matrix metalloproteases MMP7 and 
MMP10. Suggesting immunomodulation rather than suppression, 
laquinimod differentially regulated IL-1β-induced expression of 
CXC and CC chemokines, inhibiting induction of CXCL1,2,5,6,8 
and 10, and CCL8, while potentiating CCL5. IL-1β signals via the 
transcription factor NF-κB, and suggesting mechanism, laquini-
mod treatment delayed IL-1β-induced IκBα degradation and 
NF-κB p65 nuclear translocation. Moreover, compatible with a 
recent in vivo study, our data suggest that laquinimod acts as a 
ligand for the aryl hydrocarbon receptor (AhR), a potent immu-
noregulator that restricts NFκB activation via direct interaction 
with its p65 subunit. Collectively, these data reveal laquinimod as 
a regulator of the proinflammatory phenotype in a human model of 
reactive astrogliosis, and suggest that it may act in part via AhR-
mediated inhibition of NF-κB activation.
Disclosure
This research project has been funded by Teva Pharmaceuticals 
and Neta Zach is an employee from Teva Pharmaceuticals.
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An open label, single arm, phase II futility trial of Domperi-
done treatment in secondary progressive MS. Results of the 
first stage of the trial
M. Koch1, J. Kim1, G. Cerchiaro1, V.W. Yong1, G. Cutter2, L. 
Metz1
1Department of Clinical Neurosciences, University of Calgary, 
Calgary, AB, Canada, 2Department of Biostatistics, School 
of Public Health, University of Alabama at Birmingham, 
Birmingham, AL, United States
Background: Secondary progressive Multiple Sclerosis (SPMS) 
is characterized by slow and relentless worsening of disability 
independent of relapses. In SPMS multiple pathological processes 
are contributing to the accumulation of disability. The protein hor-
mone prolactin has been shown in animal studies to have neuro-
protective properties and to improve remyelination. We 
hypothesize that increasing systemic prolactin levels in patients 
with SPMS may slow disability progression. Domperidone is a 
generic dopamine D2 receptor antagonist that increases prolactin 
levels in humans. In this clinical trial, we used the Simon-2-Stage 
Futility Trial model to investigate the effect of Domperidone treat-
ment on disease progression in patients with SPMS.
Methods and design: This trial is a one year phase II Simon-2-
Stage Futility Trial. The primary endpoint was clinical worsening 
defined as worsening by 20% or more on the timed 25 foot walk 
between baseline and one year follow-up. Based on natural his-
tory and original trial data, we expected 40% of the trial cohort to 
have clinical worsening. The futility threshold was set at 25% of 
worsening in the trial cohort, using a type 1 error rate of 5% and 
80% power. Domperidone treatment is deemed futile if 12 or 
more of 30 patients enrolled in stage 1 of the trial have clinical 
worsening at one year follow-up. In the first stage of the trial, 30 
patients with SPMS were treated with 40mg of Domperidone 
daily for 12 months. Trial Registration: Clinicatrials.gov 
NCT02308137
Results: Overall 52 patients were screened of whom 35 were 
enrolled. Five patients terminated the trial early. The median age 
at baseline of the 30 patients who finished the trial was 54 years, 
23 (77%) were female, none of the trial participants were using 
disease modifying treatments. Median serum prolactin levels 
(normal range: 0-25 mg/L) increased from 9 (interquartile range: 
7-12) mg/L at screening to 92 (interquartile range: 38-140.5) 
mg/L at one month follow-up. At one year follow-up 8 patients 
had clinical worsening, significantly less than the historical rate 
of 40% (p< 0.05).
Discussion: After the first stage of this two stage trial, fewer 
patients than expected experienced clinical worsening. 
Domperidone treatment increased serum prolactin levels in the 
trial cohort. Domperidone treatment is deemed non-futile at this 
interim stage of the trial. The trial continues into the second stage.
Disclosure
This study was funded by Alberta Innovates Health Solutions 
(AIHS) through the Collaborative Research and Innovations 
(CRIO) Team Grant “Medicines for Remyelination in Multiple 
Sclerosis (MS): The Next Frontier” .
Marcus Koch: nothing to disclose
Janet Kim: nothing to disclose
Graziela Cerchiaro: nothing to disclose
Wee Yong: nothing to disclose
Gary Cutter: nothing to disclose
Luanne Metz: nothing to disclose
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Effect of MD1003 (High-Dose Biotin) in spinal progressive 
multiple sclerosis (MS-SPI): EDSS sub-scores
C. Papeix1, C. Lebrun-Frenay2, G. Defer3, P. Labauge4, M. 
Ruiz5,6,7, O. Simon7, A. Tourbah8
1Department of Neurology, GH Pitié Salpêtrière, Paris, 
2Université Côté d’Azur CHU Pasteur 2 Neurologie, Nice, 
3Service de Neurologie, CHU de Caen, Caen, 4Department 
of Neurology, CHU de Montpellier, Montpellier, 5Sorbonne 
Universités UPMC Univ Paris 06, 6Department of Neurology, 
AP-HP, Hôpital Pitié Salpêtrière, 7MedDay Pharmaceuticals, 
Paris, 8Department of Neurology, Hôpital Maison Blanche, 
Reims, France
Objectives: The MS-SPI study is a double-blind, randomised, 
placebo-controlled trial of MD1003 in progressive, not clinically 
active multiple sclerosis patients (pts) with evidence of spastic 
paraparesis. It showed a reversal of Expanded Disability Status 
Scale (EDSS) and/or timed 25-foot walk (TW25) in 12.6% of 
MD1003 pts vs 0 placebo pts (p=0.005) at 12 months (M). Here, 
we present the main study EDSS sub-score results.
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Methods: In each of the 154 pts included in the study, EDSS sub-
scores were recorded for each functional system (FS): pyramidal 
(P), sensory (S), cerebellar (C11), visual (V), brainstem (BS), 
bowel and bladder (BB), and cerebral (Cb). Change in sub-score 
from baseline at each visit was used to define pts as responders 
(improved) or worsened, depending on whether the score was 
lower or higher than baseline.
Results: Disability was well balanced in each arm and only a 
small proportion had major disability (score ≥3), other than 
for P FS. The most common baseline sub-scores (% of pts 
affected) were: P: 3-4 (~90%); S: 2-3 (~70%); C11: 2-3 
(~70%); V: 0-2 (~60%); BS: 0-2 (~50%); BB: 1-2 (~70%) and 
Cb: 0-2 (~50%).
P scores were ≥4 in 36% of MD1003 pts at baseline and 35% at 
M12, and in 43% of placebo pts at baseline and 53% at M12. 
Between M9 and M12, 10% of MD1003 pts and 2% of placebo 
pts were responders, while 6% of MD1003 pts and 13% of pla-
cebo pts worsened.
S scores were ≥4 in 3% of MD1003 pts at baseline and 2% at 
M12, and in 4% of placebo pts at baseline and 11% at M12. 
Between M9 and M12, 18% of MD1003 pts and 16% of placebo 
pts were responders, while 9% of MD1003 pts and 31% of pla-
cebo pts worsened.
For other FS, the percentage of pts defined as responders/wors-
ened was similar in each arm. For Cb, BS and V, the majority of 
pts had no impairment or had mild to moderate disability. For C11 
and BB, the majority of pts had symptoms but only mild to moder-
ate impairment. However, BB scores between M9 and M12 
showed that 10% of MD1003 pts and 13% of placebo pts were 
responders and 18% of MD1003 pts vs 27% of placebo pts 
worsened.
Discussion: For P and S scores, these results show an improve-
ment in the MD1003 group and worsening in the placebo group. 
Improvement in the active arm fits with the positive effect on 
EDSS and TW25. Pts included in the study exhibited high base-
line P and S scores while those of other FS were mild to moderate, 
and thus had less scope to improve.
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Caroline Papeix has received compensation as a consultant, advi-
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Aventis, Sanofi Genzyme and MedDay.
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Identification of main inclusion criteria of chronic progres-
sive multiple sclerosis clinical trials: a review
N. Dubuisson1, M. Marta1, S. Gnanapavan1, B. Turner2, D. 
Baker1, K. Schmierer1, G. Giovannoni1
1Neuroscience and Trauma, Blizard Institute, Barts and 
The London School of Medicine and Dentistry, Queen Mary 
University London, 2Neurology, Royal London Hospital, Barts 
Health NHS Trust, London, United Kingdom
Background: During the past two decades, many trials have been 
undertaken in order to improve our knowledge regarding the 
underlying mechanism and treatment of chronic progressive mul-
tiple sclerosis (CPMS). The latter is an old term which refers to 
advanced MS and includes both secondary progressive (SPMS) 
and primary progressive MS (PPMS). A lot of progress has been 
made in the understanding the pathogenesis and treatment of 
CPMS.
Objective: To review the criteria used by both investigator-led 
and pharmaceutical sponsored studies to recruit patients for 
chronic progressive MS trials. The objective of this review is to 
provide a summary of the different inclusion criteria which need 
to be fulfilled in order to be screened and recruited into a clinical 
trial investigating disease modifying therapies in CPMS.
Methods: Analysis of chronic progressive MS trials using a the-
clinicaltrial.gov website, Medline, EU clinical trials (EudraCT), 
Cochrane Central Register of Controlled Trials (CENTRAL) and 
ISRCTN register.
Results: 97 studies were included. Among them 17 showed posi-
tive results. Regarding subject selection, the age range is mainly 
between 18 and 65 years and very few studies include patients with 
an expanded disability status scale (EDSS) greater than 6.5. An 
important design feature of the majority of trials was the require-
ment of evidence of recent disease progression to be eligible for 
the study. This evidence can take several forms, ranging from clini-
cal history, EDSS worsening over a certain period of time, or 
reduction of a patient´s performance using specific assessment 
tools, for example the 9 Hole-Peg Test or Timed-25-Foot Walk.
Conclusions: The main criteria for inclusion in trials of progres-
sive multiple sclerosis is evidence of recent disease progression. 
However, to the best of our knowledge there does not appear to be 
a standardized protocol to assess the evolution of a patient´s dis-
ease course for inclusion in to CPMS trials. To overcome this 
issue, we believe that multiple sclerosis self-monitoring tools 
should be developed in order to help better assess the patient´s 
disease and its evolution, and to assist investigators’ in fulfilling 
the necessary inclusion criteria for clinical trials.
Disclosure
Nicolas Dubuisson is an ECTRIMS fellow, which is unrelated to 
the contents of this publication.
Monica Marta has received honoraria and travel costs from 
Genzyme, AbbVie and Novartis, unrelated to the context of this 
publication.
Sharmilee Gnanapavan has received honoraria for advisory 
boards and presentations from Genzyme and Novartis and travel 
support from Genzyme, Novartis and Teva. SG has received grant 
funding from Genzyme, which is unrelated to the contents of this 
publication.
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In-depth profiling of immune-regulatory network alterations 
during sequential treatment with natalizumab and fingoli-
mod - results of the ToFingo successor study
C. Janoschka, L. Lohmann, A. Schulte-Mecklenbeck, T. 
Schneider-Hohendorf, C. Gross, N. Schwab, S. Meuth, H. 
Wiendl, L. Klotz
Department of Neurology, University Hospital Münster, 
Münster, Germany
Multiple sclerosis (MS) is an inflammatory autoimmune disease 
of the central nervous system (CNS) with a variety of treatment 
options due to the heterogeneous disease manifestation in 
patients, demanding personalized treatment with regard to effi-
cacy and response. The ToFingo-successor study profiles in-
depth the underlining alterations of the immune-regulatory 
network during sequential treatment of 15 relapsing-remitting 
MS patients switching from natalizumab to fingolimod, which 
were analyzed providing detailed information of cell frequency, 
activation and functional properties as well as correlation to dis-
ease activity via MRI measurements. In the end of the 8-week 
washout period of natalizumab, detailed immune phenotyping of 
the peripheral blood (PB) did not reveal any alterations, indicat-
ing sufficient disease control. After 4 weeks of fingolimod treat-
ment onset, major drug-related effects such as CD4 T-cell 
trapping were already fully present. In contrast, B-cell and CD8 
T-cell decline is protracted, thus indicating that some fingoli-
mod-related effects occur delayed after treatment onset. Notably, 
the remaining lymphocytes which are able to overcome fingoli-
mods CCR7-mediated retention to the lymph nodes, display 
markers of terminal differentiation or effector function, illustrat-
ing full functionality for immune surveillance . Although in the 
cerebrospinal fluid (CSF), frequencies of CD4 and CD8 T-cells 
remain comparable under both drugs, they display, judged by 
HLA-DR, a significantly reduced activation status under fingoli-
mod. In contrast, the effect of fingolimod on non-T-cell-popula-
tions such as B-cells, monocytes and NK-cells in the CSF is less 
pronounced compared to natalizumab. Finally, we assessed 
treatment response based both on relapse rate and cMRI, respec-
tively, clinical non-responder demonstrate decreased and/or 
delayed efficacy of fingolimod treatment on several key param-
eters and less pronounced CD49d decrease under natalizumab 
which might be associated with an accelerated loss of natali-
zumab efficacy after treatment cessation and therefore to insuf-
ficient disease control. Taken together, our data suggests that 
rapid loss of natalizumab efficacy and delayed effects of fingoli-
mod treatment might be responsible for the increased rebounds 
observed in some patients during switching.
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This study was funded by Novartis, Kompetenznetz Multiple 
Sklerose (KKNMS) and SFB TR128.
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Long-term outcomes in patients with progressive forms of 
relapsing MS treated with teriflunomide: patient-level data 
from the TEMSO and TOWER extension studies and the 
real-world setting
F. Nelson1, C. Lebrun-Frenay2, W. Camu3, A. Boyko4, K. 
Thangavelu5, M. Mandel5, S. Cavalier5, P. Truffinet6, J. Liang7
1University of Texas Health Science Center McGovern Medical 
School, Houston, TX, United States, 2Hôpital Pasteur, Nice, 
3Institute for Neurosciences Montpellier, Montpellier, France, 
4Russian State Medical University, NeuroClinica at the Usupov’s 
Hospital, Moscow, Russian Federation, 5Sanofi Genzyme, 
Cambridge, MA, United States, 6Sanofi Genzyme, Chilly-
Mazarin, France, 7Sanofi, Bridgewater, NJ, United States
Background: A significant unmet need exists in the treatment of 
patients with progressive forms of MS. The phase 3 teriflunomide 
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studies, TEMSO (NCT00134563) and TOWER (NCT00751881), 
both showed a significant decrease in risk of confirmed disability 
progression (~31% with teriflunomide 14 mg). These studies 
included a small number of patients with progressive forms of 
relapsing MS (PfRMS; secondary progressive MS [SPMS] with 
relapses and progressive relapsing MS [PRMS]).
Objectives: To analyse individual long-term disability out-
comes in patients with PfRMS using data from ≤9 years’ follow-
up of TEMSO and TOWER, and to present observational 
real-world experience from patients with PfRMS treated with 
teriflunomide.
Methods: Patients with relapsing forms of MS were randomized 
1:1:1 to receive placebo or teriflunomide 7 mg or 14 mg for 108 
weeks in TEMSO or, in TOWER, for a study duration that was 
variable, ending 48 weeks after the last patient was randomized. 
Patients completing the core studies were eligible to enter exten-
sions. In the TEMSO extension (NCT00803049), teriflunomide-
treated patients continued as randomized; placebo-treated patients 
were re-randomized to teriflunomide 7 mg or 14 mg. In TOWER, 
all patients received teriflunomide 14 mg in the extension. In a 
post-hoc analysis, individual long-term Expanded Disability 
Status Scale (EDSS) outcomes were analysed and listed descrip-
tively. For patients receiving teriflunomide in the real-world set-
ting, a chart review of patients with SPMS or PRMS receiving 
treatment for ≥3 years was performed and their long-term EDSS 
scores tabulated.
Results: TEMSO and TOWER included 122 patients with PfRMS 
at randomization (SPMS, n=60; PRMS, n=62); 72 (59.0%) com-
pleted the core studies and 66 entered the extensions, of which 41 
(62.1%) completed at least 5 years. Baseline median EDSS score 
for patients with PfRMS was 4; at last follow-up (≤9 years), 
median change from baseline was 0. Over periods of up to 5 years, 
EDSS scores in patients in the real-world setting (SPMS, n=9; 
PRMS, n=1) also remained stable; longer-term follow-up of these 
patients will be presented.
Conclusions: These data from a small number of patients with 
PfRMS and a good initial response to treatment provide prelimi-
nary evidence that teriflunomide 14 mg may be associated with 
long-term stabilization of disease activity and lack of disability 
progression in patients with PfRMS. These findings need to be 
confirmed in larger patient cohorts.
Disclosure
Study supported by Sanofi Genzyme.
FN: Consulting agreements and/or honoraria (Acorda, Bayer, 
CMSC, Genentech, Mylan, Novartis, Sanofi Genzyme, Teva 
Neuroscience); research support (Alkermes, National MS Society, 
Novartis).
CL-F: Consulting fees, honoraria or scientific committee support 
(Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis, 
Teva).
WC: Honoraria and/or consulting fees (Biogen Idec, Novartis 
Pharma, Roche, Sanofi.
AB: Consulting fees as member of advisory boards; participation 
in clinical trials (sponsored by Biogen Idec, Genzyme, Novartis, 
Teva, Sanofi, Schering).
KT and PR: Employees of Sanofi Genzyme.
SC and PT: Employees of Sanofi Genzyme, with ownership 
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EP1784
Biotin in multiple sclerosis in clinical practice: a cohort of 
154 patients
A. Fromont, J. Gueniat, G. Romain, R. Arjmand, D. Audry, T. 
Moreau
Neurology, University Hospital, Dijon, France
Background: Biotin is vitamin acting as a coenzyme for carboxy-
lases involved in key steps of energy metabolism and fatty acids 
synthesis and could promote remyelination. One double blind pla-
cebo controlled trial showed improvement in a significant propor-
tion of patients with progressive multiple sclerosis (MS). Biotin is 
available in France in temporary use since July 2015.
Aim: To study baseline characteristics and follow up of patients 
treated with Biotin in Dijon (Burgundy).
MEthods: We studied all progressive MS treated with biotin for 
more than 3 months included in EDMUS database. EDMUS is 
used in Dijon since 2000 and includes patients from burgundy MS 
center. We calculated number of primary progressive (PP) or sec-
ondary progressive (SP) form of MS, mean age and EDSS at bio-
tin initiation, proportion of patients for which biotin was used as 
add on therapy or with fampyra, number of adverse events, 
Clinical Global Impression (CGI) Scale assessed by patient..
Results: 154 patients were treated with biotin, 114 had SPMS and 
40 PP. The mean age at MS onset was 32.0 and 45.6 years respec-
tively. Mean age at biotin initiation was 57.6 years with mean 
EDSS at 6.9 for SPMS; 61.6 years and 6.7 for PPMS. The mean 
duration of treatment was 8.8 months. 35 patients had biotin as 
add on therapy among SPMS and 12 for PPMS. 19 (16.7%) 
patients with SPMS reported adverse events (skin rash, hyperpi-
losity, diarrhea, anxiety asthenia, oedema) and 3 (7.5%) patients 
with PPMS (abdominal pain, diarrhea, constipation). 42% of 
patients reported CGI= 4, 39.5% CGI< 4, 18.4% CGI>4. 48 
(31.8%) patients were under fampyra and 103 (68.2%) without, 
those under fampyra reported CGI improvement more frequently 
(56% versus 32%)
Conclusion: Despite short treatment duration, biotin is well toler-
ated, and seems more effective among patients under fampyra.
Disclosure
Fromont: nothing to disclose
Gueniat: nothing to disclose
Romain: nothing to disclose
Arjmand: nothing to disclose
Audry: nothing to disclose
Moreau: nothing to disclose
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A case of acute fulminant multiple sclerosis treated with 
alemtuzumab
F. Gobbin1, A. Marangi1, R. Orlandi1, S. Richelli2, M. Turatti3, 
M. Calabrese1, A. Forgion4, F. Alessandrini3, M.D. Benedetti3, S. 
Monaco1, A. Gajofatto1
1Department of Neuroscience, Biomedicine and Movement 
Sciences, University of Verona, Verona, 2Ospedale Sacro Cuore, 
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Universitaria Integrata Verona, Verona, 4Unit of Neurology, 
Casa di Cura Pederzoli, Peschiera del Garda, Italy
Background: Marburg´s variant of MS (MVMS) is characterized 
by acute and extensive demyelination, with a typical monophasic 
fulminant course usually leading to death within few weeks. There 
is no standard treatment strategy for MVMS. Usually high dose 
intravenous steroids represent the first line option followed by 
plasma exchange or intravenous immunoglobulins. The only data 
regarding the use of immunosuppressants refer to mitoxantrone 
and cyclophosphamide, which may slow or even stop the course 
of the disease.
Objectives: We describe the case of a woman who came to our 
attention for a severe neurological presentation characterized by 
very rapidly worsening left hemiplegia, vision loss and cognitive 
impairment. The rapid clinical deterioration, the extensive 
involvement of periventricular white matter and brainstem and the 
laboratory data were highly suggestive of an active inflammatory 
demyelinating disease. A wide spectrum of differential diagnosis 
were investigated, including acute disseminated encephalomyeli-
tis (ADEM), Balo’s concentric sclerosis, neuromyelitis optica 
spectrum disorders (NMOSD) and others infectious diseases.
Results: Following exclusion of other possible etiologies, a diagno-
sis of Marburg type multiple sclerosis was made. The patient was 
treated with high dose steroids iv without improvement and then 
with plasma exchange but she became poorly responsive to verbal 
and pain stimulation, and developed right hemiplegia associated to 
focal motor seizures. Considering the high efficacy on relapse rate 
and disability accumulation in relapsing-remitting MS, treatment 
with alemtuzumab was started. In the following weeks an improve-
ment of the clinical and MRI picture was observed: the patient 
became awake, responsive to external stimuli, provided verbal 
responses and showed initial motor recruitment of the right arm.
Conclusions: To the best of our knowledge, this is the first 
reported case of Marburg type multiple sclerosis treated with 
alemtuzumab. Although a delayed effect of immunotherapies 
administered prior to alemtuzumab could not be ruled out, this 
hypothesis seems unlikely considering the continuous worsening 
of clinical and MRI picture after more than two weeks from ster-
oids and plasma exchange initiation.
Disclosure
Massimiliano Calabrese received payment for development of edu-
cational presentations including service on speakers bureaus by 
Biogen-Elan, Genzyme, TEVA, Bayer-Schering, he received 
travel/accomodation expenses by Novartis Pharma, Genzyme, 
Biogen idec, Merck Serono, Bayer-Schering, TEVA, and Advisory 
Board membership by Bayer-Shering, Genzyme, Biogen Idec.
Alberto Gajofatto received payment for participating in advisory 
board and travel support from Merck.
EP1786
Sleep and fatigue features in multiple sclerosis patients on 
alemtuzumab treatment
B. Barun1, M. Krbot Skoric2, M. Mioc3, L. Crnosija2, I. 
Adamec2, M. Mudrovcic4, N. Milosevic4, M. Habek2,4
1University Hospital Center Zagreb, 2University Hospital 
Center Zagreb, Department of Neurology, Referral Center for 
Autonomic Nervous System Disorders, 3University Psychiatric 
Hospital Vrapče, 4University of Zagreb, School of Medicine, 
Zagreb, Croatia
Introduction: Previous prevalence studies suggest that patients 
with multiple sclerosis (MS) have higher frequency of sleep disor-
ders comparing to healthy controls and that sleep disorders con-
tribute in development of fatigue. However, the impact of 
disease-modifying therapy (DMT) on sleep of MS patients 
remains unknown.
Objectives: The aim of this study was to determine sleep charac-
teristics in alemtuzumab treated MS patients and correlation 
between sleep disturbances and fatigue.
Methods: Out of 30 consecutive MS patients enrolled, 20 received 
alemtuzumab (12 females, mean age 40.00 +/- 8.96 years) and 10 
(7 females, mean age 40.50 +/- 10.75 years) were treatment naïve. 
All subjects completed standardized Croatian version of Epworth 
Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), 
Insomnia Severity Index (ISI), STOP-Bang Questionnaire, 
Restless Legs Syndrome Rating Scale (RLS-RS), Modified 
Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS).
Results: No statistically significant difference between treatment 
naïve and alemtuzumab treated patient group was observed in 
EDSS (median 1.50 vs 1.25, p=0.303). Treatment naïve patients 
had significantly higher RLS-RS score comparing to alemtu-
zumab treated patients (median 14.50 vs. 0, p=0.014). Also, posi-
tive correlation was found between ISI score and MFIS score (rs= 
0.632, p=0.050) in treatment naïve group, whereas alemtuzumab 
treated patients had positive correlation between ISI score and 
MFIS score (rs= 0.629, p=0.004), ISI score and FFS score (rs= 
0.650, p=0.003), PSQI score and MFIS score (rs= 0.664, p=0.003), 
PSQI score and FFS score (rs= 0.615, p=0.007).
Conclusion: Results of this study might suggest that alemtuzumab 
treatment eliminates other factors that contribute in development 
of fatigue besides sleep disorders. The remaining fatigue present in 
alemtuzumab treated patients might be more dependent on pres-
ence of sleep disorders than fatigue in treatment naïve patients.
Disclosure
Barbara Barun participated as speaker and has received compen-
sation for consulting services, travel expenses for scientific meet-
ings from: Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/Teva, 
Roche.
Magdalena Krbot Skorić: nothing to disclose.
Marina Mioč: nothing to disclose.
Luka Crnošija: nothing to disclose.
Ivan Adamec nothing to disclose.
Monika Mudrovčić: nothing to disclose.
Nataša Milošević: nothing to disclose.
Mario Habek participated as clinical investigator and/or speaker 
for: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva/
Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals.
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No evidence of disease activity in anti-JC virus seronegative 
patients with early relapsing-remitting multiple sclerosis 
treated with natalizumab: a prespecified 2-year analysis of 
STRIVE
J. Perumal1, R.J. Fox2, R. Balabanov3, S. Makh4, Q. Dong4, L. 
Balcer5, S. Galetta5, C. Hotermans4, J. Walsh4, L. Lee4
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1Judith Jaffe Multiple Sclerosis Center, New York, NY, 2Mellen 
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3Northwestern Universiy, Chicago, IL, 4Biogen, Cambridge, MA, 
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Background: Treatment with natalizumab early in the relapsing-
remitting multiple sclerosis (RRMS) disease course may improve 
clinical outcomes. STRIVE was designed to determine the pro-
portion of anti-JC virus antibody-negative RRMS patients initiat-
ing natalizumab early in their disease course who demonstrated no 
evidence of disease activity (NEDA).
Objective: To determine the proportion of natalizumab-treated 
early RRMS patients who achieve NEDA at year 2.
Methods: STRIVE is a multicenter, observational, open-label, 
single-arm study in which NEDA was defined as no Expanded 
Disability Status Scale (EDSS) progression (24-week-con-
firmed), no relapses, no gadolinium-enhancing (Gd+) lesions, 
and no new or enlarging T2-hyperintense lesions. Clinical 
NEDA was defined as no EDSS progression and no relapses. 
Continuous variables were analyzed with summary statistics. 
Categorical variables were analyzed with frequency distribu-
tions. P values and odds ratios (ORs) were obtained from logis-
tic regression models adjusted for baseline EDSS score (≤2 vs 
>2), age group (< 40 vs ≥40 years), number of relapses 1 year 
prior to natalizumab infusion, baseline T2 lesion volume, base-
line Gd+ lesions, and multiple sclerosis (MS) disease duration, 
as applicable.
A Kaplan-Meier analysis was used to evaluate time to disability 
worsening and time to disability improvement.
Results: The intent-to-treat population (N=222) had early 
MS with mean (standard deviation [SD]) time since MS diag-
nosis of 1.6 (0.8) years and a mean (SD) EDSS score of 2.0 
(1.1). Half (50%) of the patients had not received prior dis-
ease-modifying therapies. At year 2, 76 of 171 patients 
(44.4%) had achieved NEDA (95% confidence interval [CI]: 
37.0%-51.9%), and 131 of 181 patients (72.4%) had achieved 
clinical NEDA (95% CI: 65.9%-78.9%). A higher proportion 
of patients without than with baseline Gd+ lesions (54.7% vs 
31.9%) achieved NEDA at year 2 (OR: 2.89; 95% CI: 1.35-
6.18; P=0.006). At year 2, patients with baseline EDSS score 
≤2 had a significantly higher chance of achieving NEDA than 
those with baseline EDSS score >2 (OR: 2.33; 95% CI: 1.08-
5.04; P=0.032). At year 2, a higher proportion of patients 
experienced 24-week-confirmed EDSS improvement than 
worsening
(28.4% vs 14.1%). The serious adverse event profile up to year 2 
was consistent with natalizumab’s well-established safety 
profile.
Conclusions: These 2-year results support the effectiveness of 
natalizumab in maintaining NEDA in early RRMS patients.
Disclosure
Supported by Biogen.
JP: fees from Acorda, Biogen, Genzyme, and Teva.
RJF: consulting fees from Actelion, Biogen, Genentech, 
Mallinckrodt, MedDay, Novartis, Teva, and XenoPort; advisory 
board fees from Biogen and Novartis; grant/research support from 
Novartis.
RB: consulting fees from Biogen, Sanofi, and Teva; grant/research 
support from Biogen.
SM, QD, CH, JW, LL: employees of and hold stock and/or stock 
options in Biogen.
LB: consulting fees from Biogen and Genzyme.
SG: consulting fees from Biogen.
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Capillary leak syndrome in neuromyelitis optica treated with 
rituximab
R. Hernández Clares1,2, I. Fuentes Fernandez3, E. Carreon 
Guarnizo1,2, A.E. Baidez Guerrero1, G. Valero Lopez1, A. Leon 
Hernandez4, F. Velazquez Marin4, J. Zamarro Parra4, J. Meca 
Lallana1,2
1Multiple Sclerosis Unit, Neurology Department, Virgen de la 
Arrixaca Hospital, 2Catedra de Neuroinmunología Clinica, 
Universidad Católica San Antonio, 3Critical Care Department, 
4Neurorradiology Department, Virgen de la Arrixaca Hospital, 
Murcia, Spain
Background: Capillary leak syndrome (CLS) is a rare condition 
characterized by unexplained episodic capillary hyperpermeabil-
ity due to a shift of fluid and protein from the intravascular to the 
interstitial space with subsequent hypovolemia, hemoconcentra-
tion and hypoproteinemia. It can be idiopathic or secondary to 
some conditions like infection, malignant disease and some drugs 
like monoclonal antibodies.
Objectives: To report a 61 year-old woman diagnosed with NMO 
three years before and treated with rituximab (RTX), who suffered 
a fatal CLS one month after the last drug dose. To our knowledge, 
it is the first reported case of CLS in NMO patient after rituximab 
treatment.
Methods: 61-year-old woman with Neuromyelitis optica (NMO) 
diagnosis treated with rituximab was referred to our hospital with 
severe hypovolemic shock and anasarca. Laboratory data showed 
a progressive increase in haematocrit (max 56.2%), haemoglobin 
(max 18.6 g/dl) and white blood cell count with a normal fraction. 
Total serum protein showed a marked decrease (1.6 g/dl) without 
proteinuria. She developed a multiple organ failure and died three 
hours later.
Results: We diagnosed the patient as having capillary leak syn-
drome (CLS) because of the hypovolemic shock with hypopro-
teinemia without proteinuria and the lack of suggestive data of 
infective disease or anaphylaxis. The autopsy showed only find-
ings of diffuse oedema with ascites and pericardial effusion, with-
out evidence of infection or malignant disease, compatible with 
CLS.
Conclusions: RTX is currently considered to be an effective and 
safe treatment for NMO. Although the most frequent adverse 
events are postinfusion reactions and infections, the increasingly 
widespread and prolonged use of the drug could lead us to less 
known and potentially more serious adverse effects. Even this is 
the first CLS case in NMO patient treated with RTX, it is impor-
tant to consider the diagnosis in any patient who presents sepsis 
syndrome, in particular, when no clear infectious process can be 
identified. Increased awareness of this problem will lead to a 
higher identification of cases and the better knowledge of mono-
clonal antibodies.
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EP1789
The national incidence of PML in Sweden, 1988 - 2013
E. Iacobaeus
Dept of Clinical Neurology, Dept of Clinical Neuroscience, 
Dept of Laboratory Medicine, Karolinska Institute, Stockholm, 
Sweden
Background and aims: An increase in the incidence of progres-
sive multifocal leukoencephalopathy (PML) has been observed in 
MS patients in recent years. This study investigated the incidence 
of all PML diagnoses and patient characteristics in Sweden 
between 1988 and 2013.
Methods: All PML diagnoses in Sweden between 1988 and 2013 
were identified in the National Patient Register. Information to 
validate the diagnosis and patient characteristics was obtained 
from medical records.
Results: Medical record review classified 108 out of 250 patients 
(43%) as definite (n=84), probable (n=4) or possible (n=20) PML 
according to diagnostic criteria. Accurate diagnoses were more 
common in records obtained from neurology departments (82% of 
patients who were assessed by neurology departments) compared 
with other departments (33%) (p<0.001). The incidence of PML 
increased from a largely stable level at 0.026 (95% CI: 0.021-
0.031) per 100.000 individuals per year during 1988 - 2010 to 
0.11 (0.083-0.137) during 2011- 2013 (p<0.001). Haematological 
malignancies (n=34), HIV/AIDS (n=33) and autoimmune disease 
(n=23) were the most common underlying diseases. Treatment 
with a monoclonal antibody prior to PML diagnosis was identified 
in 26 patients.
Conclusion: An increased incidence of PML in Sweden was 
observed and coincided with the prior use of monoclonal antibody 
treatment. The high level of misdiagnosis emphasises the impor-
tance of immediate contact with a neurology centre upon suspi-
cion of PML.
Disclosure
This study was funded predominantly by F. Hoffmann - La Roche 
Ltd. Additional funding was received from the Stockholm County 
Council, Swedish Medical Research Council, The Swedish Brain 
Foundation and Karolinska Institutet.
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The therapeutic management of patients with multiple scle-
rosis in France: an analysis of the EGB database
B. Detournay1, M. Cousin1, J. Gourmelen2, V. Machuron3, P.-H. 
Depoortere3, D. Pau3
1Cemka-Eval, Bourg-la-Reine, 2INSERM UMS 011, Villejuif, 
3Roche France, Boulogne-Billancourt, France
Background and goals: Around 100,000 people are currently 
diagnosed with Multiple Sclerosis (MS) in France. To date, avail-
able therapies for the disease do not cure MS and only prevent 
flares in the relapsing-remitting forms. The objective of the analy-
sis was to describe the therapeutic management of patients with 
MS.
Method: The main French National Health Insurance database 
cover about 90% of the French population. Data from a random 
sample of ≈ 600,000 patients (1/97th) registered in this claim data-
base were used to identify adults MS patients through their Long 
standing condition status (ICD-10 code: G35)/ hospital stays dur-
ing the study period referencing MS as main diagnosis or related/ 
at least one reimbursement of an MS-specific drug over the 2007-
2014 period. Treatment sequences were identified considering 
date of delivery of MS therapies in the database.
Results: A total of 940 patients were included in the prevalent MS 
population on January 1st, 2014. On average they were 50.9 (± 
13.7) years old. 71.4% of patients were female. Nearly all patients 
(91.7%) were visited at least once during the year by a GP and 
38.9% a neurologist. Overall, 44.3% of patients have received at 
least one delivery of a primary therapy for MS in 2014 mostly 
beta-interferons and assimilated (28.8%), selective oral immuno-
suppressant (6.1%) non-selective oral immunosuppressant (5.7%), 
humanized monoclonal antibody anti-alpha-4 integrin (5.0%), 
oral Nrf2 pathway activator (3.1%), oral selective immunomodu-
latory (2.0%), chimeric anti-CD20 antibody (0.3%). 24.4% of 
patients had a symptomatic treatment at least once during the year 
(baclofen 17.7%) and 9.3% at least one delivery of injectable cor-
ticosteroids. A longitudinal analysis over 2007-2014 show most 
patients were treated discontinuously with rather long period of 
time without primary therapies for MS. In 2014, 22.1% of patients 
beneficiated of technical aids for their disabilities and 46.9% of 
patients had at least one physiotherapy session during the year. 
Finally, 6.2% of patients were hospitalized for MS for an average 
duration of 3.6 days.
Conclusions: Management strategies in MS were modified in the 
last decade with the marketing of disease-modifying treatments. 
However, in our sample, slightly more than half patients did not 
receive any primary therapies for MS while a significant part of 
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patients continue to experience symptoms and disabilities associ-
ated with MS.
Disclosure
Authors Bruno Detournay and Mathias Cousin are employees of 
Cemka-Eval a consultancy firm which was contracted by Roche 
France for this study; Bruno Detournay also received honoraria 
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Sanofi, Boehringer-Ingelheim, Pfizer.
Valérie Machuron, Paul-Henri Depoortere, David Pau are 
employed by Roche France. Julie Gourmelen has no conflict of 
interest
This study was funded by Roche France.
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Use of complementary and alternative medicine in Hispanic 
patients with multiple sclerosis
A.G. Barboza1,2, J.J. Barboza1
1Universidad del Aconcagua, 2Neurologia Clinica, Mendoza, 
Argentina
Introduction: Multiple sclerosis (MS) is a complex disease with 
several symptomatic and disease modifying treatment options. As 
it is a disabling disease and none of these treatments warrants 
relief in all patients, some of them tend to resort to complementary 
and alternative medicines (CAM). CAM are those therapies that 
are not currently considered an integral part of conventional allo-
pathic medical practice. They may lack biomedical explanations 
but as they become better researched. Different surveys in North 
America and Europe show a variable use of them, but there are not 
studies performed in neither Latin America nor Spain.
Objective: To set the frequency and describe the use of CAM use 
in a Hispanic population with MS.
Methods: An anonymous survey was performed in January 2017 
in a Hispanic population with MS that participate in patient groups 
of the social network Facebook (closed groups Esclerosis Múltiple 
and Amig@s con Esclerosis Multiple). Data obtained were age, 
sex, residence country, educational level, progressive or relaps-
ing-remitting disease, current treatment, disability, and questions 
about use of CAM. A multivariate anaylisis was performed in 
order to identify predictors of use of CAM.
Results: 463 patients answered the survey. Average age was 41 
(SD 9.73), Mean years of disease 9 (SD 7.4), 78% females. Most 
frequent residency countries were Spain, Mexico and Argentina. 
Relapsing - remitting had forms 59% and progressive forms 20%. 
Estimated disability showed 64% of fully ambulatory, 29% 
walked with assistance, and 7% restricted to wheelchair or bed. 
CAM were used in 51% of patients, of which 12% stopped immu-
nomodulatory treatment to continue only with CAM, and 34% 
never told their doctor that they used CAM. Most frequent CAM 
were dietary supplements and acupuncture. 82% noted some ben-
efit, most frequent symptomatic relief. 6% reported any adverse 
event related to CAM. Multivariate analysis identified as predic-
tors of CAM use higher level of education p 0.0008, OR 1.8 (CI 
1.28 - 2.54); country of residence Venezuela p 0.036, OR 1.26 (IC 
1.01 - 1.56); and fully ambulatory 0.002, OR for restricted to bed 
0.57 (IC 0.39 - 0.81).
Discussion: CAM utilization in this Hispanic sample seems to be 
significant, with an important number o patients stopping their 
treatment or not consulting with their doctors. Treating physicians 
should be aware of this problem and discuss with their patients.
Disclosure
No conflict of interest to declare.
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A multi-centre observational analysis of persistence to treat-
ment in the new MS era: the RESPECT study
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University School of Medicine, 23Helen Durham Centre for 
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Rieducazione Funzionale, Moncrivello, Italy
Background: In recent years there has been an increasing avail-
ability of disease-modifying treatments (DMTs) for relapsing-
remitting multiple sclerosis (RRMS), including oral drugs. The 
common perception is that these oral drugs are more accepted and 
tolerated by patients than self-injectable DMTs. However, evi-
dence that the route of administration has a relevant effect on per-
sistence to treatment is not established yet.
Objective: To investigate the short-term persistence to treatment 
with self-injectable or oral DMTs in patients with RRMS.
Methods: We retrospectively collected data of patients attending 
21 Italian MS Centres and one MS Centre in Wales, UK. Patients 
were considered eligible if they started a self-injectable or oral 
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DMT (excluding fingolimod) from January to December 2015. We 
estimated the proportion of patients discontinuing the treatment 
within a follow-up period of 12 months and analysed reasons for 
discontinuation. A Cox regression model (stratified by Centre) was 
run to explore baseline predictors of treatment discontinuation.
Results: We analyzed data of 1,841 consecutive patients (1,293 F, 
548 M) with a mean age of 40 years and median EDSS of 2.0. Of 
them, 631 (34%) were treatment-naïve, while the remaining 1,210 
(66%) were switched from another DMT. The most frequently 
prescribed treatment was dimethyl fumarate (n=1,050; 57%), fol-
lowed by teriflunomide (n=174, 15%), glatiramer acetate (GA) 20 
or 40 mg (n=175; 9.5%), low-frequency (LF) i.m. or s.c. pegylated 
Interferon beta (IFNB)-1a (n=174, 9.5%), high-frequency (HF) 
s.c. IFNB-1a or 1-b (n=165, 9%).
A total of 366 (20%) patients discontinued the prescribed DMT 
after a median time of 6 months due to lack of tolerance (n=166), 
disease activity (n=98), adverse event (n=62), pregnancy planning 
(n=22) or unspecified reasons (n=21).
The highest discontinuation rate was observed in patients treated 
with LF-IFNB (p< 0.02 versus each other DMT). There was no 
significant difference in discontinuation rate between oral drugs 
and HF-IFNB or GA (p>0.3). Female sex (HR=1.45, p=0.003) 
and previous exposure to >2 DMTs (HR=1.66, p=0.009) were 
other independent risk factors for treatment discontinuation.
Discussion: Poor tolerability was the most common cause of 
treatment discontinuation in the short-term period. Oral drugs did 
not show a better tolerability with respect to self-injectable DMTs. 
Persistence to treatment represents a clinical challenge, irrespec-
tive of the route of administration.
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Tolerability and persistence in therapy with PEGylated-IFN: 
results from a multicentric observational study in Italy
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Objectives: PEGylated Interferon (PEG) pivotal trials in Multiple 
Sclerosis (MS) have shown its efficacy compared to placebo, with 
a favourable tolerability profile. Aim of this study is to confirm 
these data in a real-life setting, and understand predictors of good 
tolerability and persistence in therapy.
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Materials and methods: We invited MS centres in Lombardy to 
collect data from all RR-MS patients receiving PEG, recording 
demographic and clinical features and laboratory tests results.
Results: 251 patients (166F) were enrolled from 10 MS centres 
(mean age 42.1 ± 10.6 years (y)), mean disease duration 11.2 ± 7.8 
y). Mean ARR in the two y before PEG was 0.2 ± 0.2; median 
baseline EDSS was 1.5. 31/251 patients were treatment naïve and 
94/251 started PEG switching from Interferon (IFN) once a week 
(IFN-1w), 109/251 switched to PEG from IFN multiple times a 
week (IFN-mw), while 17/251 switched from other therapies. 
Mean follow up was 11 ± 3.3 months (mo) (median 11 mo, I and 
III quartiles: 8-13 mo). 169/251 patients reported Adverse Events 
(AEs): 55% (n=139) complained of flu-like syndrome (FLS) (in 
28 cases leading to PEG discontinuation), and 27% of skin reac-
tions. FLS was reported more frequently by patients switching 
from IFN-1w (69%), compared to patients previously treated with 
IFN-mw (43%), naïve (58%) or other patients (53%) (p=0.03). 
Other notable AE included blood test count abnormalities (7%, 
one leading to discontinuation) and elevation in transaminases
(3%, one leading to discontinuation). 51/251 patients stopped 
PEG: 38 for AEs, 5 for pregnancy and 8 for disease activity. 29% 
of the patients switching from IFN-1w stopped PEG, with respect 
to patients previously treated with IFN-mw (14%), naïve (6%) or 
other patients (41%). Predictors of non-persistence in therapy 
were switching to PEG from IFN-1w (HR 0.15, 95% CI: 0.03-
0.76, p = 0.02), but not gender, age, disease duration, baseline 
EDSS or the number of previous therapies. Among patients 
switching to PEG from IFN-mw no increase in the relapse rate 
was observed.
Discussion and conclusion: Even with the limitations of an open 
label study with a short follow-up, our data seem to confirm the 
good tolerability profile of PEG. Switching from non-PEGylated 
IFN to PEG doesn’t seem to affect relapse rate. Persistence in 
PEG is maximized in patients whose previous IFN regime was of 
high frequency, probably because the benefit of a sharp decrease 
in the number of injections overwhelms PEG side effects.
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Bridging the gap-challenges in switching from fingolimod to 
alemtuzumab
M. Hu, O.R. Pearson, G. Ingram
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Background: Switching between disease modifying treatments in 
Multiple Sclerosis (MS) is becoming increasingly complex. In 
patients failing Fingolimod therapy, treatment can be escalated to 
Alemtuzumab to achieve disease suppression. Potential difficul-
ties with this treatment strategy include rebound disease activity, 
as there have been reports of treatment failure in up to 25% of 
patients who have switched from Fingolimod to Alemtuzumab. 
This process is thought to be mediated by prolonged sequestration 
of auto-reactive lymphocytes due to Fingolimod, which are then 
released following discontinuation. These cells (whilst seques-
tered) can also avoid the activity of Alemtuzumab, later causing 
ongoing disease activity despite Alemtuzumab treatment.
Methods: Patients with relapsing remitting MS who switched to 
Alemtuzumab from Fingolimod were reviewed from a South West 
Wales cohort.
Results
Case 1: A 31-year old female with relapsing remitting MS was 
escalated to Alemtuzumab from Fingolimod due to clinical relapse 
activity. Following the first course of Alemtuzumab treatment she 
suffered 2 further relapses and her MRI demonstrated multiple 
new T2 lesions and 6 Gadolinium-enhancing lesions. Her second 
course of treatment has been successful, achieving current disease 
stability.
Case 2: A 43-year old female with relapsing remitting MS was 
escalated from Interferon beta to Fingolimod and had been stable 
for 3 years. She subsequently developed clinical and radiological 
disease activity and was switched to Alemtuzumab. In view of the 
risk of treatment failure, a 12-week washout period was instituted, 
with a pulse of Methylprednisolone at 8 weeks to reduce the 
chance of rebound disease. On cessation of Fingolimod, MRI dis-
ease activity was noted at 8 weeks and clinical disease activity at 
12 weeks. The first course of Alemtuzumab however was success-
ful with no clinical or radiological disease activity.
Conclusion: The complexity of managing MS patients with 
disease modifying treatments, and especially of managing the 
complications of switching between treatments is rapidly 
evolving. We present an example of treatment failure following 
escalation from Fingolimod to Alemtuzumab. We discuss a 
treatment strategy that includes an extended washout period 
with corticosteroid cover, to balance the risk of potential 
Alemtuzumab treatment failure against Fingolimod withdrawal 
rebound disease activity.
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Background: Neuromyelitis Optica Spectrum Disorders 
(NMOSD) is an autoimmune disease of the central nervous sys-
tem considered rare in some countries. Due to the high risk for 
disability, maintenance therapy is required to avoid further attacks. 
In Venezuela the treatment is based on immunosuppressant drugs 
Azathioprine, Mycophenolate Mofetil and low oral dose of corti-
costeroids. Because other types of drugs like Rituximab, a mono-
clonal antibody is not provided by the Social Security for this 
disease. There has been an abrupt discontinuation in the availabil-
ity of these drugs.
Objectives: To demonstrate that the interruption of the immuno-
suppressive drug maintenance treatment in NMOSD is related to 
increased risk of relapses.
Methods: A Retrospective study including 40 consecutive 
NMOSD patients was performed in Venezuela. Demographic, 
clinical, number of relapses, serological status, inmunossupresor 
treatment with Azathioprine and Mycofenolate Mofetil between 
April 2015 and April 2016 were analyzed.
Results: Of 40 female Venezuelan relapsing NMOSD patients, in 
maintenance treatment with Azathioprine and Mycophenolato 
Mofetil 42%(n=17) stopped or decreased the dose of the drugs: 94 
%(n=16) of them had a stable disease with an annualized rate of 
0.67 and only 6%(n=1) had aggressive course with this treatment, 
Azathioprine 64%(n=11) and Mycophenolate Mofetil 35%(n=6). 
From the patients that suspend the treatment 94% (n=16) had a 
relapse between 30 to 90 days.
Conclusion: It is recommended to maintain an effective dose of 
the immunosuppressive treatment with Azathioprine and 
Mycofenolate Mofetil in patients with relapsing NMOSD, in 
order to avoid relapses and progression.
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How neurologists approach the therapeutic choice in mul-
tiple sclerosis: preliminary results of an Italian survey
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Background: Risk propensity, determined by contextual and per-
sonality factors, plays a role in the therapeutic choice of a person 
with multiple sclerosis(PwMS), due to difficulties in the percep-
tion and evaluation of benefit-risk ratio of available disease-mod-
ifying therapies(DMT). However, nothing is known about its 
possible role on physicians facing the choice of a DMT.
Aim: To evaluate risk propensity in a cohort of neurologists work-
ing with PwMS.
Materials: A questionnaire composed of:
a) Socio-demographical/professional questions;
b) Control Preferences Scale(CPS) adapted to physicians;
c) Metacognitive Functions Screening Scale-30(MFSS-30);
d) Zuckerman-Kuhlman Personality Questionnaire(ZKPQ);
e) Questions about levels of luck/depression/optimism 
before and after a potential MS diagnosis;
f) Questions and decision trees about admissible levels of 
severe disability and death risks in response to different 
pharmacological profiles;
g) Original CPS.
Methods: So far, sixty Italian physicians, previously contacted by 
mail, filled in the questionnaire, completing the ‘a-d’ section, con-
sidering their role of neurologist and the ‘e-g’ section, making the 
effort of being a potential PwMS.
Results: Subjects, aged between 26 and 65, had a mean MS 
experience(MSE) of 12.8±8.4 years and an experience of adverse 
events(EAE) of 77%. Two of them were eliminated from the e-g 
section analysis, due to potential metacognitive dysfunctions 
identified with MFSS-30. The included subjects declared they 
would feel significantly less fortunate, optimist and more 
depressed after an MS diagnosis. To gain 2 years of disease stabil-
ity they would accept a therapy with a risk of severe disability and 
death of 2.3% and 1.0%, respectively; while they would accept up 
to 3.3% and 2.0%, to gain 4years. MS progression is the risk 
which mainly worries 40% of neurologists, followed by 
PML(30%) and leukemia(23%). These results correlate only par-
tially with ZKPQ impulsive sensation seeking, without relations 
with age, gender, MSE, EAE and professional experience. An 
active patient’s role and a shared one were preferred, respectively, 
by 53% and 45% of the neurologists, with consistent results 
switching to the potential patient condition.
Conclusions: In Italian neurologists working with PwMS, risk pro-
pensity is mainly related to personality and not to contextual factors, 
suggesting the importance of the self-awareness, alongside with the 
professional knowledge, in approaching to therapeutic choice.
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D. French6
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Background: The proportion of people with relapsing forms of 
multiple sclerosis prescribed disease modifying treatments 
(DMTs) in the United Kingdom is considered low compared with 
other countries. National surveys also indicate large differences 
between UK regions (England, Wales, Scotland, Northern Ireland) 
in the proportion of people eligible for DMTs who are prescribed 
these medications. Despite this, there has been little research into 
factors influencing prescribing which could explain variation in 
treatment rates, and very few studies of clinicians’ views, deci-
sion-making processes, and prescribing practices. This study aims 
to investigate the experiences of neurologists who prescribe 
DMTs and MS specialist nurses who help patients access these 
drugs, to identify factors influencing prescribing and uptake of 
DMTs.
Methods: Semi-structured hour-long interviews were conducted 
with 18 consultant neurologists and 16 specialist nurses. 
Participants were purposively sampled from diverse National 
Health Service (NHS) settings across the four UK nations. 
Interview transcripts were analysed using a thematic framework 
analysis.
Results: Prescribing of DMTs is influenced by organisational, 
inter-professional, and individual factors. Services differed in 
procedures for identifying relapses, role of MS nurses in ascer-
taining eligibility for DMTs and facilitating patients’ decisions, 
and responsibilities of general neurologists versus MS special-
ist neurologists. Individual prescribing practices are influenced 
by organisational prescribing “cultures”, informal “bench-
marking” within peer networks, and prior experience with dif-
ferent DMTs, though non-specialist clinicians prescribing in 
isolation may miss out on these influences. Prescribers differ in 
their perceptions of the benefits and risks of DMTs, their pref-
erences for managing patient decision-making, and personal 
“thresholds” for discerning relapses and determining eligibility 
for DMTs according to treatment guidelines. These individual 
differences influence conversations with patients and the 
strength of treatment recommendations. Variation in practice 
was more evident between prescribing centres and between 
individual prescribers than between UK regions.
Conclusions: These findings reveal organisational and individual 
differences in DMT prescribing practices, which have implica-
tions for equitability of care for people with relapsing multiple 
sclerosis seeking disease modifying therapy.
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Natalizumab treatment is associated with improved patient-
reported outcomes in the treatment of multiple sclerosis: 
results from a systematic literature review
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Huang4, M. Jhaveri5, L. Lee5, S. Licata5, S. Naoshy5
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2Department of Neurology, University of Colorado School 
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Background: With over 10 years of post-marketing experience, 
natalizumab (NTZ) has well-established efficacy and long-term 
safety in relapsing-remitting multiple sclerosis patients. In addi-
tion to demonstrating the effectiveness of NTZ in significantly 
delaying and improving disability, clinical trials and real-world 
observational studies have shown significant improvement in 
patient-reported outcomes (PROs). These measures complement 
clinician-reported data and provide data on treatment impact from 
the patient perspective.
Objectives: To identify, synthesize, and summarise available 
PRO data for multiple sclerosis (MS) patients treated with NTZ.
Methods: A systematic search of the peer-reviewed Embase, 
Medline, and Cochrane databases (January 2006-April 2017), and 
conference proceedings (2015, 2016), was performed. Selection 
of eligible studies, data extraction, and quality assessment were 
undertaken independently by 2 researchers. Selection criteria 
included studies of NTZ-treated adults with MS that reported on 
any PRO outcome.
Results: Thirty-seven publications were identified, which 
included sample sizes ranging from 9 - 2,822 participants. The 
most frequently assessed domains included mental/psychosocial 
(16 studies), fatigue (16 studies), physical functioning (15 stud-
ies), depression (14 studies) and overall health-related quality of 
life (HRQoL) (9 studies). The most frequently used PROs 
included the MS Impact Scale (7 studies), Beck Depression 
Inventory (7 studies), Fatigue Scale for Motor and Cognitive 
Functions (6 studies) and Fatigue Severity Scale (6 studies). 
Changes in PRO scores were primarily examined over 6 months 
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to 5 years. NTZ generally improved HRQoL, physical function-
ing, cognition, depression, work productivity, bladder function 
and fatigue as compared to baseline scores. Eleven studies pre-
sented results comparing NTZ-treated patients to those being 
treated with other disease-modifying agents (DMTs), primarily 
interferon and fingolimod. The majority of these comparative 
studies favoured NTZ over other DMTs in the assessed domains.
Conclusion: Over the last 10 years, NTZ has demonstrated an 
improvement in PROs in most major domains of physical, emo-
tional and symptom assessment. The analysis of these relevant 
PROs will help enable more informed health care decision-mak-
ing beyond the traditional clinical endpoints.
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1Centro Hospitalar e Universitário de Coimbra, Coimbra, 
2Centro Hospitalar de São João, Porto, 3Centro Hospitalar 
Lisboa Norte, 4Centro Hospitalar Lisboa Ocidental, 5Centro 
Hospitalar Lisboa Central, Lisboa, 6Hospital Professor Doutor 
Fernando Fonseca, Amadora, 7Hospital de Braga, Braga, 
8Centro Hospitalar Vila Nova de Gaia, Gaia, 9Centro Hospitalar 
Porto, Porto, 10Novartis Farma, Lisboa, Portugal
Background: Fingolimod is a sphingosine 1-phospahte receptor 
(S1PR) modulator, approved for the treatment of RRMS in over 
80 countries, including Portugal since March 2012. The increas-
ing experience with fingolimod allows the collection of local 
real-world evidence (RWE) data to evaluate fingolimod’s clinical 
impact in the local setting.
Objective: To collect retrospective RWE from the clinical records 
of RRMS patients concerning the efficacy of fingolimod treatment.
Methods: 275 patients with RRMS from 9 centers across Portugal. 
The neurologists from the participant sites have reviewed all the 
clinical histories from patients being treated with fingolimod for 
at least 12 months.
Results: The median (IQR) age of the patients was 41.0 (12.0 
years), ranging from 18 to 78 years. When analyzed as percentage, 
relapse-free patients increased steadily and significantly up to the 
3rd year after switching to fingolimod. The percentage of patients 
free from relapses increased significantly over the years after fin-
golimod treatment when compared to the previous year, reaching 
91% after 3 years compared to 45%, one year prior to starting 
fingolimod treatment. Regarding EDSS, these patients remain sta-
ble over the 3 years.
Conclusions: The results from the REALMS study support the 
clinical efficacy of fingolimod that is demonstrated in phase III 
clinical trials and with real-world evidence data.
Disclosure
This study was funded by Novartis Farma, Portugal
Dra. Sónia Batista received compensation from Biogen, Genzyme, 
Merck Serono, Novartis Roche, Teva; Dr. Carla C. Nunes received 
compensation from Novartis, Biogen and Sanofi Genzyme; Prof. João 
de Sá received compensation for consultant and research support from 
Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche Teva; Dr. 
Vasco Salgado received compensation from Biogen, Boehringer 
Ingelheim, Genzyme Merck Serono, Novartis, Roche, Servier, Teva; 
Dra.Ana Sofia Correia received an educational sponsorship from 
Merck Serono, consultant and speaking fees from Novartis, Biogen 
Idec and Merck, as well as research support from Biogen Idec; Dr. J. 
Sequeira has received personal compensation for activities with 
Bayer, Biogen, Genzyme, Merck, Novartis and Teva; Prof. Ana 
Martins da Silva received compensation from Bayer, Biogen, 
Genzyme, Merck Serono, Novartis, Roche, Teva; Prof. João Cerqueira 
received compensation from Bayer, Biogen, Genzyme, Merck Serono, 
Novartis, Roche, Teva; Dr. Joaquim Pinheiro received compensation 
from Bayer, Biogen, Genzyme, Merck Serono, Novartis, Teva; Dra. 
Teresa Mendonça received compensation from Bayer, Biogen, 
Genzyme, Merck Serono, Novartis, Teva; Dra. Lívia Sousa received 
compensation as consultant, research support and advisory Board 
from Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche, 
Teva. Andreia Costa is employee of Novartis Farma,Portugal
EP1800
Bicycle ergometry does not improve verbal memory in mild 
relapsing remitting MS - results of a RCT
L. Baquet1, H. Hasselmann2, S. Patra1, J. Poettgen1, J.-P. 
Stellmann1, A. Engel1, S.-M. Gold1,2, G. Nolte1, K.-H. Schulz1, 
C. Heesen1
1UMC Hamburg Eppendorf, Hamburg, 2Charite 
Universitätsmedizin Berlin, Berlin, Germany
Background: Research in ageing and early dementia indicates a 
potentially protective effect of aerobic training on cognition. 
However, very few exercise intervention studies have been per-
formed in MS focusing cognitive functioning. A previous pilot 
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study in progressive MS has shown improved verbal learning and 
delayed recall as well as improvements in other cognitive and 
neuropsychiatric symptoms.
Objective and methods: This study aimed to confirm beneficial 
effects of exercise on cognition in a randomized waitlist control 
study of relapsing-remitting MS patients. The primary outcome 
was verbal memory (Verbal learning and memory test, VLMT, 
learning and recall condition). Secondary outcomes were 
VO2peak and VO2peak/kg as well as 7 other cognitive measures 
of attention, information processing and visuospatial memory. 
Patients were randomized to 12-week training or a waitlist control 
group. Patients in the training group exercised according to an 
individually tailored training plan (based on cardiorespiratory fit-
ness by ramp ergometry at baseline, t0). The training was aimed at 
2-3 sessions per week until week 12 (t1). with a follow-up at week 
24 (t2). ANCOVA analysis was performed controlling for baseline 
scores based on the intention-to-treat dataset and missing data 
imputed by last-observation-carried-forward (LOCF).
Results: From 77 screened RRMS patients 57 patients (69% female, 
mean age 39 years, mean disease duration 5.7 years, median EDSS 
1.5) (CG n= 27; IG n=30) completed the core study (t0-t1). All IG 
patients performed training intervention, however only 22 outnum-
bered 18 training sessions Median number of training session was 
22. While in general cognitive impairment was low, VLMT scores 
were not improved through the intervention. Work load increased 
during the training but only VO2peak/kg was significantly induced 
in the IG from t0-t2 (time by group interaction F=3.307; p=.045).
Conclusion: This study could not confirm previous data on 
improving verbal learning and delayed recall through an exercise 
intervention. A possible explanation is that the cohort was only 
mildly disabled and and without substantial cognitive impairment 
at baseline. Similar to aging individuals the impact of exercise on 
different cognitive domains might differ based on MS disease 
stage. Per protocol data analysis and other secondary outcome 
measure analysis is ongoing.
Disclosure
L. Baquet: nothing to disclose.
H. Hasselmann: nothing to disclose.
S. Patra: nothing to disclose.
J. Poettgen: nothing to disclose.
J.P. Stellmann has received speaker honorarries and travel grants 
from Biogen, Genzyme, Merk, Novartis.
A. Engel: nothing to disclose.
G. Nolte: nothing to disclose.
SM Gold: nothing to disclose.
K.H. Schulz: nothing to disclose.
C. Heesen: has received speaker honorarries and travel grants 
from Biogen, Genzyme, Merk, Novartis, Roche.
EP1801
Treatment patterns of disease modifying therapies in MS 
PATHS (Multiple Sclerosis Partners Advancing Technology 
and Health Solutions)
B.C. Kieseier1, M. Hyland2, J.R. Williams3, C. de Moor3, G.A. 
Phillips3, R. Rudick3
1Biogen International GmbH, Zug, Switzerland, 2University of 
Rochester Medical Center, Rochester, NY, 3Biogen, Cambridge, 
MA, United States
Background: Use of disease modifying therapy in real-world MS 
populations is heterogeneous, reflecting physician and patient 
preferences, and health system considerations. For example, in the 
single-centre EPIC cohort, 40.4% of patients were not on a dis-
ease modifying therapy (DMT) at baseline, while in MSBase, an 
international multi-centre cohort, 21.9% of patients were not on a 
DMT. Variability in DMT use across practices, regions, and coun-
tries has received little systematic study to date. Important con-
founders or biases (i.e. channelling bias) may underlie this 
variability and should be taken into account conducting observa-
tional patient outcomes research.
Objectives: To describe treatment patterns and associated demo-
graphic and clinical characteristics among patients participating in 
the MS PATHS network.
Methods: During routine clinic visits patients answered standard-
ized questionnaires, including use of DMTs, using the MS 
Performance Test, an iPad-based device. Current DMT use, 
patient demographics, and MS characteristics were characterized 
and analyzed using descriptive statistics, ANOVA, and Chi-square 
tests of independence
Results: The sample comprised 1353 patients. Mean (SD) age 
was 48.9 (12.0), disease duration 12.2 years (9.4), age of diagno-
sis was 36.4 (10.9) and PDDS was 2.4 (2.2). 19.2% of patients 
reported no current DMT use. This group was older and more 
disabled compared to the 80.2% of patients who reported current 
DMT use. The five most common DMTs (in descending order) 
were dimethyl fumarate, fingolimod, glatiramer acetate, natali-
zumab and interferons. In comparison, the five most common 
DMTs based on US market estimates were glatiramer acetate, 
interferons, dimethyl fumarate, fingolimod and natalizumab. 
Within MS PATHS the longest disease duration (mean=17.5 
years, sd=10.5) and the lowest PDDS scores (1.5, 2.0) were 
among interferon patients; the youngest age (42.0, 10.2) was 
observed among natalizumab patients.
Conclusions: DMT use patterns differed in the MS PATHS net-
work sites compared with external benchmarks. Overall DMT use 
was similar to MSBase, but higher than reported from EPIC. 
Glatiramer acetate and interferon use was less frequent in MS 
PATHS sites compared to US market estimates. MS PATHS inter-
feron users had longer disease duration and lower disability 
scores. Factors relating to treatment pattern heterogeneity across 
the international network will be presented.
Disclosure
Project funded by Biogen, Inc.
Bernd C. Kieseier, James R. Williams, Carl de Moor, Glenn A. 
Phillips and Richard Rudick are employees of, and stockholders 
in, Biogen.
Megan Hyland is employed by the University of Rochester which 
receives funding from Biogen, Chugai and Novartis.
EP1802
The effect of pilates training and massage therapy on plasma 
serum levels of IL_17 and IFNβ as pro- inflammatory cyto-
kines in patients with multiple sclerosis (MS)
K. Mehrvar1, B. Ghorbanian2, A. Mahmoudpoor3
1Neurology, Neuroisciences Research Center,Tabriz University 
of Medical Sciences, 2Sport Sciences, Faculty of Education 
and Psychology, 3Sport Sciences, Faculty ot Education and 
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Psychology, Azarbaijan Shahid Madani University, Tabriz, 
Islamic Republic of Iran
Background: Multiple Sclerosis (MS) is a chronic, debilitating 
nervous system disease, which damages the myelin of the central 
nervous system. The most common symptoms include fatigue, 
muscle spasms, tremors, double vision, lack of balance, and 
impaired walking. Cytokines play an important role in the patho-
genesis of the disease and are considered an important objective 
for therapeutic in tervention. IL_17 has a direct relationship with 
MS. On the other hand, IFNβ plays a key role in MS improvement. 
This article aimed to study The effect of Pilates training and mas-
sage therapy on plasma serum levels of IL_17 and IFNβ as pro- 
inflammatory cytokines in patients with multiple sclerosis (MS).
Methods: This is a clinical trial. A total of 36 women- who had 
medical file in Multiple Sclerosis society of Tabriz, Iran - were 
enrolled as the sample. The degree of the disease was between 0 and 
4/5. The average length of disease was 2±7 and the patients were 
between 30 and 40 years old. Selected and split in to 4 groups. 
Massage (n=9), pilates (n=9), pilates + massage (n=9), and a control 
(n=9). they were randomly assigned to Pilates and Massage groups. 
Exercise lasted for 8 weeks, 3 times a week. Each session lasted 
40- 60 minutes: 20-40 minutes for Pilates and 20 -30 minutes for 
massage. Blood samples were taken before and after intervention 
and massage in order to messure the blood variables. Serum levels 
of IL_17 cytokine and IFNβ were measured using the ELISA. The 
data were analyzed by correlated t-test and ANOVA using spss20. 
The significance level was considered.(p< 0/05).
Results: Showed that 8 weeks of Pilates and Massage caused a 
significant decline in IL_17 in Pilates, Massage, and Pilates + 
Massage groups. IFNβ also increase in Massage and Massge + 
Pilates groups. (P< 0/05).
Conclusion: Since Pilates coupled with Massge reduced pro- 
inflammatory IL_17 cytokine and increase IFNβ of MS patients, 
it seems that Pilates and Massage can beused as a complementary 
treatment along with other drug therapies for preventing the pro-
gress of MS.
Disclosure
Kaveh Mehrvar: nothing to disclose
Bahlool Gorbanian: nothing to disclose
Akram Mahmoudpoor: nothing to disclose
EP1803
Early MRI findings during disease rebound in a natali-
zumab-treated MS patient and follow-up during transition to 
alemtuzumab
J.L. Gross1,2,3, D.M. Zagar1, N.A. Blondin1, A.K. Jacobs4, C.E. 
Rodriguez4, D. Pelletier5
1Associated Neurologists of Southern Connecticut, Fairfield, 2St 
Vincent Medical Center, Bridgeport, 3Quinnipiac University, 
North Haven, CT, 4Sanofi, Cambridge, MA, 5Keck School of 
Medicine of University of Southern California, Los Angeles, CA, 
United States
Background and goal: To report early MRI findings in a clini-
cally unstable patient with active MS following natalizumab ces-
sation and during alemtuzumab initiation.
Methods: Patient case report.
Results: The patient (female, aged 39) had a 21-year history of 
MS, including periventricular T2 lesions, multiple T1 lesions, 
and signs of brain tissue loss. Prior MS treatments included SC 
and IM IFNB-1a, SC IFNB-1b, glatiramer acetate, fingolimod, 
and 2 separate periods of natalizumab (total: 75 cycles; discon-
tinued due to disease activity and John Cunningham virus [JCV] 
antibody positivity). Three months after natalizumab cessation, 
the patient was hospitalised with severe relapse (dysarthria, 
diplopia, right hemiparesis); MRI showed a new, non-Gd-
enhancing left midbrain lesion. Methylprednisolone and IVIG 
were administered. Two weeks later, the patient was confused, 
unable to walk, and LP showed red blood cells (RBC) 2/µL, 
white blood cells (WBC) 13/µL, protein 39 mg/dL, glucose 52 
mg/dL, oligoclonal band-positive, and JCV PCR-negative 
(ARUP Laboratories). One week before alemtuzumab initia-
tion, right hemiparesis had worsened; patient was lethargic and 
nonambulatory. Alemtuzumab Course 1
(12 mg; 5 consecutive days) was started 4.5 months after natali-
zumab cessation. On alemtuzumab
Day 3, decreased mentation, lethargy, poorly reactive left pupil, 
severe dysarthria, and right hemiparesis were noted. MRI after 
alemtuzumab Day 5 showed prominent diffuse T2 signals in 
juxtacortical regions of left temporal, parietal and occipital 
lobes, and right cerebellum. These lesions were not 
Gd-enhancing and were evident on diffusion-weighted imaging. 
Progressive multifocal leukoencephalopathy (PML) was con-
sidered; repeat CSF 10 days later demonstrated: RBC 14/µL, 
WBC 0/µL, protein 47 mg/dL, glucose 68 mg/dL, JCV PCR-
negative (Quest Diagnostics). MRI 3 months post-alemtuzumab 
showed substantial resolution of previous diffuse T2 changes. 
At last follow-up 5.5 months post-alemtuzumab, clinical signs 
were improved with minimal dysarthria, mild right hemiparesis, 
and unassisted walking.
Conclusion: The basis of this patient’s distinct MRI after discon-
tinuing natalizumab is uncertain. Subsequent clinical and radio-
logical improvement after alemtuzumab initiation indicates an 
explanation other than PML. This isolated case may suggest a 
beneficial role for alemtuzumab in a clinically unstable patient 
after natalizumab cessation, where a return of MS activity is occa-
sionally observed.
Study support: None.
Disclosure
JLG: Promotional speaker (Biogen, Mallinckrodt, Novartis, 
Sanofi Genzyme, and Teva); advisory board participant (Biogen, 
Genentech, Mallinckrodt, Novartis, Sanofi Genzyme, Serono, and 
Teva); clinical investigator (Biogen, Genentech, Novartis, and 
Sanofi Genzyme).
DMZ: Clinical investigator (Biogen, Genentech, Novartis, and 
Sanofi Genzyme).
NAB: Advisory board participant and consultant (Novocure, Inc).
AKJ, CER: Employees of Sanofi.
DP: Advisory board participant (EMD Serono, Novartis, Roche, 
Sanofi Genzyme, TG Therapeutics, and Vertex); grant/research 
support (Biogen).
Editorial support was provided by Richard Hogan, PhD, and 
Linda Wychowski, PhD, Envision Scientific Solutions, and was 
funded by Sanofi
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Success of a CME-certified patient-physician video vignette 
in improving knowledge of clinical factors for the personal-
ization of treatment selection in ms among neurologists
T. Finnegan1, G. Dolson2, S. Krieger3
1Medscape Education, Medscape, LLC, Glenside, PA, 
2Medscape Education, Medscape, LLC, 3Icahn School of 
Medicine at Mount Sinai, New York, NY, United States
Introduction: Clinicians who care for patients with multiple scle-
rosis (MS) are in need of education that shows the clinical imple-
mentation of best practices for optimizing the personalization of 
treatment using available pharmacologic options. The goal of this 
study was to measure the effectiveness of an interactive, continu-
ing medical education (CME)-certified, online, case-based video 
vignette with integrated expert perspectives to improve the knowl-
edge of neurologists regarding clinical factors that impact treat-
ment selection in MS.
Methods: The activity consisted of a single patient-physician 
video vignette that included 4 interactivity questions and expert 
faculty guidance on the elements of the case. The study design 
compared each participant´s responses to questions posed before 
exposure to educational content (pre-assessment measurement) 
with the same participants´ responses to the same questions after 
exposure to the educational content (post-assessment measure-
ment). McNemar’s chi-square test assessed differences from pre- 
to post-assessment. Cramer’s V determined the effect size. The 
activity launched online on December 14, 2016, and data were 
collected through March 5, 2017.
Results: Comparison of answers before and after exposure to 
the educational activity demonstrated significant improve-
ments in evidence-based decision making, with a medium edu-
cational effect size (n=77; V=0.24; P< .001). As a result of 
participation, significant overall improvements were observed 
in several specific areas, including knowledge of the John 
Cunningham (JC)-virus index value that corresponds to the 
2-year risk of PML in patients receiving natalizumab (174% 
relative improvement;
P < .05), identification of the safest disease modifying therapy 
(DMT) for pregnancy based on the ability to cross the placenta 
(17% relative improvement; P < .05), and the appropriate use 
of high-dose steroids to treat an acute relapse during pregnancy 
(35% relative improvement; P < .05). Participation in the activ-
ity resulted in a 22% improvement in confidence among neu-
rologists in identifying when to switch DMTs in a patient with 
MS.
Conclusion: The CME intervention was successful in improving 
participating neurologists’ knowledge and confidence in their 
ability to make evidence based, personalized treatment decisions 
for patients with MS. Subsequent education should address the 
practical application of the JC virus index.
Disclosure
Thomas F Finnegan: Nothing to disclose
Gena Dolson: Nothing to disclose
Stephen Krieger served as an advisor or consultant for: Acorda 
Therapeutics; Bayer HealthCare Pharmaceuticals; Biogen; 
Genentech, Inc.; Genzyme Corporation; Mallinckrodt; Novartis 
Pharmaceuticals Corporation; Teva Neuroscience, Inc.
EP1805
Patient reported adherence and treatment satisfaction in 
irish relapsing remitting multiple sclerosis patients treated 
with fingolimod
N. Murphy, K. Tyaransen, E. Horgan, R. MacIver
Novartis Pharmaceuticals, Dublin, Ireland
Objective: To assess the compliance and satisfaction in Irish 
patients taking fingolimod or relapsing-remitting multiple sclero-
sis (RRMS).
Background: Eleven disease modifying treatments are available 
in Ireland for the treatment of RRMS. Switching from one disease 
modifying therapy (DMT) to another is common in order to opti-
mise treatment.
Methods: The Irish Fingolimod Nurse Service was launched in 
Ireland in July 2012. It offers first dose observation, patient edu-
cation using motivational interviewing, blood and ophthalmology 
monitoring reminders and a free-phone helpline. Data was col-
lected via a postal survey that was sent to 400 patients who signed 
up to the Nurse Service and who agreed to be contacted for fol-
low-up. 167 patients returned a completed survey.
Results: 73.1% (n=122) of respondents were previously treated 
with another DMT, with 25.1% receiving fingolimod as their first 
treatment. In patients who were treatment naïve, the average time 
from diagnosis to initiation of fingolimod was 2.5 years (range:1-
16 years), in patients who were previously treated with another 
DMT, the average time from diagnosis was 8.8 years (range: 1 - 
41 years) Respondents switching to fingolimod from another 
DMT, mostly switched from an injectable DMT (iDMT) (76.2%), 
10.7% switched from natalizumab and 9.8% switched from an 
oral DMT (teriflunomide or dimethyl fumarate). Lack of efficacy 
was reported as the most common reason for switching (60%). 
Respondents were treated with fingolimod for an average of 
16.8±10.9 months. On a 100 point scale, patients who switched 
from a previous DMT scored their treatment satisfaction with fin-
golimod at an average of 87.5, while scoring their previous treat-
ment, 45.8. Respondents who were treatment naïve scored their 
satisfaction at 86.4. 92.1% of patients reported that they remem-
ber to take their fingolimod tablet every day. The 7.9% who 
reported forgetting to take their treatment, missed 1.3 tablets per 
month on average.
Conclusion: Fingolimod is an option for RRMS patients switch-
ing drug modifying therapy with high patient satisfaction and sig-
nificant rates of adherence.
Disclosure
Niamh Murphy is an employee of Novartis
Ruth MacIver is an employee of Novartis
Emma Horgan is an employee of Novartis
Kate Tyaransen is an employee of Novartis
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Comparison of injection site reactions and flu-like symptoms 
between users of peginterferon beta-1a and subcutaneous 
interferon beta-1a among persons with multiple sclerosis in 
the New York State Multiple Sclerosis Consortium
C. Vaughn1,2,3, K. Kavak1,3, A. Bushra3, M. Nadeem3, K. 
Zakalik1,3, B. Teter1, B. Weinstock-Guttman1,2,3
1New York State Multiple Sclerosis Consortium, 2Neurology, 
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State University of New York at Buffalo, 3Jacobs MS Center for 
Treatment and Research, Buffalo, NY, United States
Background: Interferon beta-1a is one of the most commonly 
prescribed disease modifying therapies (DMTs) to treat persons 
with multiple sclerosis (pwMS). However, use of these products is 
often accompanied by systemic symptoms and/or reactions. 
Comparing the tolerability of these medications in pwMS will 
provide valuable information to help clinicians and patients be 
better informed when considering specific therapeutic 
interventions.
Objective: Our objective was to evaluate and compare the pres-
ence of injection site reactions (ISR) and flu-like symptoms (FLS) 
between users of peginterferon beta-1a (PegIFN beta-1a) and sub-
cutaneous (sq) interferon beta-1a tiw (SQ IFN beta-1a tiw).
Methods: Patients were part of the Tolerability study; an ancil-
lary study of the New York State Multiple Sclerosis Consortium 
(NYSMSC). Of the 87 patients who have provided data to date, 
50 (57.5%) used PegIFN beta-1a; while 37 (42.5%) used SQ 
IFN beta-1a tiw. Frequencies of FLS and ISR were calculated 
and compared between the PegIFN beta-1a users and SQ IFN 
beta-1a tiw group using Chi-square analysis. Furthermore, the 
severity of FLS and ISR were compared using a Mann-Whitney 
U test.
Results: There were no significant group differences with respect 
to age (mean overall=50.4 years, SD=12.1), sex (female n=61, 
70.1%), disease duration (median= 12.4 years) or EDSS scores at 
baseline (median=3.0). FLS were reported in 33 (66.0%) PegIFN 
beta-1a users and 20 (54.1%) patients using SQ IFN beta-1a tiw 
(p=not significant [NS]). Median duration of FLS in the PegIFN 
beta-1a group was slightly longer than in the SQ IFN beta-1a tiw 
group (13-18 hours versus 0-6 respectively, p-value=0.004). ISRs 
were reported in the majority of patients in this study (46 [93.9%] 
in the PegIFN beta-1a group, 31 [83.8%] in the SQ IFN beta-1a 
tiw, p= NS). ISR redness was more frequently reported among 
patients using PegIFN beta-1a than interferon beta-1a users (46 
[95.8%] vs 28 [75.7%] respectively, p=.006). Additionally, the 
severity of redness was more severe among PegIFN beta-1a users 
(median=3.0 vs 2.0, [0-5 scale], p< .001). There were no other 
group differences in reported symptoms or severity of symptoms. 
Conclusions: On the whole, ISR and FLS are common among 
users of both types of IFN products. However, ISR redness was 
more frequently reported among PegIFN beta-1a users and dura-
tion of FLS was slightly longer in this group as well compared to 
users of SQ IFN beta-1a tiw.
Disclosure
This study was sponsored by EMD Serono, Inc., Rockland, MA
Caila B Vaughn has nothing to disclose.
Katelyn S Kavak has nothing to disclose.
Aisha Bushra has nothing to disclose.
Muhammad Nadeem has nothing to disclose.
Karen Zakalik has nothing to disclose.
Barbara E Teter has received grant and/or research support from 
Biogen Idec, Teva Neuroscience, EMD Serono, Avanir, Genzyme 
and Novartis.
Bianca Weinstock-Guttman has received honoraria as a speaker 
and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD 
Serono, Genzyme, Sanofi, Novartis and Acorda Therapeutics. Dr. 
Weinstock-Guttman has received research funds from Biogen 
Idec, Teva Pharmaceuticals, EMD Serono, Genzyme, Sanofi, 
Novartis and Acorda Therapeutics.
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BetaEval Global: prospective, non-interventional,  
multinational, observational cohort study of patients  
using BETACONNECT
F. Patti1, M.L. Martínez Ginés2, C. Norenberg3, F. Duarte Caron4
1Department of Medical and Surgical Sciences and Advanced 
Technologies, GF Ingrassia; Multiple Sclerosis Center, 
University of Catania, Catania, Italy, 2Department of Neurology, 
University Hospital Gregorio Marañón, Madrid, Spain, 3Bayer 
AG, Wuppertal, Germany, 4Bayer HealthCare Pharmaceuticals, 
Whippany, NJ, United States
Introduction: BETACONNECT™ is an electronic autoinjector 
with communication capabilities that may help patients to remain 
adherent to interferon beta-1b.
Methods: Adherence (defined as completing ≥80% of prescribed 
injections) was assessed via autoinjector recordings over 24 
weeks with visits at baseline, week 4, week 12 and week 24 in 
patients with relapsing-remitting MS (RRMS) or clinically iso-
lated syndrome (CIS) who were treated with interferon beta-1b 
using BETACONNECT.
Results: 500 patients were enrolled with 498 in the full analysis 
set (median age: 44 years; 64.6% female, 28.8% completed col-
lege or university education). 474 patients (94.8%) were diag-
nosed with RRMS and 26 (5.2%) were diagnosed with CIS, with 
a median disease duration of 76.1 and 22.7 months, respectively. 
Median baseline EDSS score was 1.5 (N=449). Median adher-
ence remained stable between 93.9% and 95.4% at all visits. 
76.4%, 67.6%, and 81.1% of patients with non-missing data had 
≥80% of planned injections recorded for study visits 1, 2, and 3, 
respectively. Multivariate logistic regression models indicated 
that higher adherence was associated with male gender, existing 
concomitant disease, shorter disease duration, higher SDMT 
score and higher satisfaction with the myBETAapp. 81.4% com-
pleted the study. The main reasons for study discontinuation 
were: switching to another injection method (25.8%), with-
drawal of consent (22.6%) and becoming lost to follow up 
(17.2%). 83.4% of the patients still used BETACONNECT at 
their final visit.
Discussion: BetaEval Global showed a relatively high rate of 
adherence among patients with RRMS or CIS using 
BETACONNECT to administer interferon beta-1b. Additional 
research will explore device satisfaction and outcomes in patients 
using the autoinjector.
Disclosure
This study was supported by Bayer AG.
F Patti served as an advisor for Almirall, Bayer, Biogen, Merck, 
Novartis, Sanofi Genzyme and TEVA and received grants for 
speaking activities from the same companies.
M Martinez-Gines has received compensation for her contribution 
to the BetaEval Global study to the account of the Department of 
Neurology, Hospital General Universitario Gregorio Marañón-
Madrid, by Bayer.
C Norenberg is a salaried employee of Bayer AG.
F Duarte Caron is a salaried employee of Bayer Healthcare.
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EP1808
Validation of the English translation of the Swedish symptom 
frequency intensity and distress (SFID) scale in persons with 
multiple sclerosis (PwMS) on interferon beta therapy
C.S. Casserly1, D. Bowman1, K. Gottberg2, A. Gardulf3, M. 
Heisel4, S.A. Morrow1
1Department of Clinical Neurological Sciences, Western 
University, London, ON, Canada, 2Department of Neurobiology, 
Care Sciences and Society, 3Department of Laboratory 
Medicine, Karolinska Institutet, Stockholm, Sweden, 
4Department of Psychiatry, Department of Epidemiology and 
Biostatistics, Western University, London, ON, Canada
Introduction: Interferon beta therapy has been a mainstay in the 
treatment of persons with multiple sclerosis(PwMS) since the intro-
duction of the first MS disease modifying therapy, Interferon beta 
1b1 in 1993. However, a major limitation of these medications is 
their flu-like side effects(FLS). This necessitates assessment and 
monitoring of FLS in an attempt to maximize compliance.
Background: Major clinical trials2-6 have reported on FLS, but 
the frequency, severity and duration of FLS have not been well 
characterized. Gottberg et al. addressed this question using the 
Swedish Symptom Frequency, Intensity and Distress(SFID) scale 
to evaluate patients’ perceptions of the FLS experienced on inter-
feron therapy7.
Objective: To validate the English SFID scale in a population of 
PwMS starting interferon therapies, as compared to a group of 
PwMS starting glatiramer acetate.
Methods: Sixty PwMS were recruited from the London 
(Ontario, Canada) MS clinic; 26 starting on interferon beta(any 
type) vs. 34 controls starting on glatiramer acetate. Interferon 
and glatiramer groups were similar in terms of age, sex, EDSS 
and disease duration at baseline; all had relapsing remitting MS, 
were relatively young (mean age 35.8 vs. 33.1), with a low 
EDSS(median 1.5 range 0-6 vs. median 1.5 range 0-4). 
Participants completed the SFID, Hospital Anxiety and 
Depression Scale(HADS), Fatigue Severity Scale(FSS), Pain 
Effects Scale(PES), Beck Depression Inventory, Fast 
Screen(BDIFS), Satisfaction with Life Scale(SWLS), Short 
Form Survey(SF-12), Health-100 and Symbol Digit Modality 
Test(SDMT) at weeks 1-8, monthly to 6 months.
Results: SFID total scores demonstrated significant positive asso-
ciations with measures of fatigue and depression, demonstrating 
convergent validity. In contrast, there was no association between 
SFID scores and age, level of education and SDMT score, demon-
strating discriminant validity. Scores on the SFID were signifi-
cantly different between the interferon and glatiramer groups, and 
peaked in the interferon group at week 4, returning to baseline by 
month 6. The SFID scale had good internal consistency, signifi-
cant test-retest reliability, and could discriminate between partici-
pants receiving interferon vs. glatiramer.
Conclusions: The SFID is a potentially valuable tool for the eval-
uation of FLS in PwMS on interferon therapy, providing improved 
quantification of FLS, and their impact on quality of life.
Disclosure
Courtney Casserly has received personal compensation for con-
sulting for EMD Serono, Genzyme, Roche and received a travel 
grant from EMD Serono and Novartis, and received funding for 
her Clinical Fellowship from Biogen Idec, and is a co-investigator 
on clinical trials for Genzyme and Roche.
In the last two years, Dr. Morrow has received honoraria for 
speaking, consulting, and advisory board participation from 
Biogen Idec, EMD Serono, Genzyme, Novartis, and Roche. She 
has acted as site principal investigator for clinical trials for 
Novartis, Genzyme and Roche. She has received investigator ini-
tiated trial funding from Genzyme.
Denise Bowman: nothing to disclose
Marnin Heisel: nothing to disclose
Kristina Gotberg: nothing to disclose
Ann Gardulf: nothing to disclose
EP1809
Efficacy and treatment satisfaction after switching therapy in 
patients with relapsing-remitting multiple sclerosis: the mul-
ticentre, observational SURFINIA study
R. Mantegazza1, M. Ulivelli2, S. Cottone3, V. Torri Clerici1, 
M.T. Ferrò4, D. De Pascalis5, A. Veneziano6, D. Cuomo6
1Istituto Nazionale Neurologico Carlo Besta, Milan, 2Azienda 
Ospedaliera Universitaria Senese, Siena, 3Ospedali Riuniti Villa 
Sofia-Cervello, Palermo, 4Azienda Socio-Sanitaria Territoriale 
di Crema, Crema, 5Ospedale Sant’Eugenio, Roma, 6Teva Italy, 
Milan, Italy
Although disease modifying therapies (DMTs) are effective in 
patients with relapsing-remitting multiple sclerosis (RRMS), 
some patients may require switching to another DMT due to sub-
optimal efficacy and/or intolerable toxicity. This multicentre, 
observational study aimed to assess the clinical course of patients 
with RRMS who switched DMT for these reasons in a real-life 
clinical setting in Italy.
Adult patients with confirmed RRMS receiving first-line ther-
apy with a DMT who were candidates for switching according to 
their treating physician were enrolled and followed for 1 year. 
The primary endpoint was the annualized relapse rate (ARR); 
secondary endpoints included the proportion of relapse-free 
patients, time to first relapse, and patient-reported treatment sat-
isfaction (using the Treatment Satisfaction Questionnaire for 
Medication [TSQM-9]). Safety was assessed by recording 
adverse events (AEs).
A total of 150 patients were enrolled (mean age 40.2 years; 28% 
male). Compared with the mean ARR at 2 and 1 years before 
switching (0.60 ± 0.57 and 0.78 ±0.77), post-switch ARR was 
significantly decreased (0.28 ± 0.80; p< 0.0001). Patients 
switching because of treatment failure had greater mean ARR 
decreases versus those switching for other reasons when com-
pared with baseline at 2 years (−0.44 ± 0.85 vs −0.24 ± 0.91; 
p=0.04) and 1 year (−0.77 ± 1.03 vs −0.30 ± 0.96; p=0.0004) 
before switching. Relapse-free rates were 42% at 1 year before 
switching and 86% post switch (p=0.0001). Time to first relapse 
after switching therapy did not differ between patients who 
switched DMT due to treatment failure versus other reasons. 
Patients had significant improvements from baseline to 12 
months in TSQM-9 effectiveness and global satisfaction scores 
(−11.47 and −11.69; p< 0.0001); there was no difference in treat-
ment satisfaction between those switching because of treatment 
failure versus other reasons. AEs were reported in 47.3% of 
patients, while 4.0% of patients reported serious AEs. The most 
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common AEs reported were multiple sclerosis relapse (16.0%), 
influenza-like illness (8.0%) and increased transaminases 
(3.3%). Thirty-nine patients reported 68 treatment-related AEs, 
which were mostly injection-site reactions.
These results show that switching from first-line DMT therapy to 
another DMT improves relapse rates in patients with RRMS with-
out notable safety concerns, particularly in patients who switched 
DMT therapy because of therapy failure rather than other reasons.
Disclosure
Dario Cuomo and Antonella Veneziano are employees of Teva 
Italia.
The other Authors declare no competing interests.
EP1810
Knee flexor muscle strength is related to gait performance in 
women with multiple sclerosis but not for healthy women
C. Ramari, A.G. Moraes, C.B. Tauil, A.C. de David
University of Brasília, Brasília, Brazil
Background: Motor impairment in people with Multiple Sclerosis 
(MS) may result in reduced mobility and physical activity level, 
which can culminate in further disabilities. Changes in balance 
control, loss of muscle strength and gait disorders are frequent in 
MS patients. The measurement of these parameters are important 
in turn to change the way to manage exercise programs for people 
with MS.
Objectives: The purpose of this study is to compare knee muscles 
strength between women with MS and controls without MS. In 
addition, to investigate the correlation between muscle strength, 
balance and gait parameters in our sample.
Methods: 15 women with relapsing-remitting MS, EDSS (1-3), 
age=29.2(±4) y, weight=59.5(±10) kg and height=161.4(±5) cm. 
The control group was composed of 11 paired women without 
MS, age=29.1(±5.7) y, weight=60(±10.5) kg and 
height=161.5(±5.1) cm. The peak torque was measured by isoki-
netic dynamometry (Biodex System 3) in four trials for each 
angular speed (60º.s-1, 90º.s-1 and 180º.s-1), for both legs. The bal-
ance control was evaluated with a force platform (AMTI Inc) on 
upright position using a foam. The 6 minute walk test was per-
formed and total distance was calculated.
Results: Regarding knee muscles strength, MS women did not 
differ from control group. The correlation between muscle 
strength and balance was not significant. The control group 
showed strong correlation (p< 0.05) between distance and knee 
extensors (KE) strength, for all angular speeds: 60º.s-1(r=0.87), 
90º.s-1(r=0.84), 180º.s-1(r=0.82). For the MS group, not only KE 
strength revealed correlation with distance, 60º.s-1(r=0.84), 90º.s-
1(r=0.87), 180º.s-1(r=0.84), but also the knee flexors (KF) mus-
cles, 60º.s-1(r=0.86), 90º.s-1(r=0.80), 180º.s-1(r=0.80).
Discussion and conclusions: The literature report that KE strength 
is best related to walking speed in healthy subjects. However, MS 
patients KF strength is most strongly related to gait velocity and 
distance. The results of this study agree with the recent findings, 
suggesting that people with MS seems to be more dependent on KF 
muscle to walk. Our results suggest that rehabilitation protocols for 
MS patients must include strength training programs which should 
prioritize strengthening of the KF and KE muscles.
Disclosure
Cintia Ramari: nothing to disclose.
Andrea G. Moraes: nothing to disclose.
Carlos B. Tauil: nothing to disclose.
Ana C. de David: nothing to disclose.
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EP1811
Therapeutic benefit of uncobotulinum toxin A for the spastic-
ity of the triceps surae in patients with multiple sclerosis: an 
observational study on gait spatiotemporal parameters
E. Leblong1, B. Fraudet1,2, S. Petrilli1, T. Berthier1, C. Lemeur1, 
S. Gambert1, C. Anne1, B. Nicolas1, P. Gallien1
1Pôle MPR St Hélier, 2Living Lab ISAR, Rennes, France
Introduction: Few data are available on the use of botulinum 
toxin for spasticity treatment in multiple sclerosis (MS). In a pre-
vious study we found that one of the main therapeutic goals was 
the improvement ok walking, in patients suffering from spasticity 
of the triceps surae.
Method: This is a pilot observational study, with the aim to 
assess the benefit of an injection of 200 UI of uncobotulinum-
toxin A in MS patients suffering from spasticity du triceps 
surae which concern patient with MS with EDSS score lower 
than 6, needing botulinum toxin for focal spasticity of the tri-
ceps surae. The last injection, if the patient had previous botu-
linum treatment must be performed more than 3 months later. 
Outcome mesure were Goal Attainment Scale, MSWS-12 
scale, TUG, and 6mn Walk test and spatiotemporal gait param-
eters by barometric pist GaitRITE, before, 6 weeks and 3 
months after the injection.
This study was approved by the local ethic comity.
Results: We present the result of 22 patients, with a mean age of 
48.2 +/-12 years, and a mean EDSS of 4.2 (median 4.7). There 
was a significant benefit on injected (0.005) and non injected 
(0.01) step length measured by GaitRITE but not on supports dis-
tribution (0.18;0.38) especially at 3 months. It could explain the 
decrease of gait fatigability and the increase of speed 6mnWT 
(0.02) although neither TUG nor MSWS-12 were improved at 3 
months after injection. 80% of the patient had reached their objec-
tive on the GAS. At 6 weeks, spatiotemporal parameters and 
6mnWT were not significantly different even though we observed 
a significant improvement for the GAS, the MSWS-12 score 
(p=0.015), and the TUG (p=0.003).
Conclusion: it tends to confirm the interest of botulinum toxin A 
for the treatment of focal spasticity of the triceps surae with a 
significant improvement of gait especially on speed and also fati-
gability and endurance. Further studies are needed to confirm the 
place of botulinum toxin in this indication, but also the modalities 
of use in term of dosage and interval between injections. The best 
results on gait parameters are obtained after 3 months that is dif-
ferent than the results on TUG and MSWS-12.
These results support the place of botulinum toxin in the focal 
spasticity of the triceps surae in MS and are in concordance with 
the French recommendations about focal spasticity treatment. 
Botulinum toxin should probably be discussed early in the man-
agement of spasticity in MS patients.
06_MSJ731285.indd   956 13/10/2017   11:11:07 AM
ePosters 23(S3) 957
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Disclosure
nothing to disclose for every authors
EP1812
Low rates of disease-modifying therapy initiation and switch-
ing after steroid treatment of patients with MS: treatment 
patterns from a US retrospective claims-based study
M. Sanchirico1, A. Caldwell-Tarr2, P. Isikwe1, L. Hashemi1, R. 
Dufour2
1Sanofi, Cambridge, MA, 2Comprehensive Health Insights, A 
Humana Company, Louisville, KY, United States
Background: In healthcare claims databases, corticosteroid use 
in MS patients likely indicates relapse. Failure to initiate or switch 
disease-modifying therapy (DMT) after relapse activity could 
indicate clinical inertia, in which patients may not be provided 
individually optimised treatment.
Goal: To assess the presence and impact of clinical inertia in MS 
patients receiving corticosteroid treatment.
Methods: This analysis included patients with a corticosteroid 
claim (as a proxy for relapse) during the 12 months prior to the 
most recent claim with a diagnosis of MS. Treatment patterns 
were assessed based on medical and pharmacy claims.
Results: 3972 MS patients (n=3304 covered by Medicare [MC] 
and n=668 covered by commercial [CM] insurance) had ≥1 claim 
for corticosteroids during the study period; 50% (MC) and 44% 
(CM) of patients received a steroid as outpatients. Among 
patients who were on DMT before the initial steroid treatment 
(n=1517 MC; n=377 CM), DMT claims after steroid were infre-
quent (10% MC, 16% CM). Of those who did receive DMT, the 
majority did so ≤60 days post-steroid. 67% (MC) and 68% (CM) 
of patients had a follow-up physician visit ≤30 days post-steroid, 
and 83% and 81% within 60 days; 19% (MC) and 17% (CM) of 
DMT-treated patients had an MRI ≤60 days post-steroid. Rates of 
post-steroid DMT switching were low (14%-18%; MC and CM) 
even in patients with ≥2 episodes of steroid use. In the DMT-
treated MC population who switched DMT, IFNB-1a was most 
often the pre-switch DMT (34% and 27%, respectively, for 
patients with 1 and ≥2 episodes of steroid use), followed by glati-
ramer acetate (30% and 27%); patients most often switched to an 
oral DMT (88% after 1 steroid episode, 82% after ≥2 episodes). 
Patterns for follow-up care were similar in patients not treated 
with DMT prior to initial steroid; however, they were more likely 
than DMT-treated patients to have an ER visit (18% each in MC 
and CM without DMT vs 15% [MC] and 9% [CM] with DMT) or 
hospitalisation (11% and 9% without DMT vs 9% and 4% with 
DMT) ≤60 days after initial steroid. No patients newly initiated 
DMT ≤60 days after initial steroid.
Conclusion: At the time of steroid treatment, only two-thirds of 
MS patients were receiving DMT. Although acute relapse care 
and follow-up were documented, DMT initiation and switch rates 
were low, which may indicate clinical inertia among treating phy-
sicians. Further studies are needed to understand the factors driv-
ing these treatment patterns.
Study support: Sanofi
Disclosure
MS, LH, PI: Employees of Sanofi
AC-T, RD: Employees of Comprehensive Health Insights: A 
Humana Company
EP1813
Managing the transition to secondary progressive multiple 
sclerosis: a scoping review
A. Giordano1, S. Köpke2, P. Confalonieri3, G. De Luca4, 
E. Pietrolongo4, M. Trojano5, C. Tortorella5, C. Borreani6, 
M. Messmer Uccelli7, V. Torri Clerici3, L. Gitto8, A.M. 
Giovannetti3, C. Heesen9, A. Solari1, ManTra Project
1Unit of Neuroepidemiology, Foundation IRCCS Neurological 
Institute C. Besta, Milan, Italy, 2Institute of Social Medicine 
and Epidemiology, University of Lübeck, Lübeck, Germany, 
3Department of Neuroimmunology and Neuromuscular Diseases, 
Foundation IRCCS Neurological Institute C. Besta, Milan, 
4Department of Neuroscience, Imaging and Clinical Sciences, G. 
d’Annunzio University of Chieti-Pescara, Chieti, 5Departments 
of Basic Medical Sciences, Neurosciences and Sense Organs, 
University of Bari, Bari, 6Unit of Clinical Psychology, 
Foundation IRCCS Istituto Nazionale per la Cura dei Tumori, 
Milan, 7Department of Health Services and Research, Italian 
Multiple Sclerosis Association (AISM), Genoa, 8CEIS Economic 
Evaluation & HTA, Università degli Studi di Roma ‘Tor 
Vergata’, Rome, Italy, 9Department of Neurology, Institute of 
Neuroimmunology and Multiple Sclerosis, University Medical 
Center Hamburg-Eppendorf, Hamburg, Germany
Background: Approximately 50% of patients with relapsing remit-
ting multiple sclerosis (RRMS) will develop secondary progressive 
MS (SPMS) within 15 years of disease onset. The transition phase 
is characterized by a period of diagnostic uncertainty that may last 
several years. Evidence about transition to SPMS is scarce.
Objectives: The ‘Managing the Transition (ManTra)’ project 
aims to develop and test a resource for people with SPMS. As a 
preparatory step, we aimed to perform a literature review.
Methods: A scoping review was performed to map the existing lit-
erature, using the Arksey & O’Malley framework. We searched 
MEDLINE, EMBASE, PsycINFO, CINAHL, Google (selective 
search) from inception to 2017. Trial and dissertation registers were 
also searched for published and unpublished studies. We included 
primary research focused on the process of transition from RRMS 
to SPMS related to patients, carers or health professionals (HPs).
Results: Five studies fulfilled the inclusion criteria and were ana-
lysed. Of these, four (80%) were qualitative studies conducted in 
UK between 2013 and 2015, and one was a retrospective cohort 
study conducted in US in 2014, the latter aiming to characterize 
the transition to SPMS. The qualitative studies investigated the 
lived experience of adults with SPMS and documented views of 
carers and HPs during transition. Main themes identified per-
tained to reclassification of SPMS, and its consequences on 
patients, carers and HPs. Furthermore, possible strategies were 
identified to support these groups. The quality of reporting of the 
qualitative studies was good.
Conclusion: Despite the importance of this topic, only few research 
results have been published targeting the process of transition to 
SPMS, mainly focussing on qualitative studies. No interventions to 
empower and support patients, carers, and HPs are available and 
more research is needed to address this important issue. This scoping 
review will inform subsequent phases of the ManTra project.
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EP1814
Does dalfampridine trigger or worsen trigeminal neuralgia in 
multiple sclerosis patients?
S. Usar Incirli
Neurology, Dr Burhan Nalbantoglu State Hospital, Nicasia, Cyprus
Objective: To determine whether trigeminal neuralgia (TN) 
emerges or worsens with the use of dalfampridine in patients with 
multiple sclerosis (MS).
Introduction: Dalfampridine (4-aminopyridine) is a broad-spec-
trum, voltage-dependent potassium channel blocker which 
improves action potential conduction in demyelinated motor 
axons. Several studies showed that dalfampridine is effective in 
treating gait impairment in MS patients.
Methods: Thirty one clinically definite MS patients using dal-
fampridine for gait impairment participated in the study. The vari-
ables examined included age, gender, type of MS, and the 
existence of trigeminal neuralgia.
Results: Nineteen (61%) of the patients were women and twelve 
were men. 55% of the patients were diagnosed as secondary pro-
gressive, 29% relapsing remitting, and 16% primary progressive 
MS. Of the thirty one patients, five (%16) had trigeminal neural-
gia. Two of these patients had preexisting TN signs, which wors-
ened following the use of dalfampridine and became unbearable. 
Three patients began to suffer from TN signs after the administra-
tion of the treatment. Brain MRIs showed no structural patholo-
gies, rather than demyelinative lesions of the brainstem. All 
patients were treated with gabapentine. Symptomatic treatment 
with gabapentine did not result in the reduction of the severity of 
the pain thus dalfampridine ceased in three patients. Discontinuation 
of dalfampridine controlled the pain well in two patients, but one 
patient continued to have severe pain.
Discussion: Evidence from this study suggests the use of dalfam-
pridine may worsen preexisting TN or trigger de novo TN symp-
toms in MS patients.
Disclosure
Sila Usar Incirli: nothing to disclose
EP1815
Effect of fampridine on the manual functions of patients with 
multiple sclerosis: difference between cerebellar and pyrami-
dal dysfunction
S. Ozakbas1, T. Kahraman2, B. Piri Cinar3, Multiple Sclerosis 
Research Group
1Department of Neurology, Faculty of Medicine, Dokuz Eylül 
University, 2Department of Physiotherapy and Rehabilitation, 
Faculty of Health Sciences, Izmir Katip Celebi University, Izmir, 
3Department of Neurology, Samsun Education and Research 
Hospital, Samsun, Turkey
Fampridine may influence upper limb dysfunction, such as strength 
and even in upper limb tremor. In this study we aimed to assess the 
effect of Fampridine treatment on upper limb function of persons 
with multiple sclerosis (PwMS). We also compared the effect of 
Fampridine on cerebellar and pyramidal dysfunctions. PwMS aged 
18 to 60 years followed-up at the Dokuz Eylul MS Center eligible 
to Fampridine treatment due to ambulatory disabilities and that in 
addition presented complains in manual function such as lack of 
coordination, deficits in fine motor skills, difficulties with dressing, 
writing and/or buttoning, were invited to participate in this study.
A total of 168 patients (109 female) were included in the study. 
Nine patients were excluded from the study due to early discon-
tinuation of Fampridine because of side effects, or personal con-
siderations. One hundred fifty-nine patients were followed up to 
12 months and 151 patients up to 24 months after initiation of the 
treatment and are included in this study. Seventy-seven (50 
female) healthy controls (HCs) were also included. No significant 
statistical differences between demographic characteristics of 
these two groups were found. Manual functions were evaluated by 
9 Hole Peg Test (9HP) and visual analog scale (VAS) for hand 
functions. For evaluating the disability EDSS was performed. 
Cerebellar and pyramidal functional system (FS) scores were 
compared.
9HPT improved by 19.8% after 1 month of treatment (p=0.004). 
Improvement was sustained on month 3, 6, 12 and 24. HC 9HPT 
results were also improved (3.6%) but not statistically significant 
(p>0.05). VAS improved by 18% after 1 month of treatment 
(p=0.02). When comparing FSs, patients with 0 to 2 cerebellar FS 
scores (n=76) were significantly more improved (23.5%) than 
patients with 3 and up cerebellar FS scores (9.2%) (p< 0.0001).
The results of this study suggest that Fampridine improves man-
ual function of PwMS. Patients with cerebellar dysfunction were 
also improved but not as much as patients without marked cere-
bellar impairment. Patients complains in manual functions due to 
pyramidal dysfunction seems to be more improved in Fampridine 
treatment then cerebellar dysfunction.
Disclosure
Serkan Ozakbas: nothing to disclose
Turhan Kahraman: nothing to disclose
Bilge Piri Cinar: nothing to disclose
EP1816
Effect of a standardized physical therapy program on objec-
tive and subjective balance in people with multiple sclerosis: 
a single- group, pretest-posttest study
C. Santoyo, M. Janer, D. Fàbregas, S. Sánchez, G. Loyola, X. 
Sibera, J. Sastre-Garriga, I. Galán, X. Montalban
Vall Hebron University Hospital | Multiple Sclerosis Centre of 
Catalonia, Cemcat-Vall Hebron University Hospital, Barcelona, 
Spain
Background: Imbalance is a frequent problem in MS and contrib-
utes to considerable patient burden, affecting outcomes such as 
independence, community participation and quality of life.
06_MSJ731285.indd   958 13/10/2017   11:11:08 AM
ePosters 23(S3) 959
Multiple Sclerosis Journal 2017; 23: (S3) 680–975journals.sagepub.com/home/msj
Objective: To evaluate the effect of a standardized exercise pro-
gramme on objective and subjective balance in people with mild 
to moderate multiple sclerosis (MS).
Methods: Prospective data were obtained from all patients with 
an EDSS ≤ 6.5 who were admitted and completed a rehabilitation 
period at the Neurorehabilitation Unit of Cemcat during the sec-
ond semester of 2016. Patients carried out a 3 days per week 5 
months long outpatient rehabilitation program. The standardized 
physical group therapy programme included three major compo-
nents modified according to each patient specific impairment and 
functional needs: muscular training, balance training and gait re-
education strategies. Outcome measures included the Berg 
Balance Scale (BBS), the Timed Up and Go Test (TUG) and the 
Activities-specific Balance Confidence Scale (ABC) measured 
before and after the rehabilitation programme. Data on self-
reported falls (indoors and outdoors) was collected retrospectively 
by interview
Results: Fifty people with MS (32% men) were included with a 
mean age of 51.44 years and a median EDSS of 4.5. Fifty-four 
percent had relapsing remitting MS, 25% had secondary progres-
sive MS, 18% had primary progressive MS and one patient, 2%, 
had a transitional form.
All three clinical outcome measures demonstrated statistically 
significant improvements after the intervention (BBS change of 
means: from 46.14 to 48.78, p< 0.05 - TUG change of means: 
15.36s to 13.88s, p< 0.05 - ABC change of means: 46.40 to 52.65, 
p< 0.05). Percentage of participants improving in each of the out-
come measures was: BBS (44%), TUG (18%), and ABC (54%). A 
reduction of fallers and falls, statistically significant, was also 
reported between the pre and post intervention period.
Conclusions: Our findings are in line with previously published 
results providing evidence that targeted physiotherapy interven-
tions can positively affect balance performance and decrease falls 
in PwMS. Improvement in static balance, dynamic balance and 
self-related perception of imbalance was statistically significant. 
A decrease in the number of falls and the proportion of fallers pre 
and post-intervention was also noted.
Disclosure
The authors have nothing to disclose as to the present work
EP1817
Physical activity and sedentary behavior in MS: impact on 
dissociable correlates of cognitive functioning
R.S. Prakash, A.L. Janssen, H. Manglani
Ohio State University, Columbus, OH, United States
Moderate-to-vigorous physical activity (MVPA) is increasingly 
being recommended to promote cognitive health in people with 
MS (PwMS). A higher level of MVPA in PwMS is associated with 
improved information processing efficiency, especially in those 
with lower disease severity scores. However, the construct of 
information processing efficiency, including both working mem-
ory and processing speed is poorly defined, leading to challenges 
in interpreting these results for PwMS. In the current study, our 
goal was to examine the differential contributions of MVPA and 
sedentary behavior in explaining variance in the constructs of 
working memory and processing speed in PwMS. Forty-four indi-
viduals with relapsing-remitting multiple sclerosis were recruited 
for the current study. All participants were administered the sub-
tests comprising the Working Memory and Processing Speed 
Indices of the Wechsler Adult Intelligence Scales (WAIS-IV) to 
quantify theoretically sound metrics of working memory and pro-
cessing speed, respectively. Additionally, all participants wore an 
Actigraph accelerometer for a 7-day period, which was then used 
to quantify both MVPA and sedentary behavior. Our results pro-
vided evidence for a double dissociation in the associations 
between physical activity, sedentary behavior and cognitive func-
tioning. Specifically, MVPA was associated with the Working 
Memory Index, specifically the mental manipulation cluster, such 
that a higher level of MVPA in PwMS was associated with better 
performance on tasks of working memory. In contrast, sedentary 
behavior in PwMS was negatively associated with the Processing 
Speed Index, such that higher engagement in sedentary behavior 
was associated with poor performance on measures of processing 
speed. Future directions for the study include analyzing resting-
state data on all participants using graph theory methodology to 
determine neural correlates of the observed associations. Given 
the physical limitations experienced by PwMS, these results 
evince support for the importance of both MVPA as well as 
reduced sedentary behavior in promoting cognitive health in MS.
Disclosure
Ruchika Prakash: nothing to disclose
Alisha Janssen: nothing to disclose
Heena Manglani: nothing to disclose
EP1818
Virtual reality training or physical activity? Which one is 
more effective in reducing pain among persons with multiple 
sclerosis? A randomized controlled trial
S. Shahrbanian
Sport Science, Bou Ali Sina University, Hamedan, Islamic 
Republic of Iran
Background: Multiple sclerosis (MS) is the most common disa-
bling disease of CNS among young adults. Pain is a common 
symptom among people with MS (pwMS). Despite a wide range 
of pain management interventions that have been applied in 
pwMS, still many of them are experiencing moderate to severe 
pain sometimes during their disease course. The benefits of physi-
cal activity for pwMS have been recognized. However, not all of 
them are able to attend physical activity sessions due to different 
barriers they may face. In recent years, virtual reality (VR) has 
become popular in clinical settings as an innovative pain distrac-
tor technique that can be used safely at home by pwMS and may 
propose alternative benefits.
Goals: The objective of this study was to investigate the effective-
ness of VR intervention (VR) in comparison to combined physical 
activity & VR training (PA&VR), physical activity alone (PA), 
and no training in reducing pain in pwMS.
Methods: This was a randomized controlled trial (RCT). Sixty 
women with MS (EDSS < 4) were randomized to one of the VR 
(Nintendo Wii), PA, PA&VR, or control groups (15 per each 
group). The experimental groups performed the assigned interven-
tion for 12 weeks (2 sessions per week, each 40 minutes). Outcomes 
included bodily pain intensity (pain subscale of RAND-36), pain 
severity (0-10 NRS), pain distribution (Margolis drawing rating 
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system), and pain duration and frequency measured at baseline and 
12 weeks later. Fatigue (Vitality subscale of RAND-36), MS sever-
ity (EDSS) and mood (0-10 NRS) were considered as explanatory 
variables.
Results: The mean age of participants was 43 ± 6.2 and mean 
years since diagnosis was 5.6± 9.0 years. The majority of partici-
pants (82%) were in relapsing-remitting course of MS. There 
were significant differences among study groups on pain related 
outcomes (p< 0.05) except for pain frequency. The post hoc analy-
sis further showed that the PA&VR did better in all pain related 
outcomes followed by either PA or VR. Mood highest change was 
seen in VR followed by PA&VR; while fatigue highest change 
was seen in PA followed by followed by PA&VR and VR group.
Conclusions: The present study identifies VR distraction tech-
niques as promising non-pharmacological approach for pain man-
agement in pwMS due to its novelty and distraction nature. The 
VR alone showed advantage over no therapy in the management of 
pain in pwMS; however, it got third place after PA&VR and PA.
Disclosure
Author declares no conflict of interest.
EP1819
Safety and efficacy of botulinum toxin A in MS patients with 
intractable chronic migraine
S. Kazemian1, A.E. Eftekhari1, S.M. Nabavi2
1Shahed University, 2Royan Institute, Tehran, Islamic Republic 
of Iran
Background: MS patients have an increased incidence of head-
aches. Headache in MS commonly could be both presented as 
episodic or chronic migraine. Chronic migraine occurring on 
more than 15 days per month for at least 3 months and a daily 
duration of at least 4 hours, is considered with possible efficacy of 
botulinum toxin A.
FDA approved botulinum as a treatment for muscle relaxation in 
MS patients in 2010 so its utilization considered to be safe. We 
used botulinum A in a cohort of MS patients with chronic and 
intractable migraine.
Method: 302 out of 1200 patients with definite MS taking stand-
ard MS treatment, complained headache fulfilling migraine crite-
ria.25 out of 302 patients didn’t respond to the common oral 
migraine treatment defined as below 30% response. We injected 
botulinum toxin A in 31 anatomical standard points on skull, 
reporting frequency, intensity, duration and medication rescue.
Results: All the cases were female with the mean age of 30.20, a 
mean disease duration of 55.72 months and mean EDSS of 1.5. 
Mean migraine frequency was 4.48 per week, intensity 78.57% 
out of 100 and duration of 9.96 hours. Standard oral migraine 
treatment response rate in these 25 patients was 21.78%.
Before injection the mean migraine frequency was 6.28 per week, 
intensity 94.8% and duration 10.36 hours. After injection the 
mean frequency 1.16 per week, the mean intensity 26 out of 100, 
and the duration was 2.24 hours. The mean Botulinum dosage was 
1.36, equal to680 unit.
Conclusion: Botulinum toxin A should be considered a safe and 
effective treatment in MS patients with intractable chronic 
migraine.
Keywords: MS, Botulinum toxin, intractable chronic migraine, 
headache
Disclosure
No conflict of interest
EP1820
Cognitive problems in people with multiple sclerosis: a mixed 
methods study on the provision and perceived effectiveness of 
cognitive rehabilitation
R. das Nair1, O. Klein2, A. Drummond2
1School of Medicine, Division of Psychiatry & Applied 
Psychology, Institute of Mental Health, 2School of Health 
Sciences, University of Nottingham, Nottingham, United 
Kingdom
Background: Two-thirds of people with multiple sclerosis (MS) 
experience cognitive problems associated with attention and 
memory. Cognitive rehabilitation to improve such cognitive defi-
cits and help people cope with these problems has emerged as a 
potential treatment approach. However, the evidence regarding its 
effectiveness is mixed and cognitive rehabilitation is not routinely 
provided in the UK. Therefore, this study addresses two main 
questions: What are patients’ perspectives on the effectiveness of 
cognitive rehabilitation? How is cognitive rehabilitation delivered 
nationally?
Method: This study comprises three phases. Phase 1 was a meta-
synthesis agglomerating findings of qualitative studies examining 
patient perspectives of the effectiveness of cognitive rehabilita-
tion programmes. Phase 2 investigates patient perspectives, using 
semi-structured interviews, of a group-based rehabilitation pro-
gramme. Phase 3 is a survey examining the provision of cognitive 
rehabilitation nationally.
Data analysis: The meta-synthesis and interview data were ana-
lysed using thematic analysis.
The survey will be analysed using descriptive statistics.
Results: The meta-synthesis highlighted the perceived benefits of 
cognitive rehabilitation in people with MS. Participants reported 
benefits in cognitive function and other areas related to their qual-
ity of life. They reported improved mood and quality of their rela-
tionships, an increase in confidence and perseverance, and the 
programme helped them to change their perceptions of their con-
dition. The group-component was often referred to as a beneficial 
aspect as it helped patients to experience a sense of community 
and support. Preliminary results of the second phase suggest that 
people do manage better after a group-based rehabilitation pro-
gramme compared to people who have not participated in cogni-
tive rehabilitation. The national survey is underway.
Conclusion: The knowledge and insight generated from each 
phase of this study will provide an overview of the provision and 
perceived impact of cognitive rehabilitation. This may inform and 
improve current practice and services for people with MS.
Disclosure
Conflict of interest: None
Source of funding: This study is supported by the MS Society 
PhD studentship ‘Delivering cognitive rehabilitation to people 
with MS’
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EP1821
De novo convulsive status epilepticus in multiple sclerosis 
patients treated with dalfampridine
E. Panicucci1, M. Cohen1, V. Bourg1, A. Civiletti2, F. Rocher2, P. 
Thomas1, C. Lebrun1
1Neurologie, CHU Nice Pasteur 2, 2Pharmacovigilance, CHU 
Nice, Nice, France
Background: Dalfampridine-ER (DAL) is a broad-spectrum 
voltage-gated potassium channels blocker, that is indicated in 
multiple sclerosis (MS) to improve nerve conduction in demyeli-
nated axons. Seizures are a known side effect of DAL, which is 
contraindicated in patients with a history of seizures.
Objective: 3 case-reports about MS patients (Pts) with «de novo» 
convulsive status epilepticus (CSE) probably related to DAL 
administration.
Methods: 3 Pts with secondary progressive MS (2 women (Pt1:26 
years,Pt2:60 years) and a man (Pt3:48 years), were admitted 
because of CSE. Their medical charts recorded:mean age at MS 
diagnosis: 22 years-old, last average EDSS 7 with spastic parapa-
resis, no history of seizures or renal impairment.
Pt 1:She observed a treatment with DAL, 10 mg tid, introduced 3 
years ago, with baclofen and tamsulosine. She presented a tonic 
clonic seizure. Intravenous (IV) diazepam was given, but myo-
clonus of left hemiface persisted. IV phenytoin then IV pheno-
barbital was given because of persistant EEG focal temporal SE.
Pt 2 :Treatment with DAL was introduced 4 years ago, with 
oxybutinin, baclofen and qizenday ATU. She presented con-
tinuous myoclonic jerks involving the right side of the body 
with impaired awareness. IV diazepam then IV phenytoin then 
IV levetiracetam were indicated because of persistant EEG 
focal ictal activity.
Pt 3:DAL was introduced 2 days ago, with baclofen. He presented 
with five tonic-clonic seizures in between impaired consciousness 
persisted. IV diazepam led to the resolution of CSE.
Biological tests were normal. Brain MRI showed diffuse cortical 
and subcortical atrophy, without active inflammatory lesion.
Results: All 3 Pts presented with CSE that were attributed to 
DAL, which was discontinued. All Pts were on baclofen at admis-
sion, which was tapered down. Anti-epileptic drug was intro-
duced: phenytoin and eslicarbazepine (Pt1), levetiracetam and 
phenytoin (Pt2). Third Pt presented 9 months after a new tonic-
clonic seizure, and levetiracetam was introduced. No DAL com-
pliance deviations were identified.
Conclusion: These case-reports illustrate that «de novo» CSE is a 
potential complication of MS patients treated with DAL. All Pts 
had important cortical and subcortical demyelination on brain 
MRI, but no renal impairment that would have enabled lowered 
renal excretion of DAL. All Pt had concomitant therapy with 
baclofen, a proepileptic drug. Potential interaction between these 
2 drugs may have precipitated CSE in our Pts.
Disclosure
CLF has participated to scientific boards for Biogen, Roche, 
Novartis, Merck, medDay. Others authors disclosed no affilia-
tions, funding sources and financial or management relationships 
that could be perceived as potential sources of bias.
EP1823
A new cognitive-linguistic patient report tool: correlation 
with the BICAMS
L. Kostich1, D. Wakefield2
1Mount Sinai Hospital, Hartford, 2UConn Health Center, 
Farmington, CT, United States
Background: Persons with Multiple Sclerosis (pwMS) each 
experience unique constellations of cognitive symptoms. 
Standardized assessment tools, such as the BICAMS, do not offer 
a pwMS the opportunity to express explicit examples of func-
tional challenges in day to day routines. Speech-Language 
Pathologists (SLPs) treat the symptoms of cognitive impairment, 
but require information from patients about cognitive challenges 
the pwMS may be experiencing. A Multiple Sclerosis Cognitive-
Linguistic Checklist (MSC-LC) was developed by a SLP at a 
Comprehensive MS Care Center in the U.S., and was revised 
through a Delphi Protocol with patients at the Comprehensive 
Care Center acting as the “experts” on the panel (unpublished). 
Content, format and appearance of the MSC-LC was generated 
with direct input of pwMS managing the disease progression on a 
daily basis. In order to provide a complete clinical picture of the 
pwMS, both objective and subjective data need to be collected. 
The MSC-LC has been in clinical use in conjunction with the 
BICAMS for approximately one year.
Goal: In order to improve the quality of patient care…determine 
if scores on the MSC-LC in correlate with the BICAMS when 
collected during the same assessment. As these are clinical data, 
there are no exclusions from these calculations.
Results: The MSC-LC contains 20 questions. Of the individual 
questions:
Eleven correlate with the SDMT at a value of p< .05; (55%)
Thirteen correlate with the CVLT2 at a value of p< .05; (65%)
Ten correlate with the BVMTR at a value of p< .05; (50%)
Correlations are as follows when the 20 questions are grouped by 
content:
Language Retrieval - SDMT (p=0.0061), CVLT2 (p=0.073), 
BVMTR (p=0.057)
Managing Distractions - SDMT (p=0.011), CVLT2 (p=0.001), 
BVMTR (p=0.057)
Conversation - SDMT (p=0.021), CVLT2 (p=0.0064), BVMTR 
(p=0.066)
Information Management - SDMT (p=0.0019), CVLT2 
(p=0.0055), BVMTR (p=0.0007)
Organization - SDMT (p=0.0013), CVLT2 (p=0.0051), BVMTR 
(p=0.454)
Conclusion: The majority of questions on the MSC-LC are cor-
related with standardized measures of cognitive impairment 
(BICAMS). Future directions- determine if ruling out groups with 
optic neuritis and/or non-native English speakers will change the 
correlations.
Disclosure
Lori Ann Kostich M.S. CCC-SLP, MSCS has nothing to 
disclose.
Dorothy Wakefield M.S. PStat has nothing to disclose.
Project Funded by a BestCare Pilot and Training Grant through 
St. Francis Hospital, Hartford, CT U.S.A.
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EP1824
At-home transcranial direct current stimulation (tDCS) 
improves mood in multiple sclerosis: results from a random-
ized, sham-controlled trial
M. Shaw, B. Dobbs, N. Pawlak, W. Pau, L. Charvet
Neurology, New York University Langone Medical Center, New 
York, NY, United States
Background: tDCS is a therapeutic approach that applies low 
amplitude currents (typically 1-4 mA) through scalp electrodes with 
the goal of altering the resting state of neurons for potential thera-
peutic benefit. A growing body of evidence indicates that tDCS 
applied to the left dorsolateral prefrontal cortex (DLPFC) may be 
beneficial in the treatment of depression, a common comorbidity 
with multiple sclerosis (MS). The DLPFC is a neurobiological sub-
strate related to both aspects of mood and cognition. We tested 
mood outcomes in a recently completed randomized sham-con-
trolled and double blinded trial of tDCS in MS participants.
Methods: Participants with MS were recruited to participate in a 
randomized, sham-controlled trial of tDCS testing remote (at-
home) delivery of treatment. Supervised in real time through vide-
oconferencing, participants completed 20 treatment sessions from 
home over four weeks. Participants were randomly assigned to 
active (2.0mA left anodal) or sham tDCS using the DLFPC mon-
tage. Sessions were administered for 20 minutes during which 
participants also completed cognitive training exercises each ses-
sion. Participants completed self-report questionnaires at baseline 
and study end visits, including the Positive and Negative Affect 
Schedule or PANAS to provide specific components of mood.
Results: Participants receiving active tDCS (n=14) reported a sig-
nificant increase in PA and decrease in NA by study end (mean 
changes of 4.4±6.2, p=0.02 and -5.7±5.9, p=0.003, respectively). 
Sham-treated participants (n=10) did not show significant change 
in either positive or negative affect (mean changes of 4.4±6.2 vs 
-0.6±6.2, p=0.068 and mean changes of -5.7±5.9 vs -2.0±5.0, 
p=0.111, respectively).
Conclusions: Twenty sessions of tDCS, administered at home 
using a telerehabilitation protocol, significantly increases positive 
affect and decreases negative affect in participants with MS. 
Findings support the role of DLPFC in regulating mood and war-
rant a clinical trial for the treatment of MS-related depression.
Disclosure
Michael Shaw has nothing to disclose.
Bryan Dobbs has nothing to disclose.
Natalie Pawlak has nothing to disclose.
William Pau has nothing to disclose.
Leigh Charvet has nothing to disclose.
EP1825
Investigation of the effects of computer assisted cognitive 
rehabilitation in multiple sclerosis patients: a randomised-
controlled study
B.C. Kavaklioglu, M. Ozerden, M.K. Bitnel, A. Ozudogru, A. 
Soysal
Neurology Department, Bakirköy Prof. Dr. Mazhar Osman 
Education and Research Hospital for Psychiatric and 
Neurological Diseases, Istanbul, Turkey
Objective: The objective of this study was to investigate the effi-
cacy of a computer assisted cognitive rehabilitation program with 
focus on memory, attention and executive functions in relapsing-
remitting multiple sclerosis patients(RRMS) with mild cognitive 
impairment; and to determine the compliance of patients to com-
puter-assisted cognitive rehabilitation.
Methods: RRMS patients with mild cognitive impairment fol-
lowed at our neurology clinics were included in the study. The 
study was designed as a prospective, randomised-controlled 
and single-blind study. Study and control subjects were evalu-
ated using standardised mini-mental test, Beck depression 
inventory, and Rao’s Brief Repeatable Battery for neuropsychi-
atric diseases.
Results: Results demonstrated that error point on Symbol Digit 
Modalities Test (SDMT) was reduced with application of com-
puter assisted cognitive rehabilitation, while increased in controls; 
Selecting Reminding Test (SRT) short term memory results were 
significantly increased with application of computer assisted cog-
nitive rehabilitation; and results of Stroop test also revealed that 
study subjects made less corrections compared to controls. 
Improved results were also obtained in Paced Auditory Serial 
Addition Test(PASAT), SDMT, and Word List Generation (WLG)-
category tests in study group compared to the control group 
although not to a statistically significant degree.
Conclusion: Computer-assisted cognitive rehabilitation applica-
tions aimed at improving specific cognitive domains proved benefi-
cial in the improvement of cognitive domains including attention, 
memory and executive function in patients with multiple sclerosis.
Disclosure
Nothing to disclose
EP1826
Implementing cognitive rehabilitation for people with MS: 
translating research into clinical practice
R. das Nair1, J.R. Mhizha-Murira2, A. Drummond2
1School of Medicine, Division of Psychiatry & Applied 
Psychology, Institute of Mental Health, 2School of Health 
Sciences, University of Nottingham, Nottingham, United 
Kingdom
Background: Memory, attention and executive function are com-
monly reported cognitive problems by people with multiple scle-
rosis (MS). These problems can severely affect quality of life of 
the individual, their family and carers. Although the effectiveness 
of cognitive rehabilitation programmes has been evaluated in 
clinical trials, inadequate reporting of the content of the interven-
tions may prevent clinical implementation.
The overall aim of this research is to develop a clinician-informed, 
evidence-based checklist to guide researchers to better report cog-
nitive rehabilitation studies in order to increase clinical impact.
Methods: This mixed-methods research consists of three stages:
(i) A systematic review and narrative synthesis of the literature on 
the content and quality of reporting of cognitive rehabilitation for 
people with MS;
(ii) A content analysis and time-sampling analysis of video record-
ings of an intervention delivered in an ongoing multi-centre trial 
of Cognitive Rehabilitation of Attention and Memory in MS 
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(CRAMMS), focusing on the content of treatment sessions. 
Findings from these two stages will form stage three;
(iii) A modified Delphi consensus study with healthcare profes-
sionals and researchers who work with people with MS, to estab-
lish key aspects of the intervention that researchers should report 
for the clinical translation of cognitive rehabilitation. This will 
result in a consensus checklist.
Results: 
(i) 52 studies involving various types of MS and techniques to 
improve difficulties with memory, attention and executive func-
tion were included in the systematic review. The results showed 
that important features of cognitive rehabilitation were not 
reported well. For example: whether participants were treated 
individually or in a group was only reported in 46% of the papers; 
the intervention techniques used and how they facilitated improve-
ment of cognitive problems and/or function was only reported in 
38% of the papers.
(ii) Data analysis of the content of the CRAMMS intervention is 
in progress.
(iii) The Delphi consensus study will commence in August 2017.
Conclusion: The development of a clinician-informed, evidence-
based checklist may enable researchers to report important aspects 
of complex interventions. This may improve potential clinical 
uptake of effective interventions.
Disclosure
This study is funded by the UK MS Society. The CRAMMS study 
mentioned is funded by the UK National Institute for Health 
Research.
The authors declare no other conflict of interest.
EP1827
Changes in activities of daily living by Fampyra
J. Jansa, Z. Sicherl, S. Martic, K. Angleitner, R. Koritnik, A.H. 
Ledinek, U. Rot, S. Sega
UMCL, Ljubljana, Slovenia
Background: In patients with multiple sclerosis (PwMS), there is 
an evidence that Fampyra LR improves walking and also the per-
formance of activities of daily living (ADL). Consequently, we 
investigated the respondence of Fampyra LR in terms of perfor-
mance and satisfaction of meaningful and self-chosen ADLs by 
using the Canadian Occupational Performance Measure (COPM).
Method: There were 111 consecutive PwMS who were referred by 
neurologists to Occupational therapy (OT). They were candidates 
for treatment with Fampyra LR, and were independently followed 
within OT. PwMS were assessed by the COPM before starting 
treatment with Fampira LR and reassessed after two weeks. COPM 
(Law et al, 1991) is standardized and well-validated semi-structured 
interview. It assesses patients´ perception and satisfaction of pur-
poseful, meaningful and self-chosen ADLs. It is therefore patient-
centred assessment. As part of the interview process, patients are 
asked to score their current level of performance and satisfaction 
with their performance of ADLs. Scores are within the range from 
1-10 ; 1 relates to great difficulty or not satisfied and 10 to no dif-
ficulties or completely satisfied. SPSS was used for analysis.
Results: In total, 106 PwMS completed the study; there were 30 
male / 81 female, average age was 51±11 years and average EDSS 
was 5.5±1.1. The average initial COPM performance score was 
4.6 ± 2.2 and the average reassessment score was 6.2± 2.3. This 
difference was significantly important (p< 0,001). The average 
initial COPM satisfaction score was 5.1± 2.3 and the average reas-
sessment score was 6.6±2.5. This difference was significantly 
important (p< 0,001).
Conclusion: The ADL performance, measured in terms of PwMS´ 
perception and satisfaction with their performance of meaningful 
and self-chosen ADLs has improved after Fampyra LR treatment. 
Further relation of this improvement with walking changes could 
additionally clarify this topic.
Disclosure
Jelka Jansa has nothing to disclose.
Zorana Sicherl has nothing to disclose.
Simona Martić has nothing to disclose.
Katja Angleitner has nothing to disclose.
Rok Koritnik has nothing to disclose.
Alenka Horvat Ledinek has nothing to disclose.
Uroš Rot has nothing to disclose.
Sasa Sega has nothing to disclose.
Quality of life
EP1828
Does mindfulness, meditation and progressive muscle relax-
ation reduce stress in people with multiple sclerosis?
S. Agland1,2, S. Shaw3, R. Lea2, S. Mortimer-Jones4, J. Lechner-
Scott2
1Neurology, John Hunter Hospital, 2Hunter Medical Research 
Institute, Newcastle, NSW, 3Eastern Health, Box Hill, VIC, 
4Murdoch University, Perth, WA, Australia
Background and aim: The National Institute for Health and Care 
Excellence clinical guidelines, together with the global consensus 
document ‘Brain Health’, acknowledge that modification of life-
style factors contribute to the holistic care of people with Multiple 
Sclerosis (MS). While people with MS often report stressful life 
events as a precursor to developing MS, and despite increasing 
evidence of perceived stress as a risk factor for disease activity, 
the evidence for effectively managing stress in this population is 
limited. This study examined the effect of an educational program 
that incorporates progressive muscle relaxation (PMR), medita-
tion and mindfulness exercises (ME), on a population of people 
with MS over a six month period.
Method: 100 people with relapsing remitting MS were randomly 
assigned to receive:
1) stress management education (SME) or
2) wait list (WL).
The SME group received four one-on-one sessions learning PMR, 
meditation and ME and asked to perform PMR, meditation and 
ME for 5-7 days of the week for six months, which was monitored 
by diary. The primary outcome was change in perceived stress as 
measured by: the stress Visual Acuity Scale (sVAS), the stress 
component of the Depression, Anxiety and Stress Score 
(DASS21), and cortisol levels collected at baseline and four 
weeks. Cortisol levels were ascertained by saliva samples col-
lected at three time points over a 24-hour period and then aver-
aged. The secondary outcome measure was change in quality of 
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life as measured by the Multiple Sclerosis International Quality of 
Life Questionnaire (MusiQoL).
Results: None of the parameters evaluated changed between pre 
and post SME (p≤ 0.05). Mean scores for sVAS at baseline and 
follow up 1 (4 weeks) were 4.8 and 4.5 for SME and 3.7 and 4.1 
for WL. Mean scores for stress component of the DASS21 were 
15.3 and 13.7 for SME and 13.8 and 12.6 for WL. Mean cortisol 
levels changed were 7.3 nmol/L to 7.6 nmol/L for SME and 5.1 
nmol/L to 7.6 nmol/L for WL. Mean MusiQoL scores were 65.2% 
and 67.3% for SME and 66.9% and 70.8% for WL. Study out-
come was potentially limited by intervention adherence; good 
adherence (5-7 days per week), reasonable adherence (2-4 days 
per week) and poor adherence (0-1 day per week) to SME was 
undertaken by 24%, 19% and 45% respectively.
Conclusions: Results indicate that SME does not significantly 
improve levels of stress or quality of life in people with MS. 
Future studies could include barriers to adherence.
Disclosure
Susan Agland: Accepted travel compensation from Novartis, 
Biogen and Merck Serono. Her institution receives the honoraria 
for talks and advisory board commitment from Bayer Health Care, 
Biogen, Genzyme Sanofi, Merck, Novartis, Teva and Roche.
Sally Shaw: nothing to disclose.
Rod Lea: nothing to disclose.
Sheila Mortimer-Jones: nothing to disclose.
Jeannette Lechner-Scott: Accepted travel compensation from 
Novartis, Biogen and Merck. Her institution receives the honoraria 
for talks and advisory board commitment from Bayer Health Care, 
Biogen, Genzyme Sanofi, Merck, Novartis, Teva and Roche, has 
been involved in clinical trials with Biogen, Novartis and Teva.
EP1829
The effectiveness of a diverse manner of functional electrical 
stimulation on balance, gait and quality of life in people with 
multiple sclerosis
T. Prokopiusova, N. Hruskova, M. Pavlikova, K. Rasova
Department of Rehabilitation Medicine, Third Faculty of 
Medicine and Faculty Hospital Kralovske Vinohrady, Charles 
University, Prague, Czech Republic
Background: Although a recently developed alternative to solve 
foot drop-the functional electrical stimulation (FES)- seems to be 
a promising treatment method, there is only one study which 
showed therapeutic effect in pwMS. To our knowledge only 3 
studies compared or connected FES and physiotherapy.
Objective: Our aim was to investigate the effectiveness of 2 dif-
ferent ways of using FES combined with physiotherapy and 
Walkaide to learn which method produced better outcomes forbal-
ance, mobility, gait and quality of life in pwMS.
Methods: 43 pwMS were divided into 3 groups which underwent:
1) physiotherapy + FES in training mode for 2 months;
2) FES for daily use for 2 months;
3) 2 months physiotherapy before 2 months Walkaide for 
daily use.
Tests examined mobility (Rivermead mobility index, Performance 
scale Mobility, Five times Sit to Stand test), balance (Berg Balance 
Scale, Timed Up and Go Test, Dynamic Gait Index), gait (Timed 
25 - foot Walk Test, 2 - Minute Walk Test). We also administered 
the following questionnaires: Multiple Sclerosis Walking Scale 12, 
The Activities - specific Balance Confidence Scale, Multiple 
Sclerosis Impact Scale-29 (MSIS29), Euroquol - 5 dimensional - 5 
levels (EQ - 5D - 5L) were assessed without FES 4 weeks before 
baseline, at baseline, after treatment and 2 months after treatment.
Results: We found a significantly positive effect of combination 
of FES and physiotherapy on Berg balance scale in group 1 and 3 
(p =0,007; 0, 04 resp.). Group 1 showed significant positive 
effects in EQ-5D-5L on mobility, usual activities, pain/discomfort 
and health; and in MSIS29; group 3 showed significant positive 
effect in EQ-5D-5L on mobility.
Conclusion: Combining FES with facilitation physiotherapy has 
a positive effect on balance and quality of life in pwMS.
Disclosure
Prokopiusová T: nothing to disclose
Hrušková N: nothing to disclose
Pavlíková M: nothing to disclose
Řasová K: nothing to disclose
EP1830
Psychopathological symptoms have a profound effect on the 
quality of life of multiple sclerosis patients
T. Biernacki1, D. Sandi1, D. Szekeres1, J. Füvesi1, Z.T. Kincses1, 
Z. Fricska-Nagy1, C. Rózsa2, K. Kása2, J. Matolcsi2, D. 
Zboznovits2, Z. Burány2, É. Langane1, L. Vécsei1,3, K. Bencsik1
1Department of Neurology, University of Szeged, Szeged, 
2Department of Neurology, Jahn Ferenc Dél-Pest Hospital, 
Budapest, 3Neuroscience Research Group, MTA-SZTE, Szeged, 
Hungary
Introduction: Multiple sclerosis (MS) not only causes somatic dis-
ability but often leads to psychopathological symptoms such as 
cognitive impairment (CI), depression and fatigue. Benedict et al 
(2005) showed that CI, depression and fatigue worsen the patients’ 
QoL as much as the physical disability. This study aimed to assess 
the impact of these symptoms on the patients’ QoL during a 1-year 
follow up.
Patients and methods: We recruited 178 relapsing-remitting and 
CIS patients to our study from two major MS clinics in Hungary 
(Szeged, Budapest); 52 were man, 126 women. We utilized the 
BICAMS battery for cognitive screening, the MSQoL-54 for the 
assessment of QoL, the FIS questionnaire for measurement of 
fatigue, and the BDI-II for the assessment of depression. The first 
evaluation was carried out in 2014-2015, the follow-up period 
was in 2015-2016, 1-year after the initial tests. For statistical anal-
ysis, we developed a linear mixed-effects model.
Results: The mean age at the follow-up of our patients was 
44.8±11.4 years, the mean disease duration was 15.3±8.0 years and 
median EDSS score was 2.0 (range: 0-6.0) points. In our model we 
found, that the appearance of fatigue significantly (p< 0.05) 
reduces the patients’ QoL in all 14 dimensions measured by the 
MSQoL-54. Similarly, the appearance depression has a significant 
(p< 0.05) impact on the patients QoL on 13 of 14 dimensions 
(except for the “Change in health” dimension; p=0.287). The 
appearance of CI does not have such a wide impact, but it signifi-
cantly reduces the patients QoL in the “Physical functioning”, 
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“Social functions” and “Cognitive functions” dimensions (p< 
0.05), even if the rate of cognitive impairment is mild.
Discussion: Our findings strongly suggest that the psychopatho-
logical changes are heavy factors in determining MS patients’ 
quality of life. Fatigue and depression have particularly strong and 
wide effects. Also, even mild CI seriously impacts the patients’ 
quality of life on both the social and the physical level.
Disclosure
Tamás Biernacki: nothing to disclose.
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Judit Füvesi: nothing to disclose.
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EP1831
How to improve self-management in multiple sclerosis? 
Directions of psychological interventions
M. Wilski1,2, T. Tasiemski1, P. Kocur2,3, W. Brola4,5
1Department of Adapted Physical Activity, Poznan University of 
Physical Education, Poznan, 2Department of Physiotherapy and 
Knowledge about Health, State University of Applied Sciences, 
Konin, 3Department of Kinesiotherapy, Poznan University 
of Physical Education, Poznan, 4Department of Neurology, 
Specialist Hospital, Końskie, 5Faculty of Medicine and Health 
Science, Institute of Physiotherapy, Jan Kochanowski University, 
Kielce, Poland
Background: Self-management of chronic illness is a key com-
ponent of patients’ active participation in treatment process and 
has been found to be associated with better quality of life, 
reduced disability and number of complications, improved out-
comes and lower costs of treatment. So far, correlates of self-
management in multiple sclerosis (MS) have not been subjected 
to extensive empirical research. An increased understanding of 
these correlations may help clinicians to identify individuals at 
an increased risk of poor self-management skills, take positive 
action towards activating the patient and implementing effective 
rehabilitation interventions.
Purpose: The aim of this study was to verify if potentially modifi-
able cognitive perceptions, such as self-efficacy, optimism, 
acceptance of illness and health locus of control are the correlates 
of self-management in MS.
Methods: The cross-sectional study included 382 patients with MS, 
who completed Multiple Sclerosis Self-Management Scale - 
Revised, and a set of questionnaires measuring self-efficacy, opti-
mism, acceptance of illness and health locus of control. Demographic 
and clinical characteristics of the participants were collected with a 
self-report survey. Correlation and regression analyses were con-
ducted to determine relationships between the variables.
Results: A hierarchical multiple regression revealed that four 
variables: health control - power of others
(b =0.42, p ≤ 0.001), optimism (b =0.27, p ≤ 0.01), health control 
- internal factors (b = -0.11, p = 0.017) and self-efficacy (b =0.11, 
p = 0.031), were significant correlates of self-management in our 
study group. These variables explained 27% of variance in the 
dependent variable. Moreover, correlations between self-manage-
ment and other measured variables were obtained.
Conclusions: Self-management of patients with MS is associated 
with perception that health professionals and family members 
control their health, higher self-efficacy, optimism, and surpris-
ingly, lower perception of personal control over one´s state of 
health. Our study indicates the key role of the physicians in the 
process of motivating the patient with MS for self-management 
activities and produce new knowledge for potential psychological 
intervention aimed at improving patient’s self-management.
Disclosure
Wilski: nothing to disclose
Tasiemski: nothing to disclose
Kocur: nothing to disclose
Brola: nothing to disclose
EP1832
The relationship between diagnosis acceptance, self-concept, 
and mental health outcomes in individuals with multiple 
sclerosis
N.K. Ward1, L. Kiropoulos2
1School of Medicine, Deakin University, Waurn Ponds, 2School 
of Psychology, Melbourne University, Parkville, VIC, Australia
Objective: This study was concerned with examining depressive 
and anxiety symptoms, overall self-concept and physical self-
concept amongst individuals with multiple sclerosis (MS) and 
determining how these differed between individuals with high and 
low MS diagnosis-acceptance. The role of MS illness duration 
was also evaluated.
Methods: 329 individuals with MS completed the an online ques-
tionnaire incorporating the Depression, Anxiety and Stress Scale 
(DASS-42), assessing depressive and anxiety symptoms, 
Acceptance of Chronic Health Conditions Scale (ACHC), assess-
ing MS diagnosis acceptance and the Tennessee Self-Concept 
Scale (TSCS-2), investigating overall self-concept and physical 
self-concept.
Results: As predicted, high MS diagnosis acceptance was signifi-
cantly associated with higher overall self-concept and physical 
self-concept, whilst low MS diagnosis acceptance was signifi-
cantly associated with lower overall self-concept and higher 
depressive and anxiety symptoms. MS duration was significantly 
positively associated with overall self-concept. Contrary to predic-
tions, there were no significant relationships between MS duration 
and physical self-concept or depressive and anxiety symptoms.
Conclusion: Results of the current study suggest that displaying 
high MS diagnosis acceptance is associated with positive out-
comes for individuals with MS, including lower depressive and 
anxiety symptoms and higher overall and physical self-concept. 
Further research should continue to explore MS diagnosis accept-
ance as it appears to confer positive benefits to individuals, who 
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have otherwise been shown to experience high rates of depressive 
and anxiety symptoms and low self-concept.
Disclosure
Natalie Ward: nothing to disclose.
Litza Kiropoulos: nothing to disclose.
EP1833
Effects of physical training on multiple sclerosis patients: a 
longitudinal study
M. Ponzano1, L. Beratto1, C. Mazza1, S. Di Tommaso1, F. Abate 
Daga1, R. Allois1, M. Gollin1,2
1Adapted Training and Performance Research Group, 2Clinical 
and Biological Sciences, University of Turin, Torino, Italy
Aim: The investigation of the effects of a 30 seconds static 
stretching protocol, Pilates® and resistance training with elastic 
bands on muscle strength, rachis morphology, flexibility and body 
balance among RRMS patients.
Methods: Twenty-two subjects with relapsing-remitting multiple 
sclerosis (RRMS, EDSS ≤ 6) were randomly divided into 3 
groups (8, 7, 7 subjects) and performed 16 weeks of training as 
follows. Static Stretching group: 2 sessions/week, 3 sets of 30 
seconds for each exercise. Elastic group: 2 resistance training 
sessions/week, 3 sets of 10 repetitions. Pilates® group: 2 sessions/
week, 2 sets of 8 repetitions for each exercise. Stabilometry, 
rachis morphology, sit and reach, and sit to stand tests were exe-
cuted three times: T0, after a month of learning training proto-
cols, to identify the initial situation; T1, two months after T0, to 
evaluate the effects brought about by the first eight weeks of 
training; T2, two months after T1, to evaluate the effects brought 
about by sixteen weeks of training.
Results: Static Stretching group. Spinal Mouse® (inclination line 
between ThSp1 and S1 from a standing position): T0 vs T2, -55%, 
ES = 0.67; Sit and Reach test: T0 vs T2, +15%, ES = 0.36. Elastic 
group. Stabilometry with eyes open: T0 vs T1, -51%, ES = 0.52; 
stabilometry with eyes closed: T0 vs T1, -52%, ES = 1.69; sit to 
stand test: T0 vs T2, +39%, ES = 1.83. Pilates group. Sit and 
Reach test: T0 vs T2, +15%, ES = 0.4; Sit to Stand test: T0 vs T2, 
+31%, ES = 1.21.
Conclusions: Static stretching, Pilates® and resistance training 
are believed valid to improve the motor control of the rachis, 
body flexibility and the performance in the Sit to Stand test. 
Hence, it is possible to hypothesize an increment in autonomy in 
the daily life of people affected by RRMS brought about by this 
three protocols.
Disclosure
No potential conflict of interest was reported by the authors. No 
financial assistance was received to complete this project.
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EP1834
Effects of multilateral exercises on motor skills in multiple 
sclerosis: a longitudinal study
L. Beratto1, F. Abate Daga1, M. Alessandria1, M. Ponzano1, M. 
Gollin1,2
1Adapted Training and Performance Research Group, University 
of Turin, 2Department of Clinical and Biological Sciences, 
University of Turin, Turin, Italy
Aim: The aim of this study is to evaluate the effect of adapted 
physical activities with micro-loads, elastic bands and balance 
exercises compared with the Pilates® method on muscle strength, 
flexibility and body balance in Multiple Sclerosis patients.
Methods: Eighteen people with Multiple Sclerosis participated in 
this study. Subjects were randomly assigned to a Multiple 
Neuromuscular Stimulation Group (10 participants, age 69±10 
years; weight 72±12 kg, height 171±7 cm, EDSS 5±2) or to Pilates 
Group (8 participants, age 70±11 years; weight 69±15 kg and 
height 169±9 cm, EDSS 3±1). Both groups performed two ses-
sions of physical activity per week during a period of 5 months. 
Sit and Reach, Sit to Stand, Saliva Antioxidant, Stabilometry were 
evaluated three times: after the first (T0) and the third (T1) month 
of physical activity and at the end (T2) of the training period.
Results: The ANOVA and post hoc tests showed statistically signifi-
cant variations. MNS group: Sit to Stand test: T0 vs T2, +13%, ES = 
0.59; average COP X: T0 vs T1, -97%, ES = 0.94; COP distance: T0 
vs T2, -32%, ES = 1.31; Average speed: T0 vs T2, -32%, ES = 1.31; 
Distance/Surface: T0 vs T1, -55%, ES = 0.86, T0 vs T2, -53%, ES = 
0.83. Pilates group: Sit and Reach test: T0 vs T2, +12%, ES = 0.26; 
Standard Deviation X: T0 vs T2, -50%, ES = 0.66; COP distance: T0 
vs T2, -70%, ES = 0.84; Average speed: T0 vs T2, -44%, ES = 2.09; 
Body Barycentre Ellipse surface: T0 vs T2, -45%, ES = 0.51.
Conclusions: Both Multiple Neuromuscular Stimulation and 
Pilates® exercises were well-tolerated. MNS and Pilates® improve 
muscle performance, flexibility and body control. Therefore, it is 
possible to suppose that these combined protocols could be useful 
to maintain physical capacity and increase the quality of life of 
patients with MS.
Disclosure
No potential conflict of interest was reported by the authors. No 
financial assistance was received to complete this project.
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EP1835
Efficacy of daclizumab beta vs intramuscular interferon 
beta-1a on patient-reported outcomes across patient demo-
graphic and disease activity subgroups in DECIDE
E. Havrdova1, B. Turner2, X. Ye3, K. Riester4, G. Giannattasio4, 
C. Wakeford4
1Department of Neurology, Charles University in Prague, 
Prague, Czech Republic, 2Barts and the London NHS Trust, 
London, United Kingdom, 3Abbvie Inc, North Chicago, IL, 
4Biogen, Cambridge, MA, United States
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Background: In DECIDE, patients with relapsing MS (RMS) 
treated with daclizumab beta (DAC BETA) 150mg every 4 weeks 
reported significantly greater mean improvements from baseline 
(BL) to Week 96 on the Multiple Sclerosis Impact Scale physical 
subscale (MSIS-29 PHYS; P< 0.001), the EQ-5D visual analogue 
scale (VAS; P< 0.001), and the EQ-5D health utility index (HUI; 
P=0.005) vs intramuscular (IM) interferon (IFN) beta-1a 30mcg 
once weekly.
Objective: Examine post hoc the effects of DAC BETA vs IM 
IFN beta-1a on patient-reported outcomes (PROs) in subgroups 
based on BL characteristics in DECIDE.
Methods: The MSIS-29 PHYS and the EQ-5D (VAS and HUI) 
were assessed at BL and then every 24 weeks. Subgroups 
included: sex (male, female); age (≤35y, >35y); time since diag-
nosis (< 3y, ≥3 to < 10y, ≥10y); relapses in prior year (≤1, ≥2); 
EDSS (< 3.5, ≥3.5); Gd+ lesions (absent, present); T2 lesion 
volume (< median, ≥median); prior disease-modifying therapy 
(DMT) (yes, no); disease activity (less active, highly active [≥2 
relapses in year prior to randomization and ≥1 Gd+ lesion at 
baseline MRI]). Analyses were based on ANCOVA, adjusted 
for relevant BL covariates.
Results: Across all subgroups, the DAC BETA group demonstrated 
greater mean improvement, or less worsening, from BL to Week 96 
in MSIS-29 PHYS score vs IM IFN beta-1a; treatment differences 
were significant (P< 0.05) for: female, age ≤35y, ≥2 relapses in 
prior year, EDSS< 3.5, Gd+ lesions present, T2 lesion volume 
≥median, no prior DMT use, time since diagnosis (< 3y, ≥10y), less 
and highly active disease activity. At Week 96, vs IM IFN beta-1a, 
the DAC BETA group also showed greater mean improvement 
from BL on the EQ-5D VAS (differences significant for: female, 
male, age ≤35 y, time since diagnosis (< 3y), ≥2 relapses in prior 
year, EDSS < 3.5, Gd+ lesions present and absent, T2 lesion volume 
≥median, no prior DMT use, less and highly active disease activity) 
and the EQ-5D HUI (differences significant for: female, age >35y, 
time since diagnosis (< 3y), ≤1 relapses in prior year, EDSS< 3.5, 
Gd+ lesions present, T2 lesion volume ≥median, no prior DMT use, 
less and highly active disease activity).
Conclusions: DAC BETA demonstrated improvements on PROs 
vs IM IFN beta-1a at Week 96 across all key subgroups. These 
effects were observed across all PROs for patients with lower 
baseline disability (EDSS< 3.5) and less time since diagnosis, 
providing further evidence of the benefits of early treatment on 
PROs.
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Improvement of quality of life and its relationship to neu-
ropsychiatric outcomes in patients with multiple sclerosis 
starting treatment with Natalizumab: a 3-years follow-up 
multicentric study
V. Planche1, X. Moisset1, R. Morello2, E. Dumont1, M. Gibelin3, 
J. Charré-Morin4, A. Saubusse4, A. Mondou5, F. Reuter6, G. 
Defer5, J. Pelletier6, B. Brochet4, P. Clavelou1
1Service de Neurologie, CHU de Clermont Ferrand, Clermont-
Ferrand, 2Unité de Biostatistique et Recherche Clinique, CHU 
de Caen, Caen, 3Réseau NeuroSEP Auvergne, Beaumont, 
4Service de Neurologie, CHU de Bordeaux, Bordeaux, 5Service 
de Neurologie, CHU de Caen, Caen, 6Service de Neurologie, 
APHM, Hopital la Timone, Marseille, France
Background: Health-related quality of life (HRQoL) is impaired 
in multiple sclerosis (MS) but can be improved by disease-modi-
fying therapies such as Natalizumab. However, no long-term fol-
low-up post-marketing study about Natalizumab and HRQoL is 
available and the predictive factors of HRQoL improvement are 
unknown.
Methods: Forty-eight patients with relapsing-remitting MS were 
included in a 3-year open-label, single group, multicenter, clinical 
trial (NCT01392872). HRQoL was measured by the MusiQoL 
questionnaire, together with physical disability, cognition, fatigue, 
anxiety and depression scores at baseline, 6 months, 12 months, 
18 months and 36 months after starting Natalizumab therapy.
Results: Compared to baseline, global HRQoL, as measured with 
the index of the MusiQoL, was significantly increased 6 months 
after the beginning of Natalizumab therapy (58.8±16.8 vs 
68.7±18.9,
p< 0.001, Cohen’s d=0.55) and this improvement was maintained 
over time for up to 3 years. The improvement of the global HRQoL 
after 18 months was correlated with an improvement of informa-
tion processing speed performances (r=0.43, p=0.003 for SDMT) 
and with a decrease in depression and fatigue scores (respectively 
r=-0.37, p=0.013 and r=-0.52, p< 0.001). The variation of the 
global HRQoL after 3 years was negatively correlated with the 
variation of fatigue score (r=-0.44, p=0.015). Higher fatigue score 
at baseline was correlated with improvement in global HRQoL 3 
years after (r=0.34, p=0.041). Higher depression score and higher 
physical disability at baseline were correlated with improvement 
in some dimensions of the MusiQoL and especially in the activi-
ties of daily living (respectively r=0.39, p=0.020 and r=0.39, 
p=0.018).
Conclusions: Natalizumab improved quickly and sustainably 
HRQoL in patients with relapsing-remitting MS. In terms of 
HRQoL, Natalizumab seems to benefit mainly patients with 
higher physical disability, fatigue and depressive symptoms at 
baseline.
Disclosure
The study was funded by Biogen Idec. The sponsor did not par-
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Energy expenditure of normal and fast walking in multiple 
sclerosis
L. Frid1, S. Menascu1, U. Givon1, A. Kalron1, D. Magalashvili1, 
M. Dolev1, A. Achiron1,2
1Multiple Sclerosis Center, Sheba Medical Center, Tel 
Hashomer, 2Sackler Faculty of Medicine, Tel Aviv University, 
Tel Aviv, Israel
Background: Patients with multiple sclerosis (MS) often suffer 
from various impairments in gait leading to decrease in walking 
distance and velocity. Physical rehabilitation in accordance is 
aimed to improve gait and promote walking practice. To establish 
effective walking practice, it is of importance to measure oxygen 
uptake (VO2) during walking at a given speed and calculate 
energy cost of walking (CoW).
Objective: To determine whether the energy expenditure during 
walking at different speeds (normal and fast) in MS patients is 
related to neurological disability as assessed by the EDSS.
Methods: Energy expenditure was measured during normal and 
fast walking in ambulatory multiple sclerosis (MS) patients with 
EDSS ≤ 4.5. Gas exchange values were acquired continuously by 
open spirometry and indirect calorimetry using a portable meta-
bolic device (COSMED K5, It). Oxygen consumption at rest was 
calculated by averaging 30-second oxygen uptake (VO2) values 
over a 5-minutr period of seated rest. Participants then performed 
normal speed and fast speed walking trials, each continuously for 
6 minutes along an indoor 30m corridor. O2cost (ml/Kg*m) was 
extracted for each speed gait indicating the amount of energy 
needed to walk one meter was assessed.
Results: 60 consecutive MS patients, 32 females, 28 males, 
mean±SD age 38.2±13.9 years, disease duration 5.9±8.5 years, 
EDSS 2.2±1.3, BMI 25.1±4.7 were included in the study. Energy 
expenditure at normal walking was 0.191±0.052 and increased 
during fast walking to 0.207±0.06. Analysis of energy expendi-
ture both in normal and fast walking was significantly different 
between patients with EDSS ≤ 2.5 (N=47) and patients with 
EDSS range between 3.0 to 4.5 (N=13), p=0.006 and p=0.002, 
respectively.
Conclusion: Gait energetic costs of normal and fast walking 
increase with metrological disability.
Disclosure
All author Declare no conflict of interest
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A mapping study to compare the educational offerings for 
patients in the fields of multiple sclerosis and HIV in Europe 
and Canada
P. Rieckmann1, E.V.D. Cantogno2, MS in the 21st Century 
Steering Group
1Sozialstiftung Bamberg Hospital, Bamberg, 2Merck KGaA, 
Darmstadt, Germany
Background: The MS in the 21st Century initiative, formed in 
2011 and led by a Steering Group (SG) of international multiple 
sclerosis (MS) specialists and patient advocates, focusses on 
developing programmes to improve the education of and commu-
nication between healthcare professionals (HCPs) and people 
with MS (PwMS). In 2016, the SG conducted a mapping exercise 
to capture the existing educational offerings for PwMS in Europe 
and Canada (Phase 1). Findings from Phase 1 indicated patient 
resources varied by topic, format and country.
Objective: Phase 2 of the research was designed to compare the 
number and type of patient resources in the field of MS to similar 
offerings for patients in the field of HIV, which the SG identified 
as a comparator chronic disease.
Method: The Phase 1 methodology was repeated for Phase 2 in 
Europe and Canada. Desktop research was undertaken using 
Google search engine. Search terms were based on a pre-deter-
mined parameter list from Phase 1 and modified for HIV. 
Research was conducted across multiple stakeholders including 
patient associations, pharmaceutical companies and public 
healthcare/government services. Resources were categorised by 
topic and format including, websites, information sheets and 
social media. This research model will be later extended to addi-
tional geographies.
Results: A total of 454 stakeholders were mapped in 21 coun-
tries resulting in the identification of 8,097 resources for HIV; 
compared to 1,867 resources identified in Phase 1 for MS. 
Resource formats identified were similar for both diseases: 
websites were the most common resource format for HIV and 
MS but represented a higher proportion of overall resources 
for HIV (74.3%) compared with MS (46.8%). Fewer printed 
materials were found for HIV (7.8%) than for MS (19.5%). 
The most frequently identified topics for both HIV and MS 
included general disease information (treatment information, 
general guides and lifestyle advice), accounting for 61.8% and 
60.1% of resources. There were more resources that dealt with 
effective patient-HCP communication for HIV (3.1%) com-
pared to MS (0.3%). The origin of the patient information was 
similar for both: the majority of resources were provided by 
patient associations/advocacy groups (HIV 69.1% and MS 
63.2%).
Conclusion: This research demonstrated that there is a large 
offering of patient educational resources for HIV in Europe and 
Canada and when compared with the field of MS, suggests PwMS 
may be underserviced.
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EP1839
Relationship between social support and perception of cogni-
tive difficulties in people with multiple sclerosis
S. Vanotti1,2, C. Yastremiz1, A. Marinangeli1, N. Cabral1, R. 
Alonso1, C. Pita1, F. Caceres2, O. Garcea1
1Ramos Mejia Hospital, 2INEBA, Buenos Aires, Argentina
Background: Social Support represents formal and informal rela-
tionships, with MS patients obtaining emotional, affective and 
instrumental support. Emotional support reflects the emotional 
feeling of being loved, the security of trusting someone and hav-
ing personal intimacy; Affective support is considered as the 
expression of real demonstrations of love, affection or empathy 
and Instrumental support refers to access to material resources, 
such as financial assistance, food and clothing. It has already been 
documented that social support impacts on the perception of qual-
ity of life, but the influence on the perception of cognitive difficul-
ties has not yet been studied.
Objectives: To analyze the difference of social support perception 
between MS patients and Healthy controls (HCs) and to evaluate the 
association between social support and the MSNQ patient report.
Methods: The sample included 105 MS patients (89.2%RR, 
8.8%SP and 2.0%PP) and 78 HCs. MS Patients: 74% were female; 
mean age: 38.88 ± 12.74 years; education: 13.24 ± 3.28 years; 
EDSS: 2.75 ± 2.11; disease evolution 10.08 ± 9.16 years; depres-
sion: 11.91 ± 9.08 (range 0-34) HCs: mean age; 41.50 ± 10.53; 
education: 14.77 ± 2.10. Outcomes measures: Medical Outcomes 
Study Social Support Survey (MOS) with 3 dimensions: emo-
tional, affective and instrumental support; Multiple Sclerosis 
Neuropsychological Questionnaire (MSNQ), Beck Depression 
Inventory II; EDSS.
Results: Affective subscales support (t (158) = -2.48, p = .014) 
and global index (t (158) = -2.025, p = .045) of the MOS Scale 
showed significant differences between MS and HCs. The MSNQ 
patient report was significantly correlated with the instrumental 
dimension of social support (r = -0.28).
Conclusion: Less instrumental social support negatively affects 
the perception of cognitive deficits in patients with MS.
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EP1840
Longitudinal changes in mental toughness, sleep distur-
bances, and physical activity in patients with multiple sclero-
sis (MS)
D. Sadeghi Bahmani1, L. Esmaeili2, V. Shaygan Nejad3, M. 
Gerber4, U. Puehse4, U. Lang4, E. Holsboer-Trachsler4, S. Brand4
1Psychiatric Clinics | Center for Affective, Stress and Sle, 
Universtity of Basel, Basel, Switzerland, 2Department of 
Psychology, University of Isfahan, 3University of Esfahan, 
Esfahan, Islamic Republic of Iran, 4University of Basel, Basel, 
Switzerland
Background: Multiple sclerosis (MS) is a chronic progressive 
autoimmune disease. fatigue, depression and cognitive impair-
ments are the most common symptoms of patients with MS. 
Whereas there is extant research on fatigue, depression, and cog-
nitive impairment of patients with MS during the clinical course, 
no research focused on the long term changes of psychological 
functioning, sleep problems, and physical activity on these 
patients. The aims of the present study were therefore to examine 
changes in physical activity, sleep disturbances, and mental tough-
ness over a 1.5-year period of time in people with multiple sclero-
sis after the onset their MS.
Methods: A total of 18 patients with diagnosed MS (mean age: M 
= 33.61 years) took part in this study. They completed a booklet of 
questionnaires covering socio-demographic data, mental tough-
ness, sleep disturbances, and physical activity, at the onset of dis-
ease and 1.5 years later
Results: 1.5 years after the onset of MS, patients had lower levels 
of vigorous physical activity, but not statistically significant 
change in moderate physical activity. Patients with sleep distur-
bances at the onset of disease had statistically significant sleep 
disturbances also 1.5 years later. Medication and EDSS scores did 
not change over time.
Conclusions: Compared to the onset of disease, 1.5 years later, 
patients with MS reported similar mental toughness traits, sleep 
disturbances and levels of moderate physical activity. The pat-
tern of results of the present pilot study suggests that the onset 
of MS is not an obstacle for doing moderate physical activity. 
Based on the result of this study, sleep disturbances remains 
stable by time.
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EP1841
A three month interim analysis of quality of life in patients 
with relapsing remitting multiple sclerosis in the UK: the 
Patient Reported Outcomes with Fingolimod in Local Expe-
rience (PROFILE) study
N. Adlard1, F. Brisbane1, J. Watson1, C. Bottomley2, M. Kroes1
1Novartis Pharmaceuticals UK Ltd, Frimley, 2pH Associates Ltd, 
Marlow, United Kingdom
Introduction: Data are limited on the quality of life (QoL) of 
patients with relapsing remitting multiple sclerosis (RRMS) treated 
with fingolimod, a disease modifying therapy (DMT), in the UK.
Methods: Prospective observational study of 144 consenting 
patients with RRMS in 14 secondary care NHS centres. Eligibility: 
aged 18-55 years at first initiation of fingolimod (‘baseline’) and 
treated within the European product licence. Baseline data col-
lected from medical records: demographics, disease characteris-
tics and DMT history; baseline, 3, 6 and 12 month (M) 
patient-reported data collected included the EQ-5D-5L, the 
Multiple Sclerosis Impact Scale (MSIS-29) and adverse events 
(AEs). Percentages have been rounded so may not total 100%; 
95% confidence intervals [CI] presented where available.
Results: The results of an interim analysis of n=110/144 patients 
(76%) who had ≥1 post-baseline assessment of MSIS-29 are pre-
sented. Mean (standard deviation [SD]) patient age at baseline: 40 
(8) years; n=87 (79%) female; n=5/110 patients (5%) had received 
no previous MS DMT, 65 (59%) had received 1, 30 (27%) had 
received 2, and 10 (9%) had received >2. Baseline mean (SD) 
MSIS-29 physical domain score: 34.7 (23.3); at 3M: 31.4 (22.2); 
mean change: -3.3 [CI:-5.7,-0.9]. Baseline mean (SD) MSIS-29 
psychological domain score: 39.5 (23.8); at 3M: 35.4 (22.7); 
mean change: -4.2 [CI:-7.8,-0.5]. Baseline mean (SD) EQ-5D util-
ity index score: 0.73 (0.21); at 3M: 0.74 (0.23); mean change: 0.01 
[CI:-0.02,0.04]. Baseline mean (SD) EQ-5D visual analogue scale 
score: 67.9 (18.4); at 3M: 69.0 (17.3); mean change: 1.0 [CI:-
2.2,4.3]. The largest increases in patients reporting no problems 
were in the EQ-5D usual activities subscale: n=38/110 (35%) at 
3M, compared to n=27/110 (25%) at baseline, and in the self-care 
subscale: n=74/110 (67%) at 3M, compared to n=67/110 (61%) at 
baseline. AEs reported by n=38/110 patients (35%) at 3M; most 
frequently reported AE: headache (n=7/110, [6%]).
Conclusions: Patients reported improved scores in both the 
physical and psychological domains of the disease-specific 
MSIS-29 at 3M, indicating an improvement in MS-related QoL 
following initiation of fingolimod. Overall utility did not change 
significantly when measured by the EQ-5D, suggesting this 
generic tool may not be sensitive enough to capture disease-
specific factors impacting on QoL. Forthcoming study assess-
ments at 6 and 12 months will support understanding of longer 
term QoL in this patient group.
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EP1842
Gait and physiotherapy: effectiveness of a physiotherapy 
circuit training on the ability to walk and quality of live in a 
multiple sclerosis´ s patients
A. Granja Dominguez1, E. Magni2, A. Hochsprung3
1Neurology, Neuroinvest, 2Neurology, Fisevi, 3Neurology, 
Hospital Universitario Virgen Macarena, Sevilla, Spain
Background: Gait abnormalities are an early clinical symptom in 
multiple sclerosis (MS), leading to decreased activity and limita-
tions in function. In addition, MS causes sensorimotor deficits and 
neurological weakness that impairs mobility in daily living activi-
ties. There are several studies showing beneficial qualities of 
physical therapy on walking function, mobility and quality of live. 
Nonetheless, the circuit training approach hasn´t been studied 
enough in people with MS and gait and quality of life. Previous 
studies have shown that physiotherapy circuit training is a good 
method to improve locomotor function and mobility in stroke 
survivors.
Objective: The aim of this study was to evaluate the effect of a 
physiotherapy circuit training on gait parameters and quality of 
life in people with MS.
Methods: An experimental trial with a sample of 60 subjects. 41 
females and 19 males with relapsing-remitting (n=43), secondary 
progressive (n=6) and primary progressive (n=11) MS with EDSS 
of 1.5 to 5.5. They were randomly assigned to 2 groups: experi-
mental group (n=30) received 12 physiotherapy circuit training 
sessions over 3 months (2 hours/each session), whereas control 
group were in wait list. The sessions included four different work-
stations: Balance trainer, whole-body vibration platform, 
Biofeedback cycling and treadmill with body weight support. 
Outcome for the gait, registered by Gaitrite Walkway System 
were : velocity, cadence, step length differential, ambulatory time 
and Functional Ambulatory Profile (FAP). Quality of life was 
assessed by: MusiQol, a specific self-reported questionnaire of 
health related quality of life. Date registered before and after the 
intervention.
Results: Significant difference in the experimental group in FAP 
(p< 0,03), ambulation time (p< 0. 32) and step length differential 
(p< 0.034) after the intervention. No changes in gait pattern were 
reported in the control group. The quality of life improved but it 
was not significant (p< 0.092).
Conclusion: The physiotherapy circuit training seems to be effec-
tive to improve gait patterns in MS patients, moreover it might 
have a positive influence in the quality of life.
Disclosure
Anabel Granja: nothing to disclose
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EP1843
The impact of nurse advisors and online advice services on 
treatment adherence in multiple sclerosis (MS)
A. Altenbuchner1, S. Haug1, C. Mohr2, U. Scorna1, K. Weber1
1Department of Social Research and Technological Impact 
Assessment (IST), 2Faculty of Social and Health Science, 
Ostbayerische Technische Hochschule Regensburg (OTH), 
Regensburg, Germany
Background: The Active-with MS support program (AMSP) 
supports patients receiving immunomodulatory disease-modify-
ing therapy with Copaxone®. The AMSP involves three face-to-
face consultations with MS nurses in the first half year of 
treatment. The program also includes a telephone consultation 
service team and an online forum. The aim of this study is to eval-
uate the AMSP and explore its impact on treatment adherence and 
discontinuation.
Methods: This social science panel study is based on a mix of 
methods, combining qualitative guideline-based expert inter-
views (n= 7 patients; n=7 MS nurses; n=7 service team members) 
and a standardized postal survey of patients in a longitudinal 
evaluation with three data collection waves (nW_1=87, nW_2=65, 
nW_3=37). The third wave involved a standardized online survey 
of MS nurses (n=86). Analysis of data was conducted by a boot-
strap resampling method.
Results: Patients said they felt to be part of the treatment decision 
making (M=4.49, SD=.742). They also have high levels of confi-
dence in their treatment (M=4.14, SD=.883) and in the effective-
ness of the advice provided by the MS nurses (M=4.46, SD=.774).
In the longitudinal study, dosing was omitted on average never to 
3.6 times (BCa 95% CI W_1 [-.02, .53], BCa 95% CI W_2 [-.33, 
2.21] and BCa 95% CI W_3 [- .04, 3.61]). Dosing regularity 
increases at Wave 3. The dropout rate of 10.1% is lower than the 
expected rate of 20-30%.
Both the importance and ratings for MS nurses were higher than 
for primary care physicians, specialist physicians, the service 
team and the online forum.
Conclusion: Patients responding to the survey have high levels of 
adherence, which increases as treatment duration progresses. 
Apart from teaching injection technique, MS nurses play an 
important role in educating patients, sharing knowledge and pro-
viding psychosocial counseling.
Keywords: Multiple sclerosis, adherence, MS nurse consultation 
service, disease coping strategies
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EP1844
Fatigue management: occupational therapy intervention in 
multiple sclerosis for Argentinean population
M.E. Scaffa, C.L. Gualtieri, M. Cordoba, M.L. Saladino, F. 
Caceres
INEBA, Buenos Aires, Argentina
Objective: To provide evidence supporting a biopsychosocial 
conceptual framework for fatigue management based on 
Occupational Therapy intervention in Argentinean MS patients 
and its participation impact.
Design: This is a study analyzing participation impact before and 
after implementation of a local fatigue management program.
Participants: Fifty-one (N-51) adults with MS who regularly 
attended a community based, maintenance rehabilitation center.
Main outcomes: Modified Fatigue Impact Scale (MFIS), 
Functional Independence Measure (FIM), The Community 
Integration Questionnaire (CIQ), visual-analogue scale.
Results: Regarding age, all patients reduced Fatigue Severity 
Scale (FSS), MFIS and improved FIM; those older than 46 also 
increased CIQ (3,5%). Both genders decreased fatigue, further-
more men increased FIM(1,3%) and CIQ(1,2%). Working 
patients reduced fatigue scales, those working full time also 
increased FIM (4,6%). Patients with higher education decreased 
fatigue and improved FIM (1,3%) and CIQ(2,9%). Regarding 
years since diagnose, both groups decreased fatigue scores and 
increased FIM (< 12 years 0,5%; >12 years 4,9%), those with 
less than 12 years also increased CIQ(2,1%). All types of MS 
reduced their fatigue; MSRR also improved FIM(0,3%) and 
CIQ(0,2%); MSPP increased FIM(4,6%). Patients without medi-
cation decreased FSS, MFIS and improved FIM(4,5%) and 
CIQ(2,6%). Patients with selective immunosuppressants 
decreased FSS and MFIS. Those with classic medication reduced 
the cognitive subscale of MFIS and improved FIM (2,2%). The 
average level of quality of life satisfaction after our intervention 
was of 6,86.
Conclusion: Our local Fatigue Management Program applied in 
Argentinean MS patients has been proven an important and sig-
nificant tool for OT interventions in all types of MS. Further stud-
ies with larger sample sizes are needed.
Disclosure
Nothing to disclose
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Dynamic contributors to low quality of life in MS along the 
disease course
M. Sepulveda, E. Solana, E. Martinez-Heras, N. Sola-Valls, Y. 
Blanco, A. Saiz, S. Llufriu
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Center of Neuroimmunology, Laboratory of Advanced Imaging 
in Neuroimmunological Diseases, Hospital Clinic of Barcelona 
and Institut d’Investigacions Biomediques August Pi i Sunyer 
(IDIBAPS), Barcelona, Spain
Background: Multiple sclerosis (MS) affects negatively quality 
of life. The Short Form Health Survey (SF36) measures various 
aspects of health‐related‐quality of life (QoL), including physical 
and mental health. Physical disability and emotional problems 
seem to have a negative impact on QoL in patients with MS, but 
their relative importance at different stages could differ.
Goals: To identify the main factors influencing QoL in patients 
with MS and to compare the contributors to low QoL soon after 
the first MS relapse and later on the disease.
Methods: We included 160 MS patients (mean age 43.6±11.2 
years, 72.3% women) and 35 healthy controls (HC, age 41.4±10.9 
years, 60% women) who completed the SF36. Eight QoL sub-
scales and two composite scores, physical (PCS) and mental 
(MCS), were calculated. Participants were also evaluated with the 
Hospital Anxiety and Depression Scale (HADS), Modified 
Fatigue Impact Scale (MFIS), Pittsburgh Sleep Quality 
Assessment and Cognitive Reserve. Clinical information includ-
ing disease duration, Expanded Disability Status Scale (EDSS), 
25-feet walk test (25FWT), 6-minutes walk test (6MWT), Paced 
Auditory Serial Addition test and Symbol Digit Modalities test 
were recorded in patients.
Results: Patients had 11.7±10.5 years of disease duration, median 
EDSS of 2.0 (range 0-6.5). They presented worse scores in all 
SF36 metrics compared to HC (p< 0.01). EDSS, walk ability 
measured with 25FWT and 6WT, HADS, fatigue, sleep and cog-
nitive reserve correlated with most subscales of SF36 (p< 0.01). In 
a multivariate model the main predictors of low PCS were worse 
MFIS, 6MWT and Pittsburgh score (corrected r2=0.52), and the 
main predictors of low MCS were worse HADS and shorter dis-
ease duration (corrected r2=0.41).
Patients with less than 2 years of disease duration (n=43), com-
pared to those with more than 15 years (n=50), presented better 
physical QoL, but showed greater loss in QoL in the last year and 
worse mental QoL scores (p< 0.01) despite their HADS values 
were similar (11.9±7.4 vs. 10.7±7.4, p=0.47).
Conclusion: Fatigue, walk impairment, low quality of sleep, anx-
iety and depression symptoms are key elements influencing low 
QoL in patients with MS, although their relative impact changes 
along the disease. In early phases, when disability is mild, QoL is 
already impaired, mainly due to worse perception of their mental 
health probably related to the recent diagnosis.
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EP1846
The 24 hour exercise marathon for multiple sclerosis - to pro-
mote benefits of regular physical activity among patients and 
their supporters
K. Novotna1,2, L. Sucha1, J. Vojackova3, K. Bemova3, D. 
Hillayova1, P. Reznicek1, R. Malinova1, D. Horakova1, E. Kubala 
Havrdova1
1Department of Neurology and Center of Clinical Neuroscience, 
First Faculty of Medicine, Charles University and General 
University Hospital in Prague, 2on behalf of All 31 Participating 
Sites, 3Impuls Endowment Czech Republic, Prague, Czech 
Republic
Background: A positive effect of physical activity in people with 
multiple sclerosis (MS) has been proven in many studies. Most 
people with MS do not maintain sufficient level of physical aktiv-
ity, due to a variety of factors (such as a lack of motivation or 
knowleadge, fear, insufficient funds or a lack of support).
Methods: We would like to report our experience with an annual 
event that involves patients, caregivers as well as healthcare pro-
fessionals. The aim of the event is to motivate patients with MS to 
remain physically active, to inform family members, sponsors and 
general public about importance and benefits of physical activity 
in MS and to raise funds for other physical therapy activities for 
MS patients organized throughout the year.
Results: The origin of this event is in Prague, Czech Republic and 
was inspired by MS patients who attended regular aerobic-resistance 
exercise and wanted to share their possitive experience with other 
MS patients. The First 24 hour Exercise Marathon for MS (MARS) 
took place in 2012 in Prague with 84 participants. This event was 
very succesfull and its reputation began spreading and encouraging 
other patients to get involved. The sixth Exercise Marathon for MS 
took place on March 3-4, 2017 and involved 3 244 participants, 31 
sites across Europe including 7 international sites (France, 
Switzerland, Poland, Turkey, Slovakia) and 24 sites in the Czech 
Republic. Each site plans activities relevant to their preferences and 
possibilities, and always includes physical activity, such as circuit 
training, yoga, Tai-chi, nordic walking, therapeutic climbing etc. All 
physical activity is planned and supervised by physiotherapists 
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specialised/experienced in in MS therapy. Exercise lessons are going 
on for 24 hours, during which teams consisting of patients, their 
friends, family members, physicians, nurses, and celebrities and 
other supporters také turns exercising. Educational activities and 
presentations take place in a meantime. Reports from participating 
sites are shared in real time on facebook and other media.
Conclusion: We would like to invite all MS centers and other 
interested groups from anywhere in the world to join the MARS in 
2018 !
This event was supported and coordinated by Impuls Endowment 
Czech Republic.
Disclosure
KN received compensation for travel and speaker honoraria from 
Merck, Novartis and Teva
DH received compensation for travel, speaker honoraria and con-
sultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi 
Genzyme, Roche, and Teva, as well as support for research activi-
ties from Biogen Idec.
EKH received compensation for travel, speaker honoraria and 
consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi 
Genzyme, Roche, and Teva, as well as support for research activi-
ties from Biogen Idec.
Enhancing CNS plasticity
EP1847
Altered brain connectivity and its changes after physiother-
apy in people with multiple sclerosis
M. Prochazkova1, J. Tintera2, S. Spanhelova3, T. Prokopiusova1, 
G. Angelova1, J. Rydlo2, K. Rasova1
1Department of Rehabilitation Medicine, Third Faculty 
of Medicine and Faculty Hospital Kralovske Vinohrady, 
Charles University, 2MR Unit, Department of Diagnostic and 
Interventional Radiology, Institute for Clinical and Experimental 
Medicine, 3Department of Rehabilitation and Sports Medicine, 
Second Faculty of Medicine and Faculty Hospital in Motol, 
Charles University, Prague, Czech Republic
Background: Regular physical activity and physiotherapy accel-
erate the ability of the brain to slow down clinical progression in 
people with multiple sclerosis (MS). It positively influences 
impaired clinical functions, fatigue, mental and cognitive func-
tions and the quality of live in the general. But the mechanism of 
this recovery is still not well described. For a better understanding 
of the pathophysiological and consequent reparative processes in 
MS are nowadays widely used imaging methods.
Aims: In this study, we want to focus on further in-depth under-
standing of the mechanism of neuroplasticity in people with MS, 
in terms of monitoring brain connectivity (centrality, regional 
homogeneity - REHO) in rest (resting state fMRI) - compared 
with healthy individuals. Further to describe changes in these 
reactions after ambulatory facilitation physiotherapy.
Methods: 39 patients with MS (mean age 46.7±12.3, Expanded 
Disability Status Scale - EDSS 4.3±1.7, disease duration 12.1±7.2 
years) and 42 healthy volunteers (mean age 43.7±14.8 years) par-
ticipated in the study. People with MS underwent a two-month 
program of facilitation physiotherapy
(2x a week, 1 hour). The resting state examination was performed 
at the beginning and at the end of the therapeutic program.
Results: The regional homogeneity (REHO) is more pronounced 
in the areas of occipital lobe (gyrus fusiform), frontal lobe (supe-
rior frontal gyrus) and temporal lobe (inferior temporal gyrus) in 
patients with MS. On the other side healthy controls have higher 
REHO in cerebellum and in parietal areas (supramarginal and 
angular gyrus) and limbic areas (posterior cingulate gyrus). The 
REHO parameter was not changed after the physiotherapy. The 
parameter of centrality was positively higher in healthy controls 
in areas of parietal lobus (superior parietal gyrus), subcortical 
grey nuclei (nucleus caudatus) and thalamus. After physiotherapy, 
the centrality was more pronounced in cerebellum, temporal lobe 
(inferior temporal gyrus) and parietal lobe (supramarginal gyrus).
Conclusions: There were found differences in connectivity meas-
ures as REHO and centrality between patients with MS and 
healthy controls. The REHO stayed unchanged after physiother-
apy, while the degree of centrality slightly increased.
The study was realized due to the support of the Grant Agency, 
Czech Republic GA13-23940S, 260388/SVV/2017 and Progres 
Q35.
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EP1848
Dance for health: the preliminary effects of a dance-inter-
vention on cognition and hippocampal activation in patients 
with MS
M. Huiskamp1, Q. van Geest1, D. Visser1, M.R. van Lingen1, 
N. Braaksma1, M.H.P.C. Vlemmix2, Y.D. van der Werf1, J.J.G. 
Geurts1, H.E. Hulst1
1Dept. Anatomy and Neurosciences, MS Center Amsterdam, 
Amsterdam Neuroscience, VU University Medical Center, 
Amsterdam, 2Dance for Health the Netherlands, Rotterdam, The 
Netherlands
Introduction: Previous studies on cognitive rehabilitation in mul-
tiple sclerosis (MS) are promising, both for cognitive training as 
well as exercise. Here, we examined the effect of a dance-inter-
vention on cognition and hippocampal activation in MS patients.
Methods: Nineteen MS patients (mean age 44.53 years ± 8.52; 18 
females) participated in a structured dance-intervention. Patients 
were eligible for participation if they met the criteria for mild cogni-
tive impairment (i.e. a score between 1 and 2 SD below norm scores 
on at least one neuropsychological test or a score of ≥2 SD below 
norm scores on exactly one test), had no signs of depression and had 
an expanded disability status scale (EDSS) of ≤6.0. Patients fol-
lowed two dance-sessions per week (one hour per session) for eight 
weeks. Before and after the dance-intervention neuropsychological 
testing (parallel versions) and structural and functional Magnetic 
Resonance Imaging (MRI) scanning (episodic memory task) at 3T 
were performed. Subjective cognitive functioning was measured 
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using the Multiple Sclerosis Neuropsychological Questionnaire 
(MSNQ). Data were analyzed using Paired Sample T-tests.
Results: At follow-up, patients improved on tests for verbal learn-
ing and memory (Δscore=6.16;
p< 0.001), information processing speed (Δscore=3.74; p=0.017), 
attention (Δscore=5.17; p=0.033) and working memory 
(Δscore=1.47; p=0.039). The MSNQ score decreased with 3.84 
points (p=0.035). On MRI, no structural changes were present, 
while increased activation of the ventral stream (including the hip-
pocampal area) and frontal areas was observed. Decreased activa-
tion was seen in the occipital pole and lingual gyrus (all analyses 
were cluster-corrected, Z≥2.3, p≤0.05).
Conclusion: Our preliminary results show promising effects of a 
dance-intervention in MS patients. Improved cognitive function-
ing was observed, subjective cognitive complaints were reduced 
and brain/hippocampal activation changed significantly. We do 
however need to interpret these results with caution, since data 
collection of patients in the control condition is not yet finished.
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EP1849
Brain atrophy in multiple sclerosis could be ameliorated by 
aerobic exercise
L. Savsek1,2, V. Strojnik3, A. Ihan4, Z. Spiclin5, S. Sega Jazbec2
1Department of Neurology, General Hospital Celje, Celje, 
2Neurology Clinic, University Medical Centre Ljubljana, 
3Faculty of Sport, 4Faculty of Medicine, 5Faculty of Electrical 
Engineering, University of Ljubljana, Ljubljana, Slovenia
Objective: Although most disease modifying drugs exert high 
antiinflammatory effect on multiple sclerosis (MS), their neuro-
protective effect is still rather unclear and is subject to many clini-
cal studies. However, even less is known about additional 
neuroprotective and regenerative strategies in MS. Previous stud-
ies on elderly populations and Alzheimer´s disease patients sug-
gest a beneficial effect of exercise on neurodegeneration. The aim 
of present study is to test the effect of aerobic exercise as a strat-
egy to ameliorate functional disability and brain atrophy progres-
sion on patients with MS.
Subjects and methods: A group of 25 age- and sex-matched 
patients with MS, treated with fingolimod for ≥6 months, no 
relapses within 3 months prior to start of study and EDSS < = 6,5, 
were randomized into intervention group (IG; n=12) and control 
group (CG; n=13). Intervention consisted of 12 weeks of super-
vised aerobic exercise twice a week (60 minutes´ duration).
Baseline 3T magnetic resonance imaging (MRI) was performed 
at start of study and follow-up at study end. Volumetric analysis 
of brain structures was performed on baseline MRI and corre-
sponding regional atrophy changes were calculated between 
baseline and followup MRI scans using automated brain segmen-
tation and deformation analysis techniques (MS Markers; 
ms.quantim.eu).
Additionally, we measured walking speed with 10-Meter Walk 
Test, resting state brain-derived neurotrophic factor (BDNF), 
interleukin-6 (IL6) and interleukin-2 (IL2) serum levels.
Results: Exercise improved EDSS score and walking speed in IG, 
while in CG a slight worsening of both measures was detected, but 
none of these changes were significant. Statistically significant 
increase in volume of parahippocampal (p=0,001) and precentral 
gyrus (p=0,048), thalamus (p=0,039) and frontal lobe (p=0,026) 
was found in IG compared to CG. After 12 weeks, resting state 
BDNF levels were significantly higher in the IG (p=0,004) com-
pared to baseline, while in CG only a mild, but not significant, 
increase was observed (p=0,8). Levels of IL6 and IL2 remained 
stable in both groups.
Conclusion: Our study supports findings from previous studies 
that certain brain structures remain pliable throughout lifetime 
and can be modified through simple techniques, like aerobic exer-
cise. Results suggest that regional brain atrophy, reflecting the 
neurodegenerative process, could be ameliorated by promoting 
aerobic exercise among patients with MS.
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Fingolimod reduces the clinical expression of active demy-
elinating lesions in MS
E. Signoriello1, D. Landi2, F. Monteleone2, C.G. Nicoletti2, 
F. Buttari3, F. Sica3, G.A. Marfia2, G. Di Iorio1, G. Lus1, D. 
Centonze2,3
1Multiple Sclerosis Center, Second Division of Neurology, 
Department of Surgical and Medical Sciences, Neurological, 
Metabolic and Aging, University of Campania “Luigi Vanvitelli’, 
Naples, 2Multiple Sclerosis Clinical and Research Unit, 
Department of Systems Medicine, Tor Vergata University, Rome, 
3IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, 
Pozzilli, Italy
Background: New demyelinating lesions may or may not be 
associated with clinical symptoms depending on the extent of 
inflammation and individual network plasticity properties. In 
animal models and relapsing remitting MS, Fingolimod 
(FTY720) has been proven to reduce neuroinflammation and 
modulate glutamate-mediated neurotransmission by enhancing 
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synaptic plasticity and compensating for demyelinating 
damage.
Objective: This study aimed at retrospectively observing whether 
treatment with FTY720 can attenuate the clinical expression of 
new lesions.
Methods: 103 patients with relapsing-remitting MS switching for 
inefficacy from first-line injectable therapy with IFNβ-1a to 
FTY720 and treated for at least 12 months were included. For 
each patient, the occurrence of new gadolinium (Gd+) enhancing 
lesions was evaluated during IFNβ-1a and FTY720 treatment. The 
number of asymptomatic active lesions was compared for the two 
treatments.
Results: Treatment with FTY720 was associated with a signifi-
cantly lower number of Gd+ lesions (p=0.01) and higher rate of 
asymptomatic lesions compared with IFNβ-1a therapy (88% vs 
30.9%, p=< 0.025). Assuming a linear trend between T2 active 
lesion accrual and annualised relapse rate (ARR), we found that 
treatment with FTY720 was associated with an increase of 0.04 in 
the ARR for each new T2 lesion and of 0.06 for each new active 
lesion against treatment with IFNβ-1a, which was associated with 
an increase of 0.29 and 0.33, respectively.
Conclusion: FTY720 limits the clinical expression of new Gd+ 
enhancing lesions, possibly modulating brain network plasticity 
in patients with suboptimal response to previous immunomodu-
lating treatments, as well as causing an overall reduction in 
neuroinflammation.
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